PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
3335306-4	1988	These inhibitory effects of PYY on pancreatic secretion and blood flow were abolished in the presence of combined phentolamine and propranolol.	Propranolol	131-142	peptide YY	Canis lupus familiaris	28-31
3346050-9	1988	The effect of beta-adrenergic modulation on the release of angiotensin II was assessed in 20 rats by adding isoproterenol (10(-10), 10(-8), and 10(-6) M), propranolol (10(-6) M), or a combination of both.	Propranolol	155-166	angiotensinogen	Rattus norvegicus	59-73
3346339-5	1988	Met-enkephalin increased specific antibody-dependent phagocytosis in a dose-dependent fashion; the optimal dose was found to be 10(-8) M. Epinephrine diminished phagocytosis in a dose-dependent manner exhibiting a maximal inhibition at 10(-4)-10(-5) M. This inhibition can be blocked by propranolol.	Propranolol	287-298	pro-opiomelanocortin-alpha	Mus musculus	0-14
3351418-7	1988	The adrenoreceptor antagonists propranolol, phenyoxybenzamine and phentolamine produced a fall in resting vasopressin concentrations while propranolol and phenoxybenzamine potentiated the osmotic release of vasopressin in association with a fall in the osmotic threshold.	Propranolol	31-42	arginine vasopressin	Rattus norvegicus	106-117
3351418-7	1988	The adrenoreceptor antagonists propranolol, phenyoxybenzamine and phentolamine produced a fall in resting vasopressin concentrations while propranolol and phenoxybenzamine potentiated the osmotic release of vasopressin in association with a fall in the osmotic threshold.	Propranolol	31-42	arginine vasopressin	Rattus norvegicus	207-218
3351418-7	1988	The adrenoreceptor antagonists propranolol, phenyoxybenzamine and phentolamine produced a fall in resting vasopressin concentrations while propranolol and phenoxybenzamine potentiated the osmotic release of vasopressin in association with a fall in the osmotic threshold.	Propranolol	139-150	arginine vasopressin	Rattus norvegicus	207-218
2834198-6	1988	This response was fully blocked by the beta 2AR antagonist, propranolol.	Propranolol	60-71	adrenergic receptor, beta 2	Mus musculus	39-47
3259432-8	1988	The tachycardia response to central CGRP was attenuated by pretreatment with propranolol or hexamethonium, indicating that the heart rate response was mediated, in part, through increases in cardiac sympathetic tone.	Propranolol	77-88	calcitonin-related polypeptide alpha	Rattus norvegicus	36-40
3387886-5	1988	Propranolol, a beta blocker with direct action on the secretory tonus of the thyroid C cells, completely annulled the stimulation effect of calcium in adrenalectomized animals but not the hypermagnesemic response.	Propranolol	0-11	amyloid beta precursor protein	Rattus norvegicus	13-19
2842561-4	1988	Propranolol (148 micrograms, 0.5 mumol), a beta-blocker, completely reversed the CRF effect, although propranolol alone affected neither sleeping time nor rectal temperature.	Propranolol	0-11	amyloid beta precursor protein	Rattus norvegicus	41-47
3285225-3	1988	Significant positive correlations were found between the increases in PRA and the increases in plasma NE and Epi concentrations caused by yohimbine, and propranolol (1.5 mg/kg, s.c.) blocked 90% of yohimbine (3 mg/kg, s.c.)-induced renin release.	Propranolol	153-164	renin	Rattus norvegicus	232-237
3285225-6	1988	An increase in circulating plasma catecholamine concentrations appeared to mediate yohimbine-induced renin release since propranolol prevented the rise in PRA caused by yohimbine in renal denervated rats.	Propranolol	121-132	renin	Rattus norvegicus	101-106
2906446-6	1988	Two out of three 5-HT1B receptor antagonists [(+/-) cyanopindolol, (-) propranolol, but not (-) pindolol)] which oppose hypophagia caused by RU 24969 (Kennett et al.	Propranolol	71-82	5-hydroxytryptamine receptor 1B	Rattus norvegicus	17-23
3128014-13	1988	These data suggest the possibility that propranolol oxidation may be mediated in part, by one or more human liver cytochrome P-450 species catalyzing phenacetin oxidation.	Propranolol	40-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-130
2451400-7	1987	By combination of the agonists (adrenaline, dexamethasone) with the respective antagonists (propranolol, a beta-blocking agent and RU 38486, a glucocorticoid antagonist) the agonist-induced changes in concentration of CRP and alpha 2-APG could be suppressed.	Propranolol	92-103	C-reactive protein	Rattus norvegicus	218-221
2824175-8	1987	The NPY-induced LH response was not blocked by pretreatment with any of the following drugs: the alpha-adrenoreceptor antagonist phenoxybenzamine, the alpha 1-adrenoreceptor antagonist prazosin, beta-adrenoreceptor antagonist propranolol, the dopamine receptor antagonist pimozide, or the opiate receptor agonist morphine.	Propranolol	226-237	neuropeptide Y	Rattus norvegicus	4-7
2961689-4	1987	Propranolol induced a significant increase in plasma vasopressin in normal subjects (from 1.3 +/- 0.1 to 2.0 +/- 0.1 pg/ml; p less than 0.05) but not in hypertensive subjects.	Propranolol	0-11	arginine vasopressin	Homo sapiens	53-64
2961689-6	1987	Propranolol abolished the change in plasma renin activity in both groups, reduced the increase in vascular resistance induced by -40 mm Hg lower body negative pressure in normotensive subjects, but did not modify the rise in vasopressin elicited by this stimulus in normal subjects or the humoral and hemodynamic reflex responses evoked in hypertensive subjects.	Propranolol	0-11	renin	Homo sapiens	43-48
2892553-4	1987	By use of saturation analysis, maximal binding capacity (Bmax) of [125I]-(-)-Pin binding in control and treated cells was assessed in the presence of 1 microM (-)-propranolol or 1 microM (+/-)-CGP 12177 which were taken to represent total or cell surface beta-adrenoceptors respectively.	Propranolol	159-174	dynein light chain LC8-type 1	Homo sapiens	77-80
3687592-6	1987	Fibroblasts derived from uninvolved skin of a psoriasis patient (PS1) were several fold more sensitive to practolol and propranolol than cells derived from normal skin but showed little change in sensitivity towards paracetamol.	Propranolol	120-131	taste 2 receptor member 62 pseudogene	Homo sapiens	65-68
3217889-5	1988	Functional ECG tests (including propranolol, piridamole, bicycle ergometry) brought about negative results with relation to CHD.	Propranolol	32-43	choline dehydrogenase	Homo sapiens	124-127
3689450-10	1987	Propranolol bound to mitochondria and sarcoplasmic reticulum in vitro, suggesting the possibility that propranolol binding to heart membranes in vivo could result in drug concentrations in these membranes high enough to inhibit phospholipase A.	Propranolol	0-11	phospholipase A and acyltransferase 1	Rattus norvegicus	228-243
3689450-10	1987	Propranolol bound to mitochondria and sarcoplasmic reticulum in vitro, suggesting the possibility that propranolol binding to heart membranes in vivo could result in drug concentrations in these membranes high enough to inhibit phospholipase A.	Propranolol	103-114	phospholipase A and acyltransferase 1	Rattus norvegicus	228-243
3330526-3	1987	The rise of heart rate induced by orthostasis was diminished by AQ-A 39 to 4 +/- 2 beats min-1 and by propranolol 9 +/- 2 beats min-1.	Propranolol	102-113	CD59 molecule (CD59 blood group)	Homo sapiens	128-133
3330526-4	1987	After submaximal exercise heart rate during placebo was 129 +/- 3, during AQ-A 39 113 +/- 3 and during propranolol 103 +/- beats min-1.	Propranolol	103-114	CD59 molecule (CD59 blood group)	Homo sapiens	129-134
3501866-8	1987	Pretreatment with propranolol significantly reduced the tachycardia responses to CGRP from 81 +/- 11 beats/min to 36 +/- 4 beats/min, but did not abolish the increase in heart rate.	Propranolol	18-29	calcitonin-related polypeptide alpha	Rattus norvegicus	81-85
2832630-6	1987	Intracoronary norepinephrine infusion caused vasodilatation but when dogs were pretreated with 0.5 to 1.0 mg/kg of systemic propranolol, a vasoconstrictor effect was observed at a 5 times higher dose than with NPY.	Propranolol	124-135	neuropeptide Y	Canis lupus familiaris	210-213
2822481-4	1987	beta-Propranolol (a beta 1-receptor antagonist) prevented potentiation, whereas phentolamine (an alpha 1-receptor antagonist) did not, indicating that regulation is through the beta 1-adrenergic receptor.	Propranolol	0-16	adrenoceptor beta 1	Rattus norvegicus	177-203
2821833-10	1987	During hypoglycemia, propranolol abolished the increase in rCBF in the hypothalamus, cerebellum, and pyramidal tract.	Propranolol	21-32	CCAAT/enhancer binding protein zeta	Rattus norvegicus	59-63
3670551-7	1987	Phentolamine, a nonspecific alpha-adrenergic antagonist, and propranolol, a beta-adrenergic antagonist at high doses (10 micrograms), produced slight increases in plasma corticosterone in LS mice only.	Propranolol	61-72	amyloid beta (A4) precursor protein	Mus musculus	74-80
3666269-2	1987	This was done in order to verify the hypothesis that an increase in T3 levels could result from adrenergic stimulation, since propranolol, a beta blocking agent, has proved to decrease T3 levels in man.	Propranolol	126-137	amyloid beta precursor protein	Homo sapiens	139-145
3306385-9	1987	The advantage of propranolol over placebo was maintained when potentially confounding variables were adjusted with use of the Cox model.	Propranolol	17-28	cytochrome c oxidase subunit 8A	Homo sapiens	126-129
2828139-9	1987	The insulin resistance was prevented by infusing propranolol (clamp I 2.29 +/- 0.29, clamp II 2.85 +/- 0.56 mg .	Propranolol	49-60	insulin	Homo sapiens	4-11
2839009-2	1987	In euhydrated rats the single dose of propranolol diminished significantly the vasopressin content in neurohypophysis.	Propranolol	38-49	arginine vasopressin	Rattus norvegicus	79-90
3435209-11	1987	Propranolol did not change the cortical but increased the thalamic rCBF resistance to ABP elevation.	Propranolol	0-11	CCAAT/enhancer binding protein zeta	Rattus norvegicus	67-71
2961012-3	1987	The response to EPI was completely blocked by equimolar propranolol but not by phenoxybenzamine suggesting that, at least in this system, the adrenergic control of ANF secretion is mediated by beta-adrenergic receptors.	Propranolol	56-67	natriuretic peptide A	Rattus norvegicus	164-167
3427528-7	1987	Following the administration of propranolol, the H2A2 interval was prolonged in group I patients by 10 to 45 ms in 11 patients, no retrograde AV nodal conduction was observed in three patients, and there was no effect in two patients.	Propranolol	32-43	H2A clustered histone 18	Homo sapiens	49-53
2828139-17	1987	The insulin resistance on both glucose production and utilisation was prevented by propranolol.	Propranolol	83-94	insulin	Homo sapiens	4-11
2828139-19	1987	The insulin resistance is due to beta-adrenergic stimulation and can be prevented by propranolol.	Propranolol	85-96	insulin	Homo sapiens	4-11
2886515-7	1987	The insulin-antagonistic effect was completely prevented by propranolol but only partly by somatostatin.	Propranolol	60-71	insulin	Homo sapiens	4-11
3622928-9	1987	The response to adrenergic agonists in combination with VIP was reduced by atropine and by phentolamine plus propranolol, but was blocked completely only by a combination of the three antagonists, indicating that both adrenergic and cholinergic mechanisms were involved.	Propranolol	109-120	vasoactive intestinal peptide	Rattus norvegicus	56-59
3613861-5	1987	Propranolol (100 micrograms/100 g BW, iv) inhibited plasma PRL responses to L-DOPS (50 micrograms/rat, icv) and NE injection (1 microgram/rat, icv) raised plasma PRL in anesthetized animals.	Propranolol	0-11	prolactin	Rattus norvegicus	59-62
3613861-5	1987	Propranolol (100 micrograms/100 g BW, iv) inhibited plasma PRL responses to L-DOPS (50 micrograms/rat, icv) and NE injection (1 microgram/rat, icv) raised plasma PRL in anesthetized animals.	Propranolol	0-11	prolactin	Rattus norvegicus	162-165
3618763-3	1987	Phenylephrine at 50 microM, in the presence of 5 microM dl-propranolol, was shown to lead to a maximal, selective alpha 1-stimulation, whereas maximal, selective beta-stimulation was achieved with 1 microM isoproterenol in the presence of 5 microM prazosin.	Propranolol	56-70	adrenoceptor alpha 1D	Homo sapiens	114-121
2444242-6	1987	The beta-adrenergic antagonist propranolol partly inhibited the aforementioned enhancement of PLAP activity, whereas the alpha-adrenergic antagonist phentolamine further enhanced PLAP activity.	Propranolol	31-42	alkaline phosphatase, placental	Homo sapiens	94-98
3555943-5	1987	Pretreatment with metoclopramide or phentolamine did not block these effects, but pretreatment with propranolol significantly (P less than 0.05) blunted the increase in fasting glucose and insulin levels.	Propranolol	100-111	insulin	Homo sapiens	189-196
2888864-1	1987	The interaction of the enantiomers of mianserin and propranolol with the binding of [3H]5-hydroxytryptamine ([3H]5-HT) to the 5-HT1A, 5-HT1B and 5-HT1C sites, and with the binding of [3H]ketanserin to the 5-HT2 site, has been evaluated in rat brain membranes.	Propranolol	52-63	5-hydroxytryptamine receptor 1A	Rattus norvegicus	126-132
2888864-1	1987	The interaction of the enantiomers of mianserin and propranolol with the binding of [3H]5-hydroxytryptamine ([3H]5-HT) to the 5-HT1A, 5-HT1B and 5-HT1C sites, and with the binding of [3H]ketanserin to the 5-HT2 site, has been evaluated in rat brain membranes.	Propranolol	52-63	5-hydroxytryptamine receptor 1B	Rattus norvegicus	134-140
2888864-4	1987	The stereoselective association of mianserin and propranolol with the 5-HT1A, 5-HT1B and 5-HT1C sites may prove useful in the characterization of these sites.	Propranolol	49-60	5-hydroxytryptamine receptor 1A	Rattus norvegicus	70-76
2888864-4	1987	The stereoselective association of mianserin and propranolol with the 5-HT1A, 5-HT1B and 5-HT1C sites may prove useful in the characterization of these sites.	Propranolol	49-60	5-hydroxytryptamine receptor 1B	Rattus norvegicus	78-84
3111480-10	1987	It is concluded that a product or products of propranolol oxidation bind irreversibly but non-selectively to human liver microsomal protein, the enzyme system responsible for the activation of propranolol appears to be related more closely to the cytochrome P-450 system which metabolizes phenacetin than to that metabolising debrisoquine, and radiolabelled propranolol is not a sufficiently specific probe for studying these cytochrome P-450 systems.	Propranolol	46-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	247-263
3111480-10	1987	It is concluded that a product or products of propranolol oxidation bind irreversibly but non-selectively to human liver microsomal protein, the enzyme system responsible for the activation of propranolol appears to be related more closely to the cytochrome P-450 system which metabolizes phenacetin than to that metabolising debrisoquine, and radiolabelled propranolol is not a sufficiently specific probe for studying these cytochrome P-450 systems.	Propranolol	46-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	426-442
3111480-10	1987	It is concluded that a product or products of propranolol oxidation bind irreversibly but non-selectively to human liver microsomal protein, the enzyme system responsible for the activation of propranolol appears to be related more closely to the cytochrome P-450 system which metabolizes phenacetin than to that metabolising debrisoquine, and radiolabelled propranolol is not a sufficiently specific probe for studying these cytochrome P-450 systems.	Propranolol	193-204	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	247-263
3111480-10	1987	It is concluded that a product or products of propranolol oxidation bind irreversibly but non-selectively to human liver microsomal protein, the enzyme system responsible for the activation of propranolol appears to be related more closely to the cytochrome P-450 system which metabolizes phenacetin than to that metabolising debrisoquine, and radiolabelled propranolol is not a sufficiently specific probe for studying these cytochrome P-450 systems.	Propranolol	193-204	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	426-442
3111480-10	1987	It is concluded that a product or products of propranolol oxidation bind irreversibly but non-selectively to human liver microsomal protein, the enzyme system responsible for the activation of propranolol appears to be related more closely to the cytochrome P-450 system which metabolizes phenacetin than to that metabolising debrisoquine, and radiolabelled propranolol is not a sufficiently specific probe for studying these cytochrome P-450 systems.	Propranolol	193-204	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	247-263
3111480-10	1987	It is concluded that a product or products of propranolol oxidation bind irreversibly but non-selectively to human liver microsomal protein, the enzyme system responsible for the activation of propranolol appears to be related more closely to the cytochrome P-450 system which metabolizes phenacetin than to that metabolising debrisoquine, and radiolabelled propranolol is not a sufficiently specific probe for studying these cytochrome P-450 systems.	Propranolol	193-204	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	426-442
3032590-1	1987	Treatment of isolated rat adipocytes with epinephrine or isoproterenol caused a time- and concentration-dependent increase in phospholipid methyltransferase (PLMT) activity that was blocked by propranolol and unaffected by phentolamine.	Propranolol	193-204	phosphatidylethanolamine N-methyltransferase	Rattus norvegicus	126-156
3032590-1	1987	Treatment of isolated rat adipocytes with epinephrine or isoproterenol caused a time- and concentration-dependent increase in phospholipid methyltransferase (PLMT) activity that was blocked by propranolol and unaffected by phentolamine.	Propranolol	193-204	phosphatidylethanolamine N-methyltransferase	Rattus norvegicus	158-162
3621985-9	1987	Physiological antagonism of the VIP response was observed after systemic pretreatment with propranolol, phentolamine, or acetazolamide.	Propranolol	91-102	VIP peptides	Oryctolagus cuniculus	32-35
2888790-8	1987	Except for a possible slight increase in plasma LCAT activity on propranolol, there was no significant change in the plasma activities of LPL, HL, and LCAT during the blockade of the beta-adrenergic receptors with the drugs used.	Propranolol	65-76	lecithin-cholesterol acyltransferase	Homo sapiens	48-52
3603593-3	1987	The positive chronotropic effect of acetone on ACR can be reduced by adding 0.002 mM of propranolol (a non-selective beta 1- and beta 2-adrenergic receptor blocker), or by pretreating the rat with reserpine (an NE depleter) (5 mg/kg body weight, i.p., 24 h prior to experiment).	Propranolol	88-99	adrenoceptor beta 1	Rattus norvegicus	117-155
3297124-0	1987	Effects of indomethacin and (+/-)-propranolol on the cardiovascular and renin responses to vasoactive intestinal polypeptide (VIP) infusion in man.	Propranolol	28-45	vasoactive intestinal peptide	Homo sapiens	91-124
3034674-6	1987	Mixed ligand experiments showed that insulin stimulated GTPase activity in an additive fashion to GTPase activity stimulated by PGE1, due to Gs; by adrenaline (+ propranolol), due to the inhibitory guanine nucleotide regulatory protein, G1 and by vasopressin, which stimulates the putative "Gp", a G-protein suggested to control the stimulation of inositol phospholipid metabolism.	Propranolol	162-173	insulin	Homo sapiens	37-44
3297124-4	1987	We recorded the effects of indomethacin and propranolol pretreatment on VIP-related changes in heart rate (HR), blood pressure (BP), forearm vascular resistance (FVR), plasma renin activity (PRA), plasma noradrenaline (PNA) and plasma arginine vasopressin (AVP) concentrations.	Propranolol	44-55	vasoactive intestinal peptide	Homo sapiens	72-75
3297124-8	1987	Although indomethacin and propranolol reduced the absolute rise in PRA and HR, respectively, during VIP infusion, the percentage changes were no different from control.	Propranolol	26-37	vasoactive intestinal peptide	Homo sapiens	100-103
3614557-7	1987	At luminal pH 7 adrenergic blockade with phentolamine and propranolol reduced vagally stimulated gastrin by 60%.	Propranolol	58-69	gastrin	Rattus norvegicus	97-104
3598968-4	1987	DL-Propranolol, a beta-antagonist, inhibited L-isoproterenol-stimulated testosterone production in a dose-dependent manner, while phentolamine, an alpha-adrenergic antagonist, had no effect.	Propranolol	0-14	amyloid beta (A4) precursor protein	Mus musculus	16-22
2437402-4	1987	Atenolol (-48%), betaxolol (-63%), and propranolol (-29%) significantly suppressed plasma renin activity (PRA), and minoxidil elevated PRA by 150-315%.	Propranolol	39-50	renin	Rattus norvegicus	90-95
3037621-7	1987	Both the administration of indomethacin and of propranolol had a suppressing effect on renin release during atriopeptin III infusion.	Propranolol	47-58	renin	Rattus norvegicus	87-92
2881580-0	1987	Inhibition of purified bovine milk lipoprotein lipase by propranolol and other beta-adrenergic blockers in vitro.	Propranolol	57-68	lipoprotein lipase	Bos taurus	35-53
2881580-4	1987	These studies demonstrate that propranolol inhibits lipoprotein lipase activity.	Propranolol	31-42	lipoprotein lipase	Bos taurus	52-70
3030607-3	1987	This effect seems to be a beta 2-dependent process, since it is prevented by propranolol (5 mg administered intravenously) and the beta 2-selective antagonist ICI 118,551 (25 mg t.i.d.	Propranolol	77-88	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	26-32
2885209-6	1987	In PX-rats, treatment with propranolol resulted in a distinct increase of the vasopressin in the neurohypophysis.	Propranolol	27-38	arginine vasopressin	Rattus norvegicus	78-89
3034621-4	1987	infusion of propranolol (1.0 microgram kg-1 min-1).	Propranolol	12-23	CD59 molecule (CD59 blood group)	Homo sapiens	44-49
2882405-2	1987	During a constant five-hour infusion of 56 micrograms/min of propranolol (nonselective beta-adrenergic receptor-blocker) in seven subjects studied, there was a significant augmentation of the GH release in response to exogenous GRH compared to the GH response during saline infusion, as measured by the peak serum GH concentrations after GRH (P = 0.019) and the integrated GH values (P = 0.019).	Propranolol	61-72	growth hormone releasing hormone	Homo sapiens	228-231
2882405-2	1987	During a constant five-hour infusion of 56 micrograms/min of propranolol (nonselective beta-adrenergic receptor-blocker) in seven subjects studied, there was a significant augmentation of the GH release in response to exogenous GRH compared to the GH response during saline infusion, as measured by the peak serum GH concentrations after GRH (P = 0.019) and the integrated GH values (P = 0.019).	Propranolol	61-72	growth hormone releasing hormone	Homo sapiens	338-341
2882405-3	1987	A similar significant enhancement of GH responses to exogenous GRH as compared to the control day was observed with the specific beta 1-adrenergic receptor-blocker atenolol in all seven subjects studied (four of whom also participated in the propranolol study).	Propranolol	242-253	growth hormone releasing hormone	Homo sapiens	63-66
3812773-6	1987	At higher concentration, U II (10(-8) M) induced a small contraction of aortic strips in Ca2+-free Krebs Henseleit solution similar to that of norepinephrine, but the U II-induced contraction was not inhibited by phentolamine or propranolol.	Propranolol	229-240	urotensin 2	Rattus norvegicus	25-29
3032649-4	1987	In addition, the inhibition of adenylate cyclase induced by alpha 2-receptor stimulation (100 microM adrenaline plus 100 microM propranolol) was completely suppressed in the cerebral cortical membranes by IAP pretreatment.	Propranolol	128-139	Cd47 molecule	Rattus norvegicus	205-208
3575348-6	1987	In addition, at the anti-aggressive doses, (+/-)propranolol (10 mg/kg) and UM-272 (10 mg/kg), significantly inhibited brain cholinesterase enzyme activity when compared to saline controls.	Propranolol	48-59	butyrylcholinesterase	Rattus norvegicus	124-138
3805863-4	1987	Propranolol produced de novo aggregation and also enhanced responses to chemotaxins, N-formyl-methionyl-leucyl-phenylalanine and C5a.	Propranolol	0-11	complement C5a receptor 1	Homo sapiens	129-132
3453073-2	1987	Oral propranolol, a beta-adrenergic blocking agent, was administered beginning 3 weeks after conception up to 18 weeks of the litters.	Propranolol	5-16	amyloid beta precursor protein	Rattus norvegicus	18-24
3549322-6	1987	These results suggest that urinary PGE2 excretion after frusemide administration may be reduced by propranolol and that the mechanism responsible for the effect of propranolol on the frusemide-induced renal PGE2 production may be, at least in part, secondary to inhibition of the renin-angiotensin system.	Propranolol	164-175	renin	Homo sapiens	280-285
2880663-5	1987	In the 12 patients randomized to propranolol, heart rate, systolic and diastolic pressures, double product were significantly reduced at rest, compared with control exercise: 67 +/- 8 versus 81 +/- 10 beats/min (p less than 0.01), 132 +/- 20 versus 146 +/- 21 mm Hg (p less than 0.02), 80 +/- 8 versus 88 +/- 10 mm Hg (p less than 0.02), 8,828 +/- 1,927 versus 11,863 +/- 2,138 mm Hg X min-1 (p less than 0.001), respectively.	Propranolol	33-44	CD59 molecule (CD59 blood group)	Homo sapiens	386-391
2455133-6	1987	The calcium antagonist verapamil and the beta-blocker propranolol may increase LDL receptor activity either per se or by its antagonizing effect on the catecholamine action.	Propranolol	54-65	low density lipoprotein receptor	Homo sapiens	79-91
2885202-4	1987	The beta 2-mediated depressor response to adrenaline infusion was abolished by propranolol and oxprenolol but persisted after atenolol.	Propranolol	79-90	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	4-10
3443139-4	1987	On the other hand, a significant decrease in lecithin cholesterol acyltransferase (LCAT) was seen in patients receiving propranolol.	Propranolol	120-131	lecithin-cholesterol acyltransferase	Homo sapiens	45-81
3443139-4	1987	On the other hand, a significant decrease in lecithin cholesterol acyltransferase (LCAT) was seen in patients receiving propranolol.	Propranolol	120-131	lecithin-cholesterol acyltransferase	Homo sapiens	83-87
2879797-7	1987	Propranolol, a beta-antagonist, counteracted the effect of beta-agonists.	Propranolol	0-11	amyloid beta precursor protein	Rattus norvegicus	13-19
2434783-4	1987	The same extent of inhibition in the renin secretion response to RNS was also obtained during infusion of DL-propranolol (100 micrograms/min).	Propranolol	106-120	renin	Canis lupus familiaris	37-42
2885202-6	1987	Lymphocyte beta 2-adrenoceptor number increased significantly following propranolol treatment, but not after oxprenolol for atenolol.	Propranolol	72-83	adrenoceptor beta 2	Homo sapiens	11-30
2891537-2	1987	The effects of 3 weeks of treatment with the beta-receptor blocking agent propranolol and a placebo on glucose tolerance, insulin secretion and peripheral insulin sensitivity have been evaluated in 7 normoglycaemic hypertensive patients by an oral glucose tolerance test and the insulin clamp technique.	Propranolol	74-85	insulin	Homo sapiens	122-129
3031208-3	1987	The locomotor stimulant action provoked by TRH was antagonized by pretreatment of ventromedial hypothalamus with either an alpha-adrenergic receptor antagonist (yohimbine), a dopaminergic receptor antagonist (haloperidol) or an opiate receptor antagonist (naloxone), but not with a beta-adrenergic receptor antagonist (propranolol).	Propranolol	319-330	thyrotropin releasing hormone	Rattus norvegicus	43-46
2879920-4	1987	The beta 1- and beta 2-adrenoceptor actions of 2 and 3 were blocked in a competitive manner by propranolol.	Propranolol	95-106	beta-2 adrenergic receptor	Cavia porcellus	16-35
3330786-2	1987	Stimulation of c-fos expression by isoproterenol was inhibited by the beta-adrenergic antagonist propranolol.	Propranolol	97-108	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	15-20
3332807-1	1987	A beta 2-selective adrenergic-receptor-blocking drug, ICI 118.551, 150 mg/day, prevented almost as effectively as the nonselective antagonist propranolol, 240 mg/day, the isoprenaline enhancement of essential tremor amplitude.	Propranolol	142-153	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	2-8
3326164-1	1987	Propranolol, a beta-adrenergic blocking agent, has been proposed previously as potentially useful in the treatment of certain otherwise treatment-unresponsive psychotic patients.	Propranolol	0-11	amyloid beta precursor protein	Homo sapiens	13-19
3554168-9	1987	In summary, we have shown that GRP stimulates basal and potentiates stimulated insulin and glucagon secretion in mice, and that the stimulatory effects of GRP on insulin and glucagon secretion are partially inhibited by muscarinic blockade by methylatropine or by beta-adrenoceptor blockade by propranolol.	Propranolol	294-305	gastrin releasing peptide	Mus musculus	155-158
3540504-7	1986	Plasma renin activity (PRA) was reduced by PRO (51%, P less than 0.01) and CLO (35%, P less than 0.05).	Propranolol	43-46	renin	Homo sapiens	7-12
3686434-0	1987	[Age-related changes of the systolic and diastolic function of the left ventricle under the action of a beta adrenergic blocker, anaprilin].	Propranolol	129-138	amyloid beta precursor protein	Homo sapiens	102-108
3432948-10	1987	The beta-blocker, propranolol, prevented this increase in leiomyomas, and led to the conclusion that the beta 2 agonist activity of medroxalol was involved in their induction.	Propranolol	18-29	hemoglobin, beta adult minor chain	Mus musculus	105-111
3789169-3	1986	Administration of the beta-antagonist propranolol, however, resulted in a significant attenuation of the vasopressin response to hemorrhage, with little effect on the blood pressure response.	Propranolol	38-49	arginine vasopressin	Rattus norvegicus	105-116
3029484-5	1986	Even in the presence of propranolol, a beta-adrenergic antagonist, CGRP stimulated increased cyclic AMP levels.	Propranolol	24-35	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	67-71
2433968-9	1986	On the other hand, pretreatment with propranolol blocked and reversed the inotropic actions of NAPA 60 mg/kg, and potentiated its negative chronotropic effects.	Propranolol	37-48	NSF attachment protein alpha	Canis lupus familiaris	95-99
3029132-1	1986	VIP-induced inhibitory responses of the guinea-pig tracheal pouch, an in vivo preparation designed to demonstrate non-noradrenergic non-cholinergic innervation, where determined in chloraloseurethane anaesthetized animals under control conditions, or pretreated with atropine, propranolol, both atropine and propranolol or atropine-propranolol with indomethacin.	Propranolol	277-288	VIP peptides	Cavia porcellus	0-3
3029132-1	1986	VIP-induced inhibitory responses of the guinea-pig tracheal pouch, an in vivo preparation designed to demonstrate non-noradrenergic non-cholinergic innervation, where determined in chloraloseurethane anaesthetized animals under control conditions, or pretreated with atropine, propranolol, both atropine and propranolol or atropine-propranolol with indomethacin.	Propranolol	308-319	VIP peptides	Cavia porcellus	0-3
3029132-4	1986	The group that received atropine alone and the combination of atropine and propranolol showed the least relaxation to VIP.	Propranolol	75-86	VIP peptides	Cavia porcellus	118-121
3029132-6	1986	The significantly greater relaxation of the pouch to VIP in the propranolol treated group suggested that the non-noradrenergic inhibitory mechanism for VIP is dependent upon the existing smooth muscle tone of the pouch.	Propranolol	64-75	VIP peptides	Cavia porcellus	53-56
3029132-6	1986	The significantly greater relaxation of the pouch to VIP in the propranolol treated group suggested that the non-noradrenergic inhibitory mechanism for VIP is dependent upon the existing smooth muscle tone of the pouch.	Propranolol	64-75	VIP peptides	Cavia porcellus	152-155
3826916-8	1986	Growth hormone (GH) secretion was evaluated in all cases by two different test: exercise-propranolol and insulin-induced hypoglycemia.	Propranolol	89-100	growth hormone 1	Homo sapiens	0-14
3023020-6	1986	beta-Receptor blockade with propranolol potentiated both NE- and AII-induced LH release.	Propranolol	28-39	angiotensinogen	Rattus norvegicus	65-68
3821924-7	1986	Finally, (-)propranolol, used as a non-selective 5-HT1A/5-HT1B receptor antagonist, shifted to the right (pA2 = 7.91) the concentration-response curve of 5-HT whereas the 5-HT1C receptor antagonist mesulergine was ineffective.	Propranolol	9-23	5-hydroxytryptamine receptor 1B	Rattus norvegicus	56-62
3821924-7	1986	Finally, (-)propranolol, used as a non-selective 5-HT1A/5-HT1B receptor antagonist, shifted to the right (pA2 = 7.91) the concentration-response curve of 5-HT whereas the 5-HT1C receptor antagonist mesulergine was ineffective.	Propranolol	9-23	5-hydroxytryptamine receptor 2C	Rattus norvegicus	171-177
2877082-5	1986	Terbutaline (10(-5) M), a relatively selective beta-2 agonist, similarly augmented the generation of cell-mediated cytotoxicity, with the increase again blocked by propranolol.	Propranolol	164-175	hemoglobin, beta adult minor chain	Mus musculus	47-53
2879019-0	1986	Tissue cholinesterase inhibition by propranolol and related drugs.	Propranolol	36-47	butyrylcholinesterase	Rattus norvegicus	7-21
2879019-1	1986	The effect of (+/-)-propranolol and some related drugs have been investigated on the cholinesterase (ChE) enzyme activity of heart and brain tissues of the rat.	Propranolol	14-31	butyrylcholinesterase	Rattus norvegicus	85-99
2879019-1	1986	The effect of (+/-)-propranolol and some related drugs have been investigated on the cholinesterase (ChE) enzyme activity of heart and brain tissues of the rat.	Propranolol	14-31	butyrylcholinesterase	Rattus norvegicus	101-104
2879019-5	1986	In-vivo, (+/-)-propranolol (30 mumol kg-1) significantly inhibited brain ChE activity in rats when compared with saline controls.	Propranolol	9-26	butyrylcholinesterase	Rattus norvegicus	73-76
2879019-6	1986	It is inferred that propranolol inhibits brain and heart ChE enzyme in a non-stereoselective manner and that this cholinomimetic action could be involved in the mediation of some of its therapeutic effects.	Propranolol	20-31	butyrylcholinesterase	Rattus norvegicus	57-60
2879022-3	1986	The responses seem to be the result of beta 2-adrenoceptor stimulation since their inhibition by practolol (beta 1) is weaker than their inhibition by propranolol (beta 1 and beta 2 dopaminergic).	Propranolol	151-162	adrenoceptor beta 2	Macaca mulatta	39-58
3539430-9	1986	Prazosin-induced tachycardia and renin release were attenuated by propranolol.	Propranolol	66-77	renin	Rattus norvegicus	33-38
3019152-11	1986	These results suggest that in uremic humans propranolol independently reduces the hepatic response to glucagon and the insulin secretory response to hyperglycemia and/or hyperglucagonemia.	Propranolol	44-55	insulin	Homo sapiens	119-126
2877020-4	1986	Propranolol abolished the effect on PP and glucagon secretion, but did not affect the inhibition of insulin secretion.	Propranolol	0-11	pancreatic polypeptide	Sus scrofa	36-38
3536538-3	1986	The infusion of phentolamine and propranolol (in each case 120 micrograms/kg/h for 3 h after a priming dose of 100 micrograms/kg) starting at the time of insulin injection significantly attenuated the restoration of normoglycaemia.	Propranolol	33-44	insulin	Sus scrofa	154-161
3095204-10	1986	The TRH tremor was suppressed by haloperidol and propranolol, but not by atropine.	Propranolol	49-60	thyrotropin releasing hormone	Mus musculus	4-7
2873850-1	1986	A short-term effect of propranolol on beta 2-adrenoceptor density in mononuclear lymphocytes was studied in 15 male patients with essential hypertension.	Propranolol	23-34	adrenoceptor beta 2	Homo sapiens	38-57
2873850-6	1986	Propranolol administration caused a decline in the initially normal or elevated plasma renin activity as well as in systolic arterial blood pressure and heart rate.	Propranolol	0-11	renin	Homo sapiens	87-92
2874859-2	1986	In rats with inflammation the effects of propranolol and oxprenolol, which are mainly bound to alpha 1-acid glycoprotein (alpha 1-AGP), were significantly less after intravenous administration, but not after intraportal administration.	Propranolol	41-52	orosomucoid 1	Rattus norvegicus	95-120
2874859-2	1986	In rats with inflammation the effects of propranolol and oxprenolol, which are mainly bound to alpha 1-acid glycoprotein (alpha 1-AGP), were significantly less after intravenous administration, but not after intraportal administration.	Propranolol	41-52	orosomucoid 1	Rattus norvegicus	122-133
3780847-6	1986	When used as a 5-HT1A/5-HT1B antagonist, (-)propranolol antagonized 5-HT whereas spiperone (a 5-HT1A displacer) did not.	Propranolol	44-55	5-hydroxytryptamine receptor 1A	Rattus norvegicus	15-21
3780847-6	1986	When used as a 5-HT1A/5-HT1B antagonist, (-)propranolol antagonized 5-HT whereas spiperone (a 5-HT1A displacer) did not.	Propranolol	44-55	5-hydroxytryptamine receptor 1B	Rattus norvegicus	22-28
2878069-3	1986	Atenolol, betaxolol and propranolol significantly suppressed plasma renin activity (PRA), whereas oxprenolol, pindolol and sotalol did not alter PRA significantly.	Propranolol	24-35	renin	Rattus norvegicus	68-73
2879220-7	1986	Propranolol, a beta-adrenergic antagonist, is thought to suppress renin secretion from the juxtaglomerular apparatus in the kidney by blocking its beta-adrenergic receptor, thus suppressing the entire renin-angiotensin-aldosterone system.	Propranolol	0-11	renin	Homo sapiens	66-71
2879220-7	1986	Propranolol, a beta-adrenergic antagonist, is thought to suppress renin secretion from the juxtaglomerular apparatus in the kidney by blocking its beta-adrenergic receptor, thus suppressing the entire renin-angiotensin-aldosterone system.	Propranolol	0-11	renin	Homo sapiens	201-206
2878817-0	1986	(-)-Propranolol blocks the inhibition of serotonergic dorsal raphe cell firing by 5-HT1A selective agonists.	Propranolol	0-15	5-hydroxytryptamine receptor 1A	Homo sapiens	82-88
2878817-1	1986	The ability of the beta-adrenoceptor antagonist propranolol to block the effects of serotonin (5-HT) and 5-HT1A-selective agonists on the spontaneous firing of serotonergic dorsal raphe neurons was assessed.	Propranolol	48-59	5-hydroxytryptamine receptor 1A	Homo sapiens	105-111
3741465-3	1986	For the capacity-limited uptake process of propranolol, the kinetic parameters in 7-week-old rats, were estimated as Vmax = 0.609 microgram X (10(6) cells)-1 X sec-1 and Km = 8.17 micrograms/ml, whereas in 24-week-old rats, Vmax = 0.348 microgram X (10(6) cells)-1 X sec-1 and Km = 9.40 micrograms/ml.	Propranolol	43-54	secretory blood group 1	Rattus norvegicus	160-165
3741465-3	1986	For the capacity-limited uptake process of propranolol, the kinetic parameters in 7-week-old rats, were estimated as Vmax = 0.609 microgram X (10(6) cells)-1 X sec-1 and Km = 8.17 micrograms/ml, whereas in 24-week-old rats, Vmax = 0.348 microgram X (10(6) cells)-1 X sec-1 and Km = 9.40 micrograms/ml.	Propranolol	43-54	secretory blood group 1	Rattus norvegicus	267-272
3525749-2	1986	Recent studies suggest that several drugs, specifically carbamazepine, propranolol, and lithium, may alleviate rage outbursts.	Propranolol	71-82	long intergenic non-protein coding RNA 914	Homo sapiens	111-115
3017797-3	1986	The adrenergic receptor mediating the adrenaline effect was characterized by concomitant infusion of propranolol (beta 1 + beta 2-antagonist) or metoprolol (beta 1-antagonist).	Propranolol	101-112	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	114-120
3017797-3	1986	The adrenergic receptor mediating the adrenaline effect was characterized by concomitant infusion of propranolol (beta 1 + beta 2-antagonist) or metoprolol (beta 1-antagonist).	Propranolol	101-112	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	123-129
3017797-9	1986	Propranolol, but not metoprolol, reversed this insulin-antagonistic effect of adrenaline.	Propranolol	0-11	insulin	Homo sapiens	47-54
2873027-4	1986	In the presence of propranolol (10(-5) M), a beta-adrenergic blocking agent, clonidine (10(-5) and 10(-4) M) stimulated GRF release more prominently in a dose-related manner, whereas propranolol (10(-5) and 10(-4) M) by itself did not affect the spontaneous GRF release.	Propranolol	19-30	growth hormone releasing hormone	Rattus norvegicus	120-123
2873027-5	1986	The stimulatory effect of clonidine (10(-4) M) on GRF release in the presence of propranolol was inhibited by yohimbine (10(-4) M), an alpha 2-adrenergic blocking agent.	Propranolol	81-92	growth hormone releasing hormone	Rattus norvegicus	50-53
2873027-4	1986	In the presence of propranolol (10(-5) M), a beta-adrenergic blocking agent, clonidine (10(-5) and 10(-4) M) stimulated GRF release more prominently in a dose-related manner, whereas propranolol (10(-5) and 10(-4) M) by itself did not affect the spontaneous GRF release.	Propranolol	19-30	growth hormone releasing hormone	Rattus norvegicus	258-261
2875397-5	1986	The decrease in lymphocyte beta 2-adrenoceptor density induced by pindolol could be completely prevented by simultaneous administration of propranolol (3 X 40 mg/day) indicating that the PAA of pindolol is the cause of its beta-adrenoceptor decreasing effect.	Propranolol	139-150	adrenoceptor beta 2	Homo sapiens	27-46
2873027-4	1986	In the presence of propranolol (10(-5) M), a beta-adrenergic blocking agent, clonidine (10(-5) and 10(-4) M) stimulated GRF release more prominently in a dose-related manner, whereas propranolol (10(-5) and 10(-4) M) by itself did not affect the spontaneous GRF release.	Propranolol	183-194	growth hormone releasing hormone	Rattus norvegicus	120-123
3016611-4	1986	The beta-antagonist propranolol (1 microM) completely blocked the NE-induced enhancement of Ca2+ signals in the dentate.	Propranolol	20-31	carbonic anhydrase 2	Homo sapiens	92-95
3722513-3	1986	The variation in blood pressure response between the two groups was statistically significant and represents a mild manifestation of the blockade of beta-2 receptors of the vascular beds from the propranolol.	Propranolol	196-207	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	149-155
3015695-2	1986	5"-GMP induced biphasic chronotropic and inotropic responses: positive those were inhibited with propranolol, the negative inotropic response could not be inhibited with atropine.	Propranolol	97-108	5'-nucleotidase, cytosolic II	Homo sapiens	3-6
3013070-5	1986	Adding propranolol reduces cAMP levels in normal cells, while it increases levels in otosclerotic cells.	Propranolol	7-18	cathelicidin antimicrobial peptide	Homo sapiens	27-31
3520212-1	1986	We have previously shown that the increase in energy expenditure following glucose/insulin infusion is, in large part, mediated by the sympathetic nervous system and that this sympathetic component can be blocked by the nonselective beta-1, beta-2 antagonist propranolol.	Propranolol	259-270	insulin	Homo sapiens	83-90
3520212-1	1986	We have previously shown that the increase in energy expenditure following glucose/insulin infusion is, in large part, mediated by the sympathetic nervous system and that this sympathetic component can be blocked by the nonselective beta-1, beta-2 antagonist propranolol.	Propranolol	259-270	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	233-239
3520212-1	1986	We have previously shown that the increase in energy expenditure following glucose/insulin infusion is, in large part, mediated by the sympathetic nervous system and that this sympathetic component can be blocked by the nonselective beta-1, beta-2 antagonist propranolol.	Propranolol	259-270	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	241-247
3013070-6	1986	The different behavior of calcium metabolism and cAMP levels after stimulation with calcitonin, depending upon the presence or absence of propranolol, seems to indicate an alteration of the transducing mechanism between stimulus, receptor, and cellular effector in otosclerotic cells.	Propranolol	138-149	cathelicidin antimicrobial peptide	Homo sapiens	49-53
3009325-7	1986	Propranolol suppressed the aldosterone response to angiotensin II, but dopamine still inhibited the response.	Propranolol	0-11	angiotensinogen	Homo sapiens	51-65
3947392-4	1986	As part of a general autacoid-serum protein binding screen, the platelet activating factor-alpha-1-acid glycoprotein (PAF-AAG) interaction was indirectly characterized by examining the ability of PAF to displace propranolol from AAG.	Propranolol	212-223	PCNA clamp associated factor	Homo sapiens	118-121
3006981-15	1986	The finding that at an equivalent reduction in Vo2max propranolol reduced performance time to a greater extent than atenolol suggests that beta 2-blockade may reduce performance by mechanisms additional to those that affect oxygen transport.	Propranolol	54-65	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	139-145
2939208-10	1986	Ambulatory monitoring showed a significant 24-h reduction of SBP after administration of propranolol (P less than 0.0025) and ketanserin (A:P less than 0.0025, B: P less than 0.005).	Propranolol	89-100	selenium binding protein 1	Homo sapiens	61-64
2423728-0	1986	Inhibitory action of propranolol on the contractions induced by nerve stimulations or calcium in the smooth muscle of rat vas deferens.	Propranolol	21-32	arginine vasopressin	Rattus norvegicus	122-125
2423728-10	1986	These results suggest that propranolol inhibits contractions by decreasing Ca-influx through the potential-operated Ca-channels in the smooth muscle cells of rat vas deferens.	Propranolol	27-38	arginine vasopressin	Rattus norvegicus	162-165
3009217-3	1986	Clone P-49 was monospecific for propranolol, with a significant preference for the 1-stereoisomer, as compared to the d form.	Propranolol	32-43	nuclear factor of kappa light polypeptide gene enhancer in B cells 2, p49/p100	Mus musculus	6-10
3009217-6	1986	When ascites cells from clone P-28 were fixed with glutaraldehyde, the anti-propranolol monoclonal antibody became cell bound.	Propranolol	76-87	B cell receptor associated protein 31	Mus musculus	30-34
3009217-7	1986	These cell-bound P-28 antibodies bind propranolol and other beta-adrenergic ligands with a similar ranking order to the soluble monoclonal antibody.	Propranolol	38-49	B cell receptor associated protein 31	Mus musculus	17-21
3010692-5	1986	Propranolol increased the CD-25 from 1.8 +/- 0.3 micrograms after placebo to 39 +/- 8 micrograms and atenolol increased the CD-25 to 8 +/- 2 micrograms.	Propranolol	0-11	interleukin 2 receptor subunit alpha	Homo sapiens	26-31
3010692-8	1986	The CD-25 with propranolol decreased after atropine (39 +/- 8 versus 25 +/- 5 micrograms) and was due to diminished plasma propranolol concentrations as the drug sensitivity (measured by Ka) was unchanged before (12 +/- 2 ml/ng) and after (10 +/- 3 ml/ng) atropine.	Propranolol	15-26	interleukin 2 receptor subunit alpha	Homo sapiens	4-9
3010692-8	1986	The CD-25 with propranolol decreased after atropine (39 +/- 8 versus 25 +/- 5 micrograms) and was due to diminished plasma propranolol concentrations as the drug sensitivity (measured by Ka) was unchanged before (12 +/- 2 ml/ng) and after (10 +/- 3 ml/ng) atropine.	Propranolol	123-134	interleukin 2 receptor subunit alpha	Homo sapiens	4-9
3947392-4	1986	As part of a general autacoid-serum protein binding screen, the platelet activating factor-alpha-1-acid glycoprotein (PAF-AAG) interaction was indirectly characterized by examining the ability of PAF to displace propranolol from AAG.	Propranolol	212-223	PCNA clamp associated factor	Homo sapiens	196-199
3947392-5	1986	Both PAF and its deacetylated metabolite (lyso-PAF), at 20 microM, doubled the fraction unbound of propranolol (0.4 microM) from purified human AAG (20 microM).	Propranolol	99-110	PCNA clamp associated factor	Homo sapiens	5-8
3947392-5	1986	Both PAF and its deacetylated metabolite (lyso-PAF), at 20 microM, doubled the fraction unbound of propranolol (0.4 microM) from purified human AAG (20 microM).	Propranolol	99-110	PCNA clamp associated factor	Homo sapiens	47-50
3947392-7	1986	Scatchard analysis indicated that PAF competitively displaced propranolol from AAG, causing the apparent affinity constant for propranolol-AAG to decrease from 1.8 X 10(5) M to 6.9 X 10(4) M. PAF behaved qualitatively like chlorpromazine (a documented inhibitor of propranolol binding to AAG), but PAF was less effective at displacing propranolol.	Propranolol	62-73	PCNA clamp associated factor	Homo sapiens	34-37
3947392-7	1986	Scatchard analysis indicated that PAF competitively displaced propranolol from AAG, causing the apparent affinity constant for propranolol-AAG to decrease from 1.8 X 10(5) M to 6.9 X 10(4) M. PAF behaved qualitatively like chlorpromazine (a documented inhibitor of propranolol binding to AAG), but PAF was less effective at displacing propranolol.	Propranolol	62-73	PCNA clamp associated factor	Homo sapiens	192-195
3947392-7	1986	Scatchard analysis indicated that PAF competitively displaced propranolol from AAG, causing the apparent affinity constant for propranolol-AAG to decrease from 1.8 X 10(5) M to 6.9 X 10(4) M. PAF behaved qualitatively like chlorpromazine (a documented inhibitor of propranolol binding to AAG), but PAF was less effective at displacing propranolol.	Propranolol	62-73	PCNA clamp associated factor	Homo sapiens	192-195
3947392-7	1986	Scatchard analysis indicated that PAF competitively displaced propranolol from AAG, causing the apparent affinity constant for propranolol-AAG to decrease from 1.8 X 10(5) M to 6.9 X 10(4) M. PAF behaved qualitatively like chlorpromazine (a documented inhibitor of propranolol binding to AAG), but PAF was less effective at displacing propranolol.	Propranolol	127-138	PCNA clamp associated factor	Homo sapiens	34-37
3947392-7	1986	Scatchard analysis indicated that PAF competitively displaced propranolol from AAG, causing the apparent affinity constant for propranolol-AAG to decrease from 1.8 X 10(5) M to 6.9 X 10(4) M. PAF behaved qualitatively like chlorpromazine (a documented inhibitor of propranolol binding to AAG), but PAF was less effective at displacing propranolol.	Propranolol	127-138	PCNA clamp associated factor	Homo sapiens	192-195
3947392-7	1986	Scatchard analysis indicated that PAF competitively displaced propranolol from AAG, causing the apparent affinity constant for propranolol-AAG to decrease from 1.8 X 10(5) M to 6.9 X 10(4) M. PAF behaved qualitatively like chlorpromazine (a documented inhibitor of propranolol binding to AAG), but PAF was less effective at displacing propranolol.	Propranolol	127-138	PCNA clamp associated factor	Homo sapiens	192-195
3947392-7	1986	Scatchard analysis indicated that PAF competitively displaced propranolol from AAG, causing the apparent affinity constant for propranolol-AAG to decrease from 1.8 X 10(5) M to 6.9 X 10(4) M. PAF behaved qualitatively like chlorpromazine (a documented inhibitor of propranolol binding to AAG), but PAF was less effective at displacing propranolol.	Propranolol	127-138	PCNA clamp associated factor	Homo sapiens	34-37
3947392-7	1986	Scatchard analysis indicated that PAF competitively displaced propranolol from AAG, causing the apparent affinity constant for propranolol-AAG to decrease from 1.8 X 10(5) M to 6.9 X 10(4) M. PAF behaved qualitatively like chlorpromazine (a documented inhibitor of propranolol binding to AAG), but PAF was less effective at displacing propranolol.	Propranolol	127-138	PCNA clamp associated factor	Homo sapiens	192-195
3947392-7	1986	Scatchard analysis indicated that PAF competitively displaced propranolol from AAG, causing the apparent affinity constant for propranolol-AAG to decrease from 1.8 X 10(5) M to 6.9 X 10(4) M. PAF behaved qualitatively like chlorpromazine (a documented inhibitor of propranolol binding to AAG), but PAF was less effective at displacing propranolol.	Propranolol	127-138	PCNA clamp associated factor	Homo sapiens	192-195
2935435-1	1986	The activity of phosphofructokinase in the perfused rabbit psoas muscle was investigated after perfusion in the presence of either propranolol or isoproterenol, and after 48 hr starvation.	Propranolol	131-142	ATP-dependent 6-phosphofructokinase, muscle type	Oryctolagus cuniculus	16-35
3002196-10	1986	The increase in ANG II release during isoproterenol (10(-6) M) infusion was blocked by propranolol (10(-6) M).	Propranolol	87-98	angiotensinogen	Rattus norvegicus	16-22
2869769-2	1986	Dibucaine, tetracaine, and propranolol, a beta-blocking agent, nonspecifically inhibited the activities of NADPH-ferrihemoprotein reductase as well as of stearoyl-CoA desaturase and the terminal component, but lidocaine and procaine had no effect on these activities.	Propranolol	27-38	stearoyl-CoA desaturase	Homo sapiens	154-177
3007162-8	1986	Plasma renin substrate was reduced by enalapril, but raised by propranolol.	Propranolol	63-74	renin	Homo sapiens	7-12
2439825-0	1986	Effect of propranolol, alprenolol, pindolol, and bopindolol on beta 2-adrenoceptor density in human lymphocytes.	Propranolol	10-21	adrenoceptor beta 2	Homo sapiens	63-82
2439825-5	1986	Propranolol treatment (4 X 40 mg/day) increased the density of beta 2-adrenoceptors by 25% after 2 days; during treatment beta 2-adrenoceptor density remained elevated.	Propranolol	0-11	adrenoceptor beta 2	Homo sapiens	63-82
2439796-3	1986	These models are then used to derive the subtype-selectivity of the classical beta-adrenoceptor antagonists (+/-)-propranolol (prop; twofold beta 2-selective) and (+/-)-atenolol (aten; 35-fold beta 1-selective), as well as of the newer antagonists (+/-)-betaxolol and (+/-)-bisoprolol (betax and biso; 35-fold and 75-fold beta 1-selective, respectively).	Propranolol	108-125	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	141-147
2439825-6	1986	After withdrawal of propranolol, beta 2-adrenoceptor density declined slowly, being still significantly increased after 3 days, although propranolol was not detectable in plasma after 24 h, though heart rate was significantly increased.	Propranolol	20-31	adrenoceptor beta 2	Homo sapiens	33-52
2427860-2	1986	Propranolol (unselective; no ISA; 4 X 40 mg/day) increased beta 2-adrenoceptor density by 25-40%; after withdrawal beta 2-adrenoceptor density declined slowly, being still elevated for 3 days.	Propranolol	0-11	adrenoceptor beta 2	Homo sapiens	59-78
2439798-9	1986	Assessing the data for a beta 1/beta 2-splitting as 1 for propranolol, the relative beta 1-selectivity (mean +/- SEM) was 12.2 +/- 1.1 for bisoprolol, 9.0 +/- 0.9 for metoprolol, 6.2 +/- 0.6 for acebutolol, and 0.6 +/- 0.06 for penbutolol.	Propranolol	58-69	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	25-31
2439798-9	1986	Assessing the data for a beta 1/beta 2-splitting as 1 for propranolol, the relative beta 1-selectivity (mean +/- SEM) was 12.2 +/- 1.1 for bisoprolol, 9.0 +/- 0.9 for metoprolol, 6.2 +/- 0.6 for acebutolol, and 0.6 +/- 0.06 for penbutolol.	Propranolol	58-69	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	32-38
2439798-9	1986	Assessing the data for a beta 1/beta 2-splitting as 1 for propranolol, the relative beta 1-selectivity (mean +/- SEM) was 12.2 +/- 1.1 for bisoprolol, 9.0 +/- 0.9 for metoprolol, 6.2 +/- 0.6 for acebutolol, and 0.6 +/- 0.06 for penbutolol.	Propranolol	58-69	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	84-90
3084458-2	1986	Treatment with steroids, propylthiouracil, propranolol, iodine, and plasmapheresis was associated with dramatic reduction in serum triiodothyronine (T3), serum thyroxine (T4), and thyroglobulin levels and prompt recovery of the patient.	Propranolol	43-54	thyroglobulin	Homo sapiens	180-193
3724981-11	1986	Bicuculline and propranolol decreased plasma PRL below that observed for restrained animals alone, while phentolamine and morphine slightly retarded the course of the decrease.	Propranolol	16-27	prolactin	Rattus norvegicus	45-48
3005063-4	1985	and 3) Effect of furosemide, upright posture, both furosemide and upright posture, propranolol, indomethacin, 9 alpha-fluorocortisol or angiotensin II (A-II) on the serum ACE activity, PRA, PAC and circulating plasma volume (CPV).	Propranolol	83-94	angiotensin I converting enzyme	Homo sapiens	171-174
4092777-1	1985	Effect of calcitonin (CT) upon the AP of contractile cardiomyocytes was absent under conditions of blockade of beta-adrenoreceptors with inderal which reduced the level of intracellular sodium and ionized calcium.	Propranolol	137-144	calcitonin related polypeptide alpha	Homo sapiens	10-20
2866062-3	1985	In a cross-over trial of placebo, atenolol (beta 1-blocker), propranolol (beta 1- and beta 2-blocker) and pindolol (beta 1- and beta 2-blocker with intrinsic sympathomimetic activity) in 11 normal men t1/2 was 11.8 +/- 0.9, 12.6 +/- 1.1, 14.3 +/- 1.7 and 12.4 +/- 1.1 min respectively.	Propranolol	61-72	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	74-80
2865730-0	1985	Blockade of beta 1- but not of beta 2-adrenergic receptors replicates propranolol"s suppression of the cerebral spread of an engram in mice.	Propranolol	70-81	hemoglobin, beta adult major chain	Mus musculus	12-18
2856815-3	1985	This effect appears to be mediated by beta 2-adrenoceptor stimulation, since the exercise-induced increase in beta 2-adrenoceptor density was markedly attenuated by pretreatment of the volunteers with propranolol (5 mg intravenously 45 min before exercise), but not by pretreatment with the beta 1-selective antagonist bisoprolol (2.5 mg intravenously 30 min before exercise).	Propranolol	201-212	adrenoceptor beta 2	Homo sapiens	38-57
2856815-3	1985	This effect appears to be mediated by beta 2-adrenoceptor stimulation, since the exercise-induced increase in beta 2-adrenoceptor density was markedly attenuated by pretreatment of the volunteers with propranolol (5 mg intravenously 45 min before exercise), but not by pretreatment with the beta 1-selective antagonist bisoprolol (2.5 mg intravenously 30 min before exercise).	Propranolol	201-212	adrenoceptor beta 2	Homo sapiens	110-129
2997214-7	1985	Thus, the high affinity binding of (-)-[3H]HBI to membranes prepared from wild-type and cyc- S49 lymphoma cells was stereoselectively inhibited by the active isomers of isoproterenol and propranolol, and was inhibited by GTP.	Propranolol	187-198	peptidylprolyl isomerase A, pseudogene 1	Mus musculus	88-91
2908820-9	1985	ICI 118,551 and propranolol equally blocked the beta 2-receptor mediated fall in diastolic pressure and the rise in noradrenaline.	Propranolol	16-27	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	48-54
4084534-1	1985	Cationic amphiphilic drugs like chlorpromazine, propranolol, and chloroquine inhibit lysosomal phospholipase A in vitro.	Propranolol	48-59	phospholipase A and acyltransferase 1	Rattus norvegicus	95-110
2997437-6	1985	Immunological determination of alpha-1-acid glycoprotein (AGP) revealed a marked increase after laparotomy and a linear relationship was found between the plasma AGP concentration and the binding capacity of high-affinity binding site for propranolol in plasma (r = 0.961, P less than .001).	Propranolol	239-250	orosomucoid 1	Rattus norvegicus	31-56
2997437-6	1985	Immunological determination of alpha-1-acid glycoprotein (AGP) revealed a marked increase after laparotomy and a linear relationship was found between the plasma AGP concentration and the binding capacity of high-affinity binding site for propranolol in plasma (r = 0.961, P less than .001).	Propranolol	239-250	orosomucoid 1	Rattus norvegicus	58-61
2997437-6	1985	Immunological determination of alpha-1-acid glycoprotein (AGP) revealed a marked increase after laparotomy and a linear relationship was found between the plasma AGP concentration and the binding capacity of high-affinity binding site for propranolol in plasma (r = 0.961, P less than .001).	Propranolol	239-250	orosomucoid 1	Rattus norvegicus	162-165
2997437-8	1985	administered propranolol was also correlated with plasma AGP concentration.	Propranolol	13-24	orosomucoid 1	Rattus norvegicus	57-60
2865730-5	1985	Propranolol"s effect consequently appears to be accounted for by its blockade of beta 1 receptors.	Propranolol	0-11	hemoglobin, beta adult major chain	Mus musculus	81-87
2932194-8	1985	The relaxant action of synthetic ANF on the renal vessels was seen in the presence of ouabain (1 mM), propranolol (1 microM), phentolamine (1 microM), atropine (1 microM) and felodipine (1 nM).	Propranolol	102-113	natriuretic peptide A	Rattus norvegicus	33-36
2866582-7	1985	The mechanism of propranolol is similar to that of vasopressin, i.e. it lowers portal pressure by reducing portal flow.	Propranolol	17-28	arginine vasopressin	Homo sapiens	51-62
3901782-7	1985	Propranolol slightly decreased plasma glucose and inhibited the hypokalemic effect of exogenous insulin to the same extent in both lines.	Propranolol	0-11	insulin	Gallus gallus	96-103
2994707-7	1985	The increase in ACTH, however, was greatest in the sulpiride group, intermediate in the controls and correct in the propranolol group.	Propranolol	116-127	proopiomelanocortin	Homo sapiens	16-20
2864782-6	1985	These vascular and motility effects of NPY were resistant to guanethidine, phentolamine, phenoxybenzamine and propranolol.	Propranolol	110-121	neuropeptide Y	Homo sapiens	39-42
2865935-4	1985	Propranolol inhibited mice brain cholinesterase at doses which enhanced Oxo-tremor.	Propranolol	0-11	butyrylcholinesterase	Mus musculus	33-47
2999616-0	1985	The affinity of (-)-propranolol for beta 1- and beta 2-adrenoceptors of human heart.	Propranolol	16-31	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	36-54
2999616-14	1985	(-)-Propranolol antagonized the effects of (-)-noradrenaline mediated by beta 2-adrenoceptors 2 to 3 times more potently than the effects mediated by beta 1-adrenoceptors.	Propranolol	0-15	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	73-79
4017966-5	1985	Treatment of rats with both T3 and 2 mg propranolol resulted in a 62% reduction in the T3-induced increment in situ muscle proteolysis [0.58 +/- 0.02 (n = 8) vs. 0.79 +/- 0.04].	Propranolol	40-51	brachyury 2	Rattus norvegicus	28-36
2864385-9	1985	Propranolol, a beta-antagonist, had little effect on the first depolarization and the first increase in [K+]o, but blocked part of the subsequent [K+]o decrease and the second, slow [K+]o increase.	Propranolol	0-11	amyloid beta precursor protein	Rattus norvegicus	13-19
2989315-0	1985	Augmentation by propranolol of growth hormone-releasing hormone-(1-44)-NH2-induced growth hormone release in normal short and normal children.	Propranolol	16-27	growth hormone releasing hormone	Homo sapiens	31-63
2989315-0	1985	Augmentation by propranolol of growth hormone-releasing hormone-(1-44)-NH2-induced growth hormone release in normal short and normal children.	Propranolol	16-27	growth hormone 1	Homo sapiens	31-45
3913663-7	1985	There was a greater increase in plasma renin activity (PRA) in the normal than in the low CI group before treatment with propranolol.	Propranolol	121-132	renin	Homo sapiens	39-44
3913663-11	1985	Such hemodynamic differences may be abolished by propranolol which has a cardioinhibitory and/or renin-suppressive effect.	Propranolol	49-60	renin	Homo sapiens	97-102
4010477-9	1985	Propranolol, a beta-adrenergic blocker, suppressed the increase in plasma glucose of rats exposed to centrifugation for 0.25 hr.	Propranolol	0-11	amyloid beta precursor protein	Rattus norvegicus	13-19
3003330-4	1985	The results showed that drugs with beta 2-adrenoceptor agonist activity and l-ephedrine caused hyperthermia in rats and this effect was selectively inhibited by pretreatment of animals with propranolol (a mixed beta-adrenoceptor antagonist) or butoxamine (a selective beta 2-adrenoceptor antagonist).	Propranolol	190-201	adrenoceptor beta 2	Rattus norvegicus	35-54
3003330-4	1985	The results showed that drugs with beta 2-adrenoceptor agonist activity and l-ephedrine caused hyperthermia in rats and this effect was selectively inhibited by pretreatment of animals with propranolol (a mixed beta-adrenoceptor antagonist) or butoxamine (a selective beta 2-adrenoceptor antagonist).	Propranolol	190-201	adrenoceptor beta 2	Rattus norvegicus	268-287
2410671-4	1985	Propranolol inhibited ACAT in normal rat aorta, atheromatous rabbit aorta, and in isolated microsomes from atheromatous rabbit aorta, and in isolated microsomes from atheromatous rabbit aorta.	Propranolol	0-11	sterol O-acyltransferase 1	Oryctolagus cuniculus	22-26
3897518-6	1985	The rise in mean plasma insulin concentration was inhibited most effectively by combined treatment with propranolol, phentolamine and atropine, which was significantly more effective than administration of atropine to lambs with cut splanchnic nerves (P less than 0.01).	Propranolol	104-115	LOC105613195	Ovis aries	24-31
3894036-3	1985	Propranolol partially blocked the increase in plasma renin concentration produced by anesthetics.	Propranolol	0-11	renin	Rattus norvegicus	53-58
3887159-4	1985	Both groups had a similar significant (P less than 0.05) increase in the plasma norepinephrine level in response to surgery; however, when compared with no treatment, treatment with propranolol reduced not only the rise in systolic (P = 0.004) and diastolic (P = 0.003) blood pressure but also the postoperative increase in plasma renin activity (P less than 0.01).	Propranolol	182-193	renin	Homo sapiens	331-336
3994770-0	1985	Modification of propranolol binding to alpha-1-acid glycoprotein by serum albumin.	Propranolol	16-27	albumin	Homo sapiens	68-81
3995701-5	1985	Aortic acyl CoA:cholesterol acyltransferase and lysosomal enzyme activities were reduced by propranolol administration, but the inhibition may have been secondary to the lesser degrees of atherosclerosis and cholesterol accumulation present.	Propranolol	92-103	sterol O-acyltransferase 1	Oryctolagus cuniculus	7-43
3995701-6	1985	In vitro inhibition of acyl CoA:cholesterol acyltransferase activity by either dl- or d-propranolol was also observed, but occurred only at propranolol concentrations of 10(-3) M or greater.	Propranolol	88-99	sterol O-acyltransferase 1	Oryctolagus cuniculus	23-59
2410671-7	1985	Propranolol, metoprolol, prazosin, and chlorthalidone also inhibited LCAT in human plasma, whereas nadolol showed no inhibitory effect.	Propranolol	0-11	lecithin-cholesterol acyltransferase	Homo sapiens	69-73
2581076-10	1985	The decrease in the noradrenaline release rate produced by propranolol alone may not be due to blockade of facilitatory presynaptic beta-adrenoceptors, but rather to depression of renin secretion.	Propranolol	59-70	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	180-185
3993544-4	1985	Systemic vascular resistance was maintained and even slightly increased after propranolol despite a decrease in cardiac output, indicating beta 2-adrenergic blockade.	Propranolol	78-89	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	139-145
3157193-7	1985	Significant and divergent influences were exerted by 6-OHDA and propranolol drug regimens on myofibrillar CPK/ATPase enzyme activity ratio.	Propranolol	64-75	dynein axonemal heavy chain 8	Homo sapiens	110-116
3920853-4	1985	Thyroxine binding globulin (TBG) concentration fell during propranolol treatment while thyroxine binding prealbumin (TBPA) concentration rose.	Propranolol	59-70	serpin family A member 7	Homo sapiens	0-26
3920853-4	1985	Thyroxine binding globulin (TBG) concentration fell during propranolol treatment while thyroxine binding prealbumin (TBPA) concentration rose.	Propranolol	59-70	serpin family A member 7	Homo sapiens	28-31
3893341-0	1985	Renin response to captopril in conscious dogs pretreated with indomethacin or propranolol.	Propranolol	78-89	renin	Canis lupus familiaris	0-5
3893341-9	1985	Statistical analysis did not give a definite evidence that propranolol inhibits captopril-induced renin release.	Propranolol	59-70	renin	Canis lupus familiaris	98-103
3894624-1	1985	The effects of the adrenoceptor blocking agents, phentolamine and propranolol, on the release of pancreatic glucagon and insulin in response to exogenous glucose have been investigated in conscious 2--6-week-old calves.	Propranolol	66-77	insulin	Bos taurus	121-128
3894624-3	1985	However, the rise in mean plasma insulin concentration was effectively abolished by pre-treatment with propranolol alone and there was a small but significant fall in mean plasma glucagon concentration which was not observed in any of the other groups.	Propranolol	103-114	insulin	Bos taurus	33-40
3981461-2	1985	The effects of 6-MBOA on NAT activity can be blocked by propranolol but not by prazosin, suggesting that 6-MBOA acts on the beta receptor.	Propranolol	56-67	N-acetyltransferase 1	Rattus norvegicus	25-28
2983567-4	1985	beta-Adrenoceptor blockade with propranolol blunted the renin secretion rate (RSR) response to graded RNS (0.3-5.0 Hz), but the extent of inhibition during low-frequency RNS was dependent on RPP.	Propranolol	32-43	renin	Canis lupus familiaris	56-61
2578477-5	1985	Eserine, amantadine, nicotine, atropine, benzylamine, and propranolol inhibit cathepsin D in concentrations causing proteolytic inhibition in cell cultures or in concentrations believed to be attained in lysosomes.	Propranolol	58-69	cathepsin D	Homo sapiens	78-89
2859043-5	1985	Ambulatory monitoring of HR showed that subjects spent 13% of their waking day at heart rates below 50 beats min-1 while on propranolol, compared with 1% on placebo and 20% on atenolol and betaxolol.	Propranolol	124-135	CD59 molecule (CD59 blood group)	Homo sapiens	109-114
3881933-3	1985	Thus, propranolol seems to decrease portal venous pressure by reducing portal venous flow, at least in part, as a result of reduction of cardiac output due to its beta 1 adrenergic receptor blocking action.	Propranolol	6-17	adrenoceptor beta 1	Homo sapiens	163-189
3915317-5	1985	Propranolol could be titrated from 40 to 240 mg BID.	Propranolol	0-11	BH3 interacting domain death agonist	Homo sapiens	48-51
2858568-1	1985	The effect of low (50 micrograms) and high (1 mg) doses of the histamine H2-receptor antagonists cimetidine and ranitidine on the first pass extraction of propranolol was studied in the rat isolated perfused liver.	Propranolol	155-166	histamine receptor H 2	Rattus norvegicus	63-84
2934070-4	1985	From day 8 to 14 of the study propranolol was given additionally in a dose of 80 mg bid.	Propranolol	30-41	BH3 interacting domain death agonist	Homo sapiens	84-87
2987340-9	1985	Following propranolol the renin response to reduction of the renal perfusion pressure was delayed and reduced, and cold stimulation, both alone and in combination with arterial obstruction, failed to stimulate renin release.	Propranolol	10-21	renin	Homo sapiens	26-31
3884574-5	1985	Treatment with ANG II (200 micrograms/kg sc) and propranolol, a beta-adrenoceptor antagonist (6 mg/kg ip), resulted in a greater depression of colonic temperature (Tco) than was observed with ANG II alone but did not affect the increase in tail skin temperature (Tsk) accompanying administration of ANG II.	Propranolol	49-60	angiotensinogen	Rattus norvegicus	192-198
3884574-5	1985	Treatment with ANG II (200 micrograms/kg sc) and propranolol, a beta-adrenoceptor antagonist (6 mg/kg ip), resulted in a greater depression of colonic temperature (Tco) than was observed with ANG II alone but did not affect the increase in tail skin temperature (Tsk) accompanying administration of ANG II.	Propranolol	49-60	angiotensinogen	Rattus norvegicus	192-198
4096539-4	1985	Phenothiazines (trifluoperazine and chlorpromazine), mepacrine, propranolol, and colchicine inhibited the effect of the purified epidermal calmodulin on the calmodulin-deficient phosphodiesterase of bovine heart.	Propranolol	64-75	calmodulin-3	Sus scrofa	139-149
4096539-4	1985	Phenothiazines (trifluoperazine and chlorpromazine), mepacrine, propranolol, and colchicine inhibited the effect of the purified epidermal calmodulin on the calmodulin-deficient phosphodiesterase of bovine heart.	Propranolol	64-75	calmodulin-3	Sus scrofa	157-167
4026815-1	1985	Recently propranolol was found to inhibit human lecithin: cholesterol acyl transferase (LCAT) activity both after oral treatment and after addition to plasma in vitro.	Propranolol	9-20	lecithin-cholesterol acyltransferase	Homo sapiens	48-86
4026815-1	1985	Recently propranolol was found to inhibit human lecithin: cholesterol acyl transferase (LCAT) activity both after oral treatment and after addition to plasma in vitro.	Propranolol	9-20	lecithin-cholesterol acyltransferase	Homo sapiens	88-92
4026815-2	1985	Now the dose-response relationship of the propranolol effect on LCAT activity was evaluated in vitro.	Propranolol	42-53	lecithin-cholesterol acyltransferase	Homo sapiens	64-68
4026815-5	1985	The maximal effect (propranolol-sensitive LCAT activity) varied between subjects depending on the preexiting lecithin: cholesterol acyl transfer rate in plasma.	Propranolol	20-31	lecithin-cholesterol acyltransferase	Homo sapiens	42-46
4026815-6	1985	Propranolol mediated inhibition of LCAT activity could be abolished when heat-inactivated plasma instead of native plasma was used as LCAT substrate.	Propranolol	0-11	lecithin-cholesterol acyltransferase	Homo sapiens	35-39
4026815-6	1985	Propranolol mediated inhibition of LCAT activity could be abolished when heat-inactivated plasma instead of native plasma was used as LCAT substrate.	Propranolol	0-11	lecithin-cholesterol acyltransferase	Homo sapiens	134-138
4026815-7	1985	It is concluded that the interindividual variability of propranolol-sensitive LCAT activity may reflect differences in the thermoinstable lipoprotein structure.	Propranolol	56-67	lecithin-cholesterol acyltransferase	Homo sapiens	78-82
2862033-3	1985	Oral beta-blockade with propranolol raised the basal serum levels of myoglobin and enhanced the exercise-related rise in serum myoglobin concentrations during ergometer cycling to exhaustion.	Propranolol	24-35	myoglobin	Homo sapiens	69-78
2862033-3	1985	Oral beta-blockade with propranolol raised the basal serum levels of myoglobin and enhanced the exercise-related rise in serum myoglobin concentrations during ergometer cycling to exhaustion.	Propranolol	24-35	myoglobin	Homo sapiens	127-136
2865145-12	1985	Possible mechanisms for this protective effect of propranolol may include a reduction in plasma renin activity, a reduction in pulmonary oedema, prevention of myocardial infarcts, and a reduction in cerebral oxygen requirements.	Propranolol	50-61	renin	Homo sapiens	96-101
2857149-7	1985	The fasting-induced decreases in the serum insulin concentration were more pronounced in dogs treated with propranolol.	Propranolol	107-118	insulin	Canis lupus familiaris	43-50
3895329-8	1985	The hydralazine-induced renin release was remarkably suppressed by either indomethacin Or propranolol.	Propranolol	90-101	renin	Rattus norvegicus	24-29
3965362-4	1985	In patients with severe liver disease (serum albumin less than 30 g/l) propranolol remained detectable in plasma 24 hours after the single 20 mg dose and high steady state concentrations (mean 266.5 ng/ml, range 84-406) were observed during regular dosing.	Propranolol	71-82	albumin	Homo sapiens	45-52
3965362-6	1985	We suggest that in patients with severe liver chronic disease (serum albumin less than 30 g/l), propranolol therapy should be initiated in hospital.	Propranolol	96-107	albumin	Homo sapiens	69-76
6098874-3	1984	Combined propranolol and phenoxybenzamine pretreatment enhanced NPY output upon nerve stimulation by about 60%.	Propranolol	9-20	neuropeptide Y	Homo sapiens	64-67
6097220-6	1984	Stimulation of mucin release by isoproterenol (10 microM), noradrenaline (10 microM) or adrenaline (10 microM) was inhibited by propranolol (30 microM) but not by phentolamine (30 microM).	Propranolol	128-139	solute carrier family 13 member 2	Rattus norvegicus	15-20
6150553-5	1984	In one of the two tissues that increased AC in response to isoproterenol, the beta-blocking drugs propranolol hydrochloride, bunitrolol hydrochloride, and tolilprolol hydrochloride decreased AC stimulation to isoproterenol at concentrations of 10(-6) M (p less than 0.05).	Propranolol	98-123	adenylate cyclase 1	Homo sapiens	41-43
6150553-5	1984	In one of the two tissues that increased AC in response to isoproterenol, the beta-blocking drugs propranolol hydrochloride, bunitrolol hydrochloride, and tolilprolol hydrochloride decreased AC stimulation to isoproterenol at concentrations of 10(-6) M (p less than 0.05).	Propranolol	98-123	adenylate cyclase 1	Homo sapiens	191-193
6150553-6	1984	Higher concentrations of propranolol (10(-4) - 10(-2) M) decreased AC stimulation to thyroid-stimulating hormone (p less than 0.01), not only in this responsive tissue but also in tissues that failed to demonstrate high-affinity binding for 125I-ICYP and AC stimulation to isoproterenol (p less than 0.01).	Propranolol	25-36	adenylate cyclase 1	Homo sapiens	67-69
6150553-6	1984	Higher concentrations of propranolol (10(-4) - 10(-2) M) decreased AC stimulation to thyroid-stimulating hormone (p less than 0.01), not only in this responsive tissue but also in tissues that failed to demonstrate high-affinity binding for 125I-ICYP and AC stimulation to isoproterenol (p less than 0.01).	Propranolol	25-36	adenylate cyclase 1	Homo sapiens	255-257
6150553-8	1984	High concentrations of propranolol in vitro decreased AC response by thyroid-stimulating hormone, but this is probably a nonreceptor-mediated effect.	Propranolol	23-34	adenylate cyclase 1	Homo sapiens	54-56
6594694-2	1984	Antibodies prepared to a cytochrome P-450 shown to be responsible for debrisoquine 4-hydroxylation in rats were found to inhibit the oxidation of debrisoquine and sparteine, encainide, and propranolol, three other drugs suggested to be associated with this phenotype, in human liver microsomes.	Propranolol	189-200	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	25-41
6481168-7	1984	The effect of sera, total immunoglobulins, and purified IgG were blocked by propranolol, suggesting the involvement of beta-adrenoreceptor in the reaction.	Propranolol	76-87	immunoglobulin heavy chain (V7183 family)	Mus musculus	56-59
6548729-0	1984	Effect of talinolol and the optical isomers of propranolol on LCAT activity in vitro.	Propranolol	47-58	lecithin-cholesterol acyltransferase	Homo sapiens	62-66
6548729-2	1984	Both D-propranolol and L-propranolol inhibited LCAT activity, the former being a little more effective.	Propranolol	5-18	lecithin-cholesterol acyltransferase	Homo sapiens	47-51
6092538-4	1984	Propranolol, a beta-adrenergic blocker, could block the increase of S-100 protein release by catecholamines, indicating that the release was mediated by the beta-adrenergic effect of catecholamines.	Propranolol	0-11	S100 calcium binding protein A1	Homo sapiens	68-73
6096938-7	1984	The apparent ED50 for stimulation of renin release by ISO was 6 X 10(-8)M and the response was antagonized by the beta-adrenergic antagonist dl-propranolol.	Propranolol	141-155	renin	Rattus norvegicus	37-42
6149447-8	1984	Phentolamine infusion did not modify the SLI or glucagon response to acute elevations of FFA, whereas propranolol suppressed the increase of SLI without preventing the concomitant decrease of IRG.	Propranolol	102-113	SHC adaptor protein 2	Homo sapiens	141-144
6149777-4	1984	TRH appeared to bean antagonist of atropine and physostigmine by locomotor activity and hypnotic effect of hexenal and to be an agonist of phenylephrine, isadrin, amphetamine and an antagonist of phentolamine and propranolol as shown by behavioral tests.	Propranolol	213-224	thyrotropin releasing hormone	Mus musculus	0-3
6095974-6	1984	The beta-adrenergic antagonist propranolol inhibits O2 production much less effectively and appears to competitively inhibit the reaction of catalase with epinephrine.	Propranolol	31-42	catalase	Homo sapiens	141-149
6496709-7	1984	Peripheral alpha-adrenergic blockade with phentolamine and beta-adrenergic blockade with propranolol blocked the cardiovascular responses to injection of vasopressin in the locus coeruleus.	Propranolol	89-100	arginine vasopressin	Rattus norvegicus	154-165
6095326-3	1984	Because vasopressin and dynorphin are sometimes co-localized, it was hypothesized that naloxone-sensitive feeding might be selectively inhibited by beta-adrenergic blockade with propranolol.	Propranolol	178-189	arginine vasopressin	Rattus norvegicus	8-19
6384249-0	1984	Chronic propranolol administration impairs glucagon release during insulin-induced hypoglycemia in normal man.	Propranolol	8-19	insulin	Homo sapiens	67-74
6434220-2	1984	Nitroprusside-induced hypotension was associated with increases in heart rate, cardiac output, plasma renin activity (PRA), and catecholamine levels; these changes were prevented by propranolol.	Propranolol	182-193	renin	Homo sapiens	102-107
6487471-5	1984	The differences in the effect on tremor of withdrawal of treatment with propranolol or atenolol in doses which produced similar reductions in heart rate, emphasise the beta 2 classification of peripheral receptors associated with normal muscle tremor but do not exclude the involvement of beta 1-adrenoceptors.	Propranolol	72-83	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	168-174
6476994-1	1984	Propranolol hydrochloride is reported to lower portal pressure and inhibit renin secretion in patients with chronic liver disease, actions that might lessen the tendency to ascites formation.	Propranolol	0-25	renin	Homo sapiens	75-80
6383035-2	1984	The greatest systolic blood pressure decrease (35 +/- 5 mm Hg) by propranolol occurred in the high-renin group (n = 9), and the smallest decrease (3 +/- 2 mm Hg) in the low-renin group (n = 9), whereas in the normal-renin group (n = 13), systolic blood pressure was decreased by propranolol by 22 +/- 5 mm Hg.	Propranolol	66-77	renin	Homo sapiens	99-104
6383035-3	1984	For all the propranolol-treated patients, the decrement in the systolic blood pressure by propranolol was related to the control plasma renin activity (r = 0.63, p less than 0.01) and to the concurrent change in plasma renin activity (r = 0.70, p less than 0.001).	Propranolol	12-23	renin	Homo sapiens	136-141
6383035-3	1984	For all the propranolol-treated patients, the decrement in the systolic blood pressure by propranolol was related to the control plasma renin activity (r = 0.63, p less than 0.01) and to the concurrent change in plasma renin activity (r = 0.70, p less than 0.001).	Propranolol	12-23	renin	Homo sapiens	219-224
6383035-3	1984	For all the propranolol-treated patients, the decrement in the systolic blood pressure by propranolol was related to the control plasma renin activity (r = 0.63, p less than 0.01) and to the concurrent change in plasma renin activity (r = 0.70, p less than 0.001).	Propranolol	90-101	renin	Homo sapiens	136-141
6383035-3	1984	For all the propranolol-treated patients, the decrement in the systolic blood pressure by propranolol was related to the control plasma renin activity (r = 0.63, p less than 0.01) and to the concurrent change in plasma renin activity (r = 0.70, p less than 0.001).	Propranolol	90-101	renin	Homo sapiens	219-224
6466702-0	1984	Effect of propranolol and cycloheximide on the ethanol-induced increase in liver tryptophan oxygenase activity in starved rats.	Propranolol	10-21	tryptophan 2,3-dioxygenase	Rattus norvegicus	81-101
6086282-0	1984	The beta-adrenoceptor-blocking drug propranolol prevents secretion of immunoreactive beta-endorphin and alpha-melanocyte-stimulating hormone in response to certain stress stimuli.	Propranolol	36-47	proopiomelanocortin	Rattus norvegicus	104-140
6381275-3	1984	The plasma levels of insulin were increased by beta-receptor stimulation (isoproterenol, phentolamine + epinephrine) and decreased by alpha-receptor stimulation (epinephrine, norepinephrine, propranolol + epinephrine).	Propranolol	191-202	insulin	Oryctolagus cuniculus	21-28
6487464-1	1984	The binding of propranolol enantiomers to human albumin (ALB), alpha 1-acid glycoprotein (alpha 1-AGP) and plasma was studied.	Propranolol	15-26	albumin	Homo sapiens	48-55
6487464-1	1984	The binding of propranolol enantiomers to human albumin (ALB), alpha 1-acid glycoprotein (alpha 1-AGP) and plasma was studied.	Propranolol	15-26	albumin	Homo sapiens	57-60
6375731-12	1984	The reciprocal changes in lipase activities occurring during norepinephrine perfusion were hampered by colchicine and propranolol, pointing towards beta-receptor and microtubular mediation of tissue lipase processing and endothelial binding.	Propranolol	118-129	lipase G, endothelial type	Rattus norvegicus	26-32
6086560-7	1984	A beta-adrenergic blocking drug, propranolol (PR) was infused at .35 mg/min for 15 min in eight experiments on five ewes.	Propranolol	33-44	amyloid beta precursor protein	Homo sapiens	0-6
6389660-4	1984	All children submitted to propranolol followed by exercise (n = 14) and to bromocriptine followed by exercise (n = 6) responded with a satisfactory increase in plasma GH levels.	Propranolol	26-37	growth hormone 1	Homo sapiens	167-169
6094273-10	1984	In one patient with hyperthyroidism, administration of propranolol decreased PRA from 3.4 to 2.3 ng/ml/h, corresponding to an apparent decrease in serum ACE activity from 38.7 to 29.6 U/ml.	Propranolol	55-66	angiotensin I converting enzyme	Homo sapiens	153-156
6147121-0	1984	Betaxolol and propranolol in glucagon stimulation of growth hormone.	Propranolol	14-25	growth hormone 1	Homo sapiens	53-67
6734048-5	1984	With long-acting propranolol, there was no significant airway dilation after 200 micrograms salbutamol but there was after 600 and 1800 micrograms inhaled salbutamol; baseline sGaw rose from 2.02 +/- 0.17 to 2.70 +/- 0.28 and 2.95 +/- 0.32 kPa-1 X sec-1.	Propranolol	17-28	secretory blood group 1, pseudogene	Homo sapiens	248-253
6747823-5	1984	Whereas the standard calmodulin antagonist W-7 inhibited both parameters by approximately 50% at 10(-4) M, diazoxide, hydralazine, 3-isobutyl-1-methylxanthine, papaverine, propranolol, nifedipine, nitrendipine, sodium nitroprusside and verapamil did not significantly inhibit either parameter at equimolar concentrations.	Propranolol	172-183	calmodulin 1	Homo sapiens	21-31
6146236-9	1984	Furthermore, PVR increased markedly with pretreatment with propranolol, although pretreatment with phenoxybenzamine prevented the large increase in PVR.	Propranolol	59-70	PVR cell adhesion molecule	Canis lupus familiaris	13-16
6375797-8	1984	Propranolol, at a dose (8 micrograms min-1) which suppressed renin secretion after isoprenaline stimulation, had no effect on the response to frusemide in indomethacin-treated rats.	Propranolol	0-11	renin	Rattus norvegicus	61-66
6468493-0	1984	Adrenal function and the action of propranolol in surgical stress-mediated insulin resistance of glucose utilization by peripheral tissues in vivo.	Propranolol	35-46	insulin	Oryctolagus cuniculus	75-82
6468493-2	1984	The effect of acute adrenalectomy and the action of propranolol on insulin-stimulated glucose utilization was investigated in an in vivo model of peripheral tissues of the rabbit after evisceration and nephrectomy.	Propranolol	52-63	insulin	Oryctolagus cuniculus	67-74
6468493-11	1984	Propranolol abolished the insulin resistance of glucose utilization of peripheral tissues mediated by the adrenals after surgical preparation of the rabbits.	Propranolol	0-11	insulin	Oryctolagus cuniculus	26-33
6468503-1	1984	(-)-Propranolol displaced 5-HT1 and 5-HT1B receptor binding (pIC50 6.76 and 6.31 respectively) and antagonized the inhibitory effect of 5-HT on continuous K+ (25 mM) evoked release of [3H]5-HT from superfused rat frontal cortex slices (apparent pA2 6.67).	Propranolol	0-15	5-hydroxytryptamine receptor 1B	Rattus norvegicus	36-42
6732837-2	1984	Numerous cationic amphiphilic drugs including imipramine, propranolol, 4,4"-bis(diethylaminoethoxy)-alpha, beta- diethyldiphenylethane and chloropromazine inhibit phospholipase A.	Propranolol	58-69	phospholipase A and acyltransferase 1	Rattus norvegicus	163-178
6326157-7	1984	The isoproterenol-induced rises in beta-END-LI and alpha-MSH-LI were inhibited by the beta-adrenergic blocker propranolol.	Propranolol	110-121	proopiomelanocortin	Rattus norvegicus	51-60
6327487-9	1984	A significant correlation was found between the CD25 measured after continuous propranolol administration and plasma propranolol level.	Propranolol	79-90	interleukin 2 receptor subunit alpha	Homo sapiens	48-52
6330618-2	1984	This protective action of TRH was blocked by pretreatment with the beta-adrenergic antagonist propranolol (5 mg/kg), or by prior administration of the cardioselective beta 1-antagonist, metoprolol (5 mg/kg), but not by pretreatment with the beta 2-selective antagonist, butoxamine (5 mg/kg).	Propranolol	94-105	thyrotropin releasing hormone	Mus musculus	26-29
6324691-3	1984	Epinephrine activation of phosphorylase was antagonized more efficiently by phenoxybenzamine, an alpha-antagonist, than by propranolol, a beta-antagonist, in normal rats, whereas it was antagonized totally by propranolol but only partially by phenoxybenzamine in cholestatic rat hepatocytes.	Propranolol	123-134	amyloid beta precursor protein	Rattus norvegicus	136-142
6376017-0	1984	Oral propranolol and metoprolol both impair glucose recovery from insulin-induced hypoglycemia in insulin-dependent diabetes mellitus.	Propranolol	5-16	insulin	Homo sapiens	66-73
6376017-4	1984	However, oral administration of the relatively selective beta 1-adrenergic antagonist metoprolol (100 mg) and of the nonselective beta-adrenergic antagonist propranolol (80 mg) both impaired recovery from insulin-induced hypoglycemia in patients with IDDM.	Propranolol	157-168	insulin	Homo sapiens	205-212
6144502-9	1984	Conversely, propranolol may decrease circulating parathyroid hormone levels and correct the hypercalcaemia seen in hyperparathyroidism.	Propranolol	12-23	parathyroid hormone	Homo sapiens	49-68
6327487-9	1984	A significant correlation was found between the CD25 measured after continuous propranolol administration and plasma propranolol level.	Propranolol	117-128	interleukin 2 receptor subunit alpha	Homo sapiens	48-52
6089015-5	1984	A beta-adrenergic effect was antagonized by propranolol but only slightly by fluphenazine.	Propranolol	44-55	amyloid beta precursor protein	Homo sapiens	0-6
6377465-2	1984	dl-Propranolol inhibited the gastrin response to hypoglycaemia markedly and more than the insignificant alteration observed after d-propranolol.	Propranolol	0-14	gastrin	Homo sapiens	29-36
6326950-8	1984	Finally, selective blockade of beta-adrenoceptive sites by propranolol diminished the effect of TRH.	Propranolol	59-70	thyrotropin releasing hormone	Mus musculus	96-99
6739457-3	1984	Noradrenaline injection to animals (1.5 to 15 micrograms/100 g) or preincubation of the hepatic homogenate with noradrenaline (10(-6) to 10(-3) M) produces a rise of the catalase activity (mainly of its bound form), being blocked by actinomycine D and non-blocked by propranolol.	Propranolol	267-278	catalase	Rattus norvegicus	170-178
6329569-0	1984	Effects of propranolol and hemodialysis on the response of glucose, insulin, C-peptide and cyclic AMP to glucagon challenge.	Propranolol	11-22	insulin	Homo sapiens	77-86
6372506-6	1984	The beta-antagonist propranolol inhibited the cold-induced increase in lipoprotein lipase activity.	Propranolol	20-31	lipoprotein lipase	Rattus norvegicus	71-89
6329569-3	1984	Propranolol was shown to have significant suppressive effect on the insulin response during OGTT.	Propranolol	0-11	insulin	Homo sapiens	68-75
6463285-5	1984	In addition, the moderate inhibition exerted by the beta-adrenergic blocker D,L-propranolol on VIP effects argued against the implication of beta-adrenergic receptors in VIP effects.	Propranolol	76-91	VIP peptides	Macaca fascicularis	95-98
6374488-2	1984	Oral administration of L-dopa plus propranolol induced a potent and sustained GH release in the subjects tested (26 +/- 6 ng/ml).	Propranolol	35-46	growth hormone 1	Homo sapiens	78-80
6370283-6	1984	The growth hormone response to exercise was potentiated by a single dose of metoprolol or propranolol, and after chronic treatment with the drugs.	Propranolol	90-101	growth hormone 1	Homo sapiens	4-18
6376011-0	1984	Effect of propranolol on delayed glucose recovery after insulin-induced hypoglycemia in normal and diabetic subjects.	Propranolol	10-21	insulin	Homo sapiens	56-63
6704473-6	1984	Treatment with propranolol or with butoxamine, a nonspecific beta- and a specific beta 2-adrenergic receptor blocker, respectively, antagonized the testicular hyposensitivity to hCG induced by stress.	Propranolol	15-26	adrenoceptor beta 2	Rattus norvegicus	61-108
6704473-6	1984	Treatment with propranolol or with butoxamine, a nonspecific beta- and a specific beta 2-adrenergic receptor blocker, respectively, antagonized the testicular hyposensitivity to hCG induced by stress.	Propranolol	15-26	hypertrichosis 2 (generalised, congenital)	Homo sapiens	178-181
6331670-10	1984	A similar increase in ganglionic ODC activity by NE was inhibited by an adrenergic blocker, propranolol (0.01 mM), and following axtotomy for a week, but not by denervation.	Propranolol	92-103	ornithine decarboxylase 1	Rattus norvegicus	33-36
6370767-4	1984	When insulin was infused together with adrenaline and propranolol in normal subjects in doses exceeding those given to the diabetics (plasma insulin rose threefold), the rise in glucose production was still threefold greater than in the diabetic patients (p less than 0.02).	Propranolol	54-65	insulin	Homo sapiens	141-148
6376011-10	1984	Thus, propranolol may interfere with glucose recovery after insulin-induced hypoglycemia in diabetic patients by blocking epinephrine"s inhibition of glucose utilization whereas, in normals, propranolol"s effect is largely accounted for by blockade of epinephrine-induced hepatic glucose production.	Propranolol	6-17	insulin	Homo sapiens	60-67
6368584-4	1984	After propranolol infusion, insulin-mediated glucose uptake was significantly reduced, 6.89 +/- 0.41 (P less than 0.02).	Propranolol	6-17	insulin	Homo sapiens	28-35
6695764-11	1984	Patients treated with propranolol had a significant decrease in plasma HDL2 and HDL3 cholesterol levels.	Propranolol	22-33	junctophilin 3	Homo sapiens	71-75
6325675-11	1984	Nephrectomy (but not ligation of the ureters) or injections of propranolol (5 mg/kg, S.C.) to prevent renin secretion prevented the enhancement of deprivation-or serotonin-induced thirst by the low dose of captopril.	Propranolol	63-74	renin	Rattus norvegicus	102-107
6143680-2	1984	retarded the disappearance of noradrenaline induced by the dopamine-beta-hydroxylase (DBH) inhibitor FLA 63, in the hypothalamus, nucleus of the solitary tract (A-2/C-2 area), and lateral reticular nucleus (A-1/C-1 area) regions, while propranolol (20 mg/kg i.p.)	Propranolol	236-247	dopamine beta-hydroxylase	Rattus norvegicus	86-89
6694555-2	1984	Propranolol decreased the pulse rate (P less than 0.01), serum triiodothyronine (T3) level (P less than 0.05), and UHxE (P less than 0.01) without modifying the serum free thyroxine index (FT4I) or parathormone (PTH) level.	Propranolol	0-11	parathyroid hormone	Homo sapiens	212-215
6200729-0	1984	Ethnic differences in response to beta 1-adrenoceptor blockade by propranolol.	Propranolol	66-77	adrenoceptor beta 1	Homo sapiens	34-53
6142645-7	1984	However, the opposite trend was apparent in patients receiving propranolol (10 mg three times a day, titrated to a maximum dose of 120 mg per day); there were decreases in high-density lipoprotein cholesterol, increases in triglycerides, and decreases in lecithin cholesterol acyltransferase, although these changes were not statistically significant.	Propranolol	63-74	lecithin-cholesterol acyltransferase	Homo sapiens	255-291
6143680-5	1984	Chloranolol and propranolol were able to antagonize the fall in adrenaline concentration due to the phenylethanolamine-N-methyltransferase (PNMT) inhibitor, Lilly 87130, only in the region of the solitary tract nucleus.	Propranolol	16-27	phenylethanolamine-N-methyltransferase	Rattus norvegicus	100-138
6143680-5	1984	Chloranolol and propranolol were able to antagonize the fall in adrenaline concentration due to the phenylethanolamine-N-methyltransferase (PNMT) inhibitor, Lilly 87130, only in the region of the solitary tract nucleus.	Propranolol	16-27	phenylethanolamine-N-methyltransferase	Rattus norvegicus	140-144
6428892-2	1984	Growth hormone secretion responded to glucagon-propranolol and showed a good response to arginine.	Propranolol	47-58	growth hormone 1	Homo sapiens	0-14
6323192-7	1984	The beta-adrenergic receptor antagonist propranolol (1.5 mg/kg s.c.), blocked the renin release and tachycardia caused by yohimbine (1 and 3 mg/kg s.c.), and the ganglionic blocking agent chlorisondamine partially inhibited the renin release elicited by 3 mg/kg (s.c.) of yohimbine.	Propranolol	40-51	renin	Rattus norvegicus	82-87
6323192-7	1984	The beta-adrenergic receptor antagonist propranolol (1.5 mg/kg s.c.), blocked the renin release and tachycardia caused by yohimbine (1 and 3 mg/kg s.c.), and the ganglionic blocking agent chlorisondamine partially inhibited the renin release elicited by 3 mg/kg (s.c.) of yohimbine.	Propranolol	40-51	renin	Rattus norvegicus	228-233
6695764-11	1984	Patients treated with propranolol had a significant decrease in plasma HDL2 and HDL3 cholesterol levels.	Propranolol	22-33	HDL3	Homo sapiens	80-84
6143602-5	1984	Propranolol significantly reduced the rise in plasma renin in rats receiving enalapril.	Propranolol	0-11	renin	Rattus norvegicus	53-58
6318856-2	1984	Experiments with a preliminary blockade of beta-adrenoreceptors with propranolol or administration of a beta-blocker following insulin injection demonstrated beta-adrenoreactive brain structures to be involved in the mechanism of action of insulin.	Propranolol	69-80	insulin	Homo sapiens	240-247
6203844-4	1984	Propranolol, a competitive antagonist of beta 2-adrenergic receptor, blocks the inhibition of release and the cAMP accumulation caused by fenoterol.	Propranolol	0-11	adrenoceptor beta 2	Homo sapiens	41-67
6697551-4	1984	Administration of propranolol and methylscopolamine together, reduced the magnitude of the bradycardia by blocking cardiac efferent mechanisms mediating baroreceptor reflexes, but left a persistent residual fall in heart rate which was independent of baroreflexes; on the other hand when the AVP antagonist was given simultaneously with propranolol and methylscopolamine the bradycardia was completely abolished.	Propranolol	18-29	vasopressin-neurophysin 2-copeptin	Oryctolagus cuniculus	292-295
6143667-10	1984	There was an increase in fasting and glucagon-stimulated serum C-peptide concentration during propranolol therapy compared with placebo (p = 0.037 and p = 0.030, respectively), although this was not reflected by a significant change in serum insulin.	Propranolol	94-105	insulin	Homo sapiens	242-249
6363281-0	1984	Plasma renin substrate concentration during chronic propranolol therapy.	Propranolol	52-63	renin	Homo sapiens	7-12
6324970-3	1984	On the contrary in the lesioned animal, iontophoresis of a beta-blocking agent (DL-propranolol) produces a marked inhibition of the serotoninergic unit firing.	Propranolol	80-94	amyloid beta precursor protein	Rattus norvegicus	57-63
6149064-5	1984	Propranolol, a beta antagonist, blocked the effect of (-)-isoproterenol while the alpha antagonist, phentolamine, was less effective.	Propranolol	0-11	amyloid beta precursor protein	Homo sapiens	13-19
6146195-10	1984	The effect could be significantly blocked by propranolol (beta 1 + beta 2-adrenoceptor blocker) and by using in conjunction the beta 1-adrenoceptor blocker practolol and the beta 2-adrenoceptor blocker H 35/25.	Propranolol	45-56	beta-2 adrenergic receptor	Canis lupus familiaris	58-86
6199591-8	1984	beta-Blockade with propranolol (nonselective), 80 mg four times a day, or atenolol (beta 1-selective), 100 mg once a day, antagonized the hypokalemic effect of isoproterenol as well as the rise in norepinephrine, but when isoproterenol was infused in doses high enough to overcome the blockade of the heart rate response, the effects on norepinephrine and potassium were abolished by propranolol and not by atenolol.	Propranolol	384-395	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	84-90
6399315-9	1984	Inhibition of renin release by propranolol or AII-blockade (by saralasin or Hoe 409) delayed recovery of urinary osmolality.	Propranolol	31-42	renin	Rattus norvegicus	14-19
6638670-8	1983	Bronchodilation mediated by VIP persisted after pretreatment with indomethacin or propranolol.	Propranolol	82-93	vasoactive intestinal peptide	Felis catus	28-31
6365642-1	1983	Insulin action was assessed in 5 cytoplasmic islet cell antibody (ICA) positive non-diabetics, 8 ICA positive (type I) non-insulin-treated diabetics, 7 ICA negative insulin-treated diabetics by measurement of steady state plasma glucose (SSPG) levels during a combined intravenous infusion of propranolol, adrenaline, glucose and insulin.	Propranolol	293-304	insulin	Homo sapiens	0-7
6579847-4	1983	DL-Propranolol, a beta 1, beta 2-adrenergic blocking agent, and D-propranolol, a non-beta-blocking isomer with nonspecific membrane stabilizing effects, both produced a significant (P less than 0.01) inhibition of the effects of PGE2 or PGD2 on CFU-E in murine bone marrow cultures.	Propranolol	0-14	hemoglobin, beta adult minor chain	Mus musculus	26-32
6152827-3	1983	The neurotensin-induced inhibitory effect did not follow activation of adrenoceptors or P1-purinoceptors since the effect of the neuropeptide was not antagonized by a combination of phentolamine plus (-)-propranolol, nor by pretreatment with theophylline.	Propranolol	200-215	neurotensin/neuromedin N	Oryctolagus cuniculus	4-15
6419418-1	1983	In 31 hypertensive patients the effect of chronic oral administration of the beta blocking agent propranolol on regional cerebral blood flow (rCBF) was studied, using the non-invasive 133Xenon inhalation technique.	Propranolol	97-108	CCAAT/enhancer binding protein zeta	Rattus norvegicus	142-146
6360452-0	1983	Effect of pindolol and propranolol on plasma renin and aldosterone in patients with renal allograft.	Propranolol	23-34	renin	Homo sapiens	45-50
6360452-3	1983	Both pindolol and propranolol suppressed the significant orthostatic rise of plasma renin activity (PRA) seen without medication.	Propranolol	18-29	renin	Homo sapiens	84-89
6138769-3	1983	Intraventricular injection of PROPR (30 micrograms), MET (40 micrograms), or IPS 339 (20 micrograms) induced a gradual elevation in plasma GH concentrations, whereas ISOPR (30 micrograms) reduced plasma GH.	Propranolol	30-35	gonadotropin releasing hormone receptor	Rattus norvegicus	139-141
6138769-3	1983	Intraventricular injection of PROPR (30 micrograms), MET (40 micrograms), or IPS 339 (20 micrograms) induced a gradual elevation in plasma GH concentrations, whereas ISOPR (30 micrograms) reduced plasma GH.	Propranolol	30-35	gonadotropin releasing hormone receptor	Rattus norvegicus	203-205
6419418-3	1983	Our study shows that during long-term therapy with low doses of propranolol (less than 120 mg/daily) the rCBF is unaffected, but it is increased significantly if higher doses (greater than 120 mg/daily) are used.	Propranolol	64-75	CCAAT/enhancer binding protein zeta	Rattus norvegicus	105-109
6419418-4	1983	In all six patients who served as their own control, as they had basic rCBF measurements before or during low-dose propranolol, the rCBF on high-dose propranolol became significantly increased.	Propranolol	115-126	CCAAT/enhancer binding protein zeta	Rattus norvegicus	132-136
6419418-4	1983	In all six patients who served as their own control, as they had basic rCBF measurements before or during low-dose propranolol, the rCBF on high-dose propranolol became significantly increased.	Propranolol	150-161	CCAAT/enhancer binding protein zeta	Rattus norvegicus	71-75
6419418-4	1983	In all six patients who served as their own control, as they had basic rCBF measurements before or during low-dose propranolol, the rCBF on high-dose propranolol became significantly increased.	Propranolol	150-161	CCAAT/enhancer binding protein zeta	Rattus norvegicus	132-136
6419418-5	1983	The possible mechanisms which may cause the increased rCBF on high-dose propranolol are discussed.	Propranolol	72-83	CCAAT/enhancer binding protein zeta	Rattus norvegicus	54-58
6652563-3	1983	Enzymatic desialylation of human orosomucoid removed 95% of the sialic acid content and reduced the binding affinity of propranolol from 8.4 X 10(5) to 6.0 X 10(5) M-1, but the affinity of progesterone was not affected.	Propranolol	120-131	myoregulin	Homo sapiens	164-167
6624970-0	1983	Use of propranolol for provoked and unprovoked episodes of rage.	Propranolol	7-18	long intergenic non-protein coding RNA 914	Homo sapiens	59-63
6624970-1	1983	The use of propranolol to treat unprovoked rage episodes in brain-damaged patients has recently been reported.	Propranolol	11-22	long intergenic non-protein coding RNA 914	Homo sapiens	43-47
6315136-5	1983	Propranolol (5 mg/kg), a beta 1- and beta 2-adrenoceptor blocking drug, which alone decreases PS, antagonized the PS increase induced by phentolamine, an alpha 1- and alpha 2-adrenoceptor blocking drug.	Propranolol	0-11	adrenoceptor beta 2	Felis catus	37-56
6652563-2	1983	The association constants of propranolol and progesterone binding to native human orosomucoid under physiological conditions were 8.4 X 10(5) and 3.2 X 10(5) M-1, respectively.	Propranolol	29-40	myoregulin	Homo sapiens	158-161
6631308-6	1983	Guanethidine, phentolamine and propranolol all produced a significant fall in the basal concentrations of vasopressin, while guanethidine, phenoxybenzamine and propranolol blocked the increase seen on breathing 12% oxygen in nitrogen.	Propranolol	31-42	arginine vasopressin	Rattus norvegicus	106-117
6319476-0	1983	Propranolol enhances the effect of ACTH on plasma cortisol, but not on aldosterone in man.	Propranolol	0-11	proopiomelanocortin	Homo sapiens	35-39
6319476-1	1983	An accidental observation led to the suspicion that propranolol (P) enhances the effect of exogenous ACTH on plasma cortisol.	Propranolol	52-63	proopiomelanocortin	Homo sapiens	101-105
6354384-12	1983	The five patients taking propranolol had a markedly attenuated renin activity response during and after surgery; the mean plasma renin activity was less than 1.5 ng X ml-1 X hr-1 at all sampling times.	Propranolol	25-36	renin	Homo sapiens	63-68
6645113-4	1983	MAO activities in the brain stem, the medulla oblongata and pons of the SHR were significantly higher than those in WKY at 7 weeks of age, and MAO activity in the brain stem of the propranolol-treated SHR was significantly lower than that in the untreated SHR.	Propranolol	181-192	monoamine oxidase A	Rattus norvegicus	0-3
6645113-4	1983	MAO activities in the brain stem, the medulla oblongata and pons of the SHR were significantly higher than those in WKY at 7 weeks of age, and MAO activity in the brain stem of the propranolol-treated SHR was significantly lower than that in the untreated SHR.	Propranolol	181-192	monoamine oxidase A	Rattus norvegicus	143-146
6645113-5	1983	Propranolol inhibited MAO activity in brain tissue in vitro, and the I50 values of propranolol were identical (1 X 10(-4) M) in SHR and WKY.	Propranolol	0-11	monoamine oxidase A	Rattus norvegicus	22-25
6645113-9	1983	It was concluded that an increase in MAO activity in SHR brain stem may trigger a reduction in noradrenaline content and that propranolol may be responsible for its restoration, thus reducing peripheral sympathetic activity; moreover, the increase in MAO activity in the hearts of SHR may be of genetic origin.	Propranolol	126-137	monoamine oxidase A	Rattus norvegicus	251-254
6354384-12	1983	The five patients taking propranolol had a markedly attenuated renin activity response during and after surgery; the mean plasma renin activity was less than 1.5 ng X ml-1 X hr-1 at all sampling times.	Propranolol	25-36	renin	Homo sapiens	129-134
6195464-5	1983	Maximum reduction was obtained after 4-5 h. Twenty minutes after administration of propranolol, heart rate and plasma renin activity were reduced, and remained so during the following 8 h. Supine plasma noradrenaline concentration did not change significantly after propranolol, but standing levels, showed a tendency to increase as blood pressure fell.	Propranolol	83-94	renin	Homo sapiens	118-123
6416659-3	1983	Propranolol caused a significant (p less than 0.05) reduction in peak oxygen uptake (VO2) during both the 30-s and 4-min tests (30-s ND, 3949 +/- 718 mL X min-1 (means +/- SD); 30-s P, 3408 +/- 778 mL X min-1; 4-min ND, 4058 +/- 409 mL X min-1; 4-min P, 3725 +/- 573 mL X min-1).	Propranolol	0-11	CD59 molecule (CD59 blood group)	Homo sapiens	155-160
6416659-3	1983	Propranolol caused a significant (p less than 0.05) reduction in peak oxygen uptake (VO2) during both the 30-s and 4-min tests (30-s ND, 3949 +/- 718 mL X min-1 (means +/- SD); 30-s P, 3408 +/- 778 mL X min-1; 4-min ND, 4058 +/- 409 mL X min-1; 4-min P, 3725 +/- 573 mL X min-1).	Propranolol	0-11	CD59 molecule (CD59 blood group)	Homo sapiens	203-208
6416659-3	1983	Propranolol caused a significant (p less than 0.05) reduction in peak oxygen uptake (VO2) during both the 30-s and 4-min tests (30-s ND, 3949 +/- 718 mL X min-1 (means +/- SD); 30-s P, 3408 +/- 778 mL X min-1; 4-min ND, 4058 +/- 409 mL X min-1; 4-min P, 3725 +/- 573 mL X min-1).	Propranolol	0-11	CD59 molecule (CD59 blood group)	Homo sapiens	203-208
6416659-3	1983	Propranolol caused a significant (p less than 0.05) reduction in peak oxygen uptake (VO2) during both the 30-s and 4-min tests (30-s ND, 3949 +/- 718 mL X min-1 (means +/- SD); 30-s P, 3408 +/- 778 mL X min-1; 4-min ND, 4058 +/- 409 mL X min-1; 4-min P, 3725 +/- 573 mL X min-1).	Propranolol	0-11	CD59 molecule (CD59 blood group)	Homo sapiens	203-208
6321587-9	1983	Propranolol pretreatment resulted in renin responses after 1 min of stimulation which were similar to the beta-blocked constant RBF group.	Propranolol	0-11	renin	Felis catus	37-42
6313393-6	1983	In like manner, supersensitivity to the vasorelaxant action of isoproterenol was demonstrated in aortic strips precontracted with angiotensin II at 72 and 96 h after propranolol withdrawal.	Propranolol	166-177	angiotensinogen	Rattus norvegicus	130-144
6313393-8	1983	These data indicate that chronic propranolol pretreatment and withdrawal results in the unmasking of supersensitivity to both beta 1 and beta 2 adrenoceptor stimulation.	Propranolol	33-44	adrenoceptor beta 1	Rattus norvegicus	126-156
6138714-10	1983	The AUC values for plasma insulin and also for the plasma insulin-glucagon ratio were significantly increased by (--)-propranolol (500 micrograms/kg i.v.)	Propranolol	113-129	insulin	Canis lupus familiaris	26-33
6138714-10	1983	The AUC values for plasma insulin and also for the plasma insulin-glucagon ratio were significantly increased by (--)-propranolol (500 micrograms/kg i.v.)	Propranolol	113-129	insulin	Canis lupus familiaris	58-65
6649642-0	1983	[The L-DOPA-propranolol test for the evaluation of reserves in secretory growth hormone].	Propranolol	12-23	growth hormone 1	Homo sapiens	73-87
6352385-0	1983	[Diagnostic value of the insulin test with propranolol administration].	Propranolol	43-54	insulin	Homo sapiens	25-32
6688273-9	1983	These results indicate that dextro-isomers of propranolol and INPEA may have a weak beta-2 adrenoceptor antagonistic action.	Propranolol	46-57	beta-2 adrenergic receptor	Canis lupus familiaris	84-103
6138007-6	1983	Indenolol and propranolol markedly lowered the plasma renin activity (PRA) in SHR, RHR and DHR.	Propranolol	14-25	renin	Rattus norvegicus	54-59
6314390-1	1983	Adult male rats were treated chronically with haloperidol (1 mg/kg) daily or propranolol (10 mg/kg bid) and evaluated for changes in shock-induced fighting.	Propranolol	77-88	BH3 interacting domain death agonist	Rattus norvegicus	99-102
6305637-8	1983	High doses of the beta-adrenergic blocker propranolol antagonized the effect of isoproterenol and caused a fall in HIOMT activity in normal rats housed under normal diurnal lighting.	Propranolol	42-53	acetylserotonin O-methyltransferase	Rattus norvegicus	115-120
6197124-1	1983	Propranolol-resistant neurogenic relaxation persisted in (carbachol-contracted) guinea-pig tracheae already relaxed by supramaximal concentrations of vasoactive intestinal polypeptide (VIP).	Propranolol	0-11	VIP peptides	Cavia porcellus	150-183
6197124-1	1983	Propranolol-resistant neurogenic relaxation persisted in (carbachol-contracted) guinea-pig tracheae already relaxed by supramaximal concentrations of vasoactive intestinal polypeptide (VIP).	Propranolol	0-11	VIP peptides	Cavia porcellus	185-188
6884429-1	1983	Both nifedipine a calcium antagonist, and propranolol a beta-adrenergic blocker, are used as protective agents of the ischemic myocardium.	Propranolol	42-53	amyloid beta precursor protein	Rattus norvegicus	54-60
6358580-0	1983	Inhibition of captopril-induced increase in plasma renin activity by propranolol.	Propranolol	69-80	renin	Rattus norvegicus	51-56
6358580-4	1983	First, the effect of propranolol on captopril-induced renin release was examined in conscious rats.	Propranolol	21-32	renin	Rattus norvegicus	54-59
6309505-1	1983	The effect of non-selective beta-blocker propranolol on the changes of plasma GH, prolactin and cortisol level during physical exercise in healthy untrained men has been evaluated.	Propranolol	41-52	prolactin	Homo sapiens	82-91
6344619-3	1983	In this study, the relation between renin activity and therapeutic response to hydrochlorothiazide or propranolol was studied.	Propranolol	102-113	renin	Homo sapiens	36-41
6344619-11	1983	When renin profile was considered, no significant variation in response to hydrochlorothiazide therapy was observed, and there was a greater reduction in diastolic blood pressure in the patients with a high renin profile receiving propranolol.	Propranolol	231-242	renin	Homo sapiens	207-212
6344619-12	1983	In comparing therapeutic response, patients with a low renin profile had a better response to hydrochlorothiazide, and propranolol was more effective in patients with a high renin profile.	Propranolol	119-130	renin	Homo sapiens	174-179
6345501-2	1983	Propranolol, a beta-adrenergic blocking agent, has been reported as effective, in uncontrolled trials, in ameliorating symptoms of tic disorder, tardive dyskinesia, and drug-induced extrapyramidal syndrome.	Propranolol	0-11	amyloid beta precursor protein	Homo sapiens	13-19
6305362-6	1983	The stimulation of ornithine decarboxylase but not the inhibition of S-adenosylmethionine decarboxylase could be abolished by propranolol (10 mg/kg), whereas phentolamine (10 mg/kg) slightly increased ornithine decarboxylase activity even when given alone.	Propranolol	126-137	ornithine decarboxylase, structural 1	Mus musculus	19-42
6305362-6	1983	The stimulation of ornithine decarboxylase but not the inhibition of S-adenosylmethionine decarboxylase could be abolished by propranolol (10 mg/kg), whereas phentolamine (10 mg/kg) slightly increased ornithine decarboxylase activity even when given alone.	Propranolol	126-137	ornithine decarboxylase, structural 1	Mus musculus	201-224
6299641-6	1983	After atropine the CD25 was unchanged after placebo (2.3 +/- 0.3 micrograms) and atenolol (7.7 +/- 1.3 micrograms); it was reduced after propranolol (24.8 +/- 5.0 micrograms), but remained different from atenolol.	Propranolol	137-148	interleukin 2 receptor subunit alpha	Homo sapiens	19-23
6341765-0	1983	Propranolol and hyperthyroidism: serum free fatty acids and glucose-induced insulin release in nondiabetic thyrotoxic patients during treatment to clinical compensation.	Propranolol	0-11	insulin	Homo sapiens	76-83
6341765-7	1983	Serum insulin and insulin:glucose ratios increased promptly, and at 5 min after glucose reached significantly higher levels than in normal subjects, before treatment as well as after clinical compensation with the propranolol therapy.	Propranolol	214-225	insulin	Homo sapiens	18-25
6341765-8	1983	Both the increased levels of FFA and of T3 could be involved in this pattern of the insulin response of nondiabetic thyrotoxic patients, since the secretion of insulin during the first 10 min after intravenous glucose was directly correlated to fasting serum FFA before propranolol, and serum T3 was directly correlated with total insulin response after clinical compensation.	Propranolol	270-281	insulin	Homo sapiens	84-91
6341765-8	1983	Both the increased levels of FFA and of T3 could be involved in this pattern of the insulin response of nondiabetic thyrotoxic patients, since the secretion of insulin during the first 10 min after intravenous glucose was directly correlated to fasting serum FFA before propranolol, and serum T3 was directly correlated with total insulin response after clinical compensation.	Propranolol	270-281	insulin	Homo sapiens	160-167
6341765-8	1983	Both the increased levels of FFA and of T3 could be involved in this pattern of the insulin response of nondiabetic thyrotoxic patients, since the secretion of insulin during the first 10 min after intravenous glucose was directly correlated to fasting serum FFA before propranolol, and serum T3 was directly correlated with total insulin response after clinical compensation.	Propranolol	270-281	insulin	Homo sapiens	160-167
6343807-0	1983	Effects of captopril and propanolol on bradykinin-induced changes in vascular pressures, lymph total protein concentration, and weight in canine forelimbs.	Propranolol	25-35	kininogen 1	Canis lupus familiaris	39-49
6343807-5	1983	Following pretreatment with both captopril and propranolol, the increase in protein efflux and edema formation produced by this larger dose of bradykinin (5 micrograms base/min) was greater than that produced by infusions of this dose of bradykinin alone or after pretreatment with captopril.	Propranolol	47-58	kininogen 1	Canis lupus familiaris	143-153
6343807-5	1983	Following pretreatment with both captopril and propranolol, the increase in protein efflux and edema formation produced by this larger dose of bradykinin (5 micrograms base/min) was greater than that produced by infusions of this dose of bradykinin alone or after pretreatment with captopril.	Propranolol	47-58	kininogen 1	Canis lupus familiaris	238-248
6343807-8	1983	In contrast, the 60-min intravenous infusion of only 5 micrograms base/min of bradykinin following pretreatment with both captopril and propranolol produced profound systemic hypotension and marked increases in protein efflux and edema formation in forelimbs perfused at a controlled flow rate comparable to that produced by the local intraarterial infusion of this dose of bradykinin alone.	Propranolol	136-147	kininogen 1	Canis lupus familiaris	78-88
6339540-2	1983	Propranolol and to a lesser extent atenolol prolonged the hypoglycemic response to insulin.	Propranolol	0-11	insulin	Homo sapiens	83-90
6189542-5	1983	The effect was blocked stereoselectively by 1 muM propranolol, suggesting that it occurred through an interaction with lung beta-adrenoceptors.	Propranolol	50-61	latexin	Homo sapiens	46-49
6298402-4	1983	The beta adrenergic component of renin release, elicited in the presence of phentolamine, was not blocked by indomethacin but abolished by propranolol.	Propranolol	139-150	renin	Canis lupus familiaris	33-38
6189502-0	1983	The effect of propranolol on CSF amine metabolites in psychiatric patients.	Propranolol	14-25	colony stimulating factor 2	Homo sapiens	29-32
6189502-3	1983	The changes in CSF HVA, 5HIAA and MHPG during treatment with propranolol (960 mg/day) in chronic schizophrenic patients were monitored on four occasions over 30 days.	Propranolol	61-72	colony stimulating factor 2	Homo sapiens	15-18
6189502-5	1983	CSF HVA levels were significantly increased by propranolol and the rise continued throughout the 30 day period.	Propranolol	47-58	colony stimulating factor 2	Homo sapiens	0-3
6298402-2	1983	Intrarenal infusions of norepinephrine and epinephrine at doses adjusted to reduce renal blood flow by 20 and 50% of baseline values elicited renin release that was not completely blocked by either alpha adrenoceptor blockade with phentolamine or beta adrenoceptor blockade with propranolol.	Propranolol	279-290	renin	Canis lupus familiaris	142-147
6298402-3	1983	The renin release that persisted during propranolol administration was abolished by the alpha adrenoceptor antagonist, phentolamine, and by the prostaglandin synthetase inhibitor, indomethacin.	Propranolol	40-51	renin	Canis lupus familiaris	4-9
6300355-10	1983	The isoproterenol effect on ACTH release is stereoselective, calcium dependent, and blocked by dl-propranolol but not by phentolamine or practolol.	Propranolol	95-109	pro-opiomelanocortin-alpha	Mus musculus	28-32
6304565-2	1983	The behavioural excitation caused by TRH was antagonized by pretreatment of the rats with either a narcotic receptor antagonist, naloxone, an alpha-adrenergic receptor antagonists, yohimbine, or a dopaminergic receptor antagonist, haloperidol, but not with a beta-adrenergic receptor antagonist, propranolol.	Propranolol	296-307	thyrotropin releasing hormone	Rattus norvegicus	37-40
6129130-3	1983	In organ culture of fetal rat liver, the induction of TAT activity by phenylephrine (100 microM) was not significantly affected by phentolamine (100 microM), whereas it was abolished by a combination of phentolamine and propranolol (both 100 microM).	Propranolol	220-231	tyrosine aminotransferase	Rattus norvegicus	54-57
6130932-1	1983	The influence of acute beta 1-receptor blockade using 50 mg metoprolol or beta 1/beta 2-blockade using 40 mg propranolol resulted in an equipotent reduction of cardiac frequency and systolic blood pressure without influencing diastolic pressure in ten healthy probands.	Propranolol	109-120	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	23-29
6130932-1	1983	The influence of acute beta 1-receptor blockade using 50 mg metoprolol or beta 1/beta 2-blockade using 40 mg propranolol resulted in an equipotent reduction of cardiac frequency and systolic blood pressure without influencing diastolic pressure in ten healthy probands.	Propranolol	109-120	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	74-87
6218831-0	1983	Inhibition of calmodulin-activated Ca2+-ATPase by propranolol and nadolol.	Propranolol	50-61	calmodulin 1	Homo sapiens	14-24
6218831-1	1983	Propranolol, at concentrations ranging from 0.05 to 0.5 mM, inhibits the calmodulin-activated Ca2+-ATPase of human erythrocyte membranes.	Propranolol	0-11	calmodulin 1	Homo sapiens	73-83
6134510-8	1983	Beta-blockers, particularly propranolol and metoprolol, with which we have the most experience, work via beta 2 adrenoceptor blockade in the heart.	Propranolol	28-39	adrenoceptor beta 2	Homo sapiens	105-124
6339104-12	1983	On the other hand, propranolol, a beta-blocking agent, is not only ineffective in suppressing coronary arterial spasm in 82% of the patients, but aggravates coronary arterial spasm in 41% of the patients.	Propranolol	19-30	amyloid beta precursor protein	Homo sapiens	32-38
6341134-8	1983	Propranolol (0.3 mg/kg, IV) prevented the increase of insulin induced by noradrenaline.	Propranolol	0-11	insulin	Canis lupus familiaris	54-61
6129130-4	1983	Isoproterenol and salbutamol caused significant increases in TAT activity, which were not affected by 100 microM atenolol but were completely inhibited by propranolol (100 microM).	Propranolol	155-166	tyrosine aminotransferase	Homo sapiens	61-64
6135797-8	1983	Propranolol, a beta antagonist, delays the first repolarization until the end of nerve stimulation and inhibits the transient hyperpolarization, second depolarization and flavoprotein reduction.	Propranolol	0-11	amyloid beta precursor protein	Rattus norvegicus	13-19
6135409-5	1983	Adrenaline-induced mucin secretion was inhibited by propranolol, but not by tolazoline.	Propranolol	52-63	mucin	Canis lupus familiaris	19-24
6849742-7	1983	6 The measurement of forearm blood flow following intravenous bolus injections of isoprenaline provides useful information about the beta 2-adrenoceptor antagonism of propranolol and practolol.	Propranolol	167-178	adrenoceptor beta 2	Homo sapiens	133-152
6615245-4	1983	Propranolol treatment was associated with consistent and significant decreases in HDL-cholesterol, apoA-I and A-II levels, whereas these changes during the other treatments were neither significant nor consistent.	Propranolol	0-11	apolipoprotein A1	Homo sapiens	99-105
6615245-4	1983	Propranolol treatment was associated with consistent and significant decreases in HDL-cholesterol, apoA-I and A-II levels, whereas these changes during the other treatments were neither significant nor consistent.	Propranolol	0-11	NLR family pyrin domain containing 3	Homo sapiens	110-114
6615245-5	1983	An increase in adipose tissue LPL-activity and a decrease in serum free fatty acids were seen in the propranolol treatment group.	Propranolol	101-112	lipoprotein lipase	Homo sapiens	30-33
6578761-8	1983	The beta-adrenergic agonist, isoproterenol, stimulated immunoreactive mucin secretion from cultured cells to approximately twice the level of unstimulated or propranolol-inhibited controls.	Propranolol	158-169	solute carrier family 13 member 2	Rattus norvegicus	70-75
6830642-0	1983	[Propranolol-exercise test for the study of growth hormone levels in children].	Propranolol	1-12	growth hormone 1	Homo sapiens	44-58
6137325-6	1983	Increases in LDL-C caused by chlorthalidone monotherapy were prevented or reversed by the addition of a beta-blocker, usually propranolol or atenolol (n = 18); increases in LDL-C during clopamide monotherapy were reversed after the addition of the beta-blocker pindolol (10 mg/day, n = 17).	Propranolol	126-137	component of oligomeric golgi complex 2	Homo sapiens	13-18
6138298-5	1983	SCC was not influenced by the beta 1-antagonist atenolol but was modified, although differently in rabbit and man, by the beta 1- and beta 2-antagonist propranolol.	Propranolol	152-163	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	122-140
6628516-8	1983	Plasma insulin was reduced by exercise after beta-blockade, most markedly after propranolol and practolol.	Propranolol	80-91	insulin	Homo sapiens	7-14
6384072-7	1983	It was concluded that: (1) the drugs, pindolol and propranolol, are equally effective as antihypertensive agents; (2) heart function and plasma renin activity are decreased by propranolol and unaltered by pindolol; (3) total peripheral resistance is decreased by pindolol and unaltered by propranolol; and (4) these findings may be explained by the intrinsic sympathomimetic activity exhibited by pindolol only.	Propranolol	176-187	renin	Homo sapiens	144-149
6384072-7	1983	It was concluded that: (1) the drugs, pindolol and propranolol, are equally effective as antihypertensive agents; (2) heart function and plasma renin activity are decreased by propranolol and unaltered by pindolol; (3) total peripheral resistance is decreased by pindolol and unaltered by propranolol; and (4) these findings may be explained by the intrinsic sympathomimetic activity exhibited by pindolol only.	Propranolol	176-187	renin	Homo sapiens	144-149
6420515-5	1983	Furthermore, the fever induced by intrahypothalamic administration of TRH was greatly reduced by pretreatment with intrahypothalamic administration of either yohimbine (a blocking agent of alpha-adrenergic receptors), phentolamine (a blocking agent of alpha-adrenergic receptors) or DL-propranolol (a blocking agent of beta-adrenergic receptors) in the rat.	Propranolol	283-297	thyrotropin releasing hormone	Rattus norvegicus	70-73
6188919-6	1983	It has been demonstrated that beta-blockers with intrinsic sympathomimetic activity (ISA), such as pindolol, and beta 1-selective blockers have a less marked effect on pulmonary function than nonselective beta-blockers without ISA, such as propranolol.	Propranolol	240-251	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	113-119
6319593-3	1983	Drugs (isoproterenol, norepinephrine, or propranolol) known to influence pineal gland NAT activity by acting directly on pinealocyte postsynaptic beta-noradrenoceptors produced comparable changes in enzyme activity at all ages studied, although larger doses of the receptor agonist were required in fetal animals to elevate NAT activity.	Propranolol	41-52	N-acetyltransferase 1	Rattus norvegicus	86-89
6319593-3	1983	Drugs (isoproterenol, norepinephrine, or propranolol) known to influence pineal gland NAT activity by acting directly on pinealocyte postsynaptic beta-noradrenoceptors produced comparable changes in enzyme activity at all ages studied, although larger doses of the receptor agonist were required in fetal animals to elevate NAT activity.	Propranolol	41-52	N-acetyltransferase 1	Rattus norvegicus	324-327
6194272-1	1983	Reserpine- and propranolol-treated rats were given salbutamol, a beta-adrenergic stimulant, intra-peritoneally in an open control study.	Propranolol	15-26	amyloid beta precursor protein	Rattus norvegicus	63-69
6138471-2	1983	The effects of oral doses of pindolol, metoprolol, and propranolol on the response to insulin-induced hypoglycemia and an oral glucose load were investigated.	Propranolol	55-66	insulin	Homo sapiens	86-93
6138471-3	1983	During hypoglycemia metoprolol and propranolol inhibited the clearance of insulin (2 p less than 0.01) and caused a delay of glucose nadirs.	Propranolol	35-46	insulin	Homo sapiens	74-81
6138471-5	1983	Epinephrine secretion and the counterregulatory response of growth hormone, ACTH and cortisol during hypoglycemia was significantly increased following metoprolol and propranolol but not after pindolol.	Propranolol	167-178	proopiomelanocortin	Homo sapiens	76-80
6318223-5	1983	Thus in haemodialysis patients, beta-2 adrenergic blockade by propranolol is associated with a significant increase in serum K not mediated by pH, aldosterone or insulin, and probably due to inhibition of intracellular K uptake.	Propranolol	62-73	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	32-38
6318223-5	1983	Thus in haemodialysis patients, beta-2 adrenergic blockade by propranolol is associated with a significant increase in serum K not mediated by pH, aldosterone or insulin, and probably due to inhibition of intracellular K uptake.	Propranolol	62-73	insulin	Homo sapiens	162-169
6763852-0	1982	[Effects of propranolol and reserpine on the stimulation of plasma renin activity and aldosterone production by furosemide].	Propranolol	12-23	renin	Homo sapiens	67-72
6623176-0	1983	[Blood prolactin level in primary hypothyroidism and its response to methyldopa and obzidan].	Propranolol	84-91	prolactin	Homo sapiens	7-16
6133409-4	1982	Propranolol attenuated both the glucose and insulin responses.	Propranolol	0-11	insulin	Felis catus	44-51
6293310-6	1982	Propranolol (1-20 micrograms/ml) significantly reduced the positive inotropic effect of prolactin.	Propranolol	0-11	prolactin	Rattus norvegicus	88-97
6814898-0	1982	Tetracaine, propranolol and trifluoperazine inhibit thyrotropin releasing hormone-induced prolactin secretion from GH3 cells by displacing membrane calcium: further evidence that TRH acts to mobilize cellular calcium.	Propranolol	12-23	prolactin	Rattus norvegicus	90-99
6754210-6	1982	There were minor, but significant, changes in norepinephrine, renin, and systolic pressure with multiple-dose methyldopa and in renin, heart rate, and systolic and diastolic pressure with propranolol.	Propranolol	188-199	renin	Homo sapiens	128-133
6814898-4	1982	Tetracaine (1 mM), propranolol (1 mM), and trifluoperazine (0.03 mM) inhibited basal and TRH-stimulated prolactin release, decreased cellular 45Ca2+ content and decreased cell-associated CTC fluorescence.	Propranolol	19-30	prolactin	Rattus norvegicus	104-113
6188189-6	1982	Tubocurarine, phentolamine and propranolol blocked the substance P-stimulated guanidinium uptake with half-maximal inhibitory concentrations of 0.5, 5 and 50 microM.	Propranolol	31-42	tachykinin precursor 1	Homo sapiens	55-66
6131020-7	1982	SH rats treated with propranolol showed a leftward shift of the pressor response curve not to norepinephrine but to angiotensin II as compared with that obtained from vehicle treated SH rats.	Propranolol	21-32	angiotensinogen	Rattus norvegicus	116-130
6127946-6	1982	Plasma renin activity was increased from placebo baseline with verapamil (p less than 0.05), but was reduced with propranolol (p less than 0.05); no significant change in plasma aldosterone was seen with either drug.	Propranolol	114-125	renin	Homo sapiens	7-12
6821292-5	1982	The pretreatments with FLA-63, DOPS and phenoxybenzamine were not influenced to the antiataxic effects of TRH, while the pretreatment with propranolol increased the antiataxic effect of TRH in RMN.	Propranolol	139-150	thyrotropin releasing hormone	Mus musculus	186-189
6130038-7	1982	The present results indicate that an inhibition of beta 2-mediated hepatic glycogenolysis by propranolol may also influence blood glucose homeostasis during exercise.	Propranolol	93-104	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	51-57
6126351-3	1982	Propranolol, a beta-adrenergic antagonist, significantly decreased portal venous SS and suppressed the isoproterenol-stimulated increases in the levels of SS, insulin, and glucagon.	Propranolol	0-11	insulin	Canis lupus familiaris	159-166
7152474-0	1982	Propranolol induced changes in plasma catecholamine, corticosterone, T4, T3 and prolactin levels in the pigeon.	Propranolol	0-11	prolactin	Homo sapiens	80-89
6761580-5	1982	The only common effect of trifluoperazine and propranolol, mainly investigated in mammals, was an inhibition of calmodulin activity via direct interaction.	Propranolol	46-57	calmodulin	Saccharomyces cerevisiae S288C	112-122
6754494-8	1982	The endogenous insulin secretion (C-peptide) was inhibited by epinephrine and propranolol in controls and subjects with IGT irrespective of a low (6 mg .	Propranolol	78-89	insulin	Homo sapiens	15-22
6754494-18	1982	In conclusion, our results have confirmed the validity of an infusion technique of glucose, insulin, epinephrine and propranolol for evaluation of insulin sensitivity in vivo.	Propranolol	117-128	insulin	Homo sapiens	147-154
6125474-0	1982	Urinary kallikrein activity, renal hemodynamics, and electrolyte handling during chronic beta blockade with propranolol in hypertension.	Propranolol	108-119	kallikrein related peptidase 4	Homo sapiens	8-18
7049625-3	1982	Alpha-adrenergic stimulation (epinephrine + propranolol) significantly reduced the GIP response (P less than 0.02) and completely inhibited the insulin response (P less than 0.005) to oral glucose, compared with control experiments.	Propranolol	44-55	gastric inhibitory polypeptide	Homo sapiens	83-86
6128255-3	1982	The decrease in the general peripheral resistance due to prolonged propranolol therapy may be determined by activation of the blood kallikrein-kinin system and enhancement of the descending inhibition of the sympathetic nervous system because of activation of the central alpha-adrenoreceptors under long-term blockade of beta-adrenoreceptors of the central nervous system.	Propranolol	67-78	kallikrein related peptidase 4	Homo sapiens	132-142
6127588-4	1982	Alpha-2 adrenergic activation, achieved with 10 muM epinephrine and 30 muM propranolol, significantly inhibited forskolin-stimulated cyclic AMP accumulation and glycerol release, shifting the dose-response curves to the right.	Propranolol	75-86	latexin	Homo sapiens	71-74
6289585-10	1982	Additional experiments in subjects treated with propranolol or indomethacin allowed the conclusion that the effect of ACTH on PRA and P-A II is not mediated by renal beta-adrenergic receptors, but perhaps (partially?)	Propranolol	48-59	proopiomelanocortin	Homo sapiens	118-122
6889972-3	1982	Isoprenaline increased the evoked vasopressin release to a maximum of 60% (EC50 10 nM) and this effect was antagonized surmountably by propranolol.	Propranolol	135-146	arginine vasopressin	Rattus norvegicus	34-45
7102534-6	1982	In contrast, after propranolol on day 0, the CD25 decreased significantly two- to fivefold below baseline from days 4 to 14 (BAS) and after metoprolol two- to threefold below baseline from days 2 to 8.	Propranolol	19-30	interleukin 2 receptor subunit alpha	Homo sapiens	45-49
6761206-5	1982	Similar results were seen in man; significant correlations were observed between height of steady-state plasma insulin concentration and advancing age during infusion of exogenous insulin and suppression of endogenous insulin with either exogenous insulin (r = 0.66, P less than 0.001) or epinephrine and propranolol (r = 0.47, P less than 0.01).	Propranolol	305-316	insulin	Homo sapiens	111-118
6761206-5	1982	Similar results were seen in man; significant correlations were observed between height of steady-state plasma insulin concentration and advancing age during infusion of exogenous insulin and suppression of endogenous insulin with either exogenous insulin (r = 0.66, P less than 0.001) or epinephrine and propranolol (r = 0.47, P less than 0.01).	Propranolol	305-316	insulin	Homo sapiens	180-187
6761206-5	1982	Similar results were seen in man; significant correlations were observed between height of steady-state plasma insulin concentration and advancing age during infusion of exogenous insulin and suppression of endogenous insulin with either exogenous insulin (r = 0.66, P less than 0.001) or epinephrine and propranolol (r = 0.47, P less than 0.01).	Propranolol	305-316	insulin	Homo sapiens	180-187
6761206-5	1982	Similar results were seen in man; significant correlations were observed between height of steady-state plasma insulin concentration and advancing age during infusion of exogenous insulin and suppression of endogenous insulin with either exogenous insulin (r = 0.66, P less than 0.001) or epinephrine and propranolol (r = 0.47, P less than 0.01).	Propranolol	305-316	insulin	Homo sapiens	180-187
7178823-5	1982	The beta-adrenergic blocking agent propranolol strongly inhibited cysteamine-induced gastrin release, whereas atropine dependent on an intact vagus and may be mediated by beta-adrenergic receptors.	Propranolol	35-46	gastrin	Rattus norvegicus	85-92
7051722-1	1982	In a double-blind cross-over trial we compared the effects of placebo and propranolol on iv tolbutamide and oral glipizide-stimulated insulin secretion in 10 non-insulin dependent diabetics.	Propranolol	74-85	insulin	Homo sapiens	134-141
7051722-6	1982	During the oral glipizide-glucose challenge propranolol decreased blood glucose at 60 min (P less than 0.01) and increased C-peptide at 0 min (P less than 0.01) and 30 min (P less than 0.05) compared with placebo.	Propranolol	44-55	insulin	Homo sapiens	123-132
6751023-3	1982	Furthermore, the appearance of insulin in arterial plasma was measured after inhibiting the endogenous insulin secretion of the pigs by epinephrine and propanolol.	Propranolol	152-162	insulin	Sus scrofa	31-38
6809365-0	1982	Propranolol improves the impaired TSH response to TRH in patients with autonomously functioning euthyroid multinodular goitre.	Propranolol	0-11	thyrotropin releasing hormone	Homo sapiens	50-53
6751023-3	1982	Furthermore, the appearance of insulin in arterial plasma was measured after inhibiting the endogenous insulin secretion of the pigs by epinephrine and propanolol.	Propranolol	152-162	insulin	Sus scrofa	103-110
6282573-6	1982	Stimulation of PRL release by l-ISO and E was blocked by the beta-receptor antagonist, propranolol, but not by the alpha-receptor blocker, prazosin.	Propranolol	87-98	prolactin	Homo sapiens	15-18
7082068-5	1982	It continues to be true at this institution that propranolol, a beta-adrenergic blocking agent, effectively neutralizes the symptoms of autonomic hyperactivity, including sweating, tremor, fever, dilation of blood vessels, and increased pulse rate without significantly affecting thyroid function.	Propranolol	49-60	amyloid beta precursor protein	Homo sapiens	62-68
7049777-1	1982	In six patients with chemical diabetes, insulin resistance was assessed by the steady-state plasma glucose (SSPG) level during a constant infusion of epinephrine, propranolol, glucose and insulin.	Propranolol	163-174	insulin	Homo sapiens	40-47
7049783-2	1982	During inhibition of endogenous insulin secretion by epinephrine + propranolol, glucose infusion produced an increase in carbohydrate oxidation when plasma glucose levels reached approximately 200 mg/100 ml.	Propranolol	67-78	insulin	Homo sapiens	32-39
6809365-5	1982	The TSH response to TRH increased significantly during the administration of propranolol.	Propranolol	77-88	thyrotropin releasing hormone	Homo sapiens	20-23
6123523-8	1982	A pressor response also occurred in propranolol-pretreated dogs during insulin hypoglycemia, but was abolished when the animals also had been pretreated with phentolamine, indicating that the vasoconstrictor action of insulin was mediated via alpha adrenergic receptors.	Propranolol	36-47	insulin	Canis lupus familiaris	71-78
6125482-4	1982	VLDL apolipoprotein-B was markedly increased by propranolol (67%), whereas apolipoprotein-A was slightly (8%) increased during metoprolol treatment.	Propranolol	48-59	apolipoprotein B	Homo sapiens	5-21
6123523-11	1982	As propranolol also diminished the inotropic response, it appears that the increase in myocardial blood flow caused by insulin in the normal dog is causally related to the increased myocardial metabolic demand.	Propranolol	3-14	insulin	Canis lupus familiaris	119-126
6125482-5	1982	The reduced low density lipoprotein phospholipids and the increased high density lipoprotein apo-A correlated with the plasma concentration of propranolol and metoprolol, respectively.	Propranolol	143-154	lipoprotein(a)	Homo sapiens	93-98
7050057-4	1982	Experiment 2 was a repetition of experiment 1 on the same subjects, except that propranolol (10 mg iv) was given at the onset of heating to block renin release.	Propranolol	80-91	renin	Homo sapiens	146-151
6288538-4	1982	Insulin treatment, on the other hand, not only improves transfer of a K load, it also alters the response to propranolol.	Propranolol	109-120	insulin	Canis lupus familiaris	0-7
6750084-6	1982	Pre-treatment with propranolol (0.25 mg kg-1) effectively suppressed release of insulin in response to exogenous glucose in atropinized lambs with intact splanchnic nerves, but not in atropinized lambs with cut splanchnic nerves.	Propranolol	19-30	LOC105613195	Ovis aries	80-87
7098380-3	1982	Mean (+/- SE) kinetic variables for IV propranolol were: elimination half-life (t 1/2 beta), 5.3 (+/- 0.6) h; volume of distribution, 2.3 (+/- 0.3) l/kg; total clearance, 4.9 (+/- 0.3) ml/min/kg; predicted extraction ratio, 0.23 (+/- 0.02).	Propranolol	39-50	interleukin 1 receptor like 1	Homo sapiens	80-90
7051046-6	1982	With a modified Krebs-Ringer solution free of plasma kininogen, a renin substrate, it was concluded that propranolol (1) induces PGI2 release from the kidney, which may contribute to a direct antihypertensive action of this beta-adrenergic blocking agent, and (2) decreases urinary kallikrein.	Propranolol	105-116	renin	Homo sapiens	66-71
6281414-9	1982	Increases in the densities of beta-1 and/or beta-2 adrenergic receptors in solid tissues may be related to some of the untoward effects observed in humans after abrupt discontinuation of propranolol administration.	Propranolol	187-198	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	30-41
6281414-9	1982	Increases in the densities of beta-1 and/or beta-2 adrenergic receptors in solid tissues may be related to some of the untoward effects observed in humans after abrupt discontinuation of propranolol administration.	Propranolol	187-198	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	44-50
6281634-11	1982	Potassium delays the increase of plasma renin activity after furosemide and propranolol inhibits the furosemide-induced renin release, both without impairing aldosterone secretion.	Propranolol	76-87	renin	Homo sapiens	120-125
6128186-0	1982	Comparison of the beta 1 and beta 2 adrenoceptor blocking properties of acebutolol and propranolol.	Propranolol	87-98	adrenoceptor beta 1	Homo sapiens	18-48
6128186-1	1982	The purposes of this study were to evaluate the beta 1 and beta 2 adrenoceptor blocking properties of acebutolol and propranolol and measure the plasma levels of acebutolol, its acetylated metabolite and propranolol.	Propranolol	117-128	adrenoceptor beta 1	Homo sapiens	48-78
6280485-5	1982	The persistence of the hypotensive effect of captopril after renin suppression by propranolol suggests that this drug has some blood pressure decreasing properties independent of plasma renin.	Propranolol	82-93	renin	Homo sapiens	61-66
6282327-9	1982	Binding of [125I]CYP and [125I]HBP is stereospecifically inhibited by propranolol and epinephrine; the (-) stereoisomers are at least 50-times more potent than the (+) stereoisomers.	Propranolol	70-81	heme binding protein 1	Homo sapiens	31-34
6120877-4	1982	Propranolol reduced distention-induced gastrin release by approximately 90% (p less than 0.02), whereas phentolamine had no significant effect on the gastrin response to distention.	Propranolol	0-11	gastrin	Homo sapiens	39-46
6120877-5	1982	In additional experiments, we evaluated the effect of the same doses of propranolol or phentolamine on the exaggerated gastrin response to gastric distention that occurred during cholinergic blockade with atropine.	Propranolol	72-83	gastrin	Homo sapiens	119-126
6120877-7	1982	), propranolol significantly (p less than 0.01) reduced distention-induced gastrin release, whereas phentolamine significantly enhanced the gastrin response to distention (p less than 0.01).	Propranolol	3-14	gastrin	Homo sapiens	75-82
6120877-8	1982	We conclude that: (1) distention-induced gastrin release was reduced by propranolol, suggesting that gastric distention releases gastrin by a beta-adrenergic mechanism and (2) distention-induced gastrin release was enhanced by phentolamine, but only in the presence of atropine.	Propranolol	72-83	gastrin	Homo sapiens	41-48
6288548-4	1982	Stimulation of NAT activity by rat serum was partially blocked by metoprolol and propranolol, but not by phentolamine or butoxamine.	Propranolol	81-92	N-acetyltransferase 1	Rattus norvegicus	15-18
6120877-8	1982	We conclude that: (1) distention-induced gastrin release was reduced by propranolol, suggesting that gastric distention releases gastrin by a beta-adrenergic mechanism and (2) distention-induced gastrin release was enhanced by phentolamine, but only in the presence of atropine.	Propranolol	72-83	gastrin	Homo sapiens	129-136
6120877-8	1982	We conclude that: (1) distention-induced gastrin release was reduced by propranolol, suggesting that gastric distention releases gastrin by a beta-adrenergic mechanism and (2) distention-induced gastrin release was enhanced by phentolamine, but only in the presence of atropine.	Propranolol	72-83	gastrin	Homo sapiens	129-136
6127792-6	1982	When propranolol was given in addition during this beta-receptor stimulation, plasma GIP after glucose increased to 82.2 (49.7-145) pM and serum insulin to 61 (9-133) mU/l.	Propranolol	5-16	gastric inhibitory polypeptide	Homo sapiens	85-88
6120716-3	1982	3 Large intravenous doses of propranolol or metoprolol attenuated, without abolishing, the rises in active renin, angiotensin II, and aldosterone; the attenuation was most evident soon after tilting and was largely overcome by 1 h upright.	Propranolol	29-40	renin	Homo sapiens	107-112
6120716-3	1982	3 Large intravenous doses of propranolol or metoprolol attenuated, without abolishing, the rises in active renin, angiotensin II, and aldosterone; the attenuation was most evident soon after tilting and was largely overcome by 1 h upright.	Propranolol	29-40	angiotensinogen	Homo sapiens	114-128
6120716-6	1982	5 Intravenous propranolol or metoprolol attenuated, without abolishing, these early increases in the components of the renin-angiotensin-aldosterone system after frusemide.	Propranolol	14-25	renin	Homo sapiens	119-124
6120716-9	1982	8 Also in contrast to earlier work, we found attenuation by both intravenous propranolol and metoprolol of the immediate rise in renin after intravenous frusemide.	Propranolol	77-88	renin	Homo sapiens	129-134
6121595-3	1982	3 Pretreatment with the beta-adrenoceptor antagonist, propranolol (10 mg/kg), totally blocked the increase in ODC activity.	Propranolol	54-65	ornithine decarboxylase, structural 1	Mus musculus	110-113
6121595-5	1982	5 Since the increase in ODC activity was blocked by a beta-adrenoceptor antagonist (propranolol) and enzyme activity was stimulated by terbutaline, a beta 2-agonist, we conclude that beta 2-adrenoceptors are selectively coupled to the regulation of murine cardiac ODC activity following catecholamine stimulation.	Propranolol	84-95	ornithine decarboxylase, structural 1	Mus musculus	24-27
6279462-6	1982	Conjunct propranolol administration negated the effects of MAO inhibition on both the level of NAT activity and melatonin content, regardless of the lighting conditions.	Propranolol	9-20	monoamine oxidase A	Rattus norvegicus	59-62
6279462-6	1982	Conjunct propranolol administration negated the effects of MAO inhibition on both the level of NAT activity and melatonin content, regardless of the lighting conditions.	Propranolol	9-20	N-acetyltransferase 1	Rattus norvegicus	95-98
7039349-3	1982	During renal arterial constriction, renin release was equal at two perfusion pressures below the range of autoregulation and was 76 +/- 24 micrograms/min higher during isoproterenol than during propranolol administration.	Propranolol	194-205	renin	Homo sapiens	36-41
7039349-5	1982	Intrarenal infusion of glucagon and dopamine increased renin release by 13 +/- 3 and 22 +/- 12 micrograms/min, respectively; enhancement of renin release was also present after propranolol administration.	Propranolol	177-188	renin	Homo sapiens	140-145
7039357-5	1982	Administration of propranolol (iv) or phentolamine directly into the renal artery totally blocked the increase in renin during activation of the reflex.	Propranolol	18-29	renin	Canis lupus familiaris	114-119
7048455-0	1982	[Propranolol effect on renin-angiotensin system kinetics during experimental hyperthyroidism (author"s transl)].	Propranolol	1-12	renin	Rattus norvegicus	23-28
6127792-1	1982	The effect of beta-adrenergic receptor stimulation with isoproterenol and blockade with propranolol on the release of gastric inhibitory polypeptide (GIP) and insulin was investigated in seven healthy volunteers.	Propranolol	88-99	gastric inhibitory polypeptide	Homo sapiens	118-148
6127792-6	1982	When propranolol was given in addition during this beta-receptor stimulation, plasma GIP after glucose increased to 82.2 (49.7-145) pM and serum insulin to 61 (9-133) mU/l.	Propranolol	5-16	insulin	Homo sapiens	145-152
6127792-1	1982	The effect of beta-adrenergic receptor stimulation with isoproterenol and blockade with propranolol on the release of gastric inhibitory polypeptide (GIP) and insulin was investigated in seven healthy volunteers.	Propranolol	88-99	gastric inhibitory polypeptide	Homo sapiens	150-153
6127792-1	1982	The effect of beta-adrenergic receptor stimulation with isoproterenol and blockade with propranolol on the release of gastric inhibitory polypeptide (GIP) and insulin was investigated in seven healthy volunteers.	Propranolol	88-99	insulin	Homo sapiens	159-166
6127792-7	1982	An isoproterenol-induced increase in the concentration of GIP and insulin was thus counteracted by propranolol.	Propranolol	99-110	gastric inhibitory polypeptide	Homo sapiens	58-61
6127792-7	1982	An isoproterenol-induced increase in the concentration of GIP and insulin was thus counteracted by propranolol.	Propranolol	99-110	insulin	Homo sapiens	66-73
6186366-3	1982	The release of TNF was weakly inhibited by the competitive alpha-blocker phentolamine and the beta-blocker propranolol.	Propranolol	107-118	tumor necrosis factor	Mus musculus	15-18
6220762-0	1982	[Inhibition of the biosynthesis of thyroglobulin with propranolol in the rat].	Propranolol	54-65	thyroglobulin	Rattus norvegicus	35-48
6220762-1	1982	Thyroglobulin biosynthesis was studied in thyroid glands of rats treated during 30 days with a daily dose of propranolol, a non-selective beta-adrenergic blocking drug.	Propranolol	109-120	thyroglobulin	Rattus norvegicus	0-13
6220762-7	1982	Propranolol reduces the biosynthesis of thyroglobulin in thyroid gland as well as the formation of T3 from T4 in peripheral tissues; its therapeutical use against thyrotoxicosis is thus justified.	Propranolol	0-11	thyroglobulin	Rattus norvegicus	40-53
6120772-0	1982	Studies on the inhibition by propranolol of some human erythrocyte membrane enzymes and plasma cholinesterase.	Propranolol	29-40	butyrylcholinesterase	Homo sapiens	95-109
6120772-1	1982	Human erythrocyte acetylcholinesterase and the plasma cholinesterase variants are not only inhibited by propranolol but have been found to show stereospecificity for its isomers.	Propranolol	104-115	butyrylcholinesterase	Homo sapiens	24-38
6125166-3	1982	2 When beta-adrenoceptor blockade was produced by (+/-)-propranolol (beta 1 + beta 2-adrenoceptor blockade) which is devoid of intrinsic sympathomimetic activity (ISA) but has membrane stabilizing effects (MSE), sotalol (beta 1 + beta 2-adrenoceptor blockade, no ISA, no MSE) and atenolol (beta 1-adrenoceptor blockade, no ISA, no MSE), all parameters were significantly increased.	Propranolol	50-67	beta-2 adrenergic receptor	Canis lupus familiaris	69-97
6125166-3	1982	2 When beta-adrenoceptor blockade was produced by (+/-)-propranolol (beta 1 + beta 2-adrenoceptor blockade) which is devoid of intrinsic sympathomimetic activity (ISA) but has membrane stabilizing effects (MSE), sotalol (beta 1 + beta 2-adrenoceptor blockade, no ISA, no MSE) and atenolol (beta 1-adrenoceptor blockade, no ISA, no MSE), all parameters were significantly increased.	Propranolol	50-67	beta-2 adrenergic receptor	Canis lupus familiaris	221-249
6125193-2	1982	2 Serum insulin and serum C-peptide secretion in response to a glucose load were inhibited (2P less than 0.01) by metoprolol and propranolol but not by pindolol.	Propranolol	129-140	insulin	Homo sapiens	8-15
6125193-3	1982	3 During hypoglycaemia metoprolol and propranolol inhibited the clearance of insulin (2P less than 0.01) and caused a delay of glucose nadirs.	Propranolol	38-49	insulin	Homo sapiens	77-84
6125193-5	1982	5 The counterregulatory response of growth hormone, ACTH and cortisol was increased following metoprolol and propranolol but not after pindolol.	Propranolol	109-120	growth hormone 1	Homo sapiens	36-50
6125193-5	1982	5 The counterregulatory response of growth hormone, ACTH and cortisol was increased following metoprolol and propranolol but not after pindolol.	Propranolol	109-120	proopiomelanocortin	Homo sapiens	52-56
6186366-11	1982	It is suggested that the inhibition of TNF release by propranolol may be due to the membrane-stabilizing activity of this agent.	Propranolol	54-65	tumor necrosis factor	Mus musculus	39-42
6759143-6	1982	Acute intravenous injection of propranolol decreased plasma renin activity less than did chronic oral treatment with the drug.	Propranolol	31-42	renin	Homo sapiens	60-65
6754155-7	1982	There were minor but significant changes in norepinephrine, renin and systolic pressure with multiple dose clonidine and methyldopa and in renin, heart rate and systolic and diastolic pressure with propranolol.	Propranolol	198-209	renin	Homo sapiens	139-144
6754156-2	1982	Control plasma renin activity tended to be predictive of the response to treatment: it correlated with the diastolic blood pressure changes produced by both the renin-lowering agent, propranolol (r=-.43, P less than 0.001), and the diuretic, chlorthalidone (r= .48, P less than 0.001).	Propranolol	183-194	renin	Homo sapiens	15-20
6754156-2	1982	Control plasma renin activity tended to be predictive of the response to treatment: it correlated with the diastolic blood pressure changes produced by both the renin-lowering agent, propranolol (r=-.43, P less than 0.001), and the diuretic, chlorthalidone (r= .48, P less than 0.001).	Propranolol	183-194	renin	Homo sapiens	161-166
6128148-18	1982	Cyproheptadine (reversibly), methergoline, mianserin and propranolol (all irreversibly) antagonised the response in the GSN.	Propranolol	57-68	gelsolin	Homo sapiens	120-123
6759143-7	1982	The observed time course of plasma renin activity was compatible with the view that suppression of this enzyme contributed to the antihypertensive effect of propranolol.	Propranolol	157-168	renin	Homo sapiens	35-40
6118758-1	1981	Treatment of hypertensive patients with dl-propranolol (640 mg/day) significantly inhibited thromboxane synthesis by their platelets and platelet aggregation induced by thrombin or arachidonic acid.	Propranolol	40-54	coagulation factor II, thrombin	Homo sapiens	169-177
6120887-1	1982	Beta-adrenergic blockade by IV propranolol treatment (5 mg/kg), resulted in an important drop in plasma immunoreactive insulin (IRI) in normal 24-hour fasted ducks, indicating that basal insulin secretion is controlled by beta-adrenergic receptors.	Propranolol	31-42	insulin	Anas platyrhynchos	119-126
6141291-5	1982	A significant decrease in plasma CT levels was observed after propranolol injection in baby rats (0.68 +/- 0.05 ng/ml vs. 0.93 +/- 0.01 ng/ml).	Propranolol	62-73	calcitonin-related polypeptide alpha	Rattus norvegicus	33-35
6281836-4	1982	The jumping elicited by TRH (20 mg/kg IP) in combination with apomorphine (0.25 mg/kg IP) was decreased by pretreatment with haloperidol (1 mg/kg IP), physostigmine (0.2 mg/kg IP) or phentolamine (10 mg/kg IP), unaffected by propranolol (10 mg/kg IP), and markedly increased by atropine (5 mg/kg IP) or clonidine (0.5 mg/kg IP).	Propranolol	225-236	thyrotropin releasing hormone	Mus musculus	24-27
7177292-1	1982	We compared ionized serum calcium and parathyroid hormone (PTH) responses to the beta-adrenergic agents, isoproterenol and propranolol, in 14 patients with hyperparathyroidism following renal transplantation and 8 normal volunteers.	Propranolol	123-134	parathyroid hormone	Homo sapiens	38-57
6121541-0	1981	Effect of chronic propranolol treatment and withdrawal on norepinephrine and tyrosine hydroxylase in sympathetic tissues.	Propranolol	18-29	tyrosine hydroxylase	Homo sapiens	77-97
6117308-3	1981	2 The CSF concentration of propranolol (lipid-soluble) and pindolol (moderately lipid-soluble) was proportional to the free plasma concentration and was similar to, although generally lower than, that theoretically predicted.	Propranolol	27-38	colony stimulating factor 2	Homo sapiens	6-9
7032775-8	1981	The fall in blood pressure following the addition of propranolol was proportional to the dose of the drug but inversely proportional to the change in renin suggesting that renin levels are to some extent determined by the blood pressure response to propranolol rather than themselves determining that response.	Propranolol	53-64	renin	Homo sapiens	150-155
7032775-8	1981	The fall in blood pressure following the addition of propranolol was proportional to the dose of the drug but inversely proportional to the change in renin suggesting that renin levels are to some extent determined by the blood pressure response to propranolol rather than themselves determining that response.	Propranolol	53-64	renin	Homo sapiens	172-177
7032775-8	1981	The fall in blood pressure following the addition of propranolol was proportional to the dose of the drug but inversely proportional to the change in renin suggesting that renin levels are to some extent determined by the blood pressure response to propranolol rather than themselves determining that response.	Propranolol	249-260	renin	Homo sapiens	172-177
7028620-6	1981	The beta-blocker propranolol at 12 micron M halved ISO-stimulated renin, and at 120 micron M eliminated it.	Propranolol	17-28	renin	Rattus norvegicus	66-71
6274461-2	1981	2 The positive inotropic response to insulin remained unaltered in atria depleted of catecholamine or when beta-adrenoceptors were blocked by addition of propranolol to the organ bath.	Propranolol	154-165	insulin	Cavia porcellus	37-44
7188565-8	1981	The application of isoprenaline but not noradrenaline to the culture media increased ODC activity acutely in SMC from WKY rats and this increase was blocked by propranolol.	Propranolol	160-171	ornithine decarboxylase 1	Rattus norvegicus	85-88
7308151-3	1981	The inotropic effect of PTH was partially blocked by propranolol and also suppressed in the papillary muscle of the rat pretreated with reserpine.	Propranolol	53-64	parathyroid hormone	Rattus norvegicus	24-27
7034664-2	1981	Disruption of the renin-angiotensin system by either the angiotensin antagonist saralasin or the beta-blocking agent propranolol does not interfere with chlorothiazide antidiuresis.	Propranolol	117-128	renin	Rattus norvegicus	18-23
7023285-24	1981	Thus propranolol, when given during SNP hypotension, exhibits an early cardiovascular response manifested as a decrease in cardiac output and heart rate and a delayed action of the kidney resulting in an inhibition of renin release.	Propranolol	5-16	renin	Homo sapiens	218-223
6973419-6	1981	Coronary artery bypass grafting in a subgroup of patients did not affect the mean plasma PF4 concentration during 1 year of follow-up after bypass surgery, but medical therapy for angina with increasing doses of propranolol and nitrates significantly reduced PF4 concentration in another subgroup of patients who were not considered to be candidates for surgical therapy.	Propranolol	212-223	platelet factor 4	Homo sapiens	259-262
6271155-0	1981	Effect of beta-adrenergic receptor blockade with propranolol on the response of plasma catecholamines and renin activity to upright tilting in normal subjects.	Propranolol	49-60	renin	Homo sapiens	106-111
7263842-1	1981	Serum immunoreactive parathyroid hormone (iPTH) response to beta-adrenergic blockade by propranolol infusion was determined in 11 normal subjects and 6 patients with primary hyperparathyroidism (PHPT) before and again after the surgical removal of abnormal parathyroid tissue.	Propranolol	88-99	parathyroid hormone	Homo sapiens	21-40
6115732-5	1981	We conclude that whereas it may be possible that 10 mg propranolol acts as a competitive antagonist of isoproterenol at beta 2-sites in skeletal muscle, 40 mg propranolol and 200 mg sotalol must have additional actions in reducing isoproterenol tremor.	Propranolol	55-66	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	120-126
6172048-0	1981	Effects of a beta-receptor blocking agent (propranolol) on synthesis of IgE in vitro by peripheral blood lymphocytes from atopic patients.	Propranolol	43-54	immunoglobulin heavy constant epsilon	Homo sapiens	72-75
6267246-5	1981	We propose that selective covalent binding of the reactive intermediate to the molecular form of cytochrome P-450 that ring hydroxylates propranolol would account for the marked inhibition of propranolol metabolism in vitro and for the increased systemic availability of propranolol in vivo after pretreatment.	Propranolol	137-148	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	97-113
6267246-5	1981	We propose that selective covalent binding of the reactive intermediate to the molecular form of cytochrome P-450 that ring hydroxylates propranolol would account for the marked inhibition of propranolol metabolism in vitro and for the increased systemic availability of propranolol in vivo after pretreatment.	Propranolol	192-203	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	97-113
6267246-5	1981	We propose that selective covalent binding of the reactive intermediate to the molecular form of cytochrome P-450 that ring hydroxylates propranolol would account for the marked inhibition of propranolol metabolism in vitro and for the increased systemic availability of propranolol in vivo after pretreatment.	Propranolol	192-203	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	97-113
6172048-2	1981	Addition of a beta-receptor blocking agent (propranolol) to lymphocytes from 9 of 10 patients with low spontaneous IgE production in vitro caused increased IgE production.	Propranolol	44-55	immunoglobulin heavy constant epsilon	Homo sapiens	115-118
7020487-0	1981	Propranolol alters renin release during nitroprusside-induced hypotension and prevents hypertension on discontinuation of nitroprusside.	Propranolol	0-11	renin	Homo sapiens	19-24
7020487-8	1981	When compared with previous work, these results indicate that propranolol attenuates nitroprusside-induced renin release, reduces the dosage of nitroprusside required to induce hypotension, suppresses reflex tachycardia, and prevents overshoot hypertension on discontinuation of nitroprusside.	Propranolol	62-73	renin	Homo sapiens	107-112
6172048-2	1981	Addition of a beta-receptor blocking agent (propranolol) to lymphocytes from 9 of 10 patients with low spontaneous IgE production in vitro caused increased IgE production.	Propranolol	44-55	immunoglobulin heavy constant epsilon	Homo sapiens	156-159
6172048-4	1981	However, when propranolol was added to the lymphocyte cultures in vitro, production of antigen-specific IgE antibodies was found.	Propranolol	14-25	immunoglobulin heavy constant epsilon	Homo sapiens	104-107
6268188-9	1981	Inhibition of pyruvate kinase activity by epinephrine, isoproterenol or phenylephrine is negated by propranolol but insensitive to phentolamine.	Propranolol	100-111	pyruvate kinase PKLR	Oryctolagus cuniculus	14-29
6795044-5	1981	The counterregulatory hormonal responses of glucagon, cortisol and growth hormone were augmented appropriately for the prolonged hypoglycaemia associated with propranolol.	Propranolol	159-170	growth hormone 1	Homo sapiens	67-81
7018734-0	1981	Effects of indomethacin, renal denervation, and propranolol on plasma renin activity in conscious dogs with chronic thoracic caval constriction.	Propranolol	48-59	renin	Canis lupus familiaris	70-75
7030443-4	1981	In the six patients who completed the whole study, plasma levels of chlorpromazine and chlorpromazine sulphoxide, total serum levels of neuroleptic and serum levels of prolactin were consistently and significantly elevated during treatment with chlorpromazine plus propranolol relative to levels during treatment with chlorpromazine alone.	Propranolol	265-276	prolactin	Homo sapiens	168-177
6114116-4	1981	Propranolol, a beta-adrenergic antagonist that acts competitively by blocking the adenylate cyclase receptor on efferent cells, is well recognized to cause increased airways resistance in some asthmatic and normal subjects.	Propranolol	0-11	amyloid beta precursor protein	Homo sapiens	13-19
7024079-3	1981	Treatment with beta receptor blocking dosages of propranolol significantly reduces K transfer capacity, but it also markedly diminishes the KCl stimulated secretory response of insulin, a powerful mediator of K transfer.	Propranolol	49-60	insulin	Canis lupus familiaris	177-184
6264937-1	1981	1 Plasma propranolol steady state concentration (Css) was determined during chronic dosage (160 mg/day) in 22 hyperthyroid patients (aged 16-75 years, 11 smokers, 11 non-smokers) and again following treatment when euthyroid.	Propranolol	9-20	cytidine monophosphate N-acetylneuraminic acid synthetase	Homo sapiens	49-52
6264937-2	1981	2 There was a positive correlation between plasma propranolol Css and age in patients both when hyperthyroid (r = 0.74, P less than 0.01) and when euthyroid (r = 0.58, P less than 0.05).	Propranolol	50-61	cytidine monophosphate N-acetylneuraminic acid synthetase	Homo sapiens	62-65
6264937-3	1981	3 Plasma propranolol Css in hyperthyroid patients were lower (P less than 0.05) in smokers than in non-smokers.	Propranolol	9-20	cytidine monophosphate N-acetylneuraminic acid synthetase	Homo sapiens	21-24
6264937-4	1981	4 Following correction of hyperthyroidism there was a significant increase (P less than 0.01) in both the plasma propranolol Css and degree of plasma protein binding of propranolol.	Propranolol	113-124	cytidine monophosphate N-acetylneuraminic acid synthetase	Homo sapiens	125-128
7249936-2	1981	He received propranolol and insulin without subsequent problems; however, when the insulin was changed to chlorpropamide, a significant increase in blood sugar occurred.	Propranolol	12-23	insulin	Homo sapiens	83-90
7250533-0	1981	Cardiac arrhythmias during epinephrine-propranolol infusions for measurement of in vivo insulin resistance.	Propranolol	39-50	insulin	Homo sapiens	88-95
6113867-1	1981	1 Stimulation of the renal nerves in the cat was previously shown to cause renin release which could be blocked by propranolol.	Propranolol	115-126	renin	Felis catus	75-80
6265141-0	1981	Effect of propranolol therapy on aldosterone responses to angiotensin II and adrenocorticotropic hormone in essential hypertension.	Propranolol	10-21	angiotensinogen	Homo sapiens	58-72
6265141-0	1981	Effect of propranolol therapy on aldosterone responses to angiotensin II and adrenocorticotropic hormone in essential hypertension.	Propranolol	10-21	proopiomelanocortin	Homo sapiens	77-104
6265141-4	1981	Basal supine plasma renin activity was decreased (P less than 0.001) after propranolol, whereas plasma aldosterone was unchanged.	Propranolol	75-86	renin	Homo sapiens	20-25
7300028-3	1981	The combination of nifedipine (10 mg, sublingually) and propranolol (0.2 mg/Kg body weight, intravenously) decreased blood pressure from 168/104 to 131/86 mmHg with decrease in heart rate and plasma renin activity.	Propranolol	56-67	renin	Homo sapiens	199-204
6117610-6	1981	On the other hand, propranolol did not lower blood pressure in acute experiment while it decreased renin release.	Propranolol	19-30	renin	Rattus norvegicus	99-104
6271426-4	1981	Growth hormone levels were higher (P less than 0.05) both pre- and post-operatively in propranolol-prepared patients, whereas prolactin levels, although similar pre-operatively, were lower (P less than 0.05) in these patients post-operatively.	Propranolol	87-98	growth hormone 1	Homo sapiens	0-14
6117262-4	1981	Atenolol and propranolol prevent genetic hypertension by I) reducing cardiac output, a reduction which is not neutralised by the simultaneous change in peripheral resistance, 2) decreasing plasma renin concentrations, and 3) limiting the development of myocardial hypertrophy.	Propranolol	13-24	renin	Rattus norvegicus	196-201
6264792-8	1981	These data indicate that when beta-adrenoceptors are blocked by propranolol, tonic neural stimulation of renin secretion is mediated by renal alpha-adrenoceptors.	Propranolol	64-75	renin	Canis lupus familiaris	105-110
6271426-5	1981	Cortisol and ACTH levels were lower (P less than 0.05) both before and following thyroidectomy in propranolol-prepared patients.	Propranolol	98-109	proopiomelanocortin	Homo sapiens	13-17
6261815-4	1981	Preferential interaction of propranolol with acidic phospholipid membranes was confirmed using the monolayer compression isotherm technique and the spin-labelling method.	Propranolol	28-39	spindlin 1	Homo sapiens	148-152
6261815-9	1981	Spin-labeling experiments show that propranolol exerts marked ordering effect on bilayers prepared from acidic phospholipids and does not change the order parameter of phosphatidylcholine membranes.	Propranolol	36-47	spindlin 1	Homo sapiens	0-4
7275342-1	1981	Propranolol is widely employed in hemodialysis patients for the control of renin-dependent hypertension.	Propranolol	0-11	renin	Homo sapiens	75-80
7236476-0	1981	Inhibition of the plasma cholinesterase variants by propranolol.	Propranolol	52-63	butyrylcholinesterase	Homo sapiens	25-39
7236476-1	1981	The inhibitory effect of (+/-) propranolol 1.69 x 10(-4)-1.69 x 10(-7) mol litre-1 on normal and atypical plasma cholinesterase variants was investigated.	Propranolol	25-42	butyrylcholinesterase	Homo sapiens	113-127
7014307-2	1981	One method, the insulin suppression test, is performed by continuously infusing epinephrine, propranolol, insulin, and glucose.	Propranolol	93-104	insulin	Homo sapiens	16-23
7014307-3	1981	Epinephrine and propranolol suppress endogenous insulin release, and steady-state plasma levels of exogenous insulin and glucose are reached in all individuals.	Propranolol	16-27	insulin	Homo sapiens	48-55
7259364-7	1981	Under the experimental conditions of this trial, propranolol inhibited beta 1 and beta 2 receptors at the same time, whereas acebutolol inhibited only beta 1 receptors.	Propranolol	49-60	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	71-77
7259364-7	1981	Under the experimental conditions of this trial, propranolol inhibited beta 1 and beta 2 receptors at the same time, whereas acebutolol inhibited only beta 1 receptors.	Propranolol	49-60	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	82-88
7275342-2	1981	Infrequent reports have linked hypoglycemia and propranolol, especially in complex situations such as malnutrition, anesthesia, and excessive insulin use.	Propranolol	48-59	insulin	Homo sapiens	142-149
7253755-0	1981	[Response of growth hormone (GH) to glucagon-propranolol stimulation in diabetic subjects (author"s transl)].	Propranolol	45-56	growth hormone 1	Homo sapiens	13-27
7253755-0	1981	[Response of growth hormone (GH) to glucagon-propranolol stimulation in diabetic subjects (author"s transl)].	Propranolol	45-56	growth hormone 1	Homo sapiens	29-31
6113715-2	1981	In contrast to Talinolol under the treatment ith the unspecific beta-blocker Propranolol a clear blocking of the beta 2-mediated glycogenolysis which can be evoked with the help of Orciprenalin and of the lipolysis evocable via beta 1-receptors was observed.	Propranolol	77-88	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	113-119
7016643-3	1981	However, recovery of blood glucose in the presence of propranolol (3 mg/3 min and 0.8 mg/min) was retarded when compared with control studies (mean plasma glucose levels +/- SEM , 50 +/- 6 mg/dl versus 66 +/- 4 mg/dl at 120 min after insulin administration) despite appropriate glucagon, epinephrine, cortisol, and growth hormone responses.	Propranolol	54-65	insulin	Homo sapiens	234-241
7016643-3	1981	However, recovery of blood glucose in the presence of propranolol (3 mg/3 min and 0.8 mg/min) was retarded when compared with control studies (mean plasma glucose levels +/- SEM , 50 +/- 6 mg/dl versus 66 +/- 4 mg/dl at 120 min after insulin administration) despite appropriate glucagon, epinephrine, cortisol, and growth hormone responses.	Propranolol	54-65	growth hormone 1	Homo sapiens	315-329
6113715-2	1981	In contrast to Talinolol under the treatment ith the unspecific beta-blocker Propranolol a clear blocking of the beta 2-mediated glycogenolysis which can be evoked with the help of Orciprenalin and of the lipolysis evocable via beta 1-receptors was observed.	Propranolol	77-88	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	228-234
6111139-1	1981	A beta-blocker, propranolol, was infused to control and irradiated rats the 1st and 3rd day after 2-kR X-ray irradiation.	Propranolol	16-27	amyloid beta precursor protein	Rattus norvegicus	0-6
7035987-4	1981	Propranolol reduced the rise in plasma renin activity and aldosteronuria provoked by the diuretic; total sodium output/24 h remained stable but sodium elimination was increased in the later samples.	Propranolol	0-11	renin	Homo sapiens	39-44
7005474-3	1981	After the initial dose-finding period of four weeks, supine DBP was significantly reduced in eight patients receiving captopril and in four of the patients receiving propranolol.	Propranolol	166-177	D-box binding PAR bZIP transcription factor	Homo sapiens	60-63
6262771-0	1981	Local anesthetics, mepacrine, and propranolol are antagonists of calmodulin.	Propranolol	34-45	calmodulin 1	Homo sapiens	65-75
6111891-8	1981	In addition propranolol, which inhibits stimulus activation of phospholipase A2, produced 70% and 55% inhibition of the reaction of mice ears to 12-DOPPA and 12-DOPPAA.	Propranolol	12-23	phospholipase A2, group IB, pancreas	Mus musculus	63-79
7030750-7	1981	It was concluded that propranolol effectively reduced BP, but diastolic BP reduction was most rapidly obtained at 320 and 640 mg daily, that the activity of the renin -aldosterone system was initially suppressed in all group, but for unknown reasons it increased towards the control level after seven to eleven weeks of therapy with 320 and 640 mg/day, and that the reduction in systolic BP increased with higher doses of propranolol and with increasing urinary propranolol excretion.	Propranolol	422-433	renin	Homo sapiens	161-166
7030750-7	1981	It was concluded that propranolol effectively reduced BP, but diastolic BP reduction was most rapidly obtained at 320 and 640 mg daily, that the activity of the renin -aldosterone system was initially suppressed in all group, but for unknown reasons it increased towards the control level after seven to eleven weeks of therapy with 320 and 640 mg/day, and that the reduction in systolic BP increased with higher doses of propranolol and with increasing urinary propranolol excretion.	Propranolol	422-433	renin	Homo sapiens	161-166
6284819-4	1981	The beta-adrenergic antagonist propranolol blocked inhibition of ODC activity produced by isoproterenol, but only if added simultaneously or less than 4 hr after the agonist.	Propranolol	31-42	ornithine decarboxylase, structural 1	Mus musculus	65-68
7457643-0	1981	Propranolol in the treatment of rage and violent behavior in patients with chronic brain syndromes.	Propranolol	0-11	long intergenic non-protein coding RNA 914	Homo sapiens	32-36
7202507-6	1981	(-)-Propranolol attenuated the overall toxic action of ouabain in EVI(+)S and facilitated its positive inotropic influence.	Propranolol	0-15	Wnt ligand secretion mediator	Rattus norvegicus	66-69
6257120-6	1981	beta-Adrenergic blockade induced by propranolol led to persistent decreases in mean plasma insulin 60% below the base line, small but variable decreases in glucose, and a sustained decrease in heart rate, but no change in period or relative amplitude of the oscillations in plasma levels of either insulin or glucose.	Propranolol	36-47	insulin	Macaca mulatta	91-98
6259059-0	1981	A possible antihypertensive mechanism of propranolol: antagonism of angiotensin II enhancement of sympathetic nerve transmission through prostaglandins.	Propranolol	41-52	angiotensinogen	Rattus norvegicus	68-82
6259059-3	1981	The dl-propranolol had no effect on the basal vasoconstrictor responses to NS and NE, yet inhibited the AII-enhanced vasoconstrictor responses to NS by 47% (p less than 0.05) and 81% (p less than 0.001) at 100 and 300 ng/ml respectively.	Propranolol	4-18	angiotensinogen	Rattus norvegicus	104-107
6259059-5	1981	A similar blockade of AII enhancement of NS was observed with the d-isomer of propranolol.	Propranolol	78-89	angiotensinogen	Rattus norvegicus	22-25
6259059-7	1981	Indomethacin, a prostaglandin synthetase inhibitor (5 mg/kg, s.c.), abolished the inhibitory effect of dl-propranolol on AII enhancement of NS.	Propranolol	103-117	angiotensinogen	Rattus norvegicus	121-124
6259059-10	1981	We conclude that propranolol antagonizes AII enhancement of NS by increasing prostaglandin levels in vascular tissue.	Propranolol	17-28	angiotensinogen	Rattus norvegicus	41-44
6119762-4	1981	The antisecretory effect of isoprenaline was significantly blocked by the beta 1-adrenoceptor blocker practolol and by the beta 1 + beta 2-adrenoceptor blocker propranolol but not by H 35/25, a beta 2-adrenoceptor blocker.	Propranolol	160-171	beta-2 adrenergic receptor	Canis lupus familiaris	123-151
7323697-2	1981	After intraduodenal infusion of glucose (82 ml 1.51 M, pH 6.5) the GIP concentration in plasma increased from 42.3 (23.1-62.2) to 225 (107-460) pM during intravenous NaCl, from 35.6 (17.3-38.9) to 251 (127-387) pM during phentolamine, and from 32.5 (5.5-63.4) to 172 (103-405) pM during propranolol administration.	Propranolol	287-298	gastric inhibitory polypeptide	Homo sapiens	67-70
6275494-6	1981	The increase in PP concentration was eliminated when propranolol was added to isoprenaline.	Propranolol	53-64	pancreatic polypeptide	Homo sapiens	16-18
6801757-0	1981	The effect of propranolol on insulin-stimulated gastric secretion in dogs.	Propranolol	14-25	insulin	Canis lupus familiaris	29-36
7323697-4	1981	It is concluded that the non-selective beta-adrenoceptor antagonist propranolol inhibits the release of GIP after intraduodenal administration of glucose.	Propranolol	68-79	gastric inhibitory polypeptide	Homo sapiens	104-107
7008812-3	1980	Carbamylcholine has been injected together with captopril, an inhibitor of the enzyme converting angiotensin I into angiotensin II, and with propranolol, which blocks the renin beta-receptors respectively.	Propranolol	141-152	renin	Rattus norvegicus	171-176
7002344-4	1980	Intrarenal infusion of propranolol (3.0 mg/kg per min) inhibited renal renin release and adrenal catecholamine secretion in response to intrarenal isoproterenol.	Propranolol	23-34	renin	Homo sapiens	71-76
6108175-3	1980	We noted that plasma renin activity and plasma aldosterone concentration were suppressed by propranolol but not by pindolol.	Propranolol	92-103	renin	Homo sapiens	21-26
7004211-6	1980	Isoproterenol-stimulated renin release was blocked by 1.2 X 10(-4) M propranolol but was unaffected by 6.3 X 10(-6) M meclofenamate.	Propranolol	69-80	renin	Rattus norvegicus	25-30
7000506-5	1980	However, beta-adrenergic blockade with propranolol completely prevented the renin response without altering the rise in vasopressin.	Propranolol	39-50	renin	Rattus norvegicus	76-81
7008891-2	1980	The mean propranolol CSF/plasma ration was 0.08, and there was good agreement between CSF and free plasma propranolol levels.	Propranolol	9-20	colony stimulating factor 2	Homo sapiens	21-24
6257942-2	1980	Plasma c-AMP level was significantly higher in untreated, diuretic-treated patients and those treated with propranolol than in normal subjects, but plasma c-GMP level was comparable in normal subjects and untreated patients.	Propranolol	107-118	cathelicidin antimicrobial peptide	Homo sapiens	7-12
6257942-5	1980	The increase in plasma c-AMP was significantly higher in untreated patients than in normal subjects and patients treated with propranolol.	Propranolol	126-137	cathelicidin antimicrobial peptide	Homo sapiens	23-28
6257942-3	1980	Plasma c-AMP decreased significantly, whereas plasma c-GMP increase significantly, after chronic propranolol therapy.	Propranolol	97-108	cathelicidin antimicrobial peptide	Homo sapiens	7-12
6257942-4	1980	Plasma c-AMP increased significantly after submaximal exercise in normal subjects, untreated patients and those treated with propranolol, but plasma c-GMP increased significantly only in normal subjects.	Propranolol	125-136	cathelicidin antimicrobial peptide	Homo sapiens	7-12
6257942-6	1980	Moreover, the percent increase in plasma c-AMP was significantly higher in untreated patients than in those treated with propranolol.	Propranolol	121-132	cathelicidin antimicrobial peptide	Homo sapiens	41-46
6162535-4	1980	SP and BK appear to exert their relaxant effects through the activation of specific receptors as the exposure of the common carotid artery to concentrations of [Leu8]-angiotensin II, propranolol, methysergide, cimetidine, or atropine sufficient to inhibit the effects of the corresponding agonists do not affect the relaxing effect of SP and BK.	Propranolol	183-194	kininogen 1	Canis lupus familiaris	7-9
6781216-3	1980	The pituitary release mechanism for growth hormone was evaluated using the propanolol/L-dopa stimulation test.	Propranolol	75-85	growth hormone 1	Homo sapiens	36-50
6254118-7	1980	This enhancement in the serum gastrin levels was also reduced to a significant extent by simultaneous administration of propranolol, which suggested the activation of G-cell beta-adrenergic receptors after serotonin administration.	Propranolol	120-131	gastrin	Rattus norvegicus	30-37
7000419-6	1980	After propranolol values of plasma renin activity at rest fell with little change occurring during head-up tilt.	Propranolol	6-17	renin	Homo sapiens	35-40
6107894-5	1980	The renin release response was almost abolished by 0.5 mg/kg of metoprolol or dl-propranolol but unaffected by 0.5 mg/kg of d-propranolol.	Propranolol	78-92	renin	Canis lupus familiaris	4-9
6107894-7	1980	dl-propranolol, 0.5 mg/kg, reduced the renin release response to about the same extent, 44%, while 2.0 mg/kg reduced it somewhat more, 59%.	Propranolol	0-14	renin	Canis lupus familiaris	39-44
6107894-8	1980	This was probably due to its membrane stabilizing properties as d-propranolol, 2.0 mg/kg and lidocaine 2.0 mg/kg + 0.1 mg x kg-1 x min-1, also reduced the renin release response.	Propranolol	64-77	renin	Canis lupus familiaris	155-160
6259250-3	1980	After propranolol administration, plasma aldosterone responsiveness to heat exposure increased, though plasma renin activity was depressed.	Propranolol	6-17	renin	Homo sapiens	110-115
6893960-1	1980	The effect of propranolol on plasma dopamine-beta-hydroxylase activity and triiodothyronine was investigated in twelve subjects with Graves" disease.	Propranolol	14-25	dopamine beta-hydroxylase	Homo sapiens	36-61
7002082-6	1980	The beta-blocker, propranolol, was as effective as indomethacin in attenuating hydralazine-induced renin release.	Propranolol	18-29	renin	Rattus norvegicus	99-104
7013951-0	1980	Propranolol in the treatment of renin-mediated hypertension.	Propranolol	0-11	renin	Homo sapiens	32-37
6893960-4	1980	There was a positive and significant correlation between changes in DBH activity and triiodothyronine caused by propranolol.	Propranolol	112-123	dopamine beta-hydroxylase	Homo sapiens	68-71
6893960-5	1980	These data offer evidence that there may be an interaction between plasma DBH activity and triiodothyronine during propranolol administration in hyperthyroidism.	Propranolol	115-126	dopamine beta-hydroxylase	Homo sapiens	74-77
6996661-0	1980	Effect of propranolol on the renin response to frusemide in man.	Propranolol	10-21	renin	Homo sapiens	29-34
7388535-0	1980	Effect of propranolol and metoprolol on parathyroid hormone and calcitonin secretions in uraemic patients.	Propranolol	10-21	calcitonin related polypeptide alpha	Homo sapiens	64-74
7388535-2	1980	Plasma concentrations of parathyroid hormone (PTH) and calcitonin fell significantly after propranolol but not after metoprolol, whereas no change in plasma concentrations of ionised calcium and phosphate occurred with either drug.	Propranolol	91-102	parathyroid hormone	Homo sapiens	25-44
7388535-2	1980	Plasma concentrations of parathyroid hormone (PTH) and calcitonin fell significantly after propranolol but not after metoprolol, whereas no change in plasma concentrations of ionised calcium and phosphate occurred with either drug.	Propranolol	91-102	calcitonin related polypeptide alpha	Homo sapiens	55-65
7388535-4	1980	The fact that propranolol acutely suppressed PTH and calcitonin secretion in uraemic patients indicates that further studies are warranted to assess the long-term effects of the drug on the secretion of these hormones and on renal osteodystrophy.	Propranolol	14-25	calcitonin related polypeptide alpha	Homo sapiens	53-63
7388535-5	1980	The contrast between the responses to propranolol and metoprolol supports the concept that PTH and calcitonin secretion is modulated through specific beta 2-receptors.	Propranolol	38-49	calcitonin related polypeptide alpha	Homo sapiens	99-109
6996018-0	1980	Effect of propranolol on the urinary excretion of prostaglandin E and plasma renin activity in hypertensive patients.	Propranolol	10-21	renin	Homo sapiens	77-82
7387339-10	1980	Melatonin and prolactin levels in serum decreased noticeably with propranolol treatment.	Propranolol	66-77	prolactin	Homo sapiens	14-23
6783422-0	1980	Exercise-induced release of pancreatic polypeptide and its inhibition by propranolol: evidence for adrenergic stimulation.	Propranolol	73-84	pancreatic polypeptide	Homo sapiens	28-50
6105025-5	1980	A small, but statistically significant, augmentation of growth hormone response was obtained during treatment with propranolol.	Propranolol	115-126	growth hormone 1	Homo sapiens	56-70
6783422-5	1980	The exercise-induced rise of PP was completely abolished by propranolol.	Propranolol	60-71	pancreatic polypeptide	Homo sapiens	29-31
7398733-5	1980	The plasma level of propranolol and the reduction in an exercise tachycardia after L.A. propranolol increased slowly to reach a peak at 6 h and then declined gradually to 24 h. The maximum plasma concentration and effect after sotalol occurred at 3 h and then declined with an elimination half-life of 12.1 h. At 24 h the percentage reduction in an exercise tachycardia was 8.3 +/- 2.5 after oxprenolol, 10.0 +/- 2.3 after <compound-id="-">S.R.	Propranolol	20-31	ataxin 3	Homo sapiens	244-248
6103674-2	1980	The nonselective beta-adrenoceptor blocking drugs propranolol, D-32, and pindolol significantly inhibited increases in heart rate and plasma renin activity and a fall of blood pressure produced by intravenous infusion of isoproterenol (10 microgram .	Propranolol	50-61	renin	Canis lupus familiaris	141-146
6244927-2	1980	PGE2 caused significant stimulation of renin release in a dose-dependent fashion at concentrations of 3 x 10(-6) to 10(-4) M. Isoproterenol (8 x 10(-7) M) stimulated renin release significantly, and its effect was completely abolished by propranolol (2 x 10(-5) M).	Propranolol	238-249	renin	Rattus norvegicus	39-44
6102511-1	1980	Recent studies in man have shown a decrease in serum L-T3 (T3) levels in subjects treated with DL-propranolol, but the mechanism of this effect is unknown.	Propranolol	95-109	solute carrier family 25 member 5	Homo sapiens	53-57
6102511-1	1980	Recent studies in man have shown a decrease in serum L-T3 (T3) levels in subjects treated with DL-propranolol, but the mechanism of this effect is unknown.	Propranolol	95-109	solute carrier family 25 member 5	Homo sapiens	55-57
7363437-5	1980	Propranolol produced a decrease in maximum blood flow velocity (from 58 +/- 4.7 to 42 +/- 5.1 cm/sec, p less than 0.002), and acceleration (from 1181 +/- 130 to 847 +/- 117 cm/sec2, p less than 0.002, max dP/dt (from 1361 +/- 70 to 1146 +/- 63 mm Hg/sec, p less than 0.002), stroke volume index (from 47 +/- 3.0 to 38 +/- 3.2 ml/m2, p less than 0.002) and total stroke work index (from 702 +/- 33 to 603 +/- 44 mJ/m2 p less than 0.04), with little change in mean aortic pressure, peak systolic pressure and LV end-diastolic pressure.	Propranolol	0-11	fucosyltransferase 2	Homo sapiens	176-180
7393346-4	1980	A beta adrenergic antagonist, propranolol, exclusively blocked desensitization in the beta-adrenergic and dopaminergic adenylate cyclase system caused by isoproterenol, while dopamine-induced refractoriness was prevented by a dopaminergic antagonist, haloperidol.	Propranolol	30-41	amyloid beta precursor protein	Rattus norvegicus	0-6
7417618-0	1980	Propranolol in high doses increases plasma prolactin concentrations in male rats.	Propranolol	0-11	prolactin	Rattus norvegicus	43-52
6989694-1	1980	The effect of alpha-adrenergic stimulation by IV adrenaline and propranolol infusion upon basal insulin and growth hormone secretion was studied in six chronic alcoholics during alcohol withdrawal, two alcoholics recently admitted to hospital with alcohol-induced hypoglycaemia and twelve healthy subjects.	Propranolol	64-75	growth hormone 1	Homo sapiens	108-122
7378257-2	1980	2 The apparent plasma clearance of propranolol was closely related both to the in vivo (antipyrine test) and in vitro (cytochrome P-450) indices of the activity of the hepatic mixed function oxidase system.	Propranolol	35-46	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	119-135
20227951-0	1980	Calculation of competitive inhibition of substrate binding to cytochrome P-450 illustrated by the interaction of d,l-propranolol with d,l-hexobarbital.	Propranolol	113-128	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	62-78
20227951-5	1980	The method is illustrated by the competitive interaction of d,l-hexobarbital and d,l-propranolol with cytochrome P-450 which show only a partial overlap for type I binding sites using rat hepatic microsomes.	Propranolol	81-96	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	102-118
7433322-1	1980	Chronic treatment with oxprenolol or propranolol in active hypertensive patients was associated with elevation of serum growth hormone (GH).	Propranolol	37-48	growth hormone 1	Homo sapiens	120-134
7433322-1	1980	Chronic treatment with oxprenolol or propranolol in active hypertensive patients was associated with elevation of serum growth hormone (GH).	Propranolol	37-48	growth hormone 1	Homo sapiens	136-138
7433322-2	1980	Propranolol, 80 mg orally, caused a marked rise in GH in 3 of 4 acromegalic patients.	Propranolol	0-11	growth hormone 1	Homo sapiens	51-53
6104918-4	1980	The increase in plasma gastrin induced by arginine pulse was significantly suppressed by the infusion of beta-adrenergic blocking agent, propranolol, while the infusion of alpha-adrenergic blocking agent, phentolamine tended to enhance the arginine-induced gastrin secretion slightly but not significantly.	Propranolol	137-148	gastrin	Homo sapiens	23-30
6101508-7	1980	Serum insulin fell minimally in the presence of propranolol but was unaffected by epinephrine.	Propranolol	48-59	insulin	Homo sapiens	6-13
6263163-0	1980	Antagonism of calmodulin by local anesthetics, mepacrine, and propranolol.	Propranolol	62-73	calmodulin 1	Homo sapiens	14-24
6768117-4	1980	We propose that covalent binding of the intermediate to the catalytic site of a form(s) of cytochrome P-450 that metabolizes propranolol would account for the marked inhibition of propranolol metabolism observed following propranolol pretreatment.	Propranolol	125-136	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	91-107
6768117-4	1980	We propose that covalent binding of the intermediate to the catalytic site of a form(s) of cytochrome P-450 that metabolizes propranolol would account for the marked inhibition of propranolol metabolism observed following propranolol pretreatment.	Propranolol	180-191	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	91-107
6768117-4	1980	We propose that covalent binding of the intermediate to the catalytic site of a form(s) of cytochrome P-450 that metabolizes propranolol would account for the marked inhibition of propranolol metabolism observed following propranolol pretreatment.	Propranolol	180-191	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	91-107
7424571-7	1980	The symptomatic effect of a beta-blocking agent combined with a permanent pacemaker is considered to be due to the reduced inotropic and chronotropic effect of propranolol during exercise as well as the elimination of a bradycardia-induced angina at rest.	Propranolol	160-171	amyloid beta precursor protein	Homo sapiens	26-32
6264899-0	1980	Cyclic nucleotide phosphodiesterase in the aorta of spontaneously hypertensive rats : variation with age and effect of propranolol.	Propranolol	119-130	phosphodiesterase 3A	Rattus norvegicus	0-35
7371605-2	1980	In not dehydrated animals the only dose of propranolol increased significantly the vasopressin and oxytocin release from the neurohypophysis.	Propranolol	43-54	arginine vasopressin	Rattus norvegicus	83-94
7226751-0	1980	Effect of propranolol treatment on serum prolactin level in schizophrenic patients.	Propranolol	10-21	prolactin	Homo sapiens	41-50
7351114-3	1980	hr/ml) after 4-mg intravenous doses of propranolol were 6.6 +/- 2.2 (mean +/- SEM) for HO-P and 55 +/- 11 for propranolol.	Propranolol	39-50	stress induced phosphoprotein 1	Homo sapiens	87-98
7002508-3	1980	Both isoproterenol and furosemide stimulated release of renin in all age animals while propranolol supressed renin release.	Propranolol	87-98	renin	Sus scrofa	109-114
7371605-3	1980	In dehydrated animals propranolol restrained somewhat the decrease of vasopressin in the neurohypophysis, but intensified the vasopressin depletion in the hypothalamus.	Propranolol	22-33	arginine vasopressin	Rattus norvegicus	70-81
7371605-3	1980	In dehydrated animals propranolol restrained somewhat the decrease of vasopressin in the neurohypophysis, but intensified the vasopressin depletion in the hypothalamus.	Propranolol	22-33	arginine vasopressin	Rattus norvegicus	126-137
7216342-0	1980	Stimulatory effect of levodopa and propranolol upon plasma growth hormone release in children and adolescents.	Propranolol	35-46	growth hormone 1	Homo sapiens	59-73
6102965-6	1980	At the 100 ng/ml concentration, DL-propranolol, timolol, metoprolol, practolol, butoxamine, and H35/25 inhibited the angiotensin II potentiation of NS by 83%, 76%, 77%, 59%, 72%, and 41% respectively.	Propranolol	32-46	angiotensinogen	Rattus norvegicus	117-131
6987282-0	1980	Hemodynamic effect of propranolol therapy in relationship to renin status and plasma catecholamines in primary hypertension.	Propranolol	22-33	renin	Homo sapiens	61-66
6246003-2	1980	Administration of potent vasodepressor agents such as the angiotensin converting enzyme inhibitor, captopril, may precipitate myocardial ischemic events in patients with coronary artery disease, particularly if this treatment is preceded by a discontinuation of beta-blocking drugs such as propranolol.	Propranolol	290-301	angiotensin I converting enzyme	Homo sapiens	58-87
7351877-3	1980	Insulin suppression was obtained by means of a constant infusion of epinephrine (6 microgram/min) and propranolol (0.08 mg/min).	Propranolol	102-113	insulin	Homo sapiens	0-7
7350185-4	1980	During propranolol-exercise, mean plasma hPP did not rise significantly above the basal level.	Propranolol	7-18	familial progressive hyperpigmentation 1	Homo sapiens	41-44
6101342-5	1980	Renin stimulation by both agonists was suppressed by propranolol (nonselective) and by acebutolol and its derivative M&amp;B 16,942 (beta-1 selective antagonists).	Propranolol	53-64	renin	Rattus norvegicus	0-5
44877-0	1979	Prolactin response and extrapyramidal side effects during propranolol and neuroleptic drugs treatment in chronic schizophrenic patients.	Propranolol	58-69	prolactin	Homo sapiens	0-9
520175-0	1979	[Improvement of growth-hormone stimulation with l-dopa/l-carbidopa by simultaneous administration of propranolol (author"s transl)].	Propranolol	101-112	growth hormone 1	Homo sapiens	16-30
520175-1	1979	The effect of simultaneous administration of 250 mg L-dopa + 25 mg L-carbidopa (Nacom) and 1 mg propranolol/kg body weight (maximal dose 40 mg propranolol) on growth-hormone secretion was tested in 96 children with growth retardation.	Propranolol	96-107	growth hormone 1	Homo sapiens	159-173
520175-3	1979	The additional administration of propranolol reduced the number of children unresponsive to adequate growth-hormone stimulation from 16% to 9.5%.	Propranolol	33-44	growth hormone 1	Homo sapiens	101-115
520175-5	1979	Some of the children who previously had failed to have a satisfactory rise in growth-hormone level after L-dopa and L-carbidopa showed satisfactory stimulation when propranolol was added.	Propranolol	165-176	growth hormone 1	Homo sapiens	78-92
7412730-0	1980	[Changes in the radiorenography curve in hypertensive patients under the influence of a beta adrenergic antagonist (propranolol)].	Propranolol	116-127	amyloid beta precursor protein	Homo sapiens	86-92
515777-2	1979	On subsequent follow-up one patient is taking no insulin and has been maintained on hydrochlorothiazide; the other patient required insulin on two occasions when challenged with a propranolol-thiazide combination, but not when the thiazide was discontinued or replaced with furosemide.	Propranolol	180-191	insulin	Homo sapiens	132-139
233412-2	1979	In animals pretreated with reserpine, propranolol, or aminophylline, pentylenetetrazol seizures were more severe, cyclic AMP elevations were attenuated or blocked, and cyclic GMP increases were unaffected or augmented.	Propranolol	38-49	5'-nucleotidase, cytosolic II	Mus musculus	175-178
120320-4	1979	Propranolol (1.5 mg/kg) inhibited saralasin-induced renin release by 93% and enhanced the suppressant effect of indomethacin from 79% to 100%.	Propranolol	0-11	renin	Rattus norvegicus	52-57
39446-0	1979	Contrasting effects of acute beta blockade with propranolol on plasma catecholamines and renin in essential hypertension: a possible basis for the delayed antihypertensive response.	Propranolol	48-59	renin	Homo sapiens	89-94
39446-4	1979	Plasma renin activity decreased progressively by 48 per cent 60 minutes after propranolol, whereas plasma norepinephrine and epinephrine were always higher after propranolol than control values.	Propranolol	78-89	renin	Homo sapiens	7-12
573555-1	1979	Propranolol, a beta-adrenergic blocking agent, has found an important position in the practice of medicine.	Propranolol	0-11	amyloid beta precursor protein	Homo sapiens	13-19
488280-1	1979	In the isolated and perfused kidney of the rat, the stimulant effect of dopamine on renin release is blocked by propranolol and not by haloperidol.	Propranolol	112-123	renin	Rattus norvegicus	84-89
44254-0	1979	[The effect of propranolol, neuroleptics and their combination on serum prolactin levels of schizophrenic patients].	Propranolol	15-26	prolactin	Homo sapiens	72-81
455885-3	1979	Plasma antipyrine clearance and cytochrome P-450 content in biopsies were related to propranolol elimination from plasma, the best fit being obtained with the clearance values.	Propranolol	85-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-48
225469-4	1979	If lowering temperature transforms the adrenoceptor from a beta type to an alpha type, one should expect that the sympathomimetic drug phenylephrine would be more potent at the low than at the high temperature, that the reverse would be true for the sympathomimetic drug isoproterenol, and that the blocking ability of the beta adrenoceptor blocking drug propranolol might be reduced and that of the alpha adrenoceptor blocking drug phentolamine increased by lowering temperature.	Propranolol	355-366	amyloid beta precursor protein	Rattus norvegicus	57-63
508010-7	1979	Thus, propranolol did not decrease blood pressure in most rats with chronic two-kidney Goldblatt hypertension; when it did lower blood pressure, its antihypertensive effect appeared related to its renin suppression effect.	Propranolol	6-17	renin	Rattus norvegicus	197-202
451694-0	1979	Combined oral L-dopa and propranolol for growth hormone provocation.	Propranolol	25-36	growth hormone 1	Homo sapiens	41-55
447846-4	1979	This increase in renin release during HH was not abolished by any single maneuver alone including beta adrenergic blockade with d,l-propranolol (n = 6), renal PG inhibition with indomethacin (n = 7), or control of RPP (n = 6).	Propranolol	128-143	renin	Canis lupus familiaris	17-22
384205-0	1979	Local anesthetics, chlorpromazine  and propranolol inhibit stimulus-activation of phospholipase A2 in human platelets.	Propranolol	39-50	phospholipase A2 group IB	Homo sapiens	82-98
113217-7	1979	This difference is attributable to propranolol"s blockade of adrenaline"s vasodilating effect mediated by beta-2 receptors in the resistance vessels.	Propranolol	35-46	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	106-112
114972-1	1979	Combined Glucagon-Propranolol test used for study of growth hormone is advantages.	Propranolol	18-29	growth hormone 1	Homo sapiens	53-67
379428-0	1979	[Effect of propranolol on the gastrin concentration in the serum and on hydrochloric acid secretion in duodenal peptic ulcer].	Propranolol	11-22	gastrin	Homo sapiens	30-37
447795-6	1979	Because a primary effect on renin might explain the renal impairment, an additional study used propranolol to lower renin activity.	Propranolol	95-106	renin	Homo sapiens	116-121
466869-10	1979	On the rat vas deferens, the pA2 value against dopamine was 7.9. t. The beta-adrenoceptor blocking agents, propranolol and oxprenolol slightly enhanced dopamine-induced contractions on vasa deferentia of both species.	Propranolol	107-118	arginine vasopressin	Rattus norvegicus	11-14
38759-1	1979	The results of a previous study on protection by propranolol and dicyclohexylamine of alpha-blockade suggested that these compounds potentiated the response of the isolated rat vas deferens to noradrenaline.	Propranolol	49-60	arginine vasopressin	Rattus norvegicus	177-180
475475-0	1979	Effect of intravenous or intracisternal clonidine and propranolol on plasma renin.	Propranolol	54-65	renin	Canis lupus familiaris	76-81
219717-5	1979	Administration of propranolol to the nonblocked kidney prevented the release of renin but not the hemodynamic changes resulting from BCO.	Propranolol	18-29	renin	Canis lupus familiaris	80-85
219717-7	1979	A step in the renin release mechanism subsequent to the alpha-adrenoceptor-mediated changes in sensitive to propranolol.	Propranolol	108-119	renin	Canis lupus familiaris	14-19
434227-3	1979	The number of bradykinin-induced venular fluorescent dextran leakage sites could be greatly reduced by the simultaneous topical application of isoproterenol, and this antagonism of the increase in macromolecular permeability could be prevented by pretreatment with propranolol.	Propranolol	265-276	kininogen 1	Canis lupus familiaris	14-24
85053-1	1979	The response to intravenous insulin was studied in seven diabetics after a dose of placebo, propranolol (40 mg), or metoprolol (50 mg).	Propranolol	92-103	insulin	Homo sapiens	28-35
427008-0	1979	Plasma prolactin levels before and during propranolol treatment in chronic schizophrenia.	Propranolol	42-53	prolactin	Homo sapiens	7-16
33189-6	1979	Propranolol, a beta-adrenergic blocking agent which inhibits epinephrine action, blocks both the epinephrine-stimulated phosphorylation and the inactivation of the carboxylase.	Propranolol	0-11	amyloid beta precursor protein	Rattus norvegicus	13-19
45268-4	1979	In contrast, when the renin response to tilt was acutely suppressed by propranolol administration, the aldosterone response was nonetheless maintained but now appeared to be under ACTH control, since concurrent increases in cortisol were observed.	Propranolol	71-82	renin	Homo sapiens	22-27
45268-4	1979	In contrast, when the renin response to tilt was acutely suppressed by propranolol administration, the aldosterone response was nonetheless maintained but now appeared to be under ACTH control, since concurrent increases in cortisol were observed.	Propranolol	71-82	proopiomelanocortin	Homo sapiens	180-184
477193-8	1979	Peripheral vein active renin was lowered by propranolol, but inactive renin was raised.	Propranolol	44-55	renin	Homo sapiens	23-28
289859-8	1979	Since propranolol can block saralasin-induced renin release, angiotensin and beta-blockers could constitute a beneficial drug interaction.	Propranolol	6-17	renin	Homo sapiens	46-51
477193-9	1979	Both the diazoxide-induced rapid rise of active renin and the fall of inactive renin observed in untreated patients were absent during treatment with propranolol.	Propranolol	150-161	renin	Homo sapiens	48-53
477193-9	1979	Both the diazoxide-induced rapid rise of active renin and the fall of inactive renin observed in untreated patients were absent during treatment with propranolol.	Propranolol	150-161	renin	Homo sapiens	79-84
34627-4	1979	The stimulations of D, A, and B cells were abolished by propranolol.alpha-Adrenergic agonism (10 ng/ml epinephrine) after beta-adrenergic blockade) moderately decreased somatostatin (-37+/-7%) secretion, moderately increased glucagon (91+/-19%), and markedly decreased insulin (-85+/-3%) release.	Propranolol	56-67	somatostatin	Canis lupus familiaris	169-181
431848-1	1979	The possible mechanism and the therapeutic activity of a beta-blocking drug (propranolol) in 50 patients with slight "hyperthyroidism" or "dysthyroidism" are examined.	Propranolol	77-88	amyloid beta precursor protein	Homo sapiens	55-61
437681-0	1979	Enhancement by propranolol of the insulin induced hypoglycemia in the chick.	Propranolol	15-26	insulin	Gallus gallus	34-41
507318-0	1979	Effect of propranolol and reserpine on the development of vasopressin hypertension in rat.	Propranolol	10-21	arginine vasopressin	Rattus norvegicus	58-69
758231-2	1979	Renin concentration was determined in arterial and renal venous plasma as follows: (1) before and after stimulation of renin release with isoproterenol or furosemide, (2) after suppression of renin release by extracellular fluid volume expansion, and (3) after administration of propranolol or indomethacin.	Propranolol	279-290	renin	Sus scrofa	0-5
37874-2	1979	In the two groups of patients the antihypertensive effectiveness of both short-term intravenous or chronically oral propranolol was directly related to the extent to which the drug produced an absolute reduction in plasma renin activity (PRA).	Propranolol	116-127	renin	Homo sapiens	222-227
758231-7	1979	Both forms of renin were suppressed by propranolol or indomethacin.	Propranolol	39-50	renin	Sus scrofa	14-19
282042-9	1978	During propranolol treatment there is a tendency for secretion of active renin to be reduced.	Propranolol	7-18	renin	Homo sapiens	73-78
503267-4	1979	Administration of the beta-adrenergic blocking agent, propranolol, prevented the decrease in glomerular filtration rate after infusion of thrombin.	Propranolol	54-65	coagulation factor II	Rattus norvegicus	138-146
44916-0	1979	Acute effects of propranolol and metoprolol on plasma concentrations of parathyroid hormone and calcitonin in uraemic patients.	Propranolol	17-28	calcitonin related polypeptide alpha	Homo sapiens	96-106
44916-2	1979	Plasma concentrations of PTH and calcitonin decreased significantly with propranolol but not with metoprolol.	Propranolol	73-84	parathyroid hormone	Homo sapiens	25-28
44916-2	1979	Plasma concentrations of PTH and calcitonin decreased significantly with propranolol but not with metoprolol.	Propranolol	73-84	calcitonin related polypeptide alpha	Homo sapiens	33-43
44916-5	1979	We conclude that (i) propranolol acutely suppresses PTH and Calcitonin secretion in uraemic patients.	Propranolol	21-32	parathyroid hormone	Homo sapiens	52-55
44916-5	1979	We conclude that (i) propranolol acutely suppresses PTH and Calcitonin secretion in uraemic patients.	Propranolol	21-32	calcitonin related polypeptide alpha	Homo sapiens	60-70
747726-5	1978	Propranolol alone, administered in the same fashion, unexpectedly induced a rise in plasma renin concentration (p less than 0.05) while blood urea and renal renin concentrations were unchanged.	Propranolol	0-11	renin	Rattus norvegicus	91-96
747726-7	1978	Plasma renin concentration rose after high dose propranolol, but decreased, although not significantly, after administration of 1 mg/kg.	Propranolol	48-59	renin	Rattus norvegicus	7-12
118391-0	1979	Thyroid-stimulating hormone and prolactin responses to thyrotropin-releasing hormone during infusion of epinephrine and propranolol in man.	Propranolol	120-131	thyrotropin releasing hormone	Homo sapiens	55-84
282043-6	1978	Propranolol decreased both active and inactive renin, but not significantly.	Propranolol	0-11	renin	Homo sapiens	47-52
30817-4	1978	A beta-blocking drug, propranolol, inhibited the stimulatory effect of the agents in both adipose tissues.	Propranolol	22-33	amyloid beta precursor protein	Rattus norvegicus	0-6
282060-7	1978	Propranolol treatment reduced the increases in blood pressure following intraventricular methionine-enkephalin and leucine-enkephalin, while only the methionine-enkephalin-induced increases in heart rate were reduced by propranolol.	Propranolol	0-11	proenkephalin	Rattus norvegicus	100-110
282060-7	1978	Propranolol treatment reduced the increases in blood pressure following intraventricular methionine-enkephalin and leucine-enkephalin, while only the methionine-enkephalin-induced increases in heart rate were reduced by propranolol.	Propranolol	0-11	proenkephalin	Rattus norvegicus	123-133
728298-0	1978	CSF/plasma ratios of propranolol in man [proceedings].	Propranolol	21-32	colony stimulating factor 2	Homo sapiens	0-3
82968-3	1978	The levels achieved compared favorably with the 250-fold increase in cyclin AMP produced by (-)isoproterenol at 37 degrees C.(-)Isoproterenol at 5 nM stimulated half-maximal cyclic AMP production at 4 degrees C and at 37 degrees C and was blocked by (-)propranolol at both temperatures.	Propranolol	250-264	proliferating cell nuclear antigen	Rattus norvegicus	69-75
213332-6	1978	The results suggest that propranolol may induce in certain patients an improvement of basal clinical status through not understood effects (probably hepatic), which leave the peripheral concentrations of insulin unchanged, whereas inhibition of insulin secretion may represent the main way by which the improvement of metabolic situation during physiological or pharmacological stimulation may have been achieved.	Propranolol	25-36	insulin	Homo sapiens	204-211
213037-1	1978	The beta-adrenoceptor antagonists, atenolol, metoprolol and propranolol, administered intravenously to anaesthetized rats in doses producing equal beta1-adrenoceptor blocking effects, caused comparable suppression of plasma renin activity (PRA) despite the fact that, at these doses, atenolol and metoprolol exhibited no beta2-adrenoceptor blocking properties.	Propranolol	60-71	renin	Rattus norvegicus	224-229
27279-4	1978	2 When employed at a concentration of 2 mumol/1 propranolol and atenolol significantly inhibited renin release (P less than 0.001 and P less than 0.01) whereas practolol and IPS 339 [t-butyl-amino-3 ol-2 propyl) oximino-9 fluorene] had little effect.	Propranolol	48-59	renin	Cavia porcellus	97-102
30617-3	1978	VIP-induced lipolysis is inhibited by propranolol but VIP-induced adenyl cyclase activity is not.	Propranolol	38-49	vasoactive intestinal peptide	Rattus norvegicus	0-3
744259-2	1978	The infusion of prostaglandin for 60 minutes at a dose unable to cause pressor modifications (2 microgram/kg/min) was shown to increase the plasma renin activity (PRA); this effect was inhibited by propranolol and strengthened by aminophylline.	Propranolol	198-209	renin	Canis lupus familiaris	147-152
30849-6	1978	However, the increase of plasma renin activity in the control group was greater than that of the propranolol treated group during 12% CO2 inhalation.	Propranolol	97-108	renin	Canis lupus familiaris	32-37
353088-0	1978	Relationships of renin and aldosterone to antihypertensive effects of spironolactone and propranolol.	Propranolol	89-100	renin	Homo sapiens	17-22
209581-8	1978	After propranolol the rCBF changes caused by alterations in the arterial PCO2 were normal and the focal flow increase during hand work could not be changed by simultaneous intracarotid propranolol.	Propranolol	6-17	CCAAT/enhancer binding protein zeta	Rattus norvegicus	22-26
205476-3	1978	Insulin resistance was also significantly greater in hypertriglyceridaemic subjects as determined by measuring the steady-state plasma glucose response during a continuous infusion of epinephrine, propranolol, glucose, and exogenous insulin.	Propranolol	197-208	insulin	Homo sapiens	0-7
668949-3	1978	3) Pretreatment with the administration of propranolol inhibited an increase in PRA after handgrip exercise in either normotensive or normal renin hypertensive patients.	Propranolol	43-54	renin	Homo sapiens	141-146
27375-2	1978	An increase in plasma renin concentration which accompanied hypercapnia in untreated dogs was completely suppressed by pretreatment with guanethidine or propranolol.	Propranolol	153-164	renin	Canis lupus familiaris	22-27
27942-4	1978	The rise in c-amp which is caused by isoprenaline, is, however, blocked by propranolol.	Propranolol	75-86	antimicrobial protein CAP18	Oryctolagus cuniculus	12-17
206480-6	1978	Propranolol blockade of beta-adrenergic receptors essentially abolishes the insulin response to KCl infusion, with and without epinephrine.	Propranolol	0-11	insulin	Canis lupus familiaris	76-83
637424-0	1978	Propranolol effects in long-term hemodialysis patients with renin-dependent hypertension.	Propranolol	0-11	renin	Homo sapiens	60-65
637424-3	1978	During propranolol treatment of dialyzed patients, mean blood pressure fell from 133 +/- 1 to 113 +/- 4 mm Hg (P less than 0.005) and plasma renin activity from 3093 +/- 423 to 689 +/- 218 ng/dl 3h (P less than 0.001).	Propranolol	7-18	renin	Homo sapiens	141-146
637424-6	1978	Thus propranolol alone reduces blood pressure and renin activity in chronically dialyzed patients with hypertension and high renin concentrations.	Propranolol	5-16	renin	Homo sapiens	50-55
637424-6	1978	Thus propranolol alone reduces blood pressure and renin activity in chronically dialyzed patients with hypertension and high renin concentrations.	Propranolol	5-16	renin	Homo sapiens	125-130
637424-8	1978	These findings suggest that propranolol may be an effective alternative to bilateral nephrectomy in the control of renin-dependent hypertension in selected patients.	Propranolol	28-39	renin	Homo sapiens	115-120
208799-5	1978	Epinephrine antagonizes the lipolysis induced by theophyline on the subscutaneous adipocytes, this action is increased by propranolol (a beta-adrenergic blocking agent).	Propranolol	122-133	amyloid beta precursor protein	Homo sapiens	135-141
641212-0	1978	The effects of clonidine and propranolol, separately and in combination, on blood pressure and plasma renin activity in essential hypertension.	Propranolol	29-40	renin	Homo sapiens	102-107
25551-3	1978	NaF, at 1 and 5 mM, progressively increased this parameter while norepinephrine caused a similar effect at 10(-3) but not at 10(-6) M. Phentolamine (1 mM) blocked the stimulatory action of TSH; propranolol and atropine did not.	Propranolol	194-205	C-X-C motif chemokine ligand 8	Homo sapiens	0-3
640802-2	1978	Support of this hypothesis was forwarded by the finding that propranolol, a blocker of renin release, reduced the deleterious effect of ischemia on kidney function.	Propranolol	61-72	renin	Rattus norvegicus	87-92
678343-2	1978	In 6 patients with high AII (135.9 pg/ml +/- 26.29) and normal ENa (98.83% +/- 1.40) propranolol significantly lowered both blood pressure (BP) and AII, suggesting that these forms of EH are renin dependent.	Propranolol	85-96	angiotensinogen	Homo sapiens	24-27
678343-2	1978	In 6 patients with high AII (135.9 pg/ml +/- 26.29) and normal ENa (98.83% +/- 1.40) propranolol significantly lowered both blood pressure (BP) and AII, suggesting that these forms of EH are renin dependent.	Propranolol	85-96	angiotensinogen	Homo sapiens	148-151
678343-2	1978	In 6 patients with high AII (135.9 pg/ml +/- 26.29) and normal ENa (98.83% +/- 1.40) propranolol significantly lowered both blood pressure (BP) and AII, suggesting that these forms of EH are renin dependent.	Propranolol	85-96	renin	Homo sapiens	191-196
678343-5	1978	In 8 patients with increase of both AII (76.53 pg/ml +/- 5.72) and ENa (112% +/- 1.72), propranolol associated with thiabutazid lowered the BP, AII and ENa suggesting that these cases are mixed forms.	Propranolol	88-99	angiotensinogen	Homo sapiens	36-39
678343-5	1978	In 8 patients with increase of both AII (76.53 pg/ml +/- 5.72) and ENa (112% +/- 1.72), propranolol associated with thiabutazid lowered the BP, AII and ENa suggesting that these cases are mixed forms.	Propranolol	88-99	angiotensinogen	Homo sapiens	144-147
633081-3	1978	Methadone administration to adult rats stimulated heart ODC, and this stimulation could be blocked by the sympatholytic agents chlorisondamine, reserpine or propranolol, suggesting that the effect is mediated via central stimulation of sympathetic nerves.	Propranolol	157-168	ornithine decarboxylase 1	Rattus norvegicus	56-59
633087-6	1978	The antagonism of the bradykinin protein efflux by both norepinephrine and isoproterenol can be prevented by prior treatment with propranolol.	Propranolol	130-141	kininogen 1	Canis lupus familiaris	22-32
75440-4	1978	The percent blockade by propranolol of the isoprenaline-induced changes ranged from 65% for diastolic pressure to 77% for heart rate and 78% for plasma-renin activity.	Propranolol	24-35	renin	Homo sapiens	152-157
628352-0	1978	Growth hormone response to propranolol and L--dopa in obese subjects.	Propranolol	27-38	growth hormone 1	Homo sapiens	0-14
628352-1	1978	Oral administration of propranolol and L-dopa produced a marked increase in plasma growth hormone values in 12 obese subjects who had failed to respond to L-dopa alone.	Propranolol	23-34	growth hormone 1	Homo sapiens	83-97
636807-4	1978	During 3% anaesthesia, plasma renin activity was markedly increased in the methyldopa group and decreased in the propranolol group.	Propranolol	113-124	renin	Rattus norvegicus	30-35
629266-0	1978	The possible importance of aldosterone as well as renin in the long-term antihypertensive action of propranolol.	Propranolol	100-111	renin	Homo sapiens	50-55
397834-0	1978	[Action of increasing doses of DL-propranolol on behavior of arterial pressure and plasma renin activity (PRA)].	Propranolol	31-45	renin	Homo sapiens	90-95
755641-2	1978	Plasma renin activity was similar in the propranolol and methyldopa groups and significantly lower (p less than 0.01) in both these groups than the diuretic treated subjects.	Propranolol	41-52	renin	Homo sapiens	7-12
157199-2	1978	A beta blocking agent, propranolol, inhibits this effect.	Propranolol	23-34	amyloid beta precursor protein	Rattus norvegicus	0-6
582936-2	1978	Propranolol behaved like a typical competitive beta 1-adrenoceptor antagonist with a pA2 value of 8.33.	Propranolol	0-11	adrenoceptor beta 1	Rattus norvegicus	47-66
202430-12	1978	The possibility is discussed that propranolol may depress renin release in the dog by an action other than that of blocking beta-adrenoreceptors.	Propranolol	34-45	renin	Canis lupus familiaris	58-63
755641-0	1978	Sympathetic nervous function and renin activity in hypertensives on long term drug treatment with propranolol, methyldopa or bendrofluazide.	Propranolol	98-109	renin	Homo sapiens	33-38
624999-9	1978	DL-Propranolol inhibited the increase in 45Ca efflux and renin release resulting from noradrenaline stimulation.	Propranolol	0-14	renin	Homo sapiens	57-62
33792-3	1978	Propranolol, a beta-adrenergic blocker (5 mg/kg iv), had no effect on GH secretion and caused a small but significant depression in PRL levels.	Propranolol	0-11	prolactin	Rattus norvegicus	132-135
713616-0	1978	[Effect of oxprenolol and propranolol on increased plasma renin activity in rats after physical exertion].	Propranolol	26-37	renin	Rattus norvegicus	58-63
219295-1	1978	The synthesis of biotinyl-hexaglycyl-NEDA (abbreviation:BGN), a biotinyl derivative of propranolol, is described.	Propranolol	87-98	biglycan	Homo sapiens	56-59
564531-4	1978	Phentolamine, an alpha-blocking agent, had no effect on the epinephrine-induced release of PGF, while propranolol, a beta-blocking agent, not only prevented in increase in PGF production induced by epinephrine but also reduced the basal release of PGF by the estrous uterus.	Propranolol	102-113	placental growth factor	Rattus norvegicus	172-175
104186-6	1978	The increase in serum Prl concentrations produced by the beta-receptor blocker propranolol was less marked than that induced by the alpha-receptor blockers phentolamine and phenoxybenzamine.	Propranolol	79-90	prolactin	Macaca mulatta	22-25
564531-4	1978	Phentolamine, an alpha-blocking agent, had no effect on the epinephrine-induced release of PGF, while propranolol, a beta-blocking agent, not only prevented in increase in PGF production induced by epinephrine but also reduced the basal release of PGF by the estrous uterus.	Propranolol	102-113	placental growth factor	Rattus norvegicus	172-175
704657-8	1978	The effect on growth hormone was prevented by carbidopa and by phentolamine but not by pimozide; propranolol potentiated the rise in growth hormone.	Propranolol	97-108	somatotropin	Canis lupus familiaris	133-147
915008-0	1977	The interrelationship between the release of renin and vasopressin as defined by orthostasis and propranolol.	Propranolol	97-108	renin	Homo sapiens	45-50
622601-3	1978	During normal sodium intake, propranolol therapy was associated with a decrease in plasma renin activity, a variable tendency to an increase in body weight and plasma volume, and a decrease in mean arterial pressure of 5 mm Hg (NS).	Propranolol	29-40	renin	Homo sapiens	90-95
915008-3	1977	Intravenous propranolol administered just before tilt was used to investigate the possibility that the delayed rise of arginine vasopressin was stimulated by renin.	Propranolol	12-23	arginine vasopressin	Homo sapiens	128-139
915008-3	1977	Intravenous propranolol administered just before tilt was used to investigate the possibility that the delayed rise of arginine vasopressin was stimulated by renin.	Propranolol	12-23	renin	Homo sapiens	158-163
915008-4	1977	Although the response of plasma renin was completely abolished by propranolol, the response of vasopressin was unaffected.	Propranolol	66-77	renin	Homo sapiens	32-37
71600-3	1977	In contrast, propranolol administration in 22 patients lowered active renin in all, but it increased prorenin by 98% in 15 in whom systolic pressure fell.	Propranolol	13-24	renin	Homo sapiens	70-75
343273-0	1977	Effects of propranolol and atenolol on blood pressure and plasma renin activity in patients with moderate hypertension.	Propranolol	11-22	renin	Homo sapiens	65-70
200948-0	1977	Effects of dibutyryl cyclic AMP and propranolol on renin secretion in dogs.	Propranolol	36-47	renin	Canis lupus familiaris	51-56
20550-4	1977	The stimulatory actions of isoproterenol and beta2-adrenergic agonists were competitively inhibited by the beta-blocking agent propranolol.	Propranolol	127-138	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	45-50
71600-6	1977	The fraction of active plasma-renin fell during propranolol administration from 43% to 18%, regardless of the blood-pressure response.	Propranolol	48-59	renin	Homo sapiens	30-35
71600-8	1977	Thus, sodium depletion stimulates total renin release, while propranolol and clonidine produce divergent responses of active renin and prorenin, the changes in prorenin depending on the changes induced in blood-pressure.	Propranolol	61-72	renin	Homo sapiens	125-130
71600-9	1977	These observations suggest that propranolol may block intrarenal conversion of prorenin to active renin while also suppressing total renin release.	Propranolol	32-43	renin	Homo sapiens	82-87
71600-9	1977	These observations suggest that propranolol may block intrarenal conversion of prorenin to active renin while also suppressing total renin release.	Propranolol	32-43	renin	Homo sapiens	98-103
616215-6	1977	The serum GH levels were of about the same magnitude after the three different treatments but the peak values were seen 30 and 40 minutes earlier after propranolol and metoprolol than after the placebo.	Propranolol	152-163	growth hormone 1	Homo sapiens	10-12
905634-0	1977	Effects of propranolol on rat myocardial l-ornithine decarboxylase activity during exercise and hypoxia.	Propranolol	11-22	ornithine decarboxylase 1	Rattus norvegicus	43-66
269762-4	1977	Bradykinin-induced reflex tachycardia was suppressed after the blockade of beta-adrenoceptors with propranolol, whereas reflex pressor responses were prevented by blocking the alpha-adrenoceptor sites with phenoxybenzamine.	Propranolol	99-110	kininogen 1	Canis lupus familiaris	0-10
330078-6	1977	Only patients with increased sympathetic nervous system activity and high plasma renin activity (PRA) had substantial falls in pressure at propranolol levels of 3 to 30 ng/ml.	Propranolol	139-150	renin	Homo sapiens	81-86
19338-1	1977	As a result of effective beta adrenergic blockade with either propranolol or practolol, plasma renin activity was suppressed in all of 11 patients with cirrhosis and ascites.	Propranolol	62-73	renin	Homo sapiens	95-100
908468-1	1977	Insulin resistance was measured in 16 normal dogs by a method involving the continuous intravenous infusion of epinephrine, propranolol, glucose and insulin.	Propranolol	124-135	insulin	Canis lupus familiaris	0-7
902149-0	1977	Effect of propranolol on renin release in the dog.	Propranolol	10-21	renin	Canis lupus familiaris	25-30
20124-5	1977	5 Although the beta1-adrenoceptor selective blocker, metoprolol, caused decreases in baseline values for blood pressure and heart rate similar to those observed with the use of the two non-selective blockrs, it was shown in a double-blind crossover comparison with propranolol that the haemodynamic changes provoked by the mental arithmetic were not less in the presence of beta1-receptor blockade than when both beta1- and beta2-receptors were blocked.	Propranolol	265-276	adrenoceptor beta 1	Homo sapiens	15-33
902149-1	1977	Infusion of d,l-propranolol in both anesthetized and conscious dogs caused decreases in heart rate (HR), plasma renin activity (PRA), and plasma aldosterone.	Propranolol	12-27	renin	Canis lupus familiaris	112-117
902149-6	1977	The data suggest that propranolol at the dose administered suppresses renin and aldosterone secretion in unstimulated dogs.	Propranolol	22-33	renin	Canis lupus familiaris	70-75
886921-0	1977	Suppression of renin secretion by propranolol in salt-depleted dogs.	Propranolol	34-45	renin	Canis lupus familiaris	15-20
874246-3	1977	Insulin resistance was estimated by measuring the steady-state plasma glucose response to a continuous infusion of insulin, glucose, epinephrine, and propranolol.	Propranolol	150-161	insulin	Homo sapiens	0-7
893737-2	1977	The average fall in mean arterial pressure for each dosage of hydralazine was no different with or without propranolol, even though propranolol inhibited rises in plasma renin activity and pulse due to hydralazine.	Propranolol	132-143	renin	Homo sapiens	170-175
893737-3	1977	However, in each of four patients who had high supine baseline plasma renin activity, propranolol enhanced the fall in blood pressure caused by hydralazine.	Propranolol	86-97	renin	Homo sapiens	70-75
893737-7	1977	Pretreating with propranolol weakens homeostatic defenses against hydralazine such as rises in pulse rate and plasma renin activity.	Propranolol	17-28	renin	Homo sapiens	117-122
893737-9	1977	In patients with high supine plasma renin activity, propranolol potentiates the fall in blood pressure induced by hydralazine, perhaps because the hypertension in such patients is renin dependent.	Propranolol	52-63	renin	Homo sapiens	36-41
893737-9	1977	In patients with high supine plasma renin activity, propranolol potentiates the fall in blood pressure induced by hydralazine, perhaps because the hypertension in such patients is renin dependent.	Propranolol	52-63	renin	Homo sapiens	180-185
879924-4	1977	Treatment with propranolol hydrochloride temporarily lowered the blood pressure and peripheral renin activity levels.	Propranolol	15-40	renin	Homo sapiens	95-100
879269-2	1977	Intravenous infusion of propranolol, a drug which prevents renin release, at 1 mg/kg for 70 minutes beginning at time of pedicle clamping resulted in significantly lower serum creatinine in this model (2.8 +/- 0.2 mg% at 48 hours with propranolol versus 5.2 +/- 0.8 mg% without).	Propranolol	24-35	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	59-64
879269-3	1977	Renin stimulation by dehydration or feeding a low-salt diet enhanced the difference between treated and untreated groups (2.6 +/- 0.4 mg% with propranolol versus 6.2 +/- 1.8 mg% without, after dehydration; 3.5 +/- 1.0 mg% with propranolol versus 7.6 +/- 1.4 mg% without, after low-salt diet).Suppression of renin production by saline feeding eliminated propranolol"s beneficial effect (5.6 +/- 0.9 mg% with propranolol versus 4.0 +/- 0.6 mg% without).	Propranolol	143-154	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	0-5
879269-3	1977	Renin stimulation by dehydration or feeding a low-salt diet enhanced the difference between treated and untreated groups (2.6 +/- 0.4 mg% with propranolol versus 6.2 +/- 1.8 mg% without, after dehydration; 3.5 +/- 1.0 mg% with propranolol versus 7.6 +/- 1.4 mg% without, after low-salt diet).Suppression of renin production by saline feeding eliminated propranolol"s beneficial effect (5.6 +/- 0.9 mg% with propranolol versus 4.0 +/- 0.6 mg% without).	Propranolol	227-238	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	0-5
879269-3	1977	Renin stimulation by dehydration or feeding a low-salt diet enhanced the difference between treated and untreated groups (2.6 +/- 0.4 mg% with propranolol versus 6.2 +/- 1.8 mg% without, after dehydration; 3.5 +/- 1.0 mg% with propranolol versus 7.6 +/- 1.4 mg% without, after low-salt diet).Suppression of renin production by saline feeding eliminated propranolol"s beneficial effect (5.6 +/- 0.9 mg% with propranolol versus 4.0 +/- 0.6 mg% without).	Propranolol	227-238	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	0-5
879269-3	1977	Renin stimulation by dehydration or feeding a low-salt diet enhanced the difference between treated and untreated groups (2.6 +/- 0.4 mg% with propranolol versus 6.2 +/- 1.8 mg% without, after dehydration; 3.5 +/- 1.0 mg% with propranolol versus 7.6 +/- 1.4 mg% without, after low-salt diet).Suppression of renin production by saline feeding eliminated propranolol"s beneficial effect (5.6 +/- 0.9 mg% with propranolol versus 4.0 +/- 0.6 mg% without).	Propranolol	227-238	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	0-5
879001-2	1977	Although plasma renin decreased substantially in patients with normal and high renin levels tasking a small dose of propranolol (40 mg/day), blood pressure was unchanged in the normal renin group, and a small decrease in systolic pressure alone was noted in those with high plasma levels of renin.	Propranolol	116-127	renin	Homo sapiens	16-21
879001-2	1977	Although plasma renin decreased substantially in patients with normal and high renin levels tasking a small dose of propranolol (40 mg/day), blood pressure was unchanged in the normal renin group, and a small decrease in systolic pressure alone was noted in those with high plasma levels of renin.	Propranolol	116-127	renin	Homo sapiens	79-84
879001-2	1977	Although plasma renin decreased substantially in patients with normal and high renin levels tasking a small dose of propranolol (40 mg/day), blood pressure was unchanged in the normal renin group, and a small decrease in systolic pressure alone was noted in those with high plasma levels of renin.	Propranolol	116-127	renin	Homo sapiens	79-84
879001-2	1977	Although plasma renin decreased substantially in patients with normal and high renin levels tasking a small dose of propranolol (40 mg/day), blood pressure was unchanged in the normal renin group, and a small decrease in systolic pressure alone was noted in those with high plasma levels of renin.	Propranolol	116-127	renin	Homo sapiens	79-84
879001-5	1977	Overall, the observed responses for plasma renin and heart were more pronounced at lower plasma propranolol concentrations than those for blood pressure.	Propranolol	96-107	renin	Homo sapiens	43-48
879018-2	1977	In vitro, and in normal man propranolol shifts the oxyhemoglobin equilibrium curve to the right, thus increasing the partial pressure of oxygen at which hemoglobin is 50% saturated (P50) and enhancing oxygen delivery.	Propranolol	28-39	nuclear factor kappa B subunit 1	Homo sapiens	182-185
879018-3	1977	The effect of propranolol on hemoglobin P50 was evaluated in 12 patients with angina pectoris and documented coronary artery disease.	Propranolol	14-25	nuclear factor kappa B subunit 1	Homo sapiens	40-43
907802-1	1977	During a five days administration, Propranolol (80 mg daily) or Acebutolol (600 mg daily) decreased significantly plasma renin activity in 14 mild essential hypertensive patients under a normal (8 patients) or low sodium (6 patients) diet.	Propranolol	35-46	renin	Homo sapiens	121-126
403030-4	1977	Pretreatment with propranolol, in a dose sufficient to inhibit renin secretion, also did not attenuate the increase in renal resistance produced by indomethacin.	Propranolol	18-29	renin	Homo sapiens	63-68
16742-5	1977	However, the presence of the beta-adrenergic antagonist, propranolol (2 X 10(-4)M) completely inhibited dopamine-induced renin release.	Propranolol	57-68	renin	Rattus norvegicus	121-126
196123-0	1977	Effect of propranolol on blood pressure and plasma renin concentration in renovascular hypertensive rats.	Propranolol	10-21	renin	Rattus norvegicus	51-56
196123-1	1977	The effect of chronic oral administration of propranolol (39--80 mg/Kg/day, for 21--27 days) on blood pressure, plasma renin concentration, and heart rate were studied in 2 types of renovascular hypertensive rats; one-kidney type with normal plasma renin and two-kidney type with high plasma renin.	Propranolol	45-56	renin	Rattus norvegicus	119-124
19152-1	1977	The ability of several beta-adrenoceptor antagonists with partial agonist activity (dl-oxprenolol, dl-acebutolol and dl-practolol) to attenuate the release of CPK that occurs during hypoxia (pO2 less than 0.8 kPa [6 MMHg]) has been studied and compared with the protection provided by dl-propranolol.	Propranolol	285-299	phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha	Homo sapiens	159-162
19152-2	1977	dl-propranolol attenuated the hypoxic-induced release of CPK.	Propranolol	0-14	phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha	Homo sapiens	57-60
19152-4	1977	dl-oxprenolol, acebutolol, and practolol were either less effective than propranolol in preventing CPK release, or they exacerbated the release.	Propranolol	73-84	phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha	Homo sapiens	99-102
16716-0	1977	Beta-2 adrenoceptor blocking activity of penbutolol and propranolol at very low doses.	Propranolol	56-67	adrenoceptor beta 2	Homo sapiens	0-19
870747-0	1977	[Behaviour of plasma renin activity during long-term treatment with propranolol (author"s transl)].	Propranolol	68-79	renin	Homo sapiens	21-26
191300-2	1977	The depressor responses induced by either propranolol or the nonapeptide expose a significant to major involvement of excess renin--angiotensin in maintaining the hypertension of some 50 to 70% of common forms of hypertension including "essential" hypertension.	Propranolol	42-53	renin	Homo sapiens	125-130
189996-0	1977	The influence of propranolol on the thyrotropin receptor.	Propranolol	17-28	thyroid stimulating hormone receptor	Homo sapiens	36-56
189996-5	1977	Scatchard analysis of the binding data indicated that propranolol increased the association constant of the thyrotropin-thyrotropin receptor interaction.	Propranolol	54-65	thyroid stimulating hormone receptor	Homo sapiens	120-140
913698-0	1977	[Studies on the effects of simultaneous administrations of propranolol and glucagon on the release of growth hormone (author"s transl)].	Propranolol	59-70	growth hormone 1	Homo sapiens	102-116
14101-6	1977	Pretreatment with propranolol (1.5 mg-kg-1) attenuated the increase in PVR during elevation in ICP; the smaller increase in PVR was associated with a marked increase in left atrial pressure and a smaller increase in pulmonary perfusion pressure than in the control group.	Propranolol	18-29	PVR cell adhesion molecule	Canis lupus familiaris	71-74
843147-0	1977	Hemodynamic and plasma renin effects of propranolol in essential hypertension.	Propranolol	40-51	renin	Homo sapiens	23-28
859212-6	1977	The involvements of adrenergic mechanism in the central pressor effect of angiotensin II were studied through observation of blood pressure changes following injection of angiotensin II, phentolamine and propranolol into the rabbit lateral ventricle of rabbit brain.	Propranolol	204-215	angiotensinogen	Rattus norvegicus	74-88
12923-8	1977	Although propranolol therapy along prolonged the PEP/LVET, a further significant prolongation followed subsequent injection of lidocaine.	Propranolol	9-20	progestagen associated endometrial protein	Homo sapiens	49-57
318874-4	1977	At concentrations similar to those achieved in vivo (0.1-1 muM), propranolol raised the thresholds for aggregation of some normal paltelets by adenosine diphosphate (ADP).	Propranolol	65-76	latexin	Homo sapiens	59-62
318874-5	1977	At higher concentrations (10-50 muM), propranolol abolished the second wave of platelet aggregation induced by ADP and epinephrine, and inhibited aggregation induced by collagen, thrombin, and the ionophore A23187.	Propranolol	38-49	latexin	Homo sapiens	32-35
318874-5	1977	At higher concentrations (10-50 muM), propranolol abolished the second wave of platelet aggregation induced by ADP and epinephrine, and inhibited aggregation induced by collagen, thrombin, and the ionophore A23187.	Propranolol	38-49	coagulation factor II, thrombin	Homo sapiens	179-187
190857-4	1977	In normal dogs propranolol 0.3 mg/kg intravenously inhibites the insulin release and the hypoglycaemia due to CS 476 suggesting involvement of beta-adrenergic receptors in its action on the pancreas.	Propranolol	15-26	insulin	Canis lupus familiaris	65-72
556882-4	1977	When intravenous phentolamine (an alpha-adrenergic blocking agent) or intravenous propranolol (a beta-adrenergic blocking agent) were administered for 1 hour, there was no significant change in serum prolactin levels.	Propranolol	82-93	amyloid beta precursor protein	Homo sapiens	95-101
318685-0	1977	Treatment of high-renin hypertension with propranolol in children after renal transplantation.	Propranolol	42-53	renin	Homo sapiens	18-23
318685-1	1977	Ten children with hypertension poorly controlled with other drugs and high peripheral plasma renin activity after renal transplantation were treated with propranolol.	Propranolol	154-165	renin	Homo sapiens	93-98
616179-12	1977	It is suggested that the impairment of autoregulation induced by guanethidine, propranolol or reserpine may be due to an inhibition of renin release.	Propranolol	79-90	renin	Rattus norvegicus	135-140
343894-1	1977	Clonidine, propranolol, bethanidine and debrisoquine effectively decrease blood pressure by suppressing renin secretion or interfering with function of the sympathetic nervous system.	Propranolol	11-22	renin	Homo sapiens	104-109
13495-2	1977	When given in equipotent beta1 blocking doses, the nonselective blocker propranolol and the beta1 selective blocker metoprolol differ markedly as regards inhibition of adrenaline induced beta2 mediated vasodilatation.	Propranolol	72-83	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	25-30
899931-3	1977	The fall in serum parathyroid hormone was abolished by beta-adrenergic blockage with propranolol.	Propranolol	85-96	parathyroid hormone	Homo sapiens	18-37
606459-4	1977	At a dose 10 mumol (3 mg) of propranolol/kg, administered by intraperitoneal injection, the onset and severity of hypertension were not affected, although plasma renin concentration was significantly lower than in the untreated hypertensive rats in the first 5 days after the operation.	Propranolol	29-40	renin	Rattus norvegicus	162-167
606459-6	1977	With 200 mumol (60 mg) of propranolol/kg, administered in the drinking water, peak blood pressure 5 days after aortic ligation was lower than in the untreated control rats, but plasma renin concentration was no lower than with the smaller dose.	Propranolol	26-37	renin	Rattus norvegicus	184-189
606459-8	1977	The development of severe hypertension despite reduction in plasma renin concentration on the low dose of propranolol suggests the participation of renal vasopressor factors other than renin in this model.	Propranolol	106-117	renin	Rattus norvegicus	67-72
218419-0	1977	Effect of propranolol on the plasma cyclic AMP and cyclic GMP levels to massive doses of glucagon in euthyroid and hyperthyroid subjects.	Propranolol	10-21	5'-nucleotidase, cytosolic II	Homo sapiens	58-61
606625-0	1977	[Dffect of propranolol on insulin-induced gastric acid secretion.	Propranolol	11-22	insulin	Homo sapiens	26-33
13495-2	1977	When given in equipotent beta1 blocking doses, the nonselective blocker propranolol and the beta1 selective blocker metoprolol differ markedly as regards inhibition of adrenaline induced beta2 mediated vasodilatation.	Propranolol	72-83	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	187-192
190674-2	1977	In this study it was shown that tremor caused by terbutaline could be blocked by propranolol, a drug with both beta1- and beta2-blocking properties, but not by metoprolol, a beta1-selective antagonist.	Propranolol	81-92	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	111-127
63837-0	1976	Propranolol in refractory high-renin dialysis.	Propranolol	0-11	renin	Homo sapiens	31-36
1071602-4	1976	An elevated heart rate at rest, shortened cardiac pre-ejection period, and greater heart rate reduction with acute beta-adrenoreceptor blockade (intravenous propranolol) in high-renin essential hypertension were indicative of adrenergic cardiac excitation.	Propranolol	157-168	renin	Homo sapiens	178-183
1071602-7	1976	Blood pressure was normalized by "total" autonomic blockade (atropine plus propranolol plus phentolamine) in the hypertensive subjects with elevated plasma renin activity.	Propranolol	75-86	renin	Homo sapiens	156-161
1071662-2	1976	The hypotensive effect of propranolol and its correlation with the changes in heart rate, plasma volume and plasma renin activity produced by this drug were studied in normotensive rats and in rats with spontaneous, renovascular and deoxycorticosterone-induced hypertension.	Propranolol	26-37	renin	Rattus norvegicus	115-120
1071604-0	1976	Change in the renin dependency of blood pressure induced by volume depletion and/or propranolol therapy in hypertensive patients.	Propranolol	84-95	renin	Homo sapiens	14-19
1071618-0	1976	The immediate plasma renin response to propranolol: evidence for a different mode of renin release in essential and renal hypertension.	Propranolol	39-50	renin	Homo sapiens	21-26
1071604-9	1976	Propranolol therapy suppressed PRA during normovolaemia as well as during volume depletion, and this was accompanied by a decrease of the renin dependency.	Propranolol	0-11	renin	Homo sapiens	138-143
1071618-0	1976	The immediate plasma renin response to propranolol: evidence for a different mode of renin release in essential and renal hypertension.	Propranolol	39-50	renin	Homo sapiens	85-90
11370235-9	1976	In dogs in which central beta-adrenergic blockade was produced by intraventricular L-propranolol, the growth hormone response to L-dopa was greater than it was in control dogs treated with intraventricular D-propranolol.	Propranolol	206-219	somatotropin	Canis lupus familiaris	102-116
1071618-2	1976	The immediate short-term effects of intravenous injections of propranolol on plasma renin activity were studied in thirty-one normal subjects, 102 patients with benign essential and sixty-six patients with renal hypertension.	Propranolol	62-73	renin	Homo sapiens	84-89
1071618-7	1976	These differences in response to propranolol, which were particularly pronounced in patients with high initial renin values, suggest a dominant role of sympathetic tone at the juxtaglomerular apparatus for basal renin release in normal individuals and essential hypertensive subjects only.	Propranolol	33-44	renin	Homo sapiens	111-116
1071618-7	1976	These differences in response to propranolol, which were particularly pronounced in patients with high initial renin values, suggest a dominant role of sympathetic tone at the juxtaglomerular apparatus for basal renin release in normal individuals and essential hypertensive subjects only.	Propranolol	33-44	renin	Homo sapiens	212-217
1071670-8	1976	Long-term anti-hypertensive propranolol effects correlated with pre-treatment renin status, renin stimulation and its suppression by acute beta-receptor blockade as well as with the exercise tachycardia and the patient"s age.	Propranolol	28-39	renin	Homo sapiens	78-83
1071670-8	1976	Long-term anti-hypertensive propranolol effects correlated with pre-treatment renin status, renin stimulation and its suppression by acute beta-receptor blockade as well as with the exercise tachycardia and the patient"s age.	Propranolol	28-39	renin	Homo sapiens	92-97
1071676-0	1976	Comparison of metoprolol and propranolol in modification of haemodynamic and renin-aldosterone responses to tilting in humans.	Propranolol	29-40	renin	Homo sapiens	77-82
1071676-8	1976	Metoprolol and propranolol both reduced the rise in plasma renin activity induced by tilting.	Propranolol	15-26	renin	Homo sapiens	59-64
187707-1	1976	The increase in aldosterone and plasma renin activity (PRA) observed after stimulation of extrahypothalamic sites within the brain of the rhesus monkey was prevented by the prior administration of the beta-adrenergic blocking agent propranolol.	Propranolol	232-243	renin	Macaca mulatta	39-44
10730-5	1976	In the new system, all patients, except the elderly and those with congestive heart failure, bradycardia or a history of asthma, are treated first with propranolol alone, a procedure which will diminish or normalize blood pressure in many patients with high and noraml renin levels.	Propranolol	152-163	renin	Homo sapiens	269-274
10730-7	1976	Subsequently, a propranolol subtraction trial picks out the low-renin patients who will usually respond to a diuretic alone.	Propranolol	16-27	renin	Homo sapiens	64-69
10730-11	1976	Moreover, the large groups who respond to therapy with propranolol alone (most high-renin and normal-renin patients) or to diuretics alone (most low-renin patients) gain the advantage of simple, more specific, long-term (i.e., antirenin or antivolume) therapy.	Propranolol	55-66	renin	Homo sapiens	84-89
1014930-0	1976	[Behavior of plasms renin activity, hemodynamic parameters and clearance values as influenced by orciprenaline and propranolol in patients with limited kidney function].	Propranolol	115-126	renin	Homo sapiens	20-25
10730-11	1976	Moreover, the large groups who respond to therapy with propranolol alone (most high-renin and normal-renin patients) or to diuretics alone (most low-renin patients) gain the advantage of simple, more specific, long-term (i.e., antirenin or antivolume) therapy.	Propranolol	55-66	renin	Homo sapiens	101-106
10730-11	1976	Moreover, the large groups who respond to therapy with propranolol alone (most high-renin and normal-renin patients) or to diuretics alone (most low-renin patients) gain the advantage of simple, more specific, long-term (i.e., antirenin or antivolume) therapy.	Propranolol	55-66	renin	Homo sapiens	101-106
976494-8	1976	Saralasin-induced renin release occurred independent of hypotension and could be inhibited by propranolol, a beta-adrenergic blocking agent.	Propranolol	94-105	renin	Homo sapiens	18-23
12072-8	1976	Propranolol and imidazole inhibit glibenclamide-induced insulin release.	Propranolol	0-11	insulin	Homo sapiens	56-63
183943-3	1976	Those who responded to propranolol had lower systolic and diastolic blood pre-treatment pressures than those who failed, were younger by an average of eight years, and in no case had decreased plasma-renin activity and demonstrated greater plasma-renin activity after furosemide.	Propranolol	23-34	renin	Homo sapiens	247-252
989880-0	1976	Propranolol effect on plasma glucose, free fatty acid, insulin, and growth hormone in Graves" disease.	Propranolol	0-11	insulin	Homo sapiens	55-62
989880-0	1976	Propranolol effect on plasma glucose, free fatty acid, insulin, and growth hormone in Graves" disease.	Propranolol	0-11	growth hormone 1	Homo sapiens	68-82
989880-4	1976	Plasma growth hormone levels were higher than normal both before and after propranolol; however, a 46% glucose-induced suppression was seen in both instances.	Propranolol	75-86	growth hormone 1	Homo sapiens	7-21
11346-1	1976	Spin-labeled analogues of dichloroisoproterenol and propranolol were synthesized.	Propranolol	52-63	spindlin 1	Homo sapiens	0-4
989880-7	1976	Plasma growth hormone was higher than normal before and after propranolol; a late suppression (at 120 min) and no suppression at all were seen, respectively.	Propranolol	62-73	growth hormone 1	Homo sapiens	7-21
989880-9	1976	It is proposed that the improvement or deterioration in carbohydrate tolerance after propranolol treatment might be related to whether or not a satisfactory propranolol-induced lipolytic blockade is achieved, leading to a decrease in plasma free fatty acid levels, improved insulin sensitivity, and better peripheral glucose utilization.	Propranolol	85-96	insulin	Homo sapiens	274-281
188635-5	1976	When beta-adrenergic condition was corrected by propranolol treatment, insulin responses were shown lowered, though in the normal range.	Propranolol	48-59	insulin	Homo sapiens	71-78
988755-4	1976	Prior treatment with propranolol (approximately 2 mg/kg) reduced the renin response by approximately 50% but did not completely abolish it.	Propranolol	21-32	renin	Rattus norvegicus	69-74
963837-1	1976	The acute effects of small doses of intravenous propranolol on renin release and on circulatory dynamics were studied at the time of renal arteriography in 12 persons with essential hypertension.	Propranolol	48-59	renin	Homo sapiens	63-68
963837-7	1976	We conclude that propranolol rapidly blocks renin release despite circulatory changes which ordinarily constitute a stimulus for renin secretion, i.e., renal vasoconstriction and reduced renal blood flow.	Propranolol	17-28	renin	Homo sapiens	44-49
963837-7	1976	We conclude that propranolol rapidly blocks renin release despite circulatory changes which ordinarily constitute a stimulus for renin secretion, i.e., renal vasoconstriction and reduced renal blood flow.	Propranolol	17-28	renin	Homo sapiens	129-134
11346-4	1976	Nonetheless, the affinity of the spin-labeled propranolol would appear to be within a range compatible with EPR measurements.	Propranolol	46-57	spindlin 1	Homo sapiens	33-37
184363-5	1976	Inhibition of lipoprotein lipase by propranolol was considered to have played a role in the reciprocal changes of lipoprotein composition.	Propranolol	36-47	lipoprotein lipase	Homo sapiens	14-32
8132-2	1976	DL-Propranolol, a beta-adrenergic blocking agent with non-specific membrane effects, partially inhibited 3",5"-diethoxycarbonyl-1,4-dihydrocollidine-induced delta-aminolevulinate synthetase activity both in rats and in chick embryo liver cells in culture.	Propranolol	0-14	amyloid beta precursor protein	Rattus norvegicus	16-22
976301-7	1976	Isoproterenol stimulated gastrin secretion was completely suppressed by propranolol, a beta-adrenergic receptor blocking agent, which had no effect on meal stimulated gastrin secretion.	Propranolol	72-83	gastrin	Homo sapiens	25-32
186198-0	1976	[Effect of propranolol and trimepranol on the activity of carboxylic esterase, acid and alkaline phosphomonoesterases and adenosinetriphosphatase in the human thyroid gland].	Propranolol	11-22	ATPase Na+/K+ transporting subunit beta 1	Homo sapiens	122-145
13028-1	1976	We showed in previous studies that pro pranolol produced a pressor action in the rat, and that this action was also observed in the spinal rat infused with adrenaline, noradrenaline and a mixture of isoproterenol and vasopressin, but not with vasopression alone.	Propranolol	35-47	arginine vasopressin	Rattus norvegicus	217-228
13028-3	1976	In the present work, conditions in the peripheral vessels in which propranolol observed in the spinal rat infused with a mixture of various doses of isoproterenol and vasopressin.	Propranolol	67-78	arginine vasopressin	Rattus norvegicus	167-178
13028-5	1976	Propranolol produced a pressor action in the spinal rat infused with a mixture of isoproterenol and vasopressin, and the magnitude of the rise depended on the mixing rate of the doses of these two drugs.	Propranolol	0-11	arginine vasopressin	Rattus norvegicus	100-111
61340-6	1976	Propranolol completely abolished the renin response.	Propranolol	0-11	renin	Homo sapiens	37-42
61340-7	1976	The difference in the ability of these agents to suppress renin release may be related to the presence (oxprenolol) or absence (propranolol) of intrinsic sympathomimetic activity.	Propranolol	128-139	renin	Homo sapiens	58-63
8187-0	1976	Comparison of propranolol, metoprolol, and acebutolol on insulin-induced hypoglycaemia.	Propranolol	14-25	insulin	Homo sapiens	57-64
932031-6	1976	In contrast, 1.0 muM propranolol essentially completely inhibited the 8-fold stimulation of 1.0 muM epinephrine but had no effect on either basal or adenosine-stimulated activity.	Propranolol	21-32	latexin	Homo sapiens	17-20
8663-4	1976	The inhibition of plasma renin activity (PRA) was more pronounced with propranolol (-69%) than with bufuralol (-47%).	Propranolol	71-82	renin	Homo sapiens	25-30
1276834-0	1976	Immediate plasma renin response to propranolol: differentiation between essential and renal hypertension.	Propranolol	35-46	renin	Homo sapiens	17-22
955298-2	1976	Insulin resistance was estimated by measuring the steady-state plasma glucose response to a continuous infusion of insulin, glucose, epinephrine, and propranolol.	Propranolol	150-161	insulin	Homo sapiens	0-7
932031-6	1976	In contrast, 1.0 muM propranolol essentially completely inhibited the 8-fold stimulation of 1.0 muM epinephrine but had no effect on either basal or adenosine-stimulated activity.	Propranolol	21-32	latexin	Homo sapiens	96-99
1276834-1	1976	The immediate short-term effect on plasma renin activity of intravenous injection of propranolol was studied in 31 normal subjects and 166 hypertensive patients.	Propranolol	85-96	renin	Homo sapiens	42-47
1269098-5	1976	Propranolol reduced PRA at rest from 8.6 +/- 1.1 to 5.9 +/- 1.1 ng Ang 1 (P less than 0.05), but there was no significant difference between resting and exercise levels, although the increments in heart rate, cardiac output, and mean aortic pressure were reduced.	Propranolol	0-11	angiopoietin 1	Canis lupus familiaris	67-72
983720-2	1976	Phentolamine and propranolol decrease stimulatory effects of Nialamide and L-DOPA only when they are given jointly with bradykinin.	Propranolol	17-28	kininogen 1	Homo sapiens	120-130
6161-7	1976	Equipotent doses of timolol and propranolol caused similar marked depression of plasma renin activity.	Propranolol	32-43	renin	Homo sapiens	87-92
181391-2	1976	After the suppression of the renin-angiotensin system by the prior administration of propranolol, insulin-induced hypoglycemia still caused a significant increase in plasma aldosterone similar to the increase in plasma cortisol, though plasma renin activity was suppressed.	Propranolol	85-96	renin	Homo sapiens	29-34
775330-2	1976	Propranolol (160 mg daily) significantly lowered mean arterial pressure in high-renin (129 +/- 2.6 to 114 +/- 2.1 mm Hg) and normal-renin (131 +/- 2.7 to 119 +/- 3.5 mm Hg) patients but not in low-renin patients.	Propranolol	0-11	renin	Homo sapiens	80-85
775330-2	1976	Propranolol (160 mg daily) significantly lowered mean arterial pressure in high-renin (129 +/- 2.6 to 114 +/- 2.1 mm Hg) and normal-renin (131 +/- 2.7 to 119 +/- 3.5 mm Hg) patients but not in low-renin patients.	Propranolol	0-11	renin	Homo sapiens	132-137
775330-2	1976	Propranolol (160 mg daily) significantly lowered mean arterial pressure in high-renin (129 +/- 2.6 to 114 +/- 2.1 mm Hg) and normal-renin (131 +/- 2.7 to 119 +/- 3.5 mm Hg) patients but not in low-renin patients.	Propranolol	0-11	renin	Homo sapiens	132-137
775330-6	1976	The antihypertensive effects of propranolol and diuretics were additive in normal-renin and high-renin hypertension.	Propranolol	32-43	renin	Homo sapiens	82-87
775330-6	1976	The antihypertensive effects of propranolol and diuretics were additive in normal-renin and high-renin hypertension.	Propranolol	32-43	renin	Homo sapiens	97-102
775330-7	1976	These data suggest that propranolol"s pressure-lowering activity is due to both renin-dependent and renin-independent effects.	Propranolol	24-35	renin	Homo sapiens	80-85
775330-7	1976	These data suggest that propranolol"s pressure-lowering activity is due to both renin-dependent and renin-independent effects.	Propranolol	24-35	renin	Homo sapiens	100-105
939071-8	1976	When the renal nerves were similarly stimulated in the presence of the beta-adrenergic receptor blocking agent, propranolol, the glomerular filtration rate was significantly reduced and the rise in plasma renin activity was significantly inhibited.	Propranolol	112-123	renin	Felis catus	205-210
1269103-6	1976	Propranolol inhibited saralasin-induced renin release by 99% in normal rats and by 75% in sodium-depleted rats but not alter the hypotensive effect of saralasin in the latter.	Propranolol	0-11	renin	Rattus norvegicus	40-45
1269103-7	1976	Saralasin potentiated phentolamine-induced renin release, hypotension, and tachycardia in normal rats, and this potentiated renin release was blocked by propranolol.	Propranolol	153-164	renin	Rattus norvegicus	124-129
1269103-12	1976	This "short-loop" feed-back mechanism is closely associated with intrarenal beta-adrenergic receptors, since propranolol impaired saralasin-induced renin release under all circumstances in our experiments.	Propranolol	109-120	renin	Rattus norvegicus	148-153
14504-13	1976	These results suggest the following: (1) Most patients with normal to high plasma renin activity respond well to moderate doses of propranolol.	Propranolol	131-142	renin	Homo sapiens	82-87
935624-1	1976	The effects of the beta-adrenergic blocking agent (propranolol) on erythropoietin production in carbon monoxide intoxicated mice were studied.	Propranolol	51-62	erythropoietin	Mus musculus	67-81
935624-2	1976	The raise in plasma erythropoietin after a 4 hour intoxication with carbon monoxide was 47% less in the propranolol treated group.	Propranolol	104-115	erythropoietin	Mus musculus	20-34
935187-0	1976	Effects of propranolol on renin release during chronic thoracic caval constriction or acute renal artery stenosis in dogs.	Propranolol	11-22	renin	Canis lupus familiaris	26-31
57453-1	1976	Analysis by angiotensin II antagonist P113 in hypertensive patients treated with salt depletion and propranolol.	Propranolol	100-111	angiotensinogen	Homo sapiens	12-26
772425-0	1976	Renin profiling in hypertension and its use in treatment with propranolol and chlorthalidone.	Propranolol	62-73	renin	Homo sapiens	0-5
57453-15	1976	renin dependency after propranolol therapy suggests that suppression of P.R.A.	Propranolol	23-34	renin	Homo sapiens	0-5
9557-0	1976	Renin kinetics in hypertension: effect of propranolol and penbutolol.	Propranolol	42-53	renin	Homo sapiens	0-5
9032-4	1976	Results obtained with the beta-receptor antagonists propranolol, practolol and H35/25 suggest that the depression in skeletal muscle contractility is due to beta2-adrenoreceptor stimulation.	Propranolol	52-63	beta-2 adrenergic receptor	Cavia porcellus	157-177
6260-7	1976	The administration of propranolol 2 and 7 h after hormone injection decreased the ability of E2 and TP to enhance [3H]leucine incorporation by 55 and 41%, respectively.	Propranolol	22-33	dihydrolipoamide S-succinyltransferase	Rattus norvegicus	93-102
1274003-3	1976	These cases suggest that reflux nephropathy can activate the renin-angiotensin system and that the renin inhibitors, methyldopa and propranolol, an useful in managing this type of hypertension.	Propranolol	132-143	renin	Homo sapiens	99-104
940711-3	1976	Beta-adrenergic blockade (propranolol) was used to enhance the effect of exercise on GH release.	Propranolol	26-37	growth hormone 1	Homo sapiens	85-87
940711-7	1976	Propranolol and exercise appears to be an effective screening test for GH function.	Propranolol	0-11	growth hormone 1	Homo sapiens	71-73
959041-0	1976	Effect of inderal on insulin secretion, glycemia and FFA concentration in normal subjects and diabetics.	Propranolol	10-17	insulin	Homo sapiens	21-28
1278094-7	1976	The alpha-adrenergic blockers phenoxybenzamine and phentolamine and the beta-blocker propranolol inhibited the prolactin surge, with phenoxybenzamine being most effective.	Propranolol	85-96	prolactin	Rattus norvegicus	111-120
940189-0	1976	[Interactions between propranolol and the renin-angiotensin system].	Propranolol	22-33	renin	Homo sapiens	42-47
950262-0	1976	EPFFECT OF PROPRanolol on plasma renin level and angiotensin sensitivity in man.	Propranolol	11-22	renin	Homo sapiens	33-38
950262-1	1976	The effect of 160 mg oral propranolol daily for a week on angiotensin sensitivity and plasma renin activity has been studied in ten patients with Kaplan"s test and by determining renin with the radioimmunoassay.	Propranolol	26-37	renin	Homo sapiens	93-98
950262-1	1976	The effect of 160 mg oral propranolol daily for a week on angiotensin sensitivity and plasma renin activity has been studied in ten patients with Kaplan"s test and by determining renin with the radioimmunoassay.	Propranolol	26-37	renin	Homo sapiens	179-184
950262-2	1976	Propranolol was found to increase angiotensin activity and to reduce the plasma renin level.	Propranolol	0-11	renin	Homo sapiens	80-85
769527-10	1976	There was a close correlation between plasma renin activity and the effects of the drugs: With increasing renin level the response to propranolol was better whereas the opposite was true for spironolactone.	Propranolol	134-145	renin	Homo sapiens	45-50
769527-10	1976	There was a close correlation between plasma renin activity and the effects of the drugs: With increasing renin level the response to propranolol was better whereas the opposite was true for spironolactone.	Propranolol	134-145	renin	Homo sapiens	106-111
769527-14	1976	It is concluded that pretreatment levels of plasma renin activity can predict the antihypertensive response to propranolol and spironolactone.	Propranolol	111-122	renin	Homo sapiens	51-56
1248068-3	1976	The reduction in blood flow was prevented by a high salt intake and partially reversed by agents which interrupt the renin-angiotensin system (BPF 9a; 1-Sar,8-Ala-angiotensin II; propranolol) but not by alpha-adrenergic blocking agents (phentolamine and phenoxybenzamine).	Propranolol	179-190	renin	Canis lupus familiaris	117-122
971700-5	1976	Plasma renin activity was significantly reduced by propranolol.	Propranolol	51-62	renin	Homo sapiens	7-12
971700-8	1976	The role of plasma renin activity reduction in the hypotensive effect of propranolol in this situation remains to be clarified.	Propranolol	73-84	renin	Homo sapiens	19-24
1155-4	1976	Tyramine-induced stimulation of renin release was blocked by the beta-blocking agent, propranolol (2 X 10(-4) M), and the neural uptake blocking agent, cocaine (10(-5) M), but not by the alpha-antagonist, phentolamine (9 X 10(-4) M).	Propranolol	86-97	renin	Rattus norvegicus	32-37
1259022-4	1976	Intrarenal infusion of propranolol at 0.05 mg/kg per h in Na-depleted dogs decreased renin secretion whereas intravenous infusion at the same dose failed to alter renin release.	Propranolol	23-34	renin	Canis lupus familiaris	85-90
1259022-5	1976	Intrarenal infusion of propranolol at this rate in Na-depleted dogs with a denervated, nonfiltering kidney also decreased renin release.	Propranolol	23-34	renin	Canis lupus familiaris	122-127
1083996-0	1976	[Influence of furosemide and propranolol (beta blocking agent) on plasmatic renin liberation in dogs].	Propranolol	29-40	renin	Canis lupus familiaris	76-81
3519-8	1976	A fourth group of dogs showed a rise in renin secretion from 205 to 880 U/min (P less than 0.001) in response to the first RNS, while the second RNS, given after an infusion of d-propranolol, caused a rise in renin secretion from 80 to 482 (P less than 0.005).	Propranolol	177-190	renin	Canis lupus familiaris	40-45
3519-1	1976	The ability of d,l-propranolol to block renin secretion in response to various extrarenal stimuli, such as hemorrhage and hypoglycemia, has been interpreted to indicate the presence of an intrarenal beta receptor regulating renin release.	Propranolol	15-30	renin	Canis lupus familiaris	40-45
3519-1	1976	The ability of d,l-propranolol to block renin secretion in response to various extrarenal stimuli, such as hemorrhage and hypoglycemia, has been interpreted to indicate the presence of an intrarenal beta receptor regulating renin release.	Propranolol	15-30	renin	Canis lupus familiaris	224-229
1248452-5	1976	When the beta adrenergic blocking agent, propranolol, was given with the epinephrine, the insulin response to theophylline was markedly reduced and similar to that observed during hypoxia.	Propranolol	41-52	insulin	Homo sapiens	90-97
764929-4	1976	The initial plasma renin activity (PRA) levels ranged from 0-4 to 5-0 mug angiotensin I l-1 h-1, and there was a close correlation between these levels and the effects of the drugs: with increasing PRA the response to propranolol was better while the opposite was true for spironolactone.	Propranolol	218-229	renin	Homo sapiens	19-24
3519-4	1976	The effects of d,l-propranolol (anesthetic and beta-blocking activity), l-propranolol (beta-blocking activity only), and d-propranolol (local anesthetic activity only) on the renin response to RNS were examined.	Propranolol	121-134	renin	Canis lupus familiaris	175-180
1032570-0	1976	Dissociation of the renin lowering and antihypertensive actions of propranolol.	Propranolol	67-78	renin	Homo sapiens	20-25
184689-5	1976	The addition of propranolol (13 mumol/l) at different times after ISNA did not influence the rate of lipolysis, although it resulted in a decrease in the tissue level of cAMP.	Propranolol	16-27	cathelicidin antimicrobial peptide	Homo sapiens	170-174
1071960-0	1976	Plasma renin activity and blood pressure during long term treatment with propranolol and diuretic.	Propranolol	73-84	renin	Homo sapiens	7-12
1032570-3	1976	In the first study, involving 22 patients with borderline hypertension, patients with elevated plasma renin levels showed normalization of the blood pressure after pharmacological autonomic blockade with intravenous atropine, propranolol and phentolamine, the time course of the pressure fall being such as to exclude suppression of renin release as the antihypertensive mechanism.	Propranolol	226-237	renin	Homo sapiens	102-107
1032570-5	1976	In two additional studies involving 21 patients in all with mild to moderately severe essential hypertension, to whom propranolol was administereed by mouth for 1--3 months, two findings were of interest:1) patients with low-renin essential hypertension showed a good antihypertensive response to propranolol, and 2) in some patients a dosedependent dissociation of the renin and blood pressure lowering action of propranolol could be demonstrated.	Propranolol	118-129	renin	Homo sapiens	370-375
964476-1	1976	The influence of propranolol, 50 mug/kg administered intravenously, on the gastrin concentration during sham feeding and after a test meal was studied in eight normal subjects.	Propranolol	17-28	gastrin	Homo sapiens	75-82
985031-0	1976	[Attempt at potentiation of the action of L-dopa on the secretion of growth hormone by benserazide, disulfiram and propranolol].	Propranolol	115-126	growth hormone 1	Homo sapiens	69-83
1017154-9	1976	The suppressive effect of propranolol on plasma renin activity did not fully correlate with the hypotensive effect of the drug.	Propranolol	26-37	renin	Homo sapiens	48-53
183794-2	1976	When dopamine-beta-hydroxylase was inhibited by bis-(4-methyl-1-homopiperazinyl-thiocarbonyl)-disulfide (Fla 63) the levodopa induced increase of cAMP levels was less marked, it was suppressed by propranolol (10 mg/kg), a beta-adrenergic blocking agent.	Propranolol	196-207	dopamine beta-hydroxylase	Rattus norvegicus	5-30
1030995-0	1976	[The effect of propranolol in arterial hypertensive syndromes with high plasma renin activity].	Propranolol	15-26	renin	Homo sapiens	79-84
6247-2	1976	Our studies of the acute and chronic effects of treatment with propranolol in hypertensive patients showed that the antihypertensive action of the drug was of later onset than the initial cardio-depressant and renin-suppressive effects and had little relationship to the pre-treatment levels of treatment-induced changes in plasma renin activity (PRA).	Propranolol	63-74	renin	Homo sapiens	210-215
6247-2	1976	Our studies of the acute and chronic effects of treatment with propranolol in hypertensive patients showed that the antihypertensive action of the drug was of later onset than the initial cardio-depressant and renin-suppressive effects and had little relationship to the pre-treatment levels of treatment-induced changes in plasma renin activity (PRA).	Propranolol	63-74	renin	Homo sapiens	331-336
1278061-3	1976	To investigate possible central mechanisms of action which were independent of peripheral effects, we tested the action of intravenously administered propranolol on the reflex rise in TPR evoked in rabbits by graded Valsalva-like manoeuvres.	Propranolol	150-161	nucleoprotein TPR	Oryctolagus cuniculus	184-187
1010180-1	1976	The hypotensive effect of propranolol and its correlation with the fall in heart rate, plasma volume and plasma renin activity produced by this drug, were studied in 20 hypertensive hospitalised patients.	Propranolol	26-37	renin	Homo sapiens	112-117
935680-7	1976	The resting PVR increased to a greater extent with propranolol than with phenoxybenzamine.	Propranolol	51-62	PVR cell adhesion molecule	Canis lupus familiaris	12-15
1010180-4	1976	It is concluded that propranolol might be the specific treatment for hypertension in those cases which are accompanied or caused by high plasma renin.	Propranolol	21-32	renin	Homo sapiens	144-149
951017-4	1976	High blood pressure and elevated plasma renin activity have been normalized with a unilateral revascularization in the elder patient, and with the treatment of propranolol in the younger one.	Propranolol	160-171	renin	Homo sapiens	40-45
787950-2	1976	This has made it possible to correlate more closely the antihypertensive action of propranolol with the renin level.	Propranolol	83-94	renin	Homo sapiens	104-109
787950-3	1976	Propranolol reduced renin in all patients but did not lower blood pressure in low renin hypertensive states.	Propranolol	0-11	renin	Homo sapiens	20-25
787950-9	1976	Accordingly, in addition to its therapeutic values, the response to propranolol may provide a pharmacological indicator of the renin involvement in essential hypertension and it also may be a useful adjunct for predicting surgical curability of renovascular hypertension.	Propranolol	68-79	renin	Homo sapiens	127-132
967771-12	1976	A further study was conducted measuring plasma propranolol in twenty hypertensive patients to investigate the fall in blood pressure in relations to the change in plasma renin activity and the inhibition of cardiac adrenergic receptors.	Propranolol	47-58	renin	Homo sapiens	170-175
6958-1	1976	Propranolol administration in the hypoxic model of acute renal failure (ARF) in rats has reduced plasma renin activity (PRA) and uraemia as compared to untreated controls.	Propranolol	0-11	renin	Rattus norvegicus	104-109
6958-4	1976	These results support the view that beta-adrenergic blockade by propranolol reduces the severity of ARF by preventing the post-hypoxic release of renin.	Propranolol	64-75	renin	Rattus norvegicus	146-151
801087-0	1976	[The effect of propranolol on basal and stimulated renin activity in patients with kidney transplantation].	Propranolol	15-26	renin	Homo sapiens	51-56
1064146-4	1976	Propranolol eliminated the gastrin response to hypoglycaemia, pindolol reduced it, and practolol caused no alteration.	Propranolol	0-11	gastrin	Homo sapiens	27-34
175422-0	1975	[The influence of propranolol, practolol and theophylline on the plasma renin activity (author"s transl)].	Propranolol	18-29	renin	Homo sapiens	72-77
1231865-0	1975	[Influence of propranolol on the response of blood cortisol to lysin vasopressin and on the daily variations of blood cortisol in the Stein-Leventhal syndrome].	Propranolol	14-25	arginine vasopressin	Homo sapiens	69-80
175422-1	1975	The stimulating effect of theophylline on the plasma renin activity (PRA) under beta-receptor blockade by propranolol or practolol was investigated in 27 patients with essential hypertension of degree I-II.	Propranolol	106-117	renin	Homo sapiens	53-58
176961-5	1975	Fla-63, an inhibitor of dopamine-beta-hydroxylase lowered the increase induced by L-Dopa which was completely suppressed by propranolol, not by phentolamine, suggesting that the cAMP increase is mediated through a central beta-adrenoceptor stimulation.	Propranolol	124-135	dopamine beta-hydroxylase	Rattus norvegicus	24-49
1183140-1	1975	The effect of propranolol therapy on plasma renin activity and blood pressure control was evaluated in 35 uremic patients receiving intermittent center-based outpatient hemodialysis.	Propranolol	14-25	renin	Homo sapiens	44-49
2125-4	1975	Inhibition of cardiac beta-receptors by propranolol suppressed the positive inotropic effect of insulin.	Propranolol	40-51	insulin	Oryctolagus cuniculus	96-103
1239331-0	1975	The effect of isoprenaline and propranolol on rat myocardial ornithine decarboxylase.	Propranolol	31-42	ornithine decarboxylase 1	Rattus norvegicus	61-84
1103606-13	1975	Treatment with propranolol resulted in marked suppression of the plasma renin activity (1.8 +/- 0.2 ng-ml-1-3 hours-1) and plasma aldosterone levels (8.9 +/- 1.3 ng-100 ml-1).	Propranolol	15-26	renin	Homo sapiens	72-77
1196739-0	1975	Propranolol-augmented, exercise-induced human growth hormone release.	Propranolol	0-11	growth hormone 1	Homo sapiens	46-60
1208570-1	1975	Propranolol administration to rats was studied for its effects on plasma renin activity, renal renin content, and adrenal and brain isorenins.	Propranolol	0-11	renin	Rattus norvegicus	73-78
1208570-1	1975	Propranolol administration to rats was studied for its effects on plasma renin activity, renal renin content, and adrenal and brain isorenins.	Propranolol	0-11	renin	Rattus norvegicus	95-100
1208570-7	1975	These observations are consistent with those seen during chronic administration of propranolol to hypertensive patients and suggest that its antihypertensive effect may in some patients be through the suppression of renin release.	Propranolol	83-94	renin	Rattus norvegicus	216-221
1193000-6	1975	Propanolol consistently reversed both the inotropic and chronotropic actions of prolactin.	Propranolol	0-10	prolactin	Oryctolagus cuniculus	80-89
1182938-7	1975	Infusion of d,l-propranolol decreased renin secretion in both the filtering and the nonfiltering kidneys.	Propranolol	12-27	renin	Canis lupus familiaris	38-43
1182938-8	1975	Following propranolol treatment, furosemide increased renin secretion in the filtering kidney but had no effect on renal resistance.	Propranolol	10-21	renin	Canis lupus familiaris	54-59
809257-7	1975	Moreover, the release of LH after intraventricular infusion of LHRH in E2-treated females was blocked (P less than 0.001) by a single iv injection (90 min before LHRH) of haloperidol (1 mg/kg BW) or phentolamine (5 mg/kg), but was not altered by phenoxybenzamine (3 mg/kg) or propranolol (5 mg/kg).	Propranolol	276-287	gonadotropin releasing hormone 1	Macaca mulatta	63-67
1173985-2	1975	Twenty-nine subjects with normal growth hormone reserves showed a mean maximum rise of 17.4 muU/ml of serum growth hormone in the insulin test whereas the intramuscular injection of glucagon after oral premedication with propranolol produced a rise of 38.5 muU/ml.	Propranolol	221-232	growth hormone 1	Homo sapiens	108-122
241651-0	1975	The effect of propranolol and phentolamine on serum gastrin concentration in response to respiratory acidosis in normal man.	Propranolol	14-25	gastrin	Homo sapiens	52-59
241651-5	1975	50 mug/kg propranolol intravenously produced a decrease of gastrin concentrations from 145 to 127 pg/ml (p less than 0.01) and a total suppression of hypergastrinaemia in response to CO2 rebreathing, suggesting activation of beta-cell receptors in respiratory acidosis.	Propranolol	10-21	gastrin	Homo sapiens	59-66
241811-0	1975	Tyrosine hydroxylase activity in rat brain regions after chronic treatment with +/--propranolol.	Propranolol	80-95	tyrosine hydroxylase	Rattus norvegicus	0-20
808558-2	1975	Since catecholamines may be involved in the regulation of both thyrotropin (TSH) and prolactin (PRL) release from the pituitary, the effect of propranolol on the TSH and PRL responses to thyrotropin-releasing hormone (TRH) was also examined.	Propranolol	143-154	prolactin	Homo sapiens	170-173
1152673-2	1975	Pretreatment of eight of these subjects with propranolol caused a modest increase in the mean peak GH after glucagon (19.4 +/- 2.8 ng/ml) but did not improve the mean peak GH after glucagon when glucose was infused (8.7 +/- 2.8 ng/ml).	Propranolol	45-56	growth hormone 1	Homo sapiens	99-101
241811-5	1975	The propranolol concentrations in the various brain regions in this chronic study were far lower than necessary to produce a significant change in tyrosine hydroxylase activity in acute experiments.	Propranolol	4-15	tyrosine hydroxylase	Rattus norvegicus	147-167
1152673-6	1975	(3) Glucose completely suppresses the propranolol-induced increase in the GH response to glucagon; an adrenergic mechanism may be involved in the control of GH secretion by glucose.	Propranolol	38-49	growth hormone 1	Homo sapiens	74-76
241811-6	1975	It was concluded that chronic propranolol treatment produces a persistent increase in bound tyrosine hydroxylase activity in rat corpus striatum.	Propranolol	30-41	tyrosine hydroxylase	Rattus norvegicus	92-112
1152673-6	1975	(3) Glucose completely suppresses the propranolol-induced increase in the GH response to glucagon; an adrenergic mechanism may be involved in the control of GH secretion by glucose.	Propranolol	38-49	growth hormone 1	Homo sapiens	157-159
1160721-11	1975	Propranolol, a beta-adrenergic blocking agent, appears to reduce the tremor in at least some patients who need treatment.	Propranolol	0-11	amyloid beta precursor protein	Homo sapiens	13-19
1143847-0	1975	[The effect of propranolol on plasma renin level and angiotensin sensitivity in man].	Propranolol	15-26	renin	Homo sapiens	37-42
1159936-4	1975	Propranolol was given to 10 hypertensive patients with CGN and hypotensive effect on renal function was observed.	Propranolol	0-11	cingulin	Homo sapiens	55-58
1149359-5	1975	Propranolol (0.125 mg/kg) caused decreases in systolic pressure and heart rate, and a significant decrease in plasma renin activity.	Propranolol	0-11	renin	Homo sapiens	117-122
1149359-6	1975	Propranolol prevented the renin-releasing effects of isoproterenol and methoxamine, but only the cardiovascular effects of isoproterenol.	Propranolol	0-11	renin	Homo sapiens	26-31
1149359-7	1975	It appears that alpha or beta agonists stimulate renin release equally in man and that at least one step in renin is propranolol-sensitive.	Propranolol	117-128	renin	Homo sapiens	108-113
1177407-0	1975	[Different reaction of plasma renin activity after propranolol in essential and renal hypertension].	Propranolol	51-62	renin	Homo sapiens	30-35
236513-2	1975	Plasma renin activity was elevated by withdrawal of propranolol in seven patients using minoxidil and propranolol.	Propranolol	52-63	renin	Homo sapiens	7-12
236513-2	1975	Plasma renin activity was elevated by withdrawal of propranolol in seven patients using minoxidil and propranolol.	Propranolol	102-113	renin	Homo sapiens	7-12
236513-4	1975	Propranolol lowered blood pressure and plasma renin activity and diminished the hypotensive response to saralasin.	Propranolol	0-11	renin	Homo sapiens	46-51
236513-6	1975	We conclude that angiotensin can be the major determinant of blood pressure in vasodilator-drug treated patients, that propranolol lowering of blood pressure in this vasodilator-beta-blocker drug interaction is related to suppression of renin release, and that the angiotensin feed-back-suppression mechanism for inhibiting renin release in functionally located proximal to beta-adrenergic receptors mediating renin release.	Propranolol	119-130	renin	Homo sapiens	237-242
236513-6	1975	We conclude that angiotensin can be the major determinant of blood pressure in vasodilator-drug treated patients, that propranolol lowering of blood pressure in this vasodilator-beta-blocker drug interaction is related to suppression of renin release, and that the angiotensin feed-back-suppression mechanism for inhibiting renin release in functionally located proximal to beta-adrenergic receptors mediating renin release.	Propranolol	119-130	renin	Homo sapiens	324-329
236513-6	1975	We conclude that angiotensin can be the major determinant of blood pressure in vasodilator-drug treated patients, that propranolol lowering of blood pressure in this vasodilator-beta-blocker drug interaction is related to suppression of renin release, and that the angiotensin feed-back-suppression mechanism for inhibiting renin release in functionally located proximal to beta-adrenergic receptors mediating renin release.	Propranolol	119-130	renin	Homo sapiens	324-329
802645-6	1975	After withdrawal of propranolol plasma renin activity rose on average 40% compared with the value obtained during treatment.	Propranolol	20-31	renin	Homo sapiens	39-44
236841-1	1975	Studies were carried out in 69 patients with essential hypertension to examine the relationship between changes in plasma renin activity (PRA) and arterial pressure (BP) in response to a beta-adrenergic blocking agent, propranolol.	Propranolol	219-230	renin	Homo sapiens	122-127
28880-10	1975	Studies with D-propranolol and with blocking agents with either beta-1 or beta-2 specificity indicated that the effects of beta-adrenoreceptor blockade on renin are directly dependent upon their action on beta-adrenergic receptors, probably of the beta-2 type.	Propranolol	13-26	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	155-160
802646-0	1975	Blood pressure decrease and responsiveness to renin-releasing stimuli under increasing doses of propranolol in patients with essential hypertension.	Propranolol	96-107	renin	Homo sapiens	46-51
802647-2	1975	Prindolol and propranolol chronically cause a fall in mean blood pressure and mean plasma renin activity, but no correlation was observed between the two variables.	Propranolol	14-25	renin	Homo sapiens	90-95
802647-6	1975	Propranolol administered acutely caused the plasma renin activity to fall with no acute change in blood pressure, whereas prindolol caused the blood pressure to fall with no change in plasma renin activity.	Propranolol	0-11	renin	Homo sapiens	51-56
1056279-0	1975	Hypotensive and renin-suppressing activities of propranolol in hypertensive patients.	Propranolol	48-59	renin	Homo sapiens	16-21
1056279-4	1975	Propranolol also reduced plasma renin activity (PRA) in the supine posture, on standing and after intravenous frusemide.	Propranolol	0-11	renin	Homo sapiens	32-37
1093756-0	1975	Effect of salt depletion and propranolol on blood pressure and plasma renin activity in various forms of hypertension.	Propranolol	29-40	renin	Homo sapiens	70-75
1141202-5	1975	Stimulation of CDP-diglyceride labeling from 32P1 occurred at propranolol concentrations between 0.03 and 1.0 mM.	Propranolol	62-73	cut-like homeobox 1	Rattus norvegicus	15-18
1093756-1	1975	The effect of propranolol therapy on the mean arterial pressure (MAP) and plasma renin activity (PRA) was studied in three groups of hypertensive patients who were also treated with saliuretics.	Propranolol	14-25	renin	Homo sapiens	81-86
1098253-15	1975	Corroborative evidence to support these three criteria can be developed from the blood pressure response to angiotensin blocking drugs or to anti-renin therapy with propranolol.	Propranolol	165-176	renin	Homo sapiens	146-151
791319-1	1975	1 Propranolol and pindolol reduced both the blood pressure and plasma renin activity when given chronically to hypertensive patients.	Propranolol	2-13	renin	Homo sapiens	70-75
791319-4	1975	4 Oral propranolol reduced plasma renin activity but did not reduce blood pressure within 4 h of administration; oral pindolol reduced blood pressure but did not reduce plasma renin activity within 4 h of administration.	Propranolol	7-18	renin	Homo sapiens	34-39
1167223-8	1975	Pretreatment with propranolol, a beta adrenergic blocking drug, impaired minoxidil-induced renin and aldosterone release.	Propranolol	18-29	renin	Rattus norvegicus	91-96
1112122-3	1975	Following propranolol the mean airway resistance (AR) in group 1 increased from 4.49 to 5.2 cm H2O/L/sec (P smaller than 0.02) and airway conductance (Gaw) decreased from 0.28 to 0.24 L/sec-1 cm.	Propranolol	10-21	secretory blood group 1, pseudogene	Homo sapiens	186-191
1112122-5	1975	In group 2 following propranolol, the mean AR increased from 3.60 to 4.67 cm H2O1 (P smaller than 0.05), and Gaw decreased from 0.30 to 0.23 L/sec-1/cm H2O1 (P smaller than 0.05).	Propranolol	21-32	secretory blood group 1, pseudogene	Homo sapiens	143-148
236325-2	1975	Propranolol can impair this renin release.	Propranolol	0-11	renin	Rattus norvegicus	28-33
236325-4	1975	In studies with normotensive rats, propranolol impaired renin release and tachycardia resulting from hydralazine and minoxidil and potentiated their hypotensive action.	Propranolol	35-46	renin	Rattus norvegicus	56-61
236325-10	1975	Propranolol was demonstrated to block hydralazine-induced increases in serum renin activity in genetically hypertensive rats.	Propranolol	0-11	renin	Rattus norvegicus	77-82
236325-11	1975	We conclude that hypotensive potentiation of vasocilating drugs by propranolol in these animal models is mediated to a large extent by impairment of renin release.	Propranolol	67-78	renin	Rattus norvegicus	149-154
1077793-0	1975	Effect of volume depletion and subsequent propranolol treatment on blood pressure and plasma renin activity in patients with essential and with renovascular hypertension.	Propranolol	42-53	renin	Homo sapiens	93-98
48835-4	1975	In the propranolol-insulin group there was a significant fall in heart-rate in most subjects and an increase in diastolic pressure.	Propranolol	7-18	insulin	Homo sapiens	19-26
1092284-1	1975	It has been suggested that depression is a disease of cholinergic dominance and since the beta-adrenergic blocking drug propranolol hydrochloride can cause depression, there arises the possibility that a beta-adrenergic stimulant could benefit the condition.	Propranolol	120-145	amyloid beta precursor protein	Homo sapiens	202-208
1233219-0	1975	Effects of metoprolol and propranolol on furosemide-stimulated renin release in healthy subjects.	Propranolol	26-37	renin	Homo sapiens	63-68
1233219-1	1975	The effects of single doses of the beta1-receptor antagonist metoprolol (40 mg orally), propranolol (40 mg orally) and placebo were compared on furosemide-stimulated plasma renin activity (PRA) in seven healthy subjects.	Propranolol	88-99	renin	Homo sapiens	173-178
1171051-8	1975	Interaction between tyramine and clonidine was also seen in vitro, but it disappeared in the reserpinized, denervated or propranolol-pretreated guinea-pig vas deferens.	Propranolol	121-132	arginine vasopressin	Rattus norvegicus	155-158
1124146-0	1975	[Effects of propranolol on some metabolic changes induced with insulin].	Propranolol	12-23	insulin	Homo sapiens	63-70
1124146-1	1975	The effect of propranolol on certain insulin-induced metabolic changes in man.	Propranolol	14-25	insulin	Homo sapiens	37-44
234978-5	1975	Propranolol infusion alone significantly inhibited the basal secretion of PTH.	Propranolol	0-11	parathyroid hormone	Homo sapiens	74-77
234380-3	1975	Phenotlamine, another alpha-adrenergic blocker, and propranolol, a beta-adrenergic blocker, also increased prolactin but the responses were small and transient.	Propranolol	52-63	prolactin	Rattus norvegicus	107-116
1117426-0	1975	Interaction between halothane and propranolol on oxytocin-induced uterine contractions.	Propranolol	34-45	oxytocin/neurophysin I prepropeptide	Homo sapiens	49-57
234005-1	1975	The influence of beta-adrenergic blockade (160 mg per day of propranolol for four weeks) on plasma renin activity, plasma volume, and arterial pressure was explored in 20 patients with essential hypertension with hyper-reninemia from long-term diuretic therapy.	Propranolol	61-72	renin	Homo sapiens	99-104
1229805-0	1975	Effect of propranolol on some adrenaline- and insulin-induced metabolic changes in man.	Propranolol	10-21	insulin	Homo sapiens	46-53
1205007-3	1975	The insulin-induced HC1 secretion was reduced by propranolol from 38 to 18 mEq/2h (p less than 0.01).	Propranolol	49-60	CYCS pseudogene 39	Homo sapiens	20-23
1205007-1	1975	In ten normal subjects the effect of propranolol on serum gastrin concentration and HC1 secretion during insulin hypoglycemia (0.2 U/kg) was studied.	Propranolol	37-48	gastrin	Homo sapiens	58-65
1205007-2	1975	Under the influence of propranolol (50 mug/kg intravenously in 3 min) the gastrin response to insulin was abolished.	Propranolol	23-34	gastrin	Homo sapiens	74-81
1222397-0	1975	[Effects of propranolol on the dynamic changes of plasma-renin-activity in essential arterial hypertension].	Propranolol	12-23	renin	Homo sapiens	57-62
1096294-5	1975	Propranolol blocked the release of renin induced by norepinephrine without affecting either the reduced blood flow thorugh the autograft or the elevated blood pressure.	Propranolol	0-11	renin	Canis lupus familiaris	35-40
1109899-4	1975	Pretreatment with propranolol resulted in a decline of the basal output of both glucagon and insulin and in their marked initial fall at the onset of the stimulus.	Propranolol	18-29	insulin	Canis lupus familiaris	93-100
127931-1	1975	Antagonistic action of propranolol and of isopropylenoradrenaline on renal ATP-ase].	Propranolol	23-34	dynein axonemal heavy chain 8	Homo sapiens	75-82
4373024-0	1974	Differential effects of propranolol on heart rate and plasma renin activity in patients treated with minoxidil.	Propranolol	24-35	renin	Homo sapiens	61-66
1227043-0	1975	[Episodical renin secretion during propranolol and pindolol administration in normal subjects].	Propranolol	35-46	renin	Homo sapiens	12-17
4421829-0	1974	Insulin response to intravenous glucose during long-term treatment with propranolol.	Propranolol	72-83	insulin	Homo sapiens	0-7
4155994-1	1974	The comparative effectiveness of propranolol and ICI 66082, in inhibiting the release of renin from the kidney resulting from renal nerve stimulation, has been studied in the cat.	Propranolol	33-44	renin	Homo sapiens	89-94
4155994-2	1974	Over the dose range 0.17-0.68 x 10(-5) mol/kg propranolol there was a dose-response relationship with the increase of plasma renin activity (PRA) achieved after 10 min stimulation.	Propranolol	46-57	renin	Homo sapiens	125-130
4415299-0	1974	Proceedings: The effect of propranolol on plasma renin and heart rate.	Propranolol	27-38	renin	Homo sapiens	49-54
4154950-1	1974	Continuous 6-h infusions of the beta adrenergic blockers d,l-propranolol or oxprenolol significantly reduced plasma renin activity (PRA) and mean blood pressure in the resting rabbit and prevented the stimulatory effects of isoproterenol on renin release and heart rate.	Propranolol	57-72	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	116-121
4154950-1	1974	Continuous 6-h infusions of the beta adrenergic blockers d,l-propranolol or oxprenolol significantly reduced plasma renin activity (PRA) and mean blood pressure in the resting rabbit and prevented the stimulatory effects of isoproterenol on renin release and heart rate.	Propranolol	57-72	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	241-246
4451780-0	1974	Proceedings: Overflow of (14C)-practolol and (14C)-racemic propranolol from the isolated rat vas deferens.	Propranolol	59-70	arginine vasopressin	Rattus norvegicus	93-96
4598059-0	1974	The effct of propranolol on plasma renin activity and blood pressure in mild essential hypertension.	Propranolol	13-24	renin	Homo sapiens	35-40
4472793-0	1974	[Diagnostic value of glucagon-propranolol test as a growth hormone secretion test].	Propranolol	30-41	growth hormone 1	Homo sapiens	52-66
4473026-0	1974	[Propranolol-glucagon stimulation test for the study of reserve capacity of growth hormone secretion--a comparison with arginine or insulin stimulation tests].	Propranolol	1-12	growth hormone 1	Homo sapiens	76-90
4834461-0	1974	Suppression of plasma renin activity by propranolol: correlation with plasma propranolol levels.	Propranolol	40-51	renin	Homo sapiens	22-27
4834461-0	1974	Suppression of plasma renin activity by propranolol: correlation with plasma propranolol levels.	Propranolol	77-88	renin	Homo sapiens	22-27
4133478-0	1974	Letter: Enhancement of levodopa-induced growth-hormone stimulation by propranolol.	Propranolol	70-81	growth hormone 1	Homo sapiens	40-54
4824603-0	1974	Inhibition of vasopressin-induced morbid effects on the rat kidney by pindolol and propranolol.	Propranolol	83-94	arginine vasopressin	Rattus norvegicus	14-25
4825234-3	1974	Concomitant infusion of propranolol (80 mug/min), a beta adrenergic antagonist, prevented the effects of isoproterenol, although propranolol itself had no effect on basal glucagon secretion.	Propranolol	24-35	amyloid beta precursor protein	Homo sapiens	50-56
4357615-5	1974	beta-Adrenergic stimulation of human leukocytes produced a dose-related reduction in beta-glucuronidase release (blocked by 10(-6) M propranolol) whereas alpha-adrenergic stimulation (phenylephrine plus propranolol) was ineffective.	Propranolol	133-144	glucuronidase beta	Homo sapiens	85-103
4476501-0	1974	[Proceedings: Effect of propranolol on plasma renin activity in hypertension].	Propranolol	24-35	renin	Homo sapiens	46-51
4149613-1	1974	Long-term treatment with propranolol was shown to produce a sustained suppression of the renin-aldosterone system in hypertensive patients, despite concurrent diuretic treatment.	Propranolol	25-36	renin	Homo sapiens	89-94
4787526-0	1973	Proceedings: Inhibitory effect of propranolol on insulin secretion.	Propranolol	34-45	insulin	Homo sapiens	49-56
4454412-0	1974	[Effect of L-DOPA, phentolamine, aminophylline and propranolol on growth hormone secretion in patients with normal anterior pituitary function and subjects with acromegaly].	Propranolol	51-62	growth hormone 1	Homo sapiens	66-80
4454541-0	1974	[Effect of propranolol on the stimulation of renin secretion due to orthostasis and furosemide].	Propranolol	11-22	renin	Homo sapiens	45-50
4149309-0	1973	Propranolol and serum gastrin in postvagotomy insulin tests.	Propranolol	0-11	insulin	Homo sapiens	46-53
4612559-0	1974	Effects of acute and chronic administration of propranolol on blood pressure and plasma renin activity in hypertensive patients.	Propranolol	47-58	renin	Homo sapiens	88-93
4753434-0	1973	Effect of propranolol on plasma growth hormone response in insulin-induced hypoglycemia in thyrotoxic patients.	Propranolol	10-21	growth hormone 1	Homo sapiens	32-46
4753434-0	1973	Effect of propranolol on plasma growth hormone response in insulin-induced hypoglycemia in thyrotoxic patients.	Propranolol	10-21	insulin	Homo sapiens	59-66
4404297-10	1972	It is suggested that the effect of renal nerve stimulation on PRA is mediated, primarily, by changes in renal blood flow and that one of the steps leading to renin release following stimulation is sensitive to propranolol.	Propranolol	210-221	renin	Felis catus	158-163
5084985-0	1972	Propranolol inhibition of renin secretion.	Propranolol	0-11	renin	Homo sapiens	26-31
4354807-0	1973	Effect of propranolol and theophylline on renin release caused by furosemide in the cat.	Propranolol	10-21	renin	Homo sapiens	42-47
4715297-0	1973	Growth hormone responses to propranolol-glucagon stimulation: a comparison with other tests of growth hormone reserve.	Propranolol	28-39	growth hormone 1	Homo sapiens	0-14
4693100-0	1973	The effect in man of (+)-propranolol and racemic propranolol on renin secretion stimulated by orthostatic stress.	Propranolol	21-36	renin	Homo sapiens	64-69
4693100-0	1973	The effect in man of (+)-propranolol and racemic propranolol on renin secretion stimulated by orthostatic stress.	Propranolol	25-36	renin	Homo sapiens	64-69
4403383-5	1972	Plasma cyclic GMP rose in response to infusions of alpha-adrenergic agents, viz., epinephrine or norepinephrine infused together with the beta-blocking agent, propranolol.	Propranolol	159-170	5'-nucleotidase, cytosolic II	Homo sapiens	14-17
4559947-10	1972	The effect of epinephrine and propranolol on acute insulin responses to secretin and glucose was also different.	Propranolol	30-41	insulin	Homo sapiens	51-58
5093710-0	1971	Depressed tolbutamide-induced insulin response in subjects treated with propranolol.	Propranolol	72-83	insulin	Homo sapiens	30-37
4403307-3	1972	Inhibitors of protein synthesis or propranolol, a beta-adrenergic blocking agent completely inhibit(s) the increase in activity of serotonin N-acetyltransferase induced by drugs, indicating that new enzyme molecules are formed via stimulation of beta-receptors of pineal cells and adenosine 3":5"-cyclic monophosphate.	Propranolol	35-46	aralkylamine N-acetyltransferase	Rattus norvegicus	131-160
5040261-0	1972	Immediate haemodynamic effects of a beta adrenergic blocking agent-propranolol-in mitral stenosis at fixed heart rates.	Propranolol	67-78	amyloid beta precursor protein	Homo sapiens	34-40
4928263-2	1971	The intravenous infusion of propranolol, a beta adrenergic-blocking agent, caused a rise in plasma HGH, a transient decrease in blood FFA, and no significant change in plasma insulin.	Propranolol	28-39	amyloid beta precursor protein	Homo sapiens	41-47
5097078-0	1971	Effects of propranolol (a beta adrenergic blocking agent) on some central nervous system parameters.	Propranolol	11-22	amyloid beta precursor protein	Homo sapiens	24-30
4928263-9	1971	On the contrary, a beta adrenergic stimulant, isoproterenol, raised plasma insulin and blood FFA, and abolished the plasma HGH response to propranolol.	Propranolol	139-150	amyloid beta precursor protein	Homo sapiens	17-23
4322478-0	1971	Propranolol-blockade of vasopressin induced increase in plasma progesterone in early human pregnancy.	Propranolol	0-11	arginine vasopressin	Homo sapiens	24-35
5547268-0	1971	Effect of propranolol on the response of serum growth hormone to glucagon.	Propranolol	10-21	growth hormone 1	Homo sapiens	47-61
5660260-0	1968	Increased plasma levels of growth hormone during infusion of propranolol.	Propranolol	61-72	growth hormone 1	Homo sapiens	27-41
5818625-0	1969	Growth hormone response to arginine in normal and hyperthyroid females under propanolol.	Propranolol	77-87	growth hormone 1	Homo sapiens	0-14
5767511-0	1969	[Effect of propranolol on the hypoglycemic action of insulin and tolbutamide in diabetic patients].	Propranolol	11-22	insulin	Homo sapiens	53-60
33751565-7	2021	In vivo, beta-adrenergic blockade with propranolol almost completely reversed the accelerated tumor growth induced by chronic restraint stress, and inactivated CXCL5-CXCR2-Erk signaling pathway.	Propranolol	39-50	chemokine (C-X-C motif) ligand 5	Mus musculus	160-165
4382032-4	1966	The rise in clotting factor VIII induced by adrenaline was blocked by pronethalol and propranalol but not by phentolamine.	Propranolol	86-97	cytochrome c oxidase subunit 8A	Homo sapiens	28-32
33751565-7	2021	In vivo, beta-adrenergic blockade with propranolol almost completely reversed the accelerated tumor growth induced by chronic restraint stress, and inactivated CXCL5-CXCR2-Erk signaling pathway.	Propranolol	39-50	chemokine (C-X-C motif) receptor 2	Mus musculus	166-171
33751565-7	2021	In vivo, beta-adrenergic blockade with propranolol almost completely reversed the accelerated tumor growth induced by chronic restraint stress, and inactivated CXCL5-CXCR2-Erk signaling pathway.	Propranolol	39-50	mitogen-activated protein kinase 1	Mus musculus	172-175
33857227-4	2021	Pharmacological analysis revealed decreased responsiveness to the beta-adrenergic blocker propranolol in CaMKIV-null mice, whereas the plasma norepinephrine level was not affected.	Propranolol	90-101	calcium/calmodulin-dependent protein kinase IV	Mus musculus	105-111
34056714-0	2021	CORRIGENDUM: Propranolol Suppresses the Growth of Colorectal Cancer Through Simultaneously Activating Autologous CD8+ T Cells and Inhibiting Tumor AKT/MAPK Pathway.	Propranolol	13-24	CD8a molecule	Homo sapiens	113-116
34056714-0	2021	CORRIGENDUM: Propranolol Suppresses the Growth of Colorectal Cancer Through Simultaneously Activating Autologous CD8+ T Cells and Inhibiting Tumor AKT/MAPK Pathway.	Propranolol	13-24	AKT serine/threonine kinase 1	Homo sapiens	147-150
34012683-8	2021	Comparing the targets of the herbal strategies and three existing drugs (atenolol, pravastatin and propranolol) and the symbols of coronary artery atherosclerosis, we discovered that MAOA, HTR1A, and ABCG2 are overlapping in the three groups.	Propranolol	99-110	monoamine oxidase A	Homo sapiens	183-187
33981600-5	2021	Propranolol inhibited the phosphorylation of AKT, MEK, and ERK proteins than control in mice tumor tissues respectively (p-AKT 26.16 vs. 56.82, P = 0.0196, p-MEK 28.27 vs. 59.28, P = 0.1102, p-ERK 48.2 vs. 107.4, P = 0.0062).	Propranolol	0-11	thymoma viral proto-oncogene 1	Mus musculus	45-48
33981600-5	2021	Propranolol inhibited the phosphorylation of AKT, MEK, and ERK proteins than control in mice tumor tissues respectively (p-AKT 26.16 vs. 56.82, P = 0.0196, p-MEK 28.27 vs. 59.28, P = 0.1102, p-ERK 48.2 vs. 107.4, P = 0.0062).	Propranolol	0-11	midkine	Mus musculus	50-53
33981600-5	2021	Propranolol inhibited the phosphorylation of AKT, MEK, and ERK proteins than control in mice tumor tissues respectively (p-AKT 26.16 vs. 56.82, P = 0.0196, p-MEK 28.27 vs. 59.28, P = 0.1102, p-ERK 48.2 vs. 107.4, P = 0.0062).	Propranolol	0-11	mitogen-activated protein kinase 1	Mus musculus	59-62
33981600-5	2021	Propranolol inhibited the phosphorylation of AKT, MEK, and ERK proteins than control in mice tumor tissues respectively (p-AKT 26.16 vs. 56.82, P = 0.0196, p-MEK 28.27 vs. 59.28, P = 0.1102, p-ERK 48.2 vs. 107.4, P = 0.0062).	Propranolol	0-11	midkine	Mus musculus	158-161
33981600-5	2021	Propranolol inhibited the phosphorylation of AKT, MEK, and ERK proteins than control in mice tumor tissues respectively (p-AKT 26.16 vs. 56.82, P = 0.0196, p-MEK 28.27 vs. 59.28, P = 0.1102, p-ERK 48.2 vs. 107.4, P = 0.0062).	Propranolol	0-11	mitogen-activated protein kinase 1	Mus musculus	193-196
33981600-9	2021	These results prove that propranolol may inhibit the growth of gastric cancer in mice model and patients and the possible mechanism was via inhibiting the AKT and MAPK pathways, but the frequency of tumor infiltration CD8+ T cells did not increase significantly.	Propranolol	25-36	AKT serine/threonine kinase 1	Homo sapiens	155-158
33950296-0	2021	Computational studies on binding, solvent, and pH effects on (S)-propranolol and methacrylic acid complex.	Propranolol	61-76	phenylalanine hydroxylase	Homo sapiens	47-49
33715934-10	2021	Serum GLUT1, IGF-2, and VEGF-A levels in patients with hemangioma receiving propranolol treatment were significantly higher than in healthy controls.	Propranolol	76-87	solute carrier family 2 member 1	Homo sapiens	6-11
33715934-10	2021	Serum GLUT1, IGF-2, and VEGF-A levels in patients with hemangioma receiving propranolol treatment were significantly higher than in healthy controls.	Propranolol	76-87	insulin like growth factor 2	Homo sapiens	13-18
33715934-10	2021	Serum GLUT1, IGF-2, and VEGF-A levels in patients with hemangioma receiving propranolol treatment were significantly higher than in healthy controls.	Propranolol	76-87	vascular endothelial growth factor A	Homo sapiens	24-30
33715934-11	2021	Serum FGF1 levels were higher in patients with IH, complicated hemangioma, and hemangioma receiving propranolol treatment than in healthy controls but the difference was not statistically significantly.	Propranolol	100-111	fibroblast growth factor 1	Homo sapiens	6-10
33715934-12	2021	CONCLUSION: Serum GLUT1, IGF-2, and VEGF-A levels were positively correlated with disease severity in patients with hemangioma, for example, in complicated hemangioma and hemangioma requiring propranolol treatment.	Propranolol	192-203	solute carrier family 2 member 1	Homo sapiens	18-23
33715934-12	2021	CONCLUSION: Serum GLUT1, IGF-2, and VEGF-A levels were positively correlated with disease severity in patients with hemangioma, for example, in complicated hemangioma and hemangioma requiring propranolol treatment.	Propranolol	192-203	vascular endothelial growth factor A	Homo sapiens	36-42
33938511-11	2021	At 24 hours, both propranolol and amitriptyline reduced TNF-alpha levels while allopurinol and ALM reduced TNF-alpha levels only in NN mice.	Propranolol	18-29	tumor necrosis factor	Mus musculus	56-65
33938511-12	2021	Propranolol, amitriptyline, and ALM demonstrated lower serum MCP-1 7 days after AE.	Propranolol	0-11	mast cell protease 1	Mus musculus	61-66
33927773-13	2021	hGH levels were higher in patients receiving propranolol therapy, but not significantly different.	Propranolol	45-56	gamma-glutamyl hydrolase	Homo sapiens	0-3
33789781-14	2021	In the validation study, robust elevations in plasma AGP were detected on days 2 and 4 in S. aureus infected rats with or without propranolol.	Propranolol	130-141	orosomucoid 1	Rattus norvegicus	53-56
33789781-16	2021	The high correlation between plasma propranolol and AGP demonstrated a direct impact of AGP on drug pharmacokinetics and pharmacodynamics.	Propranolol	36-47	orosomucoid 1	Rattus norvegicus	52-55
33789781-16	2021	The high correlation between plasma propranolol and AGP demonstrated a direct impact of AGP on drug pharmacokinetics and pharmacodynamics.	Propranolol	36-47	orosomucoid 1	Rattus norvegicus	88-91
33373851-5	2021	RESULTS: Bone marrow HMGB1, G-CSF, and neutrophil elastase expression were significantly elevated two- to four-fold after LCHS/CS, and all were decreased with the use of propranolol.	Propranolol	170-181	high mobility group box 1	Rattus norvegicus	21-26
33373851-5	2021	RESULTS: Bone marrow HMGB1, G-CSF, and neutrophil elastase expression were significantly elevated two- to four-fold after LCHS/CS, and all were decreased with the use of propranolol.	Propranolol	170-181	colony stimulating factor 3	Rattus norvegicus	28-33
33373851-5	2021	RESULTS: Bone marrow HMGB1, G-CSF, and neutrophil elastase expression were significantly elevated two- to four-fold after LCHS/CS, and all were decreased with the use of propranolol.	Propranolol	170-181	elastase, neutrophil expressed	Rattus norvegicus	39-58
33373851-8	2021	Propranolol"s ability to reduce HMGB1, G-CSF, and neutrophil elastase expression suggests that the mobilization of hematopoietic progenitor cells was driven by persistent hypercatecholaminemia.	Propranolol	0-11	high mobility group box 1	Rattus norvegicus	32-37
33373851-8	2021	Propranolol"s ability to reduce HMGB1, G-CSF, and neutrophil elastase expression suggests that the mobilization of hematopoietic progenitor cells was driven by persistent hypercatecholaminemia.	Propranolol	0-11	colony stimulating factor 3	Rattus norvegicus	39-44
33373851-8	2021	Propranolol"s ability to reduce HMGB1, G-CSF, and neutrophil elastase expression suggests that the mobilization of hematopoietic progenitor cells was driven by persistent hypercatecholaminemia.	Propranolol	0-11	elastase, neutrophil expressed	Rattus norvegicus	50-69
33782804-9	2021	Propranolol also decreased the expression of phosphorylated CREB-ATF and MEK-ERK pathways; suppressed the expression of matrix metalloproteinase-2, 9 and vascular endothelial growth factor; and inhibited gastric cancer cell migration.	Propranolol	0-11	cAMP responsive element binding protein 1	Homo sapiens	60-64
33782804-9	2021	Propranolol also decreased the expression of phosphorylated CREB-ATF and MEK-ERK pathways; suppressed the expression of matrix metalloproteinase-2, 9 and vascular endothelial growth factor; and inhibited gastric cancer cell migration.	Propranolol	0-11	matrix metallopeptidase 2	Homo sapiens	120-146
33782804-9	2021	Propranolol also decreased the expression of phosphorylated CREB-ATF and MEK-ERK pathways; suppressed the expression of matrix metalloproteinase-2, 9 and vascular endothelial growth factor; and inhibited gastric cancer cell migration.	Propranolol	0-11	glial cell derived neurotrophic factor	Homo sapiens	65-68
33782804-9	2021	Propranolol also decreased the expression of phosphorylated CREB-ATF and MEK-ERK pathways; suppressed the expression of matrix metalloproteinase-2, 9 and vascular endothelial growth factor; and inhibited gastric cancer cell migration.	Propranolol	0-11	vascular endothelial growth factor A	Homo sapiens	154-188
33782804-9	2021	Propranolol also decreased the expression of phosphorylated CREB-ATF and MEK-ERK pathways; suppressed the expression of matrix metalloproteinase-2, 9 and vascular endothelial growth factor; and inhibited gastric cancer cell migration.	Propranolol	0-11	mitogen-activated protein kinase kinase 7	Homo sapiens	73-76
33782804-9	2021	Propranolol also decreased the expression of phosphorylated CREB-ATF and MEK-ERK pathways; suppressed the expression of matrix metalloproteinase-2, 9 and vascular endothelial growth factor; and inhibited gastric cancer cell migration.	Propranolol	0-11	mitogen-activated protein kinase 1	Homo sapiens	77-80
33453362-4	2021	Since the discovery of propranolol, a non-selective beta-blocker inhibiting both beta1- and beta2-adrenoreceptors (beta-ARs), various selective beta1-blockers, including bisoprolol, have been developed to overcome disadvantages associated with beta2-AR inhibition.	Propranolol	23-34	BCL2 related protein A1	Homo sapiens	144-149
33453362-4	2021	Since the discovery of propranolol, a non-selective beta-blocker inhibiting both beta1- and beta2-adrenoreceptors (beta-ARs), various selective beta1-blockers, including bisoprolol, have been developed to overcome disadvantages associated with beta2-AR inhibition.	Propranolol	23-34	adenosine A2a receptor	Homo sapiens	244-252
33453362-4	2021	Since the discovery of propranolol, a non-selective beta-blocker inhibiting both beta1- and beta2-adrenoreceptors (beta-ARs), various selective beta1-blockers, including bisoprolol, have been developed to overcome disadvantages associated with beta2-AR inhibition.	Propranolol	23-34	BCL2 related protein A1	Homo sapiens	81-86
33654276-0	2022	Infantile hemangiomas beta3-adrenoceptor overexpression is associated with nonresponse to propranolol.	Propranolol	90-101	adrenoceptor beta 3	Homo sapiens	22-40
32842148-14	2021	Early administration of propranolol in burn patients supports erythropoiesis via the chaperone AHSP.	Propranolol	24-35	alpha hemoglobin stabilizing protein	Homo sapiens	95-99
33654276-1	2022	BACKGROUND: Propranolol (antagonist of beta1-/beta2-AR but minimally active against beta3-AR) is currently the first-line treatment for infantile hemangiomas (IH).	Propranolol	12-23	adenosine A3 receptor	Homo sapiens	84-92
33654276-10	2022	CONCLUSIONS: Although the number of biopsies is insufficient to draw definitive conclusions, and the different beta-AR pattern may be theoretically explained by the different timing of samplings, this study suggests a possible correlation between beta3-AR expression and the reduced responsiveness to propranolol treatment.	Propranolol	301-312	immunoglobulin kappa variable 2D-28	Homo sapiens	247-252
33654276-12	2022	IMPACT: Propranolol (unselective antagonist of beta1 and beta2-ARs) is currently the first-line treatment for IHs, with a success rate of ~60%.	Propranolol	8-19	BCL2 related protein A1	Homo sapiens	47-52
33654276-12	2022	IMPACT: Propranolol (unselective antagonist of beta1 and beta2-ARs) is currently the first-line treatment for IHs, with a success rate of ~60%.	Propranolol	8-19	ATPase H+ transporting V0 subunit a2	Homo sapiens	57-62
33535016-1	2021	Purpose: Propranolol, a nonselective B1/B2 adrenoceptor antagonist, promotes the regression of infantile hemangiomas likely through suppression of vascular endothelial growth factor (VEGF), which prompted its use for the prevention of retinopathy of prematurity.	Propranolol	9-20	vascular endothelial growth factor A	Rattus norvegicus	147-181
33535016-1	2021	Purpose: Propranolol, a nonselective B1/B2 adrenoceptor antagonist, promotes the regression of infantile hemangiomas likely through suppression of vascular endothelial growth factor (VEGF), which prompted its use for the prevention of retinopathy of prematurity.	Propranolol	9-20	vascular endothelial growth factor A	Rattus norvegicus	183-187
33535016-7	2021	The beneficial effects of propranolol were associated with reduced ocular VEGF and increased endogenous soluble inhibitor, sVEGFR-1, when administered topically.	Propranolol	26-37	vascular endothelial growth factor A	Rattus norvegicus	74-78
33274548-7	2021	Propranolol, a beta-adrenoreceptor which is also a LPIN1 inhibitor, enhanced the in vitro and in vivo cytotoxicity and antitumor effect of FK-A11.	Propranolol	0-11	lipin 1	Homo sapiens	51-56
33558238-0	2021	Critical role of Aquaporin-1 and telocytes in infantile hemangioma response to propranolol beta blockade.	Propranolol	79-90	aquaporin 1 (Colton blood group)	Homo sapiens	17-28
33558238-7	2021	Our functional protein association networks analysis and knockdown of ADRB2 and AQP1 indicated that propranolol treatment and AQP1 down-regulation trigger the same pathway, suggesting that AQP1 is a major driver of beta-blocker antitumor response.	Propranolol	100-111	adrenoceptor beta 2	Homo sapiens	70-75
33558238-7	2021	Our functional protein association networks analysis and knockdown of ADRB2 and AQP1 indicated that propranolol treatment and AQP1 down-regulation trigger the same pathway, suggesting that AQP1 is a major driver of beta-blocker antitumor response.	Propranolol	100-111	aquaporin 1 (Colton blood group)	Homo sapiens	80-84
33558238-9	2021	Functional in vitro studies showed that AQP1-positive TCs play a critical role in IH response to propranolol and that modulation of AQP1 in IH-TC by propranolol or shAQP1 decreases capillary-like tube formation in a Matrigel-based angiogenesis assay.	Propranolol	97-108	aquaporin 1 (Colton blood group)	Homo sapiens	40-44
33558238-9	2021	Functional in vitro studies showed that AQP1-positive TCs play a critical role in IH response to propranolol and that modulation of AQP1 in IH-TC by propranolol or shAQP1 decreases capillary-like tube formation in a Matrigel-based angiogenesis assay.	Propranolol	149-160	aquaporin 1 (Colton blood group)	Homo sapiens	132-136
33634164-5	2020	Recent work on targeting IH stem cells by inhibiting the transcription factor SOX18 using the stereoisomer R(+) propranolol, independent of beta-adrenergic blockade, opens up exciting opportunities for novel treatment of IH without the beta-adrenergic blockade-related side effects.	Propranolol	112-123	SRY-box transcription factor 18	Homo sapiens	78-83
33301422-0	2021	Propranolol inhibits cavernous vascular malformations by beta1 adrenergic receptor antagonism.	Propranolol	0-11	adrenoceptor beta 1	Danio rerio	57-82
33301422-3	2021	We report that propranolol or its S(-) enantiomer dramatically reduced embryonic venous cavernomas in ccm2 mosaic zebrafish, whereas R-(+)-propranolol, lacking beta-antagonism, had no effect.	Propranolol	15-26	CCM2 scaffold protein	Danio rerio	102-106
33301422-4	2021	Silencing of beta1, but not beta2, adrenergic receptor mimicked the beneficial effects of propranolol in a zebrafish CCM model as did a beta1-selective antagonist, metoprolol.	Propranolol	90-101	zgc:113912	Danio rerio	13-18
33301422-5	2021	Thus, propranolol ameliorates cavernous malformations by beta1 adrenergic antagonism in zebrafish.	Propranolol	6-17	zgc:113912	Danio rerio	57-62
33301422-6	2021	Oral propranolol significantly reduced lesion burden in two chronic murine models of the exceptionally aggressive Pdcd10/Ccm3 form of CCM.	Propranolol	5-16	programmed cell death 10	Mus musculus	114-120
33301422-6	2021	Oral propranolol significantly reduced lesion burden in two chronic murine models of the exceptionally aggressive Pdcd10/Ccm3 form of CCM.	Propranolol	5-16	programmed cell death 10	Mus musculus	121-125
33167255-6	2021	Limits of detection (LODs) for propranolol and atenolol were 5.0 ng mL-1 and 7.5 ng mL-1, respectively.	Propranolol	31-42	L1 cell adhesion molecule	Mus musculus	68-72
33575332-0	2021	Propranolol Participates in the Treatment of Infantile Hemangioma by Inhibiting HUVECs Proliferation, Migration, Invasion, and Tube Formation.	Propranolol	0-11	tubulin epsilon 1	Homo sapiens	127-131
33575332-6	2021	Results: Compared with the control group, propranolol could significantly inhibit the proliferation, migration, invasion, adhesion, and tube formation of HUVECs.	Propranolol	42-53	tubulin epsilon 1	Homo sapiens	136-140
33575332-8	2021	Conclusion: Propranolol can inhibit the proliferation, migration, invasion, adhesion, and tube formation of hemangioma endothelial cells; block VEGF-mediated angiogenesis signaling pathway; suppress the expressions of downstream angiogenesis-related signaling molecules; and ultimately achieve the effect of treatment of IHs.	Propranolol	12-23	tubulin epsilon 1	Homo sapiens	90-94
33575332-8	2021	Conclusion: Propranolol can inhibit the proliferation, migration, invasion, adhesion, and tube formation of hemangioma endothelial cells; block VEGF-mediated angiogenesis signaling pathway; suppress the expressions of downstream angiogenesis-related signaling molecules; and ultimately achieve the effect of treatment of IHs.	Propranolol	12-23	vascular endothelial growth factor A	Homo sapiens	144-148
33167255-6	2021	Limits of detection (LODs) for propranolol and atenolol were 5.0 ng mL-1 and 7.5 ng mL-1, respectively.	Propranolol	31-42	L1 cell adhesion molecule	Mus musculus	84-88
33397254-2	2021	CYP1A2 metabolises many clinical drugs, such as phenacetin, caffeine, clozapine, tacrine, propranolol, and mexiletine.	Propranolol	90-101	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	0-6
33098837-10	2021	Taken together, our results demonstrate that the cardioprotective effects of PRO on CLZ-induced myocarditis are related in addition to its beta-blocking activity to protection of myocardial VIM and CX43 proteins through antagonizing the CLZ-induced oxidative stress and inflammatory response, and preventing cell apoptosis.	Propranolol	77-80	vimentin	Rattus norvegicus	190-193
33098837-10	2021	Taken together, our results demonstrate that the cardioprotective effects of PRO on CLZ-induced myocarditis are related in addition to its beta-blocking activity to protection of myocardial VIM and CX43 proteins through antagonizing the CLZ-induced oxidative stress and inflammatory response, and preventing cell apoptosis.	Propranolol	77-80	gap junction protein, alpha 1	Rattus norvegicus	198-202
33098837-9	2021	Coadministration of PRO with CLZ, dose-dependently decreased the biochemical and immunohistochemical hallmarks of CLZ-induced myocardial injury and significantly decreased mRNA expression of VIM and CX43.	Propranolol	20-23	vimentin	Rattus norvegicus	191-194
33098837-9	2021	Coadministration of PRO with CLZ, dose-dependently decreased the biochemical and immunohistochemical hallmarks of CLZ-induced myocardial injury and significantly decreased mRNA expression of VIM and CX43.	Propranolol	20-23	gap junction protein, alpha 1	Rattus norvegicus	199-203
33264700-8	2021	Its applicability was finally demonstrated on the determination of apparent binding parameters of bovine serum albumin for basic drugs propranolol and lidocaine and acid drug phenylbutazone.	Propranolol	135-146	albumin	Homo sapiens	105-118
33039519-6	2020	Nerve optostimulation increased motor synaptic vesicle release in vitro and in vivo, while the presynaptic adrenoceptor blockers propranolol (beta1/beta2) and atenolol (beta1) prevented this outcome.	Propranolol	129-140	brain protein 1	Mus musculus	142-153
33301773-15	2021	After being exposed to inflammatory conditions induced by glutamate, TNF-alpha, and LPS, paeonol and propranolol pretreatment significantly increased the uptake of both [3H]paeonol and [3H]propranolol in TR-iBRB cell lines compared to their respective controls.	Propranolol	101-112	tumor necrosis factor	Rattus norvegicus	69-78
33301773-15	2021	After being exposed to inflammatory conditions induced by glutamate, TNF-alpha, and LPS, paeonol and propranolol pretreatment significantly increased the uptake of both [3H]paeonol and [3H]propranolol in TR-iBRB cell lines compared to their respective controls.	Propranolol	189-200	tumor necrosis factor	Rattus norvegicus	69-78
32418526-28	2021	Namely, in a paper about tremor, in the part about treatment, instead of (or in addition to) BB, should list "propranolol" (which blocks strongly beta2-ARs) and not e.g. bisoprolol (because it is a beta1-selective BB and therefore not indicated for tremor treatment).	Propranolol	110-121	ATPase H+ transporting V0 subunit a2	Homo sapiens	146-151
33379854-31	2020	(4) After 24 hours of culture, the phosphorylation levels of Akt of cells in simple NE group and propranolol+ NE group were significantly higher than the level in PBS group (t=8.186, 5.996, P<0.01).	Propranolol	97-108	thymoma viral proto-oncogene 1	Mus musculus	61-64
33165197-7	2020	Furthermore, in CRS rats, propranolol significantly decreased the spatial learning and memory abilities, and attenuated the fEPSP response during MWM test, and the BDNF expression and CREB activation in the dentate gyrus.	Propranolol	26-37	brain-derived neurotrophic factor	Rattus norvegicus	164-168
32450072-1	2020	Propranolol is a ss-adrenoreceptor type 2 (ADRB2) blocker that regulates heart muscle contractions, smooth muscle relaxation and glycogenolysis.	Propranolol	0-11	adrenergic receptor, beta 2	Mus musculus	43-48
32450072-3	2020	We here show that propranolol enhances IL-8-induced neutrophil chemotaxis and reduces the release of reactive oxygen species (ROS) after immune complex (IC) stimulation.	Propranolol	18-29	chemokine (C-X-C motif) ligand 15	Mus musculus	39-43
32450072-7	2020	To validate the identified propranolol gene signature obtained in human neutrophils, we analyzed a selection of genes by RT-PCR in mouse EBA skin and confirmed TNF, among others, to be differentially regulated by propranolol treatment.	Propranolol	27-38	tumor necrosis factor	Mus musculus	160-163
32450072-7	2020	To validate the identified propranolol gene signature obtained in human neutrophils, we analyzed a selection of genes by RT-PCR in mouse EBA skin and confirmed TNF, among others, to be differentially regulated by propranolol treatment.	Propranolol	213-224	tumor necrosis factor	Mus musculus	160-163
33039519-6	2020	Nerve optostimulation increased motor synaptic vesicle release in vitro and in vivo, while the presynaptic adrenoceptor blockers propranolol (beta1/beta2) and atenolol (beta1) prevented this outcome.	Propranolol	129-140	brain protein 1	Mus musculus	142-147
33228233-5	2020	We indicated a double action of propranolol in the tumour microenvironment by inhibiting the stability of HIF1alpha, thus mediating decrease of CA IX expression and, at the same time, by its possible effect on CA IX activity by decreasing the activity of protein kinase A (PKA).	Propranolol	32-43	hypoxia inducible factor 1 subunit alpha	Homo sapiens	106-115
33255421-6	2020	METHODS: We used conditional Slc6a3DTR/+ mice to model progressive DA deficiency and the beta-adrenergic receptor (beta-AR) antagonist propranolol to limit the activity of striatal cholinergic interneurons (ChIs).	Propranolol	135-146	adrenergic receptor, beta 1	Mus musculus	115-122
33228233-5	2020	We indicated a double action of propranolol in the tumour microenvironment by inhibiting the stability of HIF1alpha, thus mediating decrease of CA IX expression and, at the same time, by its possible effect on CA IX activity by decreasing the activity of protein kinase A (PKA).	Propranolol	32-43	carbonic anhydrase 9	Homo sapiens	144-149
33228233-0	2020	Impairment of Hypoxia-Induced CA IX by Beta-Blocker Propranolol-Impact on Progression and Metastatic Potential of Colorectal Cancer Cells.	Propranolol	52-63	carbonic anhydrase 9	Homo sapiens	30-35
33228233-5	2020	We indicated a double action of propranolol in the tumour microenvironment by inhibiting the stability of HIF1alpha, thus mediating decrease of CA IX expression and, at the same time, by its possible effect on CA IX activity by decreasing the activity of protein kinase A (PKA).	Propranolol	32-43	carbonic anhydrase 9	Homo sapiens	210-215
33228233-6	2020	Moreover, the inhibition of beta-adrenoreceptors by propranolol enhanced apoptosis, decreased number of mitochondria and lowered the amount of proteins involved in oxidative phosphorylation (V-ATP5A, IV-COX2, III-UQCRC2, II-SDHB, I-NDUFB8).	Propranolol	52-63	ATP synthase F1 subunit alpha	Homo sapiens	193-198
33228233-4	2020	Non-selective beta-blocker propranolol decreased ability of tumour cells to adapt to hypoxia by reducing levels of HIF1alpha and carbonic anhydrase IX in 3D spheroids.	Propranolol	27-38	hypoxia inducible factor 1 subunit alpha	Homo sapiens	115-124
33228233-4	2020	Non-selective beta-blocker propranolol decreased ability of tumour cells to adapt to hypoxia by reducing levels of HIF1alpha and carbonic anhydrase IX in 3D spheroids.	Propranolol	27-38	carbonic anhydrase 9	Homo sapiens	129-150
33228233-6	2020	Moreover, the inhibition of beta-adrenoreceptors by propranolol enhanced apoptosis, decreased number of mitochondria and lowered the amount of proteins involved in oxidative phosphorylation (V-ATP5A, IV-COX2, III-UQCRC2, II-SDHB, I-NDUFB8).	Propranolol	52-63	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	203-207
32311699-9	2020	Patients with higher bFGF and VEGF levels showed better response to propranolol at 1 year.	Propranolol	68-79	fibroblast growth factor 2	Homo sapiens	21-25
33228181-1	2020	In this work, one of the most prevalent polypharmacology drug-drug interaction events that occurs between two widely used beta-blocker drugs-i.e., acebutolol and propranolol-with the most abundant blood plasma fibrinogen protein was evaluated.	Propranolol	162-173	fibrinogen beta chain	Homo sapiens	210-220
32980903-10	2020	Tumors from propranolol-treated rats exhibited reduced concentrations of pro-inflammatory cytokines IL-6 and TNF-alpha.	Propranolol	12-23	interleukin 6	Rattus norvegicus	100-104
32980903-10	2020	Tumors from propranolol-treated rats exhibited reduced concentrations of pro-inflammatory cytokines IL-6 and TNF-alpha.	Propranolol	12-23	tumor necrosis factor	Rattus norvegicus	109-118
32761352-6	2020	A 4-h intracerebroventricular (ICV) pretreatment with the CYP2D inhibitor propranolol increased harmine-induced hypothermia and tremor in TG and increased harmine-induced hypothermia in WT.	Propranolol	74-85	cytochrome P450, 2d region	Mus musculus	58-63
32761352-8	2020	A 24-h ICV propranolol pretreatment, which selectively and irreversibly inhibits human CYP2D6 in TG brain, increased harmine-induced hypothermia.	Propranolol	11-22	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	87-93
32394273-2	2020	Recent studies suggest that propranolol (common treatment for ET) can augment pathologic expression of alpha-synuclein.	Propranolol	28-39	synuclein alpha	Homo sapiens	103-118
32311699-9	2020	Patients with higher bFGF and VEGF levels showed better response to propranolol at 1 year.	Propranolol	68-79	vascular endothelial growth factor A	Homo sapiens	30-34
32311699-11	2020	Pretreatment bFGF and VEGF could be novel biomarkers for predicting response to propranolol.	Propranolol	80-91	fibroblast growth factor 2	Homo sapiens	13-17
32311699-11	2020	Pretreatment bFGF and VEGF could be novel biomarkers for predicting response to propranolol.	Propranolol	80-91	vascular endothelial growth factor A	Homo sapiens	22-26
32980771-6	2020	Those with dystonic golfer"s cramp had more putts with the yips and yips with co-contraction when two-handed putting looking at the ball, no increase when putting right hand only, less smoothness of putter movement, and all of these improved following propranolol and when looking at the hole.	Propranolol	252-263	cathelicidin antimicrobial peptide	Homo sapiens	29-34
32311699-12	2020	IMPACT: We found that decreases in the concentrations of MMP-2, bFGF, VEGF, and MCP-1 were associated with regression of the hemangioma, which indicates that one of the mechanisms of propranolol in the treatment of proliferative hemangiomas may involve downregulation of those cytokines.Patients with higher bFGF and VEGF levels showed better response to propranolol at 1 year.	Propranolol	183-194	matrix metallopeptidase 2	Homo sapiens	57-62
32980771-9	2020	Propranolol and looking at the hole only improved dystonic golfer"s cramp putting.	Propranolol	0-11	cathelicidin antimicrobial peptide	Homo sapiens	68-73
32311699-12	2020	IMPACT: We found that decreases in the concentrations of MMP-2, bFGF, VEGF, and MCP-1 were associated with regression of the hemangioma, which indicates that one of the mechanisms of propranolol in the treatment of proliferative hemangiomas may involve downregulation of those cytokines.Patients with higher bFGF and VEGF levels showed better response to propranolol at 1 year.	Propranolol	183-194	fibroblast growth factor 2	Homo sapiens	64-68
32311699-12	2020	IMPACT: We found that decreases in the concentrations of MMP-2, bFGF, VEGF, and MCP-1 were associated with regression of the hemangioma, which indicates that one of the mechanisms of propranolol in the treatment of proliferative hemangiomas may involve downregulation of those cytokines.Patients with higher bFGF and VEGF levels showed better response to propranolol at 1 year.	Propranolol	183-194	vascular endothelial growth factor A	Homo sapiens	70-74
32311699-12	2020	IMPACT: We found that decreases in the concentrations of MMP-2, bFGF, VEGF, and MCP-1 were associated with regression of the hemangioma, which indicates that one of the mechanisms of propranolol in the treatment of proliferative hemangiomas may involve downregulation of those cytokines.Patients with higher bFGF and VEGF levels showed better response to propranolol at 1 year.	Propranolol	183-194	C-C motif chemokine ligand 2	Homo sapiens	80-85
32311699-12	2020	IMPACT: We found that decreases in the concentrations of MMP-2, bFGF, VEGF, and MCP-1 were associated with regression of the hemangioma, which indicates that one of the mechanisms of propranolol in the treatment of proliferative hemangiomas may involve downregulation of those cytokines.Patients with higher bFGF and VEGF levels showed better response to propranolol at 1 year.	Propranolol	183-194	fibroblast growth factor 2	Homo sapiens	308-312
32311699-12	2020	IMPACT: We found that decreases in the concentrations of MMP-2, bFGF, VEGF, and MCP-1 were associated with regression of the hemangioma, which indicates that one of the mechanisms of propranolol in the treatment of proliferative hemangiomas may involve downregulation of those cytokines.Patients with higher bFGF and VEGF levels showed better response to propranolol at 1 year.	Propranolol	183-194	vascular endothelial growth factor A	Homo sapiens	317-321
32311699-13	2020	Importantly, serum bFGF higher than 37.07 pg/mL may predict an excellent response to propranolol.	Propranolol	85-96	fibroblast growth factor 2	Homo sapiens	19-23
32311699-14	2020	Therefore, along with the patient"s age and the size and visual characteristics of the lesion, bFGF levels could help determine the viability of propranolol use in the treatment of IHs.Our study represented extensive serum profiling in IH, reporting the indicators and molecules clearly related to IH regression with propranolol treatment.	Propranolol	145-156	fibroblast growth factor 2	Homo sapiens	95-99
32585157-13	2020	In vitro studies showed that propranolol does not affect beta-MHC expression on its own but antagonizes catecholamine effects on beta-MHC expression.	Propranolol	29-40	myosin, heavy polypeptide 7, cardiac muscle, beta	Mus musculus	129-137
32941854-11	2020	The presented findings may have clinical implications for the prediction of potential drug-drug interactions involving the asenapine-induced inhibition of metabolism of CYP1A2 substrates (e.g. caffeine, theophylline, melatonin, tricyclic antidepressants, phenacetin, propranolol) and iloperidone-induced inhibition of CYP3A4 substrates (e.g. antidepressants, benzodiazepines, atorvastatin, macrolide antibiotics, calcium channel antagonists).	Propranolol	267-278	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	169-175
33051441-2	2020	Propranolol administration during CS retrieval-induced reconsolidation can impair fear memory that is specific to the reactivated CS.	Propranolol	0-11	citrate synthase	Homo sapiens	34-36
33051441-2	2020	Propranolol administration during CS retrieval-induced reconsolidation can impair fear memory that is specific to the reactivated CS.	Propranolol	0-11	citrate synthase	Homo sapiens	130-132
33051441-4	2020	The present study sought to develop and test a US-based memory retrieval interference procedure with propranolol to disrupt the original fear memory and eliminate all CS-associated fear responses in humans.	Propranolol	101-112	citrate synthase	Homo sapiens	167-169
33051441-9	2020	However, propranolol administration before CS retrieval only inhibited the fear memory that was related to the reactivated CS.	Propranolol	9-20	citrate synthase	Homo sapiens	123-125
31904616-9	2020	RESULTS: Propranolol and clonidine significantly decreased bone marrow MMP-9 expression, plasma corticosterone levels, and HPC mobilization, and significantly increased hemoglobin levels.	Propranolol	9-20	matrix metallopeptidase 9	Rattus norvegicus	71-76
31904616-13	2020	Attenuating the neuroendocrine response to injury and stress with propranolol and clonidine reduced MMP-9 expression, corticosterone levels, HPC mobilization, and the degree of anemia.	Propranolol	66-77	matrix metallopeptidase 9	Rattus norvegicus	100-105
32921577-4	2020	Finally, the incidence was evaluated in mice that had received perioperative administration of aprepitant (an NK1R inhibitor), propranolol (a beta-blocker) or vehicle.	Propranolol	127-138	amyloid beta (A4) precursor protein	Mus musculus	140-146
32801034-8	2020	Furthermore, there was a significant reduction (p <= 0.05) in the effect of norepinephrine on cell migration when the beta2-AR was inhibited by propranolol.	Propranolol	144-155	adenosine A2a receptor	Homo sapiens	118-126
32854260-6	2020	Propranolol and ICI-118,551 activated apoptosis inhibited gene and protein expression of HIF-2alpha, CAIX, and VEGF, and impaired partially the nuclear internalization of HIF-2alpha and NFkB/p65.	Propranolol	0-11	carbonic anhydrase 9	Homo sapiens	101-105
32418204-6	2020	Propranolol downregulated the expression of p-AKT/p-ERK/p-MEK in tumor tissue.	Propranolol	0-11	AKT serine/threonine kinase 1	Homo sapiens	46-49
32418204-6	2020	Propranolol downregulated the expression of p-AKT/p-ERK/p-MEK in tumor tissue.	Propranolol	0-11	mitogen-activated protein kinase 1	Homo sapiens	52-55
32418204-6	2020	Propranolol downregulated the expression of p-AKT/p-ERK/p-MEK in tumor tissue.	Propranolol	0-11	mitogen-activated protein kinase kinase 7	Homo sapiens	58-61
32418204-8	2020	The expression of GzmB/IFN-gamma/T-bet in the CD8+ T-cell population was significantly increased in propranolol treated mice tumor tissue.	Propranolol	100-111	granzyme B	Mus musculus	18-22
32418204-8	2020	The expression of GzmB/IFN-gamma/T-bet in the CD8+ T-cell population was significantly increased in propranolol treated mice tumor tissue.	Propranolol	100-111	interferon gamma	Mus musculus	23-32
32418204-8	2020	The expression of GzmB/IFN-gamma/T-bet in the CD8+ T-cell population was significantly increased in propranolol treated mice tumor tissue.	Propranolol	100-111	T-box 21	Mus musculus	33-38
32418204-9	2020	In propranolol-treated surgical specimens, the expression of p-ERK was decreased and the frequency of CD8+ was significantly elevated.	Propranolol	3-14	mitogen-activated protein kinase 1	Mus musculus	63-66
32418204-10	2020	The expression of GzmB in the CD8+ T-cell population was significantly increased in propranolol-treated subjects.	Propranolol	84-95	granzyme B	Mus musculus	18-22
32418204-11	2020	Together these data show propranolol simultaneously activating autologous CD8+ T cells and decreasing the expression of p-AKT/p-ERK/p-MEK in mouse tumor models, while inhibiting the expression of p-ERK in clinical colorectal cancer.	Propranolol	25-36	thymoma viral proto-oncogene 1	Mus musculus	122-125
32418204-11	2020	Together these data show propranolol simultaneously activating autologous CD8+ T cells and decreasing the expression of p-AKT/p-ERK/p-MEK in mouse tumor models, while inhibiting the expression of p-ERK in clinical colorectal cancer.	Propranolol	25-36	mitogen-activated protein kinase 1	Mus musculus	128-131
32418204-11	2020	Together these data show propranolol simultaneously activating autologous CD8+ T cells and decreasing the expression of p-AKT/p-ERK/p-MEK in mouse tumor models, while inhibiting the expression of p-ERK in clinical colorectal cancer.	Propranolol	25-36	midkine	Mus musculus	134-137
32418204-11	2020	Together these data show propranolol simultaneously activating autologous CD8+ T cells and decreasing the expression of p-AKT/p-ERK/p-MEK in mouse tumor models, while inhibiting the expression of p-ERK in clinical colorectal cancer.	Propranolol	25-36	mitogen-activated protein kinase 1	Mus musculus	198-201
32854260-6	2020	Propranolol and ICI-118,551 activated apoptosis inhibited gene and protein expression of HIF-2alpha, CAIX, and VEGF, and impaired partially the nuclear internalization of HIF-2alpha and NFkB/p65.	Propranolol	0-11	endothelial PAS domain protein 1	Homo sapiens	89-99
32854260-6	2020	Propranolol and ICI-118,551 activated apoptosis inhibited gene and protein expression of HIF-2alpha, CAIX, and VEGF, and impaired partially the nuclear internalization of HIF-2alpha and NFkB/p65.	Propranolol	0-11	vascular endothelial growth factor A	Homo sapiens	111-115
32854260-6	2020	Propranolol and ICI-118,551 activated apoptosis inhibited gene and protein expression of HIF-2alpha, CAIX, and VEGF, and impaired partially the nuclear internalization of HIF-2alpha and NFkB/p65.	Propranolol	0-11	endothelial PAS domain protein 1	Homo sapiens	171-181
32854260-6	2020	Propranolol and ICI-118,551 activated apoptosis inhibited gene and protein expression of HIF-2alpha, CAIX, and VEGF, and impaired partially the nuclear internalization of HIF-2alpha and NFkB/p65.	Propranolol	0-11	RELA proto-oncogene, NF-kB subunit	Homo sapiens	191-194
32854260-9	2020	In summary, propranolol and ICI-118,551 have shown antitumor benefits in VHL-derived ccRCC, and since ccRCCs comprise 63% of the total RCCs, targeting ADRB2 becomes a promising drug for VHL and other non-VHL tumors.	Propranolol	12-23	von Hippel-Lindau tumor suppressor	Homo sapiens	73-76
32854260-9	2020	In summary, propranolol and ICI-118,551 have shown antitumor benefits in VHL-derived ccRCC, and since ccRCCs comprise 63% of the total RCCs, targeting ADRB2 becomes a promising drug for VHL and other non-VHL tumors.	Propranolol	12-23	adrenoceptor beta 2	Homo sapiens	151-156
32854260-9	2020	In summary, propranolol and ICI-118,551 have shown antitumor benefits in VHL-derived ccRCC, and since ccRCCs comprise 63% of the total RCCs, targeting ADRB2 becomes a promising drug for VHL and other non-VHL tumors.	Propranolol	12-23	von Hippel-Lindau tumor suppressor	Homo sapiens	186-189
31668121-5	2020	NFKB/NF-kappaB and MAPK14/p38 activation was required for propranolol-induced IL23A secretion whereas the NLRP3 inflammasome was dispensable.	Propranolol	58-69	nuclear factor kappa B subunit 1	Homo sapiens	5-14
32903469-14	2020	Conclusion: We successfully recapitulated the clinical phenotype of LQT3 using patient-derived hiPSC-CMs and determined that the mechanism, by which propranolol inhibited the late sodium current, was independent of beta-adrenergic receptor signaling pathway.	Propranolol	149-160	sodium voltage-gated channel alpha subunit 5	Homo sapiens	68-72
32922532-0	2020	Propranolol induced apoptosis and autophagy via the ROS/JNK signaling pathway in Human Ovarian Cancer.	Propranolol	0-11	mitogen-activated protein kinase 8	Homo sapiens	56-59
32922532-6	2020	In addition, reactive oxygen species (ROS) increased dramatically after Propranolol treatment and Propranolol activated the phosphorylation of JNK.	Propranolol	72-83	mitogen-activated protein kinase 8	Homo sapiens	143-146
32922532-6	2020	In addition, reactive oxygen species (ROS) increased dramatically after Propranolol treatment and Propranolol activated the phosphorylation of JNK.	Propranolol	98-109	mitogen-activated protein kinase 8	Homo sapiens	143-146
32922532-7	2020	What is more, p38 inhibitor SB203580 and JNK inhibitor SP600125 attenuated the upregulated expression of LC3-II and cleaved-caspase-3 by the effect of Propranolol.	Propranolol	151-162	mitogen-activated protein kinase 14	Homo sapiens	14-17
32922532-7	2020	What is more, p38 inhibitor SB203580 and JNK inhibitor SP600125 attenuated the upregulated expression of LC3-II and cleaved-caspase-3 by the effect of Propranolol.	Propranolol	151-162	mitogen-activated protein kinase 8	Homo sapiens	41-44
32922532-7	2020	What is more, p38 inhibitor SB203580 and JNK inhibitor SP600125 attenuated the upregulated expression of LC3-II and cleaved-caspase-3 by the effect of Propranolol.	Propranolol	151-162	caspase 3	Homo sapiens	124-133
32922532-8	2020	ROS exclusive inhibitor antioxidant N-acetyl cysteine (NAC) weakens the phosphorylation of JNK proteins induced by Propranolol.	Propranolol	115-126	mitogen-activated protein kinase 8	Homo sapiens	91-94
32922532-9	2020	In summary, these results suggested that Propranolol induced cell apoptosis and protective autophagy through the ROS/JNK signaling pathway in human ovarian cancer cells.	Propranolol	41-52	mitogen-activated protein kinase 8	Homo sapiens	117-120
31668121-5	2020	NFKB/NF-kappaB and MAPK14/p38 activation was required for propranolol-induced IL23A secretion whereas the NLRP3 inflammasome was dispensable.	Propranolol	58-69	mitogen-activated protein kinase 14	Homo sapiens	19-25
31668121-5	2020	NFKB/NF-kappaB and MAPK14/p38 activation was required for propranolol-induced IL23A secretion whereas the NLRP3 inflammasome was dispensable.	Propranolol	58-69	mitogen-activated protein kinase 14	Homo sapiens	26-29
31668121-5	2020	NFKB/NF-kappaB and MAPK14/p38 activation was required for propranolol-induced IL23A secretion whereas the NLRP3 inflammasome was dispensable.	Propranolol	58-69	interleukin 23 subunit alpha	Homo sapiens	78-83
31668121-8	2020	Propranolol specifically induced reactive oxygen species production, which was critical for IL23A secretion, in Langerhans-like cells.	Propranolol	0-11	interleukin 23 subunit alpha	Homo sapiens	92-97
32623336-5	2020	Furthermore, anoikis resistance and YAP1 activation induced by norepinephrine could be rescued by a broad beta-adrenergic receptor antagonist, propranolol.	Propranolol	143-154	yes-associated protein 1	Mus musculus	36-40
31970786-7	2020	The cell migration was studied in MCF-7 and MDA-MB231 cells following the inhibition of lipin-1 by propranolol.	Propranolol	99-110	lipin 1	Homo sapiens	88-95
32077112-5	2020	Concentrations of sulpiride (D2 antagonist) could explain 73% of antagonistic activities against the D2 receptor; those of metoprolol, atenolol and propranolol (beta1 antagonists) could explain 16% of activities against the beta1 receptor; and those of pirenzepine (M1 antagonist) could explain 15% of activities against the M1 receptor.	Propranolol	148-159	immunoglobulin kappa variable 2D-30	Homo sapiens	161-166
32249994-11	2020	Treatment of cerebellar DAOY cells with the ET drug propranolol identified increases in SHF when treated, suggesting it may rescue the underexpression.	Propranolol	52-63	Src homology 2 domain containing F	Homo sapiens	88-91
32249994-14	2020	The treatment of cells with propranolol showed that the drug restored levels of SHF.	Propranolol	28-39	Src homology 2 domain containing F	Homo sapiens	80-83
32361123-6	2020	GAS6 expression was downregulated in osteoblasts through activation of the cAMP pathway and was targeted in vitro and in vivo using pharmacological agents (propranolol and phentolamine).	Propranolol	156-167	growth arrest specific 6	Homo sapiens	0-4
32361123-7	2020	Propranolol increased expression of GAS6 by osteoblasts, and phentolamine significantly inhibited expression.	Propranolol	0-11	growth arrest specific 6	Homo sapiens	36-40
32361123-8	2020	Propranolol treatment was sufficient to both increase GAS6 expression in marrow osteoblasts as well as eliminate the effects of NE signaling on GAS6 expression.	Propranolol	0-11	growth arrest specific 6	Homo sapiens	54-58
32361123-8	2020	Propranolol treatment was sufficient to both increase GAS6 expression in marrow osteoblasts as well as eliminate the effects of NE signaling on GAS6 expression.	Propranolol	0-11	growth arrest specific 6	Homo sapiens	144-148
32591592-7	2020	Mechanistically, we found that propranolol reduced the activity of the multidrug resistance efflux pump P-gp, thereby increasing the intracellular doxorubicin concentration and antitumour activity.	Propranolol	31-42	phosphoglycolate phosphatase	Homo sapiens	104-108
32591592-8	2020	In addition, propranolol attenuated the Akt-dependent survival signal induced by doxorubicin and strongly reduced the activation of the NF-kB/COX-2 pathway, increasing cell sensitivity to docetaxel.	Propranolol	13-24	AKT serine/threonine kinase 1	Homo sapiens	40-43
32591592-8	2020	In addition, propranolol attenuated the Akt-dependent survival signal induced by doxorubicin and strongly reduced the activation of the NF-kB/COX-2 pathway, increasing cell sensitivity to docetaxel.	Propranolol	13-24	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	142-147
32476028-7	2020	alpha2-Agonists such as dexmedetomidine may hold some slight clinical efficacy over agents like propofol, and with respect to oral medications, propranolol might convey some slight advantage compared to others.	Propranolol	144-155	glycoprotein hormone subunit alpha 2	Homo sapiens	0-6
32581369-9	2020	pi-pi EDA interaction, hydrophobic interaction and hydrogen bonding were speculated to be the main adsorption mechanisms for PRO adsorption on MWCNTs.	Propranolol	125-128	ectodysplasin A	Homo sapiens	6-9
32492962-5	2020	The neuroprotection caused by propranolol was accompanied by a reduction in fasting glucose, fasting insulin, glucose tolerance impairment, plasma C-reactive protein, plasma free fatty acids, plasma corticosterone, brain oxidative stress, and brain inflammation.	Propranolol	30-41	C-reactive protein	Rattus norvegicus	147-165
32492962-7	2020	Additionally, the impairment of insulin signaling in the gastrocnemius muscles was noted in rats with cerebral ischemia, with propranolol improving the impairment by reducing oxidative stress and tumor necrosis factor-alpha signaling.	Propranolol	126-137	tumor necrosis factor	Rattus norvegicus	196-223
32493842-3	2020	The purpose of this study was to determine, in a porcine model, whether propranolol at doses higher than clinically recommended could block ventricular electrophysiological effects of sympathoexcitation via stellate ganglia stimulation, and if any residual effects are mediated by NPY.	Propranolol	72-83	neuropeptide Y	Homo sapiens	281-284
32366133-6	2020	FT-IR study and molecular modeling were conducted to describe the types and interaction sites between drug and PSA molecule.Results: The results demonstrated that propranolol interacted with -OH and -COOR groups of PSA, which interrupted the interaction inter the PSA molecules, resulting in a plasticizing phenomenon of PSA.	Propranolol	163-174	aminopeptidase puromycin sensitive	Homo sapiens	111-114
32366133-6	2020	FT-IR study and molecular modeling were conducted to describe the types and interaction sites between drug and PSA molecule.Results: The results demonstrated that propranolol interacted with -OH and -COOR groups of PSA, which interrupted the interaction inter the PSA molecules, resulting in a plasticizing phenomenon of PSA.	Propranolol	163-174	aminopeptidase puromycin sensitive	Homo sapiens	215-218
32366133-6	2020	FT-IR study and molecular modeling were conducted to describe the types and interaction sites between drug and PSA molecule.Results: The results demonstrated that propranolol interacted with -OH and -COOR groups of PSA, which interrupted the interaction inter the PSA molecules, resulting in a plasticizing phenomenon of PSA.	Propranolol	163-174	aminopeptidase puromycin sensitive	Homo sapiens	215-218
32366133-6	2020	FT-IR study and molecular modeling were conducted to describe the types and interaction sites between drug and PSA molecule.Results: The results demonstrated that propranolol interacted with -OH and -COOR groups of PSA, which interrupted the interaction inter the PSA molecules, resulting in a plasticizing phenomenon of PSA.	Propranolol	163-174	aminopeptidase puromycin sensitive	Homo sapiens	215-218
32244188-16	2020	Injections of norepinephrine into the ArcPomc-/- female mice reduced circulating adiponectin levels, whereas injections of propranolol significantly increased adiponectin levels.	Propranolol	123-134	adiponectin, C1Q and collagen domain containing	Mus musculus	159-170
32189192-9	2020	propranolol irreversibly inhibited human CYP2D6 in TG brain but not mouse CYP2D in TG and WT brain.	Propranolol	0-11	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	41-47
32189192-9	2020	propranolol irreversibly inhibited human CYP2D6 in TG brain but not mouse CYP2D in TG and WT brain.	Propranolol	0-11	cytochrome P450, 2d region	Mus musculus	41-46
32455528-5	2020	Propranolol and SL-327 were able to antagonize the activation of hypothalamic-pituitary adrenal (HPA) axis and the phosphorylation of HSP-27 observed during morphine withdrawal.	Propranolol	0-11	heat shock protein family B (small) member 1	Homo sapiens	134-140
32145394-3	2020	In the present study, we formulated a propranolol delivery system based on mesoporous silica nanoparticles (PRN@MSN) and investigated the interplay between autophagic activities mediated by nanoparticles and improved therapeutic efficacy of PRN@MSN.	Propranolol	38-49	cytosolic iron-sulfur assembly component 3	Homo sapiens	108-111
33191227-0	2020	Curcuma"s extraction attenuates propranolol-induced psoriasis like in mice by inhibition of keratin, proliferating cell nuclear antigen and toll-like receptor expression.	Propranolol	32-43	proliferating cell nuclear antigen	Mus musculus	101-135
32331276-9	2020	Clathrin-mediated endocytosis inhibition or beta-arrestin1 dominant-negative mutant abrogated PROP-induced cell adhesion and COFILIN phosphorylation.	Propranolol	94-98	arrestin beta 1	Homo sapiens	44-58
32331276-9	2020	Clathrin-mediated endocytosis inhibition or beta-arrestin1 dominant-negative mutant abrogated PROP-induced cell adhesion and COFILIN phosphorylation.	Propranolol	94-98	cofilin 1	Homo sapiens	125-132
32331276-7	2020	ISO and PROP induced a reorganization of actin cytoskeleton increasing F-actin, p-COFILIN and p-LIMK.	Propranolol	8-12	cofilin 1	Homo sapiens	82-89
32331276-7	2020	ISO and PROP induced a reorganization of actin cytoskeleton increasing F-actin, p-COFILIN and p-LIMK.	Propranolol	8-12	LIM domain kinase 1	Homo sapiens	96-100
32317001-6	2020	A decline in end point ambulatory blood pressure (p = 0.031) and greater mean reduction in office SBP (29.7 +- 13.0 mmHg, p = 0.021) was noted in the propranolol arm.	Propranolol	150-161	selenium binding protein 1	Homo sapiens	98-101
32145394-3	2020	In the present study, we formulated a propranolol delivery system based on mesoporous silica nanoparticles (PRN@MSN) and investigated the interplay between autophagic activities mediated by nanoparticles and improved therapeutic efficacy of PRN@MSN.	Propranolol	38-49	moesin	Homo sapiens	112-115
32145394-3	2020	In the present study, we formulated a propranolol delivery system based on mesoporous silica nanoparticles (PRN@MSN) and investigated the interplay between autophagic activities mediated by nanoparticles and improved therapeutic efficacy of PRN@MSN.	Propranolol	38-49	cytosolic iron-sulfur assembly component 3	Homo sapiens	108-115
32145394-4	2020	The results showed that PRN@MSN nanoparticles exhibited higher cytotoxicity compared with free propranolol in vitro and in vivo, which could induce excessive autophagosome accumulation through increased autophagosome formation and impaired autophagic degradation.	Propranolol	95-106	cytosolic iron-sulfur assembly component 3	Homo sapiens	24-27
32145394-4	2020	The results showed that PRN@MSN nanoparticles exhibited higher cytotoxicity compared with free propranolol in vitro and in vivo, which could induce excessive autophagosome accumulation through increased autophagosome formation and impaired autophagic degradation.	Propranolol	95-106	moesin	Homo sapiens	28-31
32120430-8	2020	The results indicate an increase in caspase-3 activity and a decrease in the ATP level in cardiomyocytes after exposure to propranolol and atenolol.	Propranolol	123-134	caspase 3	Rattus norvegicus	36-45
31875337-5	2020	Then, these compounds were tested in vitro, and two selected compounds, C7 and C8, as well as propranolol showed inhibition of AChE.	Propranolol	94-105	acetylcholinesterase	Rattus norvegicus	127-131
32138352-3	2020	This study explores the modulation of beta1 and beta2 adrenergic receptors (ADRB1/ADRB2) by propranolol treatment on the peripheral and splenic immune dysfunction of cirrhotic mice.	Propranolol	92-103	brain protein 1	Mus musculus	38-43
32256446-12	2020	Of particular interest was the finding that room temperature housing reduced, whereas propranolol increased, expression of the gene for acetyl-CoA carboxylase (Acacb), the rate-limiting step for fatty acid synthesis and a key regulator of beta-oxidation.	Propranolol	86-97	acetyl-Coenzyme A carboxylase beta	Mus musculus	136-158
32256446-12	2020	Of particular interest was the finding that room temperature housing reduced, whereas propranolol increased, expression of the gene for acetyl-CoA carboxylase (Acacb), the rate-limiting step for fatty acid synthesis and a key regulator of beta-oxidation.	Propranolol	86-97	acetyl-Coenzyme A carboxylase beta	Mus musculus	160-165
32219146-0	2020	Influence of Cytochrome P450 2D6 Polymorphisms on the Efficacy of Oral Propranolol in Treating Infantile Hemangioma.	Propranolol	71-82	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	13-32
32219146-1	2020	Objective: The aim of this study is to evaluate the association of genetic polymorphisms in Cytochrome P450 2D6(CYP2D6) and the change in VEGF levels with the response to propranolol in patients with Infantile hemangiomas (IH).	Propranolol	171-182	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	92-111
32219146-1	2020	Objective: The aim of this study is to evaluate the association of genetic polymorphisms in Cytochrome P450 2D6(CYP2D6) and the change in VEGF levels with the response to propranolol in patients with Infantile hemangiomas (IH).	Propranolol	171-182	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	112-118
32219146-1	2020	Objective: The aim of this study is to evaluate the association of genetic polymorphisms in Cytochrome P450 2D6(CYP2D6) and the change in VEGF levels with the response to propranolol in patients with Infantile hemangiomas (IH).	Propranolol	171-182	vascular endothelial growth factor A	Homo sapiens	138-142
32219146-10	2020	Patients with CYP2D6 (rs1135840) G/G homozygote had the highest response rate to propranolol.	Propranolol	81-92	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	14-20
32219146-13	2020	Conclusion: The response to propranolol treatment in IH patients was associated with the gene polymorphism of CYP2D6 (rs1135840).	Propranolol	28-39	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	110-116
31943597-9	2020	Furthermore, immunohistochemical analysis revealed that atenolol, butoxamine and propranolol decreased the number of RANKL- and SOST-positive osteocytes on the compression side.	Propranolol	81-92	TNF superfamily member 11	Rattus norvegicus	117-122
31943597-9	2020	Furthermore, immunohistochemical analysis revealed that atenolol, butoxamine and propranolol decreased the number of RANKL- and SOST-positive osteocytes on the compression side.	Propranolol	81-92	sclerostin	Rattus norvegicus	128-132
32164890-7	2020	Using telemetry monitoring, the authors observed that mdx mice, which lack dystrophin, had an arrhythmic death when stimulated with isoproterenol; the lethal arrhythmias were rescued, in part, by propranolol pre-treatment.	Propranolol	196-207	dystrophin, muscular dystrophy	Mus musculus	75-85
32138352-3	2020	This study explores the modulation of beta1 and beta2 adrenergic receptors (ADRB1/ADRB2) by propranolol treatment on the peripheral and splenic immune dysfunction of cirrhotic mice.	Propranolol	92-103	adrenergic receptor, beta 1	Mus musculus	76-81
32138352-3	2020	This study explores the modulation of beta1 and beta2 adrenergic receptors (ADRB1/ADRB2) by propranolol treatment on the peripheral and splenic immune dysfunction of cirrhotic mice.	Propranolol	92-103	adrenergic receptor, beta 2	Mus musculus	82-87
32138352-9	2020	Acute propranolol treatment inhibited apoptosis, Treg-conditioned differentiation, and promoted Th2-conditioned differentiation through ADRB-cyclic adenosine monophosphate (cAMP) signals in cirrhotic mice.	Propranolol	6-17	heart and neural crest derivatives expressed 2	Mus musculus	96-99
32138352-10	2020	In conclusion, suppression of ADRB1 and ADRB2 expressions in spleen and splenic T lymphocytes by acute and chronic propranolol treatment ameliorate systemic and splenic immune dysfunction in cirrhosis.	Propranolol	115-126	adrenergic receptor, beta 1	Mus musculus	30-35
32138352-10	2020	In conclusion, suppression of ADRB1 and ADRB2 expressions in spleen and splenic T lymphocytes by acute and chronic propranolol treatment ameliorate systemic and splenic immune dysfunction in cirrhosis.	Propranolol	115-126	adrenergic receptor, beta 2	Mus musculus	40-45
32366144-8	2020	Ozone-induced pulmonary protein leakage, inflammation and IL-6 increases were inhibited by PROP or PROP + DEX and exacerbated by CLEN or CLEN + MIFE.	Propranolol	91-95	interleukin 6	Rattus norvegicus	58-62
32366144-8	2020	Ozone-induced pulmonary protein leakage, inflammation and IL-6 increases were inhibited by PROP or PROP + DEX and exacerbated by CLEN or CLEN + MIFE.	Propranolol	99-103	interleukin 6	Rattus norvegicus	58-62
32139988-4	2020	In this study, we attempted to assess whether propranolol has any effect on vascular endothelial growth factor (VEGF) and tissue inhibitor of metalloproteinase-2 (TIMP-2) over a period of time, and if it is there, how long it affects it.	Propranolol	46-57	vascular endothelial growth factor A	Homo sapiens	76-110
32139988-4	2020	In this study, we attempted to assess whether propranolol has any effect on vascular endothelial growth factor (VEGF) and tissue inhibitor of metalloproteinase-2 (TIMP-2) over a period of time, and if it is there, how long it affects it.	Propranolol	46-57	vascular endothelial growth factor A	Homo sapiens	112-116
32139988-4	2020	In this study, we attempted to assess whether propranolol has any effect on vascular endothelial growth factor (VEGF) and tissue inhibitor of metalloproteinase-2 (TIMP-2) over a period of time, and if it is there, how long it affects it.	Propranolol	46-57	TIMP metallopeptidase inhibitor 2	Homo sapiens	122-161
32139988-4	2020	In this study, we attempted to assess whether propranolol has any effect on vascular endothelial growth factor (VEGF) and tissue inhibitor of metalloproteinase-2 (TIMP-2) over a period of time, and if it is there, how long it affects it.	Propranolol	46-57	TIMP metallopeptidase inhibitor 2	Homo sapiens	163-169
29984678-12	2020	Propranolol (group B) but not esmolol (group D) administration resulted in elevated TNF-alpha levels, comparable to those observed in group A.	Propranolol	0-11	tumor necrosis factor	Rattus norvegicus	84-93
31778284-0	2020	The adrenergic receptor antagonists propranolol and carvedilol decrease bone sarcoma cell viability and sustained carvedilol reduces clonogenic survival and increases radiosensitivity in canine osteosarcoma cells.	Propranolol	36-47	androgen receptor	Canis lupus familiaris	4-23
31778284-2	2020	AR antagonists like propranolol and carvedilol inhibit proliferation, induce apoptosis and synergize with chemotherapy agents in some cancers.	Propranolol	20-31	androgen receptor	Canis lupus familiaris	0-2
32190401-8	2020	The IF values of MIP 1 were atenolol (204.62), metoprolol (3.36), and propranolol (1.27).	Propranolol	70-81	transportin 1	Homo sapiens	17-22
32085406-4	2020	The CB1R-dependent one was already effective at Rimonabant concentrations of less than 1 microM and after short-term incubation, partially additive to beta-adrenergic agonists and blocked by insulin and, in part, by adenosine deaminase, but not by propranolol.	Propranolol	248-259	adenosine deaminase	Rattus norvegicus	216-235
32027744-8	2020	Relative to the control group, propranolol-treated patients showed greater decreases from baseline to HCT day -2 and day +28 for both CTRA gene expression (P = .017) and bioinformatic measures of CD16- classical monocyte activation (P = .005).	Propranolol	31-42	Fc gamma receptor IIIa	Homo sapiens	196-200
32027744-9	2020	Propranolol-treated patients also showed relative upregulation of CD34+ cell-associated gene transcripts (P = .011) and relative downregulation of myeloid progenitor-containing CD33+ cell-associated gene transcripts (P = .001).	Propranolol	0-11	CD34 molecule	Homo sapiens	66-70
32027744-9	2020	Propranolol-treated patients also showed relative upregulation of CD34+ cell-associated gene transcripts (P = .011) and relative downregulation of myeloid progenitor-containing CD33+ cell-associated gene transcripts (P = .001).	Propranolol	0-11	CD33 molecule	Homo sapiens	177-181
32051218-3	2020	We present the case of a patient with involuted IH treated with propranolol that showed a full and rapid regrowth during the intravenous administration of salbutamol, a selective beta2-adrenergic agonist, for an episode of severe obstructive bronchitis.	Propranolol	64-75	G protein-coupled receptor 162	Homo sapiens	179-184
32094357-6	2020	Based on our integrative data approach and confirmatory experiments, we concluded that hypoxia in IHs is regulated by EPAS1 (HIF-2alpha) instead of HIF-1alpha, and also that propranolol-induced apoptosis in endothelial cells may occur via mitochondrial stress.	Propranolol	174-185	endothelial PAS domain protein 1	Homo sapiens	125-135
31743801-12	2020	The IL-1beta release followed LPS stimulation was significantly suppressed when the superfusion media contained propranolol (p < .05).	Propranolol	112-123	interleukin 1 alpha	Rattus norvegicus	4-12
31832629-3	2020	In this work, a novel capillary electrophoresis method using the ionic liquid 3-methyl-1-(3-sulfopropyl)-1H-imidazol-3-ium lactobionate (MSI-LA) as a chiral selector was developed for the enantioseparation of propranolol, metoprolol, bisoprolol, esmolol, atenolol, sotalol, terbutaline and clenbuterol.	Propranolol	209-220	RB binding protein 4, chromatin remodeling factor	Homo sapiens	137-140
31648367-0	2020	Propranolol is a mechanism-based inhibitor of CYP2D and CYP2D6 in humanized CYP2D6-transgenic mice: effects on activity and drug response.	Propranolol	0-11	cytochrome P450, 2d region	Mus musculus	46-51
31648367-0	2020	Propranolol is a mechanism-based inhibitor of CYP2D and CYP2D6 in humanized CYP2D6-transgenic mice: effects on activity and drug response.	Propranolol	0-11	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	56-62
31648367-0	2020	Propranolol is a mechanism-based inhibitor of CYP2D and CYP2D6 in humanized CYP2D6-transgenic mice: effects on activity and drug response.	Propranolol	0-11	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	76-82
31648367-3	2020	Our purpose was to characterize propranolol as a CYP2D inhibitor in human and mouse, and to develop a method for in vivo manipulation of CYP2D6 enzyme activity which could be used to investigate the role of CYP2D6 in drug-induced behaviours.	Propranolol	32-43	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	49-54
31648367-5	2020	We also examined the impact of 24 h propranolol pre-treatment on serum levels of the CYP2D6 substrate haloperidol and haloperidol-induced catalepsy.	Propranolol	36-47	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	85-91
31648367-7	2020	Propranolol acted as a mechanism-based inhibitor (MBI), inactivating CYP2D in liver microsomes from TG and WT mice, and humans.	Propranolol	0-11	cytochrome P450, 2d region	Mus musculus	69-74
31648367-11	2020	Manipulation of CYP2D with propranolol in vivo in TG and WT mice alters drug response, which will be useful for future investigation of the impact of variation in CYP2D6 on drug interactions and drug responses.	Propranolol	27-38	cytochrome P450, 2d region	Mus musculus	16-21
31648367-11	2020	Manipulation of CYP2D with propranolol in vivo in TG and WT mice alters drug response, which will be useful for future investigation of the impact of variation in CYP2D6 on drug interactions and drug responses.	Propranolol	27-38	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	163-169
30604050-7	2020	The concomitant intake of CYP2D6 inhibitors, risperidone, metoprolol, or propranolol was found to increase aripiprazole concentrations in patients with at least one wild-type CYP2D6*1 allele.	Propranolol	73-84	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	175-181
32080341-10	2020	Pharmacological inhibition of PAP1 with propranolol suppressed UVB-induced production of IL-6 and IL-8 in NHEKs and reconstituted human skin models.	Propranolol	40-51	lipin 1	Homo sapiens	30-34
32010289-6	2020	The tumor volume of the two groups was significantly reduced after treatment, with statistically significant difference (P&lt;0.05); miR-4295 expression was reduced in the two groups (P&lt;0.05); adverse reactions in propranolol group were less than pingyangmycin group during treatment (P&lt;0.05).	Propranolol	217-228	microRNA 4295	Homo sapiens	133-141
31838054-0	2020	Propranolol inhibits proliferation and induces apoptosis of hemangioma-derived endothelial cells via Akt pathway by down-regulating Ang-2 expression.	Propranolol	0-11	AKT serine/threonine kinase 1	Homo sapiens	101-104
32080341-10	2020	Pharmacological inhibition of PAP1 with propranolol suppressed UVB-induced production of IL-6 and IL-8 in NHEKs and reconstituted human skin models.	Propranolol	40-51	interleukin 6	Homo sapiens	89-93
32080341-10	2020	Pharmacological inhibition of PAP1 with propranolol suppressed UVB-induced production of IL-6 and IL-8 in NHEKs and reconstituted human skin models.	Propranolol	40-51	C-X-C motif chemokine ligand 8	Homo sapiens	98-102
31838054-13	2020	Mechanistical analysis showed that propranolol inhibited the Akt pathway by regulating Ang-2 expression in HemECs.	Propranolol	35-46	AKT serine/threonine kinase 1	Homo sapiens	61-64
31838054-12	2020	Functional analysis revealed that Ang-2 attenuated the effects of propranolol on HemEC proliferation and apoptosis.	Propranolol	66-77	angiopoietin 2	Homo sapiens	34-39
31838054-0	2020	Propranolol inhibits proliferation and induces apoptosis of hemangioma-derived endothelial cells via Akt pathway by down-regulating Ang-2 expression.	Propranolol	0-11	angiopoietin 2	Homo sapiens	132-137
31838054-13	2020	Mechanistical analysis showed that propranolol inhibited the Akt pathway by regulating Ang-2 expression in HemECs.	Propranolol	35-46	angiopoietin 2	Homo sapiens	87-92
31838054-15	2020	In conclusion, propranolol inhibited proliferation and induced apoptosis of HemECs via Akt pathway by down-regulating Ang-2 expression, which contributes to our understanding on the pathogenesis of hemangioma and promotes the development of therapeutic approaches for hemangioma.	Propranolol	15-26	AKT serine/threonine kinase 1	Homo sapiens	87-90
31838054-11	2020	Moreover, propranolol inhibited the expressions of Ang-2 and Tie-2 in HUVECs and HemECs.	Propranolol	10-21	angiopoietin 2	Homo sapiens	51-56
31838054-15	2020	In conclusion, propranolol inhibited proliferation and induced apoptosis of HemECs via Akt pathway by down-regulating Ang-2 expression, which contributes to our understanding on the pathogenesis of hemangioma and promotes the development of therapeutic approaches for hemangioma.	Propranolol	15-26	angiopoietin 2	Homo sapiens	118-123
31838054-11	2020	Moreover, propranolol inhibited the expressions of Ang-2 and Tie-2 in HUVECs and HemECs.	Propranolol	10-21	TEK receptor tyrosine kinase	Homo sapiens	61-66
33372436-0	2020	Serum levels of VEGF and bFGF in infantile hemangiomas treated with propranolol.	Propranolol	68-79	vascular endothelial growth factor A	Homo sapiens	16-20
31991558-1	2020	This study explored the feasibility of utilizing a novel sorbent humic acid (HA) coated Fe3O4/attapulgite (MATP) magnetic nanoparticles (HMATP) for the sorption of propranolol from aqueous solutions.	Propranolol	164-175	solute carrier family 45 member 2	Homo sapiens	107-111
31991558-9	2020	In all conditions, sorption capacity of propranolol on HMATP was obviously higher than that on MATP, which indicated that surface-coated HA played an important role in the propranolol sorption process.	Propranolol	40-51	solute carrier family 45 member 2	Homo sapiens	56-60
31991558-9	2020	In all conditions, sorption capacity of propranolol on HMATP was obviously higher than that on MATP, which indicated that surface-coated HA played an important role in the propranolol sorption process.	Propranolol	172-183	solute carrier family 45 member 2	Homo sapiens	56-60
31963151-9	2020	However, treatment with the beta-blocker propranolol prevented hyperaldosteronism in the adrenal GRK2-overexpressing rats.	Propranolol	41-52	G protein-coupled receptor kinase 2	Rattus norvegicus	97-101
31884457-6	2020	In order to explore Ang1"s act manner, Ang1 expression of human dermal microvascular endothelial cells pre-treated by propranolol IC50 was detected by western blotting.	Propranolol	118-129	angiopoietin 1	Homo sapiens	20-24
31884457-6	2020	In order to explore Ang1"s act manner, Ang1 expression of human dermal microvascular endothelial cells pre-treated by propranolol IC50 was detected by western blotting.	Propranolol	118-129	angiopoietin 1	Homo sapiens	39-43
31884457-7	2020	RESULTS: Immunohistochemistry, western blotting and reverse transcription PCR showed that human dermal microvascular endothelial cells, human brain microvascular endothelial cells and human umbilical vein endothelial cells all expressed Ang1, and propranolol significantly inhibited Ang1 expression of human dermal microvascular endothelial cells.	Propranolol	247-258	angiopoietin 1	Homo sapiens	237-241
32286940-8	2020	Propranolol is a substrate of CYP2D6, CYP1A2 and CYP2C19, retaining potential pharmacokinetic interactions with co-administered drugs.	Propranolol	0-11	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	30-36
32286940-8	2020	Propranolol is a substrate of CYP2D6, CYP1A2 and CYP2C19, retaining potential pharmacokinetic interactions with co-administered drugs.	Propranolol	0-11	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	38-44
32286940-8	2020	Propranolol is a substrate of CYP2D6, CYP1A2 and CYP2C19, retaining potential pharmacokinetic interactions with co-administered drugs.	Propranolol	0-11	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	49-56
30474540-5	2020	RESULTS: An in-silico result of current investigation has shown the good interaction of metformin, propranolol, and amitriptyline towards various targets (Beta-lactamase, Penicillin-binding proteins, Staphylokinase protein, Oxidoreductase protein, etc.)	Propranolol	99-110	thioredoxin reductase 1	Homo sapiens	224-238
31980035-8	2020	She was started on valproic acid, citalopram, propranolol, and quetiapine.	Propranolol	46-57	Src homology 2 domain containing E	Homo sapiens	0-3
33164541-10	2020	It was found that propranolol treatment enhanced the activity of caspase-3 while the expression of bax, wee1, gadd153, grp78 and AIF decreased bcl-2 which is antiapoptotic protein in cSCC cell lines.	Propranolol	18-29	caspase 3	Homo sapiens	65-74
33164541-10	2020	It was found that propranolol treatment enhanced the activity of caspase-3 while the expression of bax, wee1, gadd153, grp78 and AIF decreased bcl-2 which is antiapoptotic protein in cSCC cell lines.	Propranolol	18-29	BCL2 associated X, apoptosis regulator	Homo sapiens	99-102
33164541-10	2020	It was found that propranolol treatment enhanced the activity of caspase-3 while the expression of bax, wee1, gadd153, grp78 and AIF decreased bcl-2 which is antiapoptotic protein in cSCC cell lines.	Propranolol	18-29	WEE1 G2 checkpoint kinase	Homo sapiens	104-108
33164541-10	2020	It was found that propranolol treatment enhanced the activity of caspase-3 while the expression of bax, wee1, gadd153, grp78 and AIF decreased bcl-2 which is antiapoptotic protein in cSCC cell lines.	Propranolol	18-29	DNA damage inducible transcript 3	Homo sapiens	110-117
33164541-10	2020	It was found that propranolol treatment enhanced the activity of caspase-3 while the expression of bax, wee1, gadd153, grp78 and AIF decreased bcl-2 which is antiapoptotic protein in cSCC cell lines.	Propranolol	18-29	heat shock protein family A (Hsp70) member 5	Homo sapiens	119-124
33164541-10	2020	It was found that propranolol treatment enhanced the activity of caspase-3 while the expression of bax, wee1, gadd153, grp78 and AIF decreased bcl-2 which is antiapoptotic protein in cSCC cell lines.	Propranolol	18-29	apoptosis inducing factor mitochondria associated 1	Homo sapiens	129-132
33164541-10	2020	It was found that propranolol treatment enhanced the activity of caspase-3 while the expression of bax, wee1, gadd153, grp78 and AIF decreased bcl-2 which is antiapoptotic protein in cSCC cell lines.	Propranolol	18-29	BCL2 apoptosis regulator	Homo sapiens	143-148
33372436-0	2020	Serum levels of VEGF and bFGF in infantile hemangiomas treated with propranolol.	Propranolol	68-79	fibroblast growth factor 2	Homo sapiens	25-29
33372436-3	2020	METHODS: In this prospective study, we aimed to investigate the relationship between serum VEGF and bFGF levels and clinical characteristics and the serological changes in VEGF and bFGF levels associated with propranolol treatment in infants diagnosed with IH.	Propranolol	209-220	vascular endothelial growth factor A	Homo sapiens	172-176
33372436-3	2020	METHODS: In this prospective study, we aimed to investigate the relationship between serum VEGF and bFGF levels and clinical characteristics and the serological changes in VEGF and bFGF levels associated with propranolol treatment in infants diagnosed with IH.	Propranolol	209-220	fibroblast growth factor 2	Homo sapiens	181-185
33372436-8	2020	In 18 infants who were treated with propranolol with serial measurements, median serum bFGF levels were 10.7 ng/ml, 9.8 ng/ml and 10.5 ng/ml (p= 0.8), and median serum VEGF levels were 68.6 ng/ml, 63.5 ng/ml and 45.1 ng/ml (p < 0.001) at initial diagnosis, at first and third months, respectively.	Propranolol	36-47	fibroblast growth factor 2	Homo sapiens	87-91
31847911-4	2019	METHODS: We first looked at the spatial distribution of the noradrenaline (NA)-synthesizing enzyme, DBH (dopamine beta-hydroxylase), in comparison with NA receptors-beta1, beta2, and beta3 adrenergic receptors (beta1-AR, beta2-AR, and beta3-AR)-after which we examined the effects of the beta-blocker propranolol and alpha-blockers prazosin and yohimbine on stress-induced microglial activation.	Propranolol	301-312	dopamine beta hydroxylase	Mus musculus	100-103
31800964-1	2019	Purpose: Beta-adrenergic receptor (AR) antagonists, like propranolol, inhibit angiogenesis in multiple ocular conditions through an unknown mechanism.	Propranolol	57-68	ferredoxin reductase	Mus musculus	9-33
31800964-1	2019	Purpose: Beta-adrenergic receptor (AR) antagonists, like propranolol, inhibit angiogenesis in multiple ocular conditions through an unknown mechanism.	Propranolol	57-68	ferredoxin reductase	Mus musculus	35-37
31800964-2	2019	We previously showed that propranolol reduces choroidal neovascularization (CNV) by decreasing interleukin-6 levels.	Propranolol	26-37	interleukin 6	Mus musculus	95-108
31800964-12	2019	Moreover, propranolol increased the numbers of MHCII+ and MHCII- macrophages by 1.9 (P = 0.07) and 3.1 (P < 0.05) fold in lasered female mice with no change in macrophage numbers in males.	Propranolol	10-21	histocompatibility-2, MHC	Mus musculus	47-52
31800964-12	2019	Moreover, propranolol increased the numbers of MHCII+ and MHCII- macrophages by 1.9 (P = 0.07) and 3.1 (P < 0.05) fold in lasered female mice with no change in macrophage numbers in males.	Propranolol	10-21	histocompatibility-2, MHC	Mus musculus	58-63
30827533-3	2019	We hypothesized that propranolol and clonidine would decrease bone marrow expression of high-mobility group box-1 (HMGB1) and increase expression of stem cell factor (SCF) and B-cell lymphoma-extra large (Bcl-xL).	Propranolol	21-32	high mobility group box 1	Rattus norvegicus	88-113
31588689-8	2019	RESULTS: The results showed that propranolol exerts potent anti-proliferative effects, attenuates migration, reduces VEGF and induces cell cycle arrest and apoptosis in both UM and CM in a dose-dependent manner.	Propranolol	33-44	vascular endothelial growth factor A	Homo sapiens	117-121
30827533-6	2019	RESULTS: Following LCHS, HMGB1 was decreased by propranolol (49% decrease, p = 0.012) and clonidine (54% decrease, p &lt; 0.010).	Propranolol	48-59	high mobility group box 1	Rattus norvegicus	25-30
30474469-5	2019	Likewise, propranolol ameliorates tumour exosomes-associated cachectic wasting through upregulating the PPARgamma expression.	Propranolol	10-21	peroxisome proliferator activated receptor gamma	Mus musculus	104-113
31222761-0	2019	Propranolol inhibits neonatal Nav1.5 activity and invasiveness of MDA-MB-231 breast cancer cells: Effects of combination with ranolazine.	Propranolol	0-11	sodium voltage-gated channel alpha subunit 5	Homo sapiens	30-36
31222761-3	2019	Short-term (acute) application of the beta-AR antagonist propranolol (25 muM) led to reduction of peak current and quickening of current inactivation (the latter occurred only in 5% fetal bovine serum).	Propranolol	57-68	latexin	Homo sapiens	73-76
31222761-4	2019	Long-term (48 hr) incubation with propranolol (25 muM) resulted in several changes in VGSC characteristics: shifts in (a) current-voltage relationship and (b) steady-state inactivation, both to more negative potentials and (c) the slowing of recovery from inactivation.	Propranolol	34-45	latexin	Homo sapiens	50-53
31222761-7	2019	Propranolol (2.5 and 25 muM) and ranolazine (5 muM), and their combination inhibited lateral motility.	Propranolol	0-11	latexin	Homo sapiens	24-27
31222761-8	2019	Also, propranolol (25 muM) and ranolazine (5 muM), and their combination inhibited invasion.	Propranolol	6-17	latexin	Homo sapiens	22-25
31222761-10	2019	Propranolol also significantly decreased total neonatal Nav1.5 protein expression, the predominant VGSC subtype expressed in these cells.	Propranolol	0-11	sodium voltage-gated channel alpha subunit 5	Homo sapiens	56-62
30827533-7	2019	SCF was decreased following LCHS/CS, and was increased by propranolol (629% increase, p &lt; 0.001) and clonidine (468% increase, p &lt; 0.001).	Propranolol	58-69	KIT ligand	Rattus norvegicus	0-3
30827533-3	2019	We hypothesized that propranolol and clonidine would decrease bone marrow expression of high-mobility group box-1 (HMGB1) and increase expression of stem cell factor (SCF) and B-cell lymphoma-extra large (Bcl-xL).	Propranolol	21-32	high mobility group box 1	Rattus norvegicus	115-120
30827533-8	2019	Bcl-xL was decreased following LCHS/CS, and was increased by propranolol (59% increase, p = 0.006) and clonidine (77% increase, p &lt; 0.001).	Propranolol	61-72	Bcl2-like 1	Rattus norvegicus	0-6
30827533-3	2019	We hypothesized that propranolol and clonidine would decrease bone marrow expression of high-mobility group box-1 (HMGB1) and increase expression of stem cell factor (SCF) and B-cell lymphoma-extra large (Bcl-xL).	Propranolol	21-32	KIT ligand	Rattus norvegicus	149-165
30827533-3	2019	We hypothesized that propranolol and clonidine would decrease bone marrow expression of high-mobility group box-1 (HMGB1) and increase expression of stem cell factor (SCF) and B-cell lymphoma-extra large (Bcl-xL).	Propranolol	21-32	KIT ligand	Rattus norvegicus	167-170
30827533-3	2019	We hypothesized that propranolol and clonidine would decrease bone marrow expression of high-mobility group box-1 (HMGB1) and increase expression of stem cell factor (SCF) and B-cell lymphoma-extra large (Bcl-xL).	Propranolol	21-32	Bcl2-like 1	Rattus norvegicus	176-203
31609806-10	2019	We also found a 100 muM concentration of propranolol cutoff point.	Propranolol	41-52	latexin	Homo sapiens	20-23
31609806-12	2019	However, propranolol resulted in a sharp and significant variation in cell morphology and survival rates at high concentrations (100, 200, and 400 muM).	Propranolol	9-20	latexin	Homo sapiens	147-150
31609806-15	2019	Furthermore, the expressions of phosphorylated AKT and peroxisome proliferator-activated receptor gamma (PPARgamma) were increased with a 100 muM concentration of propranolol in HemSC culture.	Propranolol	163-174	AKT serine/threonine kinase 1	Homo sapiens	47-50
31609806-15	2019	Furthermore, the expressions of phosphorylated AKT and peroxisome proliferator-activated receptor gamma (PPARgamma) were increased with a 100 muM concentration of propranolol in HemSC culture.	Propranolol	163-174	peroxisome proliferator activated receptor gamma	Homo sapiens	55-103
31609806-15	2019	Furthermore, the expressions of phosphorylated AKT and peroxisome proliferator-activated receptor gamma (PPARgamma) were increased with a 100 muM concentration of propranolol in HemSC culture.	Propranolol	163-174	peroxisome proliferator activated receptor gamma	Homo sapiens	105-114
31609806-15	2019	Furthermore, the expressions of phosphorylated AKT and peroxisome proliferator-activated receptor gamma (PPARgamma) were increased with a 100 muM concentration of propranolol in HemSC culture.	Propranolol	163-174	latexin	Homo sapiens	142-145
30827533-3	2019	We hypothesized that propranolol and clonidine would decrease bone marrow expression of high-mobility group box-1 (HMGB1) and increase expression of stem cell factor (SCF) and B-cell lymphoma-extra large (Bcl-xL).	Propranolol	21-32	Bcl2-like 1	Rattus norvegicus	205-211
31609806-17	2019	Propranolol may upregulate PPARgamma via PI3K pathways, thereby accelerating lipogenesis and enhancing IH HemSC adipogenesis.	Propranolol	0-11	peroxisome proliferator activated receptor gamma	Homo sapiens	27-36
31542162-9	2019	RESULTS: Propranolol administration prevented impairment of hypotensive dilation in both male and female newborn pigs after fluid percussion injury, which was paralleled by reduced upregulation of IL-6 in the CSF.	Propranolol	9-20	interleukin-6	Sus scrofa	197-201
31542162-12	2019	CONCLUSIONS: These data indicate that sympathetic hyperactivity noted after TBI can be limited by propranolol administration to result in improved brain outcome post-injury via block of IL-6 upregulation, and this effect is irrespective of sex.	Propranolol	98-109	interleukin-6	Sus scrofa	186-190
31542162-0	2019	Propranolol protects cerebral autoregulation and reduces hippocampal neuronal cell death through inhibition of interleukin-6 upregulation after traumatic brain injury in pigs.	Propranolol	0-11	interleukin-6	Sus scrofa	111-124
31682714-14	2019	We found that propranolol increased pigment epithelium-derived factor (PEDF) expression in MPs.	Propranolol	14-25	serine (or cysteine) peptidase inhibitor, clade F, member 1	Mus musculus	36-69
31542162-5	2019	We tested the hypothesis that propranolol would prevent the impairment of cerebral autoregulation and tissue changes after TBI via inhibition of interleukin-6 (IL-6) upregulation.	Propranolol	30-41	interleukin-6	Sus scrofa	145-158
31542162-5	2019	We tested the hypothesis that propranolol would prevent the impairment of cerebral autoregulation and tissue changes after TBI via inhibition of interleukin-6 (IL-6) upregulation.	Propranolol	30-41	interleukin-6	Sus scrofa	160-164
31527069-4	2019	Using a mouse model of vaccine-based immunotherapy, we showed that propranolol, a nonselective beta-blocker, strongly improved the efficacy of an antitumor STxBE7 vaccine by enhancing the frequency of CD8+ T lymphocytes infiltrating the tumor (TIL).	Propranolol	67-78	CD8a molecule	Homo sapiens	201-204
31527069-6	2019	In contrast, naive CD8+ T-cell activation was strongly inhibited by beta-AR signaling, and the beneficial effect of propranolol mainly occurred during CD8+ T-cell priming in the tumor-draining lymph node.	Propranolol	116-127	CD8a molecule	Homo sapiens	151-154
31682714-14	2019	We found that propranolol increased pigment epithelium-derived factor (PEDF) expression in MPs.	Propranolol	14-25	serine (or cysteine) peptidase inhibitor, clade F, member 1	Mus musculus	71-75
31682714-15	2019	Trapping of PEDF with an antibody abrogated antiangiogenic effects of propranolol.	Propranolol	70-81	serine (or cysteine) peptidase inhibitor, clade F, member 1	Mus musculus	12-16
31682714-17	2019	Conclusions: We hereby show that propranolol confers on MPs antiangiogenic properties by increasing PEDF expression, which complements its effects on vascular tissue resulting in inhibition of choroidal vasoproliferation in inflammatory conditions.	Propranolol	33-44	serine (or cysteine) peptidase inhibitor, clade F, member 1	Mus musculus	100-104
31425494-12	2019	H&amp;E-staining revealed that more neurons in the hippocampal-CA1 area underwent apoptosis in the placebo-group compared to the beta-blocker-group.Post-injury propranolol administration results in improved memory, learning and cognitive functions in a murine model of moderate TBI.	Propranolol	160-171	carbonic anhydrase 1	Mus musculus	63-66
31849395-7	2019	Results: Low doses of propranolol suppressed the systemic production of CRP, TNF-alpha, and IL-6; however, the hematological parameters were not affected.	Propranolol	22-33	C-reactive protein	Rattus norvegicus	72-75
31849395-7	2019	Results: Low doses of propranolol suppressed the systemic production of CRP, TNF-alpha, and IL-6; however, the hematological parameters were not affected.	Propranolol	22-33	tumor necrosis factor	Rattus norvegicus	77-86
31849395-7	2019	Results: Low doses of propranolol suppressed the systemic production of CRP, TNF-alpha, and IL-6; however, the hematological parameters were not affected.	Propranolol	22-33	interleukin 6	Rattus norvegicus	92-96
31425494-13	2019	Propranolol increases the expression of anti-apoptotic-protein (Hsp-70) and decreases cell death in the hippocampal-CA1 area compared to the placebo.Basic Science.	Propranolol	0-11	heat shock protein 1B	Mus musculus	64-70
31425494-13	2019	Propranolol increases the expression of anti-apoptotic-protein (Hsp-70) and decreases cell death in the hippocampal-CA1 area compared to the placebo.Basic Science.	Propranolol	0-11	carbonic anhydrase 1	Mus musculus	116-119
31701018-9	2019	We confirmed that propranolol isomers downregulated ANGPTL4 in endothelial cells, with greater downregulation of ANGPTL4 using the beta blockade inactive R-propranolol.	Propranolol	18-29	angiopoietin like 4	Homo sapiens	52-59
31701018-9	2019	We confirmed that propranolol isomers downregulated ANGPTL4 in endothelial cells, with greater downregulation of ANGPTL4 using the beta blockade inactive R-propranolol.	Propranolol	18-29	angiopoietin like 4	Homo sapiens	113-120
31701018-9	2019	We confirmed that propranolol isomers downregulated ANGPTL4 in endothelial cells, with greater downregulation of ANGPTL4 using the beta blockade inactive R-propranolol.	Propranolol	156-167	angiopoietin like 4	Homo sapiens	113-120
31668109-6	2022	We observed a decrease in serum ang2 level after usage of ICZ &amp; propranolol and the change in serum angiopoietin2 level before and after treatment in each group was statistically significant (p &lt; 0.001).Conclusion: Oral itraconazole can be an equivalent option for oral propranolol while safer and shorter treatment periods.	Propranolol	68-79	angiopoietin 2	Homo sapiens	32-36
31668109-6	2022	We observed a decrease in serum ang2 level after usage of ICZ &amp; propranolol and the change in serum angiopoietin2 level before and after treatment in each group was statistically significant (p &lt; 0.001).Conclusion: Oral itraconazole can be an equivalent option for oral propranolol while safer and shorter treatment periods.	Propranolol	277-288	angiopoietin 2	Homo sapiens	32-36
31668109-6	2022	We observed a decrease in serum ang2 level after usage of ICZ &amp; propranolol and the change in serum angiopoietin2 level before and after treatment in each group was statistically significant (p &lt; 0.001).Conclusion: Oral itraconazole can be an equivalent option for oral propranolol while safer and shorter treatment periods.	Propranolol	277-288	angiopoietin 2	Homo sapiens	104-117
31648256-6	2019	In another treatment using non-differentiated HSG cells, it was evident that both expression and secretion of cystatin C increased upon addition of the beta-adrenergic agonist, and these effects were essentially eliminated by the antagonist propranolol.	Propranolol	241-252	cystatin C	Homo sapiens	110-120
31709066-4	2019	The method was applied to the human beta2-adrenergic receptor, resulting in eight room-temperature co-crystal structures with six different ligands, including previously unreported structures with carvedilol and propranolol.	Propranolol	212-223	adrenoceptor beta 2	Homo sapiens	36-61
31624248-9	2019	These effects were reversed by the ADRB antagonists propranolol and ICI118,551 (an ADRB2-specific antagonist).	Propranolol	52-63	adrenoceptor beta 2	Homo sapiens	83-88
31176001-8	2019	In vitro, catecholamine treatment triggered the M2 polarization of macrophages, enhanced the expression of VEGF, promoted tumor angiogenesis, and these catecholamine-stimulated effects could be reversed by the adrenergic receptor antagonist propranolol.	Propranolol	241-252	vascular endothelial growth factor A	Homo sapiens	107-111
31108171-10	2019	Finally, mice treated with the beta-adrenergic receptor antagonist, propranolol, were resistant to handling stress-induced loss of NOR and caspase-1 activation.	Propranolol	68-79	caspase 1	Mus musculus	139-148
31265849-1	2019	We present a computational analysis coupled with experimental studies, focusing on the binding-interaction between beta-adrenoreceptor blocking agents (acebutolol and propranolol) with fibrinogen protein (E-region).	Propranolol	167-178	fibrinogen beta chain	Homo sapiens	185-195
31265849-5	2019	In this regard, we identify a docking-mechanism of interaction for the propranolol and acebutolol mainly based on non-covalent hydrophobic contacts with the fibrinogen E-region binding-site.	Propranolol	71-82	fibrinogen beta chain	Homo sapiens	157-167
31356776-11	2019	Finally, we found that AMPK inhibitor (8-bAMP) and mTOR activator (propranolol) both abolished the effects of ACE2 activator (resorcinolnaphthalein) on the expression of lung autophagy proteins Beclin-1, LC3-I and LC3-II.	Propranolol	67-78	mechanistic target of rapamycin kinase	Mus musculus	51-55
31356776-11	2019	Finally, we found that AMPK inhibitor (8-bAMP) and mTOR activator (propranolol) both abolished the effects of ACE2 activator (resorcinolnaphthalein) on the expression of lung autophagy proteins Beclin-1, LC3-I and LC3-II.	Propranolol	67-78	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	110-114
31356776-11	2019	Finally, we found that AMPK inhibitor (8-bAMP) and mTOR activator (propranolol) both abolished the effects of ACE2 activator (resorcinolnaphthalein) on the expression of lung autophagy proteins Beclin-1, LC3-I and LC3-II.	Propranolol	67-78	beclin 1, autophagy related	Mus musculus	194-202
31391149-6	2019	Molecular docking studies have found that existing drugs such as propranolol, naphthazarin and thymoquinone have favourable interactions with specific domains of UHRF1.	Propranolol	65-76	ubiquitin like with PHD and ring finger domains 1	Homo sapiens	162-167
31391149-12	2019	A scientifically established solution in the form of targeted treatment must follow such a discovery and therefore, several natural and synthetic compounds such as thymoquinone and the well-known antihypertensive, propranolol have been docked and reported to have favourable interactions with the SRA (Set and Ring Associated) domain of UHRF1 in this review.	Propranolol	214-225	macrophage scavenger receptor 1	Homo sapiens	297-300
31391149-12	2019	A scientifically established solution in the form of targeted treatment must follow such a discovery and therefore, several natural and synthetic compounds such as thymoquinone and the well-known antihypertensive, propranolol have been docked and reported to have favourable interactions with the SRA (Set and Ring Associated) domain of UHRF1 in this review.	Propranolol	214-225	ubiquitin like with PHD and ring finger domains 1	Homo sapiens	337-342
30019362-7	2019	Lastly, animals were given dietary lithium (Li+ ), to inhibit the activation of GSK3beta, or injections of the ss-adrenoceptor antagonist propranolol, which potently inhibits CREB as a secondary mechanism of action, and any changes in ropinirole-induced increases in compulsive-like engagement in the rSMT evaluated.	Propranolol	138-149	cAMP responsive element binding protein 1	Rattus norvegicus	175-179
31091531-1	2019	BACKGROUND: Propranolol is the preferred treatment for problematic proliferating infantile hemangioma (IH) by targeting the renin-angiotensin system (RAS) expressed by IH endothelium.	Propranolol	12-23	renin	Homo sapiens	124-129
30471093-2	2019	Preclinical evidence and meta-analysis data demonstrate that melanoma shows a positive response to beta-adrenoceptor blockers and in particular to propranolol acting mainly at beta1 - and beta2 -adrenoceptors.	Propranolol	147-158	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	176-181
31358114-3	2019	Here, we report successful treatment of pericardial edema with propranolol in a patient with Hypotrichosis-Lymphedema-Telangiectasia and Renal (HLTRS) syndrome, caused by a mutation in SOX18.	Propranolol	63-74	SRY-box transcription factor 18	Homo sapiens	185-190
31358114-5	2019	Dissection of the molecular mechanism identified the R(+)-propranolol enantiomer as a small molecule inhibitor of the SOX18 transcription factor, independent of any anti-adrenergic effect.	Propranolol	58-69	SRY (sex determining region Y)-box 18	Mus musculus	118-123
31296894-4	2019	Propranolol, a non-specific beta1-and beta2-adrenergic receptor antagonist, was recently designated as the first therapeutic (orphan) drug for VHL disease.	Propranolol	0-11	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	28-33
31296894-4	2019	Propranolol, a non-specific beta1-and beta2-adrenergic receptor antagonist, was recently designated as the first therapeutic (orphan) drug for VHL disease.	Propranolol	0-11	adrenoceptor beta 2	Homo sapiens	38-63
30471093-2	2019	Preclinical evidence and meta-analysis data demonstrate that melanoma shows a positive response to beta-adrenoceptor blockers and in particular to propranolol acting mainly at beta1 - and beta2 -adrenoceptors.	Propranolol	147-158	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	188-193
30986805-8	2019	Collectively, our data provided evidence that propranolol may repress infantile hemangioma cell growth and promote apoptosis through upregulating the miR-125b expression, which exerted its suppression of tumor development by targeting TFAP4.	Propranolol	46-57	transcription factor AP-4	Homo sapiens	235-240
30847700-5	2019	Very recently, the use of topical propranolol or of timolol has been reported in several patients undergoing treatment with EGFR inhibitors and developing pyogenic granulomas of the nail.	Propranolol	34-45	epidermal growth factor receptor	Homo sapiens	124-128
31370004-7	2019	Interestingly, treatment with the  -adrenergic receptor antagonist propranolol mildly but selectively improved metrics of cortical bone mass in GR-CKO mice during CR, suggesting interaction between adrenergic and glucocorticoid signaling pathways that affects cortical bone.	Propranolol	67-78	nuclear receptor subfamily 3, group C, member 1	Mus musculus	144-150
30965238-0	2019	The sustained and targeted treatment of hemangiomas by propranolol-loaded CD133 aptamers conjugated liposomes-in-microspheres.	Propranolol	55-66	prominin 1	Mus musculus	74-79
30965238-3	2019	Therefore, we hereby encapsulated propranolol-loaded CD133 aptamers conjugated liposomes in poly(lactic-co-glycolic acid (PLGA) microspheres to develop propranolol-loaded CD133 aptamers conjugated liposomes-in-microspheres (PCLIM), to realize the aim of the sustained and targeted therapy of hemangiomas.	Propranolol	152-163	prominin 1	Mus musculus	53-58
30965238-3	2019	Therefore, we hereby encapsulated propranolol-loaded CD133 aptamers conjugated liposomes in poly(lactic-co-glycolic acid (PLGA) microspheres to develop propranolol-loaded CD133 aptamers conjugated liposomes-in-microspheres (PCLIM), to realize the aim of the sustained and targeted therapy of hemangiomas.	Propranolol	152-163	prominin 1	Mus musculus	171-176
31466709-5	2019	RESULTS: Neoadjuvant propranolol decreased expression of the pro-proliferative Ki-67 and pro-survival Bcl-2 markers, and increased pro-apoptotic p53 expression in a patient with stage III breast cancer.	Propranolol	21-32	BCL2 apoptosis regulator	Homo sapiens	102-107
31466709-5	2019	RESULTS: Neoadjuvant propranolol decreased expression of the pro-proliferative Ki-67 and pro-survival Bcl-2 markers, and increased pro-apoptotic p53 expression in a patient with stage III breast cancer.	Propranolol	21-32	tumor protein p53	Homo sapiens	145-148
30965238-3	2019	Therefore, we hereby encapsulated propranolol-loaded CD133 aptamers conjugated liposomes in poly(lactic-co-glycolic acid (PLGA) microspheres to develop propranolol-loaded CD133 aptamers conjugated liposomes-in-microspheres (PCLIM), to realize the aim of the sustained and targeted therapy of hemangiomas.	Propranolol	34-45	prominin 1	Mus musculus	53-58
31466709-7	2019	Furthermore, propranolol treatment of breast cancer cells increased p53 levels, enhanced caspase cleavage, and induced apoptosis.	Propranolol	13-24	tumor protein p53	Homo sapiens	68-71
30965238-3	2019	Therefore, we hereby encapsulated propranolol-loaded CD133 aptamers conjugated liposomes in poly(lactic-co-glycolic acid (PLGA) microspheres to develop propranolol-loaded CD133 aptamers conjugated liposomes-in-microspheres (PCLIM), to realize the aim of the sustained and targeted therapy of hemangiomas.	Propranolol	34-45	prominin 1	Mus musculus	171-176
30841438-0	2019	Propranolol selectively inhibits cervical cancer cell growth by suppressing the cGMP/PKG pathway.	Propranolol	0-11	protein kinase cGMP-dependent 1	Homo sapiens	85-88
30694975-10	2019	Pretreatment of mice with propranolol attenuated the epinephrine-induced increase in FST expression.	Propranolol	26-37	follistatin	Mus musculus	85-88
31245608-14	2019	Conclusions: Propranolol could be used to treat retinal hemangioblastomas in VHL patients, although more studies are needed to determine the ideal dose and long-term effect.	Propranolol	13-24	von Hippel-Lindau tumor suppressor	Homo sapiens	77-80
31125347-6	2019	On multivariate Cox regression analysis of HCC mortality, propranolol significantly reduced the mortality risk by 22% (hazard ratio [HR] = 0.78, 95% confidence interval [CI] 0.72-0.84, P &lt;0.001).	Propranolol	58-69	cytochrome c oxidase subunit 8A	Homo sapiens	16-19
31173327-0	2019	Propranolol regulates ERK1/2 signaling pathway and promotes chronic wound healing in diabetic rats.	Propranolol	0-11	mitogen activated protein kinase 3	Rattus norvegicus	22-28
31173327-1	2019	OBJECTIVE: This study aimed to investigate if propranolol could regulate ERK1/2 signaling pathway and promote chronic wound healing in diabetic rats.	Propranolol	46-57	mitogen activated protein kinase 3	Rattus norvegicus	73-79
31173327-10	2019	There was a significant increase in the expression of the p-ERK1/2 protein in the wound tissue of the propranolol group compared with that in the control group, except for the 11th day (p<0.05).	Propranolol	102-113	mitogen activated protein kinase 3	Rattus norvegicus	60-66
31173327-11	2019	The relative expression of Vascular Endothelial Growth Factor (VEGF) in the propranolol group was significantly higher than that in the control group on the 2nd day (p<0.05), while the relative expression of VEGF in the propranolol group was significantly increased on the 11th day after modeling (p<0.05).	Propranolol	76-87	vascular endothelial growth factor A	Rattus norvegicus	27-61
31173327-11	2019	The relative expression of Vascular Endothelial Growth Factor (VEGF) in the propranolol group was significantly higher than that in the control group on the 2nd day (p<0.05), while the relative expression of VEGF in the propranolol group was significantly increased on the 11th day after modeling (p<0.05).	Propranolol	76-87	vascular endothelial growth factor A	Rattus norvegicus	63-67
31173327-11	2019	The relative expression of Vascular Endothelial Growth Factor (VEGF) in the propranolol group was significantly higher than that in the control group on the 2nd day (p<0.05), while the relative expression of VEGF in the propranolol group was significantly increased on the 11th day after modeling (p<0.05).	Propranolol	76-87	vascular endothelial growth factor A	Rattus norvegicus	208-212
31173327-11	2019	The relative expression of Vascular Endothelial Growth Factor (VEGF) in the propranolol group was significantly higher than that in the control group on the 2nd day (p<0.05), while the relative expression of VEGF in the propranolol group was significantly increased on the 11th day after modeling (p<0.05).	Propranolol	220-231	vascular endothelial growth factor A	Rattus norvegicus	27-61
31173327-11	2019	The relative expression of Vascular Endothelial Growth Factor (VEGF) in the propranolol group was significantly higher than that in the control group on the 2nd day (p<0.05), while the relative expression of VEGF in the propranolol group was significantly increased on the 11th day after modeling (p<0.05).	Propranolol	220-231	vascular endothelial growth factor A	Rattus norvegicus	208-212
31173327-12	2019	On the 20th day, the expressions of IL-6 and TNF-alpha in the propranolol group were significantly higher than those in the control group, and there were significant differences (p<0.05).	Propranolol	62-73	interleukin 6	Rattus norvegicus	36-40
31173327-12	2019	On the 20th day, the expressions of IL-6 and TNF-alpha in the propranolol group were significantly higher than those in the control group, and there were significant differences (p<0.05).	Propranolol	62-73	tumor necrosis factor	Rattus norvegicus	45-54
31173327-13	2019	It was found that the IL-6 and TNF-alpha expressions in the propranolol group reached the peak on the 11th day and then gradually decreased (p<0.05).	Propranolol	60-71	interleukin 6	Rattus norvegicus	22-26
31173327-13	2019	It was found that the IL-6 and TNF-alpha expressions in the propranolol group reached the peak on the 11th day and then gradually decreased (p<0.05).	Propranolol	60-71	tumor necrosis factor	Rattus norvegicus	31-40
31173327-14	2019	CONCLUSIONS: The results indicated that propranolol can accelerate the healing of diabetic wounds by regulating the expression of VEGF by phosphorylation of ERK1/2 protein, thus promoting chronic wound healing in diabetes.	Propranolol	40-51	vascular endothelial growth factor A	Rattus norvegicus	130-134
31173327-14	2019	CONCLUSIONS: The results indicated that propranolol can accelerate the healing of diabetic wounds by regulating the expression of VEGF by phosphorylation of ERK1/2 protein, thus promoting chronic wound healing in diabetes.	Propranolol	40-51	mitogen activated protein kinase 3	Rattus norvegicus	157-163
31035526-7	2019	RESULTS: Propranolol combined with radiation or cisplatin decreased clonogenic survival of PC9 and A549 cells in vitro (p &lt; 0.05).	Propranolol	9-20	proprotein convertase subtilisin/kexin type 9	Homo sapiens	91-94
30368887-0	2019	Propranolol suppresses HUVEC viability, migration, VEGF expression, and promotes apoptosis by downregulation of miR-4295.	Propranolol	0-11	vascular endothelial growth factor A	Homo sapiens	51-55
30368887-0	2019	Propranolol suppresses HUVEC viability, migration, VEGF expression, and promotes apoptosis by downregulation of miR-4295.	Propranolol	0-11	microRNA 4295	Homo sapiens	112-120
30368887-11	2019	Meanwhile, the expressions of VEGF, VEGF-A, FLT1, FLT2, and FOXF1 were downregulated by propranolol exposure.	Propranolol	88-99	vascular endothelial growth factor A	Homo sapiens	30-34
30368887-11	2019	Meanwhile, the expressions of VEGF, VEGF-A, FLT1, FLT2, and FOXF1 were downregulated by propranolol exposure.	Propranolol	88-99	vascular endothelial growth factor A	Homo sapiens	36-42
30368887-11	2019	Meanwhile, the expressions of VEGF, VEGF-A, FLT1, FLT2, and FOXF1 were downregulated by propranolol exposure.	Propranolol	88-99	fms related receptor tyrosine kinase 1	Homo sapiens	44-48
30368887-11	2019	Meanwhile, the expressions of VEGF, VEGF-A, FLT1, FLT2, and FOXF1 were downregulated by propranolol exposure.	Propranolol	88-99	fibroblast growth factor receptor 1	Homo sapiens	50-54
30368887-11	2019	Meanwhile, the expressions of VEGF, VEGF-A, FLT1, FLT2, and FOXF1 were downregulated by propranolol exposure.	Propranolol	88-99	forkhead box F1	Homo sapiens	60-65
30368887-12	2019	Further study showed that miR-4295 expression was upregulated in IH tissues, and propranolol treatment downregulated miR-4295 expression in HUVECs.	Propranolol	81-92	microRNA 4295	Homo sapiens	117-125
30368887-14	2019	Propranolol suppressed HUVEC viability, migration, the expression of VEGF, VEGF-A, FLT1/2, FOXF1, and promoted apoptosis via downregulation of miR-4295.	Propranolol	0-11	vascular endothelial growth factor A	Homo sapiens	69-73
30368887-14	2019	Propranolol suppressed HUVEC viability, migration, the expression of VEGF, VEGF-A, FLT1/2, FOXF1, and promoted apoptosis via downregulation of miR-4295.	Propranolol	0-11	vascular endothelial growth factor A	Homo sapiens	75-81
30368887-14	2019	Propranolol suppressed HUVEC viability, migration, the expression of VEGF, VEGF-A, FLT1/2, FOXF1, and promoted apoptosis via downregulation of miR-4295.	Propranolol	0-11	fms related receptor tyrosine kinase 1	Homo sapiens	83-89
30368887-14	2019	Propranolol suppressed HUVEC viability, migration, the expression of VEGF, VEGF-A, FLT1/2, FOXF1, and promoted apoptosis via downregulation of miR-4295.	Propranolol	0-11	forkhead box F1	Homo sapiens	91-96
30368887-14	2019	Propranolol suppressed HUVEC viability, migration, the expression of VEGF, VEGF-A, FLT1/2, FOXF1, and promoted apoptosis via downregulation of miR-4295.	Propranolol	0-11	microRNA 4295	Homo sapiens	143-151
30711897-7	2019	In males, administration of propranolol had no effect on IL-1beta expression in non-stressed controls but significantly reduced IL-1beta in the hippocampus and amygdala of chronically stressed animals.	Propranolol	28-39	interleukin 1 alpha	Rattus norvegicus	128-136
30711897-8	2019	In females, propranolol significantly reduced IL-1beta in the amygdala and hypothalamus of both control and stressed rats.	Propranolol	12-23	interleukin 1 alpha	Rattus norvegicus	46-54
30711897-10	2019	Interestingly, propranolol treatment blocked the metyrapone-induced increase in brain IL-1beta indicating the increase in brain IL-1beta following metyrapone treatment was due to increase beta-AR activation.	Propranolol	15-26	interleukin 1 alpha	Rattus norvegicus	86-94
30711897-10	2019	Interestingly, propranolol treatment blocked the metyrapone-induced increase in brain IL-1beta indicating the increase in brain IL-1beta following metyrapone treatment was due to increase beta-AR activation.	Propranolol	15-26	interleukin 1 alpha	Rattus norvegicus	128-136
30711897-10	2019	Interestingly, propranolol treatment blocked the metyrapone-induced increase in brain IL-1beta indicating the increase in brain IL-1beta following metyrapone treatment was due to increase beta-AR activation.	Propranolol	15-26	ferredoxin reductase	Rattus norvegicus	193-195
30877244-6	2019	Importantly, posttraining inactivation of the BLA by the noradrenergic antagonist propranolol abolished the effect of GR agonist administration into the PrL on memory enhancement of both the identity and location of the object.	Propranolol	82-93	nuclear receptor subfamily 3, group C, member 1	Rattus norvegicus	118-120
30877244-7	2019	BLA inactivation by propranolol also blocked the effect of GR agonist administration into the PrL on inducing changes in neuronal activity within the aIC and dHPC during the postlearning consolidation period as well as on structural changes in spine morphology assessed 24 hours later.	Propranolol	20-31	nuclear receptor subfamily 3, group C, member 1	Rattus norvegicus	59-61
30713220-12	2019	NIPBL downregulation inhibited propranolol resistance of HemSCs.	Propranolol	31-42	NIPBL cohesin loading factor	Homo sapiens	0-5
30713220-13	2019	Re-introduction of NIPBL reversed miR-187-3p-meidated higher propranolol sensitivity of HemSCs.	Propranolol	61-72	NIPBL cohesin loading factor	Homo sapiens	19-24
30713220-14	2019	MiR-187-3p enhanced propranolol sensitivity of hemangioma stem cells via targeting NIPBL.	Propranolol	20-31	NIPBL cohesin loading factor	Homo sapiens	83-88
30871232-2	2019	Yet even in tumors with active ADRB2 signaling propranolol may be ineffective.	Propranolol	47-58	adrenoceptor beta 2	Homo sapiens	31-36
30871232-5	2019	Therefore, a comprehensive analysis of ADRB2 signaling in the context of other signaling mechanisms is necessary to identify patients who will benefit from propranolol therapy.	Propranolol	156-167	adrenoceptor beta 2	Homo sapiens	39-44
30871232-6	2019	This review discusses how information on the antiapoptotic mechanisms activated by ADRB2 can guide clinical trials of ADRB2 antagonist propranolol as potential life-extending therapy for prostate cancer.	Propranolol	135-146	adrenoceptor beta 2	Homo sapiens	83-88
30871232-6	2019	This review discusses how information on the antiapoptotic mechanisms activated by ADRB2 can guide clinical trials of ADRB2 antagonist propranolol as potential life-extending therapy for prostate cancer.	Propranolol	135-146	adrenoceptor beta 2	Homo sapiens	118-123
30584986-5	2019	Knockdown of ID-1 inhibited proliferation, facilitated apoptosis, and enhanced propranolol cytotoxicity in HDECs.	Propranolol	79-90	inhibitor of DNA binding 1, HLH protein	Homo sapiens	13-17
30677171-6	2019	The nonlinear behavior of lnk" against 1/T for propranolol, atenolol, and metoprolol suggested the presence of multiple binding mechanisms for these analytes on CSP with variation of temperature.	Propranolol	47-58	SH2B adaptor protein 3	Homo sapiens	26-29
30867686-13	2019	Our previous research showed that propranolol accelerated adipogenesis in HemSCs and induced the upregulation of IGF-2.	Propranolol	34-45	insulin like growth factor 2	Homo sapiens	113-118
30867686-14	2019	The results of the present study indicate that IGF-2 is able to accelerate adipogenesis, and the propranolol-induced promotion of dysregulated adipogenesis may be mediated by the IGF-2 via IGF-1R and PI3K pathways.	Propranolol	97-108	insulin like growth factor 2	Homo sapiens	179-184
30867686-14	2019	The results of the present study indicate that IGF-2 is able to accelerate adipogenesis, and the propranolol-induced promotion of dysregulated adipogenesis may be mediated by the IGF-2 via IGF-1R and PI3K pathways.	Propranolol	97-108	insulin like growth factor 1 receptor	Homo sapiens	189-195
30600100-4	2019	Propranolol, irrespective of exogenous noradrenaline presence, more prominently augmented IL-2 production and proliferation of CD4+ lymphocytes in male than female rat dLN cell cultures.	Propranolol	0-11	interleukin 2	Rattus norvegicus	90-94
30399481-3	2019	In this work, the interaction of purified CYP2C19 WT (CYP2C19) with seven drugs (phenytoin, S-mephenytoin, omeprazole, lansoprazole, cimetidine, propranolol, and warfarin) was investigated using spectroscopic methods.	Propranolol	145-156	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	42-49
30399481-3	2019	In this work, the interaction of purified CYP2C19 WT (CYP2C19) with seven drugs (phenytoin, S-mephenytoin, omeprazole, lansoprazole, cimetidine, propranolol, and warfarin) was investigated using spectroscopic methods.	Propranolol	145-156	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	54-61
30600100-5	2019	In neuroantigen-stimulated dLN cells of both sexes propranolol increased IL-1beta and IL-23/p19 expression and IL-17+ CD4+ cell frequency, but enhanced IL-17 production only in male rat CD4+ lymphocytes, thereby abrogating sexual dimorphism in IL-17 concentration observed in propranolol-free cultures.	Propranolol	51-62	interleukin 1 beta	Rattus norvegicus	73-81
30600100-5	2019	In neuroantigen-stimulated dLN cells of both sexes propranolol increased IL-1beta and IL-23/p19 expression and IL-17+ CD4+ cell frequency, but enhanced IL-17 production only in male rat CD4+ lymphocytes, thereby abrogating sexual dimorphism in IL-17 concentration observed in propranolol-free cultures.	Propranolol	51-62	interleukin 17A	Rattus norvegicus	111-116
30600100-5	2019	In neuroantigen-stimulated dLN cells of both sexes propranolol increased IL-1beta and IL-23/p19 expression and IL-17+ CD4+ cell frequency, but enhanced IL-17 production only in male rat CD4+ lymphocytes, thereby abrogating sexual dimorphism in IL-17 concentration observed in propranolol-free cultures.	Propranolol	51-62	interleukin 17A	Rattus norvegicus	152-157
30600100-5	2019	In neuroantigen-stimulated dLN cells of both sexes propranolol increased IL-1beta and IL-23/p19 expression and IL-17+ CD4+ cell frequency, but enhanced IL-17 production only in male rat CD4+ lymphocytes, thereby abrogating sexual dimorphism in IL-17 concentration observed in propranolol-free cultures.	Propranolol	51-62	interleukin 17A	Rattus norvegicus	152-157
30229289-6	2019	The effect of ISO was specifically dependent upon beta2-AR, since it was not seen in adrb2-/- CD8+ T-cells and was blocked by the beta-AR antagonist propranolol.	Propranolol	149-160	adrenergic receptor, beta 2	Mus musculus	50-58
31468460-6	2019	Addition of paeonol and propranolol to TNF-alpha pre-treated cells had no significant effect on [3H]taurine uptake, but the addition of 10 mM taurine caused a reduction.	Propranolol	24-35	tumor necrosis factor	Rattus norvegicus	39-48
31061315-9	2019	In the presence of propranolol (10-6 M), noradrenaline-induced relaxation was competitively inhibited by bupranolol (3 x 10-7-3 x 10-6 M) or SR59230A (10-7-10-6 M; selective beta3-adrenoceptor antagonist), with their pA2 values calculated to be 6.64 and 7.27, respectively.	Propranolol	19-30	adrenoceptor beta 3	Rattus norvegicus	174-192
30521840-5	2019	In cardiomyocytes, isoprenaline induced dephosphorylation, and thus activation of CRTC1, which was prevented by propranolol.	Propranolol	112-123	CREB regulated transcription coactivator 1	Mus musculus	82-87
30643142-6	2019	Sympathetic tone is increased in sensory denervation models, and propranolol, a beta2-adrenergic antagonist, rescues bone loss.	Propranolol	65-76	histocompatibility 2, O region beta locus	Mus musculus	78-85
30229289-6	2019	The effect of ISO was specifically dependent upon beta2-AR, since it was not seen in adrb2-/- CD8+ T-cells and was blocked by the beta-AR antagonist propranolol.	Propranolol	149-160	adrenergic receptor, beta 2	Mus musculus	130-137
31132768-3	2019	RESULTS: Irrespective of sex, in propranolol-treated (PT) rats, migration of CD11b+ antigen-presenting cells from the site of immunization to dLNs was impaired compared with saline-treated controls and consequently the frequency of all CD11b+ cells in dLNs and activated cells among them, too.	Propranolol	33-44	integrin subunit alpha M	Homo sapiens	77-82
30361859-2	2019	Emission spectral characteristics of fluorescent molecule, propranolol (PPH) was intact in presence of metal ions.	Propranolol	59-70	enolase 1	Homo sapiens	72-75
30695785-6	2019	RESULTS: We found that the concentration of NE was significantly elevated after TBI, and the dysfunction of CD4+ and CD8+ T cells was reversed by the SNS blocker propranolol in vivo and imitated by the SNS neurotransmitter NE in vitro.	Propranolol	162-173	Cd4 molecule	Rattus norvegicus	108-111
30695785-7	2019	The expression of PD-1 on CD4+ and CD8+ T cells was upregulated after aTBI, which was reversed by propranolol administration in vivo and imitated by NE stimulation in vitro.	Propranolol	98-109	CD4 molecule	Sus scrofa	26-29
30325031-4	2019	The order of Kb values between drugs such as adrenaline hydrochloride, norepinephrine bitartrate, and propranolol hydrochloride with beta2 -AR is well consistent with that reported in the literature.	Propranolol	102-127	adrenoceptor beta 2	Homo sapiens	133-142
31132768-3	2019	RESULTS: Irrespective of sex, in propranolol-treated (PT) rats, migration of CD11b+ antigen-presenting cells from the site of immunization to dLNs was impaired compared with saline-treated controls and consequently the frequency of all CD11b+ cells in dLNs and activated cells among them, too.	Propranolol	33-44	integrin subunit alpha M	Homo sapiens	236-241
30448832-4	2019	Effects of propranolol on apoptosis and expressions of cell cycle-related genes, CDK4 and cyclin D1, were detected by flow cytometry and RT-PCR respectively.	Propranolol	11-22	cyclin dependent kinase 4	Homo sapiens	81-85
30542705-11	2019	Collectively, propranolol and ICI 118,551 inhibited the viability of MDA-MB-231 cells by downregulating the ERK/COX-2 signaling pathway and inducing apoptosis.	Propranolol	14-25	mitogen-activated protein kinase 1	Homo sapiens	108-111
30448832-4	2019	Effects of propranolol on apoptosis and expressions of cell cycle-related genes, CDK4 and cyclin D1, were detected by flow cytometry and RT-PCR respectively.	Propranolol	11-22	cyclin D1	Homo sapiens	90-99
30448832-6	2019	RESULTS: Propranolol significantly inhibited the CoCl2-induced hypoxic proliferation of HUVECs in a dose-dependent manner, and also induced apoptosis and suppressed the expression of CDK4 and cyclin D1.	Propranolol	9-20	cyclin dependent kinase 4	Homo sapiens	183-187
30448832-6	2019	RESULTS: Propranolol significantly inhibited the CoCl2-induced hypoxic proliferation of HUVECs in a dose-dependent manner, and also induced apoptosis and suppressed the expression of CDK4 and cyclin D1.	Propranolol	9-20	cyclin D1	Homo sapiens	192-201
30448832-7	2019	Propranolol also decreased the release of VEGF and LDH in the supernatant.	Propranolol	0-11	vascular endothelial growth factor A	Homo sapiens	42-46
30225948-1	2018	OBJECTIVE: A recent study observed a 2-fold greater risk of Parkinson disease (PD) in relation to the beta2-adrenoreceptor antagonist propranolol and a markedly lower risk of PD for the beta2-adrenoreceptor agonist salbutamol.	Propranolol	134-145	adrenoceptor beta 2	Homo sapiens	102-122
30943497-4	2019	RESULTS: Ambulatory monitoring showed that during night-time SBP and DBP values were unaffected by bromazepam as compared to placebo, whereas SBP was significantly reduced by propranolol both when taken alone and in combination with bromazepam.	Propranolol	175-186	selenium binding protein 1	Homo sapiens	142-145
30422889-3	2018	This study determined the expression of the AT1, AT2, B1, and B2 receptors and of the enzymes ACE and ACE2 in hypertensive rats treated with captopril-propranolol or losartan-propranolol.	Propranolol	175-186	angiotensin II receptor, type 1a	Rattus norvegicus	44-47
30422889-3	2018	This study determined the expression of the AT1, AT2, B1, and B2 receptors and of the enzymes ACE and ACE2 in hypertensive rats treated with captopril-propranolol or losartan-propranolol.	Propranolol	175-186	angiotensin I converting enzyme 2	Rattus norvegicus	102-106
30513596-8	2018	Here, we show that glucose deprivation synergizes with propranolol for anti-cancer activity, and that the rational combination of propranolol and dichloroacetate (DCA), a clinically available glycolytic inhibitor, dramatically attenuates tumor cell metabolism and mTOR signaling, inhibits proliferation and colony formation, and induces apoptosis.	Propranolol	130-141	mechanistic target of rapamycin kinase	Homo sapiens	264-268
30180543-2	2018	Nevertheless, while TAML/H2O2 rapidly degrades the drug propranolol, a micropollutant (MP) of broad concern, propranolol is shown to inhibit its own destruction under concentration conditions amenable to kinetics studies ([propranolol] = 50 muM).	Propranolol	109-120	latexin	Homo sapiens	241-244
30359265-6	2018	In vitro the use of propranolol ameliorates tumour exosomes-associated cachectic wasting through upregulating the PPARgamma expression.	Propranolol	20-31	peroxisome proliferator activated receptor gamma	Homo sapiens	114-123
30130526-0	2018	Propranolol inhibits proliferation and invasion of hemangioma-derived endothelial cells by suppressing the DLL4/Notch1/Akt pathway.	Propranolol	0-11	delta like canonical Notch ligand 4	Homo sapiens	107-111
30130526-0	2018	Propranolol inhibits proliferation and invasion of hemangioma-derived endothelial cells by suppressing the DLL4/Notch1/Akt pathway.	Propranolol	0-11	notch receptor 1	Homo sapiens	112-118
30130526-0	2018	Propranolol inhibits proliferation and invasion of hemangioma-derived endothelial cells by suppressing the DLL4/Notch1/Akt pathway.	Propranolol	0-11	AKT serine/threonine kinase 1	Homo sapiens	119-122
30130526-11	2018	Propranolol inhibited the invasion ability of HemECs and reduced the expression levels of MMP-2 and MMP-9 in HemECs.	Propranolol	0-11	matrix metallopeptidase 2	Homo sapiens	90-95
30130526-11	2018	Propranolol inhibited the invasion ability of HemECs and reduced the expression levels of MMP-2 and MMP-9 in HemECs.	Propranolol	0-11	matrix metallopeptidase 9	Homo sapiens	100-105
30130526-12	2018	Besides, propranolol treatment blocked the DLL4/Notch1 and Akt signaling and inhibited VEGF expression in HemECs.	Propranolol	9-20	delta like canonical Notch ligand 4	Homo sapiens	43-47
30130526-12	2018	Besides, propranolol treatment blocked the DLL4/Notch1 and Akt signaling and inhibited VEGF expression in HemECs.	Propranolol	9-20	notch receptor 1	Homo sapiens	48-54
30130526-12	2018	Besides, propranolol treatment blocked the DLL4/Notch1 and Akt signaling and inhibited VEGF expression in HemECs.	Propranolol	9-20	AKT serine/threonine kinase 1	Homo sapiens	59-62
30130526-12	2018	Besides, propranolol treatment blocked the DLL4/Notch1 and Akt signaling and inhibited VEGF expression in HemECs.	Propranolol	9-20	vascular endothelial growth factor A	Homo sapiens	87-91
30497198-8	2018	Similar to prior reports in infantile hemangiomas, propranolol induced apoptosis and paradoxically increased VEGF-A mRNA expression in patient-derived VHL-HBs and 786-O cells.	Propranolol	51-62	vascular endothelial growth factor A	Homo sapiens	109-115
30008082-6	2018	K2P17.1 channels expressed in Xenopus laevis oocytes were screened for sensitivity to antiarrhythmic drugs, revealing significant activation by propafenone (+ 296%; 100 muM), quinidine (+ 58%; 100 muM), mexiletine (+ 21%; 100 muM), propranolol (+ 139%; 100 muM), and metoprolol (+ 17%; 100 muM) within 60 min.	Propranolol	232-243	potassium two pore domain channel subfamily K member 17	Homo sapiens	0-7
30153111-8	2018	We took advantage of the beta1-AR selectivity gradient of these drugs (propranolol [nonselective] &lt;&lt; atenolol [relatively beta1-AR selective] &lt; nebivolol [highly beta1-AR selective]) to define the beta-AR selectivity for SNS effects on bone.	Propranolol	71-82	adrenoceptor beta 1	Homo sapiens	25-33
30232552-0	2018	Propranolol inhibits the activity of PI3K, AKT, and HIF-1alpha in infantile hemangiomas.	Propranolol	0-11	thymoma viral proto-oncogene 1	Mus musculus	43-46
30232552-1	2018	PURPOSE: We sought to evaluate effect of propranolol in the treatment of infantile hemangiomas by quantifying the amount of phosphatidylinositol 3-kinase (PI3K), protein kinase B (AKT), and hypoxia-inducible factor-1alpha (HIF-1alpha).	Propranolol	41-52	phosphoinositide-3-kinase regulatory subunit 1	Mus musculus	124-153
30232552-1	2018	PURPOSE: We sought to evaluate effect of propranolol in the treatment of infantile hemangiomas by quantifying the amount of phosphatidylinositol 3-kinase (PI3K), protein kinase B (AKT), and hypoxia-inducible factor-1alpha (HIF-1alpha).	Propranolol	41-52	thymoma viral proto-oncogene 1	Mus musculus	180-183
30232552-1	2018	PURPOSE: We sought to evaluate effect of propranolol in the treatment of infantile hemangiomas by quantifying the amount of phosphatidylinositol 3-kinase (PI3K), protein kinase B (AKT), and hypoxia-inducible factor-1alpha (HIF-1alpha).	Propranolol	41-52	hypoxia inducible factor 1, alpha subunit	Mus musculus	190-221
30232552-1	2018	PURPOSE: We sought to evaluate effect of propranolol in the treatment of infantile hemangiomas by quantifying the amount of phosphatidylinositol 3-kinase (PI3K), protein kinase B (AKT), and hypoxia-inducible factor-1alpha (HIF-1alpha).	Propranolol	41-52	hypoxia inducible factor 1, alpha subunit	Mus musculus	223-233
30232552-8	2018	CONCLUSION: Propranolol can promote regression of infantile hemangiomas, which may be related to the inhibition of PI3K, AKT, and HIF-1alpha activity.	Propranolol	12-23	thymoma viral proto-oncogene 1	Mus musculus	121-124
30232552-8	2018	CONCLUSION: Propranolol can promote regression of infantile hemangiomas, which may be related to the inhibition of PI3K, AKT, and HIF-1alpha activity.	Propranolol	12-23	hypoxia inducible factor 1, alpha subunit	Mus musculus	130-140
30180543-2	2018	Nevertheless, while TAML/H2O2 rapidly degrades the drug propranolol, a micropollutant (MP) of broad concern, propranolol is shown to inhibit its own destruction under concentration conditions amenable to kinetics studies ([propranolol] = 50 muM).	Propranolol	109-120	latexin	Homo sapiens	241-244
30180543-8	2018	However, based on the measured kI and calculated equilibrium constant K for propranolol-TAML binding, it is possible to project the impact on kI of reducing [propranolol] from 50 muM to the ultradilute regime typical of MP contaminated waters (&lt;=2 ppb, &lt;=7 nM for propranolol) where inhibition nearly vanishes.	Propranolol	76-87	latexin	Homo sapiens	179-182
30180543-8	2018	However, based on the measured kI and calculated equilibrium constant K for propranolol-TAML binding, it is possible to project the impact on kI of reducing [propranolol] from 50 muM to the ultradilute regime typical of MP contaminated waters (&lt;=2 ppb, &lt;=7 nM for propranolol) where inhibition nearly vanishes.	Propranolol	158-169	latexin	Homo sapiens	179-182
30180543-8	2018	However, based on the measured kI and calculated equilibrium constant K for propranolol-TAML binding, it is possible to project the impact on kI of reducing [propranolol] from 50 muM to the ultradilute regime typical of MP contaminated waters (&lt;=2 ppb, &lt;=7 nM for propranolol) where inhibition nearly vanishes.	Propranolol	158-169	latexin	Homo sapiens	179-182
30180543-9	2018	Projecting from 50 muM to higher concentrations, propranolol completely inhibits its own oxidation before reaching mM concentrations.	Propranolol	49-60	latexin	Homo sapiens	19-22
29438832-2	2018	The effect of different types of short-chain alkyl imidazolium ILs within the concentration range of 10.0-1000.0 mumol L-1 on a propranolol (PRO)-AGP model was firstly investigated by ILATPS/ACE system.	Propranolol	128-139	angiotensin I converting enzyme	Homo sapiens	184-194
30100069-2	2018	Nonselective beta-antagonist propranolol is in clinical trials for the treatment of ROP due to its effect of reducing VEGF expression and inhibiting retinal angiogenesis in oxygen-induced ROP models (OIR), but the mechanism by which propranolol acts on ROP vessels is still unclear.	Propranolol	29-40	vascular endothelial growth factor A	Mus musculus	118-122
30024340-7	2018	When phentolamine and propranolol were delivered during HBO2 at the onset of phase II, only propranolol led to sustained reductions in heart rate and rCBF, preventing the appearance of epileptiform discharges.	Propranolol	22-33	CCAAT/enhancer binding protein zeta	Rattus norvegicus	150-154
29752864-1	2018	AIM: To examine the interference of beta-blockers with the chemokine stromal cell-derived factor-1 (SDF-1) found in cell homing receptors, C-X-C chemokine receptor type 4 (CXCR-4) and CXCR-7, and regulatory proteins of homing pathways, we administered atenolol, carvedilol, metoprolol, and propranolol for 30 days using an orogastric tube to hypertensive rats.	Propranolol	290-301	C-X-C motif chemokine ligand 12	Rattus norvegicus	100-105
29871829-10	2018	Nonselective beta-blockers (such as propranolol) should be considered first line, as they simultaneously decrease ATPase activity, limit insulin secretion, and address the underlying disorder.	Propranolol	36-47	insulin	Homo sapiens	137-144
29758415-7	2018	Compared with the vaccine group, immunization with tumor lysate in combination with propranolol significantly increased IL-2, IL-4, IL-12, IL-17, and IFN-gamma cytokines.	Propranolol	84-95	interleukin 2	Mus musculus	120-124
29758415-7	2018	Compared with the vaccine group, immunization with tumor lysate in combination with propranolol significantly increased IL-2, IL-4, IL-12, IL-17, and IFN-gamma cytokines.	Propranolol	84-95	interleukin 4	Mus musculus	126-130
29758415-7	2018	Compared with the vaccine group, immunization with tumor lysate in combination with propranolol significantly increased IL-2, IL-4, IL-12, IL-17, and IFN-gamma cytokines.	Propranolol	84-95	interleukin 17A	Mus musculus	139-144
29758415-7	2018	Compared with the vaccine group, immunization with tumor lysate in combination with propranolol significantly increased IL-2, IL-4, IL-12, IL-17, and IFN-gamma cytokines.	Propranolol	84-95	interferon gamma	Mus musculus	150-159
30258563-3	2018	Unexpectedly, the beta-blocker propranolol showed selectively towards cancerous PC3 compared to non-cancerous PNT2 prostate cells, demonstrating the potential of this approach to identify new anti-cancer drug leads.	Propranolol	31-42	chromobox 8	Homo sapiens	80-83
30024340-7	2018	When phentolamine and propranolol were delivered during HBO2 at the onset of phase II, only propranolol led to sustained reductions in heart rate and rCBF, preventing the appearance of epileptiform discharges.	Propranolol	92-103	CCAAT/enhancer binding protein zeta	Rattus norvegicus	150-154
29427463-0	2018	Salivary levels of angiopoietin-2 in infants with infantile haemangiomas treated with and without systemic propranolol.	Propranolol	107-118	angiopoietin 2	Homo sapiens	19-33
29476776-2	2018	Propranolol, a nonspecific beta1-, beta2-adrenergic receptor (AR) inverse agonist, counters the hypermetabolic response to elevated catecholamines and may decrease hypertrophic scarring by an unknown mechanism.	Propranolol	0-11	adrenoceptor beta 1	Homo sapiens	27-60
29767244-0	2018	Propranolol induces hemangioma endothelial cell apoptosis via a p53-BAX mediated pathway.	Propranolol	0-11	tumor protein p53	Sus scrofa	64-67
29767244-0	2018	Propranolol induces hemangioma endothelial cell apoptosis via a p53-BAX mediated pathway.	Propranolol	0-11	apoptosis regulator BAX	Sus scrofa	68-71
29767244-3	2018	The aim of the present study was to investigate the expression of proteins regulated by cellular tumor antigen p53 (p53) in associated apoptosis pathways in IH endothelial cells (HemECs) treated with propranolol.	Propranolol	200-211	tumor protein p53	Sus scrofa	88-114
29767244-3	2018	The aim of the present study was to investigate the expression of proteins regulated by cellular tumor antigen p53 (p53) in associated apoptosis pathways in IH endothelial cells (HemECs) treated with propranolol.	Propranolol	200-211	tumor protein p53	Sus scrofa	111-114
29767244-16	2018	This result suggested that there is an association between p53 expression and the rate of apoptosis of propranolol-treated HemECs.	Propranolol	103-114	tumor protein p53	Sus scrofa	59-62
29767244-17	2018	The results of the western blot analysis demonstrated an upregulation of BAX expression and a downregulation of IGF-BP3 expression in the HemECs treated with propranolol.	Propranolol	158-169	apoptosis regulator BAX	Sus scrofa	73-76
29767244-17	2018	The results of the western blot analysis demonstrated an upregulation of BAX expression and a downregulation of IGF-BP3 expression in the HemECs treated with propranolol.	Propranolol	158-169	insulin-like growth factor-binding protein 3	Sus scrofa	112-119
29767244-20	2018	The results of the present study additionally suggest that the propranolol-induced HemEC apoptosis pathway is a mitochondrial apoptosis pathway and is regulated by p53-BAX signaling.	Propranolol	63-74	tumor protein p53	Sus scrofa	164-167
29767244-20	2018	The results of the present study additionally suggest that the propranolol-induced HemEC apoptosis pathway is a mitochondrial apoptosis pathway and is regulated by p53-BAX signaling.	Propranolol	63-74	apoptosis regulator BAX	Sus scrofa	168-171
29724816-0	2018	Modulation of LIN28B/Let-7 Signaling by Propranolol Contributes to Infantile Hemangioma Involution.	Propranolol	40-51	lin-28 homolog B	Homo sapiens	14-20
29724816-4	2018	APPROACH AND RESULTS: LIN28B is highly expressed in proliferative IH and is less expressed in involuted and in propranolol-treated IH samples as measured by immunofluorescence staining and quantitative RT-PCR.	Propranolol	111-122	lin-28 homolog B	Homo sapiens	22-28
29724816-7	2018	Propranolol treatment of induced pluripotent stem cells, which express mir-498(46) endogenously, reduced the expression of both LIN28B and mir-498(46) and increased the expression of let-7.	Propranolol	0-11	lin-28 homolog B	Homo sapiens	128-134
29724816-9	2018	CONCLUSIONS: This work uncovers the role of the LIN28B/let-7 switch in IH pathogenesis and provides a novel mechanism by which propranolol induces IH involution.	Propranolol	127-138	lin-28 homolog B	Homo sapiens	48-54
29930510-9	2018	In contrast, pretreatment by idazoxan, propranolol or the beta2 antagonist ICI 118551 markedly inhibited the anti-allodynic effect of "agomelatine + gabapentin" in both CCI-SN and CCI-ION rats, whereas pretreatment by the MT1/MT2 receptor antagonist S22153 was inactive.	Propranolol	39-50	metallothionein 1	Rattus norvegicus	222-225
29664206-0	2018	Pigment epithelium-derived factor/vascular endothelial growth factor ratio plays a crucial role in the spontaneous regression of infant hemangioma and in the therapeutic effect of propranolol.	Propranolol	180-191	serpin family F member 1	Homo sapiens	0-33
29664206-0	2018	Pigment epithelium-derived factor/vascular endothelial growth factor ratio plays a crucial role in the spontaneous regression of infant hemangioma and in the therapeutic effect of propranolol.	Propranolol	180-191	vascular endothelial growth factor A	Homo sapiens	34-68
29664206-2	2018	Propranolol, the first-line therapy for IH, inhibits angiogenesis by downregulating activation of the vascular endothelial growth factor (VEGF) pathway, which is hyperactivated in IH.	Propranolol	0-11	vascular endothelial growth factor A	Homo sapiens	102-136
29664206-2	2018	Propranolol, the first-line therapy for IH, inhibits angiogenesis by downregulating activation of the vascular endothelial growth factor (VEGF) pathway, which is hyperactivated in IH.	Propranolol	0-11	vascular endothelial growth factor A	Homo sapiens	138-142
29664206-9	2018	Interestingly, we found that propranolol increased the PEDF/VEGF ratio but did so by lowering VEGF expression rather than by upregulating PEDF as expected.	Propranolol	29-40	serpin family F member 1	Homo sapiens	55-59
29664206-9	2018	Interestingly, we found that propranolol increased the PEDF/VEGF ratio but did so by lowering VEGF expression rather than by upregulating PEDF as expected.	Propranolol	29-40	vascular endothelial growth factor A	Homo sapiens	60-64
29664206-9	2018	Interestingly, we found that propranolol increased the PEDF/VEGF ratio but did so by lowering VEGF expression rather than by upregulating PEDF as expected.	Propranolol	29-40	vascular endothelial growth factor A	Homo sapiens	94-98
29664206-9	2018	Interestingly, we found that propranolol increased the PEDF/VEGF ratio but did so by lowering VEGF expression rather than by upregulating PEDF as expected.	Propranolol	29-40	serpin family F member 1	Homo sapiens	138-142
29664206-11	2018	Consequently, our results suggested that the PEDF/VEGF ratio played a pivotal role in the spontaneous regression of IH and that the combination of PEDF and propranolol might be a promising treatment strategy for propranolol-resistant IH.	Propranolol	212-223	serpin family F member 1	Homo sapiens	147-151
29244114-3	2018	We speculated that propranolol, known to downregulate VEGF signalling, could be beneficial in patients with recurrent bleeding episodes and anaemia.	Propranolol	19-30	vascular endothelial growth factor A	Homo sapiens	54-58
29427463-5	2018	This pilot study investigates the saliva Ang2 levels in infants with IH treated with and without systemic propranolol.	Propranolol	106-117	angiopoietin 2	Homo sapiens	41-45
29514109-10	2018	Furthermore, we also found that propranolol inhibited PDGF-BB-induced hepatic stellate cell migration, fibrogenesis, and PDGFR/Akt phosphorylation.	Propranolol	32-43	thymoma viral proto-oncogene 1	Mus musculus	127-130
29514109-0	2018	Propranolol prevents liver cirrhosis by inhibiting hepatic stellate cell activation mediated by the PDGFR/Akt pathway.	Propranolol	0-11	platelet derived growth factor receptor, beta polypeptide	Mus musculus	100-105
29514109-11	2018	Taken together, propranolol might prevent CCl4-induced liver injury and fibrosis at least partially through inhibiting the PDGF-BB-induced PDGFR/Akt pathway.	Propranolol	16-27	chemokine (C-C motif) ligand 4	Mus musculus	42-46
29514109-0	2018	Propranolol prevents liver cirrhosis by inhibiting hepatic stellate cell activation mediated by the PDGFR/Akt pathway.	Propranolol	0-11	thymoma viral proto-oncogene 1	Mus musculus	106-109
29514109-11	2018	Taken together, propranolol might prevent CCl4-induced liver injury and fibrosis at least partially through inhibiting the PDGF-BB-induced PDGFR/Akt pathway.	Propranolol	16-27	platelet derived growth factor receptor, beta polypeptide	Mus musculus	139-144
29514109-3	2018	The aim of this study was to investigate the therapeutic effects of propranolol on carbon tetrachloride (CCl4)-induced liver fibrosis in a mouse model and the intrinsic mechanisms underlying those effects.	Propranolol	68-79	chemokine (C-C motif) ligand 4	Mus musculus	105-109
29514109-10	2018	Furthermore, we also found that propranolol inhibited PDGF-BB-induced hepatic stellate cell migration, fibrogenesis, and PDGFR/Akt phosphorylation.	Propranolol	32-43	platelet derived growth factor receptor, beta polypeptide	Mus musculus	121-126
29514109-11	2018	Taken together, propranolol might prevent CCl4-induced liver injury and fibrosis at least partially through inhibiting the PDGF-BB-induced PDGFR/Akt pathway.	Propranolol	16-27	thymoma viral proto-oncogene 1	Mus musculus	145-148
29636598-10	2018	Decreased expression of NF-kappaB was also observed in treatment groups where both propranolol and radiation were used, leading to the reduction of COX-2, EGFR, and VEGF expression compared to that in the other groups.	Propranolol	83-94	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	24-33
29790692-0	2018	Serum concentrations of VEGF and bFGF in the course of propranolol therapy of infantile hemangioma in children: Are we closer to understand the mechanism of action of propranolol on hemangiomas?	Propranolol	55-66	fibroblast growth factor 2	Homo sapiens	33-37
29790692-4	2018	OBJECTIVES: The aim of the study was to assess serum concentrations of VEGF and bFGF in the course of propranolol therapy of IH in children, and to assess their clinical implications.	Propranolol	102-113	vascular endothelial growth factor A	Homo sapiens	71-75
29790692-4	2018	OBJECTIVES: The aim of the study was to assess serum concentrations of VEGF and bFGF in the course of propranolol therapy of IH in children, and to assess their clinical implications.	Propranolol	102-113	fibroblast growth factor 2	Homo sapiens	80-84
29790692-13	2018	CONCLUSIONS: Serum concentrations of VEGF and bFGF decreased during the propranolol treatment of IH, which may indicate the effect of propranolol on both.	Propranolol	72-83	vascular endothelial growth factor A	Homo sapiens	37-41
29790692-13	2018	CONCLUSIONS: Serum concentrations of VEGF and bFGF decreased during the propranolol treatment of IH, which may indicate the effect of propranolol on both.	Propranolol	72-83	fibroblast growth factor 2	Homo sapiens	46-50
29790692-13	2018	CONCLUSIONS: Serum concentrations of VEGF and bFGF decreased during the propranolol treatment of IH, which may indicate the effect of propranolol on both.	Propranolol	134-145	vascular endothelial growth factor A	Homo sapiens	37-41
29790692-13	2018	CONCLUSIONS: Serum concentrations of VEGF and bFGF decreased during the propranolol treatment of IH, which may indicate the effect of propranolol on both.	Propranolol	134-145	fibroblast growth factor 2	Homo sapiens	46-50
29515233-9	2018	We suggest that blocking beta2AR with propranolol or inhibiting FAK activation with PF562 271 may be novel strategies for depressed patients with invasive prostate cancer.	Propranolol	38-49	adrenoceptor beta 2	Homo sapiens	25-32
29393410-9	2018	Propranolol treatment decreased the expression of adrenergic receptor beta-2 to a greater extent than adrenergic receptor beta-1, and induced apoptosis in the liver cancer cells.	Propranolol	0-11	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	70-76
29393410-11	2018	Propranolol promoted poly (ADP-ribose) polymerase cleavage and decreased the expression of full-length caspase-3 in liver cancer cell lines; it induced S-phase arrest in HepG2 and HepG2.2.15 cell lines, while HL-7702 cells were arrested at the G0/G1 phase of the cell cycle.	Propranolol	0-11	caspase 3	Homo sapiens	103-112
29588232-4	2018	Propranolol administration was associated with reduced baseline levels of heart rate and IL-1Ra, and systolic blood pressure (BP) in men.	Propranolol	0-11	interleukin 1 receptor antagonist	Homo sapiens	89-95
29854879-6	2018	A prospective analysis of non- selective beta-AR antagonists in a single arm clinical study of metastatic angiosarcoma patients revealed that incorporation of either propranolol or carvedilol into patients" treatment regimens leads to a median progression free and overall survival of 9 and 36 months, respectively.	Propranolol	166-177	adrenergic receptor, beta 1	Mus musculus	41-48
29666796-9	2018	The apparent level of PIP2 in such vesicles could be reduced by incubating eggs in the drug propranolol which also reversibly inhibited PLCzeta induced, but not Sr2+ induced, Ca2+ oscillations.	Propranolol	92-103	phospholipase C, zeta 1	Mus musculus	136-143
29636598-10	2018	Decreased expression of NF-kappaB was also observed in treatment groups where both propranolol and radiation were used, leading to the reduction of COX-2, EGFR, and VEGF expression compared to that in the other groups.	Propranolol	83-94	cytochrome c oxidase II, mitochondrial	Mus musculus	148-153
29636598-10	2018	Decreased expression of NF-kappaB was also observed in treatment groups where both propranolol and radiation were used, leading to the reduction of COX-2, EGFR, and VEGF expression compared to that in the other groups.	Propranolol	83-94	epidermal growth factor receptor	Mus musculus	155-159
29636598-10	2018	Decreased expression of NF-kappaB was also observed in treatment groups where both propranolol and radiation were used, leading to the reduction of COX-2, EGFR, and VEGF expression compared to that in the other groups.	Propranolol	83-94	vascular endothelial growth factor A	Mus musculus	165-169
29636598-11	2018	Conclusion: The present study indicated that propranolol potentiates the antitumor effects of radiotherapy in gastric cancer by inhibiting NF-kappaB expression and its downstream genes: VEGF, EGFR, and COX-2.	Propranolol	45-56	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	139-148
29636598-11	2018	Conclusion: The present study indicated that propranolol potentiates the antitumor effects of radiotherapy in gastric cancer by inhibiting NF-kappaB expression and its downstream genes: VEGF, EGFR, and COX-2.	Propranolol	45-56	vascular endothelial growth factor A	Mus musculus	186-190
29636598-11	2018	Conclusion: The present study indicated that propranolol potentiates the antitumor effects of radiotherapy in gastric cancer by inhibiting NF-kappaB expression and its downstream genes: VEGF, EGFR, and COX-2.	Propranolol	45-56	epidermal growth factor receptor	Mus musculus	192-196
29636598-11	2018	Conclusion: The present study indicated that propranolol potentiates the antitumor effects of radiotherapy in gastric cancer by inhibiting NF-kappaB expression and its downstream genes: VEGF, EGFR, and COX-2.	Propranolol	45-56	cytochrome c oxidase II, mitochondrial	Mus musculus	202-207
29928672-9	2018	Epinephrine and Foradil also exacerbated LPS-induced IL1beta activation in human THP-1-derived macrophages, by increasing acetylated H4K12, and these increases were abrogated by propranolol.	Propranolol	178-189	interleukin 1 beta	Homo sapiens	53-60
29538343-7	2018	PNLIP expression in mouse primary pancreatic acinar cells and 266-6 cell lines increased with isoproterenol treatment, which was blocked by propranolol.	Propranolol	140-151	pancreatic lipase	Mus musculus	0-5
29928672-6	2018	Propranolol, a beta-blocker, markedly ameliorated the inflammatory response and IL1beta overexpression by mitigating against epigenetic modifications.	Propranolol	0-11	interleukin 1 beta	Rattus norvegicus	80-87
29928672-9	2018	Epinephrine and Foradil also exacerbated LPS-induced IL1beta activation in human THP-1-derived macrophages, by increasing acetylated H4K12, and these increases were abrogated by propranolol.	Propranolol	178-189	GLI family zinc finger 2	Homo sapiens	81-86
29226500-6	2018	RESULTS: We found that the co-administration of propranolol with carrageenan in the TMJ of female rats significantly reduced several parameters of the inflammatory response induced by carrageenan such as plasma extravasation, neutrophil migration and the release of the pro-inflammatory cytokines TNF-alpha, IL-1beta and CINC-1.	Propranolol	48-59	tumor necrosis factor	Rattus norvegicus	297-306
29226500-6	2018	RESULTS: We found that the co-administration of propranolol with carrageenan in the TMJ of female rats significantly reduced several parameters of the inflammatory response induced by carrageenan such as plasma extravasation, neutrophil migration and the release of the pro-inflammatory cytokines TNF-alpha, IL-1beta and CINC-1.	Propranolol	48-59	interleukin 1 beta	Rattus norvegicus	308-316
29226500-6	2018	RESULTS: We found that the co-administration of propranolol with carrageenan in the TMJ of female rats significantly reduced several parameters of the inflammatory response induced by carrageenan such as plasma extravasation, neutrophil migration and the release of the pro-inflammatory cytokines TNF-alpha, IL-1beta and CINC-1.	Propranolol	48-59	C-X-C motif chemokine ligand 1	Rattus norvegicus	321-327
29472588-4	2018	Here, we directly quantified the local concentration of BODIPY630/650-PEG8-S-propranolol (BY-propranolol), a fluorescent derivative of the classical beta-blocker propranolol, at various distances above membranes of single living cells using fluorescence correlation spectroscopy.	Propranolol	77-88	IGF2 antisense RNA	Homo sapiens	70-74
29611347-7	2018	Pretreatment with propranolol, a beta1- and beta2-adrenergic receptor (AR) antagonist, trended toward rescuing the inhibitory effects of NE in primary cell culture.	Propranolol	18-29	adrenergic receptor, beta 2	Mus musculus	44-69
29611347-7	2018	Pretreatment with propranolol, a beta1- and beta2-adrenergic receptor (AR) antagonist, trended toward rescuing the inhibitory effects of NE in primary cell culture.	Propranolol	18-29	adrenergic receptor, beta 2	Mus musculus	71-73
29472588-6	2018	We further show a clear role of both the cell membrane and the beta2-adrenoceptor in determining high local BY-propranolol concentrations at the cell surface.	Propranolol	111-122	adrenoceptor beta 2	Homo sapiens	63-81
28570310-2	2018	We have recently found that administering a nonselective beta 1,2-adrenergic blocker propranolol (PR) was effective in reversing myelo-erythroid commitment through MafB regulation and increase megakaryocyte erythrocyte progenitors in burn patients" peripheral blood mononuclear cell (PBMC)-derived ex vivo culture system.	Propranolol	85-96	MAF bZIP transcription factor B	Homo sapiens	164-168
29317519-5	2018	Overexpression of beta-arrestin2 in the infralimbic prefrontal cortex promoted extinction learning, which was blocked by propranolol.	Propranolol	121-132	arrestin beta 2	Homo sapiens	18-32
28973254-13	2018	After adjusting for known prognostic factors, Cox models confirmed that use of propranolol at the time of diagnosis was significantly inversely associated with recurrence of melanoma with approximately an 80% risk reduction for propranolol users (hazard ratio, 0.18; 95% CI, 0.04-0.89; P = .03).	Propranolol	79-90	cytochrome c oxidase subunit 8A	Homo sapiens	46-49
29158167-4	2018	We found that ClC-3 expression was reduced in isoprenaline-induced hypertrophic H9c2 cells, primary rat neonatal cardiomyocytes and myocardium of C57/BL/6 mice, and this reduction was prevented by the pretreatment of propranolol.	Propranolol	217-228	chloride voltage-gated channel 3	Rattus norvegicus	14-19
29210030-6	2018	Propranolol and nadolol block the beta-1 in the heart and the peripheral beta-2 adrenergic receptors.	Propranolol	0-11	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	34-40
29210030-6	2018	Propranolol and nadolol block the beta-1 in the heart and the peripheral beta-2 adrenergic receptors.	Propranolol	0-11	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	73-79
29374256-6	2018	We identified sulfapyridine and propranolol with activity against CRH and COX-2 that deserve further study.	Propranolol	32-43	corticotropin releasing hormone	Homo sapiens	66-69
29374256-6	2018	We identified sulfapyridine and propranolol with activity against CRH and COX-2 that deserve further study.	Propranolol	32-43	prostaglandin-endoperoxide synthase 2	Homo sapiens	74-79
29175389-8	2018	By treating the stressed mice with RU486 (antagonist of GR) or propranolol (antagonist of beta-AR), we demonstrated that GR was responsible for the changes of spleen induced by 7 days of RRS and beta-AR was for 21 days of RRS.	Propranolol	63-74	adrenergic receptor, beta 1	Mus musculus	90-97
29155181-4	2018	Propranolol and expression of lysophosphatidyl acid acyltransferase 1, which increase the level of phosphatidic acid augment cell activation via MyD88.	Propranolol	0-11	MYD88 innate immune signal transduction adaptor	Homo sapiens	145-150
29304162-7	2018	This inhibitory action was reversed by either yohimbine (an alpha2 antagonist, 10 nM) or propranolol (a beta antagonist, 10 nM).	Propranolol	89-100	amyloid beta precursor protein	Rattus norvegicus	102-108
29175389-8	2018	By treating the stressed mice with RU486 (antagonist of GR) or propranolol (antagonist of beta-AR), we demonstrated that GR was responsible for the changes of spleen induced by 7 days of RRS and beta-AR was for 21 days of RRS.	Propranolol	63-74	adrenergic receptor, beta 1	Mus musculus	195-202
29936502-3	2018	From a serendipitous discovery, the nonselective beta-adrenoceptor blocker propranolol (which blocks beta1-adrenoceptors, beta2-adrenoceptors, and beta3-adrenoceptors) emerged as an alternative therapy to treat this pathology and it quickly became a first-line treatment for IH.	Propranolol	75-86	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	122-127
28930945-10	2018	The novel finding of an increase in plasma concentrations of epinephrine and syndecan-1 after propranolol treatment in traumatic brain injury is of unclear significance and should be investigated further.	Propranolol	94-105	syndecan 1	Rattus norvegicus	77-87
28930945-8	2018	Unexpectedly, propranolol and propranolol/clonidine caused an increase in epinephrine and syndecan-1 levels.	Propranolol	14-25	syndecan 1	Rattus norvegicus	90-100
28930945-8	2018	Unexpectedly, propranolol and propranolol/clonidine caused an increase in epinephrine and syndecan-1 levels.	Propranolol	30-41	syndecan 1	Rattus norvegicus	90-100
29375312-9	2017	Also our data argue that propranolol, through the inhibition of the Akt-mammalian target of rapamycin pathway, activates autophagy which decreases retinal cell death.	Propranolol	25-36	AKT serine/threonine kinase 1	Homo sapiens	68-71
29527294-6	2017	Here we show how the combination of high doses of the beta blocker propranolol (3 mg/Kg/day) and the DNA intercalating agent, temozolomide, has been successful in the treatment of a SDHA metastatic paraganglioma.	Propranolol	67-78	succinate dehydrogenase complex flavoprotein subunit A	Homo sapiens	182-186
29416656-6	2018	The Ki67 index was significantly reduced in propranolol and Sun L combination treated group compared with single Sun L treated group.	Propranolol	44-55	antigen identified by monoclonal antibody Ki 67	Mus musculus	4-8
28802992-2	2017	Due to the plentiful polar functional groups on BC200, cationic propranolol exhibited higher levels of sorption than naphthalene on BC200 while naphthalene and propranolol showed similar sorption capacities on BC700.	Propranolol	64-75	brain cytoplasmic RNA 1	Homo sapiens	48-53
28802992-2	2017	Due to the plentiful polar functional groups on BC200, cationic propranolol exhibited higher levels of sorption than naphthalene on BC200 while naphthalene and propranolol showed similar sorption capacities on BC700.	Propranolol	64-75	brain cytoplasmic RNA 1	Homo sapiens	132-137
28802992-6	2017	Complexation between polar functional groups on BC200 and heavy metals slightly enhanced the sorption of neutral naphthalene and significantly enhanced that of anionic 4-nitro-1-naphtol, while limited the sorption of cationic propranolol.	Propranolol	226-237	brain cytoplasmic RNA 1	Homo sapiens	48-53
28974436-4	2017	Permeability of propranolol and caffeine across filter-grown TR146 cells was decreased by the presence of mucin, whereas no effect was found on nicotine and mannitol.	Propranolol	16-27	LOC100508689	Homo sapiens	106-111
29416656-4	2018	Western blot showed that propranolol and sunitinib combination significantly down-regulated phospho-Rb, phospho-ERK, Cyclin D1, and Cyclin E, but had no effect on Bax, Bcl-2, or cleaved PARP expression.	Propranolol	25-36	mitogen-activated protein kinase 1	Mus musculus	112-115
28974436-3	2017	Four small molecules (nicotine, mannitol, propranolol, caffeine) showed decreased permeability across mucin dispersions, compared to controls, and a greater effect was seen with HFDS than with PGM.	Propranolol	42-53	LOC100508689	Homo sapiens	102-107
29490757-0	2017	Promotion of Propranolol Delivery to Hemangiomas by Using Anti-VEGFR Antibody-Conjugated Poly(lactic-co-glycolic acid) Nanoparticles.	Propranolol	13-24	kinase insert domain receptor	Homo sapiens	63-68
29490757-5	2017	To reduce the adverse effects and high administration frequency of propranolol, we developed propranolol-loaded nanoparticles conjugated with anti-VEGFR antibody (PNP-VEGFR) as a controlled- and targeted-release system to treat infantile hemangiomas.	Propranolol	93-104	kinase insert domain receptor	Homo sapiens	147-152
29490757-5	2017	To reduce the adverse effects and high administration frequency of propranolol, we developed propranolol-loaded nanoparticles conjugated with anti-VEGFR antibody (PNP-VEGFR) as a controlled- and targeted-release system to treat infantile hemangiomas.	Propranolol	93-104	kinase insert domain receptor	Homo sapiens	167-172
29490757-8	2017	PNP-VEGFR was efficiently bound to human umbilical vein endothelial cells and human hemangioma endothelial cells in a VEGFR-dependent manner, resulting in enhanced cytotoxic effects and stronger inhibition of VEGF expression, compared to that of the untargeted propranolol-loaded nanoparticles (PNP) and propranolol.	Propranolol	261-272	kinase insert domain receptor	Homo sapiens	4-9
29490757-8	2017	PNP-VEGFR was efficiently bound to human umbilical vein endothelial cells and human hemangioma endothelial cells in a VEGFR-dependent manner, resulting in enhanced cytotoxic effects and stronger inhibition of VEGF expression, compared to that of the untargeted propranolol-loaded nanoparticles (PNP) and propranolol.	Propranolol	261-272	kinase insert domain receptor	Homo sapiens	118-123
29490757-8	2017	PNP-VEGFR was efficiently bound to human umbilical vein endothelial cells and human hemangioma endothelial cells in a VEGFR-dependent manner, resulting in enhanced cytotoxic effects and stronger inhibition of VEGF expression, compared to that of the untargeted propranolol-loaded nanoparticles (PNP) and propranolol.	Propranolol	261-272	vascular endothelial growth factor A	Homo sapiens	4-8
29490757-8	2017	PNP-VEGFR was efficiently bound to human umbilical vein endothelial cells and human hemangioma endothelial cells in a VEGFR-dependent manner, resulting in enhanced cytotoxic effects and stronger inhibition of VEGF expression, compared to that of the untargeted propranolol-loaded nanoparticles (PNP) and propranolol.	Propranolol	304-315	kinase insert domain receptor	Homo sapiens	4-9
29490757-8	2017	PNP-VEGFR was efficiently bound to human umbilical vein endothelial cells and human hemangioma endothelial cells in a VEGFR-dependent manner, resulting in enhanced cytotoxic effects and stronger inhibition of VEGF expression, compared to that of the untargeted propranolol-loaded nanoparticles (PNP) and propranolol.	Propranolol	304-315	kinase insert domain receptor	Homo sapiens	118-123
29490757-8	2017	PNP-VEGFR was efficiently bound to human umbilical vein endothelial cells and human hemangioma endothelial cells in a VEGFR-dependent manner, resulting in enhanced cytotoxic effects and stronger inhibition of VEGF expression, compared to that of the untargeted propranolol-loaded nanoparticles (PNP) and propranolol.	Propranolol	304-315	vascular endothelial growth factor A	Homo sapiens	4-8
29490757-10	2017	PNP-VEGFR was shown to provide targeted delivery and sustained release of propranolol to infantile hemangiomas.	Propranolol	74-85	kinase insert domain receptor	Homo sapiens	4-9
29416656-4	2018	Western blot showed that propranolol and sunitinib combination significantly down-regulated phospho-Rb, phospho-ERK, Cyclin D1, and Cyclin E, but had no effect on Bax, Bcl-2, or cleaved PARP expression.	Propranolol	25-36	cyclin D1	Mus musculus	117-126
29416656-4	2018	Western blot showed that propranolol and sunitinib combination significantly down-regulated phospho-Rb, phospho-ERK, Cyclin D1, and Cyclin E, but had no effect on Bax, Bcl-2, or cleaved PARP expression.	Propranolol	25-36	poly (ADP-ribose) polymerase family, member 1	Mus musculus	186-190
29416656-7	2018	This synergistic effect between propranolol and sunitinib to inhibit MM proliferation was through suppressing ERK/Cyclin D1/Rb/Cyclin E pathways and inducing G0/G1/S phase arrest, rather than by inducing tumor cell apoptosis.	Propranolol	32-43	mitogen-activated protein kinase 1	Mus musculus	110-113
29416656-7	2018	This synergistic effect between propranolol and sunitinib to inhibit MM proliferation was through suppressing ERK/Cyclin D1/Rb/Cyclin E pathways and inducing G0/G1/S phase arrest, rather than by inducing tumor cell apoptosis.	Propranolol	32-43	cyclin D1	Mus musculus	114-123
29162996-7	2017	While losartan or captopril with propranolol potentiated bradykinin-induced vasodilation effect, the propranolol-losartan interaction decreased the angiotensin II-induced vasoconstriction.	Propranolol	101-112	angiotensinogen	Rattus norvegicus	148-162
29107282-9	2017	The acute chronotropic actions of GLP-1R agonists were attenuated by propranolol but not atropine.	Propranolol	69-80	glucagon-like peptide 1 receptor	Mus musculus	34-40
29209205-7	2017	The combined effect of propranolol and morphine was attenuated by haloperidol (D2 receptor antagonist, 1.5 mg/Kg, IP), and bicuculline (GABAA receptor antagonist, 2 mg/Kg, IP).	Propranolol	23-34	dopamine receptor D2	Mus musculus	79-90
28960167-0	2017	PLGA nanoparticles with CD133 aptamers for targeted delivery and sustained release of propranolol to hemangioma.	Propranolol	86-97	prominin 1	Homo sapiens	24-29
28960167-1	2017	AIM: To develop propranolol-loaded poly(lactic-co-glycolic acid) nanoparticle with CD133 aptamers (PPN-CD133) to treat infantile hemangioma.	Propranolol	16-27	prominin 1	Homo sapiens	83-88
28960167-1	2017	AIM: To develop propranolol-loaded poly(lactic-co-glycolic acid) nanoparticle with CD133 aptamers (PPN-CD133) to treat infantile hemangioma.	Propranolol	16-27	prominin 1	Homo sapiens	103-108
28601470-5	2017	Here, for the first time, we propose a comprehensive approach by analyzing the expression levels of metalloproteinases-2/9 (MMPs-2/9) and tissue metalloproteinase inhibitor-2 (TIMP-2) in vivo on both, molecular and immunohistochemical levels, and in both, IH tissues and in the serum of IH patients, and relates the obtained results to the tumor"s biology and systemic propranolol treatment.	Propranolol	369-380	matrix metallopeptidase 2	Homo sapiens	124-132
28601470-5	2017	Here, for the first time, we propose a comprehensive approach by analyzing the expression levels of metalloproteinases-2/9 (MMPs-2/9) and tissue metalloproteinase inhibitor-2 (TIMP-2) in vivo on both, molecular and immunohistochemical levels, and in both, IH tissues and in the serum of IH patients, and relates the obtained results to the tumor"s biology and systemic propranolol treatment.	Propranolol	369-380	TIMP metallopeptidase inhibitor 2	Homo sapiens	176-182
28601470-8	2017	CONCLUSION: MMPs-2/9 and TIMP-2 are both involved in the biology of IH and the propranolol pathways enabling their antiangiogenic properties.	Propranolol	79-90	matrix metallopeptidase 2	Homo sapiens	12-20
28601470-8	2017	CONCLUSION: MMPs-2/9 and TIMP-2 are both involved in the biology of IH and the propranolol pathways enabling their antiangiogenic properties.	Propranolol	79-90	TIMP metallopeptidase inhibitor 2	Homo sapiens	25-31
29059199-8	2017	Among the beta-blockers, nadolol showed a significant risk reduction in both LQT1 and LQT2 (HR 0.47 and 0.27, respectively), whereas atenolol and propranolol decreased the risk only in LQT1 (HR 0.36 and 0.46, respectively).	Propranolol	146-157	potassium voltage-gated channel subfamily Q member 1	Homo sapiens	185-189
28960167-6	2017	PPN-CD133 represents a very promising approach to locally and efficiently deliver propranolol leading to significant inhibition of infantile hemangioma.	Propranolol	82-93	prominin 1	Homo sapiens	4-9
28848401-4	2017	The treatment with propranolol, a beta-adrenergic receptor (beta-AR) antagonist, after US (FS)-retrieval impaired freezing behavior evoked by either CS-A or CS-B.	Propranolol	19-30	chorionic somatomammotropin hormone 2	Homo sapiens	149-151
28087723-8	2017	RESULTS: Prophylactic propranolol in the prescribed dose of 1 mg/kg/day showed a decreasing trend in the incidence of ROP (56.8% vs 68.6%; p=0.39), need for laser therapy (21.56% vs 31.37%; p=0.37), treatment with anti-VEGF (3.92% vs 15.68%; p=0.09) or visual outcomes at 1 year in the study and control groups, respectively, though these reductions were not statistically significant.	Propranolol	22-33	vascular endothelial growth factor A	Homo sapiens	219-223
29059256-6	2017	A permeability test of reference compounds displayed a similar rank order (digoxin &lt; R123 &lt; quinidine, verapamil &lt; propranolol) in ECV304 and bEnd3 cells.	Propranolol	124-135	BEN domain containing 3	Mus musculus	151-156
28977119-0	2017	Propranolol inhibits the proliferation, migration and tube formation of hemangioma cells through HIF-1alpha dependent mechanisms.	Propranolol	0-11	hypoxia inducible factor 1 subunit alpha	Homo sapiens	97-107
28977119-4	2017	Significantly increased HIF-1alpha level was found in the hemangioma tissues compared to that in normal vascular tissues, whereas propranolol treatment decreased the HIF-1alpha level in hemangioma tissues in a time- and dose-dependent manner.	Propranolol	130-141	hypoxia inducible factor 1 subunit alpha	Homo sapiens	166-176
28977119-5	2017	Moreover, propranolol treatment significantly decreased cell proliferation, migration and tube formation as well as promoted cell apoptosis in HIF-1alpha overexpression and knockdown hemangioma cells.	Propranolol	10-21	hypoxia inducible factor 1 subunit alpha	Homo sapiens	143-153
28977119-6	2017	Propranolol suppressed the cells proliferation, migration and tube formation of hemangioma cells through HIF-1alpha dependent mechanisms.	Propranolol	0-11	hypoxia inducible factor 1 subunit alpha	Homo sapiens	105-115
28666582-1	2017	BACKGROUND: We hypothesized that clonidine and propranolol would increase VEGF and VEGF-receptor expression and promote lung healing following severe trauma and chronic stress.	Propranolol	47-58	vascular endothelial growth factor A	Rattus norvegicus	74-78
28666582-1	2017	BACKGROUND: We hypothesized that clonidine and propranolol would increase VEGF and VEGF-receptor expression and promote lung healing following severe trauma and chronic stress.	Propranolol	47-58	vascular endothelial growth factor A	Rattus norvegicus	83-87
28666582-10	2017	Propranolol minimally affected VEGF and did not improve lung healing.	Propranolol	0-11	vascular endothelial growth factor A	Rattus norvegicus	31-35
28700539-8	2017	Furthermore, propranolol prevents (1) the elevated touch-evoked Fos expression within the trigeminocervical complex, (2) enhanced both spontaneous activity, and evoked responses of second-order trigeminovascular neurons, (3) elevated touch-evoked rostral ventromedial medulla and locus coeruleus Fos expression and (4) diffuse noxious inhibitory controls impairment, induced by repeated IS injections.	Propranolol	13-24	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	64-67
28700539-8	2017	Furthermore, propranolol prevents (1) the elevated touch-evoked Fos expression within the trigeminocervical complex, (2) enhanced both spontaneous activity, and evoked responses of second-order trigeminovascular neurons, (3) elevated touch-evoked rostral ventromedial medulla and locus coeruleus Fos expression and (4) diffuse noxious inhibitory controls impairment, induced by repeated IS injections.	Propranolol	13-24	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	296-299
28720509-10	2017	We demonstrate that vWF extrusion and multimer expression is promoted by thrombin, that isoproterenol (a beta-adrenergic receptor agonist) augments this effect, whereas co-treatment with the beta-blockers propranolol and carvedilol blocks this effect.	Propranolol	205-216	von Willebrand factor	Homo sapiens	20-23
28434969-6	2017	Propranolol blocked the decrease in SBP and attenuated HR increase at 100mg/kg mirabegron.	Propranolol	0-11	selenium binding protein 1	Homo sapiens	36-39
28848401-4	2017	The treatment with propranolol, a beta-adrenergic receptor (beta-AR) antagonist, after US (FS)-retrieval impaired freezing behavior evoked by either CS-A or CS-B.	Propranolol	19-30	chorionic somatomammotropin hormone 2	Homo sapiens	157-161
28848401-6	2017	However, propranolol treatment after retrieval by one CS (e.g., CS-A) only inhibited freezing behavior evoked by the same CS (i.e., CS-A), not the other CS (CS-B).	Propranolol	9-20	chorionic somatomammotropin hormone 2	Homo sapiens	54-56
28848401-6	2017	However, propranolol treatment after retrieval by one CS (e.g., CS-A) only inhibited freezing behavior evoked by the same CS (i.e., CS-A), not the other CS (CS-B).	Propranolol	9-20	chorionic somatomammotropin hormone 2	Homo sapiens	64-66
28848401-6	2017	However, propranolol treatment after retrieval by one CS (e.g., CS-A) only inhibited freezing behavior evoked by the same CS (i.e., CS-A), not the other CS (CS-B).	Propranolol	9-20	chorionic somatomammotropin hormone 2	Homo sapiens	64-66
28848401-6	2017	However, propranolol treatment after retrieval by one CS (e.g., CS-A) only inhibited freezing behavior evoked by the same CS (i.e., CS-A), not the other CS (CS-B).	Propranolol	9-20	chorionic somatomammotropin hormone 2	Homo sapiens	64-66
28848401-6	2017	However, propranolol treatment after retrieval by one CS (e.g., CS-A) only inhibited freezing behavior evoked by the same CS (i.e., CS-A), not the other CS (CS-B).	Propranolol	9-20	chorionic somatomammotropin hormone 2	Homo sapiens	64-66
28848401-6	2017	However, propranolol treatment after retrieval by one CS (e.g., CS-A) only inhibited freezing behavior evoked by the same CS (i.e., CS-A), not the other CS (CS-B).	Propranolol	9-20	chorionic somatomammotropin hormone 2	Homo sapiens	157-161
28848401-9	2017	In addition, propranolol treatment suppressed memory retrieval-induced CREB activation.	Propranolol	13-24	cAMP responsive element binding protein 1	Homo sapiens	71-75
28454738-4	2017	Rat brain, but not liver, CYP2D activity was irreversibly inhibited with intracerebral propranolol and/or induced by seven days of subcutaneous nicotine pre-treatment.	Propranolol	87-98	cytochrome P450 family 2 subfamily D member 7 (gene/pseudogene)	Homo sapiens	26-31
28363114-9	2017	Propranolol 7mg/kg/day, under the regimen usage, seems to be appropriate to blockade SNS activity on mandible mechanical performance in NGR rats, probably associated to an effect on bone mechanostat system ability to detect disuse mode as an error.	Propranolol	0-11	reticulon 4 receptor	Rattus norvegicus	136-139
28369986-4	2017	Mesoporous silica functionalized with octadecyl groups (denoted SBA15-C18) was prepared by a postsynthesis method and applied for the preconcentration of atenolol, propranolol, metoprolol, and pindolol enantiomers in waters by off-line SPE.	Propranolol	164-175	Bardet-Biedl syndrome 9	Homo sapiens	70-73
28539257-3	2017	We hypothesized that beta-AR blockade with propranolol would restore endothelial function and vascular insulin signaling in obesity, associated with an anti-inflammatory effect.	Propranolol	43-54	adrenergic receptor, beta 1	Mus musculus	21-28
28539257-7	2017	Protective effect of propranolol administration in endothelial function was associated with increased nitric oxide (NO) production and phosphorylation of Akt (Ser473) and eNOS (Ser1177), but with reduced phospho-IRS-1(Ser307) and phospho-ERK1/2 (Thr202/Tyr204).	Propranolol	21-32	thymoma viral proto-oncogene 1	Mus musculus	154-157
28539257-8	2017	In addition, beta-blocker propranolol prevented the NF-kB nuclear translocation and the increase in phospho-IkappaB-alpha (Ser32) and in interleukin(IL)-6 expression in aorta of obese mice, without significant changes in either aortic reactive oxygen species production or in circulating IL-6 and TNF-alpha levels.	Propranolol	26-37	interleukin 6	Mus musculus	137-154
28539257-8	2017	In addition, beta-blocker propranolol prevented the NF-kB nuclear translocation and the increase in phospho-IkappaB-alpha (Ser32) and in interleukin(IL)-6 expression in aorta of obese mice, without significant changes in either aortic reactive oxygen species production or in circulating IL-6 and TNF-alpha levels.	Propranolol	26-37	interleukin 6	Mus musculus	288-292
28539257-8	2017	In addition, beta-blocker propranolol prevented the NF-kB nuclear translocation and the increase in phospho-IkappaB-alpha (Ser32) and in interleukin(IL)-6 expression in aorta of obese mice, without significant changes in either aortic reactive oxygen species production or in circulating IL-6 and TNF-alpha levels.	Propranolol	26-37	tumor necrosis factor	Mus musculus	297-306
28539257-10	2017	In conclusion, our results suggest that beta-AR blockade with propranolol is effective to prevent the endothelial dysfunction, vascular IR and pro-inflammatory state displayed in HFD-induced obesity, independent of changes in body weight.	Propranolol	62-73	adrenergic receptor, beta 1	Mus musculus	40-47
28472633-4	2017	Results indicated that administration of beta1-adrenoceptor blocker propranolol (0.1mg/kg) impaired fear memory retrieval.	Propranolol	68-79	adrenergic receptor, beta 1	Mus musculus	41-59
28376078-9	2017	The action of propranolol on IH may be the result of reductions in ACE and AGTR1.	Propranolol	14-25	angiotensin I converting enzyme	Homo sapiens	67-70
28240622-2	2017	Propranolol, a nonselective beta1, beta2-adrenergic receptor antagonist, reduces resting heart rate and cardiac work caused by elevated circulating catecholamines.	Propranolol	0-11	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	28-33
28240622-2	2017	Propranolol, a nonselective beta1, beta2-adrenergic receptor antagonist, reduces resting heart rate and cardiac work caused by elevated circulating catecholamines.	Propranolol	0-11	adrenoceptor beta 2	Homo sapiens	35-60
28376078-9	2017	The action of propranolol on IH may be the result of reductions in ACE and AGTR1.	Propranolol	14-25	angiotensin II receptor type 1	Homo sapiens	75-80
28556385-1	2017	BACKGROUND/OBJECTIVES: The nonselective beta-blocker propranolol is the current criterion standard for treatment of infantile hemangiomas (IHs) and the first therapy that the U.S. Food and Drug Administration has approved for the condition, but concern about adverse effects, such as bronchospasm, hypoglycemia, and sleep disturbances, has sparked interest in the use of alternative agents such as the selective beta1 antagonist atenolol.	Propranolol	53-64	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	412-417
28761821-14	2017	Pharmacodynamic differences in responding to beta blocker drugs by Renin secretion or having a different sensibility to beta receptors might play a role in making our population have a different response to propranolol.	Propranolol	207-218	renin	Homo sapiens	67-72
28721035-5	2017	beta2R antagonism by propranolol or ICI 118.551 (10-12-10-4 M) resulted in concentration-dependent inhibition of VI-induced cAMP production, and ICI 118.551 was more potent.	Propranolol	21-32	adrenoceptor beta 2	Homo sapiens	0-6
26303231-6	2017	Propranolol decreased cardiac output from 9 3 +- 2 8 l min-1 to 3 5 +- 0 47 l min-1 (P&lt;0 05).	Propranolol	0-11	CD59 molecule (CD59 blood group)	Homo sapiens	55-60
28513740-4	2017	In addition, l-Orn-induced GH-releasing activity was inhibited by propranolol, an antagonist of beta-adrenergic receptor, which is known to be coupled to ghrelin release.	Propranolol	66-77	gonadotropin releasing hormone receptor	Rattus norvegicus	27-29
28513740-4	2017	In addition, l-Orn-induced GH-releasing activity was inhibited by propranolol, an antagonist of beta-adrenergic receptor, which is known to be coupled to ghrelin release.	Propranolol	66-77	ghrelin and obestatin prepropeptide	Rattus norvegicus	154-161
28611684-3	2017	Methods:In vitro, neonatal rat cardiomyocytes (NRCMs) were subjected to LPA3 knocked-down, or pretreated with a beta-adrenergic receptor (beta-AR) antagonist (propranolol) before LPA/ISO treatment.	Propranolol	159-170	adrenergic receptor, beta 1	Mus musculus	138-145
28603578-7	2017	From a mechanistic standpoint, RRS increased expression of FOXP3, CXCL-10, and granzyme B in mouse tumors, and the effects were reversed by propranolol.	Propranolol	140-151	forkhead box P3	Mus musculus	59-64
28603578-7	2017	From a mechanistic standpoint, RRS increased expression of FOXP3, CXCL-10, and granzyme B in mouse tumors, and the effects were reversed by propranolol.	Propranolol	140-151	chemokine (C-X-C motif) ligand 10	Mus musculus	66-73
28603578-7	2017	From a mechanistic standpoint, RRS increased expression of FOXP3, CXCL-10, and granzyme B in mouse tumors, and the effects were reversed by propranolol.	Propranolol	140-151	granzyme B	Mus musculus	79-89
28588707-13	2017	The results of the present study indicated that a number of potential target genes, including AXL receptor tyrosine kinase, coatomer subunit alpha, DR1-associated protein 1 and ERBB receptor feedback inhibitor 1 may be involved in the effect of propranolol on angiosarcoma.	Propranolol	245-256	AXL receptor tyrosine kinase	Homo sapiens	94-97
28588707-13	2017	The results of the present study indicated that a number of potential target genes, including AXL receptor tyrosine kinase, coatomer subunit alpha, DR1-associated protein 1 and ERBB receptor feedback inhibitor 1 may be involved in the effect of propranolol on angiosarcoma.	Propranolol	245-256	DR1 associated protein 1	Homo sapiens	148-211
26303231-6	2017	Propranolol decreased cardiac output from 9 3 +- 2 8 l min-1 to 3 5 +- 0 47 l min-1 (P&lt;0 05).	Propranolol	0-11	CD59 molecule (CD59 blood group)	Homo sapiens	78-83
28279700-0	2017	Molecular and immunohistochemical expression of apoptotic proteins Bax, Bcl-2 and Caspase 3 in infantile hemangioma tissues as an effect of propranolol treatment.	Propranolol	140-151	BCL2 associated X, apoptosis regulator	Homo sapiens	67-70
28279700-0	2017	Molecular and immunohistochemical expression of apoptotic proteins Bax, Bcl-2 and Caspase 3 in infantile hemangioma tissues as an effect of propranolol treatment.	Propranolol	140-151	BCL2 apoptosis regulator	Homo sapiens	72-77
28279700-0	2017	Molecular and immunohistochemical expression of apoptotic proteins Bax, Bcl-2 and Caspase 3 in infantile hemangioma tissues as an effect of propranolol treatment.	Propranolol	140-151	caspase 3	Homo sapiens	82-91
28279700-6	2017	RESULTS: Both methods revealed a statistically significant decrease in Bcl-2 expression and an increase in Bax in IHs tissues after propranolol treatment.	Propranolol	132-143	BCL2 apoptosis regulator	Homo sapiens	71-76
28279700-6	2017	RESULTS: Both methods revealed a statistically significant decrease in Bcl-2 expression and an increase in Bax in IHs tissues after propranolol treatment.	Propranolol	132-143	BCL2 associated X, apoptosis regulator	Homo sapiens	107-110
28279700-7	2017	CONCLUSIONS: The results obtained for Bax and Bcl-2 proteins may indicate a link between the effect of propranolol and apoptosis.	Propranolol	103-114	BCL2 associated X, apoptosis regulator	Homo sapiens	38-41
28279700-7	2017	CONCLUSIONS: The results obtained for Bax and Bcl-2 proteins may indicate a link between the effect of propranolol and apoptosis.	Propranolol	103-114	BCL2 apoptosis regulator	Homo sapiens	46-51
28279700-8	2017	Higher Bax and lower Bcl-2 expression in the propranolol treated group indicates a strong pro- apoptotic action countering any anti-apoptotic activity; apoptosis was indicted in IH tissue as a potential result of propranolol treatment, with potential clinical impact in other tumors.	Propranolol	45-56	BCL2 associated X, apoptosis regulator	Homo sapiens	7-10
28279700-8	2017	Higher Bax and lower Bcl-2 expression in the propranolol treated group indicates a strong pro- apoptotic action countering any anti-apoptotic activity; apoptosis was indicted in IH tissue as a potential result of propranolol treatment, with potential clinical impact in other tumors.	Propranolol	45-56	BCL2 apoptosis regulator	Homo sapiens	21-26
28344958-7	2017	The mean decrease of CA 125 during the seven perioperative days was 83.1+-8.9% in the propranolol group and 72.4+-14.7% in the placebo group.	Propranolol	86-97	mucin 16, cell surface associated	Homo sapiens	21-27
28299842-5	2017	EA treatment of rats undergoing partial rupture of the Achilles tendon resulted in reduced mechanical hyperalgesia, increased serum interleukin-10 levels and tendon remodeling, effects blocked in propranolol-treated rodents.	Propranolol	196-207	interleukin 10	Rattus norvegicus	132-146
28112362-0	2017	Downregulation of miR-382 by propranolol inhibits the progression of infantile hemangioma via the PTEN-mediated AKT/mTOR pathway.	Propranolol	29-40	microRNA 382	Homo sapiens	18-25
28112362-0	2017	Downregulation of miR-382 by propranolol inhibits the progression of infantile hemangioma via the PTEN-mediated AKT/mTOR pathway.	Propranolol	29-40	phosphatase and tensin homolog	Homo sapiens	98-102
28112362-0	2017	Downregulation of miR-382 by propranolol inhibits the progression of infantile hemangioma via the PTEN-mediated AKT/mTOR pathway.	Propranolol	29-40	AKT serine/threonine kinase 1	Homo sapiens	112-115
28112362-0	2017	Downregulation of miR-382 by propranolol inhibits the progression of infantile hemangioma via the PTEN-mediated AKT/mTOR pathway.	Propranolol	29-40	mechanistic target of rapamycin kinase	Homo sapiens	116-120
28112362-5	2017	Through a series of experiments, we discovered that miR-382 is a novel miRNA associated with IHs, which was overexpressed in XPTS-1 cells and was conversely downregulated by treatment with propranolol.	Propranolol	189-200	microRNA 382	Homo sapiens	52-59
28035008-9	2017	Chronic propranolol treatment of mice prevented the observed increases in ischemic injury and the GRK2 phosphorylation observed in RGS6-/- hearts.	Propranolol	8-19	G protein-coupled receptor kinase 2	Mus musculus	98-102
28035008-9	2017	Chronic propranolol treatment of mice prevented the observed increases in ischemic injury and the GRK2 phosphorylation observed in RGS6-/- hearts.	Propranolol	8-19	regulator of G-protein signaling 6	Mus musculus	131-135
28219708-7	2017	The propranolol pKB was 8.87 in mouse and 8.91 in rat atria, reading very similarly to those values from beta-adrenoceptor agonist assays under equilibrium conditions.	Propranolol	4-15	thymoma viral proto-oncogene 2	Mus musculus	16-19
28031160-5	2017	beta-Blocker administration (propranolol) for 6 days after burn, not only reduced the number of LSKs and MafB+ cells in multipotent progenitors, but also influenced myelo-erythroid bifurcation by increasing the MEPs and reducing the granulocyte monocyte progenitors in the bone marrow of burn mice.	Propranolol	29-40	v-maf musculoaponeurotic fibrosarcoma oncogene family, protein B (avian)	Mus musculus	105-109
28031160-7	2017	Also, MafB+ cells that were significantly increased following standard burn care could be mitigated when propranolol was administered to burn patients, establishing the mechanistic regulation of erythroid commitment by myeloid regulatory transcription factor MafB.	Propranolol	105-116	MAF bZIP transcription factor B	Homo sapiens	6-10
28031160-7	2017	Also, MafB+ cells that were significantly increased following standard burn care could be mitigated when propranolol was administered to burn patients, establishing the mechanistic regulation of erythroid commitment by myeloid regulatory transcription factor MafB.	Propranolol	105-116	MAF bZIP transcription factor B	Homo sapiens	259-263
28112362-7	2017	Our results revealed that propranolol inhibited XPTS-1 cell migration and proliferation, and promoted apoptosis, and these effects were reversed by the restoration of miR-382 expression by transfection of the cells with an miR-382 overexpression vector.	Propranolol	26-37	microRNA 382	Homo sapiens	167-174
28112362-7	2017	Our results revealed that propranolol inhibited XPTS-1 cell migration and proliferation, and promoted apoptosis, and these effects were reversed by the restoration of miR-382 expression by transfection of the cells with an miR-382 overexpression vector.	Propranolol	26-37	microRNA 382	Homo sapiens	223-230
28112362-9	2017	The expression of PTEN was upregulated, while that of p-AKT, p-mTOR and p-p70S6K was downregulated by propranolol; these effects were partly reversed by the overexpression of miR-382.	Propranolol	102-113	phosphatase and tensin homolog	Homo sapiens	18-22
28112362-9	2017	The expression of PTEN was upregulated, while that of p-AKT, p-mTOR and p-p70S6K was downregulated by propranolol; these effects were partly reversed by the overexpression of miR-382.	Propranolol	102-113	AKT serine/threonine kinase 1	Homo sapiens	56-59
28112362-9	2017	The expression of PTEN was upregulated, while that of p-AKT, p-mTOR and p-p70S6K was downregulated by propranolol; these effects were partly reversed by the overexpression of miR-382.	Propranolol	102-113	mechanistic target of rapamycin kinase	Homo sapiens	63-67
28112362-9	2017	The expression of PTEN was upregulated, while that of p-AKT, p-mTOR and p-p70S6K was downregulated by propranolol; these effects were partly reversed by the overexpression of miR-382.	Propranolol	102-113	ribosomal protein S6 kinase B1	Homo sapiens	74-80
28112362-9	2017	The expression of PTEN was upregulated, while that of p-AKT, p-mTOR and p-p70S6K was downregulated by propranolol; these effects were partly reversed by the overexpression of miR-382.	Propranolol	102-113	microRNA 382	Homo sapiens	175-182
28112362-10	2017	On the whole, our study identified that the downregulation of miR-382 by propranolol inhibits the progression of IHs via the PTEN-mediated AKT/mTOR pathway.	Propranolol	73-84	microRNA 382	Homo sapiens	62-69
28112362-10	2017	On the whole, our study identified that the downregulation of miR-382 by propranolol inhibits the progression of IHs via the PTEN-mediated AKT/mTOR pathway.	Propranolol	73-84	phosphatase and tensin homolog	Homo sapiens	125-129
28112362-10	2017	On the whole, our study identified that the downregulation of miR-382 by propranolol inhibits the progression of IHs via the PTEN-mediated AKT/mTOR pathway.	Propranolol	73-84	AKT serine/threonine kinase 1	Homo sapiens	139-142
28112362-10	2017	On the whole, our study identified that the downregulation of miR-382 by propranolol inhibits the progression of IHs via the PTEN-mediated AKT/mTOR pathway.	Propranolol	73-84	mechanistic target of rapamycin kinase	Homo sapiens	143-147
28344958-11	2017	Even with the small sample size and short term use of the drug, perioperative propranolol was effective in reducing tumor burden (as measured by CA 125) suggesting its potential benefits in decreasing perioperative tumor growth.	Propranolol	78-89	mucin 16, cell surface associated	Homo sapiens	145-151
28031536-8	2017	Molecular analysis revealed that propranolol treatment of the SK-BR-3 breast cancer line, which showed high sensitivity to beta blockade, led to a reduction in Ki67 protein expression, decreased phosphorylation of the mitogenic signaling regulators p44/42 MAPK, p38 MAPK, JNK, and CREB, increased phosphorylation of the cell survival/apoptosis regulators AKT, p53, and GSK3beta.	Propranolol	33-44	mitogen-activated protein kinase 8	Homo sapiens	272-275
28219980-8	2017	We observed a dose-dependent pressor response to S6c in ETB-deficient rats that was reversed by prazosin treatment and augmented by propranolol.	Propranolol	132-143	endothelin receptor type B	Rattus norvegicus	56-59
28031536-8	2017	Molecular analysis revealed that propranolol treatment of the SK-BR-3 breast cancer line, which showed high sensitivity to beta blockade, led to a reduction in Ki67 protein expression, decreased phosphorylation of the mitogenic signaling regulators p44/42 MAPK, p38 MAPK, JNK, and CREB, increased phosphorylation of the cell survival/apoptosis regulators AKT, p53, and GSK3beta.	Propranolol	33-44	interferon induced protein 44	Homo sapiens	249-252
28031536-8	2017	Molecular analysis revealed that propranolol treatment of the SK-BR-3 breast cancer line, which showed high sensitivity to beta blockade, led to a reduction in Ki67 protein expression, decreased phosphorylation of the mitogenic signaling regulators p44/42 MAPK, p38 MAPK, JNK, and CREB, increased phosphorylation of the cell survival/apoptosis regulators AKT, p53, and GSK3beta.	Propranolol	33-44	mitogen-activated protein kinase 14	Homo sapiens	262-265
28031536-8	2017	Molecular analysis revealed that propranolol treatment of the SK-BR-3 breast cancer line, which showed high sensitivity to beta blockade, led to a reduction in Ki67 protein expression, decreased phosphorylation of the mitogenic signaling regulators p44/42 MAPK, p38 MAPK, JNK, and CREB, increased phosphorylation of the cell survival/apoptosis regulators AKT, p53, and GSK3beta.	Propranolol	33-44	cAMP responsive element binding protein 1	Homo sapiens	281-285
28031536-8	2017	Molecular analysis revealed that propranolol treatment of the SK-BR-3 breast cancer line, which showed high sensitivity to beta blockade, led to a reduction in Ki67 protein expression, decreased phosphorylation of the mitogenic signaling regulators p44/42 MAPK, p38 MAPK, JNK, and CREB, increased phosphorylation of the cell survival/apoptosis regulators AKT, p53, and GSK3beta.	Propranolol	33-44	AKT serine/threonine kinase 1	Homo sapiens	355-358
28031536-8	2017	Molecular analysis revealed that propranolol treatment of the SK-BR-3 breast cancer line, which showed high sensitivity to beta blockade, led to a reduction in Ki67 protein expression, decreased phosphorylation of the mitogenic signaling regulators p44/42 MAPK, p38 MAPK, JNK, and CREB, increased phosphorylation of the cell survival/apoptosis regulators AKT, p53, and GSK3beta.	Propranolol	33-44	tumor protein p53	Homo sapiens	360-363
28031536-8	2017	Molecular analysis revealed that propranolol treatment of the SK-BR-3 breast cancer line, which showed high sensitivity to beta blockade, led to a reduction in Ki67 protein expression, decreased phosphorylation of the mitogenic signaling regulators p44/42 MAPK, p38 MAPK, JNK, and CREB, increased phosphorylation of the cell survival/apoptosis regulators AKT, p53, and GSK3beta.	Propranolol	33-44	glycogen synthase kinase 3 beta	Homo sapiens	369-377
29131026-11	2017	In vitro experiments showed that TRPML1 overexpression or treatment with the mTOR activator propranolol attenuated the Abeta1-42-suppressed cell viability and the Abeta1-42-decreased lysosomal [Ca2+] ion concentration in primary neurons.	Propranolol	92-103	mechanistic target of rapamycin kinase	Mus musculus	77-81
27818241-4	2017	KSR:ERL blends were investigated as coating materials to improve the robustness, mechanical strength and drug release from the HPMC matrix tablets containing propranolol HCl, caffeine and carbamazepine as model drugs.	Propranolol	158-173	kinase suppressor of ras 1	Homo sapiens	0-3
28848082-9	2017	The expression of caspase 3/7, 8, and 9 was elevated in propranolol-treated myeloma cells.	Propranolol	56-67	caspase 3	Homo sapiens	18-39
29131026-12	2017	TRPML1 overexpression or treatment with the mTOR activator propranolol also attenuated the Abeta1-42-inhibited mTOR/S6K signalling pathway and the Abeta1-42-induced ALR-related protein expression levels.	Propranolol	59-70	mucolipin 1	Mus musculus	0-6
29131026-12	2017	TRPML1 overexpression or treatment with the mTOR activator propranolol also attenuated the Abeta1-42-inhibited mTOR/S6K signalling pathway and the Abeta1-42-induced ALR-related protein expression levels.	Propranolol	59-70	mechanistic target of rapamycin kinase	Mus musculus	44-48
29131026-12	2017	TRPML1 overexpression or treatment with the mTOR activator propranolol also attenuated the Abeta1-42-inhibited mTOR/S6K signalling pathway and the Abeta1-42-induced ALR-related protein expression levels.	Propranolol	59-70	mechanistic target of rapamycin kinase	Mus musculus	111-115
27899275-8	2017	Administration of breast tumor lysates with propranolol increased the concentration of IL-12, IL-17, 1L-2 and IFN-gamma cytokines in tumor microenvironment.	Propranolol	44-55	interleukin 17A	Mus musculus	94-105
27899275-8	2017	Administration of breast tumor lysates with propranolol increased the concentration of IL-12, IL-17, 1L-2 and IFN-gamma cytokines in tumor microenvironment.	Propranolol	44-55	interferon gamma	Mus musculus	110-119
27515792-7	2017	ED1 increased Fos expression in DH, LC, and DR, and DH Fos was decreased by systemic S-propranolol.	Propranolol	85-98	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	55-58
27237101-14	2017	NE up-regulates LPS-induced c-Fos expression, which is counteracted by propranolol, U0126, and SP600125.	Propranolol	71-82	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	28-33
27856623-7	2017	The results showed that ovarian KISS1 decreased but FSHR increased after both propranolol administration and the surgical denervation in rats of 8, 10 and 12 months of age.	Propranolol	78-89	KiSS-1 metastasis-suppressor	Rattus norvegicus	32-37
27856623-7	2017	The results showed that ovarian KISS1 decreased but FSHR increased after both propranolol administration and the surgical denervation in rats of 8, 10 and 12 months of age.	Propranolol	78-89	follicle stimulating hormone receptor	Rattus norvegicus	52-56
28848192-10	2017	The beta2-adrenergic antagonist propranolol could restore IFN-gamma production, whereas only the norepinephrine-induced increase in IL-17 production was abrogated.	Propranolol	32-43	hemoglobin, beta adult minor chain	Mus musculus	4-9
28848192-10	2017	The beta2-adrenergic antagonist propranolol could restore IFN-gamma production, whereas only the norepinephrine-induced increase in IL-17 production was abrogated.	Propranolol	32-43	interferon gamma	Mus musculus	58-67
29514151-11	2017	Dopamine significantly increased the p65-NFkappaB subunit levels in the nuclear extracts, which were reduced in the presence of propranolol in keratinocytes.	Propranolol	128-139	RELA proto-oncogene, NF-kB subunit	Homo sapiens	37-40
29514151-11	2017	Dopamine significantly increased the p65-NFkappaB subunit levels in the nuclear extracts, which were reduced in the presence of propranolol in keratinocytes.	Propranolol	128-139	nuclear factor kappa B subunit 1	Homo sapiens	41-49
29514151-13	2017	Dopamine significantly increased IL-8 production in human macrophages, an effect that was partially reduced by propranolol.	Propranolol	111-122	C-X-C motif chemokine ligand 8	Homo sapiens	33-37
28102631-0	2017	Cytochrome P450 isoform genotyping in poor propranolol responders for hemangioma treatment.	Propranolol	43-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
27788481-4	2016	Propranolol treatment delayed primary tumor growth and metastases development in MT/Ret mice.	Propranolol	0-11	ret proto-oncogene	Mus musculus	84-87
27699900-3	2016	Surprisingly, this facilitating effect persists when slices are only pretreated with beta-receptor agonists followed by wash out and application of the unspecific beta-adrenoreceptor (betaAR) antagonist propranolol.	Propranolol	203-214	adrenergic receptor, beta 1	Mus musculus	184-190
26991797-0	2016	Propranolol for infantile hemangioma: Effect on plasma vascular endothelial growth factor.	Propranolol	0-11	vascular endothelial growth factor A	Homo sapiens	55-89
26991797-2	2016	The aim of this study was therefore to determine the efficacy of propranolol treatment and to evaluate changes in plasma VEGF in IH patients who underwent propranolol treatment.	Propranolol	155-166	vascular endothelial growth factor A	Homo sapiens	121-125
27847559-10	2016	Co-incubation with NE and antagonists revealed a dose-dependent inhibition of the NE suppression of TNFalpha by PROP, but not by YOH or PRAZ.	Propranolol	112-116	tumor necrosis factor	Homo sapiens	100-108
27582542-0	2016	Propranolol induced G0/G1/S phase arrest and apoptosis in melanoma cells via AKT/MAPK pathway.	Propranolol	0-11	thymoma viral proto-oncogene 1	Mus musculus	77-80
27582542-0	2016	Propranolol induced G0/G1/S phase arrest and apoptosis in melanoma cells via AKT/MAPK pathway.	Propranolol	0-11	mitogen-activated protein kinase 1	Mus musculus	81-85
27582542-5	2016	Western blots showed 100muM propranolol significantly reduced the expression of Bcl-2 while increasing the expressions of Bax, cytochrome c, cleaved capase-9 and cleaved caspase-3, and down-regulated the levels of p-AKT, p-BRAF, p-MEK1/2 and p-ERK1/2 in melanoma cells, after a 24h incubation.	Propranolol	28-39	B cell leukemia/lymphoma 2	Mus musculus	80-85
27582542-5	2016	Western blots showed 100muM propranolol significantly reduced the expression of Bcl-2 while increasing the expressions of Bax, cytochrome c, cleaved capase-9 and cleaved caspase-3, and down-regulated the levels of p-AKT, p-BRAF, p-MEK1/2 and p-ERK1/2 in melanoma cells, after a 24h incubation.	Propranolol	28-39	BCL2-associated X protein	Mus musculus	122-125
27582542-5	2016	Western blots showed 100muM propranolol significantly reduced the expression of Bcl-2 while increasing the expressions of Bax, cytochrome c, cleaved capase-9 and cleaved caspase-3, and down-regulated the levels of p-AKT, p-BRAF, p-MEK1/2 and p-ERK1/2 in melanoma cells, after a 24h incubation.	Propranolol	28-39	thymoma viral proto-oncogene 1	Mus musculus	216-219
27582542-5	2016	Western blots showed 100muM propranolol significantly reduced the expression of Bcl-2 while increasing the expressions of Bax, cytochrome c, cleaved capase-9 and cleaved caspase-3, and down-regulated the levels of p-AKT, p-BRAF, p-MEK1/2 and p-ERK1/2 in melanoma cells, after a 24h incubation.	Propranolol	28-39	Braf transforming gene	Mus musculus	223-227
27582542-5	2016	Western blots showed 100muM propranolol significantly reduced the expression of Bcl-2 while increasing the expressions of Bax, cytochrome c, cleaved capase-9 and cleaved caspase-3, and down-regulated the levels of p-AKT, p-BRAF, p-MEK1/2 and p-ERK1/2 in melanoma cells, after a 24h incubation.	Propranolol	28-39	mitogen-activated protein kinase kinase 1	Mus musculus	231-237
27582542-5	2016	Western blots showed 100muM propranolol significantly reduced the expression of Bcl-2 while increasing the expressions of Bax, cytochrome c, cleaved capase-9 and cleaved caspase-3, and down-regulated the levels of p-AKT, p-BRAF, p-MEK1/2 and p-ERK1/2 in melanoma cells, after a 24h incubation.	Propranolol	28-39	mitogen-activated protein kinase 3	Mus musculus	244-250
27582542-12	2016	Propranolol also reduced Ki67, inhibited phosphorylation of AKT, BRAF, MEK1/2 and ERK1/2 in xenografts.	Propranolol	0-11	antigen identified by monoclonal antibody Ki 67	Mus musculus	25-29
27582542-12	2016	Propranolol also reduced Ki67, inhibited phosphorylation of AKT, BRAF, MEK1/2 and ERK1/2 in xenografts.	Propranolol	0-11	thymoma viral proto-oncogene 1	Mus musculus	60-63
27582542-12	2016	Propranolol also reduced Ki67, inhibited phosphorylation of AKT, BRAF, MEK1/2 and ERK1/2 in xenografts.	Propranolol	0-11	Braf transforming gene	Mus musculus	65-69
27582542-12	2016	Propranolol also reduced Ki67, inhibited phosphorylation of AKT, BRAF, MEK1/2 and ERK1/2 in xenografts.	Propranolol	0-11	mitogen-activated protein kinase kinase 1	Mus musculus	71-77
27582542-12	2016	Propranolol also reduced Ki67, inhibited phosphorylation of AKT, BRAF, MEK1/2 and ERK1/2 in xenografts.	Propranolol	0-11	mitogen-activated protein kinase 3	Mus musculus	82-88
27582542-13	2016	These are the first data to demonstrate that propranolol might inhibit melanoma by activating the intrinsic apoptosis pathway and inactivating the MAPK and AKT pathways.	Propranolol	45-56	mitogen-activated protein kinase 1	Mus musculus	147-151
27582542-13	2016	These are the first data to demonstrate that propranolol might inhibit melanoma by activating the intrinsic apoptosis pathway and inactivating the MAPK and AKT pathways.	Propranolol	45-56	thymoma viral proto-oncogene 1	Mus musculus	156-159
27454346-7	2016	Recombinant hCE2 and mfCES2v3 showed similar Km values for both enantiomers of all propranolol derivatives tested.	Propranolol	83-94	carboxylesterase 2	Homo sapiens	12-16
27133786-8	2016	The beta1-AR/beta2-AR inhibitor propranolol reduced the numbers of the neutrophils in the circulation, suppressed neutrophil infiltration into colonic tissues, and attenuated the colonic tissue damage promoted by chronic stress.	Propranolol	32-43	adrenoceptor beta 1	Homo sapiens	4-12
27133786-8	2016	The beta1-AR/beta2-AR inhibitor propranolol reduced the numbers of the neutrophils in the circulation, suppressed neutrophil infiltration into colonic tissues, and attenuated the colonic tissue damage promoted by chronic stress.	Propranolol	32-43	adrenoceptor beta 2	Homo sapiens	13-21
27650973-6	2016	ARbeta blocker, propranolol, inhibited NE-induced IL-6 production and phosphorylation of p38 in SSc fibroblasts.	Propranolol	16-27	interleukin 6	Homo sapiens	50-54
27650973-6	2016	ARbeta blocker, propranolol, inhibited NE-induced IL-6 production and phosphorylation of p38 in SSc fibroblasts.	Propranolol	16-27	mitogen-activated protein kinase 1	Homo sapiens	89-92
27454346-10	2016	Docking simulations of the protein-ligand complex demonstrated that the enantioselectivity of mfCES2v3 for propranolol derivatives was possibly caused by the orientation of its active site being deformed by an amino acid change of Leu107 to Gln107 and the insertion of Met309, compared with hCE2.	Propranolol	107-118	carboxylesterase 2	Homo sapiens	291-295
27668163-1	2016	beta Blockers such as propranolol and labetalol are known to induce toxic myopathy because of their partial beta2 adrenoceptor agonistic effect.	Propranolol	22-33	adrenoceptor beta 2	Homo sapiens	108-126
26762757-6	2016	Cavernous IGF-1 bioavailability and the concentrations of cavernous cyclic guanosine monophosphate were both significantly decreased in the hypertensive and the propranolol treatment groups compared to the normal control group (P &lt; 0.01).	Propranolol	161-172	insulin-like growth factor 1	Rattus norvegicus	10-15
27366681-9	2016	CONCLUSION: The periocular administration of propranolol and celecoxib can significantly reduce ocular VEGF levels in a diabetic mouse model.	Propranolol	45-56	vascular endothelial growth factor A	Mus musculus	103-107
27409177-5	2016	Propranolol reversed this effect of NA by reducing beta-arrestin2 expression.	Propranolol	0-11	arrestin beta 2	Homo sapiens	51-65
27409177-11	2016	The activation of the sympathetic pathway could partly account for the specific immunological alterations found in SAI patients including HLA-DR decrease and IL-10 increase, which both could be reversed by propranolol.	Propranolol	206-217	interleukin 10	Homo sapiens	158-163
27178307-0	2016	Serum and tissue profile of VEGF and its receptors VGFR1/R2 in children with infantile hemangiomas on systemic propranolol treatment.	Propranolol	111-122	vascular endothelial growth factor A	Homo sapiens	28-32
27178307-4	2016	To investigate this claim, this study aims to analyze the serum and tissue profiles of VEGF and VEGRR1/2 in patients treated with propranolol.	Propranolol	130-141	vascular endothelial growth factor A	Homo sapiens	87-91
27178307-7	2016	Then we used immunohistochemistry to evaluate tissue expression of VEGF and VEGFR1/2 in IH treated (n=27) and not treated (n=45) with propranolol (II.).	Propranolol	134-145	vascular endothelial growth factor A	Homo sapiens	67-71
27178307-12	2016	(III) VEGF and VEGFR1 mRNA expression was significantly lower in IH tissue after propranolol treatment compared to those without treatment.	Propranolol	81-92	vascular endothelial growth factor A	Homo sapiens	6-10
27178307-12	2016	(III) VEGF and VEGFR1 mRNA expression was significantly lower in IH tissue after propranolol treatment compared to those without treatment.	Propranolol	81-92	fms related receptor tyrosine kinase 1	Homo sapiens	15-21
27366681-0	2016	Effect of periocular injection of celecoxib and propranolol on ocular level of vascular endothelial growth factor in a diabetic mouse model.	Propranolol	48-59	vascular endothelial growth factor A	Mus musculus	79-113
27366681-1	2016	AIM: To investigate the effects of periocular injection of propranolol and celecoxib on ocular levels of vascular endothelial growth factor (VEGF) in a diabetic mouse model.	Propranolol	59-70	vascular endothelial growth factor A	Mus musculus	105-139
27366681-1	2016	AIM: To investigate the effects of periocular injection of propranolol and celecoxib on ocular levels of vascular endothelial growth factor (VEGF) in a diabetic mouse model.	Propranolol	59-70	vascular endothelial growth factor A	Mus musculus	141-145
27366681-7	2016	Both periocular propranolol and celecoxib significantly reduced ocular VEGF levels (P=0.047 and P&lt;0.001, respectively).	Propranolol	16-27	vascular endothelial growth factor A	Mus musculus	71-75
27432558-6	2016	Propranolol treatment inhibited growth and induced apoptosis of 8505C cells in vitro and in vivo, which are closely associated with decreased expressions of cyclin D1 and anti-apoptotic Bcl-2.	Propranolol	0-11	cyclin D1	Homo sapiens	157-166
27432558-6	2016	Propranolol treatment inhibited growth and induced apoptosis of 8505C cells in vitro and in vivo, which are closely associated with decreased expressions of cyclin D1 and anti-apoptotic Bcl-2.	Propranolol	0-11	BCL2 apoptosis regulator	Homo sapiens	186-191
27432558-7	2016	Expression of hexokinase 2 (HK2) and glucose transporter 1 (GLUT1) also decreased following propranolol intervention.	Propranolol	92-103	hexokinase 2	Homo sapiens	14-26
27432558-7	2016	Expression of hexokinase 2 (HK2) and glucose transporter 1 (GLUT1) also decreased following propranolol intervention.	Propranolol	92-103	hexokinase 2	Homo sapiens	28-31
27432558-7	2016	Expression of hexokinase 2 (HK2) and glucose transporter 1 (GLUT1) also decreased following propranolol intervention.	Propranolol	92-103	solute carrier family 2 member 1	Homo sapiens	37-58
27432558-7	2016	Expression of hexokinase 2 (HK2) and glucose transporter 1 (GLUT1) also decreased following propranolol intervention.	Propranolol	92-103	solute carrier family 2 member 1	Homo sapiens	60-65
26728293-5	2016	We found significant increases in both the pore diameter and density, accompanied by a significant increase in portal IL-6 concentration; these changes were significantly attenuated by pretreatment with propranolol, a beta adrenergic receptor antagonist.	Propranolol	203-214	interleukin 6	Rattus norvegicus	118-122
26969754-10	2016	Propranolol abrogated the increased Treg activity and accompanying suppression of CD4(+)T cell responses after surgery.	Propranolol	0-11	CD4 molecule	Homo sapiens	82-85
27035124-9	2016	Propranolol decreased beta2-adrenergic receptor-activated invasion.	Propranolol	0-11	adrenoceptor beta 2	Homo sapiens	22-47
26487394-9	2016	RESULTS: Highly expressed phospho-STAT3 protein in cirrhotic rats could successfully be inhibited by AG490 or AG490 + propranolol treatments but not by propranolol alone.	Propranolol	118-129	signal transducer and activator of transcription 3	Rattus norvegicus	34-39
26487394-9	2016	RESULTS: Highly expressed phospho-STAT3 protein in cirrhotic rats could successfully be inhibited by AG490 or AG490 + propranolol treatments but not by propranolol alone.	Propranolol	152-163	signal transducer and activator of transcription 3	Rattus norvegicus	34-39
26487394-12	2016	Increased markers of bacterial translocation (LBP and IL6) were greatly reduced by propranolol but not by AG490.	Propranolol	83-94	lipopolysaccharide binding protein	Rattus norvegicus	46-49
26487394-12	2016	Increased markers of bacterial translocation (LBP and IL6) were greatly reduced by propranolol but not by AG490.	Propranolol	83-94	interleukin 6	Rattus norvegicus	54-57
27252810-9	2016	RESULTS: Propranolol significantly decreased the T helper type 1 cytokine profile [Interleukin-2 (IL-2) and Interferon- gamma (IFN-gamma)] production in PHA stimulated Molt-4 and Jurkat cells, after 48 hour of incubation time, dose-dependently compared to untreated control cells.	Propranolol	9-20	interleukin 2	Homo sapiens	83-96
26801314-5	2016	When sympathetic input was blocked with propranolol, the heart rate of Brs3 null mice was unchanged, while the heart rate in control mice was reduced to the level of the null mice.	Propranolol	40-51	bombesin-like receptor 3	Mus musculus	71-75
27252810-9	2016	RESULTS: Propranolol significantly decreased the T helper type 1 cytokine profile [Interleukin-2 (IL-2) and Interferon- gamma (IFN-gamma)] production in PHA stimulated Molt-4 and Jurkat cells, after 48 hour of incubation time, dose-dependently compared to untreated control cells.	Propranolol	9-20	interleukin 2	Homo sapiens	98-102
27252810-9	2016	RESULTS: Propranolol significantly decreased the T helper type 1 cytokine profile [Interleukin-2 (IL-2) and Interferon- gamma (IFN-gamma)] production in PHA stimulated Molt-4 and Jurkat cells, after 48 hour of incubation time, dose-dependently compared to untreated control cells.	Propranolol	9-20	interferon gamma	Homo sapiens	108-125
27252810-9	2016	RESULTS: Propranolol significantly decreased the T helper type 1 cytokine profile [Interleukin-2 (IL-2) and Interferon- gamma (IFN-gamma)] production in PHA stimulated Molt-4 and Jurkat cells, after 48 hour of incubation time, dose-dependently compared to untreated control cells.	Propranolol	9-20	interferon gamma	Homo sapiens	127-136
27252810-10	2016	CONCLUSION: Our data showed a dose dependent inhibitory effect of propranolol on the IL-2 and IFN-gamma production in human leukemic Molt-4 and Jurkat cells.	Propranolol	66-77	interleukin 2	Homo sapiens	85-89
27252810-10	2016	CONCLUSION: Our data showed a dose dependent inhibitory effect of propranolol on the IL-2 and IFN-gamma production in human leukemic Molt-4 and Jurkat cells.	Propranolol	66-77	interferon gamma	Homo sapiens	94-103
27252810-11	2016	The anti- inflammatory effect of propranolol reported by other investigators may be in part due to its suppressive effect on production of inflammatory cytokines such as IL-2 and IFN-gamma.	Propranolol	33-44	interleukin 2	Homo sapiens	170-174
27252810-11	2016	The anti- inflammatory effect of propranolol reported by other investigators may be in part due to its suppressive effect on production of inflammatory cytokines such as IL-2 and IFN-gamma.	Propranolol	33-44	interferon gamma	Homo sapiens	179-188
26454691-0	2016	A beta-blocker, propranolol, decreases the efficacy from enzyme replacement therapy in Pompe disease.	Propranolol	16-27	amyloid beta (A4) precursor protein	Mus musculus	0-6
27747797-2	2016	Propranolol, a beta-adrenergic blocker mainly indicated for hypertension, has proven effective in treating these types of tumors.	Propranolol	0-11	amyloid beta precursor protein	Homo sapiens	13-19
26612192-0	2016	Serum levels of renin, angiotensin-converting enzyme and angiotensin II in patients treated by surgical excision, propranolol and captopril for problematic proliferating infantile haemangioma.	Propranolol	114-125	angiotensinogen	Homo sapiens	57-71
26548443-2	2016	We describe two cases where a switch to bisoprolol resulted in worsening of arrhythmia control: A man with LQT2, asymptomatic on propranolol, experienced syncope after switching to bisoprolol 5 mg daily.	Propranolol	129-140	potassium voltage-gated channel subfamily H member 2	Homo sapiens	107-111
26904545-2	2016	MATERIALS AND METHODS: We measured serial serum levels of AFP in patients with problematic proliferating IH treated with surgical excision or propranolol treatment.	Propranolol	142-153	alpha fetoprotein	Homo sapiens	58-61
26904545-4	2016	RESULTS: Serum levels of AFP normalized following surgical excision or propranolol treatment.	Propranolol	71-82	alpha fetoprotein	Homo sapiens	25-28
26904545-7	2016	CONCLUSION: This study demonstrates the association of proliferating IH with elevated serum levels of AFP, which normalized following surgical excision or propranolol treatment.	Propranolol	155-166	alpha fetoprotein	Homo sapiens	102-105
26527066-8	2016	Propranolol treatment decreased serum FGF23 and loss of renal calcium and phosphate and increased serum phosphate concentration in gsk3(KI) mice.	Propranolol	0-11	fibroblast growth factor 23	Mus musculus	38-43
26527066-8	2016	Propranolol treatment decreased serum FGF23 and loss of renal calcium and phosphate and increased serum phosphate concentration in gsk3(KI) mice.	Propranolol	0-11	glycogen synthase kinase 3 beta	Mus musculus	131-135
26395120-7	2016	Administration of propranolol and TNF-alpha receptor antagonist led to reduction of post-receptor actions of TNF-alpha and ubiquitin-proteasome activity in cirrhotic rats.	Propranolol	18-29	tumor necrosis factor	Rattus norvegicus	109-118
26489037-0	2016	Influence of CYP2D6 and beta2-adrenergic receptor gene polymorphisms on the hemodynamic response to propranolol in Chinese Han patients with cirrhosis.	Propranolol	100-111	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	13-19
26489037-0	2016	Influence of CYP2D6 and beta2-adrenergic receptor gene polymorphisms on the hemodynamic response to propranolol in Chinese Han patients with cirrhosis.	Propranolol	100-111	adrenoceptor beta 2	Homo sapiens	24-49
26489037-2	2016	This study is to evaluate the relationship between CYP2D6 and beta2-adrenergic receptor (beta2-AR) gene polymorphisms and the hemodynamic response to propranolol in Chinese Han patients.	Propranolol	150-161	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	51-57
26489037-2	2016	This study is to evaluate the relationship between CYP2D6 and beta2-adrenergic receptor (beta2-AR) gene polymorphisms and the hemodynamic response to propranolol in Chinese Han patients.	Propranolol	150-161	adrenoceptor beta 2	Homo sapiens	62-87
26489037-2	2016	This study is to evaluate the relationship between CYP2D6 and beta2-adrenergic receptor (beta2-AR) gene polymorphisms and the hemodynamic response to propranolol in Chinese Han patients.	Propranolol	150-161	adrenoceptor beta 2	Homo sapiens	89-97
26489037-12	2016	The multivariate logistic regression analysis indicated that CYP2D6 (188C&gt;T) genotype was an independent predicting factor for HVPG response to propranolol (P = 0.033).	Propranolol	147-158	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	61-67
26489037-13	2016	CONCLUSIONS: CYP2D6 (188C&gt;T) gene polymorphisms influence the hemodynamic response to propranolol in this population of Chinese Han patients with gastroesophageal varices.	Propranolol	89-100	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	13-19
26762378-2	2016	Propranolol, a beta-adrenergic antagonist with anxiolytic effects, has been shown to improve verbal fluency and working memory in adults and adolescents with ASD in single-dose challenges.	Propranolol	0-11	amyloid beta precursor protein	Homo sapiens	13-19
27094283-5	2016	Here, we present a standard computational protocol to evaluate the binding properties of the two enantiomers of the non-selective beta-blocker propanolol in the beta2 adrenergic receptor"s binding site.	Propranolol	143-153	adrenoceptor beta 2	Homo sapiens	161-186
26907387-0	2016	The embryo-placental CD15-positive "vasculogenic zones" as a source of propranolol-sensitive pediatric vascular tumors.	Propranolol	71-82	fucosyltransferase 4	Homo sapiens	21-25
26907387-3	2016	In this study, we tested the hypothesis that propranolol-responsive vascular tumors are derived from common vessel-forming CD15 + progenitor cells which occur in early gestation.	Propranolol	45-56	fucosyltransferase 4	Homo sapiens	123-127
27455575-4	2016	Preliminary administration of direct renin inhibitor aliskiren (4 mg/kg, orally, 7 days) is accompanied by 2.30-fold increase in the diuretic effect of propranolol, 2.56-fold increase in natriuresis, and 2.27-fold increase in urine potassium excretion (p &lt; 0.05).	Propranolol	152-163	renin	Rattus norvegicus	37-42
26574555-11	2016	We have thus demonstrated that propranolol acts on HemSCs in IH to suppress proliferation and promote apoptosis in a dose-dependent fashion via beta2AR perturbation, resulting in reduced cAMP and MAPK activation.	Propranolol	31-42	adrenoceptor beta 2	Homo sapiens	144-151
26652903-7	2016	Treatment with beta-blockers, including propranolol and metoprolol antagonized isoproterenol-mediated insulin resistance in the heart.	Propranolol	40-51	insulin	Homo sapiens	102-109
26574555-3	2016	Propranolol is a nonselective beta-adrenergic receptor (betaAR) antagonist that can lower cAMP levels and activate the mitogen-activated protein kinase (MAPK) pathway downstream of betaARs.	Propranolol	0-11	adrenoceptor beta 1	Homo sapiens	56-62
26574555-3	2016	Propranolol is a nonselective beta-adrenergic receptor (betaAR) antagonist that can lower cAMP levels and activate the mitogen-activated protein kinase (MAPK) pathway downstream of betaARs.	Propranolol	0-11	mitogen-activated protein kinase 3	Homo sapiens	153-157
26574555-11	2016	We have thus demonstrated that propranolol acts on HemSCs in IH to suppress proliferation and promote apoptosis in a dose-dependent fashion via beta2AR perturbation, resulting in reduced cAMP and MAPK activation.	Propranolol	31-42	mitogen-activated protein kinase 3	Homo sapiens	196-200
26574555-5	2016	In isolated HemSCs, propranolol suppressed cAMP levels and activated extracellular signal-regulated kinase (ERK)1/2 in a dose-dependent fashion.	Propranolol	20-31	mitogen-activated protein kinase 1	Homo sapiens	69-115
26574555-7	2016	Propranolol at &gt;=10(-5) M reduced cAMP levels and activated ERK1/2, and this correlated with HemSC apoptosis and cytotoxicity at &gt;=10(-4) M. Stimulation with a betaAR agonist, isoprenaline, promoted HemSC proliferation and rescued the antiproliferative effects of propranolol, suggesting that propranolol inhibits betaAR signaling in HemSCs.	Propranolol	0-11	mitogen-activated protein kinase 3	Homo sapiens	63-69
26574555-7	2016	Propranolol at &gt;=10(-5) M reduced cAMP levels and activated ERK1/2, and this correlated with HemSC apoptosis and cytotoxicity at &gt;=10(-4) M. Stimulation with a betaAR agonist, isoprenaline, promoted HemSC proliferation and rescued the antiproliferative effects of propranolol, suggesting that propranolol inhibits betaAR signaling in HemSCs.	Propranolol	0-11	adrenoceptor beta 1	Homo sapiens	166-172
26574555-7	2016	Propranolol at &gt;=10(-5) M reduced cAMP levels and activated ERK1/2, and this correlated with HemSC apoptosis and cytotoxicity at &gt;=10(-4) M. Stimulation with a betaAR agonist, isoprenaline, promoted HemSC proliferation and rescued the antiproliferative effects of propranolol, suggesting that propranolol inhibits betaAR signaling in HemSCs.	Propranolol	0-11	adrenoceptor beta 1	Homo sapiens	320-326
26574555-8	2016	Treatment with a cAMP analog or a MAPK inhibitor partially rescued the HemSC cell viability suppressed by propranolol.	Propranolol	106-117	mitogen-activated protein kinase 3	Homo sapiens	34-38
26574555-9	2016	A selective beta2AR antagonist mirrored propranolol"s effects on HemSCs in a dose-dependent fashion, and a selective beta1AR antagonist had no effect, supporting a role for beta2AR signaling in IH pathobiology.	Propranolol	40-51	adrenoceptor beta 2	Homo sapiens	12-19
26574555-10	2016	In a mouse model of IH, propranolol reduced the vessel caliber and blood flow assessed by ultrasound Doppler and increased activation of ERK1/2 in IH cells.	Propranolol	24-35	mitogen-activated protein kinase 3	Mus musculus	137-143
26574555-14	2016	Propranolol, a nonselective beta-adrenergic receptor (betaAR) antagonist, has proven efficacy; however, understanding of its mechanism of action on HemSCs is limited.	Propranolol	0-11	adrenoceptor beta 1	Homo sapiens	54-60
26574555-15	2016	The presented data demonstrate that propranolol, via betaAR perturbation, dose dependently suppresses cAMP levels and activated extracellular signal-regulated kinase 1/2.	Propranolol	36-47	adrenoceptor beta 1	Homo sapiens	53-59
26574555-15	2016	The presented data demonstrate that propranolol, via betaAR perturbation, dose dependently suppresses cAMP levels and activated extracellular signal-regulated kinase 1/2.	Propranolol	36-47	mitogen-activated protein kinase 1	Homo sapiens	128-169
26574555-16	2016	Furthermore, propranolol acts via perturbation of beta2AR, and not beta1AR, although both receptors are expressed in HemSCs.	Propranolol	13-24	adrenoceptor beta 2	Homo sapiens	50-57
26354876-0	2015	Ultraviolet light converts propranolol, a nonselective beta-blocker and potential lupus-inducing drug, into a proinflammatory AhR ligand.	Propranolol	27-38	aryl hydrocarbon receptor	Homo sapiens	126-129
26408544-6	2015	In the presence of high-dose propranolol (30 mg/kg), high-dose leptin only reduced heart rate and sometimes caused sinus pauses and ventricular tachycardia.	Propranolol	29-40	leptin	Rattus norvegicus	63-69
26228348-0	2015	Propranolol decreases retention of fear memory by modulating the stability of surface glutamate receptor GluA1 subunits in the lateral amygdala.	Propranolol	0-11	glutamate ionotropic receptor AMPA type subunit 1	Homo sapiens	105-110
26228348-4	2015	KEY RESULTS: Propranolol attenuated reactivation-induced strengthening of fear retention while reducing enhanced surface expression of GluA1 subunits and restoring the impaired long-term depression in LA.	Propranolol	13-24	glutamate ionotropic receptor AMPA type subunit 1	Homo sapiens	135-140
26228348-5	2015	These effects of propranolol were mediated by antagonizing reactivation-induced enhancement of adrenergic signalling, which activates PKA and calcium/calmodulin-dependent protein kinase II and then regulates the trafficking of AMPA receptors via phosphorylation of GluA1 subunits at the C-terminus.	Propranolol	17-28	glutamate ionotropic receptor AMPA type subunit 1	Homo sapiens	265-270
26211486-7	2015	Here, we showed that administration of alprenolol, carvedilol or propranolol in the absence of interference from adrenaline using Ova S/C PNMT(-/-) mice resulted in the development of an asthma phenotype, whereas nadolol had no effect.	Propranolol	65-76	phenylethanolamine-N-methyltransferase	Mus musculus	138-142
26132918-5	2015	The surgical denervation and beta-adrenergic antagonist propranolol up-regulated TNF-alpha mRNA in both epiWAT and BAT in vivo.	Propranolol	56-67	tumor necrosis factor	Mus musculus	81-90
25757646-5	2016	Moreover, the QPM-MSA-coated tablets had a greater PPN release rate than the QPM-GSA-coated tablets, and drug release was dependent on the film-coating levels.	Propranolol	51-54	thyroid peroxidase	Homo sapiens	18-21
26547106-5	2015	Importantly, in W, propranolol promoted a further improvement in glycemic control, which was accompanied by decreased PKA and Tnf expression, and increased Slc2a4 and GLUT4 in EDL.	Propranolol	19-30	tumor necrosis factor	Rattus norvegicus	126-129
26547106-5	2015	Importantly, in W, propranolol promoted a further improvement in glycemic control, which was accompanied by decreased PKA and Tnf expression, and increased Slc2a4 and GLUT4 in EDL.	Propranolol	19-30	solute carrier family 2 member 4	Rattus norvegicus	156-162
26547106-5	2015	Importantly, in W, propranolol promoted a further improvement in glycemic control, which was accompanied by decreased PKA and Tnf expression, and increased Slc2a4 and GLUT4 in EDL.	Propranolol	19-30	solute carrier family 2 member 4	Rattus norvegicus	167-172
26547106-7	2015	DISCUSSION: Propranolol-induced decrease in beta-adrenergic activity in skeletal muscles of insulin-treated diabetic Wistar rats increases GLUT4 expression in EDL, improving glycemic control.	Propranolol	12-23	solute carrier family 2 member 4	Rattus norvegicus	139-144
26269192-4	2015	Additionally, propranolol induced lytic gene expression in association with downregulation of CDK6.	Propranolol	14-25	cyclin dependent kinase 6	Homo sapiens	94-98
26254103-8	2015	Furthermore, propranolol pretreatment of mouse aortas exposed to L-NAME prevented the difference in responses between Lcat(wt) and Lcat(KO) mice.	Propranolol	13-24	lecithin cholesterol acyltransferase	Mus musculus	118-122
26254103-8	2015	Furthermore, propranolol pretreatment of mouse aortas exposed to L-NAME prevented the difference in responses between Lcat(wt) and Lcat(KO) mice.	Propranolol	13-24	lecithin cholesterol acyltransferase	Mus musculus	131-135
26354876-5	2015	We also show that propranolol, a potential lupus-inducing drug, induced stronger AhR activation in PBMCs of SLE patients than in those of controls.	Propranolol	18-29	aryl hydrocarbon receptor	Homo sapiens	81-84
26354876-6	2015	AhR agonist activity of propranolol was enhanced by UV light exposure.	Propranolol	24-35	aryl hydrocarbon receptor	Homo sapiens	0-3
26489635-0	2015	Effect of topical propranolol gel on plasma renin, angiotensin II and vascular endothelial growth factor in superficial infantile hemangiomas.	Propranolol	18-29	renin	Homo sapiens	44-49
26489635-0	2015	Effect of topical propranolol gel on plasma renin, angiotensin II and vascular endothelial growth factor in superficial infantile hemangiomas.	Propranolol	18-29	angiotensinogen	Homo sapiens	51-65
26489635-8	2015	Propranolol gel may suppress the proliferation of IHs by reducing VEGF.	Propranolol	0-11	vascular endothelial growth factor A	Homo sapiens	66-70
26489635-0	2015	Effect of topical propranolol gel on plasma renin, angiotensin II and vascular endothelial growth factor in superficial infantile hemangiomas.	Propranolol	18-29	vascular endothelial growth factor A	Homo sapiens	70-104
26489635-1	2015	The effect of topical propranolol gel on the levels of plasma renin, angiotensin II (ATII) and vascular endothelial growth factor (VEGF) in superficial infantile hemangiomas (IHs) was investigated.	Propranolol	22-33	renin	Homo sapiens	62-67
26489635-1	2015	The effect of topical propranolol gel on the levels of plasma renin, angiotensin II (ATII) and vascular endothelial growth factor (VEGF) in superficial infantile hemangiomas (IHs) was investigated.	Propranolol	22-33	angiotensinogen	Homo sapiens	69-83
26489635-1	2015	The effect of topical propranolol gel on the levels of plasma renin, angiotensin II (ATII) and vascular endothelial growth factor (VEGF) in superficial infantile hemangiomas (IHs) was investigated.	Propranolol	22-33	vascular endothelial growth factor A	Homo sapiens	95-129
26489635-1	2015	The effect of topical propranolol gel on the levels of plasma renin, angiotensin II (ATII) and vascular endothelial growth factor (VEGF) in superficial infantile hemangiomas (IHs) was investigated.	Propranolol	22-33	vascular endothelial growth factor A	Homo sapiens	131-135
26394686-0	2015	Propranolol reduces viability and induces apoptosis in hemangioblastoma cells from von Hippel-Lindau patients.	Propranolol	0-11	von Hippel-Lindau tumor suppressor	Homo sapiens	83-100
26394686-8	2015	HIF1-alpha and Hif-2alpha expression after propranolol treatment was analyzed by western blotting.	Propranolol	43-54	endothelial PAS domain protein 1	Homo sapiens	15-25
25963796-8	2015	Propranolol decreased ovarian expression of Foxo3, Srd5a1, and Hif1a.	Propranolol	0-11	forkhead box O3	Rattus norvegicus	44-49
25963796-8	2015	Propranolol decreased ovarian expression of Foxo3, Srd5a1, and Hif1a.	Propranolol	0-11	steroid 5 alpha-reductase 1	Rattus norvegicus	51-57
25963796-8	2015	Propranolol decreased ovarian expression of Foxo3, Srd5a1, and Hif1a.	Propranolol	0-11	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	63-68
26617741-0	2015	S-propranolol protected H9C2 cells from ischemia/reperfusion-induced apoptosis via downregultion of RACK1 Gene.	Propranolol	0-13	receptor for activated C kinase 1	Rattus norvegicus	100-105
25947339-2	2015	Propranolol might be an interesting new medical option in JA treatment, as it reduces mesenchymal cell growth and decreases the number of CD31-positive cells in vitro.	Propranolol	0-11	platelet and endothelial cell adhesion molecule 1	Homo sapiens	138-142
25947339-8	2015	Propranolol addition reduced the number of CD31-positive cells and inhibited mesenchymal cell growth.	Propranolol	0-11	platelet and endothelial cell adhesion molecule 1	Homo sapiens	43-47
25517250-8	2015	Epinephrine and G-CSF-induced up-regulation of CXCR4 mRNA is dependent on beta receptors, so incubation of HSCs with propranolol led to inhibition of such increased expression.	Propranolol	117-128	colony stimulating factor 3	Homo sapiens	16-21
25517250-8	2015	Epinephrine and G-CSF-induced up-regulation of CXCR4 mRNA is dependent on beta receptors, so incubation of HSCs with propranolol led to inhibition of such increased expression.	Propranolol	117-128	C-X-C motif chemokine receptor 4	Homo sapiens	47-52
26617741-4	2015	RACK1 may be a target protein of S-propranolol during I/R.	Propranolol	33-46	receptor for activated C kinase 1	Rattus norvegicus	0-5
26617741-11	2015	Furthermore, RACK1 RNAi and S-propranolol, separately and in combination, significantly reduced caspase-3 activity, cytochrome c release and JNK activation.	Propranolol	28-41	caspase 3	Rattus norvegicus	96-105
26622443-0	2015	Clinical efficacy of propranolol in the treatment of hemangioma and changes in serum VEGF, bFGF and MMP-9.	Propranolol	21-32	vascular endothelial growth factor A	Homo sapiens	85-89
26622443-0	2015	Clinical efficacy of propranolol in the treatment of hemangioma and changes in serum VEGF, bFGF and MMP-9.	Propranolol	21-32	fibroblast growth factor 2	Homo sapiens	91-95
26622443-0	2015	Clinical efficacy of propranolol in the treatment of hemangioma and changes in serum VEGF, bFGF and MMP-9.	Propranolol	21-32	matrix metallopeptidase 9	Homo sapiens	100-105
26622443-9	2015	The mechanism underlying the effects of propranolol may be associated with the downregulation of VEGF, bFGF and MMP-9 expression.	Propranolol	40-51	vascular endothelial growth factor A	Homo sapiens	97-101
26622443-9	2015	The mechanism underlying the effects of propranolol may be associated with the downregulation of VEGF, bFGF and MMP-9 expression.	Propranolol	40-51	fibroblast growth factor 2	Homo sapiens	103-107
26622443-9	2015	The mechanism underlying the effects of propranolol may be associated with the downregulation of VEGF, bFGF and MMP-9 expression.	Propranolol	40-51	matrix metallopeptidase 9	Homo sapiens	112-117
26617741-11	2015	Furthermore, RACK1 RNAi and S-propranolol, separately and in combination, significantly reduced caspase-3 activity, cytochrome c release and JNK activation.	Propranolol	28-41	mitogen-activated protein kinase 8	Rattus norvegicus	141-144
26617741-3	2015	Our previous studies showed that activated protein kinase C1 (RACK1) was significantly down-regulated in human umbilical vein endothelial cells by S-propranolol.	Propranolol	147-160	receptor for activated C kinase 1	Homo sapiens	62-67
26238450-0	2015	The therapeutic response in Gorham"s syndrome to the beta-blocking agent propranolol is correlated to VEGF-A, but not to VEGF-C or FLT1 expression.	Propranolol	73-84	vascular endothelial growth factor A	Homo sapiens	102-108
26209570-9	2015	The addition of propranolol to lung contusion/chronic restraint stress and lung contusion/hemorrhagic shock/chronic restraint stress models greatly decreased HPC mobilization and restored G-CSF levels to that of naive animals without worsening lung injury scores.	Propranolol	16-27	colony stimulating factor 3	Rattus norvegicus	188-193
26209570-10	2015	CONCLUSION: The daily administration of propranolol after both lung contusion and lung contusion/hemorrhagic shock subjected to chronic restraint stress decreased the prolonged mobilization of HPC from the bone marrow and decreased plasma G-CSF levels.	Propranolol	40-51	colony stimulating factor 3	Rattus norvegicus	239-244
26238450-8	2015	Furthermore, the patient responded favorably and the disease was stabilized following treatment with the beta-blocking agent Propranolol alone which acts on VEGF-A alone, but not on soluble VEGF receptor-1 levels.	Propranolol	125-136	vascular endothelial growth factor A	Homo sapiens	157-163
26238450-10	2015	Furthermore, Propranolol acts on VEGF-A but not FLT1 expression.	Propranolol	13-24	vascular endothelial growth factor A	Homo sapiens	33-39
25933122-8	2015	However, if the autonomic nervous system was blocked by propranolol and atropine, in line with the in vitro data, LPS induced a significant reduction of heart-rate, which was not additive to ivabradine.	Propranolol	56-67	toll-like receptor 4	Mus musculus	114-117
25957836-6	2015	In the present study, we found that epinephrine increased the expression of TH in a dose- and time-dependent manner in PC12 cells, which was inhibited by propranolol (beta-adrenergic receptor inhibitor), but not by phenoxybenzamine (alpha-adrenergic receptor inhibitor).	Propranolol	154-165	tyrosine hydroxylase	Rattus norvegicus	76-78
25728347-11	2015	NO and VEGF release induced by norepinephrine was decreased by propranolol pretreatment, coincident with alterations in the phosphorylation of Akt, eNOS, and VEGFR-2.	Propranolol	63-74	vascular endothelial growth factor A	Homo sapiens	7-11
26058426-8	2015	Altogether these data suggest that beta2-AR plays an important role in prostate cancer metastasis formation and that the treatment with antagonist propanolol, could represents an interesting tool to control this process in cells overexpressing beta2AR.	Propranolol	147-157	adrenoceptor beta 2	Homo sapiens	244-251
25728347-0	2015	Propranolol induces regression of hemangioma cells via the down-regulation of the PI3K/Akt/eNOS/VEGF pathway.	Propranolol	0-11	AKT serine/threonine kinase 1	Homo sapiens	87-90
25728347-0	2015	Propranolol induces regression of hemangioma cells via the down-regulation of the PI3K/Akt/eNOS/VEGF pathway.	Propranolol	0-11	nitric oxide synthase 3	Homo sapiens	91-95
25728347-0	2015	Propranolol induces regression of hemangioma cells via the down-regulation of the PI3K/Akt/eNOS/VEGF pathway.	Propranolol	0-11	vascular endothelial growth factor A	Homo sapiens	96-100
25728347-9	2015	RESULTS: Propranolol blocked norepinephrine-induced HemECs cell cycle progression as well as the expression of cyclin A2 and cyclin D2; whereas p21 and p27 proteins were altered conversely.	Propranolol	9-20	cyclin A2	Homo sapiens	111-120
25690341-1	2015	PURPOSE: Recent controversial publications, citing studies purporting to show that P-gp mediates the transport of propranolol, proposed that passive biological membrane transport is negligible.	Propranolol	114-125	PGP	Canis lupus familiaris	83-87
25690341-6	2015	RESULTS: S-propranolol exhibited efflux ratios lower than 1 in MDCK, MDCK-MDR1 and Caco-2 cells.	Propranolol	9-22	ATP binding cassette subfamily B member 1	Canis lupus familiaris	74-78
25728347-13	2015	CONCLUSIONS: The current study demonstrated the antiangiogenic properties of propranolol in vitro and that the drug was able to induce the regression of hemangioma cells via the inhibition of cell cycle progression, invasion, and tube formation, concomitantly with decreased NO and VEGF levels through the down-regulation of the PI3K/Akt/eNOS/VEGF pathway.	Propranolol	77-88	vascular endothelial growth factor A	Homo sapiens	282-286
25728347-13	2015	CONCLUSIONS: The current study demonstrated the antiangiogenic properties of propranolol in vitro and that the drug was able to induce the regression of hemangioma cells via the inhibition of cell cycle progression, invasion, and tube formation, concomitantly with decreased NO and VEGF levels through the down-regulation of the PI3K/Akt/eNOS/VEGF pathway.	Propranolol	77-88	AKT serine/threonine kinase 1	Homo sapiens	334-337
25728347-13	2015	CONCLUSIONS: The current study demonstrated the antiangiogenic properties of propranolol in vitro and that the drug was able to induce the regression of hemangioma cells via the inhibition of cell cycle progression, invasion, and tube formation, concomitantly with decreased NO and VEGF levels through the down-regulation of the PI3K/Akt/eNOS/VEGF pathway.	Propranolol	77-88	nitric oxide synthase 3	Homo sapiens	338-342
25728347-13	2015	CONCLUSIONS: The current study demonstrated the antiangiogenic properties of propranolol in vitro and that the drug was able to induce the regression of hemangioma cells via the inhibition of cell cycle progression, invasion, and tube formation, concomitantly with decreased NO and VEGF levels through the down-regulation of the PI3K/Akt/eNOS/VEGF pathway.	Propranolol	77-88	vascular endothelial growth factor A	Homo sapiens	343-347
25929826-5	2015	Propranolol treatment during PSD reversed these effects, indicating a major inhibitory role of beta-adrenergic receptors (beta-AR) on NK cells function.	Propranolol	0-11	adrenergic receptor, beta 2	Mus musculus	122-129
25728347-9	2015	RESULTS: Propranolol blocked norepinephrine-induced HemECs cell cycle progression as well as the expression of cyclin A2 and cyclin D2; whereas p21 and p27 proteins were altered conversely.	Propranolol	9-20	cyclin D2	Homo sapiens	125-134
25728347-10	2015	Propranolol inhibited norepinephrine-induced cell invasion by reducing the expression of MMP-9, VEGF, and p-cofilin.	Propranolol	0-11	matrix metallopeptidase 9	Homo sapiens	89-94
25728347-10	2015	Propranolol inhibited norepinephrine-induced cell invasion by reducing the expression of MMP-9, VEGF, and p-cofilin.	Propranolol	0-11	vascular endothelial growth factor A	Homo sapiens	96-100
26219508-9	2015	RANKL expression by MSCs decreased after propranolol administration and increased after isoproterenol administration.	Propranolol	41-52	TNF superfamily member 11	Rattus norvegicus	0-5
26436973-0	2015	"Cyrano nose" associated with hepatic hemangiomas successfully treated with propranolol.	Propranolol	76-87	OIP5 antisense RNA 1	Homo sapiens	1-7
26436973-2	2015	We describe a patient who presented at two months of age with a "Cyrano nose" associated with multiple hepatic and cutaneous hemangiomas, which completely resolved after therapy with propranolol.	Propranolol	183-194	OIP5 antisense RNA 1	Homo sapiens	65-71
25837585-6	2015	These effects on the BODIPY-TMR-CGP dissociation rate were markedly enhanced in beta1-adrenoceptor homodimers constrained by bimolecular fluorescence complementation (9.8- and 9.9-fold for 1 microM CGP 12177 and 1 microM propranolol, respectively) and abolished in beta1-adrenoceptors containing TM4 mutations vital for the second conformation pharmacology.	Propranolol	221-232	adrenoceptor beta 1	Homo sapiens	80-98
26109805-0	2015	beta-2 Adrenergic receptor gene polymorphism and response to propranolol in cirrhosis.	Propranolol	61-72	adrenoceptor beta 2	Homo sapiens	0-26
26665926-0	2015	[Effect of propranolol gel on plasma VEGF, bFGF and MMP-9 in proliferating infantile hemangiomas of superficial type].	Propranolol	11-22	vascular endothelial growth factor A	Homo sapiens	37-41
26665926-0	2015	[Effect of propranolol gel on plasma VEGF, bFGF and MMP-9 in proliferating infantile hemangiomas of superficial type].	Propranolol	11-22	matrix metallopeptidase 9	Homo sapiens	52-57
26665926-1	2015	OBJECTIVE: To investigate the effect of topical propranolol gel on the levels of plasma vascular endothelial growth factor (VEGF), basic fibroblastic growth factor (bFGF) and matrix metalloproteinases-9 (MMP-9) in proliferating infantile hemangiomas (IHs) of superficial type.	Propranolol	48-59	vascular endothelial growth factor A	Homo sapiens	88-122
26665926-1	2015	OBJECTIVE: To investigate the effect of topical propranolol gel on the levels of plasma vascular endothelial growth factor (VEGF), basic fibroblastic growth factor (bFGF) and matrix metalloproteinases-9 (MMP-9) in proliferating infantile hemangiomas (IHs) of superficial type.	Propranolol	48-59	vascular endothelial growth factor A	Homo sapiens	124-128
26665926-1	2015	OBJECTIVE: To investigate the effect of topical propranolol gel on the levels of plasma vascular endothelial growth factor (VEGF), basic fibroblastic growth factor (bFGF) and matrix metalloproteinases-9 (MMP-9) in proliferating infantile hemangiomas (IHs) of superficial type.	Propranolol	48-59	fibroblast growth factor 2	Homo sapiens	131-163
26665926-1	2015	OBJECTIVE: To investigate the effect of topical propranolol gel on the levels of plasma vascular endothelial growth factor (VEGF), basic fibroblastic growth factor (bFGF) and matrix metalloproteinases-9 (MMP-9) in proliferating infantile hemangiomas (IHs) of superficial type.	Propranolol	48-59	fibroblast growth factor 2	Homo sapiens	165-169
26665926-11	2015	CONCLUSIONS: Propranolol gel may suppress the proliferation of superficial infantile bemangiomas by reducing VEGF and bFGF.	Propranolol	13-24	vascular endothelial growth factor A	Homo sapiens	109-113
26665926-11	2015	CONCLUSIONS: Propranolol gel may suppress the proliferation of superficial infantile bemangiomas by reducing VEGF and bFGF.	Propranolol	13-24	fibroblast growth factor 2	Homo sapiens	118-122
26109805-1	2015	AIM: To evaluate the association of beta-2 adrenergic receptor (beta2-AR) gene polymorphism with response of variceal pressure to propranolol in cirrhosis.	Propranolol	130-141	adrenoceptor beta 2	Homo sapiens	36-62
26109805-1	2015	AIM: To evaluate the association of beta-2 adrenergic receptor (beta2-AR) gene polymorphism with response of variceal pressure to propranolol in cirrhosis.	Propranolol	130-141	adrenoceptor beta 2	Homo sapiens	64-72
26109805-6	2015	CONCLUSION: The variceal pressure response to propranolol was associated with polymorphism of beta2-AR gene.	Propranolol	46-57	adrenoceptor beta 2	Homo sapiens	94-102
26062974-6	2015	The FMO2 biocatalysts were employed for substrate screening purposes, revealing trifluoperazine and propranolol as FMO2 substrates.	Propranolol	100-111	flavin containing dimethylaniline monoxygenase 2	Homo sapiens	4-8
26062974-6	2015	The FMO2 biocatalysts were employed for substrate screening purposes, revealing trifluoperazine and propranolol as FMO2 substrates.	Propranolol	100-111	flavin containing dimethylaniline monoxygenase 2	Homo sapiens	115-119
25872592-7	2015	Our data further demonstrated that propranolol inhibited the signal transducer and activator of transcription 3 (STAT3), a critical oncogenic signaling molecule, and the anti-apoptotic protein Bcl-2.	Propranolol	35-46	signal transducer and activator of transcription 3	Mus musculus	113-118
26068931-8	2015	Pretreatment of adipocytes with propranolol and a specific beta1-AR antagonist demonstrated that ZAG effects on basal glucose uptake and GLUT4 expression are mediated via beta1-AR, whereas inhibition of insulin action is dependent on beta2-AR activation.	Propranolol	32-43	alpha-2-glycoprotein 1, zinc-binding	Homo sapiens	97-100
25872592-7	2015	Our data further demonstrated that propranolol inhibited the signal transducer and activator of transcription 3 (STAT3), a critical oncogenic signaling molecule, and the anti-apoptotic protein Bcl-2.	Propranolol	35-46	B cell leukemia/lymphoma 2	Mus musculus	193-198
25872592-0	2015	Propranolol represses infantile hemangioma cell growth through the beta2-adrenergic receptor in a HIF-1alpha-dependent manner.	Propranolol	0-11	adrenergic receptor, beta 2	Mus musculus	67-92
25872592-8	2015	Additionally, overexpression of HIF-1alpha significantly reversed the inhibitory effects of propranolol on STAT3 signaling.	Propranolol	92-103	hypoxia inducible factor 1, alpha subunit	Mus musculus	32-42
25872592-0	2015	Propranolol represses infantile hemangioma cell growth through the beta2-adrenergic receptor in a HIF-1alpha-dependent manner.	Propranolol	0-11	hypoxia inducible factor 1, alpha subunit	Mus musculus	98-108
25872592-8	2015	Additionally, overexpression of HIF-1alpha significantly reversed the inhibitory effects of propranolol on STAT3 signaling.	Propranolol	92-103	signal transducer and activator of transcription 3	Mus musculus	107-112
25872592-4	2015	In infantile hemangioma patients, we found that propranolol significantly decreased the expression levels of the hypoxia inducible factor (HIF)-1alpha in serum and urine, as well as in hemangioma tissues.	Propranolol	48-59	hypoxia inducible factor 1 subunit alpha	Homo sapiens	113-150
25872592-9	2015	In a mouse xenograft hemangioma model, overexpression of HIF-1alpha significantly attenuated the therapeutic effects of propranolol and inhibited propranolol-induced hemangioma cell apoptosis.	Propranolol	120-131	hypoxia inducible factor 1, alpha subunit	Mus musculus	57-67
25872592-5	2015	In vitro analysis revealed that propranolol reduces the expression of HIF-1alpha in hemangioma cells in a dose- and time-dependent manner, mainly by acting on beta2-AR.	Propranolol	32-43	hypoxia inducible factor 1, alpha subunit	Mus musculus	70-80
25872592-9	2015	In a mouse xenograft hemangioma model, overexpression of HIF-1alpha significantly attenuated the therapeutic effects of propranolol and inhibited propranolol-induced hemangioma cell apoptosis.	Propranolol	146-157	hypoxia inducible factor 1, alpha subunit	Mus musculus	57-67
25872592-5	2015	In vitro analysis revealed that propranolol reduces the expression of HIF-1alpha in hemangioma cells in a dose- and time-dependent manner, mainly by acting on beta2-AR.	Propranolol	32-43	adrenergic receptor, beta 2	Mus musculus	159-167
25872592-6	2015	Interestingly, it was observed that overexpression of HIF-1alpha apparently abrogated the inhibitory effects of propranolol on vascular endothelial growth factor (VEGF) expression and cell growth.	Propranolol	112-123	hypoxia inducible factor 1, alpha subunit	Mus musculus	54-64
25872592-10	2015	Moreover, the protein levels of VEGF, phosphorylated STAT3, total STAT3 and Bcl-2 were significantly upregulated by HIF-1alpha overexpression in propranolol-treated nude mice bearing hemangiomas.	Propranolol	145-156	vascular endothelial growth factor A	Mus musculus	32-36
25872592-6	2015	Interestingly, it was observed that overexpression of HIF-1alpha apparently abrogated the inhibitory effects of propranolol on vascular endothelial growth factor (VEGF) expression and cell growth.	Propranolol	112-123	vascular endothelial growth factor A	Mus musculus	127-161
25872592-10	2015	Moreover, the protein levels of VEGF, phosphorylated STAT3, total STAT3 and Bcl-2 were significantly upregulated by HIF-1alpha overexpression in propranolol-treated nude mice bearing hemangiomas.	Propranolol	145-156	signal transducer and activator of transcription 3	Mus musculus	53-58
25872592-6	2015	Interestingly, it was observed that overexpression of HIF-1alpha apparently abrogated the inhibitory effects of propranolol on vascular endothelial growth factor (VEGF) expression and cell growth.	Propranolol	112-123	vascular endothelial growth factor A	Mus musculus	163-167
25872592-7	2015	Our data further demonstrated that propranolol inhibited the signal transducer and activator of transcription 3 (STAT3), a critical oncogenic signaling molecule, and the anti-apoptotic protein Bcl-2.	Propranolol	35-46	signal transducer and activator of transcription 3	Mus musculus	61-111
25872592-10	2015	Moreover, the protein levels of VEGF, phosphorylated STAT3, total STAT3 and Bcl-2 were significantly upregulated by HIF-1alpha overexpression in propranolol-treated nude mice bearing hemangiomas.	Propranolol	145-156	signal transducer and activator of transcription 3	Mus musculus	66-71
25872592-10	2015	Moreover, the protein levels of VEGF, phosphorylated STAT3, total STAT3 and Bcl-2 were significantly upregulated by HIF-1alpha overexpression in propranolol-treated nude mice bearing hemangiomas.	Propranolol	145-156	B cell leukemia/lymphoma 2	Mus musculus	76-81
25872592-10	2015	Moreover, the protein levels of VEGF, phosphorylated STAT3, total STAT3 and Bcl-2 were significantly upregulated by HIF-1alpha overexpression in propranolol-treated nude mice bearing hemangiomas.	Propranolol	145-156	hypoxia inducible factor 1, alpha subunit	Mus musculus	116-126
25872592-11	2015	Collectively, our data provide evidence that propranolol may regress infantile hemangiomas by suppressing VEGF and STAT3 signaling pathways in an HIF-1alpha-dependent manner.	Propranolol	45-56	vascular endothelial growth factor A	Mus musculus	106-110
25872592-11	2015	Collectively, our data provide evidence that propranolol may regress infantile hemangiomas by suppressing VEGF and STAT3 signaling pathways in an HIF-1alpha-dependent manner.	Propranolol	45-56	signal transducer and activator of transcription 3	Mus musculus	115-120
25872592-11	2015	Collectively, our data provide evidence that propranolol may regress infantile hemangiomas by suppressing VEGF and STAT3 signaling pathways in an HIF-1alpha-dependent manner.	Propranolol	45-56	hypoxia inducible factor 1, alpha subunit	Mus musculus	146-156
25843793-6	2015	beta-adrenoreceptor inhibitor propranolol blocked NE-induced IL-6 expression in mRNA and protein levels in U937 macrophages.	Propranolol	30-41	interleukin 6	Homo sapiens	61-65
26019344-7	2015	Infusion of the beta-adrenergic receptor (betaAR) inhibitor propranolol and glucocorticoid receptor (GR) inhibitor RU486 into the CA1 area of the dorsal hippocampus before novelty exposure blocked the effect of novelty on extinction memory.	Propranolol	60-71	carbonic anhydrase 1	Rattus norvegicus	130-133
26019344-8	2015	Propranolol prevented activation of the hippocampal PKA-CREB pathway, and RU486 prevented activation of the hippocampal extracellular signal-regulated kinase 1/2 (Erk1/2)-CREB pathway induced by novelty exposure.	Propranolol	0-11	cAMP responsive element binding protein 1	Rattus norvegicus	56-60
25849891-5	2015	In the ECG recording (R-R interval), orexin/ataxin-3 transgenic rats showed decreased responsiveness to the beta-adrenergic blocker propranolol.	Propranolol	132-143	hypocretin neuropeptide precursor	Rattus norvegicus	37-43
25849891-5	2015	In the ECG recording (R-R interval), orexin/ataxin-3 transgenic rats showed decreased responsiveness to the beta-adrenergic blocker propranolol.	Propranolol	132-143	ataxin 3	Rattus norvegicus	44-52
25793392-8	2015	We show that blocking this signaling pathway in vivo through use of the beta-blocker propanolol completely mitigates the protective effect of cold-stress on HSPC apoptosis.	Propranolol	85-95	proteasome 20S subunit alpha 7	Homo sapiens	157-161
25834103-10	2015	Most interestingly, lipin-1 depletion or lipins inhibition with propranolol sensitized cancer cells to rapamycin.	Propranolol	64-75	lipin 1	Homo sapiens	20-27
25748393-9	2015	The IPR-induced redistribution of Galphas was prevented (SMG) or reduced (parotid) by prior injection of propranolol.	Propranolol	105-116	GNAS (guanine nucleotide binding protein, alpha stimulating) complex locus	Mus musculus	34-41
25523517-2	2015	The efficacy of propranolol was related to the beta2-AR blockade and the consequent inhibition of the production of vascular endothelial growth factor (VEGF), suggesting the hypothesis that propranolol could also be effective in treating retinopathy of prematurity (ROP), a retinal pathology characterized by VEGF-induced neoangiogenesis.	Propranolol	16-27	adrenoceptor beta 2	Homo sapiens	47-55
25523517-2	2015	The efficacy of propranolol was related to the beta2-AR blockade and the consequent inhibition of the production of vascular endothelial growth factor (VEGF), suggesting the hypothesis that propranolol could also be effective in treating retinopathy of prematurity (ROP), a retinal pathology characterized by VEGF-induced neoangiogenesis.	Propranolol	16-27	vascular endothelial growth factor A	Homo sapiens	116-150
25523517-2	2015	The efficacy of propranolol was related to the beta2-AR blockade and the consequent inhibition of the production of vascular endothelial growth factor (VEGF), suggesting the hypothesis that propranolol could also be effective in treating retinopathy of prematurity (ROP), a retinal pathology characterized by VEGF-induced neoangiogenesis.	Propranolol	16-27	vascular endothelial growth factor A	Homo sapiens	152-156
25523517-2	2015	The efficacy of propranolol was related to the beta2-AR blockade and the consequent inhibition of the production of vascular endothelial growth factor (VEGF), suggesting the hypothesis that propranolol could also be effective in treating retinopathy of prematurity (ROP), a retinal pathology characterized by VEGF-induced neoangiogenesis.	Propranolol	16-27	vascular endothelial growth factor A	Homo sapiens	309-313
25523517-2	2015	The efficacy of propranolol was related to the beta2-AR blockade and the consequent inhibition of the production of vascular endothelial growth factor (VEGF), suggesting the hypothesis that propranolol could also be effective in treating retinopathy of prematurity (ROP), a retinal pathology characterized by VEGF-induced neoangiogenesis.	Propranolol	190-201	adrenoceptor beta 2	Homo sapiens	47-55
25523517-2	2015	The efficacy of propranolol was related to the beta2-AR blockade and the consequent inhibition of the production of vascular endothelial growth factor (VEGF), suggesting the hypothesis that propranolol could also be effective in treating retinopathy of prematurity (ROP), a retinal pathology characterized by VEGF-induced neoangiogenesis.	Propranolol	190-201	vascular endothelial growth factor A	Homo sapiens	116-150
25523517-2	2015	The efficacy of propranolol was related to the beta2-AR blockade and the consequent inhibition of the production of vascular endothelial growth factor (VEGF), suggesting the hypothesis that propranolol could also be effective in treating retinopathy of prematurity (ROP), a retinal pathology characterized by VEGF-induced neoangiogenesis.	Propranolol	190-201	vascular endothelial growth factor A	Homo sapiens	152-156
25387586-0	2015	Regulation of cerebral CYP2D alters tramadol metabolism in the brain: interactions of tramadol with propranolol and nicotine.	Propranolol	100-111	cytochrome P450 family 2 subfamily D member 7 (gene/pseudogene)	Homo sapiens	23-28
25387586-5	2015	Propranolol (20 mug, intracerebroventricular injection), CYP2D inhibitor, prolonged the elimination t1/2 of tramadol (40 mg/kg, intraperitoneal injection) in the CSF; meanwhile, lower Cmax and AUC0-  values of M1 were observed.	Propranolol	0-11	cytochrome P450 family 2 subfamily D member 7 (gene/pseudogene)	Homo sapiens	57-62
25460028-6	2015	Pretreatment with alpha-adrenoreceptor antagonist phentolamine and beta-adrenoceptor antagonist propranolol respectively attenuated the pressor response induced by opiorphin.	Propranolol	96-107	opiorphin prepropeptide	Homo sapiens	164-173
25729581-3	2015	Selected Pgp transport ligands include: Amiodarone, Bepridil, Diltiazem, Dipyridamole, Nicardipine, Nifedipine, Propranolol, and Quinidine.	Propranolol	112-123	phosphoglycolate phosphatase	Mus musculus	9-12
25760846-9	2015	The peak GH after the propranolol-exercise provocative test was significantly higher than that after the insulin provocative test (P&lt;0.01).	Propranolol	22-33	growth hormone 1	Homo sapiens	9-11
25676919-10	2015	Propranolol attenuated the induction of pro-inflammatory cytokines TNF-alpha and IL-6, as well as fibrinolysis markers plasmin antiplasmin complex and tissue-type plasminogen activator.	Propranolol	0-11	tumor necrosis factor	Rattus norvegicus	67-76
25676919-10	2015	Propranolol attenuated the induction of pro-inflammatory cytokines TNF-alpha and IL-6, as well as fibrinolysis markers plasmin antiplasmin complex and tissue-type plasminogen activator.	Propranolol	0-11	interleukin 6	Rattus norvegicus	81-85
25676919-10	2015	Propranolol attenuated the induction of pro-inflammatory cytokines TNF-alpha and IL-6, as well as fibrinolysis markers plasmin antiplasmin complex and tissue-type plasminogen activator.	Propranolol	0-11	plasminogen activator, tissue type	Rattus norvegicus	151-184
25676919-11	2015	The increased serum syndecan-1 and soluble thrombomodulin were inhibited by propranolol, and the NF-kappaB expression was also decreased by propranolol pretreatment.	Propranolol	76-87	syndecan 1	Rattus norvegicus	20-30
25676919-11	2015	The increased serum syndecan-1 and soluble thrombomodulin were inhibited by propranolol, and the NF-kappaB expression was also decreased by propranolol pretreatment.	Propranolol	76-87	thrombomodulin	Rattus norvegicus	43-57
25676919-11	2015	The increased serum syndecan-1 and soluble thrombomodulin were inhibited by propranolol, and the NF-kappaB expression was also decreased by propranolol pretreatment.	Propranolol	140-151	syndecan 1	Rattus norvegicus	20-30
25678777-11	2015	CONCLUSION: Short-term treatment with interferon-alpha2a can be used as a safe and effective treatment for alarming infantile hemangiomas that are resistant to propranolol or corticosteroids, and that endanger the proper functioning of the affected organ or the patient"s life.	Propranolol	160-171	interferon alpha 2	Homo sapiens	38-56
25561369-6	2015	The effect of A on CD11b was antagonized by yohimbine and propranolol, and increased by prazosin.	Propranolol	58-69	integrin subunit alpha M	Homo sapiens	19-24
24517276-9	2015	When chronically administered to CCl4 -cirrhotic rats, propranolol + droxidopa caused a decrease in PP, a significant reduction in SMABF and an increase in SMAR.	Propranolol	55-66	C-C motif chemokine ligand 4	Rattus norvegicus	33-37
25760846-10	2015	Peak GH occurred mostly at 30-60 minutes after the insulin provocative test, while that occurred mostly at 120 minutes after the propranolol-exercise provocative test.	Propranolol	129-140	growth hormone 1	Homo sapiens	5-7
25760846-12	2015	CONCLUSIONS: Coincidence rates in stimulating the secretion of GH are high between the propranolol-exercise provocative test and the insulin provocative test.	Propranolol	87-98	growth hormone 1	Homo sapiens	63-65
25760846-13	2015	Compared with the insulin provocative test, the propranolol-exercise provocative test is more likely to stimulate the secretion of GH.	Propranolol	48-59	growth hormone 1	Homo sapiens	131-133
25301937-6	2015	Unlike the human UGT1A10, however, it failed to catalyze considerable rates of R-propranolol, diclofenac, and indomethacin glucuronidation.	Propranolol	79-92	UDP glucuronosyltransferase family 1 member A10	Homo sapiens	17-24
25808280-2	2015	The result showed that the presence of vitamin E promoted a stable release rate of soluble drug propranolol HCl from aged PEO matrix tablets, which was similar to fresh sample, regardless of molecular weight (MW) of PEO.	Propranolol	96-111	twinkle mtDNA helicase	Homo sapiens	122-125
25461918-5	2015	In mice treated with (S)-propranolol, the percentage of splenic T lymphocytes producing IFN-gamma after antigen challenge was determined by flow cytometry.	Propranolol	21-36	interferon gamma	Mus musculus	88-97
25461918-6	2015	In mice infected with 1x10(6) parasites, only (S)-propranolol caused a reduction of footpad swelling (p&lt;0.05, weeks 11-12), without effects on parasite burden, or in the percentage of IFN-gamma-immunopositive CD4(+) or CD8(+) T lymphocytes.	Propranolol	46-61	CD4 antigen	Mus musculus	212-215
25489735-11	2014	Interestingly, the preincubation with propranolol, an inhibitor of the pathway of PLD-1, a known interactor of PED/PEA-15, responsible for its deleterious effects on glucose tolerance, abolishes the antiapoptotic effects of PED/PEA-15 overexpression in Ins-1E beta-cells.	Propranolol	38-49	phospholipase D1	Rattus norvegicus	82-87
25549103-5	2014	After the memory reactivation we administer an oral dose of 40 mg of propranolol HCl, a beta-adrenergic receptor antagonist that indirectly targets the protein synthesis required for reconsolidation by inhibiting the noradrenaline-stimulated CREB phosphorylation.	Propranolol	69-84	cAMP responsive element binding protein 1	Homo sapiens	242-246
26139101-8	2015	The -logKB values were 8.12 +- 0.17, 8.03 +- 0.05 and 7.23 +- 0.05 for propranolol, ICI 118551 and atenolol, respectively, indicating the possible involvement of both beta1- and beta2-adrenoceptor subtypes.	Propranolol	71-82	adrenoceptor beta 1	Homo sapiens	167-196
25489735-11	2014	Interestingly, the preincubation with propranolol, an inhibitor of the pathway of PLD-1, a known interactor of PED/PEA-15, responsible for its deleterious effects on glucose tolerance, abolishes the antiapoptotic effects of PED/PEA-15 overexpression in Ins-1E beta-cells.	Propranolol	38-49	preimplantation embryo development	Mus musculus	111-114
25489735-11	2014	Interestingly, the preincubation with propranolol, an inhibitor of the pathway of PLD-1, a known interactor of PED/PEA-15, responsible for its deleterious effects on glucose tolerance, abolishes the antiapoptotic effects of PED/PEA-15 overexpression in Ins-1E beta-cells.	Propranolol	38-49	proliferation and apoptosis adaptor protein 15	Rattus norvegicus	115-121
25489735-11	2014	Interestingly, the preincubation with propranolol, an inhibitor of the pathway of PLD-1, a known interactor of PED/PEA-15, responsible for its deleterious effects on glucose tolerance, abolishes the antiapoptotic effects of PED/PEA-15 overexpression in Ins-1E beta-cells.	Propranolol	38-49	preimplantation embryo development	Mus musculus	224-227
25489735-11	2014	Interestingly, the preincubation with propranolol, an inhibitor of the pathway of PLD-1, a known interactor of PED/PEA-15, responsible for its deleterious effects on glucose tolerance, abolishes the antiapoptotic effects of PED/PEA-15 overexpression in Ins-1E beta-cells.	Propranolol	38-49	proliferation and apoptosis adaptor protein 15	Rattus norvegicus	228-234
25443743-8	2014	Propranolol dose-dependent effect was evident for IL-10 and Hsp70, and even only the high dose significantly increased and decreased TLR2 and survivin, respectively.	Propranolol	0-11	interleukin 10	Mus musculus	50-55
25294216-6	2014	Propranolol did not prevent muscle D2 induction, but it impaired the decrease of D2 in BAT and soleus after 10 days at 4 C. Cold exposure is accompanied by increased oxygen consumption, UCP3, and PGC-1alpha genes expression in skeletal muscles, which were partialy prevented by propranolol in soleus and gastrocnemius.	Propranolol	0-11	uncoupling protein 3	Rattus norvegicus	186-190
25294216-6	2014	Propranolol did not prevent muscle D2 induction, but it impaired the decrease of D2 in BAT and soleus after 10 days at 4 C. Cold exposure is accompanied by increased oxygen consumption, UCP3, and PGC-1alpha genes expression in skeletal muscles, which were partialy prevented by propranolol in soleus and gastrocnemius.	Propranolol	0-11	PPARG coactivator 1 alpha	Rattus norvegicus	196-206
25443743-8	2014	Propranolol dose-dependent effect was evident for IL-10 and Hsp70, and even only the high dose significantly increased and decreased TLR2 and survivin, respectively.	Propranolol	0-11	heat shock protein 1B	Mus musculus	60-65
25443743-8	2014	Propranolol dose-dependent effect was evident for IL-10 and Hsp70, and even only the high dose significantly increased and decreased TLR2 and survivin, respectively.	Propranolol	0-11	baculoviral IAP repeat-containing 5	Mus musculus	142-150
25150071-7	2014	Our results showed that the mice immunized with propranolol induced higher levels of antibody, IFN-gamma and TNF-alpha as well as stronger lymphocyte proliferative responses compared with other groups.	Propranolol	48-59	interferon gamma	Mus musculus	95-104
24810750-2	2014	We present the first case of laryngomalacia with simultaneous mammalian target of Rapamycin (mTOR)-positive KHE of the neck and thoracic inlet and concurrent Kasabach-Meritt Phenomenon (KMP) in an 11-month-old boy suffering life-threatening progress despite intravenous vincristine, corticosteroids, propranolol and local interstitial laser-application.	Propranolol	300-311	mechanistic target of rapamycin kinase	Homo sapiens	93-97
25026350-1	2014	CONTEXT: Propranolol, atenolol, and ICI118,551 are non-selective beta-adrenergic receptor (AR), beta1-AR, and beta2-AR antagonists, respectively.	Propranolol	9-20	adrenoceptor beta 1	Homo sapiens	96-104
25026350-1	2014	CONTEXT: Propranolol, atenolol, and ICI118,551 are non-selective beta-adrenergic receptor (AR), beta1-AR, and beta2-AR antagonists, respectively.	Propranolol	9-20	adrenoceptor beta 2	Homo sapiens	110-118
25323788-5	2014	The inflammatory-related cytokines interleukin (IL)-1beta, IL-6 and IL-8 were detected after pretreatment with the alpha1/beta2-AR blockers phentolamine/propranolol, both in vitro and in vivo.	Propranolol	153-164	interleukin 1 beta	Homo sapiens	35-57
25323788-5	2014	The inflammatory-related cytokines interleukin (IL)-1beta, IL-6 and IL-8 were detected after pretreatment with the alpha1/beta2-AR blockers phentolamine/propranolol, both in vitro and in vivo.	Propranolol	153-164	adrenoceptor beta 2	Homo sapiens	115-130
25033380-10	2014	The reduced tooth movement observed in the animals treated with 0.1mg/kg of propranolol (G3) occurred due to decreased amounts of IL-1beta and IL-6, in addition to lower ICAM-1 and RANKL expression.	Propranolol	76-87	interleukin 1 beta	Rattus norvegicus	130-138
25033380-10	2014	The reduced tooth movement observed in the animals treated with 0.1mg/kg of propranolol (G3) occurred due to decreased amounts of IL-1beta and IL-6, in addition to lower ICAM-1 and RANKL expression.	Propranolol	76-87	interleukin 6	Rattus norvegicus	143-147
25033380-10	2014	The reduced tooth movement observed in the animals treated with 0.1mg/kg of propranolol (G3) occurred due to decreased amounts of IL-1beta and IL-6, in addition to lower ICAM-1 and RANKL expression.	Propranolol	76-87	intercellular adhesion molecule 1	Rattus norvegicus	170-176
25033380-10	2014	The reduced tooth movement observed in the animals treated with 0.1mg/kg of propranolol (G3) occurred due to decreased amounts of IL-1beta and IL-6, in addition to lower ICAM-1 and RANKL expression.	Propranolol	76-87	TNF superfamily member 11	Rattus norvegicus	181-186
25490818-0	2014	[Expression of serum and urinary vascular endothelial growth factor-A and epidermal growth factor-like domain 7 in proliferating hemangioma treated with propranolol].	Propranolol	153-164	vascular endothelial growth factor A	Homo sapiens	33-69
25490818-0	2014	[Expression of serum and urinary vascular endothelial growth factor-A and epidermal growth factor-like domain 7 in proliferating hemangioma treated with propranolol].	Propranolol	153-164	EGF like domain multiple 7	Homo sapiens	74-111
25490818-1	2014	OBJECTIVE: This study aims to investigate the expression levels of serum and urinary vascular endothelial growth factor-A (VEGF-A) and epidermal growth factor-like domain 7 (EGFL7) in proliferating infantile hemangioma patients under propranolol treatment.	Propranolol	234-245	vascular endothelial growth factor A	Homo sapiens	85-121
25490818-1	2014	OBJECTIVE: This study aims to investigate the expression levels of serum and urinary vascular endothelial growth factor-A (VEGF-A) and epidermal growth factor-like domain 7 (EGFL7) in proliferating infantile hemangioma patients under propranolol treatment.	Propranolol	234-245	vascular endothelial growth factor A	Homo sapiens	123-129
25490818-1	2014	OBJECTIVE: This study aims to investigate the expression levels of serum and urinary vascular endothelial growth factor-A (VEGF-A) and epidermal growth factor-like domain 7 (EGFL7) in proliferating infantile hemangioma patients under propranolol treatment.	Propranolol	234-245	EGF like domain multiple 7	Homo sapiens	174-179
25300058-10	2014	There were also significant reductions in VEGF immunoreactivity scores and both stroma and epithelium MMP-2 and MMP-9 immunoreactivity scores in the propranolol-treated group compared with the control group (p&lt;0.005 for all scores).	Propranolol	149-160	vascular endothelial growth factor A	Rattus norvegicus	42-46
25300058-10	2014	There were also significant reductions in VEGF immunoreactivity scores and both stroma and epithelium MMP-2 and MMP-9 immunoreactivity scores in the propranolol-treated group compared with the control group (p&lt;0.005 for all scores).	Propranolol	149-160	matrix metallopeptidase 2	Rattus norvegicus	102-107
25300058-10	2014	There were also significant reductions in VEGF immunoreactivity scores and both stroma and epithelium MMP-2 and MMP-9 immunoreactivity scores in the propranolol-treated group compared with the control group (p&lt;0.005 for all scores).	Propranolol	149-160	matrix metallopeptidase 9	Rattus norvegicus	112-117
25300058-11	2014	CONCLUSIONS: Propranolol may suppress endometrial tissue by its antiangiogenic activity through inhibitory actions on VEGF, MMP-2, and MMP-9.	Propranolol	13-24	vascular endothelial growth factor A	Rattus norvegicus	118-122
25300058-11	2014	CONCLUSIONS: Propranolol may suppress endometrial tissue by its antiangiogenic activity through inhibitory actions on VEGF, MMP-2, and MMP-9.	Propranolol	13-24	matrix metallopeptidase 2	Rattus norvegicus	124-129
25300058-11	2014	CONCLUSIONS: Propranolol may suppress endometrial tissue by its antiangiogenic activity through inhibitory actions on VEGF, MMP-2, and MMP-9.	Propranolol	13-24	matrix metallopeptidase 9	Rattus norvegicus	135-140
25150071-7	2014	Our results showed that the mice immunized with propranolol induced higher levels of antibody, IFN-gamma and TNF-alpha as well as stronger lymphocyte proliferative responses compared with other groups.	Propranolol	48-59	tumor necrosis factor	Mus musculus	109-118
24886880-7	2014	Moreover, the leftward shift of the noradrenaline curves promoted by uptake blockers (cocaine and corticosterone) and beta-adrenoceptor antagonist (propranolol) was reduced in the vas deferens of treated group.	Propranolol	148-159	arginine vasopressin	Rattus norvegicus	180-183
25069723-5	2014	beta-Adrenoceptor blockade with propranolol or inhibition of its downstream cAMP/PKA signaling attenuated, while beta-adrenoceptor agonists and cAMP/PKA activators enhanced, the oxidant-mediated PARP1 activation.	Propranolol	32-43	poly(ADP-ribose) polymerase 1	Homo sapiens	195-200
25069723-8	2014	Propranolol also suppressed PARP1 activation in peripheral blood leukocytes during bacterial lipopolysaccharide (LPS)-induced systemic inflammation in mice.	Propranolol	0-11	poly (ADP-ribose) polymerase family, member 1	Mus musculus	28-33
25158819-6	2014	The perivascular CD90 mesenchymal stem cell population was preserved in both propranolol treated patients.Using rarely obtained biopsies from IH patients treated with propranolol, we show increased apoptosis by propranolol for the first time in vivo.	Propranolol	77-88	Thy-1 cell surface antigen	Homo sapiens	17-21
25115372-14	2014	Consistent with accelerated adipogenesis, propranolol significantly increased the expression of the proadipogenic genes, PPARgamma, C/EBPbeta, and C/EBPgamma compared to control.	Propranolol	42-53	peroxisome proliferator activated receptor gamma	Homo sapiens	121-130
25115372-14	2014	Consistent with accelerated adipogenesis, propranolol significantly increased the expression of the proadipogenic genes, PPARgamma, C/EBPbeta, and C/EBPgamma compared to control.	Propranolol	42-53	CCAAT enhancer binding protein beta	Homo sapiens	132-141
25115372-11	2014	During adipogenesis, transcript levels of PPARdelta, PPARgamma, C/EBPbeta, and C/EBPdelta were significantly increased (P&lt;0.01) in propranolol-treated cells relative to control cells.	Propranolol	134-145	peroxisome proliferator activated receptor delta	Homo sapiens	42-51
25115372-11	2014	During adipogenesis, transcript levels of PPARdelta, PPARgamma, C/EBPbeta, and C/EBPdelta were significantly increased (P&lt;0.01) in propranolol-treated cells relative to control cells.	Propranolol	134-145	peroxisome proliferator activated receptor gamma	Homo sapiens	53-62
25115372-14	2014	Consistent with accelerated adipogenesis, propranolol significantly increased the expression of the proadipogenic genes, PPARgamma, C/EBPbeta, and C/EBPgamma compared to control.	Propranolol	42-53	CCAAT enhancer binding protein gamma	Homo sapiens	147-157
25115372-11	2014	During adipogenesis, transcript levels of PPARdelta, PPARgamma, C/EBPbeta, and C/EBPdelta were significantly increased (P&lt;0.01) in propranolol-treated cells relative to control cells.	Propranolol	134-145	CCAAT enhancer binding protein beta	Homo sapiens	64-73
25115372-11	2014	During adipogenesis, transcript levels of PPARdelta, PPARgamma, C/EBPbeta, and C/EBPdelta were significantly increased (P&lt;0.01) in propranolol-treated cells relative to control cells.	Propranolol	134-145	CCAAT enhancer binding protein delta	Homo sapiens	79-89
25115372-15	2014	However, propranolol treatment also led to improper induction of PPARdelta and suppression of C/EBPalpha, RXRalpha, and RXRgamma.	Propranolol	9-20	peroxisome proliferator activated receptor delta	Homo sapiens	65-74
25115372-12	2014	In contrast, RXRalpha and RXRgamma levels were significantly decreased (P&lt;0.05), and C/EBPalpha, a gene required for terminal adipocyte differentiation, was strongly suppressed by propranolol when compared to vehicle-treated cells (P&lt;0.01).	Propranolol	183-194	retinoid X receptor alpha	Homo sapiens	13-21
25115372-15	2014	However, propranolol treatment also led to improper induction of PPARdelta and suppression of C/EBPalpha, RXRalpha, and RXRgamma.	Propranolol	9-20	CCAAT enhancer binding protein alpha	Homo sapiens	94-104
25115372-12	2014	In contrast, RXRalpha and RXRgamma levels were significantly decreased (P&lt;0.05), and C/EBPalpha, a gene required for terminal adipocyte differentiation, was strongly suppressed by propranolol when compared to vehicle-treated cells (P&lt;0.01).	Propranolol	183-194	CCAAT enhancer binding protein alpha	Homo sapiens	88-98
25115372-15	2014	However, propranolol treatment also led to improper induction of PPARdelta and suppression of C/EBPalpha, RXRalpha, and RXRgamma.	Propranolol	9-20	retinoid X receptor alpha	Homo sapiens	106-114
24393528-0	2014	Propranolol, a beta-adrenergic antagonist, attenuates the decrease in trabecular bone mass in high calorie diet fed growing mice.	Propranolol	0-11	amyloid beta (A4) precursor protein	Mus musculus	13-19
24621648-5	2014	On the contrary, treatment with propranolol, a beta-AR antagonist, caused an approximately 70% increase in VEGF-mediated microvessel sprouting.	Propranolol	32-43	adrenergic receptor, beta 1	Mus musculus	47-54
24837395-8	2014	Moreover, propranolol treatment was associated (albeit not significantly) with restoring beta2 -adrenoceptor expression in airway epithelia.	Propranolol	10-21	adrenoceptor beta 2	Rattus norvegicus	89-108
24837395-9	2014	Propranolol had a more beneficial effect on cigarette smoking-induced lung damage than metoprolol in a smoking rat model that may be associated with restoration of endogenous beta2 -adrenoceptor density in the airway epithelial cells.	Propranolol	0-11	adrenoceptor beta 2	Rattus norvegicus	175-194
24845846-6	2014	A slight increase in GPx and GR activities and GSH level was observed with propranolol and furosemide treatment alone, while the two drugs together caused a significant increase in GPx and GR activities (35% and 42%, respectively) and GSH content (35%) in ACHN cell lysates (p &lt; 0.05).	Propranolol	75-86	glutathione-disulfide reductase	Homo sapiens	29-31
24845846-6	2014	A slight increase in GPx and GR activities and GSH level was observed with propranolol and furosemide treatment alone, while the two drugs together caused a significant increase in GPx and GR activities (35% and 42%, respectively) and GSH content (35%) in ACHN cell lysates (p &lt; 0.05).	Propranolol	75-86	glutathione-disulfide reductase	Homo sapiens	189-191
25071172-7	2014	Central PREP regulation of insulin and glucagon secretion appears to be mediated by the autonomic nervous system because Prep(gt/gt) mice have elevated sympathetic outflow and norepinephrine levels in the pancreas, and propranolol treatment reversed glucose intolerance in these mice.	Propranolol	219-230	prolyl endopeptidase	Mus musculus	8-12
24816257-7	2014	With propranolol, heart rate (8 +- 1 vs. 14 +- 3 beats/min) and RPP responses to Cold + Grip were significantly attenuated.	Propranolol	5-16	glutamate receptor interacting protein 1	Homo sapiens	88-92
24933041-5	2014	In particular, the beta2-AR seems to be the mostly involved in these responses, and the beta1-/beta2-AR blocker propranolol results highly effective in inhibiting both the increase of VEGF expression caused by a hypoxic insult and the consequent neovascular response.	Propranolol	112-123	adrenoceptor beta 2	Homo sapiens	95-103
24933041-5	2014	In particular, the beta2-AR seems to be the mostly involved in these responses, and the beta1-/beta2-AR blocker propranolol results highly effective in inhibiting both the increase of VEGF expression caused by a hypoxic insult and the consequent neovascular response.	Propranolol	112-123	vascular endothelial growth factor A	Homo sapiens	184-188
24837703-11	2014	Consistently, in the presence of propranolol (10(-6)M), a beta-AR blocker, the arterenol (10(-8)M) effects on thymocytes were augmented.	Propranolol	33-44	adrenoceptor beta 2	Homo sapiens	63-65
24621648-5	2014	On the contrary, treatment with propranolol, a beta-AR antagonist, caused an approximately 70% increase in VEGF-mediated microvessel sprouting.	Propranolol	32-43	vascular endothelial growth factor A	Mus musculus	107-111
24905583-4	2014	NCI-H292 epithelial cell line was used to determine the contribution of beta2-AR signaling to CSE-induced MUC5AC production by treatment with beta2-AR antagonists propranolol and ICI118551 and beta2-AR-targeted small interfering RNA.	Propranolol	163-174	adrenoceptor beta 2	Homo sapiens	72-80
24874709-8	2014	Our results show that orexin A decreases significantly the time spent in the arms (open/open+closed) and this action is reversed by bicuculline, phenoxybenzamine and propranolol, but not by atropine, haloperidol or nitro-l-arginine.	Propranolol	166-177	hypocretin	Mus musculus	22-30
25120757-9	2014	Propranolol at 100-150 muM inhibited proliferation of hemSCs, not did 50 muM.	Propranolol	0-11	latexin	Homo sapiens	23-26
25120757-10	2014	Propranolol down-regulated VEGF expression of hemSCs, instead of inducing apoptosis.	Propranolol	0-11	vascular endothelial growth factor A	Homo sapiens	27-31
25120757-12	2014	Therefore, our current results suggested propranolol could not induce apoptosis of hemSCs, but played a curative role though suppressing VEGF synthesis and enhancement of adipogenesis of hemSCs.	Propranolol	41-52	vascular endothelial growth factor A	Homo sapiens	137-141
24977755-15	2014	The use of propranolol blunts early tachycardia, reduces HPC mobilization, and results in a faster return to baseline of the G-CSF peak seen after injury.	Propranolol	11-22	colony stimulating factor 3	Homo sapiens	125-130
24553734-3	2014	Intra-CA1 infusion of NE during the late phase (12 h) after extinction selectively promoted extinction LTM at 14 days after extinction that was blocked by the beta-receptor antagonist propranolol, protein kinase A (PKA) inhibitor Rp-cAMPS, and protein synthesis inhibitors anisomycin and emetine.	Propranolol	184-195	carbonic anhydrase 1	Homo sapiens	6-9
24905583-10	2014	In vivo, we found that administration of propranolol (25 mg kg(-1) d(-1)) for 28 days significantly attenuated the airway goblet cell metaplasia, mucus hypersecretion and MUC5AC expression of rats exposed to CS.	Propranolol	41-52	mucin 5AC, oligomeric mucus/gel-forming	Rattus norvegicus	171-177
24905583-4	2014	NCI-H292 epithelial cell line was used to determine the contribution of beta2-AR signaling to CSE-induced MUC5AC production by treatment with beta2-AR antagonists propranolol and ICI118551 and beta2-AR-targeted small interfering RNA.	Propranolol	163-174	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	106-112
24905583-12	2014	Chronic propranolol administration ameliorated airway mucus hypersecretion and MUC5AC expression in smoking rats.	Propranolol	8-19	mucin 5AC, oligomeric mucus/gel-forming	Rattus norvegicus	79-85
24905583-4	2014	NCI-H292 epithelial cell line was used to determine the contribution of beta2-AR signaling to CSE-induced MUC5AC production by treatment with beta2-AR antagonists propranolol and ICI118551 and beta2-AR-targeted small interfering RNA.	Propranolol	163-174	adrenoceptor beta 2	Homo sapiens	142-150
24905583-4	2014	NCI-H292 epithelial cell line was used to determine the contribution of beta2-AR signaling to CSE-induced MUC5AC production by treatment with beta2-AR antagonists propranolol and ICI118551 and beta2-AR-targeted small interfering RNA.	Propranolol	163-174	adrenoceptor beta 2	Homo sapiens	142-150
24905583-8	2014	We found that pretreating NCI-H292 cells with propranolol, ICI118551 for 30 min or beta2AR-targeted siRNA for 48 h reduced MUC5AC mRNA and protein levels stimulated by CSE.	Propranolol	46-57	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	123-129
24582917-8	2014	Conversely, administration of beta-adrenergic receptor antagonist propranolol reduced fear conditioning training-induced c-Fos protein expression in BLA neurons and reduced conditioned fear responses in susceptible mice.	Propranolol	66-77	FBJ osteosarcoma oncogene	Mus musculus	121-126
24155262-7	2014	Moreover, injection of 2,3-dichloro-a-methylbenzylamine, a PNMT enzyme inhibitor, (10 mg/kg) before corticosterone treatment caused a leftward shift in the dose-response curve for corticosterone and injection of propranolol (5 mg/kg), but not phentolamine, also shifted the dose-response curve to the left during the late phase.	Propranolol	212-223	phenylethanolamine-N-methyltransferase	Mus musculus	59-63
24560961-6	2014	Neutrophil number and neutrophil elastase protein expression were increased in propranolol-treated group when compared with control group.	Propranolol	79-90	elastase, neutrophil expressed	Mus musculus	22-41
24768830-3	2014	These effects were reversed by propranolol, which by itself increased p-ERK1/2 in ECs.	Propranolol	31-42	mitogen activated protein kinase 3	Rattus norvegicus	72-78
24553185-5	2014	Norepinephrine (NE) reduced the nAChR currents, an effect partially mimicked by a beta-adrenergic receptor agonist, isoproterenol, and blocked by a beta-adrenergic receptor antagonist, propranolol.	Propranolol	185-196	cholinergic receptor nicotinic beta 1 subunit	Rattus norvegicus	32-37
24560961-7	2014	Propranolol administration delayed macrophage mobilization and metalloproteinase-12 protein expression and reduced monocyte chemoattractant protein-1 protein expression.	Propranolol	0-11	chemokine (C-C motif) ligand 2	Mus musculus	115-149
24560961-9	2014	Propranolol administration increased neo-epidermis thickness, reduced collagen deposition, and enhanced tenascin-C expression resulting in the formation of an immature and disorganized collagenous scar.	Propranolol	0-11	tenascin C	Mus musculus	104-114
24119207-1	2014	Propranolol, the substrate of cytochrome P450 (CYP) 1A2 and CYP2D6, has been reported to be in high concentrations in end-stage renal disease (ESRD) patients.	Propranolol	0-11	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	30-55
23206241-10	2014	We prevented Cx43 inhibition using propranolol, and observed increased basal mRNA levels of beta-adrenergic receptors without significant changes in the ratio beta1 to beta2.	Propranolol	35-46	gap junction protein, alpha 1	Mus musculus	13-17
24119207-1	2014	Propranolol, the substrate of cytochrome P450 (CYP) 1A2 and CYP2D6, has been reported to be in high concentrations in end-stage renal disease (ESRD) patients.	Propranolol	0-11	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	60-66
24119207-10	2014	In conclusion, this study suggests that the increase of the bioavailability of propranolol in ESRD is partly induced by the inhibition of the hepatic metabolism of CYP1A2 by xanthine in the uremic serum.	Propranolol	79-90	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	164-170
24412598-7	2014	Interestingly, a high Ep-induced TLR5 expression was observed on the Caco2 cell surface, which was inhibited by an inhibitor of phosphoinositide3-kinase (PI3K), Ly294002, as well as a beta-adrenergic blocker, propranolol.	Propranolol	209-220	toll like receptor 5	Homo sapiens	33-37
24412598-8	2014	In addition, the EX-induced TNF-alpha production observed in response to FG was also attenuated by pretreatment with propranolol.	Propranolol	117-128	tumor necrosis factor	Mus musculus	28-37
24701069-1	2014	We present a case of a 32-year-old male doctor, with type I diabetes mellitus on daily insulin therapy, who allegedly consumed large doses of digoxin and propranolol along with simultaneous administration of large dose of insulin with suicidal intent.	Propranolol	154-165	insulin	Homo sapiens	87-94
24555849-6	2014	RESULTS: We found that NE upregulated the expression of VEGF, IL-8 and IL-6 in vitro and stimulated tumor growth in vivo, which was mediated by beta-AR/cAMP/PKA signaling pathway and could be inhibited by propranolol, a beta-blocker for hypertension for decades.	Propranolol	205-216	vascular endothelial growth factor A	Mus musculus	56-60
24504055-0	2014	Propranolol inhibits glucose metabolism and 18F-FDG uptake of breast cancer through posttranscriptional downregulation of hexokinase-2.	Propranolol	0-11	hexokinase 2	Mus musculus	122-134
24504055-12	2014	The protein expression and posttranscriptional level of HK-2 were significantly decreased by treatment with propranolol in vitro, whereas GLUT-1 expression was not significantly altered by pharmacologic intervention.	Propranolol	108-119	hexokinase 2	Mus musculus	56-60
24504055-15	2014	Immunohistochemical analysis and Western blotting revealed reduced HK-2 expression in the tumors of propranolol-treated mice.	Propranolol	100-111	hexokinase 2	Mus musculus	67-71
24256707-9	2014	Using propranolol (beta1 and beta2 antagonist) together with nebivolol we showed that the induction of these genes was still present suggesting again beta3AR activation.	Propranolol	6-17	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	19-24
24256707-9	2014	Using propranolol (beta1 and beta2 antagonist) together with nebivolol we showed that the induction of these genes was still present suggesting again beta3AR activation.	Propranolol	6-17	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	29-34
24256707-9	2014	Using propranolol (beta1 and beta2 antagonist) together with nebivolol we showed that the induction of these genes was still present suggesting again beta3AR activation.	Propranolol	6-17	adrenoceptor beta 3	Homo sapiens	150-157
24389287-0	2014	Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma.	Propranolol	63-74	adrenoceptor beta 1	Homo sapiens	32-51
24389287-3	2014	In a high-throughput screen of FDA-approved drugs we identified anti-NB activity for the nonselective beta-adrenergic receptor antagonist propranolol hydrochloride.	Propranolol	138-163	adrenoceptor beta 1	Homo sapiens	107-126
24211255-4	2014	The memory-enhancing effect of NPS could be blocked by the beta-adrenoceptor antagonist propranolol.	Propranolol	88-99	neuropeptide S	Mus musculus	31-34
23978104-7	2014	For propranolol, inflammation resulted in increased concentration but reduced response and down-regulation of beta1- AR.	Propranolol	4-15	adrenoceptor beta 1	Homo sapiens	110-119
24033364-5	2014	The potential mechanisms of VEGF/VEGFR-2-induced HaemEC survival were investigated, and the role of the autocrine VEGF/VEGFR-2 loop in preventing propranolol-induced apoptotic HaemEC death was also analysed.	Propranolol	146-157	kinase insert domain receptor	Homo sapiens	119-126
24033364-10	2014	Moreover, HaemECs acquired greater resistance to propranolol treatment than HUVECs, whereas inhibition of VEGF/VEGFR-2 signalling in HaemECs sensitized these cells to propranolol-induced apoptosis.	Propranolol	167-178	vascular endothelial growth factor A	Homo sapiens	106-110
24033364-10	2014	Moreover, HaemECs acquired greater resistance to propranolol treatment than HUVECs, whereas inhibition of VEGF/VEGFR-2 signalling in HaemECs sensitized these cells to propranolol-induced apoptosis.	Propranolol	167-178	kinase insert domain receptor	Homo sapiens	111-118
24695277-3	2014	Sequential metabolic reactions by Phase I and then Phase II enzymes were found in diclofenac [CYP2C9 and UDP-glucuronyltransferases (UGTs)], midazolam (CYP3A4 and UGTs) and propranolol (CYP1A2/2D6 and UGTs).	Propranolol	173-184	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	94-100
24695277-3	2014	Sequential metabolic reactions by Phase I and then Phase II enzymes were found in diclofenac [CYP2C9 and UDP-glucuronyltransferases (UGTs)], midazolam (CYP3A4 and UGTs) and propranolol (CYP1A2/2D6 and UGTs).	Propranolol	173-184	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	152-158
24695277-3	2014	Sequential metabolic reactions by Phase I and then Phase II enzymes were found in diclofenac [CYP2C9 and UDP-glucuronyltransferases (UGTs)], midazolam (CYP3A4 and UGTs) and propranolol (CYP1A2/2D6 and UGTs).	Propranolol	173-184	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	186-192
24211255-5	2014	Furthermore, post-training intra-BLA infusions of NPS (0.5nmol/side) improved 24-h memory for objects, which was impaired by co-administration of propranolol (0.5mug/side).	Propranolol	146-157	neuropeptide S	Mus musculus	50-53
24364277-0	2013	[Effect of propranolol on dialysate myoglobin levels evoked by ischemia/reperfusion].	Propranolol	11-22	myoglobin	Rattus norvegicus	36-45
24427325-0	2014	Propranolol inhibits angiogenesis via down-regulating the expression of vascular endothelial growth factor in hemangioma derived stem cell.	Propranolol	0-11	vascular endothelial growth factor A	Mus musculus	72-106
24554803-5	2013	RESULTS: Results gained shows that following the blockade of beta-2 adrenergic receptor with Propranolol (20 mg-aerosol), stimulation of alpha adrenergic receptor with Oxedrine (120 mg-aerosol) and blockage of these receptors with Tolazoline (20 mg-aerosol), does not change significantly the bronchomotor tonus of the tracheobronchial tree (p &gt; 0.1).	Propranolol	93-104	adrenoceptor beta 2	Homo sapiens	61-87
24157129-3	2013	Upon showing that prepubertal orchidectomy augmented the efficacy of thymopoiesis through increasing the thymocyte surface density of Thy-1, whose expression is negatively regulated by beta2-AR-mediated signaling, we examined the effects of orchidectomy and 14-day-long propranolol (PROP) treatment in orchidectomized (ORX) and sham-ORX rats on thymic norepinephrine (NE) concentration and metabolism and beta2-AR expression.	Propranolol	270-281	Thy-1 cell surface antigen	Rattus norvegicus	134-139
24157129-3	2013	Upon showing that prepubertal orchidectomy augmented the efficacy of thymopoiesis through increasing the thymocyte surface density of Thy-1, whose expression is negatively regulated by beta2-AR-mediated signaling, we examined the effects of orchidectomy and 14-day-long propranolol (PROP) treatment in orchidectomized (ORX) and sham-ORX rats on thymic norepinephrine (NE) concentration and metabolism and beta2-AR expression.	Propranolol	283-287	Thy-1 cell surface antigen	Rattus norvegicus	134-139
24314187-8	2013	Furthermore, vascular endothelial growth factor (VEGF), metalloproteinase-2 (MMP-2), and metalloproteinase-9 (MMP-9) levels were significantly lower in the groups with propranolol treated dosage of 5 and 10 mg kg(-1)day(-1) than in the control group.	Propranolol	168-179	vascular endothelial growth factor A	Mus musculus	13-47
24314187-8	2013	Furthermore, vascular endothelial growth factor (VEGF), metalloproteinase-2 (MMP-2), and metalloproteinase-9 (MMP-9) levels were significantly lower in the groups with propranolol treated dosage of 5 and 10 mg kg(-1)day(-1) than in the control group.	Propranolol	168-179	vascular endothelial growth factor A	Mus musculus	49-53
24314187-8	2013	Furthermore, vascular endothelial growth factor (VEGF), metalloproteinase-2 (MMP-2), and metalloproteinase-9 (MMP-9) levels were significantly lower in the groups with propranolol treated dosage of 5 and 10 mg kg(-1)day(-1) than in the control group.	Propranolol	168-179	matrix metallopeptidase 2	Mus musculus	77-82
24314187-8	2013	Furthermore, vascular endothelial growth factor (VEGF), metalloproteinase-2 (MMP-2), and metalloproteinase-9 (MMP-9) levels were significantly lower in the groups with propranolol treated dosage of 5 and 10 mg kg(-1)day(-1) than in the control group.	Propranolol	168-179	matrix metallopeptidase 9	Mus musculus	110-115
23768694-7	2013	Changes in markers of synaptic pathology, as shown by decreases in phosphorylation of Akt and in the expression of BDNF in Tg2676 mice, were also counteracted by propranolol treatment.	Propranolol	162-173	thymoma viral proto-oncogene 1	Mus musculus	86-89
23768694-7	2013	Changes in markers of synaptic pathology, as shown by decreases in phosphorylation of Akt and in the expression of BDNF in Tg2676 mice, were also counteracted by propranolol treatment.	Propranolol	162-173	brain derived neurotrophic factor	Mus musculus	115-119
23768694-8	2013	Tau hyperphosphorylation shown by Tg2576 mice was also decreased in the hippocampus of propranolol-treated mice, an effect probably related to an increase of GSK3beta phosphorylation (inactive form) and a decreased JNK1 expression.	Propranolol	87-98	glycogen synthase kinase 3 alpha	Mus musculus	158-166
23768694-8	2013	Tau hyperphosphorylation shown by Tg2576 mice was also decreased in the hippocampus of propranolol-treated mice, an effect probably related to an increase of GSK3beta phosphorylation (inactive form) and a decreased JNK1 expression.	Propranolol	87-98	mitogen-activated protein kinase 8	Mus musculus	215-219
24364277-10	2013	Reperfusion-induced increase in myoglobin level was suppressed by administration of propranolol immediately before reperfusion.	Propranolol	84-95	myoglobin	Rattus norvegicus	32-41
24009211-1	2013	Propranolol, a beta 1 (ADBR1) and beta 2 (ADBR2) adrenergic receptor blocker, accelerates regression of proliferating infantile hemangiomas (IH-P) while not affecting non-involuting congenital hemangiomas (NICH) and nonproliferating IH (IH-NP).	Propranolol	0-11	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	34-40
23735844-7	2013	Moreover, these cardiovascular responses were blocked by intravenous pretreatment with: the ganglionic blocker mecamylamine (2mg/Kg); the nonselective beta-adrenergic receptor antagonist propranolol (2mg/Kg); the beta1-adrenergic receptor selective antagonist atenolol (1mg/kg).	Propranolol	187-198	adrenoceptor beta 1	Rattus norvegicus	213-238
24499577-6	2013	After 30 min of sympathetic stimulation, SGLT1 increased in the luminal membrane of ductal cells, and that was blocked by previous injection of propranolol.	Propranolol	144-155	solute carrier family 5 member 1	Rattus norvegicus	41-46
24135743-0	2013	Propranolol-mediated attenuation of MMP-9 excretion in infants with hemangiomas.	Propranolol	0-11	matrix metallopeptidase 9	Homo sapiens	36-41
23291092-0	2013	Propranolol given orally for proliferating infantile haemangiomas: analysis of efficacy and serological changes in vascular endothelial growth factor and endothelial nitric oxide synthase in 35 patients.	Propranolol	0-11	vascular endothelial growth factor A	Homo sapiens	115-149
23291092-0	2013	Propranolol given orally for proliferating infantile haemangiomas: analysis of efficacy and serological changes in vascular endothelial growth factor and endothelial nitric oxide synthase in 35 patients.	Propranolol	0-11	nitric oxide synthase 3	Homo sapiens	154-187
24214595-5	2013	Adding of beta2AR antagonist propranolol to the Jurkat cells pre-incubated with isoproterenol didn"t change expression of IL-2.	Propranolol	29-40	adrenoceptor beta 2	Homo sapiens	10-17
24214595-6	2013	beta2AR antagonist propranolol induced slight increase of IL-2 expression in PHA-stimulated Jurkat cells pre-incubated with isoproterenol.	Propranolol	19-30	adrenoceptor beta 2	Homo sapiens	0-7
24214595-6	2013	beta2AR antagonist propranolol induced slight increase of IL-2 expression in PHA-stimulated Jurkat cells pre-incubated with isoproterenol.	Propranolol	19-30	interleukin 2	Homo sapiens	58-62
24214595-10	2013	Propranolol prevented increase of IL-10 expression in the PHA-stimulated Jurkat cells pre-incubated with beta2AR agonist.	Propranolol	0-11	interleukin 10	Homo sapiens	34-39
24214595-10	2013	Propranolol prevented increase of IL-10 expression in the PHA-stimulated Jurkat cells pre-incubated with beta2AR agonist.	Propranolol	0-11	adrenoceptor beta 2	Homo sapiens	105-112
23929318-0	2013	Propranolol for infantile hemangioma (PINCH): an open-label trial to assess the efficacy of propranolol for treating infantile hemangiomas and for determining the decline in heart rate to predict response to propranolol.	Propranolol	0-11	LIM zinc finger domain containing 1	Homo sapiens	38-43
24135743-15	2013	Patients treated with propranolol demonstrated attenuation of excreted matrix metalloproteinase 9 (MMP-9) in urine over the proliferative phase of the condition compared with prednisolone-treated patients.	Propranolol	22-33	matrix metallopeptidase 9	Homo sapiens	71-97
24135743-15	2013	Patients treated with propranolol demonstrated attenuation of excreted matrix metalloproteinase 9 (MMP-9) in urine over the proliferative phase of the condition compared with prednisolone-treated patients.	Propranolol	22-33	matrix metallopeptidase 9	Homo sapiens	99-104
24135743-16	2013	These findings were validated with Western blot analysis and quantified with ELISA, which confirmed mean urinary MMP-9 levels in the first year of life to be significantly lower in propranolol-treated patients with IH compared with prednisolone-treated patients with IH (0.118 vs 0.501 ng/mL; P = .03) or with nontreated patients with IH (0.118 vs 3.69 ng/mL; P = .02).	Propranolol	181-192	matrix metallopeptidase 9	Homo sapiens	113-118
24135743-17	2013	CONCLUSIONS AND RELEVANCE: Propranolol treatment decreases urinary excretion of MMP-9 in patients with IH.	Propranolol	27-38	matrix metallopeptidase 9	Homo sapiens	80-85
24135743-18	2013	Matrix metalloproteinase 9 may be a biomarker for IH propranolol responsiveness, and its signaling pathways may represent the molecular target of this drug.	Propranolol	53-64	matrix metallopeptidase 9	Homo sapiens	0-26
23287855-4	2013	In vitro analysis suggested that the purified CYP102A5 metabolizes typical substrates of human CYP2C9, CYP2D6, CYP2E1, and CYP3A4, such as coumarin, propranolol, aniline, chlorzoxazone, p-nitrophenol, and nifedipine.	Propranolol	149-160	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	95-101
23892031-12	2013	Propranolol and atropine fully blocked the NmU-induced anxiolytic action, while haloperidol, phenoxybenzamine and nitro-l-arginine were ineffective.	Propranolol	0-11	neuromedin U	Mus musculus	43-46
24019886-6	2013	The effects of NE/EPI/NPY and adrenoceptor antagonists prazosin (PRZ)/propranolol (PRL) on hHSC fibrogenic functions and the involved kinases and interleukin pathways were examined.	Propranolol	70-81	fucosyltransferase 1 (H blood group)	Homo sapiens	91-95
23287855-4	2013	In vitro analysis suggested that the purified CYP102A5 metabolizes typical substrates of human CYP2C9, CYP2D6, CYP2E1, and CYP3A4, such as coumarin, propranolol, aniline, chlorzoxazone, p-nitrophenol, and nifedipine.	Propranolol	149-160	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	103-109
23287855-4	2013	In vitro analysis suggested that the purified CYP102A5 metabolizes typical substrates of human CYP2C9, CYP2D6, CYP2E1, and CYP3A4, such as coumarin, propranolol, aniline, chlorzoxazone, p-nitrophenol, and nifedipine.	Propranolol	149-160	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	111-117
23287855-4	2013	In vitro analysis suggested that the purified CYP102A5 metabolizes typical substrates of human CYP2C9, CYP2D6, CYP2E1, and CYP3A4, such as coumarin, propranolol, aniline, chlorzoxazone, p-nitrophenol, and nifedipine.	Propranolol	149-160	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	123-129
23752204-4	2013	Treatment with the beta-adrenergic receptor (beta-AR) antagonist propranolol during HFF completely prevented muscle-based DIT in Sln(-/-) mice; however, it had no effect in WT mice, resulting in greater differences in whole-body metabolic rate and diet-induced weight gain.	Propranolol	65-76	adrenergic receptor, beta 1	Mus musculus	19-43
23742798-7	2013	Haloperidol, propranolol, atropine, methysergide, and naloxone, blocked the Ucn 3-induced anxiolytic action, while phenoxybenzamine and bicuculline were ineffective.	Propranolol	13-24	urocortin 3	Mus musculus	76-81
23752204-4	2013	Treatment with the beta-adrenergic receptor (beta-AR) antagonist propranolol during HFF completely prevented muscle-based DIT in Sln(-/-) mice; however, it had no effect in WT mice, resulting in greater differences in whole-body metabolic rate and diet-induced weight gain.	Propranolol	65-76	sarcolipin	Mus musculus	129-132
23752204-4	2013	Treatment with the beta-adrenergic receptor (beta-AR) antagonist propranolol during HFF completely prevented muscle-based DIT in Sln(-/-) mice; however, it had no effect in WT mice, resulting in greater differences in whole-body metabolic rate and diet-induced weight gain.	Propranolol	65-76	adrenergic receptor, beta 1	Mus musculus	45-52
23909679-0	2013	Serum-level changes of vascular endothelial growth factor in children with infantile hemangioma after oral propranolol therapy.	Propranolol	107-118	vascular endothelial growth factor A	Homo sapiens	23-57
23601333-9	2013	Both adjunctive therapies were associated with greater decreases in TNF-alpha levels (in both peripheral and hepatic venous blood) that resulted from propranolol-only treatment.	Propranolol	150-161	tumor necrosis factor	Homo sapiens	68-77
23909679-2	2013	The aim of this study was to evaluate the change in serum vascular endothelial growth factor (VEGF) levels in patients with IH who underwent propranolol treatment.	Propranolol	141-152	vascular endothelial growth factor A	Homo sapiens	58-92
23909679-2	2013	The aim of this study was to evaluate the change in serum vascular endothelial growth factor (VEGF) levels in patients with IH who underwent propranolol treatment.	Propranolol	141-152	vascular endothelial growth factor A	Homo sapiens	94-98
23909679-8	2013	Serum VEGF levels were higher in patients with IH and fell after 1 month of oral propranolol treatment.	Propranolol	81-92	vascular endothelial growth factor A	Homo sapiens	6-10
23977191-10	2013	Nebivolol-mediated phosphorylation of ERK was sensitive to propranolol (non-selective beta-AR-blocker), AG1478 (EGFR inhibitor), indicating that the signaling emanates from beta-ARs and involves the EGFR.	Propranolol	59-70	mitogen-activated protein kinase 1	Mus musculus	38-41
23977191-10	2013	Nebivolol-mediated phosphorylation of ERK was sensitive to propranolol (non-selective beta-AR-blocker), AG1478 (EGFR inhibitor), indicating that the signaling emanates from beta-ARs and involves the EGFR.	Propranolol	59-70	adrenergic receptor, beta 1	Mus musculus	86-93
23977191-10	2013	Nebivolol-mediated phosphorylation of ERK was sensitive to propranolol (non-selective beta-AR-blocker), AG1478 (EGFR inhibitor), indicating that the signaling emanates from beta-ARs and involves the EGFR.	Propranolol	59-70	epidermal growth factor receptor	Mus musculus	199-203
23652597-4	2013	The beta-receptor blocker propranolol or PKA inhibitor Rp-cAMPS blocks the effects of isoproterenol on the nuclear influx of HDAC4-GFP, and Rp-cAMPS blocks the effects of Db cAMP.	Propranolol	26-37	histone deacetylase 4	Homo sapiens	125-130
24137229-5	2013	Annexin-V staining revealed that propranolol at 40, 50 and 60 mug/ml caused a concentration-dependent increase in the apoptosis of IHECs.	Propranolol	33-44	annexin A5	Homo sapiens	0-9
24137229-7	2013	Gene expression analyses revealed that propranolol treatment led to a marked increase in the expression of caspase-8, cytochrome c, apoptosis-inducing factor, caspase-3 and poly (ADP-ribose) polymerase 1, as well as a concomitant reduction in lamin B1 expression.	Propranolol	39-50	caspase 8	Homo sapiens	107-116
24137229-7	2013	Gene expression analyses revealed that propranolol treatment led to a marked increase in the expression of caspase-8, cytochrome c, apoptosis-inducing factor, caspase-3 and poly (ADP-ribose) polymerase 1, as well as a concomitant reduction in lamin B1 expression.	Propranolol	39-50	cytochrome c, somatic	Homo sapiens	118-130
24137229-7	2013	Gene expression analyses revealed that propranolol treatment led to a marked increase in the expression of caspase-8, cytochrome c, apoptosis-inducing factor, caspase-3 and poly (ADP-ribose) polymerase 1, as well as a concomitant reduction in lamin B1 expression.	Propranolol	39-50	caspase 3	Homo sapiens	159-203
24137229-7	2013	Gene expression analyses revealed that propranolol treatment led to a marked increase in the expression of caspase-8, cytochrome c, apoptosis-inducing factor, caspase-3 and poly (ADP-ribose) polymerase 1, as well as a concomitant reduction in lamin B1 expression.	Propranolol	39-50	lamin B1	Homo sapiens	243-251
24020447-0	2013	Early propranolol treatment induces lung heme-oxygenase-1, attenuates metabolic dysfunction, and improves survival following experimental sepsis.	Propranolol	6-17	heme oxygenase 1	Rattus norvegicus	41-57
24020447-11	2013	Finally, propranolol led to a significant increase in lung hemeoxygenase-1 expression, a key cellular protective heat shock protein (HSP) in the lung.	Propranolol	9-20	selenoprotein K	Rattus norvegicus	113-131
24020447-11	2013	Finally, propranolol led to a significant increase in lung hemeoxygenase-1 expression, a key cellular protective heat shock protein (HSP) in the lung.	Propranolol	9-20	selenoprotein K	Rattus norvegicus	133-136
23722687-7	2013	The experimental and control samples were both analyzed by MALDI-MS. Based on the relative intensity fading (IF) of the ligand to propranolol, the MS conditions were optimized and then used to study the binding of eight alkaloids and calmodulin.	Propranolol	130-141	calmodulin 1	Homo sapiens	234-244
23722687-10	2013	Compared with propranolol, the relative intensities of six free drugs (berbamine, tetrandrine, papaverine, reserpine, brucine and tetrahydropalmatine) clearly faded after the addition of calmodulin, indicating that they can bind with CaM.	Propranolol	14-25	calmodulin 1	Homo sapiens	187-197
23661402-0	2013	Stereoselective accumulation of propranolol enantiomers in K562 and K562/ADR cells.	Propranolol	32-43	aldo-keto reductase family 1 member B	Homo sapiens	73-76
23194475-5	2013	Increased levels of Abeta in the hippocampus of corticosterone-treated mice were counteracted by propranolol treatment, purportedly through an increased IDE expression.	Propranolol	97-108	insulin degrading enzyme	Mus musculus	153-156
23194475-9	2013	One of the main kinases involved in tau phosphorylation, glycogen synthase kinase 3beta (GSK3beta), which is inactivated by phosphorylation by pAkt, was found to be decreased after corticosterone and increased after propranolol treatment.	Propranolol	216-227	glycogen synthase kinase 3 beta	Mus musculus	57-87
23194475-9	2013	One of the main kinases involved in tau phosphorylation, glycogen synthase kinase 3beta (GSK3beta), which is inactivated by phosphorylation by pAkt, was found to be decreased after corticosterone and increased after propranolol treatment.	Propranolol	216-227	glycogen synthase kinase 3 beta	Mus musculus	89-97
24250662-0	2013	Propranolol Prevents Osteoporosis and up-regulates Leptin in Ovariectomized Rats.	Propranolol	0-11	leptin	Rattus norvegicus	51-57
24250662-6	2013	Propranolol could also up-regulate the level of peripheral leptin and the level of leptin receptor expression in ovariectomized rat hypothalamus.	Propranolol	0-11	leptin	Rattus norvegicus	59-65
24250662-6	2013	Propranolol could also up-regulate the level of peripheral leptin and the level of leptin receptor expression in ovariectomized rat hypothalamus.	Propranolol	0-11	leptin	Rattus norvegicus	83-89
24250662-7	2013	Our results indicate the effect of propranolol on ovariectomy-induced osteoporosis may be exerted, at least partly, through the regulation of leptin signaling and there may be an interaction between the SNS and leptin on the regulation of bone metabolism.	Propranolol	35-46	leptin	Rattus norvegicus	142-148
23661402-1	2013	The stereoselective uptake of propranolol enantiomers was investigated by using the K562 and K562 adriamycin-resistant cell line (K562/ADR) as a model.	Propranolol	30-41	aldo-keto reductase family 1 member B	Homo sapiens	135-138
23661402-2	2013	An enantioselective RP-HPLC method was applied to determine the accumulation of propranolol (PPL) stereoisomers in K562 and K562/ADR cells.	Propranolol	80-91	aldo-keto reductase family 1 member B	Homo sapiens	129-132
23661402-2	2013	An enantioselective RP-HPLC method was applied to determine the accumulation of propranolol (PPL) stereoisomers in K562 and K562/ADR cells.	Propranolol	93-96	aldo-keto reductase family 1 member B	Homo sapiens	129-132
23661402-3	2013	The concentration, time and temperature dependent studies showed that the accumulation of S-(-)-PPL was higher than R-(+)-PPL in K562 cells and uptake of R-(+)-PPL was significantly higher than that of S-(-)-PPL in K562/ADR cells.	Propranolol	90-99	aldo-keto reductase family 1 member B	Homo sapiens	220-223
23661402-3	2013	The concentration, time and temperature dependent studies showed that the accumulation of S-(-)-PPL was higher than R-(+)-PPL in K562 cells and uptake of R-(+)-PPL was significantly higher than that of S-(-)-PPL in K562/ADR cells.	Propranolol	154-163	aldo-keto reductase family 1 member B	Homo sapiens	220-223
23661402-4	2013	The results indicate the enantioselective accumulation of propranolol enantiomers in K562 and K562 / ADR cells.	Propranolol	58-69	aldo-keto reductase family 1 member B	Homo sapiens	101-104
23837045-7	2013	Propranolol and PKAI were able to eliminate this reduction in ANGPTL2 levels whereas phentolamine and LY294002 were not.	Propranolol	0-11	angiopoietin like 2	Homo sapiens	62-69
23528535-7	2013	Propranolol ophthalmic solutions reduced VEGF and IGF-1 up-regulation in response to hypoxia and drastically inhibited HIF-1alpha accumulation and STAT3 phosphorylation.	Propranolol	0-11	signal transducer and activator of transcription 3	Mus musculus	147-152
23528535-10	2013	These findings strengthen the hypothesis that beta-AR blockade can efficiently counteract OIR and suggest that topical eye application of propranolol can represent an alternative delivery route to systemic administration thus avoiding the risk of associated complications and side effects that could make this drug unsafe in the ROP treatment.	Propranolol	138-149	adrenergic receptor, beta 1	Mus musculus	46-53
23528535-2	2013	In this model, we have recently shown that subcutaneous (sc) administration of the non-selective beta-adrenergic receptor (beta-AR) blocker propranolol ameliorates angiogenic processes in the retina when its effects are evaluated at postnatal day (PD) 17.	Propranolol	140-151	adrenergic receptor, beta 1	Mus musculus	97-121
23528535-2	2013	In this model, we have recently shown that subcutaneous (sc) administration of the non-selective beta-adrenergic receptor (beta-AR) blocker propranolol ameliorates angiogenic processes in the retina when its effects are evaluated at postnatal day (PD) 17.	Propranolol	140-151	adrenergic receptor, beta 1	Mus musculus	123-130
23247798-0	2013	Telmisartan plus propranolol improves liver fibrosis and bile duct proliferation in the PSC-like Abcb4-/- mouse model.	Propranolol	17-28	ATP-binding cassette, sub-family B (MDR/TAP), member 4	Mus musculus	97-102
23528535-7	2013	Propranolol ophthalmic solutions reduced VEGF and IGF-1 up-regulation in response to hypoxia and drastically inhibited HIF-1alpha accumulation and STAT3 phosphorylation.	Propranolol	0-11	vascular endothelial growth factor A	Mus musculus	41-45
23528535-7	2013	Propranolol ophthalmic solutions reduced VEGF and IGF-1 up-regulation in response to hypoxia and drastically inhibited HIF-1alpha accumulation and STAT3 phosphorylation.	Propranolol	0-11	insulin-like growth factor 1	Mus musculus	50-55
23811546-3	2013	OBJECTIVES: To evaluate the effect of propranolol on efficacy of HSP-70 rich lysate vaccine in immunotherapy of fibrosarcoma.	Propranolol	38-49	heat shock protein 1B	Mus musculus	65-71
23811546-6	2013	RESULTS: A significant increase in the level of IFN-gamma in the mice vaccinated with WEHI-164 cells enriched with HSP-70 and co-treated with propranolol was observed compared to controls.	Propranolol	142-153	interferon gamma	Mus musculus	48-57
23151525-12	2013	In addition, the expression of CXCR4 was suppressed by propranolol most likely through the Akt and MAPK pathways.	Propranolol	55-66	C-X-C motif chemokine receptor 4	Homo sapiens	31-36
23151525-12	2013	In addition, the expression of CXCR4 was suppressed by propranolol most likely through the Akt and MAPK pathways.	Propranolol	55-66	AKT serine/threonine kinase 1	Homo sapiens	91-94
23151525-13	2013	CONCLUSIONS: Propranolol inhibits stromal-cell-derived factor 1alpha-induced endothelial progenitor cell homing by suppressing the expression of CXCR4 most likely through the Akt and MAPK pathways.	Propranolol	13-24	C-X-C motif chemokine receptor 4	Homo sapiens	145-150
23151525-13	2013	CONCLUSIONS: Propranolol inhibits stromal-cell-derived factor 1alpha-induced endothelial progenitor cell homing by suppressing the expression of CXCR4 most likely through the Akt and MAPK pathways.	Propranolol	13-24	AKT serine/threonine kinase 1	Homo sapiens	175-178
23416460-4	2013	In this study, we found that Eph induced Trx-1 expression, which was inhibited by propranolol (beta-adrenergic receptor inhibitor), but not by phenoxybenzamine (alpha-adrenergic receptor inhibitor) in rat pheochromocytoma PC12 cells.	Propranolol	82-93	thioredoxin 1	Rattus norvegicus	41-46
23247798-7	2013	CONCLUSIONS: Telmisartan plus propranolol reduces liver fibrosis and bile duct proliferation in the PSC-like Abcb4 (-/-) mouse model, even when started at late stages of fibrosis, and may thus represent a novel therapeutic option for cholestatic liver diseases such as PSC.	Propranolol	30-41	ATP-binding cassette, sub-family B (MDR/TAP), member 4	Mus musculus	109-114
23585898-5	2013	Treatment with the adrenoceptor (AR) antagonists phentolamine (PHE, alpha-AR antagonist) and propranolol (PRO, beta-AR antagonist) significantly inhibited the CRS-enhanced CRC cell growth in nude mice.	Propranolol	93-104	adrenergic receptor, beta 1	Mus musculus	111-118
23348107-9	2013	Phenoxybenzamine, yohimbine, propranolol, methysergide, cyproheptadine, atropine, bicuculline and nitro-l-arginine prevented the action of kisspeptin-13 on passive avoidance learning, but haloperidol and naloxone did not block the effects of kisspeptin-13.	Propranolol	29-40	KiSS-1 metastasis-suppressor	Mus musculus	139-149
23180813-7	2013	However, propranolol treatment, via beta2-adrenoceptor blockade, increased production of TNF-alpha by macrophages in both non-operated and adrenalectomized rats (showing dramatically enhanced TNF-alpha production due to a lack of circulating glucocorticoids) for the same value.	Propranolol	9-20	adrenoceptor beta 2	Rattus norvegicus	36-54
23433451-5	2013	Propranolol significantly reversed the inhibitory effect of 100 mum tramadol on KCl-induced myometrial contractility but not that of 300 mum tramadol.	Propranolol	0-11	latexin	Homo sapiens	64-67
23528058-0	2013	Propranolol induces apoptosis of human umbilical vein endothelial cells through downregulation of CD147.	Propranolol	0-11	basigin (Ok blood group)	Homo sapiens	98-103
23528058-5	2013	OBJECTIVES: To investigate the role of CD147 in propranolol-induced apoptosis in human umbilical vein endothelial cells (HUVECs).	Propranolol	48-59	basigin (Ok blood group)	Homo sapiens	39-44
23528058-11	2013	(iv) The level of phosphorylation of Bcl-2-associated death promoter (BAD) at Ser112 in HUVECs after propranolol treatment and/or CD147 shRNA transfection was detected by Western blotting.	Propranolol	101-112	BCL2 associated agonist of cell death	Homo sapiens	37-68
23528058-14	2013	Knocking down CD147 not only induced apoptosis but also exacerbated the apoptosis triggered by propranolol in HUVECs.	Propranolol	95-106	basigin (Ok blood group)	Homo sapiens	14-19
23528058-15	2013	Overexpression of CD147 can protect HUVECs from apoptosis and propranolol-induced apoptosis.	Propranolol	62-73	basigin (Ok blood group)	Homo sapiens	18-23
23528058-16	2013	Furthermore, knockdown of both propranolol and CD147 can downregulate Ser112 phosphorylation of BAD, indicating that propranolol and CD147 induce apoptosis in HUVECs through the same signalling transduction pathway.	Propranolol	31-42	basigin (Ok blood group)	Homo sapiens	133-138
23528058-16	2013	Furthermore, knockdown of both propranolol and CD147 can downregulate Ser112 phosphorylation of BAD, indicating that propranolol and CD147 induce apoptosis in HUVECs through the same signalling transduction pathway.	Propranolol	117-128	basigin (Ok blood group)	Homo sapiens	47-52
23528058-17	2013	CONCLUSIONS: Our studies demonstrate that propranolol-induced apoptosis may be mediated through the downregulation of CD147 in HUVECs.	Propranolol	42-53	basigin (Ok blood group)	Homo sapiens	118-123
23266935-8	2013	NA enhanced inhibition in MCs across a broad concentration range (0.1-30 muM) and its effects were completely abolished by a mixture of alpha1- and beta-AR antagonists (1 muM prazosin and 10 muM propranolol).	Propranolol	195-206	adrenoceptor alpha 1D	Homo sapiens	136-155
23370410-2	2013	Recently, propranolol, a nonselective beta1- and beta2-adrenoceptor inhibitor, was introduced into the therapy of severe proliferating IH with excellent results.	Propranolol	10-21	adrenoceptor beta 1	Homo sapiens	38-67
23104933-2	2013	The purpose of this study was to examine whether pyrolidine dithiocarbamate (PDTC), a nuclear factor-kappaB inhibitor and antioxidant, and the beta-adrenergic blocker propranolol would affect the PGC-1alpha-induced mitochondrial transcription factors, enzymes and proteins involved in energy metabolism and antioxidant defense in response to endurance training.	Propranolol	167-178	PPARG coactivator 1 alpha	Rattus norvegicus	196-206
23180813-7	2013	However, propranolol treatment, via beta2-adrenoceptor blockade, increased production of TNF-alpha by macrophages in both non-operated and adrenalectomized rats (showing dramatically enhanced TNF-alpha production due to a lack of circulating glucocorticoids) for the same value.	Propranolol	9-20	tumor necrosis factor	Rattus norvegicus	89-98
23180813-7	2013	However, propranolol treatment, via beta2-adrenoceptor blockade, increased production of TNF-alpha by macrophages in both non-operated and adrenalectomized rats (showing dramatically enhanced TNF-alpha production due to a lack of circulating glucocorticoids) for the same value.	Propranolol	9-20	tumor necrosis factor	Rattus norvegicus	192-201
23180813-8	2013	The expression of beta2-adrenoceptor was increased in peritoneal macrophages that were freshly isolated from non-operated, propranolol-treated and adrenalectomized rats (due to adrenal catecholamine deficiency).	Propranolol	123-134	adrenoceptor beta 2	Rattus norvegicus	18-36
23180813-10	2013	Given that propranolol increased the density of macrophage tyrosine hydroxylase expression only in non-operated rats and affected the mRNA expression of monoamine oxidase-A in neither non-operated nor adrenalectomized animals, a significant influence of propranolol on peritoneal exudate cell noradrenaline content was found only in non-operated rats.	Propranolol	11-22	monoamine oxidase A	Rattus norvegicus	153-172
23080133-4	2013	METHODS: Time-dependent antiproliferation and apoptotic effects of propranolol were subsequently determined by MTT cell proliferation assay, changes in caspase-3 activity, loss of mitochondrial membrane potential (MMP), and also the localization of phosphatidylserine in the plasma membrane.	Propranolol	67-78	caspase 3	Homo sapiens	152-161
23080133-7	2013	There were significant increases in caspase-3 activity, loss of MMP, and increases in apoptotic cell population in response to propranolol in U266 cells in a time- and dose-dependent manner.	Propranolol	127-138	caspase 3	Homo sapiens	36-45
23065569-4	2013	VEGF-C protein levels produced by oral malignant cell lines after stimulation with different norepinephrine concentrations or blocking with propranolol was statistically similar (p &gt; 0.05) to those of the control group (nonstimulated OSCC cell lines).	Propranolol	140-151	vascular endothelial growth factor C	Homo sapiens	0-6
22824191-7	2013	Tau hyperphosphorylation (PHF-1 epitope) shown by SAMP8 mice at this age was also decreased in the hippocampus of propranolol-treated mice, an effect probably related to a decrease in JNK1 expression.	Propranolol	114-125	PHD finger protein 1	Mus musculus	26-31
23287463-6	2013	Here, we show that chronic restraint stress in mice recapitulates the effects of isoproterenol infusion to reduce p53 levels and results in the accumulation of DNA damage in the frontal cortex of the brain, two effects that are abrogated by the beta-blocker, propranolol and by genetic deletion of beta-arrestin-1.	Propranolol	259-270	arrestin, beta 1	Mus musculus	298-313
25621308-8	2013	RESULTS: Propranolol at 5 and 10 mg/kg significantly reduced HPC mobilization, restored BM cellularity and BM HPC growth, and decreased plasma G-CSF levels.	Propranolol	9-20	colony stimulating factor 3	Rattus norvegicus	143-148
23017014-6	2013	Similarly, in rats undergoing sympathetic nerve block with propranolol, BDNF mRNA and protein were detected in the adrenal medulla during 60-min stress.	Propranolol	59-70	brain-derived neurotrophic factor	Rattus norvegicus	72-76
22824191-7	2013	Tau hyperphosphorylation (PHF-1 epitope) shown by SAMP8 mice at this age was also decreased in the hippocampus of propranolol-treated mice, an effect probably related to a decrease in JNK1 expression.	Propranolol	114-125	mitogen-activated protein kinase 8	Mus musculus	184-188
22824191-8	2013	Interestingly, propranolol also phosphorylated Akt in SAMP8 mice, which was associated with an increase of glycogen synthase kinase-3beta phosphorylation, contributing therefore to the reductions in Tau hyperphosphorylation.	Propranolol	15-26	thymoma viral proto-oncogene 1	Mus musculus	47-50
22824191-8	2013	Interestingly, propranolol also phosphorylated Akt in SAMP8 mice, which was associated with an increase of glycogen synthase kinase-3beta phosphorylation, contributing therefore to the reductions in Tau hyperphosphorylation.	Propranolol	15-26	glycogen synthase kinase 3 beta	Mus musculus	107-137
22824191-9	2013	Synaptic pathology in SAMP8 mice, as shown by decreases in synaptophysin and BDNF, was also counteracted by propranolol treatment.	Propranolol	108-119	synaptophysin	Mus musculus	59-72
22824191-9	2013	Synaptic pathology in SAMP8 mice, as shown by decreases in synaptophysin and BDNF, was also counteracted by propranolol treatment.	Propranolol	108-119	brain derived neurotrophic factor	Mus musculus	77-81
23745443-1	2013	INTRODUCTION: Propranolol (P) treatment exerts a preventive effect against the detrimental consequences to bone status in mildly chronically food-restricted growing rats (NGR) by an increment in cortical bone and by improving its spatial distribution.	Propranolol	14-25	reticulon 4 receptor	Rattus norvegicus	171-174
23341903-12	2013	In vitro studies showed that propranolol prevented the inhibitory effects of beta2-agonists on zolmitriptan-induced vasoconstriction and the combination of propranolol and zolmitriptan significantly reduced the elevation of cAMP caused by beta2-agonists.	Propranolol	29-40	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	77-82
23341903-12	2013	In vitro studies showed that propranolol prevented the inhibitory effects of beta2-agonists on zolmitriptan-induced vasoconstriction and the combination of propranolol and zolmitriptan significantly reduced the elevation of cAMP caused by beta2-agonists.	Propranolol	156-167	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	239-244
23257321-3	2013	Our study aimed to assess the effect of propranolol on pediatric LM and the relationship between its effectiveness and vascular endothelial growth factor (VEGF) family members (VEGF-A, C and D).	Propranolol	40-51	vascular endothelial growth factor A	Homo sapiens	155-159
23086294-0	2012	Rationalization of stereospecific binding of propranolol to cytochrome P450 2D6 by free energy calculations.	Propranolol	45-56	cytochrome P450 2D6	Homo sapiens	60-79
22796551-9	2012	Administration of propranolol (10mg/kg; non-selective beta-adrenergic receptor antagonist) was shown to block these "priming" effects at the 14h time-point.	Propranolol	18-29	adrenergic receptor, beta 1	Mus musculus	54-78
23026071-6	2012	Pretreatment with the selective beta(2)-adrenoceptor antagonist ICI 118,551 (10, 15, and 20 nmol/100 nL) significantly increased the restraint-evoked tachycardiac response after doses of 15 and 20 nmol, an effect that was similar to that observed after the pretreatment with propranolol at a dose of 15 nmol, without a significant effect on the BP response.	Propranolol	275-286	adrenoceptor beta 2	Rattus norvegicus	32-52
23217879-7	2012	We explored the potential mechanisms of propranolol-induced HemEC dysfunction using western blot analysis, a caspase assay kit, and real-time quantitative PCR.	Propranolol	40-51	caspase 9	Homo sapiens	109-116
23217879-10	2012	Vascular endothelial growth factor (VEGF) expression was down-regulated by propranolol in a dose-dependent manner.	Propranolol	75-86	vascular endothelial growth factor A	Homo sapiens	0-34
23217879-10	2012	Vascular endothelial growth factor (VEGF) expression was down-regulated by propranolol in a dose-dependent manner.	Propranolol	75-86	vascular endothelial growth factor A	Homo sapiens	36-40
23217879-11	2012	We also demonstrated activation of the caspase cascade, including caspase-9 and caspase-3 of the intrinsic pathway, and an increased p53 gene expression and Bax/Bcl-xL ratio in HemECs treated with 100 muM propranolol.	Propranolol	205-216	caspase 9	Homo sapiens	66-75
23217879-11	2012	We also demonstrated activation of the caspase cascade, including caspase-9 and caspase-3 of the intrinsic pathway, and an increased p53 gene expression and Bax/Bcl-xL ratio in HemECs treated with 100 muM propranolol.	Propranolol	205-216	caspase 3	Homo sapiens	80-89
23217879-11	2012	We also demonstrated activation of the caspase cascade, including caspase-9 and caspase-3 of the intrinsic pathway, and an increased p53 gene expression and Bax/Bcl-xL ratio in HemECs treated with 100 muM propranolol.	Propranolol	205-216	BCL2 like 1	Homo sapiens	161-167
23186269-10	2012	The beta2AR blocker propranolol abrogated the growth inhibitory effect of formoterol.	Propranolol	20-31	adrenoceptor beta 2	Homo sapiens	4-11
22933300-10	2012	The beta-adrenergic receptor antagonist propranolol or the PKA inhibitor H-89 completely blocked isoproterenol + IBMX-induced increase on surface NKCC2, while propranolol or H-89 alone had no effect.	Propranolol	40-51	solute carrier family 12 member 1	Rattus norvegicus	146-151
22743651-3	2012	In a prior report, we identified expression of beta2-AR (B2-AR) and its phosphorylated form (B2-ARP) in a case of infantile hemangioma that responded to propranolol treatment.	Propranolol	153-164	adrenoceptor beta 2	Homo sapiens	47-55
22743651-3	2012	In a prior report, we identified expression of beta2-AR (B2-AR) and its phosphorylated form (B2-ARP) in a case of infantile hemangioma that responded to propranolol treatment.	Propranolol	153-164	adrenoceptor beta 2	Homo sapiens	57-62
22750684-1	2012	The inclusion interaction between propranolol (PPL) and p-sulfonatocalix[6]arene (SCX6) was investigated by fluorescence and (1)H NMR spectroscopy.	Propranolol	34-45	periplakin	Homo sapiens	47-50
22889981-7	2012	4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone also stimulated a time-dependent increase in FAK and ERK activation that was suppressed by propranolol or apigenin.	Propranolol	138-149	protein tyrosine kinase 2	Homo sapiens	92-95
22889981-7	2012	4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone also stimulated a time-dependent increase in FAK and ERK activation that was suppressed by propranolol or apigenin.	Propranolol	138-149	mitogen-activated protein kinase 1	Homo sapiens	100-103
23096601-10	2012	RESULTS: Annexin V levels were increased in propranolol-treated endothelial cells but not in stem cells.	Propranolol	44-55	annexin A5	Homo sapiens	9-18
23096601-13	2012	Transcript levels of C/EBPbeta (p &lt; 0.05), RXRgamma (p &lt; 0.05), and PPARgamma (p &lt; 0.02) were significantly increased when treated with 50 or 100 muM propranolol; and C/EBPdelta (p &lt; 0.05), RXRalpha (p &lt; 0.05), and PPARdelta (p &lt; 0.01) transcripts were increased when treated with 100 muM propranolol.	Propranolol	159-170	CCAAT enhancer binding protein beta	Homo sapiens	21-30
23096601-13	2012	Transcript levels of C/EBPbeta (p &lt; 0.05), RXRgamma (p &lt; 0.05), and PPARgamma (p &lt; 0.02) were significantly increased when treated with 50 or 100 muM propranolol; and C/EBPdelta (p &lt; 0.05), RXRalpha (p &lt; 0.05), and PPARdelta (p &lt; 0.01) transcripts were increased when treated with 100 muM propranolol.	Propranolol	307-318	CCAAT enhancer binding protein beta	Homo sapiens	21-30
22841997-8	2012	In addition to anxiety-like behavior the SDR induced splenomegaly and increase in plasma IL-6, TNFalpha, and MCP-1 were each reversed by pre-treatment with propranolol.	Propranolol	156-167	interleukin 6	Mus musculus	89-93
22841997-8	2012	In addition to anxiety-like behavior the SDR induced splenomegaly and increase in plasma IL-6, TNFalpha, and MCP-1 were each reversed by pre-treatment with propranolol.	Propranolol	156-167	tumor necrosis factor	Mus musculus	95-103
22841997-8	2012	In addition to anxiety-like behavior the SDR induced splenomegaly and increase in plasma IL-6, TNFalpha, and MCP-1 were each reversed by pre-treatment with propranolol.	Propranolol	156-167	mast cell protease 1	Mus musculus	109-114
22841997-9	2012	Furthermore, flow cytometric analysis of cells from propranolol pretreated mice reduced the SDR-induced increase in the percentage of CD11b(+) splenic macrophages and significantly decreased the expression of TLR2, TLR4, and CD86 on the surface of these cells.	Propranolol	52-63	integrin alpha M	Mus musculus	134-139
22841997-9	2012	Furthermore, flow cytometric analysis of cells from propranolol pretreated mice reduced the SDR-induced increase in the percentage of CD11b(+) splenic macrophages and significantly decreased the expression of TLR2, TLR4, and CD86 on the surface of these cells.	Propranolol	52-63	toll-like receptor 2	Mus musculus	209-213
22841997-9	2012	Furthermore, flow cytometric analysis of cells from propranolol pretreated mice reduced the SDR-induced increase in the percentage of CD11b(+) splenic macrophages and significantly decreased the expression of TLR2, TLR4, and CD86 on the surface of these cells.	Propranolol	52-63	toll-like receptor 4	Mus musculus	215-219
22841997-9	2012	Furthermore, flow cytometric analysis of cells from propranolol pretreated mice reduced the SDR-induced increase in the percentage of CD11b(+) splenic macrophages and significantly decreased the expression of TLR2, TLR4, and CD86 on the surface of these cells.	Propranolol	52-63	CD86 antigen	Mus musculus	225-229
22841997-10	2012	In addition, supernatants from 18h LPS-stimulated ex vivo cultures of splenocytes from propranolol-treated SDR mice contained less IL-6.	Propranolol	87-98	interleukin 6	Mus musculus	131-135
22841997-11	2012	Likewise propranolol pre-treatment abrogated the glucocorticoid insensitivity of CD11b(+) cells ex vivo when compared to splenocytes from SDR vehicle-treated mice.	Propranolol	9-20	integrin subunit alpha M	Homo sapiens	81-86
23092836-5	2012	In response to propranolol, DeltaNp63alpha decreased, whereas TAp73beta and downstream proapoptotic p53 family target genes increased.	Propranolol	15-26	tumor protein p53	Homo sapiens	100-103
22903615-8	2012	The effect of ZAG on body weight, rectal temperature, urinary glucose excretion, improvement in glucose disposal, and increased insulin sensitivity were attenuated by propanolol, as was the increase in murine ZAG in the serum.	Propranolol	167-177	alpha-2-glycoprotein 1, zinc	Mus musculus	14-17
23170111-7	2012	Our data reveal that propranolol treatment of IH endothelial cells, as well as a panel of normal primary endothelial cells, blocks endothelial cell proliferation, migration, and formation of the actin cytoskeleton coincident with alterations in vascular endothelial growth factor receptor-2 (VEGFR-2), p38 and cofilin signaling.	Propranolol	21-32	kinase insert domain receptor	Homo sapiens	245-290
23170111-7	2012	Our data reveal that propranolol treatment of IH endothelial cells, as well as a panel of normal primary endothelial cells, blocks endothelial cell proliferation, migration, and formation of the actin cytoskeleton coincident with alterations in vascular endothelial growth factor receptor-2 (VEGFR-2), p38 and cofilin signaling.	Propranolol	21-32	kinase insert domain receptor	Homo sapiens	292-299
23170111-7	2012	Our data reveal that propranolol treatment of IH endothelial cells, as well as a panel of normal primary endothelial cells, blocks endothelial cell proliferation, migration, and formation of the actin cytoskeleton coincident with alterations in vascular endothelial growth factor receptor-2 (VEGFR-2), p38 and cofilin signaling.	Propranolol	21-32	mitogen-activated protein kinase 14	Homo sapiens	302-305
23170111-7	2012	Our data reveal that propranolol treatment of IH endothelial cells, as well as a panel of normal primary endothelial cells, blocks endothelial cell proliferation, migration, and formation of the actin cytoskeleton coincident with alterations in vascular endothelial growth factor receptor-2 (VEGFR-2), p38 and cofilin signaling.	Propranolol	21-32	cofilin 1	Homo sapiens	310-317
23092836-9	2012	CONCLUSIONS: Our results demonstrate that propranolol reduced HNSCC viability, induced apoptosis, and inhibited production of the proangiogenic protein VEGF.	Propranolol	42-53	vascular endothelial growth factor A	Homo sapiens	152-156
22647273-8	2012	Pretreatment with SL327 or propranolol significantly reduced morphine withdrawal-induced increases of plasma adrenocorticotropin and Hsp27 phosphorylation at Ser82 without any changes in plasma corticosterone levels.	Propranolol	27-38	heat shock protein family B (small) member 1	Rattus norvegicus	133-138
22445869-4	2012	Males treated with propranolol, fenofibric acid and with mixtures, showed an increase of vitellogenin immunostaining, compared with the control.	Propranolol	19-30	vitellogenin	Danio rerio	89-101
22854530-6	2012	Randomized trials of doxycycline, roxithromycin, and propranolol in patients with small AAA have been published.	Propranolol	53-64	AAA1	Homo sapiens	88-91
22580939-0	2012	Propranolol induces regression of hemangioma cells through HIF-1alpha-mediated inhibition of VEGF-A.	Propranolol	0-11	hypoxia inducible factor 1 subunit alpha	Homo sapiens	59-69
22580939-0	2012	Propranolol induces regression of hemangioma cells through HIF-1alpha-mediated inhibition of VEGF-A.	Propranolol	0-11	vascular endothelial growth factor A	Homo sapiens	93-99
22580939-11	2012	CONCLUSIONS: Collectively, these data suggest that propranolol exerts its suppressive effects on hemangiomas through the HIF-1alpha-VEGF-A angiogenesis axis, with effects mediated through the PI3/Akt and p38/MAPK pathways.	Propranolol	51-62	hypoxia inducible factor 1 subunit alpha	Homo sapiens	121-131
22580939-11	2012	CONCLUSIONS: Collectively, these data suggest that propranolol exerts its suppressive effects on hemangiomas through the HIF-1alpha-VEGF-A angiogenesis axis, with effects mediated through the PI3/Akt and p38/MAPK pathways.	Propranolol	51-62	vascular endothelial growth factor A	Homo sapiens	132-136
22580939-11	2012	CONCLUSIONS: Collectively, these data suggest that propranolol exerts its suppressive effects on hemangiomas through the HIF-1alpha-VEGF-A angiogenesis axis, with effects mediated through the PI3/Akt and p38/MAPK pathways.	Propranolol	51-62	peptidase inhibitor 3	Homo sapiens	192-195
22580939-11	2012	CONCLUSIONS: Collectively, these data suggest that propranolol exerts its suppressive effects on hemangiomas through the HIF-1alpha-VEGF-A angiogenesis axis, with effects mediated through the PI3/Akt and p38/MAPK pathways.	Propranolol	51-62	AKT serine/threonine kinase 1	Homo sapiens	196-199
22580939-11	2012	CONCLUSIONS: Collectively, these data suggest that propranolol exerts its suppressive effects on hemangiomas through the HIF-1alpha-VEGF-A angiogenesis axis, with effects mediated through the PI3/Akt and p38/MAPK pathways.	Propranolol	51-62	mitogen-activated protein kinase 14	Homo sapiens	204-207
22750445-6	2012	Importantly, a suppression of noradrenergic activity within the NAc shell with the beta-adrenoceptor antagonist propranolol blocked the facilitating effect of a concurrently administered GR agonist on memory consolidation in both the appetitive and aversive learning task.	Propranolol	112-123	nuclear receptor subfamily 3, group C, member 1	Rattus norvegicus	187-189
22675821-2	2012	When ET becomes refractory to propranolol, primidone and other, second-choice compounds, deep brain stimulation of the VIM nucleus of the thalamus can be considered.	Propranolol	30-41	vimentin	Homo sapiens	119-122
22552254-11	2012	Interestingly, propranolol showed some profibrinolytic activity, decreasing PAI-1 levels.	Propranolol	15-26	serpin family E member 1	Homo sapiens	76-81
22236039-10	2012	Propranolol also blunted icv alcohol-induced PVN Fos expression.	Propranolol	0-11	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	49-52
22571264-6	2012	Pretreatment of platelets with 1-butanol significantly attenuated thrombin-induced increase in [Ca2+](i) , while thrombin-induced increase in [Ca2+](i) was augmented in the presence of propranolol.	Propranolol	185-196	coagulation factor II, thrombin	Homo sapiens	113-121
22396018-0	2012	Propranolol improves impaired hepatic phosphatidylinositol 3-kinase/akt signaling after burn injury.	Propranolol	0-11	AKT serine/threonine kinase 1	Homo sapiens	68-71
22396018-4	2012	Here, we show that administration of propranolol, a nonselective beta1/2 adrenergic receptor antagonist, attenuates ER stress and JNK activation.	Propranolol	37-48	adrenoceptor beta 1	Homo sapiens	65-92
22396018-4	2012	Here, we show that administration of propranolol, a nonselective beta1/2 adrenergic receptor antagonist, attenuates ER stress and JNK activation.	Propranolol	37-48	mitogen-activated protein kinase 8	Homo sapiens	130-133
22396018-5	2012	Attenuation of ER stress by propranolol results in increased insulin sensitivity, as determined by activation of hepatic phosphatidylinositol 3-kinase and Akt.	Propranolol	28-39	AKT serine/threonine kinase 1	Homo sapiens	155-158
22490378-7	2012	The effect of formoterol on OCR in RPTC was inhibited by the beta-AR antagonist propranolol and the beta(2)-AR inverse agonist 3-(isopropylamino)-1-[(7-methyl-4-indanyl)oxy]butan-2-ol hydrochloride (ICI-118,551).	Propranolol	80-91	adrenergic receptor, beta 1	Mus musculus	61-68
22743370-9	2012	Interleukin 1beta expression was affected by BARKO and propranolol after TBI; attenuation of interleukin 6 and increased HSP70 expression were noted only with BARKO.	Propranolol	55-66	interleukin 1 beta	Mus musculus	0-17
22203431-2	2012	Propranolol was shown to modify matrix metalloproteinase (MMP) levels, which are associated with tumour pathogenesis.	Propranolol	0-11	matrix metallopeptidase 2	Homo sapiens	58-61
22203431-3	2012	We hypothesized that urinary MMP2/9 is higher in patients with infantile haemangioma compared to healthy infants and that propranolol reduces MMP2/9 levels and thus leads to an involution of the haemangioma.	Propranolol	122-133	matrix metallopeptidase 2	Homo sapiens	142-148
22203431-11	2012	The MMP2 levels were significantly higher after 2 weeks of propranolol than prior to therapy.	Propranolol	59-70	matrix metallopeptidase 2	Homo sapiens	4-8
22203431-14	2012	Unexpectedly, MMP2 was lower in the urine of haemangioma patients and higher 2 weeks after propranolol treatment.	Propranolol	91-102	matrix metallopeptidase 2	Homo sapiens	14-18
22203431-15	2012	Taking this and the diverse results in literature into account, the correlation between MMPs, proliferation, and regression of haemangiomas and propranolol remains unclear.	Propranolol	144-155	matrix metallopeptidase 2	Homo sapiens	88-92
22414705-5	2012	AX-CPT performance was assessed following administration of a single dose of propranolol (a beta adrenergic antagonist) and following placebo (sugar pill) administration.	Propranolol	77-88	amyloid beta precursor protein	Homo sapiens	90-96
22593501-1	2012	BACKGROUND: In a retrospective controlled study, a tumor-protective effect, regarding breast cancer, was determined for the medicines metformin and glitazone (anti-diabetics), bisoprolol, and propranolol (cardioselective beta1 adrenoceptor antagonists).	Propranolol	192-203	adrenoceptor beta 1	Homo sapiens	221-239
22764579-2	2012	In this study, the co-expression enzyme of human recombinant CYPOR, CYPb5 and CYP2D6.1 or CYP2D6.10 with the Bac-to-Bac system in baculovirus-infected insect cells was used to study the catalytical activity to imipramine metabolism and stereoselective metabolism of propranolol.	Propranolol	266-277	cytochrome p450 oxidoreductase	Homo sapiens	61-66
22764579-2	2012	In this study, the co-expression enzyme of human recombinant CYPOR, CYPb5 and CYP2D6.1 or CYP2D6.10 with the Bac-to-Bac system in baculovirus-infected insect cells was used to study the catalytical activity to imipramine metabolism and stereoselective metabolism of propranolol.	Propranolol	266-277	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	78-84
22764579-2	2012	In this study, the co-expression enzyme of human recombinant CYPOR, CYPb5 and CYP2D6.1 or CYP2D6.10 with the Bac-to-Bac system in baculovirus-infected insect cells was used to study the catalytical activity to imipramine metabolism and stereoselective metabolism of propranolol.	Propranolol	266-277	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	90-96
22764579-9	2012	Both of CYP2D6.1 and CYP2D6.10 produced more hydroxyl propranolol from the R-(+)-isomer than from the S-(-)-isomer while there was no obvious difference for N-desisopropylation propranolol production between R-(+)- and S-(-)- isomer.	Propranolol	54-65	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	8-14
22764579-9	2012	Both of CYP2D6.1 and CYP2D6.10 produced more hydroxyl propranolol from the R-(+)-isomer than from the S-(-)-isomer while there was no obvious difference for N-desisopropylation propranolol production between R-(+)- and S-(-)- isomer.	Propranolol	54-65	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	21-27
22188668-8	2012	The nicotinic agonists acetylcholine, nicotine, and its nitrosated carcinogenic derivative NNK induced the phosphorylation of CREB, ERK, Src, and AKT and these responses were inhibited by propranolol.	Propranolol	188-199	cAMP responsive element binding protein 1	Homo sapiens	126-130
22422658-0	2012	Asymmetric hydrolytic kinetic resolution with recyclable macrocyclic Co(III)-salen complexes: a practical strategy in the preparation of (R)-mexiletine and (S)-propranolol.	Propranolol	156-171	mitochondrially encoded cytochrome c oxidase III	Homo sapiens	72-75
22284265-1	2012	A 41-year-old man with a history of hyperthyroidism had been treated with methimazole and propranolol for the past 2 months.	Propranolol	90-101	EH domain containing 2	Homo sapiens	110-116
22250754-7	2012	The bound concentration of propranolol enantiomers in the presence of AGP was found to be greater for (S)-propranolol than (R)-propranolol for solutions containing constant concentrations of AGP (50 muM).	Propranolol	27-38	latexin	Homo sapiens	199-202
22030895-4	2012	Nadolol had a ~20% non-use-dependent blocking effect on peak sodium current and no effect on the persistent current evoked by the LQT3 mutant A1330D, whereas propranolol blocked Nav1.5 in a use-dependent manner and reduced A1330D persistent current.	Propranolol	158-169	sodium voltage-gated channel alpha subunit 5	Homo sapiens	178-184
22351865-0	2012	Decreased eNOS protein expression in involuting and propranolol-treated hemangiomas.	Propranolol	52-63	nitric oxide synthase 3	Homo sapiens	10-14
22351865-1	2012	OBJECTIVE: To examine the location and degree of endothelial nitric oxide synthase (eNOS) protein expression in hemangioma growth, involution, and during propranolol therapy.	Propranolol	154-165	nitric oxide synthase 3	Homo sapiens	49-82
22351865-1	2012	OBJECTIVE: To examine the location and degree of endothelial nitric oxide synthase (eNOS) protein expression in hemangioma growth, involution, and during propranolol therapy.	Propranolol	154-165	nitric oxide synthase 3	Homo sapiens	84-88
22351865-11	2012	In a separate propranolol treatment group (n = 7), the eNOS protein level was significantly lower than in age-matched controls (n = 7; 0.08 [0.1] vs 0.45 [0.45]; P = .03).	Propranolol	14-25	nitric oxide synthase 3	Homo sapiens	55-59
22351865-14	2012	Propranolol may suppress hemangioma growth by inhibiting expression of eNOS protein and subsequent production of nitric oxide.	Propranolol	0-11	nitric oxide synthase 3	Homo sapiens	71-75
22188668-8	2012	The nicotinic agonists acetylcholine, nicotine, and its nitrosated carcinogenic derivative NNK induced the phosphorylation of CREB, ERK, Src, and AKT and these responses were inhibited by propranolol.	Propranolol	188-199	AKT serine/threonine kinase 1	Homo sapiens	146-149
21950592-8	2012	RESULTS: Propranolol at 0.1 and 5 mg kg(-1) reduced the bone resorption as well as ICAM-1 and RANKL expression.	Propranolol	9-20	intercellular adhesion molecule 1	Rattus norvegicus	83-89
21950592-8	2012	RESULTS: Propranolol at 0.1 and 5 mg kg(-1) reduced the bone resorption as well as ICAM-1 and RANKL expression.	Propranolol	9-20	TNF superfamily member 11	Rattus norvegicus	94-99
21950592-10	2012	Propranolol also suppressed in vitro osteoclast differentiation and resorptive activity by inhibiting the nuclear factor of activated T cells (NFATc)1 pathway and the expression of tartrate-resistant acid phosphatase (TRAP), cathepsin K and MMP-9.	Propranolol	0-11	nuclear factor of activated T-cells 1	Rattus norvegicus	143-150
21950592-10	2012	Propranolol also suppressed in vitro osteoclast differentiation and resorptive activity by inhibiting the nuclear factor of activated T cells (NFATc)1 pathway and the expression of tartrate-resistant acid phosphatase (TRAP), cathepsin K and MMP-9.	Propranolol	0-11	acid phosphatase 5, tartrate resistant	Rattus norvegicus	181-216
21950592-10	2012	Propranolol also suppressed in vitro osteoclast differentiation and resorptive activity by inhibiting the nuclear factor of activated T cells (NFATc)1 pathway and the expression of tartrate-resistant acid phosphatase (TRAP), cathepsin K and MMP-9.	Propranolol	0-11	acid phosphatase 5, tartrate resistant	Rattus norvegicus	218-222
21950592-10	2012	Propranolol also suppressed in vitro osteoclast differentiation and resorptive activity by inhibiting the nuclear factor of activated T cells (NFATc)1 pathway and the expression of tartrate-resistant acid phosphatase (TRAP), cathepsin K and MMP-9.	Propranolol	0-11	cathepsin K	Rattus norvegicus	225-236
21950592-10	2012	Propranolol also suppressed in vitro osteoclast differentiation and resorptive activity by inhibiting the nuclear factor of activated T cells (NFATc)1 pathway and the expression of tartrate-resistant acid phosphatase (TRAP), cathepsin K and MMP-9.	Propranolol	0-11	matrix metallopeptidase 9	Rattus norvegicus	241-246
21950592-11	2012	CONCLUSIONS AND IMPLICATIONS: Low doses of propranolol suppress bone resorption by inhibiting RANKL-mediated osteoclastogenesis as well as inflammatory markers without affecting haemodynamic parameters.	Propranolol	43-54	TNF superfamily member 11	Rattus norvegicus	94-99
22133559-7	2012	A recent study showed that propranolol, a beta adrenergic receptor (beta-AR) antagonist, was effective as treatment for infantile hemangioma.	Propranolol	27-38	adrenoceptor beta 2	Homo sapiens	68-75
22086914-7	2012	Investigation of cardiac skinned fibers isolated from WT and heterozygous mice revealed that the WT cTnI was completely phosphorylated at Ser(23)/Ser(24) unless the mice were pre-treated with propranolol.	Propranolol	192-203	troponin I, cardiac 3	Mus musculus	100-104
22086914-9	2012	However, after treatment with propranolol and PKA, the R21C cTnI mutation reduced (R21C+/-) or abolished (R21C+/+) the well known decrease in the Ca(2+) sensitivity of tension that accompanies Ser(23)/Ser(24) cTnI phosphorylation.	Propranolol	30-41	troponin I, cardiac 3	Mus musculus	60-64
22086914-9	2012	However, after treatment with propranolol and PKA, the R21C cTnI mutation reduced (R21C+/-) or abolished (R21C+/+) the well known decrease in the Ca(2+) sensitivity of tension that accompanies Ser(23)/Ser(24) cTnI phosphorylation.	Propranolol	30-41	troponin I, cardiac 3	Mus musculus	209-213
23097963-6	2012	Beta2-adrenergcic stimulator-Hexoprenaline (2 inh x 0.2 mg), shows an protective effect in the decrease of pO2 (p &lt; 0.05) following the bronchoconstriction being provoked by Propranolol.	Propranolol	177-188	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	0-5
21963428-5	2012	We found that OTR-mediated ERK1/2 activation was attenuated significantly when cells were pretreated with the beta(2)AR agonist isoproterenol or two antagonists, propranolol or timolol.	Propranolol	162-173	oxytocin receptor	Homo sapiens	14-17
21963428-5	2012	We found that OTR-mediated ERK1/2 activation was attenuated significantly when cells were pretreated with the beta(2)AR agonist isoproterenol or two antagonists, propranolol or timolol.	Propranolol	162-173	mitogen-activated protein kinase 3	Homo sapiens	27-33
23507624-3	2012	This study intends to determine the effects of isoproterenol (ISO; beta-agonist) and propranolol (PRO; beta-antagonist) on the production of IFN-gamma, IL-4, and IL-17.	Propranolol	85-96	interferon gamma	Homo sapiens	141-150
23507624-3	2012	This study intends to determine the effects of isoproterenol (ISO; beta-agonist) and propranolol (PRO; beta-antagonist) on the production of IFN-gamma, IL-4, and IL-17.	Propranolol	85-96	interleukin 4	Homo sapiens	152-156
23507624-3	2012	This study intends to determine the effects of isoproterenol (ISO; beta-agonist) and propranolol (PRO; beta-antagonist) on the production of IFN-gamma, IL-4, and IL-17.	Propranolol	85-96	interleukin 17A	Homo sapiens	162-167
22327786-10	2012	The alpha(2C)AR(-/-) mice showed impaired glucose tolerance that was reversed by pretreatment with (+-)-propranolol.	Propranolol	99-115	adrenergic receptor, alpha 2c	Mus musculus	4-12
23049757-10	2012	The beta-receptor antagonist propranolol blocked the inhibitory effect of (R)-albuterol on TNF-alpha-induced ICAM-1 expression.	Propranolol	29-40	tumor necrosis factor	Homo sapiens	91-100
23051896-10	2012	The dopamine-induced IL-6 secretion was partially reduced by sulpiride and abrogated by propranolol.	Propranolol	88-99	interleukin 6	Homo sapiens	21-25
22108711-13	2012	Furthermore, in whole animal and cardiomyocyte cell culture preparations, DPDPE induced myocardial protein-kinase A (PKA) activation which was abrogated in the animals pretreated with propranolol+CGRP(8-37).	Propranolol	184-195	calcitonin related polypeptide alpha	Homo sapiens	196-200
23049757-10	2012	The beta-receptor antagonist propranolol blocked the inhibitory effect of (R)-albuterol on TNF-alpha-induced ICAM-1 expression.	Propranolol	29-40	intercellular adhesion molecule 1	Homo sapiens	109-115
21771889-6	2011	The NE-mediated TORC2 dephosphorylation was blocked by cotreatment with propranolol (a beta-adrenergic antagonist) but not prazosin (an alpha(1)-adrenergic antagonist) and mimicked by dibutyryl cAMP, indicating the participation of the beta-adrenergic receptor/cAMP pathway.	Propranolol	72-83	CREB regulated transcription coactivator 2	Rattus norvegicus	16-21
21736560-0	2011	Propranolol modulates the collateral vascular responsiveness to vasopressin via a G(alpha)-mediated pathway in portal hypertensive rats.	Propranolol	0-11	arginine vasopressin	Rattus norvegicus	64-75
21736560-10	2011	Propranolol pre-incubation elevated the perfusion pressure changes of collaterals in response to AVP, which was inhibited by suramin.	Propranolol	0-11	arginine vasopressin	Rattus norvegicus	97-100
21736560-11	2011	The splenorenal shunt G(alphaq) and G(alpha11) mRNA expression were enhanced by propranolol.	Propranolol	80-91	G protein subunit alpha 11	Rattus norvegicus	36-45
21736560-12	2011	The group treated with propranolol plus suramin had a down-regulation of G(alpha11) as compared with the propranolol group.	Propranolol	23-34	G protein subunit alpha 11	Rattus norvegicus	73-82
21736560-13	2011	Chronic propranolol treatment reduced mean arterial pressure, PP (portal pressure) and the perfusion pressure changes of collaterals to AVP.	Propranolol	8-19	arginine vasopressin	Rattus norvegicus	136-139
21736560-15	2011	In conclusion, propranolol pre-incubation enhanced the portal-systemic collateral AVP responsiveness in portal hypertensive rats, which was related to G(alphaq) and G(alpha11) up-regulation.	Propranolol	15-26	arginine vasopressin	Rattus norvegicus	82-85
21736560-15	2011	In conclusion, propranolol pre-incubation enhanced the portal-systemic collateral AVP responsiveness in portal hypertensive rats, which was related to G(alphaq) and G(alpha11) up-regulation.	Propranolol	15-26	G protein subunit alpha 11	Rattus norvegicus	165-174
21736560-16	2011	In contrast, the attenuated AVP responsiveness by chronic propranolol treatment was related to G(alphas) up-regulation.	Propranolol	58-69	arginine vasopressin	Rattus norvegicus	28-31
22184028-1	2011	To interfere with the drug-cue memory processes of addicts such as reconsolidation by the administration of the beta-adrenergic receptor (beta-AR) of norepinephrine (NE) antagonist propranolol (PRO) has become a potential therapy in the future to decrease or inhibit relapse.	Propranolol	181-192	adrenergic receptor, beta 1	Mus musculus	112-136
22184028-1	2011	To interfere with the drug-cue memory processes of addicts such as reconsolidation by the administration of the beta-adrenergic receptor (beta-AR) of norepinephrine (NE) antagonist propranolol (PRO) has become a potential therapy in the future to decrease or inhibit relapse.	Propranolol	181-192	adrenergic receptor, beta 1	Mus musculus	138-145
21988318-2	2011	In mice with OIR, beta-adrenergic receptor (beta-AR) blockade with propranolol has been shown to ameliorate different aspects of retinal dysfunction in response to hypoxia.	Propranolol	67-78	adrenergic receptor, beta 1	Mus musculus	18-42
21988318-2	2011	In mice with OIR, beta-adrenergic receptor (beta-AR) blockade with propranolol has been shown to ameliorate different aspects of retinal dysfunction in response to hypoxia.	Propranolol	67-78	adrenergic receptor, beta 1	Mus musculus	44-51
22006582-3	2011	In vitro proliferation assay showed that propranolol (from 50-100 muM) induces dose-dependent anti-proliferative effects in a panel of 9 human cancer and "normal" cell lines.	Propranolol	41-52	latexin	Homo sapiens	66-69
22006582-4	2011	Matrigel assays revealed that propranolol displays potent anti-angiogenic properties at non-toxic concentrations (less than 50 muM) but exert no vascular-disrupting activity.	Propranolol	30-41	latexin	Homo sapiens	127-130
22006582-7	2011	Furthermore, Matrigel assays indicated that low concentrations of propranolol (10 - 50 muM) potentiated the anti-angiogenic effects of 5-FU and paclitaxel.	Propranolol	66-77	latexin	Homo sapiens	87-90
22024455-1	2012	The interaction between human serum albumin (HSA) and two drugs - amlodipine and propranolol - was investigated using fluorescence, UV absorption and circular dichroism (CD) spectroscopy.	Propranolol	81-92	albumin	Homo sapiens	30-43
21615725-6	2011	Propranolol, at plasma concentrations ranging from 10 to 140 ng mL(-1) , blunted the LVW/BW ratio increase in TAC mice, while significantly increasing expression of 10 cell cycle genes including mitotic cyclins and proliferative markers such as Ki67.	Propranolol	0-11	antigen identified by monoclonal antibody Ki 67	Mus musculus	245-249
21874030-0	2011	Increased expression of insulin-like growth factor-binding protein-3 is implicated in erectile dysfunction in two-kidney one-clip hypertensive rats after propranolol treatment.	Propranolol	154-165	insulin-like growth factor binding protein 3	Rattus norvegicus	24-68
21874030-7	2011	IGFBP-3 mRNA and protein expression was increased in the propranolol treatment group compared to the hypertensive control group (P&lt;0.01), whereas IGF-1 expression was decreased in the propranolol treatment group compared to the hypertensive control group (P&lt;0.01).	Propranolol	57-68	insulin-like growth factor binding protein 3	Rattus norvegicus	0-7
21874030-7	2011	IGFBP-3 mRNA and protein expression was increased in the propranolol treatment group compared to the hypertensive control group (P&lt;0.01), whereas IGF-1 expression was decreased in the propranolol treatment group compared to the hypertensive control group (P&lt;0.01).	Propranolol	187-198	insulin-like growth factor 1	Rattus norvegicus	149-154
21870877-5	2011	A fluorescent diethylene glycol linked propranolol derivative (18a) had the highest affinity (log K(D) of -9.53 and -8.46 as an antagonist of functional beta2- and beta1-mediated responses, respectively).	Propranolol	39-50	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	153-169
21699891-1	2011	To prevent cardiovascular effects of peripherally administered propranolol, the aim of this study was to evaluate the spinal anesthetic effect of propranolol, a Na(+-) channel blocker.	Propranolol	146-157	sodium voltage-gated channel alpha subunit 8	Rattus norvegicus	161-175
20870476-0	2011	Expression of components of the renin-angiotensin system in proliferating infantile haemangioma may account for the propranolol-induced accelerated involution.	Propranolol	116-127	renin	Homo sapiens	32-37
22259987-2	2011	METHODS: The serum VEGF, MMP-9 was detected with ELISA assay before treatment and after 4 weeks and 8 weeks of propranolol treatment.	Propranolol	111-122	vascular endothelial growth factor A	Homo sapiens	19-23
22259987-7	2011	CONCLUSIONS: Propranolol can treat the proliferative hemangioma through decreasing the serum VEGF and MMP-9.	Propranolol	13-24	vascular endothelial growth factor A	Homo sapiens	93-97
22259987-7	2011	CONCLUSIONS: Propranolol can treat the proliferative hemangioma through decreasing the serum VEGF and MMP-9.	Propranolol	13-24	matrix metallopeptidase 9	Homo sapiens	102-107
21368715-5	2011	Another aim of the study was to test the effect of propranolol (an effective treatment of patients with burns) on the activation of PARP in skeletal muscle biopsies.	Propranolol	51-62	poly(ADP-ribose) polymerase 1	Homo sapiens	132-136
21368715-11	2011	There was a marked suppression of PARP activation in the skeletal muscle biopsies of patients who received propranolol treatment.	Propranolol	107-118	poly(ADP-ribose) polymerase 1	Homo sapiens	34-38
21368715-14	2011	Some of the clinical benefit of propranolol in burns may be related to its inhibitory effect on PARP activation.	Propranolol	32-43	poly(ADP-ribose) polymerase 1	Homo sapiens	96-100
20870476-7	2011	We present here a plausible model involving the renin-angiotensin system that may account for the propranolol-induced accelerated involution of proliferating infantile haemangioma.	Propranolol	98-109	renin	Homo sapiens	48-53
20715173-9	2011	In addition, pretreatment of cells with propranolol, a beta-adrenergic receptor (AR) blocker, completely abolished induction of VEGF expression and HIF-1alpha protein amount by NE in all of the tested cancer cells.	Propranolol	40-51	vascular endothelial growth factor A	Homo sapiens	128-132
20715173-9	2011	In addition, pretreatment of cells with propranolol, a beta-adrenergic receptor (AR) blocker, completely abolished induction of VEGF expression and HIF-1alpha protein amount by NE in all of the tested cancer cells.	Propranolol	40-51	hypoxia inducible factor 1 subunit alpha	Homo sapiens	148-158
21177286-4	2011	Stimulation of beta(2)-AR by isoproterenol inhibited Col II mRNA and protein levels by ~50% beginning at 2 h, with both remaining suppressed over 24 h. This inhibition was blocked by propranolol and inhibitors of either MEK1 or PKA.	Propranolol	183-194	adrenergic receptor, beta 2	Mus musculus	15-25
21693252-7	2011	QT(c) interval was significantly lower, whereas RMSSD, HF, SD1, and sample entropy were significantly higher in the propranolol group than in the control group.	Propranolol	116-127	CUP2Q35	Homo sapiens	59-62
21693252-8	2011	Correlation coefficients between QT(c) interval and RMSSD, HF, SD1, and sample entropy were higher in the propranolol group than in the control group.	Propranolol	106-117	CUP2Q35	Homo sapiens	63-66
21252158-5	2011	METHODS AND RESULTS: Culturing neonatal rat ventricular myocytes in the presence of phenylephrine (PE) plus propranolol (Pro), to selectively activate alpha(1)-adrenergic receptors, caused reductions in I(to,f), as well as KChIP2 and Kv4.3 expression, while increasing Kv4.2 expression.	Propranolol	121-124	potassium voltage-gated channel interacting protein 2	Rattus norvegicus	223-229
21365657-6	2011	In contrast, for the more lipophilic compound propranolol, apparent liposome-aqueous phase distribution coefficients (D(lip) ) were successfully determined by both electrokinetic chromatography (log D(lip) =2.10) and by CE frontal analysis (log D(lip) =2.14).	Propranolol	46-57	SMG1 nonsense mediated mRNA decay associated PI3K related kinase	Homo sapiens	26-29
21365657-6	2011	In contrast, for the more lipophilic compound propranolol, apparent liposome-aqueous phase distribution coefficients (D(lip) ) were successfully determined by both electrokinetic chromatography (log D(lip) =2.10) and by CE frontal analysis (log D(lip) =2.14).	Propranolol	46-57	SMG1 nonsense mediated mRNA decay associated PI3K related kinase	Homo sapiens	68-71
21365657-6	2011	In contrast, for the more lipophilic compound propranolol, apparent liposome-aqueous phase distribution coefficients (D(lip) ) were successfully determined by both electrokinetic chromatography (log D(lip) =2.10) and by CE frontal analysis (log D(lip) =2.14).	Propranolol	46-57	SMG1 nonsense mediated mRNA decay associated PI3K related kinase	Homo sapiens	68-71
21187140-8	2011	These effects were blocked by the beta-adrenergic antagonist propranolol, supporting a role for beta-ARs in IL-6 secretion.	Propranolol	61-72	interleukin 6	Homo sapiens	108-112
21193565-8	2011	During propranolol alone, the rise in FVC (Delta from normoxic baseline) due to hypoxic exercise was 217 +- 29 and 415 +- 41 ml min(-1) 100 mmHg(-1) (10% and 20% of maximum, respectively).	Propranolol	7-18	CD59 molecule (CD59 blood group)	Homo sapiens	128-134
21193565-9	2011	Combined propranolol-l-NMMA infusion during hypoxic exercise attenuated DeltaFVC at 20% (352 +- 44 ml min(-1) 100 mmHg(-1); P &lt; 0.001) but not at 10% (202 +- 28 ml min(-1) 100 mmHg(-1); P = 0.08) of maximum compared with propranolol alone.	Propranolol	9-20	CD59 molecule (CD59 blood group)	Homo sapiens	102-108
21193565-9	2011	Combined propranolol-l-NMMA infusion during hypoxic exercise attenuated DeltaFVC at 20% (352 +- 44 ml min(-1) 100 mmHg(-1); P &lt; 0.001) but not at 10% (202 +- 28 ml min(-1) 100 mmHg(-1); P = 0.08) of maximum compared with propranolol alone.	Propranolol	9-20	CD59 molecule (CD59 blood group)	Homo sapiens	167-173
21110747-11	2011	NMR and mass spectroscopic data have been extensively used for the unambiguous characterization of 4- and 5-hydroxylated and glucuronidated derivatives, all of them corresponding to the major animal and human metabolites of propranolol, a typical substrate of CYP2D6.	Propranolol	224-235	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	260-266
21252158-5	2011	METHODS AND RESULTS: Culturing neonatal rat ventricular myocytes in the presence of phenylephrine (PE) plus propranolol (Pro), to selectively activate alpha(1)-adrenergic receptors, caused reductions in I(to,f), as well as KChIP2 and Kv4.3 expression, while increasing Kv4.2 expression.	Propranolol	121-124	potassium voltage-gated channel subfamily D member 3	Rattus norvegicus	234-239
21252158-5	2011	METHODS AND RESULTS: Culturing neonatal rat ventricular myocytes in the presence of phenylephrine (PE) plus propranolol (Pro), to selectively activate alpha(1)-adrenergic receptors, caused reductions in I(to,f), as well as KChIP2 and Kv4.3 expression, while increasing Kv4.2 expression.	Propranolol	121-124	potassium voltage-gated channel subfamily D member 2	Rattus norvegicus	269-274
21184751-0	2011	Regio- and stereoselective oxidation of propranolol enantiomers by human CYP2D6, cynomolgus monkey CYP2D17 and marmoset CYP2D19.	Propranolol	40-51	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	73-79
20796031-7	2011	The restoration of memory functions in TIP39-KO mice after injection of a beta-adrenoreceptor-blocker, propranolol, suggested involvement of the noradrenergic system.	Propranolol	103-114	parathyroid hormone 2	Mus musculus	39-44
20921947-9	2011	Propranolol treatment of Mdr2(-/-) mice improved liver architecture.	Propranolol	0-11	ATP-binding cassette, sub-family B (MDR/TAP), member 4	Mus musculus	25-29
21166930-4	2011	RESULTS: Inhibition of beta-adrenergic receptors by propranolol increased hydraulic conductivity, reduced both cAMP levels and TER of microvascular endothelial cell monolayers and induced fragmentation of VE-cadherin staining.	Propranolol	52-63	cadherin 5	Rattus norvegicus	205-216
20959119-2	2011	However, it remains unknown which subtype of beta-adrenoceptors, beta(1)- or beta(2)-adrenoceptor, is primarily responsible for the detrimental effects of propranolol on anaphylactic hypotension.	Propranolol	155-166	adrenoceptor beta 2	Rattus norvegicus	77-97
20739470-12	2011	Propranolol dose-dependently reduced upregulated VEGF and decreased hypoxic levels of IGF-1 mRNA and HIF-1alpha.	Propranolol	0-11	vascular endothelial growth factor A	Mus musculus	49-53
20739470-12	2011	Propranolol dose-dependently reduced upregulated VEGF and decreased hypoxic levels of IGF-1 mRNA and HIF-1alpha.	Propranolol	0-11	insulin-like growth factor 1	Mus musculus	86-91
20739470-12	2011	Propranolol dose-dependently reduced upregulated VEGF and decreased hypoxic levels of IGF-1 mRNA and HIF-1alpha.	Propranolol	0-11	hypoxia inducible factor 1, alpha subunit	Mus musculus	101-111
20739470-15	2011	Propranolol ameliorated the retinopathy score, restored occludin and albumin, and reduced hypoxia-induced plasma extravasation without influencing the vascular permeability induced by intravitreal VEGF.	Propranolol	0-11	occludin	Mus musculus	56-64
21184751-0	2011	Regio- and stereoselective oxidation of propranolol enantiomers by human CYP2D6, cynomolgus monkey CYP2D17 and marmoset CYP2D19.	Propranolol	40-51	cytochrome P450 family 2 subfamily D member 6	Macaca fascicularis	99-106
21184751-0	2011	Regio- and stereoselective oxidation of propranolol enantiomers by human CYP2D6, cynomolgus monkey CYP2D17 and marmoset CYP2D19.	Propranolol	40-51	cytochrome P450 2D19	Callithrix jacchus	120-127
21184751-3	2011	The present study was performed to compare regio- and stereoselectivity in the oxidation of propranolol (PL), a chiral substrate, by cytochrome P450 2D (CYP2D) enzymes among humans, cynomolgus monkeys and marmosets.	Propranolol	92-103	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	133-151
21184751-3	2011	The present study was performed to compare regio- and stereoselectivity in the oxidation of propranolol (PL), a chiral substrate, by cytochrome P450 2D (CYP2D) enzymes among humans, cynomolgus monkeys and marmosets.	Propranolol	92-103	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	153-158
21184751-3	2011	The present study was performed to compare regio- and stereoselectivity in the oxidation of propranolol (PL), a chiral substrate, by cytochrome P450 2D (CYP2D) enzymes among humans, cynomolgus monkeys and marmosets.	Propranolol	105-107	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	133-151
21184751-3	2011	The present study was performed to compare regio- and stereoselectivity in the oxidation of propranolol (PL), a chiral substrate, by cytochrome P450 2D (CYP2D) enzymes among humans, cynomolgus monkeys and marmosets.	Propranolol	105-107	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	153-158
20978230-10	2011	When the rats were treated with a nonselective beta-adrenergic receptor blocker, propranolol, before induction of cerebral ischemic injury, the acute stroke-induced increase in TNF-alpha and MCP-1 was blocked, and fasting blood insulin concentration and homeostasis model assessment-insulin resistance were decreased.	Propranolol	81-92	tumor necrosis factor	Rattus norvegicus	177-186
20978230-10	2011	When the rats were treated with a nonselective beta-adrenergic receptor blocker, propranolol, before induction of cerebral ischemic injury, the acute stroke-induced increase in TNF-alpha and MCP-1 was blocked, and fasting blood insulin concentration and homeostasis model assessment-insulin resistance were decreased.	Propranolol	81-92	C-C motif chemokine ligand 2	Rattus norvegicus	191-196
21865739-8	2011	RESULTS: Propranolol increased the mean fluorescence intensity (MFI) of beta(1), beta(2)-adrenoceptor and the frequency of beta(1)-,beta(2)- adrenoceptor positive macrophages.	Propranolol	9-20	adrenoceptor beta 2	Rattus norvegicus	81-101
21952155-7	2011	Propranolol blunted LVW/BW ratio increase by approximately 50% while causing about a 3-fold increase in the expression of two genes, namely Brca1 and Cdkn2a, belonging to the TGF-beta and estrogen pathways, respectively.	Propranolol	0-11	breast cancer 1, early onset	Mus musculus	140-145
21952155-7	2011	Propranolol blunted LVW/BW ratio increase by approximately 50% while causing about a 3-fold increase in the expression of two genes, namely Brca1 and Cdkn2a, belonging to the TGF-beta and estrogen pathways, respectively.	Propranolol	0-11	cyclin dependent kinase inhibitor 2A	Mus musculus	150-156
21952155-7	2011	Propranolol blunted LVW/BW ratio increase by approximately 50% while causing about a 3-fold increase in the expression of two genes, namely Brca1 and Cdkn2a, belonging to the TGF-beta and estrogen pathways, respectively.	Propranolol	0-11	transforming growth factor, beta 1	Mus musculus	175-183
20637865-8	2011	Both, isoproterenol and norepinephrine (non-selective b-AR agonists), as well as salbutamol (selective b(2)-AR agonist) increased autophagic flux, and these effects were blocked by propanolol (b-AR antagonist), ICI-118,551 (selective b(2)-AR antagonist), 3-methyladenine but not by atenolol (selective b(1)-AR antagonist).	Propranolol	181-191	adrenoceptor beta 1	Rattus norvegicus	302-309
20858461-7	2011	In contrast, inhibition of PA hydrolysis with propranolol enhanced fMLF-mediated VAT-1 recruitment to membranes.	Propranolol	46-57	vesicle amine transport 1	Homo sapiens	81-86
21865739-10	2011	Furthermore, both propranolol and atenolol promoted LPS-mediated dopamine beta-hydroxylase protein expression and increased noradrenaline production in rat alveolar macrophages.	Propranolol	18-29	dopamine beta-hydroxylase	Rattus norvegicus	65-90
21541209-0	2011	Insulin versus Lipid Emulsion in a Rabbit Model of Severe Propranolol Toxicity: A Pilot Study.	Propranolol	58-69	insulin	Oryctolagus cuniculus	0-7
21541209-14	2011	High dose insulin resulted in greater rate pressure product compared with lipid emulsion in this rabbit model of severe enteric/intravenous propranolol toxicity.	Propranolol	140-151	insulin	Oryctolagus cuniculus	10-17
20870013-5	2010	This effect is prevented by the beta-adrenergic receptor antagonist propranolol (2 muM).	Propranolol	68-79	latexin	Homo sapiens	83-86
22615657-2	2011	METHODS: Propranolol hydrochloride-loaded microballoons were prepared by the non-aqueous O/O emulsion solvent diffusion evaporation method using Eudragit RSPO as polymer.	Propranolol	9-34	R-spondin 1	Homo sapiens	154-158
21833183-7	2010	The biophysical effects of R-(+)-propranolol on NaV1.5 and NaV1.1 resembled that of the prototypical local anesthetic lidocaine including the requirement for a critical phenylalanine residue (F1760 in NaV1.5) in the domain 4 S6 segment.	Propranolol	27-44	sodium voltage-gated channel alpha subunit 5	Homo sapiens	48-54
21833183-7	2010	The biophysical effects of R-(+)-propranolol on NaV1.5 and NaV1.1 resembled that of the prototypical local anesthetic lidocaine including the requirement for a critical phenylalanine residue (F1760 in NaV1.5) in the domain 4 S6 segment.	Propranolol	27-44	sodium voltage-gated channel alpha subunit 1	Homo sapiens	59-65
21833183-7	2010	The biophysical effects of R-(+)-propranolol on NaV1.5 and NaV1.1 resembled that of the prototypical local anesthetic lidocaine including the requirement for a critical phenylalanine residue (F1760 in NaV1.5) in the domain 4 S6 segment.	Propranolol	27-44	sodium voltage-gated channel alpha subunit 5	Homo sapiens	201-207
21078978-4	2010	Here we show that propranolol and carvedilol, two beta-blocker drugs that inhibit beta-adrenergic signaling via heterotrimeric G proteins, function in hippocampal pyramidal neurons as potent and selective activators of an alternate receptor-linked calcium signaling pathway mediated by beta-arrestin-2 and ERK1/2.	Propranolol	18-29	arrestin beta 2	Homo sapiens	286-301
21078978-4	2010	Here we show that propranolol and carvedilol, two beta-blocker drugs that inhibit beta-adrenergic signaling via heterotrimeric G proteins, function in hippocampal pyramidal neurons as potent and selective activators of an alternate receptor-linked calcium signaling pathway mediated by beta-arrestin-2 and ERK1/2.	Propranolol	18-29	mitogen-activated protein kinase 3	Homo sapiens	306-312
20728450-9	2010	In addition, spontaneous hypertrophy was noted in aged akt2(-/-) hearts that was inhibited by treatment with the betaAR blocker propranolol.	Propranolol	128-139	thymoma viral proto-oncogene 2	Mus musculus	55-59
20728450-12	2010	Accordingly, propranolol attenuated the development of cardiac hypertrophy in the PPARalpha transgenic mice as well.	Propranolol	13-24	peroxisome proliferator activated receptor alpha	Mus musculus	82-91
20847309-10	2010	The beta-blocker propranolol prevented the upregulation of MMPs, whereas MMP inhibition prevented the adverse remodeling with both therapies, preventing the functional deterioration in banded PI3KgammaKO mice.	Propranolol	17-28	matrix metallopeptidase 13	Mus musculus	59-63
21124749-8	2010	Propranolol inhibition of IkappaB phosphorylation was shown to occur with optimal efficacy at 30 muM.	Propranolol	0-11	latexin	Homo sapiens	97-100
21124749-9	2010	Although propranolol, at up to 100 muM, did not affect cell viability, it potentiated PMA- mediated signaling that ultimately led to diminished phosphorylation of Akt.	Propranolol	9-20	latexin	Homo sapiens	35-38
21124749-9	2010	Although propranolol, at up to 100 muM, did not affect cell viability, it potentiated PMA- mediated signaling that ultimately led to diminished phosphorylation of Akt.	Propranolol	9-20	AKT serine/threonine kinase 1	Homo sapiens	163-166
21124749-11	2010	Our data are therefore indicative of a pharmacological role for propranolol against beta-adrenergic receptor signaling functions involving the nuclear factor-kappaB-mediated regulation of MMP-9.	Propranolol	64-75	matrix metallopeptidase 9	Homo sapiens	188-193
21042766-0	2010	The beta-adrenoceptor antagonist, propranolol, induces human gastric cancer cell apoptosis and cell cycle arrest via inhibiting nuclear factor kappaB signaling.	Propranolol	34-45	nuclear factor kappa B subunit 1	Homo sapiens	143-149
21042766-5	2010	In addition, propranolol also induced apoptosis in both cell lines, as determined by Annexin V staining assay.	Propranolol	13-24	annexin A5	Homo sapiens	85-94
21042766-6	2010	Furthermore, propranolol decreased the level of NF-kappaB and then downregulated VEGF, Cox-2, MMP-2 and MMP-9 expression.	Propranolol	13-24	nuclear factor kappa B subunit 1	Homo sapiens	48-57
21042766-6	2010	Furthermore, propranolol decreased the level of NF-kappaB and then downregulated VEGF, Cox-2, MMP-2 and MMP-9 expression.	Propranolol	13-24	vascular endothelial growth factor A	Homo sapiens	81-85
21042766-6	2010	Furthermore, propranolol decreased the level of NF-kappaB and then downregulated VEGF, Cox-2, MMP-2 and MMP-9 expression.	Propranolol	13-24	prostaglandin-endoperoxide synthase 2	Homo sapiens	87-92
21042766-6	2010	Furthermore, propranolol decreased the level of NF-kappaB and then downregulated VEGF, Cox-2, MMP-2 and MMP-9 expression.	Propranolol	13-24	matrix metallopeptidase 2	Homo sapiens	94-99
21042766-6	2010	Furthermore, propranolol decreased the level of NF-kappaB and then downregulated VEGF, Cox-2, MMP-2 and MMP-9 expression.	Propranolol	13-24	matrix metallopeptidase 9	Homo sapiens	104-109
21042766-7	2010	Collectively, these results suggested that propranolol repressed gastric cancer cell growth through the inhibition of beta-ARs and the downstream NF-kappaB-VEGF/MMP-2/9/COX-2 pathway.	Propranolol	43-54	nuclear factor kappa B subunit 1	Homo sapiens	149-155
21042766-7	2010	Collectively, these results suggested that propranolol repressed gastric cancer cell growth through the inhibition of beta-ARs and the downstream NF-kappaB-VEGF/MMP-2/9/COX-2 pathway.	Propranolol	43-54	vascular endothelial growth factor A	Homo sapiens	156-160
21042766-7	2010	Collectively, these results suggested that propranolol repressed gastric cancer cell growth through the inhibition of beta-ARs and the downstream NF-kappaB-VEGF/MMP-2/9/COX-2 pathway.	Propranolol	43-54	matrix metallopeptidase 2	Homo sapiens	161-166
21042766-7	2010	Collectively, these results suggested that propranolol repressed gastric cancer cell growth through the inhibition of beta-ARs and the downstream NF-kappaB-VEGF/MMP-2/9/COX-2 pathway.	Propranolol	43-54	prostaglandin-endoperoxide synthase 2	Homo sapiens	169-174
21124749-6	2010	We next found that propranolol dose-dependently inhibited induction of the key extracellular matrix-degrading and blood-brain barrier disrupting enzyme matrix metalloproteinase- 9 (MMP-9) by phorbol 12-myristate 13-acetate (PMA).	Propranolol	19-30	matrix metallopeptidase 9	Homo sapiens	152-179
21124749-6	2010	We next found that propranolol dose-dependently inhibited induction of the key extracellular matrix-degrading and blood-brain barrier disrupting enzyme matrix metalloproteinase- 9 (MMP-9) by phorbol 12-myristate 13-acetate (PMA).	Propranolol	19-30	matrix metallopeptidase 9	Homo sapiens	181-186
21124749-7	2010	Propranolol not only inhibited PMA- induced phosphorylation of the extracellular signal-regulated kinase (Erk), but also that of IkappaB (IkappaB), preventing the IkappaB phosphorylation which is a prerequisite for IkappaB degradation.	Propranolol	0-11	mitogen-activated protein kinase 1	Homo sapiens	67-104
21124749-7	2010	Propranolol not only inhibited PMA- induced phosphorylation of the extracellular signal-regulated kinase (Erk), but also that of IkappaB (IkappaB), preventing the IkappaB phosphorylation which is a prerequisite for IkappaB degradation.	Propranolol	0-11	mitogen-activated protein kinase 1	Homo sapiens	106-109
20847309-11	2010	In banded wild-type mice, long-term propranolol prevented the adverse remodeling and systolic dysfunction with preservation of the N-cadherin levels.	Propranolol	36-47	cadherin 2	Mus musculus	131-141
20602110-9	2010	The propranolol treatment completely inhibited exercise-induced TNF-alpha and IFN-alpha suppression in response to R-848 in the mice.	Propranolol	4-15	tumor necrosis factor	Mus musculus	64-73
20966593-6	2010	The IMO-induced Cx43 translocation was inhibited by pretreatment with the alpha(1)-adrenoceptor blockers, prazosin (1mg/kg, PO) and bunazosin (4mg/kg, PO), but not with either the beta(1)-blocker, metoprolol (10mg/kg, IP), or the beta(1+2)-blocker, propranolol (1mg/kg, PO).	Propranolol	249-260	gap junction protein, alpha 1	Rattus norvegicus	16-20
20602110-6	2010	In addition, the effect of propranolol (10 mg kg(-1)) as blockade of beta-adrenergic receptors on R-848-induced TNF-alpha and IFN-alpha production in the exercised mice was examined.	Propranolol	27-38	tumor necrosis factor	Mus musculus	112-121
20602110-9	2010	The propranolol treatment completely inhibited exercise-induced TNF-alpha and IFN-alpha suppression in response to R-848 in the mice.	Propranolol	4-15	interferon alpha	Mus musculus	78-87
20732454-6	2010	Furthermore, inhibition by propranolol of vascular endothelial growth factor (VEGF)-induced tyrosine phosphorylation of VEGF receptor-2 lead to inhibition of downstream signaling such as the activation of the extracellular signal-regulated kinase-1/2 and the secretion of the extracellular matrix degrading enzyme MMP-2.	Propranolol	27-38	vascular endothelial growth factor A	Homo sapiens	42-76
20952611-6	2010	Under basal conditions, CST (from 11 nmol l-1 to 165 nmol l-1) caused a concentration-dependent negative inotropism, which was abolished by inhibitors of either beta1/beta2 (propranolol) or beta3 (SR59230) adrenergic receptors, or by G(i/o) protein (PTx) or nitric oxide synthase (L-NMMA), or guanylate cyclase (ODQ) blockers.	Propranolol	174-185	chromogranin A	Homo sapiens	24-27
20807785-8	2010	Isoproterenol (isoprenaline; betaAR agonist) dilated 1A, 2A and 3A near-maximally with similar potency and efficacy; these dilatations were inhibited by 10(-7) m propranolol (betaAR antagonist) which otherwise had no effect on responses to NA, PE, or UK.	Propranolol	162-173	adrenergic receptor, beta 1	Mus musculus	29-35
20807785-8	2010	Isoproterenol (isoprenaline; betaAR agonist) dilated 1A, 2A and 3A near-maximally with similar potency and efficacy; these dilatations were inhibited by 10(-7) m propranolol (betaAR antagonist) which otherwise had no effect on responses to NA, PE, or UK.	Propranolol	162-173	adrenergic receptor, beta 1	Mus musculus	175-181
20732454-6	2010	Furthermore, inhibition by propranolol of vascular endothelial growth factor (VEGF)-induced tyrosine phosphorylation of VEGF receptor-2 lead to inhibition of downstream signaling such as the activation of the extracellular signal-regulated kinase-1/2 and the secretion of the extracellular matrix degrading enzyme MMP-2.	Propranolol	27-38	vascular endothelial growth factor A	Homo sapiens	78-82
20732454-6	2010	Furthermore, inhibition by propranolol of vascular endothelial growth factor (VEGF)-induced tyrosine phosphorylation of VEGF receptor-2 lead to inhibition of downstream signaling such as the activation of the extracellular signal-regulated kinase-1/2 and the secretion of the extracellular matrix degrading enzyme MMP-2.	Propranolol	27-38	vascular endothelial growth factor A	Homo sapiens	120-124
20732454-6	2010	Furthermore, inhibition by propranolol of vascular endothelial growth factor (VEGF)-induced tyrosine phosphorylation of VEGF receptor-2 lead to inhibition of downstream signaling such as the activation of the extracellular signal-regulated kinase-1/2 and the secretion of the extracellular matrix degrading enzyme MMP-2.	Propranolol	27-38	mitogen-activated protein kinase 3	Homo sapiens	209-250
20732454-6	2010	Furthermore, inhibition by propranolol of vascular endothelial growth factor (VEGF)-induced tyrosine phosphorylation of VEGF receptor-2 lead to inhibition of downstream signaling such as the activation of the extracellular signal-regulated kinase-1/2 and the secretion of the extracellular matrix degrading enzyme MMP-2.	Propranolol	27-38	matrix metallopeptidase 2	Homo sapiens	314-319
20629735-11	2010	Stress and control + propranolol groups presented a delay in wound contraction, re-epithelialization, F4/80-positive macrophages, neutrophils and mast cells infiltration, cellular proliferation, angiogenesis, myofibroblastic differentiation, MMP-2 and MMP-9 activation and TNF-alpha expression, whereas an increase in the nitrite levels.	Propranolol	21-32	adhesion G protein-coupled receptor E1	Mus musculus	102-107
20977754-10	2010	CONCLUSIONS: Taken together, these results suggested that propranolol enhanced the sensitivity of gastric cancer cells to radiation through the inhibition of beta-ARs and the downstream NF-kappaB-VEGF/EGFR/COX-2 pathway.	Propranolol	58-69	epidermal growth factor receptor	Homo sapiens	201-205
20977754-10	2010	CONCLUSIONS: Taken together, these results suggested that propranolol enhanced the sensitivity of gastric cancer cells to radiation through the inhibition of beta-ARs and the downstream NF-kappaB-VEGF/EGFR/COX-2 pathway.	Propranolol	58-69	prostaglandin-endoperoxide synthase 2	Homo sapiens	206-211
20977754-9	2010	In addition, treatment with propranolol decreased the level of NF-kappaB and, subsequently, down-regulated VEGF, COX-2, and EGFR expression.	Propranolol	28-39	nuclear factor kappa B subunit 1	Homo sapiens	63-72
20977754-9	2010	In addition, treatment with propranolol decreased the level of NF-kappaB and, subsequently, down-regulated VEGF, COX-2, and EGFR expression.	Propranolol	28-39	vascular endothelial growth factor A	Homo sapiens	107-111
20977754-9	2010	In addition, treatment with propranolol decreased the level of NF-kappaB and, subsequently, down-regulated VEGF, COX-2, and EGFR expression.	Propranolol	28-39	prostaglandin-endoperoxide synthase 2	Homo sapiens	113-118
20977754-9	2010	In addition, treatment with propranolol decreased the level of NF-kappaB and, subsequently, down-regulated VEGF, COX-2, and EGFR expression.	Propranolol	28-39	epidermal growth factor receptor	Homo sapiens	124-128
20977754-10	2010	CONCLUSIONS: Taken together, these results suggested that propranolol enhanced the sensitivity of gastric cancer cells to radiation through the inhibition of beta-ARs and the downstream NF-kappaB-VEGF/EGFR/COX-2 pathway.	Propranolol	58-69	nuclear factor kappa B subunit 1	Homo sapiens	189-195
20977754-10	2010	CONCLUSIONS: Taken together, these results suggested that propranolol enhanced the sensitivity of gastric cancer cells to radiation through the inhibition of beta-ARs and the downstream NF-kappaB-VEGF/EGFR/COX-2 pathway.	Propranolol	58-69	vascular endothelial growth factor A	Homo sapiens	196-200
20554934-5	2010	In a further study, propranolol was used to antagonize remaining beta-adrenergic input (beta(1)- and beta(2)-ARs) in beta(3)-AR(-/-) mice, and this treatment blocked &gt;50% of the MR-induced increase in total EE and UCP1 induction in both BAT and WAT.	Propranolol	20-31	adrenergic receptor, beta 1	Mus musculus	65-112
20554934-5	2010	In a further study, propranolol was used to antagonize remaining beta-adrenergic input (beta(1)- and beta(2)-ARs) in beta(3)-AR(-/-) mice, and this treatment blocked &gt;50% of the MR-induced increase in total EE and UCP1 induction in both BAT and WAT.	Propranolol	20-31	adrenergic receptor, beta 3	Mus musculus	117-127
20554934-5	2010	In a further study, propranolol was used to antagonize remaining beta-adrenergic input (beta(1)- and beta(2)-ARs) in beta(3)-AR(-/-) mice, and this treatment blocked &gt;50% of the MR-induced increase in total EE and UCP1 induction in both BAT and WAT.	Propranolol	20-31	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	217-221
20629735-11	2010	Stress and control + propranolol groups presented a delay in wound contraction, re-epithelialization, F4/80-positive macrophages, neutrophils and mast cells infiltration, cellular proliferation, angiogenesis, myofibroblastic differentiation, MMP-2 and MMP-9 activation and TNF-alpha expression, whereas an increase in the nitrite levels.	Propranolol	21-32	matrix metallopeptidase 2	Mus musculus	242-247
20629735-11	2010	Stress and control + propranolol groups presented a delay in wound contraction, re-epithelialization, F4/80-positive macrophages, neutrophils and mast cells infiltration, cellular proliferation, angiogenesis, myofibroblastic differentiation, MMP-2 and MMP-9 activation and TNF-alpha expression, whereas an increase in the nitrite levels.	Propranolol	21-32	matrix metallopeptidase 9	Mus musculus	252-257
20629735-11	2010	Stress and control + propranolol groups presented a delay in wound contraction, re-epithelialization, F4/80-positive macrophages, neutrophils and mast cells infiltration, cellular proliferation, angiogenesis, myofibroblastic differentiation, MMP-2 and MMP-9 activation and TNF-alpha expression, whereas an increase in the nitrite levels.	Propranolol	21-32	tumor necrosis factor	Mus musculus	273-282
20399918-7	2010	Ghrelin and propranolol dose-dependently increased AMPK phosphorylation and activity.	Propranolol	12-23	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	51-55
20554760-4	2010	We found that inhibition of PA hydrolysis by propranolol, in the absence of ligand, provokes internalization of inactive (neither tyrosine-phosphorylated nor ubiquitinated) EGFR, accompanied by a transient increase in PA levels and PDE4s activity.	Propranolol	45-56	epidermal growth factor receptor	Homo sapiens	173-177
20554760-4	2010	We found that inhibition of PA hydrolysis by propranolol, in the absence of ligand, provokes internalization of inactive (neither tyrosine-phosphorylated nor ubiquitinated) EGFR, accompanied by a transient increase in PA levels and PDE4s activity.	Propranolol	45-56	phosphodiesterase 4A	Homo sapiens	232-236
20600248-7	2010	The enhancement of freezing response in Ntsr1-KO mice at second exposure was abolished by propranolol, a beta-adrenergic blocker that suppresses fear memory reconsolidation, and suppressed by MK-801, an NMDA receptor antagonist.	Propranolol	90-101	neurotensin receptor 1	Mus musculus	40-45
21716798-4	2010	He was found to have IFN-related autoimmune thyrotoxicosis and responded to antithyroid drugs and propanolol.	Propranolol	98-108	interferon alpha 1	Homo sapiens	21-24
20510341-4	2010	Propranolol exposure depressed both the number of reinforced responses in the operant conditioning task and BDNF expression in occipital cortex.	Propranolol	0-11	brain-derived neurotrophic factor	Rattus norvegicus	108-112
20510341-5	2010	Taken together, our results suggest that propranolol impairs memory formation by inhibiting cortical LTP induction and associated BDNF expression.	Propranolol	41-52	brain-derived neurotrophic factor	Rattus norvegicus	130-134
20417698-5	2010	Propranolol (phosphatidic acid phospholydrolase inhibitor) and quinacrine (phospholipase A2 inhibitor) had weak effects on H(2)O(2)-induced PLD activation but reversed H(2)O(2)-induced injury.	Propranolol	0-11	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	140-143
20555027-5	2010	In CNP-Tg/Nppc(-/-) mice, rectal temperature at 1600 h was higher by 1.1 C, and uncoupling protein-1 mRNA expression in the brown adipose tissue was 2-fold increased, which was canceled by propranolol administration, as compared with CNP-Tg/Nppc(+/+) mice.	Propranolol	189-200	natriuretic peptide type C	Mus musculus	3-6
20424515-6	2010	beta2-adrenergic antagonist ICI118,551 and beta1/2-adrenergic antagonist propranolol significantly suppressed cell invasion and proliferation in comparison to beta1-adrenergic antagonist metoprolol and control in a Matrigel invasion assay and subrenal capsular assay.	Propranolol	73-84	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	43-50
20424515-6	2010	beta2-adrenergic antagonist ICI118,551 and beta1/2-adrenergic antagonist propranolol significantly suppressed cell invasion and proliferation in comparison to beta1-adrenergic antagonist metoprolol and control in a Matrigel invasion assay and subrenal capsular assay.	Propranolol	73-84	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	43-48
20147605-7	2010	In the presence of 10(-5) M propranolol, the effect of norepinephrine to prevent the inhibition of chloride transport by ANG II was still present.	Propranolol	28-39	angiotensinogen	Rattus norvegicus	121-127
19644937-1	2010	Stereoselective metabolism of propranolol side-chain glucuronidation was studied for two recombinant human uridine diphosphate glucuronosyltransferases (UGTs), UGT1A9 and UGT2B7.	Propranolol	30-41	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	171-177
19644937-4	2010	UGT1A9 prefers catalyzing S-enantiomer to R-enantiomer and the intrinsic clearance (CL(int)) ratios of S-enantiomer to R-enantiomer are 3.8 times and 6.5 times for racemic propranolol and individual enantiomers, respectively.	Propranolol	172-183	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	0-6
19644937-6	2010	The high concentration of racemic propranolol (&gt;0.57 mmol/l) and individual enantiomers (&gt;0.69 mmol/l) exhibited substrate inhibition of glucuronidation for UGT2B7, but only the S-enantiomer (&gt;0.44 mmol/l) in racemic propranolol exhibited substrate inhibition for UGT1A9.	Propranolol	34-45	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	163-169
19644937-6	2010	The high concentration of racemic propranolol (&gt;0.57 mmol/l) and individual enantiomers (&gt;0.69 mmol/l) exhibited substrate inhibition of glucuronidation for UGT2B7, but only the S-enantiomer (&gt;0.44 mmol/l) in racemic propranolol exhibited substrate inhibition for UGT1A9.	Propranolol	34-45	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	273-279
20193756-6	2010	The ability of combined treatment with reboxetine and idazoxan to induce IL-10 and SOCS3 expression was mediated by beta-adrenoceptor activation, as their induction was blocked by pre-treatment with the beta-adrenoceptor antagonist propranolol.	Propranolol	232-243	interleukin 10	Rattus norvegicus	73-78
20193756-6	2010	The ability of combined treatment with reboxetine and idazoxan to induce IL-10 and SOCS3 expression was mediated by beta-adrenoceptor activation, as their induction was blocked by pre-treatment with the beta-adrenoceptor antagonist propranolol.	Propranolol	232-243	suppressor of cytokine signaling 3	Rattus norvegicus	83-88
20193756-7	2010	Moreover, administration of the brain penetrant beta(2)-adrenoceptor agonist clenbuterol induced a time- and dose-dependent increase in central IL-10 and SOCS3 expression, and the ability of clenbuterol to induce IL-10 and SOCS-3 expression was blocked by the centrally acting beta-adrenoceptor antagonist, propranolol, and was mimicked by the highly selective beta(2)-adrenoceptor agonist formoterol.	Propranolol	307-318	adrenoceptor beta 2	Rattus norvegicus	48-68
20042659-0	2010	Systemic propranolol reduces b-wave amplitude in the ERG and increases IGF-1 receptor phosphorylation in rat retina.	Propranolol	9-20	insulin-like growth factor 1 receptor	Rattus norvegicus	71-85
20042659-1	2010	PURPOSE: To determine whether systemic application of propranolol, a nonselective beta-adrenergic receptor antagonist, with an osmotic pump will decrease the b-wave amplitude of the electroretinogram (ERG) and increase insulin-like growth factor (IGF)-1 receptor signaling.	Propranolol	54-65	insulin-like growth factor 1 receptor	Rattus norvegicus	219-262
21042492-4	2010	Prescribing beta blocker (propranolol) with insulin is contraindicated.	Propranolol	26-37	insulin	Homo sapiens	44-51
20499050-1	2010	It was recently suggested that the antiarrhythmic effect of propranolol, a ss-adrenoceptor antagonist, on ischemic myocardium includes restoration of I(K1) current and Cx43 conductance; however, little is known whether effects on the transient outward current I(to) contribute.	Propranolol	60-71	gap junction protein, alpha 1	Rattus norvegicus	168-172
20499050-6	2010	Propranolol restored the diminished I(to) density and Kv4.2 protein in MI hearts.	Propranolol	0-11	potassium voltage-gated channel subfamily D member 2	Rattus norvegicus	54-59
20502989-2	2010	Propranolol, a beta-adrenergic antagonist, has revealed benefit during performance of tasks involving flexibility of access to networks, a benefit also seen in ASD.	Propranolol	0-11	amyloid beta precursor protein	Homo sapiens	13-19
20523006-5	2010	From roughly quantitative stereoselective glucuronidation study of racemic beta-blocker analogues by UGT1A9, propranolol had a high ratio of the ratios of S- to R-isomer glucuronide (S-G/R-G), about 4.3, the ratios of terbutaline, atenolol and esomolol were 3.3, 3.1 and 2.8 respectively, sotalol and propafenone were 2.3 and 2.0.	Propranolol	109-120	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	101-107
20523006-5	2010	From roughly quantitative stereoselective glucuronidation study of racemic beta-blocker analogues by UGT1A9, propranolol had a high ratio of the ratios of S- to R-isomer glucuronide (S-G/R-G), about 4.3, the ratios of terbutaline, atenolol and esomolol were 3.3, 3.1 and 2.8 respectively, sotalol and propafenone were 2.3 and 2.0.	Propranolol	109-120	testis expressed 101	Homo sapiens	183-190
20020526-0	2010	Effect of altered AGP plasma binding on heart rate changes by S(-)-propranolol in rats using mechanism-based estimations of in vivo receptor affinity (K(B,vivo)).	Propranolol	62-78	orosomucoid 1	Rattus norvegicus	18-21
20020526-6	2010	Using nonlinear mixed effects modeling, AGP concentration was a covariate for intercompartmental clearance for the third compartment of the pharmacokinetic model of S(-)-propranolol.	Propranolol	165-181	orosomucoid 1	Rattus norvegicus	40-43
20020526-7	2010	Individual values of AGP concentrations ranged between 110 and 1150 microg/mL, and were associated with K(B,vivo) values of S(-)-propranolol from 7.0 to 30 nM.	Propranolol	125-140	orosomucoid 1	Rattus norvegicus	21-24
20132043-9	2010	The lipolytic effect of EBR involved beta(3)-AR modulation, as inferred from the inhibition by the beta(3)-AR antagonist propranolol.	Propranolol	121-132	adrenergic receptor, beta 3	Mus musculus	99-109
20345925-7	2010	Treatment of cells with CYP2D6 inhibitors (quinidine, propanolol, metoprolol or timolol) at varying concentrations significantly increased the neurotoxicity caused by 1-methyl-4-phenylpyridinium (MPP+) at 10 and 25 microM by between 9 +/- 1 and 22 +/- 5% (P &lt; 0.01).	Propranolol	54-64	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	24-30
20117846-7	2010	Besides, an inhibition of MMP-9 and HBMEC expression by propanolol is discussed as possible mechanism influencing the growth of haemangiomas.	Propranolol	56-66	matrix metallopeptidase 9	Homo sapiens	26-31
20132473-7	2010	When stressed rats had the production of glucocorticoids blocked by the selective inhibitor metyrapone, a large increase of MCP-1 concentration was observed in cortex, whereas propranolol (a beta adrenergic receptor blocker) avoided modifications of MCP-1 after stress.	Propranolol	176-187	C-C motif chemokine ligand 2	Rattus norvegicus	250-255
20082593-6	2010	Ki-67 labelling indicated that liver regeneration was attenuated by propranolol through inhibition of mitosis.	Propranolol	68-79	antigen identified by monoclonal antibody Ki 67	Mus musculus	0-5
20216107-0	2010	Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.	Propranolol	67-78	catechol-O-methyltransferase	Homo sapiens	10-38
20216107-4	2010	We hypothesized that the nonselective beta-adrenergic antagonist propranolol will reduce clinical and experimental pain in TMD patients in a manner dependent on the individuals" COMT diplotype.	Propranolol	65-76	catechol-O-methyltransferase	Homo sapiens	178-182
20216107-10	2010	When stratified by the COMT high activity haplotype, a beneficial effect of propranolol on pain perception was noted in patients not carrying this haplotype, a diminished benefit was observed in the heterozygotes, and no benefit was noted in the homozygotes.	Propranolol	76-87	catechol-O-methyltransferase	Homo sapiens	23-27
20216107-11	2010	CONCLUSION: COMT haplotypes may serve as genetic predictors of propranolol treatment outcome, identifying a subgroup of TMD patients who will benefit from propranolol therapy.	Propranolol	63-74	catechol-O-methyltransferase	Homo sapiens	12-16
20216107-11	2010	CONCLUSION: COMT haplotypes may serve as genetic predictors of propranolol treatment outcome, identifying a subgroup of TMD patients who will benefit from propranolol therapy.	Propranolol	155-166	catechol-O-methyltransferase	Homo sapiens	12-16
20035031-11	2010	Additional beta(2)-adrenoceptor blockade with propranolol further inhibited myocardial oxygen supply during exercise, resulting in a further clockwise rotation of the relationship between myocardial oxygen consumption and coronary venous Po(2).	Propranolol	46-57	adrenoceptor beta 2	Sus scrofa	11-31
20372009-3	2010	Major metabolism of drugs was ascribed to CYP1A2 for theophylline and caffeine, and CYP1A2 and CYP2D6 for propranolol and mexiletine.	Propranolol	106-117	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	84-90
20372009-3	2010	Major metabolism of drugs was ascribed to CYP1A2 for theophylline and caffeine, and CYP1A2 and CYP2D6 for propranolol and mexiletine.	Propranolol	106-117	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	95-101
20152444-1	2010	In this work, the effect of the serum protein, bovine serum albumin (BSA), on the detection of propranolol in artificial serum by ion-transfer voltammetry at an array of micro-interfaces between two immiscible electrolyte solutions (microITIES) is presented.	Propranolol	95-106	albumin	Homo sapiens	54-67
19481549-4	2010	Here we report that the beta-blocker propranolol interacts with wild type (WT) and LQT-3 mutant Na(+) channels in a manner that resembles the actions of local anesthetic drugs.	Propranolol	37-48	sodium voltage-gated channel alpha subunit 5	Homo sapiens	83-88
19853591-1	2010	Oxidative metabolism of propranolol (PL) enantiomers (R-PL and S-PL) to 4-hydroxypropranolol (4-OH-PL), 5-OH-PL and N-deisopropylpropranolol (NDP) was examined in hepatic microsomes from cynomolgus and marmoset monkeys and in small intestinal microsomes from monkeys and humans.	Propranolol	24-35	norrin cystine knot growth factor NDP	Homo sapiens	142-145
19853591-1	2010	Oxidative metabolism of propranolol (PL) enantiomers (R-PL and S-PL) to 4-hydroxypropranolol (4-OH-PL), 5-OH-PL and N-deisopropylpropranolol (NDP) was examined in hepatic microsomes from cynomolgus and marmoset monkeys and in small intestinal microsomes from monkeys and humans.	Propranolol	37-39	norrin cystine knot growth factor NDP	Homo sapiens	142-145
19853591-1	2010	Oxidative metabolism of propranolol (PL) enantiomers (R-PL and S-PL) to 4-hydroxypropranolol (4-OH-PL), 5-OH-PL and N-deisopropylpropranolol (NDP) was examined in hepatic microsomes from cynomolgus and marmoset monkeys and in small intestinal microsomes from monkeys and humans.	Propranolol	54-58	norrin cystine knot growth factor NDP	Homo sapiens	142-145
19853591-2	2010	In hepatic microsomes, levels of oxidation activities were similar between the two monkey species, and substrate enantioselectivity (R-PL&lt;S-PL) was observed in the formation of 5-OH-PL and/or NDP.	Propranolol	133-137	norrin cystine knot growth factor NDP	Homo sapiens	195-198
19853591-5	2010	In small intestinal microsomes, activity levels were much higher in cynomolgus monkeys than in marmosets and humans and reversed substrate enantioselectivity (R-PL&gt;S-PL) was seen in the formation of NDP in cynomolgus monkeys and humans and in the formation of 5-OH-PL in marmosets.	Propranolol	159-163	norrin cystine knot growth factor NDP	Homo sapiens	202-205
19853591-5	2010	In small intestinal microsomes, activity levels were much higher in cynomolgus monkeys than in marmosets and humans and reversed substrate enantioselectivity (R-PL&gt;S-PL) was seen in the formation of NDP in cynomolgus monkeys and humans and in the formation of 5-OH-PL in marmosets.	Propranolol	161-163	norrin cystine knot growth factor NDP	Homo sapiens	202-205
20634935-9	2010	Propranolol resulting in hepatic compromise as indicated by high lactate dehydrogenase and alanine aminotransferase levels.	Propranolol	0-11	glutamic--pyruvic transaminase	Homo sapiens	91-115
20460826-7	2010	Ligand binding experiments using propranolol as a F1(*)S ligand and disopyramide as an A specific ligand indicated that the capacity of rF1(*)S and C149R-A is equivalent to those ligands as well as F1(*)S and A from serum.	Propranolol	33-44	Renal disease susceptibility QTL 1	Rattus norvegicus	136-139
20460826-7	2010	Ligand binding experiments using propranolol as a F1(*)S ligand and disopyramide as an A specific ligand indicated that the capacity of rF1(*)S and C149R-A is equivalent to those ligands as well as F1(*)S and A from serum.	Propranolol	33-44	Renal disease susceptibility QTL 1	Rattus norvegicus	137-139
19778180-2	2010	The present study was designed to assess the alteration of basic fibroblast growth factor (bFGF) and transforming growth factor-beta (TGFbeta) expression in the rat ventral prostate in response to beta-AR blockade with propranolol.	Propranolol	219-230	fibroblast growth factor 2	Rattus norvegicus	59-89
19778180-2	2010	The present study was designed to assess the alteration of basic fibroblast growth factor (bFGF) and transforming growth factor-beta (TGFbeta) expression in the rat ventral prostate in response to beta-AR blockade with propranolol.	Propranolol	219-230	fibroblast growth factor 2	Rattus norvegicus	91-95
19778180-5	2010	Propranolol treatment resulted in considerable decrease of bFGF staining intensity in both stromal and epithelial cells, while the immunostaining pattern for TGFbeta was almost abolished.	Propranolol	0-11	fibroblast growth factor 2	Rattus norvegicus	59-63
19740083-4	2009	METHOD: Using Madin-Darby canine kidney II cells stably expressing the uptake transporter OCT2, we analysed whether the beta-blockers bisoprolol, carvedilol, metoprolol and propranolol inhibit the transport of OCT2 substrates 1-methyl-4-phenylpyridinium (MPP(+)) and metformin.	Propranolol	173-184	solute carrier family 22 member 2	Canis lupus familiaris	210-214
19581315-1	2009	AIMS: The present study was designed to investigate whether the beneficial effects of beta-blocker propranolol are related to regulation of microRNA miR-1.	Propranolol	99-110	microRNA 1	Rattus norvegicus	149-154
19581315-3	2009	Overexpression of miR-1 was observed in ischaemic myocardium and strikingly, administration of propranolol reversed the up-regulation of miR-1 nearly back to the control level.	Propranolol	95-106	microRNA 1	Rattus norvegicus	18-23
19581315-3	2009	Overexpression of miR-1 was observed in ischaemic myocardium and strikingly, administration of propranolol reversed the up-regulation of miR-1 nearly back to the control level.	Propranolol	95-106	microRNA 1	Rattus norvegicus	137-142
19581315-4	2009	In agreement with its miR-1-reducing effect, propranolol relieved myocardial injuries during ischaemia, restored the membrane depolarization and cardiac conduction slowing, by rescuing the expression of inward rectifying K(+) channel subunit Kir2.1 and gap junction channel connexin 43.	Propranolol	45-56	microRNA 1	Rattus norvegicus	22-27
19581315-4	2009	In agreement with its miR-1-reducing effect, propranolol relieved myocardial injuries during ischaemia, restored the membrane depolarization and cardiac conduction slowing, by rescuing the expression of inward rectifying K(+) channel subunit Kir2.1 and gap junction channel connexin 43.	Propranolol	45-56	gap junction protein, alpha 1	Rattus norvegicus	274-285
19581315-6	2009	Moreover, propranolol inhibited the beta-adrenoceptor-cAMP-PKA signalling pathway and suppressed SRF expression.	Propranolol	10-21	serum response factor	Rattus norvegicus	97-100
19740083-6	2009	Moreover, all beta-blockers significantly inhibited OCT2-mediated metformin uptake (IC(50) for bisoprolol: 2.4 microM, IC(50) for carvedilol: 2.3 microM, IC(50) for metoprolol: 50.2 microM and IC(50) for propranolol: 8.3 microM).	Propranolol	204-215	solute carrier family 22 member 2	Canis lupus familiaris	52-56
19467330-0	2009	Propranolol adrenergic blockade inhibits human brain endothelial cells tubulogenesis and matrix metalloproteinase-9 secretion.	Propranolol	0-11	matrix metallopeptidase 9	Homo sapiens	89-115
19467330-7	2009	Propranolol significantly reduced MMP-9 secretion upon treatment with the tumor-promoting agent phorbol 12-myristate 13-acetate, while secretion of MMP-2 remained unaffected.	Propranolol	0-11	matrix metallopeptidase 9	Homo sapiens	34-39
19467330-9	2009	Our data are therefore indicative of a selective role for propranolol in inhibiting MMP-9 secretion and HBMEC tubulogenesis which could potentially add to propranolol"s anti-angiogenic properties.	Propranolol	58-69	matrix metallopeptidase 9	Homo sapiens	84-89
19230851-5	2009	We observed that the AA release induced by exposure of RAW 264.7 macrophages to the TLR-4 specific agonist Kdo(2)-Lipid A is blocked by the PAP-1 inhibitors bromoenol lactone (BEL) and propranolol as well as the PKC inhibitor Ro 31-8220; however these inhibitors did not reduce AA release stimulated by Ca+2 influx induced by the P2X7 purinergic receptor agonist ATP.	Propranolol	185-196	toll like receptor 4	Homo sapiens	84-89
19747477-6	2009	In contrast, the tachycardiac responses to 26RFa were significantly attenuated by bilateral cervical vagotomy and beta-adrenoreceptor antagonist propranolol.	Propranolol	145-156	pyroglutamylated RFamide peptide	Rattus norvegicus	43-48
19230851-5	2009	We observed that the AA release induced by exposure of RAW 264.7 macrophages to the TLR-4 specific agonist Kdo(2)-Lipid A is blocked by the PAP-1 inhibitors bromoenol lactone (BEL) and propranolol as well as the PKC inhibitor Ro 31-8220; however these inhibitors did not reduce AA release stimulated by Ca+2 influx induced by the P2X7 purinergic receptor agonist ATP.	Propranolol	185-196	PDGFA associated protein 1	Homo sapiens	140-145
19464246-7	2009	The IC(50) values for beta(2)-adrenergic antagonist propranolol were 60 and 37 nM, the Z" values were 0.51 and 0.77, and the signal-to-background ratios were 5.5 and 16.0 for C0 and C12, respectively.	Propranolol	52-63	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	22-28
19946348-8	2009	RESULTS: Propranolol significantly decreased VEGF production and also MMP-2 activity in PMA-activated human leukemic cell lines Molt-4, Jurkat and U937 at 30 microM concentration of the drug compared to untreated control cells (P&lt;0.05).	Propranolol	9-20	vascular endothelial growth factor A	Homo sapiens	45-49
19946348-8	2009	RESULTS: Propranolol significantly decreased VEGF production and also MMP-2 activity in PMA-activated human leukemic cell lines Molt-4, Jurkat and U937 at 30 microM concentration of the drug compared to untreated control cells (P&lt;0.05).	Propranolol	9-20	matrix metallopeptidase 2	Homo sapiens	70-75
19577538-6	2009	The cold exposure-induced changes of CIDEA and UCP1 were attenuated by intraperitoneal pretreatment with propranolol (a non-selective beta-adrenoreceptor antagonist) (2mg/animal) or SR59230A (a selective beta(3)-adrenoreceptor antagonist) (2mg/animal), respectively.	Propranolol	105-116	cell death-inducing DFFA-like effector a	Rattus norvegicus	37-42
19577538-6	2009	The cold exposure-induced changes of CIDEA and UCP1 were attenuated by intraperitoneal pretreatment with propranolol (a non-selective beta-adrenoreceptor antagonist) (2mg/animal) or SR59230A (a selective beta(3)-adrenoreceptor antagonist) (2mg/animal), respectively.	Propranolol	105-116	uncoupling protein 1	Rattus norvegicus	47-51
19577538-6	2009	The cold exposure-induced changes of CIDEA and UCP1 were attenuated by intraperitoneal pretreatment with propranolol (a non-selective beta-adrenoreceptor antagonist) (2mg/animal) or SR59230A (a selective beta(3)-adrenoreceptor antagonist) (2mg/animal), respectively.	Propranolol	105-116	adrenoceptor beta 3	Rattus norvegicus	204-226
19502419-4	2009	The effects of IL-6 on both AMPK activity and energy state were inhibited by coincubation with propranolol, suggesting involvement of beta-adrenergic signaling.	Propranolol	95-106	interleukin 6	Rattus norvegicus	15-19
19446054-5	2009	Adrenaline also significantly inhibited gene transactivation by sry-type HMG box 9 (Sox9) family members essential for chondrogenic differentiation in a manner prevented by the general betaAdR antagonist propranolol, with a concomitant significant decrease in the levels of Sox6 mRNA and corresponding protein, in ATDC5 cells and primary cultured mouse costal chondrocytes.	Propranolol	204-215	SRY (sex determining region Y)-box 9	Mus musculus	64-82
19446054-5	2009	Adrenaline also significantly inhibited gene transactivation by sry-type HMG box 9 (Sox9) family members essential for chondrogenic differentiation in a manner prevented by the general betaAdR antagonist propranolol, with a concomitant significant decrease in the levels of Sox6 mRNA and corresponding protein, in ATDC5 cells and primary cultured mouse costal chondrocytes.	Propranolol	204-215	SRY (sex determining region Y)-box 9	Mus musculus	84-88
19446054-5	2009	Adrenaline also significantly inhibited gene transactivation by sry-type HMG box 9 (Sox9) family members essential for chondrogenic differentiation in a manner prevented by the general betaAdR antagonist propranolol, with a concomitant significant decrease in the levels of Sox6 mRNA and corresponding protein, in ATDC5 cells and primary cultured mouse costal chondrocytes.	Propranolol	204-215	SRY (sex determining region Y)-box 6	Mus musculus	274-278
19429833-7	2009	Propranolol (1 microM) inhibited the rise in NO induced by isoproterenol or the beta(2)-adrenoceptor agonists salbutamol, terbutaline, or fenoterol.	Propranolol	0-11	adrenoceptor beta 2	Rattus norvegicus	80-100
19904008-8	2009	Hence, taking account of CYP1A2 contribution to the metabolism of endogenous substances (steroids), drugs (xanthine derivatives, phenacetin, propranolol, imipramine, phenothiazine neuroleptics, clozapine) and carcinogenic compounds, the inhibition of CYP1A2 by perazine may be of physiological, pharmacological and toxicological importance.	Propranolol	141-152	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	25-31
19053964-6	2009	Propranolol reduced resting heart rate (58 +/- 6 vs. 69 +/- 8 beats min(-1)) and at exercise exhaustion, cardiac output (16.6 +/- 3.6 L min(-1)) and arterial lactate (9.4 +/- 3.7 mM) were attenuated with a reduction in exercise capacity from 239 +/- 42 to 209 +/- 31 W (all P &lt; 0.05).	Propranolol	0-11	CD59 molecule (CD59 blood group)	Homo sapiens	68-74
19053964-6	2009	Propranolol reduced resting heart rate (58 +/- 6 vs. 69 +/- 8 beats min(-1)) and at exercise exhaustion, cardiac output (16.6 +/- 3.6 L min(-1)) and arterial lactate (9.4 +/- 3.7 mM) were attenuated with a reduction in exercise capacity from 239 +/- 42 to 209 +/- 31 W (all P &lt; 0.05).	Propranolol	0-11	CD59 molecule (CD59 blood group)	Homo sapiens	136-142
19463919-4	2009	It was hypothesized that 3 weeks of activity-wheel running would (1) reverse deficits in male copulatory performance and (2) increase GAL mRNA in the MPOA after beta-adrenoreceptor blockade with propranolol.	Propranolol	195-206	galanin and GMAP prepropeptide	Rattus norvegicus	134-137
19401196-4	2009	Although portal pressure and portal flow were reduced, treatment with either propranolol or nifedipine alone for 3 weeks did not decrease the augmented opening angle of the portal vein, while combined treatment with propranolol and nifedipine markedly reduced the increased opening angle of the portal vein and endothelial nitric oxide synthase (eNOS) mRNA expression but not inducible nitric oxide synthase (iNOS) mRNA expression.	Propranolol	216-227	nitric oxide synthase 2	Rattus norvegicus	376-407
19387337-8	2009	Our data suggest that propranolol may prevent the development of PDAC by blocking cAMP-dependent intracellular signaling, cAMP-dependent release of epidermal growth factor, and PKA-dependent release of vascular endothelial growth factor while additionally downregulating the alpha7 nAChR by inhibiting cAMP-mediated subunit assembly.	Propranolol	22-33	vascular endothelial growth factor A	Homo sapiens	202-236
19381505-5	2009	For all patients a provocative growth hormone test was performed with propranolol and L-dopa and serum IGF-1 and IGFBP-3 were measured.	Propranolol	70-81	growth hormone 1	Homo sapiens	31-45
19334040-10	2009	Fenoterol nearly doubled RANKL mRNA and this was inhibited by propranolol.	Propranolol	62-73	TNF superfamily member 11	Homo sapiens	25-30
19401196-4	2009	Although portal pressure and portal flow were reduced, treatment with either propranolol or nifedipine alone for 3 weeks did not decrease the augmented opening angle of the portal vein, while combined treatment with propranolol and nifedipine markedly reduced the increased opening angle of the portal vein and endothelial nitric oxide synthase (eNOS) mRNA expression but not inducible nitric oxide synthase (iNOS) mRNA expression.	Propranolol	216-227	nitric oxide synthase 2	Rattus norvegicus	409-413
19380024-4	2009	The mRNA expression of the ABCB1 gene (previously MDR1) in human colon carcinoma HT-29 cell line was measured after treatment with an adrenergic receptor agonist (adrenaline) and various antagonists (propranolol, prazosin, and yohimbine).	Propranolol	200-211	ATP binding cassette subfamily B member 1	Homo sapiens	27-32
19454479-6	2009	This is particularly evident in propranolol-treated retinas, in which the DHA-mediated increase in SNARE pairing overcomes the tethering block, including dissociation of Sec8 into the cytosol.	Propranolol	32-43	exocyst complex component 4	Homo sapiens	170-174
19453634-5	2009	We found that Per1 and Cry2 genes were similarly regulated by the nocturnal release of NE: levels of Per1 and Cry2 mRNA displayed a nocturnal increase that was maintained after 2 days in constant darkness (DD) but abolished after 2 days under constant light (LL), a condition that suppresses endogenous NE release, or after an early night administration of the adrenergic antagonist propranolol.	Propranolol	383-394	cryptochrome-2	Mesocricetus auratus	23-27
19351748-9	2009	In the HeyA8 and SKOV3ip1 models, surgery significantly increased microvessel density (CD31) and vascular endothelial growth factor expression, which were blocked by propranolol treatment.	Propranolol	166-177	platelet/endothelial cell adhesion molecule 1	Mus musculus	87-91
19251820-10	2009	Moreover, out of a set of 27 compounds p.270Ala>Ser OCT2 was significantly less sensitive to inhibition by cimetidine, flurazepam, metformin, mexiletine, propranolol, and verapamil than wild-type OCT2 (e.g., for propranolol: IC(50) wild type versus p.270Ala>Ser 189 versus 895 microM, P < 0.001).	Propranolol	154-165	solute carrier family 22 member 2	Homo sapiens	52-56
19251820-10	2009	Moreover, out of a set of 27 compounds p.270Ala>Ser OCT2 was significantly less sensitive to inhibition by cimetidine, flurazepam, metformin, mexiletine, propranolol, and verapamil than wild-type OCT2 (e.g., for propranolol: IC(50) wild type versus p.270Ala>Ser 189 versus 895 microM, P < 0.001).	Propranolol	154-165	solute carrier family 22 member 2	Homo sapiens	196-200
19251820-10	2009	Moreover, out of a set of 27 compounds p.270Ala>Ser OCT2 was significantly less sensitive to inhibition by cimetidine, flurazepam, metformin, mexiletine, propranolol, and verapamil than wild-type OCT2 (e.g., for propranolol: IC(50) wild type versus p.270Ala>Ser 189 versus 895 microM, P < 0.001).	Propranolol	212-223	solute carrier family 22 member 2	Homo sapiens	52-56
19222907-4	2009	Adrenergic antagonists such as phentolamine and propranolol were added to the incubation medium to investigate their effects on Rg1 uptake.	Propranolol	48-59	protein phosphatase 1 regulatory subunit 3A	Homo sapiens	128-131
19320892-11	2009	The levels of matrix metalloproteases (MMP-2 and MMP-9) decreased in the propranolol- and atenolol-treated animals.	Propranolol	73-84	matrix metallopeptidase 2	Rattus norvegicus	39-44
19222907-9	2009	The effect of adrenergic antagonists on adrenaline-induced uptake of Rg1 was investigated and it was found that the enhancement effect was attenuated by the co-treatment with propranolol but not phentolamine.	Propranolol	175-186	protein phosphatase 1 regulatory subunit 3A	Homo sapiens	69-72
19320892-11	2009	The levels of matrix metalloproteases (MMP-2 and MMP-9) decreased in the propranolol- and atenolol-treated animals.	Propranolol	73-84	matrix metallopeptidase 9	Rattus norvegicus	49-54
19754423-5	2009	Typical CYP1A2 substrates generally contain planar ring that can fit the narrow and planar active site of the enzyme, such as propranolol, clozapine, guanabenz, flutamide, imatinib, thalidomide, carbamazepine, lidocaine, theophylline, tacrine, tizanidine, zolpidem, riluzole, zileuton, and leflunomide.	Propranolol	126-137	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	8-14
19259968-10	2009	On the contrary, the beta-AR antagonists propranolol or sotalol, the beta(1)/beta(2)-AR antagonists alprenolol or pindolol, or the specific beta(2)-AR antagonist ICI 118,551 blocked the action of nortriptyline.	Propranolol	41-52	adrenergic receptor, beta 1	Mus musculus	21-28
18814142-4	2009	Exposure to adrenaline not only increased cAMP formation, phosphorylation of cAMP responsive element (CRE) binding protein (CREB) on serine133 and CRE reporter activity in a manner sensitive to propranolol, but also rendered C3H10T1/2 cells resistant to the cytotoxicity of hydrogen peroxide, but not of either 2,4-dinitirophenol or tunicamycin.	Propranolol	194-205	cAMP responsive element binding protein 1	Mus musculus	124-128
19672719-7	2009	Also, the absorption of various drugs such as propranolol through P-glycoprotein (P-gp) efflux transporter is low and erratic.	Propranolol	46-57	ATP binding cassette subfamily B member 1	Homo sapiens	66-80
19672719-7	2009	Also, the absorption of various drugs such as propranolol through P-glycoprotein (P-gp) efflux transporter is low and erratic.	Propranolol	46-57	ATP binding cassette subfamily B member 1	Homo sapiens	82-86
19095864-10	2009	In Experiment 2, CSF IL-6 concentrations in the propranolol and butoxamine groups were significantly lower compared with those in the control group (P &lt; 0.01 and P &lt; 0.05 for each group).	Propranolol	48-59	interleukin 6	Rattus norvegicus	21-25
19817501-25	2009	Since the contribution of CYP2D6 is greater for metoprolol than for carvedilol, propranolol and timolol, a stronger gene-dose effect is seen with this beta-blocker, while such an effect is lesser or marginal in other beta-blockers.	Propranolol	80-91	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	26-32
19195502-0	2009	Effect of beta blockers (metoprolol or propranolol) on effect of simvastatin in lowering C-reactive protein in acute myocardial infarction.	Propranolol	39-50	C-reactive protein	Homo sapiens	89-107
19219745-4	2009	Testosterone, propranolol, diclofenac, and midazolam were determined as specific substrates of rat CYP2C11, CYP2D2, CYP2C6, and CYP3A, respectively.	Propranolol	14-25	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	99-106
19060758-0	2009	Propranolol restores the tumor necrosis factor-alpha response of circulating inflammatory monocytes and granulocytes after burn injury and sepsis.	Propranolol	0-11	tumor necrosis factor	Mus musculus	25-52
19060758-17	2009	Of importance, propranolol treatment partially restored the MFI of ic-TNF (2177 +/- 114) and increased the percentage of inflammatory monocyte subset (F4/80+Gr1+) in BS by 70% compared with saline treatment.	Propranolol	15-26	tumor necrosis factor	Mus musculus	70-73
19060758-17	2009	Of importance, propranolol treatment partially restored the MFI of ic-TNF (2177 +/- 114) and increased the percentage of inflammatory monocyte subset (F4/80+Gr1+) in BS by 70% compared with saline treatment.	Propranolol	15-26	adhesion G protein-coupled receptor E1	Mus musculus	151-156
19010431-8	2009	Propranolol also attenuated the expression of conditioned fear responses when applied before the CS1 test session.	Propranolol	0-11	catalase	Rattus norvegicus	97-100
19219745-4	2009	Testosterone, propranolol, diclofenac, and midazolam were determined as specific substrates of rat CYP2C11, CYP2D2, CYP2C6, and CYP3A, respectively.	Propranolol	14-25	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	128-133
19808432-9	2008	CONCLUSIONS: Our study demonstrates the molecular basis for a malignant perinatal presentation of long-QT syndrome, illustrates novel functional and pharmacological properties of SCN5A-G1631D, which caused the disorder, and reveals therapeutic benefits of propranolol block of mutant sodium channels in this setting.	Propranolol	256-267	sodium voltage-gated channel alpha subunit 5	Homo sapiens	179-184
19052221-5	2008	We were able to see that propranolol significantly reduced PMd-Fos expression in response to cat odor and that beta-adrenoceptor blockade in the PMd, before cat odor exposure, reduced defensive responses to the cat odor and to the cat odor-related environment.	Propranolol	25-36	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	63-66
18805435-5	2008	Treatment of cells with alpha-bungarotoxin (alpha-BTX, alpha7nAChR antagonist) or propranolol (beta-adrenergic receptor antagonist) blocked NNK-induced COX-2/PGE(2) and cell proliferation, while nicotine-mediated cell growth and COX-2/PGE(2) induction can only be suppressed by propranolol, but not alpha-BTX.	Propranolol	82-93	prostaglandin-endoperoxide synthase 2	Homo sapiens	152-157
19043274-4	2008	Diclofenac and propranolol are reported to bind to albumin and alpha(1)-acid glycoprotein (AGP), respectively.	Propranolol	15-26	orosomucoid 1	Rattus norvegicus	63-89
19043274-4	2008	Diclofenac and propranolol are reported to bind to albumin and alpha(1)-acid glycoprotein (AGP), respectively.	Propranolol	15-26	orosomucoid 1	Rattus norvegicus	91-94
19050521-13	2008	Cellular proliferation, myofibroblast density, collagen deposition, and active matrix metalloproteinase-2 levels were reduced in the control group compared with the propranolol-treated group 63 days after burning.	Propranolol	165-176	matrix metallopeptidase 2	Rattus norvegicus	79-105
18805435-5	2008	Treatment of cells with alpha-bungarotoxin (alpha-BTX, alpha7nAChR antagonist) or propranolol (beta-adrenergic receptor antagonist) blocked NNK-induced COX-2/PGE(2) and cell proliferation, while nicotine-mediated cell growth and COX-2/PGE(2) induction can only be suppressed by propranolol, but not alpha-BTX.	Propranolol	82-93	prostaglandin-endoperoxide synthase 2	Homo sapiens	229-234
19058308-0	2008	Effect of propranolol on the splanchnic and peripheral renin angiotensin system in cirrhotic patients.	Propranolol	10-21	renin	Homo sapiens	55-60
18725258-3	2008	Coadministration of propranolol, a P-gp inhibitor, decreased the distribution of itraconazole to the skin in wild-type mice, but not in mdr1a/1b(-/-) mice.	Propranolol	20-31	phosphoglycolate phosphatase	Mus musculus	35-39
18421015-5	2008	Propranolol inhalation resulted in enhanced LPS-induced lung inflammation, which was reflected by a stronger secretion of TNF-alpha, IL-6, and monocyte chemoattractant protein-1 into BALF and by enhanced coagulation activation (thrombin-antithrombin complexes).	Propranolol	0-11	tumor necrosis factor	Mus musculus	122-131
18790839-8	2008	Intrinsic HR (IHR) and chronotropic responses to a full-blocking dose of propranolol and atropine were reduced during diabetes (260 +/- 7 vs. 316 +/- 6, -19 +/- 2 vs. -43 +/- 6, and 39 +/- 3 vs. 68 +/- 8 beats/min), and leptin treatment restored these variables to normal (300 +/- 7, -68 +/- 10, and 71 +/- 8 beats/min).	Propranolol	73-84	leptin	Rattus norvegicus	220-226
18814223-1	2008	OBJECTIVE: The present study tested the hypothesis that intracoronary (IC) propranolol improves clinical outcomes with percutaneous coronary intervention (PCI) when used with background Gp IIb/IIIa receptor blockade.	Propranolol	75-86	integrin subunit alpha 2b	Homo sapiens	186-192
18606741-4	2008	We expressed and purified the R108E and R108E/D293N mutants and compared their ability with that of native CYP2C9 to interact with (S)-warfarin, diclofenac, pyrene, propranolol, and ibuprofen amine.	Propranolol	165-176	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	107-113
18421015-5	2008	Propranolol inhalation resulted in enhanced LPS-induced lung inflammation, which was reflected by a stronger secretion of TNF-alpha, IL-6, and monocyte chemoattractant protein-1 into BALF and by enhanced coagulation activation (thrombin-antithrombin complexes).	Propranolol	0-11	interleukin 6	Mus musculus	133-137
18421015-5	2008	Propranolol inhalation resulted in enhanced LPS-induced lung inflammation, which was reflected by a stronger secretion of TNF-alpha, IL-6, and monocyte chemoattractant protein-1 into BALF and by enhanced coagulation activation (thrombin-antithrombin complexes).	Propranolol	0-11	chemokine (C-C motif) ligand 2	Mus musculus	143-177
18563911-1	2008	Propranolol, a nonselective beta blocker, exerts blocking activity both on beta1 adrenoceptors and beta2 ones, with the S-enantiomer being more active than the R-enantiomer.	Propranolol	0-11	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	99-104
18755242-7	2008	The effect of 1 microg/rat of orexin-A on plasma FFA was eliminated by propranolol hydrochloride, a beta-adrenergic receptor blocker, and also by diphenhydramine.	Propranolol	71-96	hypocretin neuropeptide precursor	Rattus norvegicus	30-38
18574075-7	2008	In normotensive subjects, t-PA release by epinephrine was not affected by phentolamine (8 microg/100 mL per minute) coinfusion and was abolished in the presence of propanolol (10 microg/100 mL per minute).	Propranolol	164-174	plasminogen activator, tissue type	Homo sapiens	26-30
18403423-5	2008	Administration of a non-selective beta-adrenergic (beta(1) + beta(2)) receptor antagonist (propranolol) reduced heart rate (69 +/- 8 to 58 +/- 6 beats min(-1)) and exercise capacity (239 +/- 42 to 209 +/- 31 W; P &lt; 0.05) with arterial lactate reaching 9.4 +/- 3.6 mm.	Propranolol	91-102	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	34-58
18534571-4	2008	Propranolol and ICI 118551, but not atenolol, demonstrated a concentration-dependent inhibition of caspase 3-like activity.	Propranolol	0-11	caspase 3	Homo sapiens	99-108
18534571-5	2008	Propranolol and ICI 118551 directly inhibited the enzymatic activity of recombinant caspase 9 while atenolol did not; however, none of the beta-adrenoceptor blockers that were examined directly blocked caspases 2 or 3 activity.	Propranolol	0-11	caspase 9	Homo sapiens	84-93
18534571-6	2008	In isolated mitochondria, propranolol and ICI 118551 inhibited staurosporine-induced cytochrome c release while atenolol did not.	Propranolol	26-37	cytochrome c, somatic	Homo sapiens	85-97
18534571-7	2008	We conclude that propranolol and ICI 118551 protect SH-SY5Y cells against staurosporine-induced apoptosis through a dual action on the mitochondria and on caspase 9 in a cell type and an apoptotic paradigm where the conventional inhibitors of mitochondrial permeability transition such as cyclosporin A and bongkrekic acid demonstrate no protection.	Propranolol	17-28	caspase 9	Homo sapiens	155-164
18588611-8	2008	The amount of necessary oxytocin for the first day of induction was less in the propranolol group.	Propranolol	80-91	oxytocin/neurophysin I prepropeptide	Homo sapiens	24-32
18588611-9	2008	CONCLUSION: Propranolol may shorten the induction duration and labor and reduce the amount of necessary oxytocin.	Propranolol	12-23	oxytocin/neurophysin I prepropeptide	Homo sapiens	104-112
18645412-5	2008	The pressor response to systemic CARTp was blocked by the beta-adrenergic receptor antagonist propranolol (2 mg/kg IV).	Propranolol	94-105	CART prepropeptide	Rattus norvegicus	33-38
18403719-5	2008	Here, we took advantage of the fact that isoproterenol, bucindolol and propranolol (full, partial, and inverse agonists for the AC pathway, respectively) all activate MAPK through the beta1-adrenergic receptor (beta1AR) to probe such conformational-biased signaling.	Propranolol	71-82	adrenoceptor beta 1	Homo sapiens	184-209
18403719-5	2008	Here, we took advantage of the fact that isoproterenol, bucindolol and propranolol (full, partial, and inverse agonists for the AC pathway, respectively) all activate MAPK through the beta1-adrenergic receptor (beta1AR) to probe such conformational-biased signaling.	Propranolol	71-82	adrenoceptor beta 1	Homo sapiens	211-218
18485346-0	2008	Propranolol promotes Egr1 gene expression in cardiomyocytes via beta-adrenoceptors.	Propranolol	0-11	early growth response 1	Mus musculus	21-25
18485346-1	2008	Recent research has revealed that propranolol, a beta-adrenoceptor antagonist, causes extracellular signal-regulated kinase (ERK) cascade activation, nuclear translocation of phospho-ERK and increased transcriptional activity in cultured cell lines.	Propranolol	34-45	mitogen-activated protein kinase 1	Mus musculus	86-123
18485346-1	2008	Recent research has revealed that propranolol, a beta-adrenoceptor antagonist, causes extracellular signal-regulated kinase (ERK) cascade activation, nuclear translocation of phospho-ERK and increased transcriptional activity in cultured cell lines.	Propranolol	34-45	mitogen-activated protein kinase 1	Mus musculus	125-128
18485346-1	2008	Recent research has revealed that propranolol, a beta-adrenoceptor antagonist, causes extracellular signal-regulated kinase (ERK) cascade activation, nuclear translocation of phospho-ERK and increased transcriptional activity in cultured cell lines.	Propranolol	34-45	mitogen-activated protein kinase 1	Mus musculus	183-186
18485346-2	2008	Given the importance of beta-adrenoceptor antagonists in the treatment of heart failure, we evaluated the capability of propranolol of promoting the ERK-dependent gene expression at the cardiomyocyte level.	Propranolol	120-131	mitogen-activated protein kinase 1	Mus musculus	149-152
18485346-4	2008	Propranolol, administered at the dose of 10 mg/kg/day in C57BL/6 mice, caused a approximately 19-fold increase of Egr1 mRNA expression in left ventricular myocardium along with a approximately 2.1-fold increase of Egr1 protein expression.	Propranolol	0-11	early growth response 1	Mus musculus	114-118
18485346-4	2008	Propranolol, administered at the dose of 10 mg/kg/day in C57BL/6 mice, caused a approximately 19-fold increase of Egr1 mRNA expression in left ventricular myocardium along with a approximately 2.1-fold increase of Egr1 protein expression.	Propranolol	0-11	early growth response 1	Mus musculus	214-218
18485346-7	2008	The effect of propranolol on Egr1 mRNA expression was abrogated in mice lacking beta(1)- and beta(2)-adrenoceptors indicating that propranolol increases Egr1 mRNA expression in a beta-adrenoceptor-dependent manner.	Propranolol	14-25	early growth response 1	Mus musculus	29-33
18485346-7	2008	The effect of propranolol on Egr1 mRNA expression was abrogated in mice lacking beta(1)- and beta(2)-adrenoceptors indicating that propranolol increases Egr1 mRNA expression in a beta-adrenoceptor-dependent manner.	Propranolol	14-25	early growth response 1	Mus musculus	153-157
18485346-7	2008	The effect of propranolol on Egr1 mRNA expression was abrogated in mice lacking beta(1)- and beta(2)-adrenoceptors indicating that propranolol increases Egr1 mRNA expression in a beta-adrenoceptor-dependent manner.	Propranolol	131-142	early growth response 1	Mus musculus	29-33
18485346-7	2008	The effect of propranolol on Egr1 mRNA expression was abrogated in mice lacking beta(1)- and beta(2)-adrenoceptors indicating that propranolol increases Egr1 mRNA expression in a beta-adrenoceptor-dependent manner.	Propranolol	131-142	early growth response 1	Mus musculus	153-157
18485346-8	2008	The role of beta-adrenoceptors was further confirmed by showing that propranolol was able to increase Egr1 mRNA and protein levels in cultured neonatal cardiomyocytes.	Propranolol	69-80	early growth response 1	Mus musculus	102-106
18485346-9	2008	Collectively, these results indicate that propranolol promotes Egr1 gene expression in cardiomyocytes via beta-adrenoceptors with a mechanism which is independent of its ability to antagonize the effects of catecholamines.	Propranolol	42-53	early growth response 1	Mus musculus	63-67
18422814-11	2008	CONCLUSIONS: Combination treatment of propranolol plus irbesartan is well tolerated in cirrhotic patients when titrating the angiotensin II antagonist in a step-up manner, and it increases sodium excretion in patients with compensated or moderately decompensated cirrhosis.	Propranolol	38-49	angiotensinogen	Homo sapiens	125-139
18346817-7	2008	Moreover, pretreatment with a beta-adrenergic blocker, propranolol (5 mg kg(-1), iv), blocked all responses elicited by either icv or iv administration of amylin, whereas ablation of the area postrema in the hindbrain did not influence the effects of icv-administered amylin.	Propranolol	55-66	islet amyloid polypeptide	Rattus norvegicus	155-161
18346817-7	2008	Moreover, pretreatment with a beta-adrenergic blocker, propranolol (5 mg kg(-1), iv), blocked all responses elicited by either icv or iv administration of amylin, whereas ablation of the area postrema in the hindbrain did not influence the effects of icv-administered amylin.	Propranolol	55-66	islet amyloid polypeptide	Rattus norvegicus	268-274
21499463-13	2008	Propranolol treatment alone produced depression, and antagonized the effects of alprazolam and imipramine, even producing depression in combined treatments.In conclusion, our results reveal that alprazolam may produce antidepressant effects through the release of noradrenaline, which stimulates beta2 receptors to produce an antidepressant action.	Propranolol	0-11	hemoglobin, beta adult minor chain	Mus musculus	296-301
18445492-8	2008	Furthermore, the protective effect of Ang II on GI-R injury was abolished by propranolol (1 mg/kg, i.v.)	Propranolol	77-88	angiotensinogen	Rattus norvegicus	38-44
18535530-7	2008	Co administration of venlafaxine and propranolol, 2 drugs with affinity for the same cytochrome P450 isoenzyme (CYP2D6), may have contributed to drug accumulation and pulmonary toxicity.	Propranolol	37-48	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	112-118
18086539-8	2008	The effects of CRH were attenuated by intraventricular co-administration of the beta-adrenergic antagonist, propanolol, at bilateral doses that had no effect on retention alone (0.1, 1.0 microg).	Propranolol	108-118	corticotropin releasing hormone	Rattus norvegicus	15-18
20046763-8	2008	The optimized microcapsule formulation developed was found to comply with the USP drug release test-1 for extended release propranolol hydrochloride capsules.	Propranolol	123-148	serine protease 21	Homo sapiens	95-101
18222471-5	2008	Receptor stability in detergent solution was studied by isothermal denaturation, and it was found that the E122W and E122Y mutations enhanced the beta(2)AR thermal half-life by 9.3- and 6.7-fold, respectively, at 37 degrees C. The beta(1)AR was also stabilized by the introduction of tryptophan at Glu147(3.41), and the effect on protein behavior was similar to the rescue of the unstable wild-type receptor by the antagonist propranolol.	Propranolol	426-437	adrenoceptor beta 2	Homo sapiens	146-155
18328831-3	2008	Arachidonic acid release appeared to be dependent on calcium-independent phospholipase A(2) activation (iPLA(2)); bromoenol lactone, a specific inhibitor of calcium-independent iPLA(2), blocked arachidonic acid release with an IC(50) of approximately 2 x 10(-7)M. Propanolol, an inhibitor of phosphatidate phosphatase, and RHC-80267, an inhibitor of diglyceride lipase, had no effect on arachidonic acid release.	Propranolol	264-274	phospholipase A2, group VI	Mus musculus	177-184
18190786-4	2008	We bilaterally infused a high dose of the beta-AR antagonist propranolol (15mug in 1mul saline) into the CA1 region 30min before retention test and found that propranolol produced no deficit in retrieval of either 1-day or 7-day contextual fear.	Propranolol	61-72	carbonic anhydrase 1	Homo sapiens	105-108
18191303-14	2008	Propranolol and tetrodotoxin significantly (p&lt;0.01) inhibited 55% and 60%, respectively, the toxin-induced ANP release.	Propranolol	0-11	natriuretic peptide A	Rattus norvegicus	110-113
18356686-8	2008	The combination of aspirin with propranolol, single aspirin, and single propranolol all attenuated the acute response in plasma VWF:Ag levels to psychosocial stress.	Propranolol	32-43	von Willebrand factor	Homo sapiens	128-131
18356686-8	2008	The combination of aspirin with propranolol, single aspirin, and single propranolol all attenuated the acute response in plasma VWF:Ag levels to psychosocial stress.	Propranolol	72-83	von Willebrand factor	Homo sapiens	128-131
18297058-3	2008	Mining the resulting compendium revealed, first, that protein synthesis inhibitors can decouple coordination of nuclear and mtDNA transcription; second, that a subset of HMG-CoA reductase inhibitors, combined with propranolol, can cause mitochondrial toxicity, yielding potential clues about the etiology of statin myopathy; and, third, that structurally diverse microtubule inhibitors stimulate OXPHOS transcription while suppressing reactive oxygen species, via a transcriptional mechanism involving PGC-1alpha and ERRalpha, and thus may be useful in treating age-associated degenerative disorders.	Propranolol	214-225	PPARG coactivator 1 alpha	Homo sapiens	502-512
18297058-3	2008	Mining the resulting compendium revealed, first, that protein synthesis inhibitors can decouple coordination of nuclear and mtDNA transcription; second, that a subset of HMG-CoA reductase inhibitors, combined with propranolol, can cause mitochondrial toxicity, yielding potential clues about the etiology of statin myopathy; and, third, that structurally diverse microtubule inhibitors stimulate OXPHOS transcription while suppressing reactive oxygen species, via a transcriptional mechanism involving PGC-1alpha and ERRalpha, and thus may be useful in treating age-associated degenerative disorders.	Propranolol	214-225	estrogen related receptor alpha	Homo sapiens	517-525
17716858-3	2008	Here we show that the beta-adrenergic receptors antagonist propranolol along with peptidoglycan, but not LPS, combined with intradermal injection of a soluble protein, shifted the recall memory response to the Th1 type.	Propranolol	59-70	negative elongation factor complex member C/D	Homo sapiens	210-213
18301218-11	2008	Propranolol also accentuated the sepsis-induced increase in both IL-6 and TNF-alpha protein in muscle.	Propranolol	0-11	interleukin 6	Rattus norvegicus	65-69
18301218-11	2008	Propranolol also accentuated the sepsis-induced increase in both IL-6 and TNF-alpha protein in muscle.	Propranolol	0-11	tumor necrosis factor	Rattus norvegicus	74-83
18226521-5	2008	Using the new composite nanofiber mats as solid phase extraction materials, trace amount of propranolol (1 ng mL(-1)) in tap water can be easily detected after a simple sample preparation.	Propranolol	92-103	filamin B	Homo sapiens	121-124
17765415-4	2008	The simulated plasma concentrations and AUC values of propranolol increased proportionally to its dose; these levels were almost equivalent to intrinsic clearance (CLint1), presumed to be non-saturable.	Propranolol	54-65	clathrin interactor 1	Homo sapiens	164-170
17881186-2	2008	We investigated the effect of aspirin and propranolol on the responsiveness of plasma IL-6 levels to acute psychosocial stress.	Propranolol	42-53	interleukin 6	Homo sapiens	86-90
18446469-9	2008	The permeability of films to model drugs propranolol hydrochloride and diclofenac sodium was inversely proportional to the film thickness and dibutyl phthalate concentration in them; the permeability being greatest in PD-2 films containing 10% PEG 200.	Propranolol	41-66	PAF1 homolog, Paf1/RNA polymerase II complex component	Homo sapiens	218-222
18459050-8	2008	The in vitro drug release study revealed that HPMC K15 at a concentration of 40% of the dosage form weight was able to control the release of propranolol hydrochloride for 12 h, exhibit non-Fickian diffusion with first-order release kinetics where as at 40% KollidonSR same dosage forms show zero-order release kinetics.	Propranolol	142-167	keratin 15	Homo sapiens	51-54
18180620-0	2008	Effects of aspirin and propranolol on the acute psychological stress response in factor VIII coagulant activity: a randomized, double-blind, placebo-controlled experimental study.	Propranolol	23-34	cytochrome c oxidase subunit 8A	Homo sapiens	88-92
18180620-2	2008	We investigated whether aspirin and propranolol affect the responsiveness of plasma clotting factor VIII activity levels to acute psychosocial stress.	Propranolol	36-47	cytochrome c oxidase subunit 8A	Homo sapiens	100-104
18180620-7	2008	The clotting factor VIII activity level decreased from prestress to immediately poststress in the aspirin/propranolol group relative to the placebo group (P = 0.048) and the aspirin group (P &lt; 0.06).	Propranolol	106-117	cytochrome c oxidase subunit 8A	Homo sapiens	20-24
18180620-8	2008	Between 45 min and 105 min poststress, clotting factor VIII levels increased in the aspirin/propranolol group relative to the placebo group (P = 0.007) and the aspirin group (P = 0.039).	Propranolol	92-103	cytochrome c oxidase subunit 8A	Homo sapiens	55-59
18180620-10	2008	Propranolol in combination with aspirin diminished the acute response in clotting factor VIII activity to psychosocial stress compared with placebo medication and aspirin alone.	Propranolol	0-11	cytochrome c oxidase subunit 8A	Homo sapiens	89-93
17854797-8	2007	Our findings, coupled with the clinical course of the disease and the underlying pathomorphological changes, clearly suggest that differential mechanisms were responsible for the changes in the percentage of CD4(+)CD25(+) T lymphocytes in propranolol-treated adrenalectomized rats and only propranolol-treated rats with experimental allergic encephalomyelitis.	Propranolol	290-301	Cd4 molecule	Rattus norvegicus	208-211
17854797-8	2007	Our findings, coupled with the clinical course of the disease and the underlying pathomorphological changes, clearly suggest that differential mechanisms were responsible for the changes in the percentage of CD4(+)CD25(+) T lymphocytes in propranolol-treated adrenalectomized rats and only propranolol-treated rats with experimental allergic encephalomyelitis.	Propranolol	239-250	Cd4 molecule	Rattus norvegicus	208-211
17986621-8	2008	Moreover, pre-treatment with (+/-)-propanolol, an inhibitor of phosphatidic acid phosphohydrolases that are the downstream signaling molecules in the PLD pathway, significantly blocked hBD-2 mRNA induction by PMA in a dose-dependent manner.	Propranolol	29-45	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	150-153
17986621-8	2008	Moreover, pre-treatment with (+/-)-propanolol, an inhibitor of phosphatidic acid phosphohydrolases that are the downstream signaling molecules in the PLD pathway, significantly blocked hBD-2 mRNA induction by PMA in a dose-dependent manner.	Propranolol	29-45	defensin beta 4A	Homo sapiens	185-190
17975110-4	2007	However, IP injection of atropine (1 mg/kg), propranolol (1 mg/kg), or both drugs in combination unmasked elevated heart rates in PI3Kgamma(-/-) mice, suggesting altered sinoatrial node (SAN) function.	Propranolol	45-56	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	Mus musculus	130-139
17974982-5	2007	Activation of STAT3 was inhibited by blockade of the beta1- and beta2-adrenergic receptors with propranolol, and by blocking protein kinase A with KT5720, but not with the alpha receptor blockers prazosin (alpha1) and/or yohimbine (alpha2).	Propranolol	96-107	signal transducer and activator of transcription 3	Mus musculus	14-19
17974982-5	2007	Activation of STAT3 was inhibited by blockade of the beta1- and beta2-adrenergic receptors with propranolol, and by blocking protein kinase A with KT5720, but not with the alpha receptor blockers prazosin (alpha1) and/or yohimbine (alpha2).	Propranolol	96-107	hemoglobin, beta adult major chain	Mus musculus	53-58
17541981-6	2007	Moreover, PA-induced expressions of Bcl-2 and Bcl-xL were enhanced by propranolol, an inhibitor of PA phospholydrolase (PAP), whereas completely blocked by mepacrine, an inhibitor of phospholipase A(2) (PLA(2)), suggesting that PLA(2) metabolite of PA is responsible for the increases in Bcl-2 and Bcl-xL protein levels.	Propranolol	70-81	phospholipase A2, group IB, pancreas	Mus musculus	203-209
18165191-1	2007	The objective of the present research was to develop a bilayer tablet of propranolol hydrochloride using superdisintegrant sodium starch glycolate for the fast release layer and water immiscible polymers such as ethylcellulose, Eudragit RLPO and Eudragit RSPO for the sustaining layer.	Propranolol	73-98	R-spondin 1	Homo sapiens	255-259
17660394-9	2007	Propranolol, in contrast to hexamethonium, blocked the CGRP-evoked increase in heart rate in both transgenic and control animals.	Propranolol	0-11	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	55-59
18229608-4	2007	In culture supernatants of TNF-alpha-stimulated HaCaT cells, production of IL-6 and TNF-alpha could be enhanced by lithium carbonate; production of IL-6 and a panel of cytokines and growth factors could be enhanced by propranolol hydrochloride; and IL-6 was up-regulated by chloroquine diphosphate as well.	Propranolol	218-243	tumor necrosis factor	Homo sapiens	27-36
18229608-4	2007	In culture supernatants of TNF-alpha-stimulated HaCaT cells, production of IL-6 and TNF-alpha could be enhanced by lithium carbonate; production of IL-6 and a panel of cytokines and growth factors could be enhanced by propranolol hydrochloride; and IL-6 was up-regulated by chloroquine diphosphate as well.	Propranolol	218-243	interleukin 6	Homo sapiens	148-152
18229608-4	2007	In culture supernatants of TNF-alpha-stimulated HaCaT cells, production of IL-6 and TNF-alpha could be enhanced by lithium carbonate; production of IL-6 and a panel of cytokines and growth factors could be enhanced by propranolol hydrochloride; and IL-6 was up-regulated by chloroquine diphosphate as well.	Propranolol	218-243	interleukin 6	Homo sapiens	148-152
18229608-6	2007	Compared with HaCaT cells cultured with medium alone, propranolol hydrochloride at the concentration of 1 x 10(-6) mol x L(-1) could stimulate HaCaT cells to express higher level of IL-6 mRNA (P &lt; 0.05).	Propranolol	54-79	interleukin 6	Homo sapiens	182-186
17541981-6	2007	Moreover, PA-induced expressions of Bcl-2 and Bcl-xL were enhanced by propranolol, an inhibitor of PA phospholydrolase (PAP), whereas completely blocked by mepacrine, an inhibitor of phospholipase A(2) (PLA(2)), suggesting that PLA(2) metabolite of PA is responsible for the increases in Bcl-2 and Bcl-xL protein levels.	Propranolol	70-81	B cell leukemia/lymphoma 2	Mus musculus	36-41
17541981-6	2007	Moreover, PA-induced expressions of Bcl-2 and Bcl-xL were enhanced by propranolol, an inhibitor of PA phospholydrolase (PAP), whereas completely blocked by mepacrine, an inhibitor of phospholipase A(2) (PLA(2)), suggesting that PLA(2) metabolite of PA is responsible for the increases in Bcl-2 and Bcl-xL protein levels.	Propranolol	70-81	BCL2-like 1	Mus musculus	46-52
17609430-6	2007	Epinephrine-induced SS RBC adhesion, vaso-occlusion, and RBC organ trapping could be prevented by the beta-adrenergic receptor (beta-AR) antagonist, propranolol.	Propranolol	149-160	adrenergic receptor, beta 1	Mus musculus	102-126
17609430-6	2007	Epinephrine-induced SS RBC adhesion, vaso-occlusion, and RBC organ trapping could be prevented by the beta-adrenergic receptor (beta-AR) antagonist, propranolol.	Propranolol	149-160	adrenergic receptor, beta 1	Mus musculus	128-135
17592507-7	2007	Although propranolol blunted cardiomyocyte growth, with approximately an 11% increase in the LVW/BW ratio, it enhanced the expression of ANP, beta-MHC and skACT genes (10.5-fold, 27.7-fold and 22.7-fold, respectively).	Propranolol	9-20	myosin, heavy polypeptide 7, cardiac muscle, beta	Mus musculus	142-150
17592507-8	2007	Propranolol also enhanced phenylephrine-stimulated ANP and beta-MHC gene expression in cultured cardiomyocytes.	Propranolol	0-11	myosin, heavy polypeptide 7, cardiac muscle, beta	Mus musculus	59-67
17592507-10	2007	CONCLUSIONS AND IMPLICATIONS: Propranolol enhances expression of the hypertrophy-associated foetal genes mainly via the beta(1)-adrenoceptor blockade.	Propranolol	30-41	adrenergic receptor, beta 1	Mus musculus	120-140
17541981-6	2007	Moreover, PA-induced expressions of Bcl-2 and Bcl-xL were enhanced by propranolol, an inhibitor of PA phospholydrolase (PAP), whereas completely blocked by mepacrine, an inhibitor of phospholipase A(2) (PLA(2)), suggesting that PLA(2) metabolite of PA is responsible for the increases in Bcl-2 and Bcl-xL protein levels.	Propranolol	70-81	phospholipase A2, group IB, pancreas	Mus musculus	228-234
17541981-6	2007	Moreover, PA-induced expressions of Bcl-2 and Bcl-xL were enhanced by propranolol, an inhibitor of PA phospholydrolase (PAP), whereas completely blocked by mepacrine, an inhibitor of phospholipase A(2) (PLA(2)), suggesting that PLA(2) metabolite of PA is responsible for the increases in Bcl-2 and Bcl-xL protein levels.	Propranolol	70-81	B cell leukemia/lymphoma 2	Mus musculus	288-293
17541981-6	2007	Moreover, PA-induced expressions of Bcl-2 and Bcl-xL were enhanced by propranolol, an inhibitor of PA phospholydrolase (PAP), whereas completely blocked by mepacrine, an inhibitor of phospholipase A(2) (PLA(2)), suggesting that PLA(2) metabolite of PA is responsible for the increases in Bcl-2 and Bcl-xL protein levels.	Propranolol	70-81	BCL2-like 1	Mus musculus	298-304
17333164-1	2007	Detailed molecular dynamics (MD) simulations have been performed to reproduce and rationalize the experimental finding that the F483A mutant of CYP2D6 has lower affinity for R-propranolol than for S-propranolol.	Propranolol	174-187	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	144-150
17631921-8	2007	The effects of specific TSPO ligands PK 11195 and Ro5-4864 were reproduced by diazepam, which binds with high affinity both TSPO and central benzodiazepine receptors, but not by clonazepam, which binds exclusively to GABA receptor, and other amphiphilic substances such as DIDS and propranolol.	Propranolol	282-293	translocator protein	Homo sapiens	24-28
17446185-5	2007	The clenbuterol-induced increase in PGC-1alpha mRNA expression in mice was inhibited by pretreatment with the beta-AR antagonist propranolol.	Propranolol	129-140	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	36-46
17446185-5	2007	The clenbuterol-induced increase in PGC-1alpha mRNA expression in mice was inhibited by pretreatment with the beta-AR antagonist propranolol.	Propranolol	129-140	adrenergic receptor, beta 1	Mus musculus	110-117
17446185-9	2007	The exercise-induced increase in PGC-1alpha mRNA was inhibited by approximately 70% by propranolol or the beta2-AR-specific inhibitor ICI 118,551.	Propranolol	87-98	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	33-43
17333164-1	2007	Detailed molecular dynamics (MD) simulations have been performed to reproduce and rationalize the experimental finding that the F483A mutant of CYP2D6 has lower affinity for R-propranolol than for S-propranolol.	Propranolol	197-210	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	144-150
17333164-5	2007	The approach that calculates the free energies of exchanging R-propranolol with S-propranolol in the F483A mutant relative to the exchange free energy in WT CYP2D6 accurately reproduced the experimental binding data.	Propranolol	61-74	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	157-163
17376707-12	2007	Ex vivo, an increase in AGP serum concentration from 55 to 675 microg/ml resulted in a profound decrease in the free fraction of S(-)-propranolol from 14+/-0.6 to 1.9+/-0.3%.	Propranolol	130-145	orosomucoid 1	Rattus norvegicus	24-27
17253964-5	2007	Pre-treatment of rats with the beta-blocker propranolol fully blocked exercise-induced AMPK activation.	Propranolol	44-55	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	87-91
17635398-14	2007	During inhalation of isoflurane, the increased release of NO and iNOS protein from alveolar macrophages was also completely inhibited by propranolol.	Propranolol	137-148	nitric oxide synthase 2	Rattus norvegicus	65-69
17589660-1	2007	OBJECTIVE: To evaluate the analytical micromethod using liquid chromatography for the quantification of propranolol in children submitted to surgery of tetralogy of Fallot (TLF).	Propranolol	104-115	TATA-box binding protein like 1	Homo sapiens	173-176
17589660-10	2007	CONCLUSION: Propranolol monitoring of plasma concentrations of children (TLF) normalized after the last preoperative dose revealed a decline from the beginning of surgery to the second postoperative day, suggesting that, once redistribution was restored, propranolol washout was complete.	Propranolol	12-23	TATA-box binding protein like 1	Homo sapiens	73-76
17253964-7	2007	Adrenaline incubation of isolated adipocytes also increased the AMP/ATP ratio and AMPK activities, an effect blocked by propranolol.	Propranolol	120-131	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	82-86
17303121-7	2007	There was no significant difference in VEGF levels in diabetic rats and propranolol-treated diabetic rats (p&gt;0.05), but there was a significant difference in VEGF protein and mRNA expression in propranolol-treated diabetic rats and fosenopril sodium-treated diabetic rats (p&lt;0.01) without any significant difference in systolic blood pressure in the latter two groups (p&gt;0.05).	Propranolol	197-208	vascular endothelial growth factor A	Rattus norvegicus	161-165
17414346-1	2007	BACKGROUND: Propranolol, a nonselective beta1-2 antagonist, attenuates hypermetabolism and catabolism in severely burned patients.	Propranolol	12-23	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	40-47
17306457-7	2007	The effect of leptin on plasma FFA was eliminated by pretreatment with diphenhydramine and propranolol, a beta-adrenergic receptor blocker, and disappeared in suprachiasmatic nucleus (SCN)-lesioned rats.	Propranolol	91-102	leptin	Rattus norvegicus	14-20
17084978-7	2007	This phenomenon is completely blocked by the nonselective beta-adrenergic antagonist propranolol or by the combined administration of selective beta(2)- and beta(3)-adrenergic antagonists, while administration of beta(1)-adrenergic, alpha-adrenergic, or dopaminergic receptor antagonists fail to alter COMT-dependent pain sensitivity.	Propranolol	85-96	catechol-O-methyltransferase	Homo sapiens	302-306
17414346-12	2007	Analysis of the cytokine expression profile in 20 patients in each group revealed that propranolol significantly decreased serum tumor necrosis factor and interleukin-1beta compared with controls (p &lt; 0.05).	Propranolol	87-98	interleukin 1 beta	Homo sapiens	155-172
17079456-5	2006	Norepi treatment increased MMP-2, MMP-9, and VEGF levels in culture supernatants of HONE-1 cells, which could be inhibited by the beta-blocker propranolol.	Propranolol	143-154	matrix metallopeptidase 2	Homo sapiens	27-32
17108236-8	2007	Prenatal lung fluid absorption, when present as well as IL-1beta(Fr)-induced, was always propranolol- and amiloride-sensitive, suggesting that beta-adrenoceptor stimulation and the epithelial Na(+) channel (ENaC) were critical for the induced/stimulated lung fluid absorption.	Propranolol	89-100	interleukin-1 beta	Cavia porcellus	56-64
17118511-7	2007	RESULTS: Administration of propranolol in septic mice increased the splenocyte apoptosis rate, reduced the proliferative capacity of splenocytes, and modulated cellular cytokine release (IL-6, IFN-gamma).	Propranolol	27-38	interleukin 6	Mus musculus	187-191
17118511-7	2007	RESULTS: Administration of propranolol in septic mice increased the splenocyte apoptosis rate, reduced the proliferative capacity of splenocytes, and modulated cellular cytokine release (IL-6, IFN-gamma).	Propranolol	27-38	interferon gamma	Mus musculus	193-202
17265554-8	2007	Our results suggested that propranolol, Fcs and needling on Sanyinjiao (SP-6) and Neiguan (PC-6) may improve the bone mass of OVX rats, and it provides an alternative and potential therapy for the prevention of postmenopausal osteoporosis.	Propranolol	27-38	Sp6 transcription factor	Rattus norvegicus	72-76
17265554-8	2007	Our results suggested that propranolol, Fcs and needling on Sanyinjiao (SP-6) and Neiguan (PC-6) may improve the bone mass of OVX rats, and it provides an alternative and potential therapy for the prevention of postmenopausal osteoporosis.	Propranolol	27-38	proprotein convertase subtilisin/kexin type 5	Rattus norvegicus	91-95
17713356-9	2007	However, pretreatment of rats with the nonselective beta-AR blocker propranolol almost completely reversed the exercise-induced suppression of plasma TNF-alpha in response to LPS.	Propranolol	68-79	tumor necrosis factor	Rattus norvegicus	150-159
17079161-5	2006	This relaxation was fully abolished by 0.1microM propranolol or 1microM ICI 118,551 (a selective beta(2)-adrenoceptor antagonist).	Propranolol	49-60	beta-2 adrenergic receptor	Cavia porcellus	97-117
17151288-8	2007	Perturbation of this signaling pathway via inhibition of lipid phosphate phosphatase-1 (LPP-1) by propranolol or inhibition of the phosphatidylcholine-derived phosphatidic acid (PA) formation by PLD with a primary alcohol significantly attenuated platelet activation by PAR1-AP.	Propranolol	98-109	phospholipid phosphatase 1	Homo sapiens	57-86
17151288-8	2007	Perturbation of this signaling pathway via inhibition of lipid phosphate phosphatase-1 (LPP-1) by propranolol or inhibition of the phosphatidylcholine-derived phosphatidic acid (PA) formation by PLD with a primary alcohol significantly attenuated platelet activation by PAR1-AP.	Propranolol	98-109	phospholipid phosphatase 1	Homo sapiens	88-93
17184481-9	2007	The orexin-A induced heart rate response was attenuated when beta-adrenoceptors were blocked with propranolol (1 mg/kg, i.v.	Propranolol	98-109	hypocretin neuropeptide precursor	Rattus norvegicus	4-12
16950767-5	2006	Inhibition of PAP-1 by bromoenol lactone, propranolol, or ethanol resulted in a decrease in LPS-induced COX-2 mRNA transcript production, COX-2 protein expression, and prostaglandin E(2) release from U937 macrophages.	Propranolol	42-53	PDGFA associated protein 1	Homo sapiens	14-19
16950767-5	2006	Inhibition of PAP-1 by bromoenol lactone, propranolol, or ethanol resulted in a decrease in LPS-induced COX-2 mRNA transcript production, COX-2 protein expression, and prostaglandin E(2) release from U937 macrophages.	Propranolol	42-53	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	104-109
16950767-5	2006	Inhibition of PAP-1 by bromoenol lactone, propranolol, or ethanol resulted in a decrease in LPS-induced COX-2 mRNA transcript production, COX-2 protein expression, and prostaglandin E(2) release from U937 macrophages.	Propranolol	42-53	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	138-143
17079456-5	2006	Norepi treatment increased MMP-2, MMP-9, and VEGF levels in culture supernatants of HONE-1 cells, which could be inhibited by the beta-blocker propranolol.	Propranolol	143-154	matrix metallopeptidase 9	Homo sapiens	34-39
17079456-5	2006	Norepi treatment increased MMP-2, MMP-9, and VEGF levels in culture supernatants of HONE-1 cells, which could be inhibited by the beta-blocker propranolol.	Propranolol	143-154	vascular endothelial growth factor A	Homo sapiens	45-49
16837570-4	2006	Interestingly, propranolol derivatives, good substrates for hCE-2, were easily hydrolyzed by substitution of the methyl group on the 2-position of the acyl moiety, but were barely hydrolyzed when the methyl group was substituted on the 3-position.	Propranolol	15-26	carboxylesterase 2	Homo sapiens	60-65
17244943-7	2006	In contrast, beta-adrenoceptor antagonist propranolol (1.0 mg/kg) completely blocked orexin A-induced HR changes, without influence on MAP, peripheral blood flows and the survival rate.	Propranolol	42-53	hypocretin neuropeptide precursor	Rattus norvegicus	85-93
17046558-9	2006	Propranolol treatment induced an increase (approximately 60%, P &lt; .05) in GLUT4 mRNA at the end of the fasting period.	Propranolol	0-11	solute carrier family 2 member 4	Rattus norvegicus	77-82
17046558-10	2006	In contrast, propranolol treatment attenuated GLUT4 mRNA induction after refeeding; the latter may be due to attenuation of postprandial insulin levels.	Propranolol	13-24	solute carrier family 2 member 4	Rattus norvegicus	46-51
16763014-5	2006	The glucuronidation kinetics of R-propranolol by UGT2B4 exhibited a sigmoid curve, whereas the glucuronidation of the same substrate by UGT2B7 was inhibited by substrate concentrations above 1 mM.	Propranolol	32-45	UDP glucuronosyltransferase family 2 member B4	Homo sapiens	49-55
16901967-7	2006	Specific beta(2)- and beta(3)-AR agonists had similar effects as the pan-agonist and were blocked by the beta-AR antagonist propranolol.	Propranolol	124-135	adrenergic receptor, beta 1	Mus musculus	105-112
16763014-5	2006	The glucuronidation kinetics of R-propranolol by UGT2B4 exhibited a sigmoid curve, whereas the glucuronidation of the same substrate by UGT2B7 was inhibited by substrate concentrations above 1 mM.	Propranolol	32-45	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	136-142
16763014-6	2006	Among the UGTs of subfamily 1A, UGT1A9 and UGT1A10 displayed high and, surprisingly, opposite stereoselectivity in the glucuronidation of propranolol enantiomers.	Propranolol	138-149	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	32-38
16763014-6	2006	Among the UGTs of subfamily 1A, UGT1A9 and UGT1A10 displayed high and, surprisingly, opposite stereoselectivity in the glucuronidation of propranolol enantiomers.	Propranolol	138-149	UDP glucuronosyltransferase family 1 member A10	Homo sapiens	43-50
16763014-7	2006	UGT1A9 glucuronidated S-propranolol much faster than R-propranolol, whereas UGT1A10 exhibited the opposite enantiomer preference.	Propranolol	22-35	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	0-6
16916329-0	2006	Tracheal responsiveness to both isoprenaline and beta2-adrenoreceptor blockade by propranolol in cigarette smoke exposed and sensitized guinea pigs.	Propranolol	82-93	beta-2 adrenergic receptor	Cavia porcellus	49-69
16962476-6	2006	This insulin-mediated positive inotropic effect was unchanged in the presence of propranolol (1 micromol/liter).	Propranolol	81-92	insulin	Homo sapiens	5-12
16794485-3	2006	RESULTS: Angiotensin II and the alpha1-adrenoceptor agonist phenylephrine constricted HCMAs to maximally 63 +/- 10 and 46 +/- 15% of the contraction to 100 mmol/l K. Neither carvedilol, metoprolol, the nonselective beta-adrenoceptor antagonist propranolol, nor the alpha1-adrenoceptor antagonist prazosin affected the constrictor response to angiotensin II.	Propranolol	244-255	angiotensinogen	Homo sapiens	9-23
16908771-5	2006	Propranolol, a nonselective beta-AR antagonist, aggravated EAM on day 21 and decreased mRNA levels, whereas metoprolol, a beta1-selective AR antagonist, showed no effect.	Propranolol	0-11	adrenoceptor beta 2	Rattus norvegicus	33-35
16880627-4	2006	Serum albumin concentration was time-dependently decreased and correlated well with 3 major biologic determinants of drug clearance, hepatic blood flow (HBF), intrinsic clearance (CL(int)), and the unbound fraction of drugs in plasma (fp) after intravenous administration of cyclophosphamide, tolbutamide, zonisamide, and chlorzoxazone (as probe drugs for low hepatic extraction) and propranolol and lidocaine (as high-hepatic extraction drugs).	Propranolol	384-395	albumin	Rattus norvegicus	6-13
16918313-10	2006	The formation of NDP from propranolol in liver microsomes was significantly inhibited by alpha-naphthoflavone (ANF, a selective CYP1A2 inhibitor), but not by quinidine (a CYP2D inhibitor).	Propranolol	26-37	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	128-134
16918313-11	2006	These results indicated that EGb 761 pretreatment decreased the plasma concentrations of propranolol by accelerated conversion of parental drug to NDP due to induction of CYP1A2.	Propranolol	89-100	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	171-177
16291573-9	2006	Propranolol reduced the lipolytic rate during both E1 and E2 compared with the probe with phentolamine.	Propranolol	0-11	small nucleolar RNA, H/ACA box 73A	Homo sapiens	51-60
16899794-8	2006	Administration of alpha-methyl-p-tyrosine or a combination of SR59230A and propranolol reversed the cold-exposure-induced decreases in serum adiponectin concentrations and adiponectin mRNA expression in these tissues.	Propranolol	75-86	adiponectin, C1Q and collagen domain containing	Mus musculus	141-152
16899794-8	2006	Administration of alpha-methyl-p-tyrosine or a combination of SR59230A and propranolol reversed the cold-exposure-induced decreases in serum adiponectin concentrations and adiponectin mRNA expression in these tissues.	Propranolol	75-86	adiponectin, C1Q and collagen domain containing	Mus musculus	172-183
16682960-9	2006	pretreatment with the 5-HT(1A) receptor antagonist propranolol ((S)-1-isopropylamino-3-(1-naphthyloxy)-2-propanol hydrochloride) (injected 10 min prior to i.t.	Propranolol	51-62	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	22-39
16671962-4	2006	Therefore, we investigated the P-glycoprotein-mediated transport of propranolol, metoprolol, bisoprolol, carvedilol and sotalol in P-glycoprotein-expressing Caco-2 monolayers and inhibition of P-glycoprotein-mediated digoxin transport by the beta-adrenoceptor antagonists.	Propranolol	68-79	ATP binding cassette subfamily B member 1	Homo sapiens	31-45
16671962-6	2006	Moreover, propranolol and carvedilol inhibited P-glycoprotein-mediated digoxin transport with IC(50) values of 24.8 and 0.16 microm, respectively, whereas metoprolol and sotalol had no effect.	Propranolol	10-21	ATP binding cassette subfamily B member 1	Homo sapiens	47-61
16671962-9	2006	In addition, the beta-adrenoceptor antagonists propranolol and carvedilol significantly inhibit P-glycoprotein function thereby possibly contributing to drug interactions in humans (e.g. digoxin-carvedilol and cyclosporine-carvedilol).	Propranolol	47-58	ATP binding cassette subfamily B member 1	Homo sapiens	96-110
16456084-6	2006	Ten micromoles of d-propranolol suppressed the caspase 3 activation by 63% (p &lt; 0.05) and preserved cell survival back to 88% of control (p &lt; 0.01).	Propranolol	18-31	caspase 3	Bos taurus	47-56
16777678-8	2006	In the absence of octylmaltoside, the P(app) values for insulin and the markers were in the following order: propanolol &gt; mannitol &gt; insulin.	Propranolol	109-119	insulin	Homo sapiens	56-63
16574604-2	2006	Treatment of rats with propranolol (Inderal 500 mg/L of water for 5 weeks) reduced by 48%, 50% and 29% the L-propranolol-, LHRH- or PDBu-induced testosterone secretion, respectively, when compared to cells from controls.	Propranolol	23-34	gonadotropin releasing hormone 1	Rattus norvegicus	123-127
16574604-2	2006	Treatment of rats with propranolol (Inderal 500 mg/L of water for 5 weeks) reduced by 48%, 50% and 29% the L-propranolol-, LHRH- or PDBu-induced testosterone secretion, respectively, when compared to cells from controls.	Propranolol	36-43	gonadotropin releasing hormone 1	Rattus norvegicus	123-127
16520739-3	2006	Stimulation of PAR-2 by trypsin-induced relaxation of carbachol- and KCl-induced contractions in normal rat colonic smooth muscle was completely resolved by tissue pretreatment with apamin, but not by pretreatment with l-NMMA or a cocktail of neuronal blockers (tetrodotoxin, hexamethonium and propranolol).	Propranolol	294-305	F2R like trypsin receptor 1	Rattus norvegicus	15-20
16595015-8	2006	In line, inhalation of either salmeterol or salbutamol was associated with a reduced early TNFalpha production in lungs of mice infected intranasally with NTHi, an effect that was reversed by concurrent treatment with the beta blocker propranolol.	Propranolol	235-246	tumor necrosis factor	Mus musculus	91-99
16474417-9	2006	Propranolol eliminated the responses elicited by the lower dose of isoprenaline and substantially diminished the responses elicited by the higher dose of the beta1-, beta2- and beta3-adrenoceptor agonist.	Propranolol	0-11	adrenoceptor beta 1	Rattus norvegicus	158-195
16314852-6	2006	Carvedilol (nonselective), propranolol (nonselective) and ICI 118551 (beta(2)-selective) inhibited HERG current in a concentration-dependent manner (IC(50) 0.51, 3.9 and 9.2 microM, respectively).	Propranolol	27-38	potassium voltage-gated channel subfamily H member 2	Homo sapiens	99-103
16898077-6	2006	The liver in damaged animals showed an increase of propranolol level under lidocaine co-administration, probably due to CCl4 induced liver enzyme activity, resulting in a rapid propranolol metabolism or to competition between both drug protein binding sites.	Propranolol	51-62	C-C motif chemokine ligand 4	Rattus norvegicus	120-124
16898077-6	2006	The liver in damaged animals showed an increase of propranolol level under lidocaine co-administration, probably due to CCl4 induced liver enzyme activity, resulting in a rapid propranolol metabolism or to competition between both drug protein binding sites.	Propranolol	177-188	C-C motif chemokine ligand 4	Rattus norvegicus	120-124
16386803-6	2006	We found that propranolol blocked the IL-1beta response to footshock in both the hypothalamus and the spleen, while the noradrenergic reuptake inhibitor desipramine significantly augmented the footshock-induced IL-1beta response in both of these sites.	Propranolol	14-25	interleukin 1 beta	Rattus norvegicus	38-46
16565443-7	2006	D-Pro lowered total release of tissue iron, conjugated diene content, LDH activity, and NAGA activity 4.59-, 2.55-, 3.04-, and 4.14-fold, respectively, in the effluent of I/R hearts from the iron-loaded group.	Propranolol	0-5	O-GlcNAcase	Rattus norvegicus	88-92
16314852-9	2006	Inhibition of HERG current by carvedilol, propranolol and ICI 118551 was partially but significantly attenuated in Y652A and F656C mutant channels.	Propranolol	42-53	potassium voltage-gated channel subfamily H member 2	Homo sapiens	14-18
16314853-7	2006	Haemodynamic effects of hUII were attenuated by propranolol or L-NAME and abolished by indomethacin.	Propranolol	48-59	urotensin 2	Homo sapiens	24-28
16166348-10	2006	The hepatic extraction, metabolism, and ion trapping of propranolol were significantly impaired in adjuvant-treated rats and could be correlated with altered iron store and cytochrome P-450 activity.	Propranolol	56-67	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	173-189
16714778-1	2006	The in vitro effect of digoxin, verapamil, propranolol, carbamazepine, diazepam and promethazine were investigated on the ecto-ATPase activity of synaptosomal plasma membranes from the rat brain.	Propranolol	43-54	CEA cell adhesion molecule 1	Rattus norvegicus	122-133
16495759-6	2006	Neurotensin-mediated inotropic responses were also abolished by co-administration of the beta-adrenoreceptor blockers, propranolol and atenolol.	Propranolol	119-130	neurotensin	Rattus norvegicus	0-11
16374847-0	2006	Influence of beta-2 adrenergic receptor gene polymorphism on the hemodynamic response to propranolol in patients with cirrhosis.	Propranolol	89-100	adrenoceptor beta 2	Homo sapiens	13-39
16883636-3	2006	BPI-induced vascular relaxations were also markedly attenuated by the addition of verapamil or diltiazem, while the relaxant effect of BPI was not blocked by pretreatment with indomethacine, glibenclamide, tetraethylammonium (TEA), atropine, or propranolol.	Propranolol	245-256	bactericidal/permeability-increasing protein	Rattus norvegicus	0-3
16883636-3	2006	BPI-induced vascular relaxations were also markedly attenuated by the addition of verapamil or diltiazem, while the relaxant effect of BPI was not blocked by pretreatment with indomethacine, glibenclamide, tetraethylammonium (TEA), atropine, or propranolol.	Propranolol	245-256	bactericidal/permeability-increasing protein	Rattus norvegicus	135-138
16177222-5	2006	SR 59119A-induced relaxation was unaffected by the blockade of ADRB1 and ADRB2 by 0.1 microM propranolol but was significantly decreased by the blockade of ADRB1, ADRB2, and ADRB3 by 10 microM propranolol.	Propranolol	193-204	adrenoceptor beta 2	Homo sapiens	163-168
16177222-5	2006	SR 59119A-induced relaxation was unaffected by the blockade of ADRB1 and ADRB2 by 0.1 microM propranolol but was significantly decreased by the blockade of ADRB1, ADRB2, and ADRB3 by 10 microM propranolol.	Propranolol	193-204	adrenoceptor beta 3	Homo sapiens	174-179
16331293-1	2006	1.--The cardiostimulant effects of CGP12177, mediated through a beta(1)-adrenoceptor site with low affinity for (-)-propranolol, are potentiated by the nonselective PDE inhibitor IBMX but the role of PDE isoenzymes is unknown.	Propranolol	112-127	adrenoceptor beta 1	Rattus norvegicus	64-84
16785762-6	2006	Carbachol and isoproterenol-induced CREB phosphorylation was blocked by atropine (a muscarinic acetylcholine antagonist) and propranolol (a beta-adrenergic antagonist), respectively.	Propranolol	125-136	cAMP responsive element binding protein 1	Mus musculus	36-40
16443457-3	2006	Chiral separation of propranolol, alprenolol and oxprenolol was lost on the Trp-modified chicken alpha1-AGP column, while chlorpheniramine, ketoprofen and benzoin were still enantioseparated on the Trp-modified chicken alpha1-AGP column despite of lower enantioselectivity than that on the chicken alpha1-AGP column.	Propranolol	21-32	orosomucoid 1 (ovoglycoprotein)	Gallus gallus	97-107
16374847-3	2006	We hypothesized that gene polymorphisms at the beta2-AR may influence the hemodynamic response to propranolol in patients with cirrhosis.	Propranolol	98-109	adrenoceptor beta 2	Homo sapiens	47-55
16339749-4	2005	The decrease in insulin-stimulated glucose transport caused by levodopa was attenuated by propranolol (a beta-adrenergic antagonist) and prevented by NSD-1015 (NSD), an inhibitor of DOPA decarboxylase (DDC; converts levodopa to dopamine).	Propranolol	90-101	insulin	Homo sapiens	16-23
16051698-7	2005	This was sensitive to inhibition by the beta(2)-adrenoceptor antagonists propranolol, timolol, and ICI 118551.	Propranolol	73-84	adrenergic receptor, beta 2	Mus musculus	40-60
16335946-3	2005	This inhibition was counteracted by addition of the beta(2)-AR antagonist propranolol (LZP).	Propranolol	74-85	adrenoceptor beta 2	Homo sapiens	52-62
15923319-9	2005	Propranolol also suppressed gene expression of TNF-alpha, IL-6, and IL-10.	Propranolol	0-11	tumor necrosis factor	Homo sapiens	47-56
15923319-9	2005	Propranolol also suppressed gene expression of TNF-alpha, IL-6, and IL-10.	Propranolol	0-11	interleukin 6	Homo sapiens	58-62
15923319-9	2005	Propranolol also suppressed gene expression of TNF-alpha, IL-6, and IL-10.	Propranolol	0-11	interleukin 10	Homo sapiens	68-73
16113995-1	2005	A liquid chromatography stationary phase containing immobilized membranes obtained from a cell line that expresses the human organic cation transporter (hOCT1-IAM) has been used to study the binding of the enantiomers of propranolol, atenolol, pseudoephedrine, and alpha-methylbenzylamine to the immobilized hOCT1.	Propranolol	221-232	solute carrier family 22 member 1	Homo sapiens	153-158
16150441-0	2005	Propranolol inhibits the human ether-a-go-go-related gene potassium channels.	Propranolol	0-11	ETS transcription factor ERG	Homo sapiens	31-57
16150441-6	2005	To examine the underlying mechanisms for these clinical findings, we studied the effects of propranolol on the human cardiac potassium channels encoded by the ether-a-go-go-related gene (ERG) using the whole cell voltage-clamp technique.	Propranolol	92-103	ETS transcription factor ERG	Homo sapiens	159-185
16150441-6	2005	To examine the underlying mechanisms for these clinical findings, we studied the effects of propranolol on the human cardiac potassium channels encoded by the ether-a-go-go-related gene (ERG) using the whole cell voltage-clamp technique.	Propranolol	92-103	ETS transcription factor ERG	Homo sapiens	187-190
16150441-7	2005	We found that propranolol blocked hERG currents in a concentration-dependent manner with an IC50 of 9.9+/-1.3 microM which is relevant to the predicted plasma level of propranolol in this case report.	Propranolol	14-25	ETS transcription factor ERG	Homo sapiens	34-38
16150441-7	2005	We found that propranolol blocked hERG currents in a concentration-dependent manner with an IC50 of 9.9+/-1.3 microM which is relevant to the predicted plasma level of propranolol in this case report.	Propranolol	168-179	ETS transcription factor ERG	Homo sapiens	34-38
16150441-8	2005	The present study demonstrated that propranolol can inhibit hERG channels.	Propranolol	36-47	ETS transcription factor ERG	Homo sapiens	60-64
16150441-9	2005	The interaction between propranolol and hERG channels could lead to delayed cardiac repolarization and might be a molecular mechanism for the previously reported QTc prolongation when propranolol is overdosed.	Propranolol	24-35	ETS transcription factor ERG	Homo sapiens	40-44
16150441-9	2005	The interaction between propranolol and hERG channels could lead to delayed cardiac repolarization and might be a molecular mechanism for the previously reported QTc prolongation when propranolol is overdosed.	Propranolol	184-195	ETS transcription factor ERG	Homo sapiens	40-44
16040722-8	2005	The enhanced toxicity in beta2-/- mice was also recapitulated in wild-type mice with the beta2-selective antagonist ICI-118,551, although the rescue effect of the beta1-deletion was not recapitulated using the beta1-selective antagonist metoprolol or the nonselective beta-antagonist propranolol.	Propranolol	284-295	hemoglobin, beta adult minor chain	Mus musculus	25-30
15914506-5	2005	The beta-adrenoceptor antagonist propranolol (0.3 microM) completely antagonized the inhibitory effect of epinephrine on insulin-stimulated glucose uptake, whereas the alpha-adrenoceptor antagonist phentolamine (10 microM) had no effect.	Propranolol	33-44	insulin	Homo sapiens	121-128
16102256-6	2005	Treatment of VSMCs with propranolol inhibited isoproterenol-induced changes in cAMP but had no effect on either oestrogen-induced increases in cAMP levels or inhibition of collagen synthesis.	Propranolol	24-35	cathelicidin antimicrobial peptide	Homo sapiens	79-83
15961351-8	2005	ELISA results illustrate that norepinephrine significantly increases PEDF secretion by RPE cells and propranolol slightly decreases PEDF secretion into RPE cell medium.	Propranolol	101-112	serpin family F member 1	Rattus norvegicus	132-136
16092941-7	2005	Furthermore, the extent of inhibition of Cyt c release correlated with the degree of suppression of iPLA(2) by the inhibitors propranolol, dibucaine, 4-bromophenacyl bromide, and bromenol lactone.	Propranolol	126-137	phospholipase A2 group VI	Rattus norvegicus	100-107
16005083-1	2005	In the present study, we observed that isoproterenol, a beta-adrenergic receptor (beta-AR) agonist, stimulated rat C6 glioma cell proliferation, while propranolol, a beta-AR blocker, greatly reduced the proliferative effect of TNF-alpha on C6 cells.	Propranolol	151-162	tumor necrosis factor	Rattus norvegicus	227-236
15680470-6	2005	The following receptor blockers diminished the action of PACAP-38 on the facilitation of extinction: propranolol, haloperidol, naloxone, bicuculline and nitro-L-arginine, the latter by blocking nitric oxide formation.	Propranolol	101-112	adenylate cyclase activating polypeptide 1	Rattus norvegicus	57-62
15890841-6	2005	Basal and d-amphetamine-induced GluR1 phosphorylation was reduced by propranolol, a general beta-adrenoceptor antagonist, and betaxolol, a beta1-antagonist, but not by (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-butanol (ICI-118,515), a beta2-antagonist.	Propranolol	69-80	glutamate receptor, ionotropic, AMPA1 (alpha 1)	Mus musculus	32-37
15966380-3	2005	METHODS: Propranolol (n=22) or esmolol (n= 29) was given intravenously when the heart rate was above 100 beats x min(-1) during emergence from anesthesia.	Propranolol	9-20	CD59 molecule (CD59 blood group)	Homo sapiens	113-119
15966380-5	2005	RESULTS: The total dose of propranolol was 0.52+/-0.21 mg (mean+/-SD), which decreased the heart rate significantly from 109.2 +/- 19.0 to 89.2 +/-11.8 beats x min(-1).	Propranolol	27-38	CD59 molecule (CD59 blood group)	Homo sapiens	160-166
16082424-0	2005	Polymorphic variants of the beta2-adrenergic receptor (ADRB2) gene and ADRB2-related propanolol-induced dyslipidemia in the Colombian population.	Propranolol	85-95	adrenoceptor beta 2	Homo sapiens	71-76
16082424-4	2005	To examine the association between the Gln27Glu polymorphism of the ADRB2 gene and dyslipidemia induced by propranolol, we recruited 19 healthy individuals who were homozygous for either the Gln27 (wild-type, N = 11) or the Glu27 (homozygous mutant, N = 8) genotype.	Propranolol	107-118	adrenoceptor beta 2	Homo sapiens	68-73
16082424-8	2005	Significant changes in physiological parameters (HR, SBP, DBP) have been found in association with ADRB2 variants in both native and mutant subgroups after propranolol intake.	Propranolol	156-167	adrenoceptor beta 2	Homo sapiens	99-104
16082424-11	2005	The evidence that subjects homozygous for Gln27 in the ADRB2 gene show a significant reduction of HDL-CHO levels, as well as the increased TG levels in subjects homozygous for Glu27 after propranolol administration, suggest that the Gln27Glu polymorphism represents a risk factor for dyslipidemia induced by propranolol.	Propranolol	308-319	adrenoceptor beta 2	Homo sapiens	55-60
15927711-5	2005	The HR response to atropine was similar but the response to propranolol was higher in kallikrein rats than control group (61+/-7 vs. 60+/-9 vs. 38+/-7 bpm, respectively).	Propranolol	60-71	kallikrein related peptidase 4	Homo sapiens	86-96
15927711-11	2005	The rats with overexpression of kallikrein showed an increase of sympathetic activity that regulates the heart rate, characterized by increased HR response to propranolol and increased sympathetic tonus, accompanied by decreased bradycardic responses to electrical vagal stimulation.	Propranolol	159-170	kallikrein related peptidase 4	Homo sapiens	32-42
15834445-9	2005	The inhibitory effect of propranolol in "intact" rats was mimicked by the beta(2)-adrenoceptor antagonist ICI 118551 (1 micromol kg(-1)), but not by the beta(1)-adrenoceptor antagonist CGP 20712 (1 micromol kg(-1)).	Propranolol	25-36	adrenoceptor beta 2	Rattus norvegicus	74-94
15990776-8	2005	RESULTS: (R)-enantiomers significantly reduced GM-CSF release by as much as 41% ( P &lt; .05), which was reversible with propranolol.	Propranolol	121-132	colony stimulating factor 2	Homo sapiens	47-53
15990776-11	2005	Both propranolol and ICI-118,551 alone increased GM-CSF release in a concentration-dependent fashion, similar to (S)-enantiomers.	Propranolol	5-16	colony stimulating factor 2	Homo sapiens	49-55
15585594-8	2005	Furthermore, we show that the effects of beta-adrenergic ligands on liver glycogen observed in humans are reproduced in these mice: liver glycogen levels are strongly decreased by the beta2-AR agonist clenbuterol and increased by the beta-AR antagonist propranolol.	Propranolol	253-264	adrenergic receptor, beta 1	Mus musculus	234-241
15801678-8	2005	Multiple UGT1A and 2B may be involved in stereoselective O-glucuronidation of propranolol enantiomers in rat liver microsomes.	Propranolol	78-89	Ugt1a@	Rattus norvegicus	9-21
15710352-4	2005	The involvement of beta-adrenergic receptors was confirmed using the general beta(1)/beta(2) receptor antagonist propranolol, which was able to abrogate the protection conferred by isoproterenol and clenbuterol in astrocytes treated with LPS.	Propranolol	113-124	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	77-84
15710461-3	2005	Treatment with the beta-adrenergic receptor antagonists propranolol or ICI 118,551 increased LPS-induced production of IL-1(beta), whereas treatment with the alpha-adrenergic antagonists phentolamine or yohimbine decreased IL-1(beta).	Propranolol	56-67	interleukin 1 beta	Mus musculus	119-129
15710461-3	2005	Treatment with the beta-adrenergic receptor antagonists propranolol or ICI 118,551 increased LPS-induced production of IL-1(beta), whereas treatment with the alpha-adrenergic antagonists phentolamine or yohimbine decreased IL-1(beta).	Propranolol	56-67	interleukin 1 beta	Mus musculus	223-233
15679475-4	2005	Propranolol caused a concentration-dependent inhibition of HERG current with an IC50 value of 81 microM at -10 mV.	Propranolol	0-11	potassium voltage-gated channel subfamily H member 2	Homo sapiens	59-63
15679475-7	2005	The propranolol analogue ICI118551 ((+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-butanol hydrochloride) blocked the HERG channel with similar affinity, whereas the beta1-receptor antagonists metoprolol and atenolol showed weak effects.	Propranolol	4-15	potassium voltage-gated channel subfamily H member 2	Homo sapiens	148-152
16165282-6	2005	Prazosin attenuated stress-induced plasma IL-1beta and IL-6, but had no effect on tissue IL-1beta levels, while propranolol attenuated plasma IL-6 and blocked tissue IL-1beta elevation, and labetalol, which cannot cross the blood-brain barrier, attenuated plasma IL-1beta and IL-6, blocked pituitary IL-1beta, but had no effect on central tissue IL-1beta levels.	Propranolol	112-123	interleukin 6	Rattus norvegicus	142-146
21166164-4	2005	(2) Pretreatment of reserpine or propranolol abolished the cardiac effect of IL-2 at 50 U/ml, while pretreatment with phentolamine did not change the effect of IL-2.	Propranolol	33-44	interleukin 2	Rattus norvegicus	77-81
15869009-9	2005	RESULTS: Carvedilol and propranolol inhibited platelet aggregation in the rank order of stimuli: PMA &gt; thrombin &gt; A23187 &gt; epinephrine.	Propranolol	24-35	coagulation factor II, thrombin	Homo sapiens	106-114
21166164-6	2005	(4) After pretreatment of reserpine or propranolol, IL-2 failed to increase the number of PVC, but caused decrease of LVDP, HR and CF, and elevation of LVEDP.	Propranolol	39-50	interleukin 2	Rattus norvegicus	52-56
16029148-11	2005	In MWA patients, a beta-blocker, propranolol, could mitigate migraine, whose cessation coincided with a drop of TNF-alpha serum concentration.	Propranolol	33-44	tumor necrosis factor	Homo sapiens	112-121
16165282-6	2005	Prazosin attenuated stress-induced plasma IL-1beta and IL-6, but had no effect on tissue IL-1beta levels, while propranolol attenuated plasma IL-6 and blocked tissue IL-1beta elevation, and labetalol, which cannot cross the blood-brain barrier, attenuated plasma IL-1beta and IL-6, blocked pituitary IL-1beta, but had no effect on central tissue IL-1beta levels.	Propranolol	112-123	interleukin 6	Rattus norvegicus	142-146
15454113-3	2004	Moreover, PA and TNF-alpha-induced expression of CD83 was slightly increased by propranolol, an inhibitor of PA phosphohydrolase but was unaffected by phospholipase A2 inhibitor.	Propranolol	80-91	tumor necrosis factor	Homo sapiens	17-26
15603589-10	2004	Exposure of MDA-MB-453 cells for 6 days to the beta-blocker propranolol (1 microM) increased the GIRK1 mRNA levels and decreased beta2-adrenergic mRNA levels, while treatment for 30 minutes daily for 7 days had no effect.	Propranolol	60-71	potassium inwardly rectifying channel subfamily J member 3	Homo sapiens	97-102
15603589-10	2004	Exposure of MDA-MB-453 cells for 6 days to the beta-blocker propranolol (1 microM) increased the GIRK1 mRNA levels and decreased beta2-adrenergic mRNA levels, while treatment for 30 minutes daily for 7 days had no effect.	Propranolol	60-71	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	129-134
15454113-3	2004	Moreover, PA and TNF-alpha-induced expression of CD83 was slightly increased by propranolol, an inhibitor of PA phosphohydrolase but was unaffected by phospholipase A2 inhibitor.	Propranolol	80-91	CD83 molecule	Homo sapiens	49-53
15467015-6	2004	Differences in BP50 and gain between N-AII, G-AII, and control mice persisted after parasympathetic blockade with atropine but were eliminated after sympathetic blockade with propranolol, indicating the effects of ANG II were selective for cardiosympathetic arm of the reflex.	Propranolol	175-186	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	214-220
15595859-7	2004	Zonal displacement chromatography using CGP 12177A as the marker and racemic mixtures of the antagonists nadolol and propranolol demonstrated that the immobilized beta(2)-AR retained its ability to specifically bind these compounds.	Propranolol	117-128	adrenoceptor beta 2	Homo sapiens	163-173
15345674-3	2004	The increase in D2 mRNA and activity in the circadian variation was reduced by the administration of prazosin, an alpha1-adrenergic antagonist, and propranolol, a beta- adrenergic antagonist.	Propranolol	148-159	amyloid beta precursor protein	Rattus norvegicus	161-167
15527789-2	2004	We now report a marked nocturnal increase in the expression of a MAPK phosphatase, MAP kinase phosphatase-1 (MKP-1), that was blocked by maintaining animals in constant light or treatment with propranolol.	Propranolol	193-204	dual specificity phosphatase 1	Rattus norvegicus	83-107
15527789-2	2004	We now report a marked nocturnal increase in the expression of a MAPK phosphatase, MAP kinase phosphatase-1 (MKP-1), that was blocked by maintaining animals in constant light or treatment with propranolol.	Propranolol	193-204	dual specificity phosphatase 1	Rattus norvegicus	109-114
15526107-12	2004	Involvement of an additional receptor site (e.g. the propranolol-resistant state of the beta(1)-adrenoceptor), however, cannot be excluded.	Propranolol	53-64	adrenoceptor beta 1	Homo sapiens	88-108
15644939-7	2004	The relaxing response of nociceptin in coronary arteries was significantly reduced by removal of endothelium and by the presence of L-NNA, cGMP, and [Nphe1]NC(1-13)NH2, the selective nociceptin receptor antagonist, but not by naloxone, the nonselestive opioid receptor blocker or propranolol, which blocks the adrenergic beta-receptor.	Propranolol	280-291	prepronociceptin	Homo sapiens	25-35
15644939-7	2004	The relaxing response of nociceptin in coronary arteries was significantly reduced by removal of endothelium and by the presence of L-NNA, cGMP, and [Nphe1]NC(1-13)NH2, the selective nociceptin receptor antagonist, but not by naloxone, the nonselestive opioid receptor blocker or propranolol, which blocks the adrenergic beta-receptor.	Propranolol	280-291	prepronociceptin	Homo sapiens	183-193
15297444-4	2004	In cells treated with NE for 2 and 4 h, the inclusion of prazosin or propranolol reduced NE-induced MKK3/6 and p38MAPK phosphorylation, indicating involvement of both alpha- and beta-adrenergic receptors for the sustained response.	Propranolol	69-80	mitogen activated protein kinase kinase 3	Rattus norvegicus	100-106
15383152-10	2004	The enhancing effect of proatherogenic cytokine production by epinephrine was down regulated by the beta1 and beta2 adrenoceptor antagonist, propranolol, but not by the beta1 adrenoceptor antagonist, atenolol, suggesting the effect involved beta2 adrenoceptors.	Propranolol	141-152	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase like 1	Homo sapiens	100-105
15339862-8	2004	Only the initial tachycardic response to hUII was antagonised by propranolol.	Propranolol	65-76	urotensin 2	Homo sapiens	41-45
15524192-2	2004	Based on the systematic optimization of operation variables, the chiral separation of mexiletine, chlorpheniramine and propranolol was achieved in the pH 7.4 phosphate buffer by using HSA, PSA and PSA as selectors, respectively.	Propranolol	119-130	aminopeptidase puromycin sensitive	Homo sapiens	189-192
15524192-2	2004	Based on the systematic optimization of operation variables, the chiral separation of mexiletine, chlorpheniramine and propranolol was achieved in the pH 7.4 phosphate buffer by using HSA, PSA and PSA as selectors, respectively.	Propranolol	119-130	aminopeptidase puromycin sensitive	Homo sapiens	197-200
15383152-10	2004	The enhancing effect of proatherogenic cytokine production by epinephrine was down regulated by the beta1 and beta2 adrenoceptor antagonist, propranolol, but not by the beta1 adrenoceptor antagonist, atenolol, suggesting the effect involved beta2 adrenoceptors.	Propranolol	141-152	adrenoceptor beta 2	Homo sapiens	110-128
15383152-10	2004	The enhancing effect of proatherogenic cytokine production by epinephrine was down regulated by the beta1 and beta2 adrenoceptor antagonist, propranolol, but not by the beta1 adrenoceptor antagonist, atenolol, suggesting the effect involved beta2 adrenoceptors.	Propranolol	141-152	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	110-115
15328477-0	2004	Brain-IL-1 beta triggers astrogliosis through induction of IL-6: inhibition by propranolol and IL-10.	Propranolol	79-90	interleukin 6	Rattus norvegicus	59-63
15328477-12	2004	On the other hand, substances which decrease IL-beta-induced IL-6 production, such as propranolol and IL-10, also dramatically decreased IL-beta triggered gliosis.	Propranolol	86-97	interleukin 6	Rattus norvegicus	61-65
15328477-14	2004	Accordingly, blockade of the IL-beta-induced IL-6 release by IL-10 and propranolol decreases GFAP expression.	Propranolol	71-82	interleukin 6	Rattus norvegicus	45-49
15328477-14	2004	Accordingly, blockade of the IL-beta-induced IL-6 release by IL-10 and propranolol decreases GFAP expression.	Propranolol	71-82	glial fibrillary acidic protein	Rattus norvegicus	93-97
15481458-2	2004	In two companion papers, we have described the influence of the concentration and the nature of completely dissociated salts dissolved in the mobile phase (methanol:water, 40:60, v/v) on the adsorption behavior of propranolol (R"-NH2+-R, Cl-) on XTerra-C18 and on Symmetry-C18.	Propranolol	214-225	Bardet-Biedl syndrome 9	Homo sapiens	253-256
15481458-2	2004	In two companion papers, we have described the influence of the concentration and the nature of completely dissociated salts dissolved in the mobile phase (methanol:water, 40:60, v/v) on the adsorption behavior of propranolol (R"-NH2+-R, Cl-) on XTerra-C18 and on Symmetry-C18.	Propranolol	214-225	Bardet-Biedl syndrome 9	Homo sapiens	273-276
15252280-4	2004	The administration of atenolol (a beta 1-antagonist) or propranolol (a beta-antagonist) produced a memory impairment.	Propranolol	56-67	histocompatibility 2, class II antigen A, beta 1	Mus musculus	69-75
15276086-1	2004	P-glycoprotein (PGP) substrates with high membrane permeability, such as propranolol and verapamil, are considered to be essentially "transparent" to PGP since the transporter does not significantly limit their absorption or elimination.	Propranolol	73-84	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
15276086-1	2004	P-glycoprotein (PGP) substrates with high membrane permeability, such as propranolol and verapamil, are considered to be essentially "transparent" to PGP since the transporter does not significantly limit their absorption or elimination.	Propranolol	73-84	ATP binding cassette subfamily B member 1	Homo sapiens	16-19
15276086-7	2004	The induction of PGP by propranolol and verapamil was rapid with significant increases occurring within 3h with maximal stimulation after 6h exposure.	Propranolol	24-35	ATP binding cassette subfamily B member 1	Homo sapiens	17-20
15276086-9	2004	In conclusion, verapamil and propranolol, whose trans-epithelial permeability are unaffected by PGP, appear to be effective inducers of PGP expression in gut epithelial cells in vitro.	Propranolol	29-40	ATP binding cassette subfamily B member 1	Homo sapiens	136-139
15264218-6	2004	This mechanism was proved to function in vivo by stimulation of FGF-1 expression in neurons of the cerebral cortex after intracerebral administration of propranolol, an antagonist of adrenergic beta receptors.	Propranolol	153-164	fibroblast growth factor 1	Rattus norvegicus	64-69
15281255-3	2004	In a previous report, the influence of the pH, the concentration, and the nature of the buffer on the retention and overloading behavior of propranolol (pKa = 9.45) was studied on Kromasil-C18 at 2.75 &lt; pH &lt; 6.75, using four buffers (phosphate, acetate, phthalate, and succinate), at three concentrations, 6, 20, and 60 mM.	Propranolol	140-151	Bardet-Biedl syndrome 9	Homo sapiens	189-192
15171939-11	2004	The advantage of the developed method lies in the simultaneous determination of propranolol, a passive integrity marker, routinely employed in permeability studies and its selectivity in presence of various P-gp modulators and permeability markers.	Propranolol	80-91	phosphoglycolate phosphatase	Rattus norvegicus	207-211
15389299-4	2004	In the presence of the beta1-antagonist CGP20712A and of the beta2-antagonist ICI 118,551, a 25-30% decrease in isoproterenol intrinsic activity was observed on both cell types and on taenia coli, the nonselective beta1/beta2-antagonist propranolol produced a rightward shift of the isoproterenol concentration-response curve with mean estimated pKB values (8.12 +/- 0.27 at 0.1 microM and 6.45 +/- 0.13 at 1 microM) lower than that expected for both beta1- and beta2-adrenoceptors.	Propranolol	237-248	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	23-28
15389299-4	2004	In the presence of the beta1-antagonist CGP20712A and of the beta2-antagonist ICI 118,551, a 25-30% decrease in isoproterenol intrinsic activity was observed on both cell types and on taenia coli, the nonselective beta1/beta2-antagonist propranolol produced a rightward shift of the isoproterenol concentration-response curve with mean estimated pKB values (8.12 +/- 0.27 at 0.1 microM and 6.45 +/- 0.13 at 1 microM) lower than that expected for both beta1- and beta2-adrenoceptors.	Propranolol	237-248	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	61-66
15206940-8	2004	Moreover, propranolol, which causes an increase in PLD-derived phosphatidic acid accumulation, caused a selective increase in agonist-stimulated myeloperoxidase release.	Propranolol	10-21	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	51-54
15206940-8	2004	Moreover, propranolol, which causes an increase in PLD-derived phosphatidic acid accumulation, caused a selective increase in agonist-stimulated myeloperoxidase release.	Propranolol	10-21	myeloperoxidase	Homo sapiens	145-160
15084649-3	2004	NCX-950 (10(-8)-10(-5) M) elicited a relaxation of human isolated bronchi moderately higher than salbutamol, which was reduced by a beta-adrenergic blocking drug, propranolol, but not by an inhibitor of guanylate cyclase, ODQ (1H-[1,2,4]oxadiazolo[4,3-] quinolaxin-1-one).	Propranolol	163-174	T cell leukemia homeobox 2	Homo sapiens	0-3
15187419-4	2004	The vanadate-induced activations of PKA and PDE3 were inhibited in part by propranolol or genistein, suggesting that vanadate may exert its actions via dual signaling pathways of beta-adrenergic receptors and receptor tyrosine kinases of growth factors.	Propranolol	75-86	phosphodiesterase 4D, cAMP-specific-like 1	Rattus norvegicus	44-48
15084649-6	2004	Propranolol, but not ODQ, suppressed the inhibitory activity of NCX-950 on neutrophil influx and IL-6 release in BAL fluids.	Propranolol	0-11	T cell leukemia, homeobox 2	Mus musculus	64-67
15084649-6	2004	Propranolol, but not ODQ, suppressed the inhibitory activity of NCX-950 on neutrophil influx and IL-6 release in BAL fluids.	Propranolol	0-11	interleukin 6	Mus musculus	97-101
15271010-8	2004	Patients with VVS were treated with propranolol or fluoxetine.	Propranolol	36-47	VVS	Homo sapiens	14-17
15178312-1	2004	Four sensitive and accurate spectrophotometric methods have been developed for the assay of Acebutolol Hydrochloride (ACH), Atenolol (ATE) and Propranolol Hydrochloride (PRH), which are based on the complexation of drugs with copper(II) (Cu(II)) and cobalt(II) (Co(II)).	Propranolol	143-168	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	250-260
15178312-1	2004	Four sensitive and accurate spectrophotometric methods have been developed for the assay of Acebutolol Hydrochloride (ACH), Atenolol (ATE) and Propranolol Hydrochloride (PRH), which are based on the complexation of drugs with copper(II) (Cu(II)) and cobalt(II) (Co(II)).	Propranolol	143-168	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	262-268
15178312-1	2004	Four sensitive and accurate spectrophotometric methods have been developed for the assay of Acebutolol Hydrochloride (ACH), Atenolol (ATE) and Propranolol Hydrochloride (PRH), which are based on the complexation of drugs with copper(II) (Cu(II)) and cobalt(II) (Co(II)).	Propranolol	170-173	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	250-260
15178312-1	2004	Four sensitive and accurate spectrophotometric methods have been developed for the assay of Acebutolol Hydrochloride (ACH), Atenolol (ATE) and Propranolol Hydrochloride (PRH), which are based on the complexation of drugs with copper(II) (Cu(II)) and cobalt(II) (Co(II)).	Propranolol	170-173	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	262-268
15037618-7	2004	The fact that beta-adrenergic receptor inhibitor (propranolol) blocks nicotine-induced activation of ERK1/2, AKT, PKA, Bad phosphorylation, and cell survival suggests that nicotine-induced Bad phosphorylation may occur through the upstream beta-adrenergic receptors.	Propranolol	50-61	mitogen-activated protein kinase 3	Homo sapiens	101-107
15037618-7	2004	The fact that beta-adrenergic receptor inhibitor (propranolol) blocks nicotine-induced activation of ERK1/2, AKT, PKA, Bad phosphorylation, and cell survival suggests that nicotine-induced Bad phosphorylation may occur through the upstream beta-adrenergic receptors.	Propranolol	50-61	AKT serine/threonine kinase 1	Homo sapiens	109-112
14722032-7	2004	Epinephrine-stimulated IL-6 expression was attenuated by the alpha-adrenergic receptor antagonist phentolamine and completely blocked by either the beta1/2-adrenergic receptor antagonist propranalol or the beta2-antagonist ICI-118551.	Propranolol	187-198	interleukin 6	Mus musculus	23-27
14722032-7	2004	Epinephrine-stimulated IL-6 expression was attenuated by the alpha-adrenergic receptor antagonist phentolamine and completely blocked by either the beta1/2-adrenergic receptor antagonist propranalol or the beta2-antagonist ICI-118551.	Propranolol	187-198	adrenergic receptor, beta 1	Mus musculus	148-175
15021963-12	2004	Simultaneous use of the beta(2)-AR antagonist propranolol augmented LPS-induced liver failure, suggesting a role of endogenous adrenoceptor-agonists in prevention of organ-failure during systemic inflammation.	Propranolol	46-57	adrenoceptor beta 2	Rattus norvegicus	24-34
15094063-4	2004	Moreover, TG stimulated the production of diacylglycerol (DAG) by activating phospholipase D (PLD) as propranolol (PROP) (a PLD inhibitor), but not U73122 (a phospholipase C inhibitor), inhibited TG-evoked DAG production in these cells.	Propranolol	102-113	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	77-92
15094063-4	2004	Moreover, TG stimulated the production of diacylglycerol (DAG) by activating phospholipase D (PLD) as propranolol (PROP) (a PLD inhibitor), but not U73122 (a phospholipase C inhibitor), inhibited TG-evoked DAG production in these cells.	Propranolol	102-113	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	94-97
15094063-4	2004	Moreover, TG stimulated the production of diacylglycerol (DAG) by activating phospholipase D (PLD) as propranolol (PROP) (a PLD inhibitor), but not U73122 (a phospholipase C inhibitor), inhibited TG-evoked DAG production in these cells.	Propranolol	115-119	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	77-92
15072290-2	2004	In a companion paper, we describe the influence of the concentration and the nature of salts dissolved in the mobile phase (methanol:water, 40:60, v/v) on the adsorption behavior of propranolol (R"-NH2+ -R, Cl-) on XTerra-C18.	Propranolol	182-193	Bardet-Biedl syndrome 9	Homo sapiens	222-225
15023456-2	2004	Propranolol is a poorly soluble drug and known substrate of the P-glycoprotein (P-gp) efflux transporter.	Propranolol	0-11	ATP binding cassette subfamily B member 1	Homo sapiens	64-78
15023456-2	2004	Propranolol is a poorly soluble drug and known substrate of the P-glycoprotein (P-gp) efflux transporter.	Propranolol	0-11	ATP binding cassette subfamily B member 1	Homo sapiens	80-84
14871558-0	2004	Propranolol prevents enhanced stress signaling in Gs alpha cardiomyopathy: potential mechanism for beta-blockade in heart failure.	Propranolol	0-11	GNAS (guanine nucleotide binding protein, alpha stimulating) complex locus	Mus musculus	50-58
15000889-0	2004	Propranolol and verapamil inhibit mRNA expression of RyR2 and SERCA in L-thyroxin-induced rat ventricular hypertrophy.	Propranolol	0-11	ryanodine receptor 2	Rattus norvegicus	53-57
15000889-4	2004	Propranolol was effective to inhibit the increase in RyR2 (51+/-7) and SERCA (63+/-13) mRNA expression in hypertrophied rats, respectively.	Propranolol	0-11	ryanodine receptor 2	Rattus norvegicus	53-57
15000889-6	2004	CONCLUSION: Both RyR2 and SERCA mRNA level in L-thyroxin-induced cardiac hypertrophy was over-expressed and propranolol or verapamil inhibited the alteration.	Propranolol	108-119	ryanodine receptor 2	Rattus norvegicus	17-21
14744938-8	2004	Next, erythromycin and propranolol were explored as positive and negative control substrates for Pgp/CYP3A interactions, respectively.	Propranolol	23-34	ATP binding cassette subfamily B member 1	Homo sapiens	97-100
14744938-8	2004	Next, erythromycin and propranolol were explored as positive and negative control substrates for Pgp/CYP3A interactions, respectively.	Propranolol	23-34	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	101-106
14871558-6	2004	Treatment of 9-10 months old Gs alpha mice with propranolol for 5 weeks reverted the phospho-kinase levels of these kinases known to be involved in the growth and death of cardiac myocytes.	Propranolol	48-59	GNAS (guanine nucleotide binding protein, alpha stimulating) complex locus	Mus musculus	29-37
14744619-4	2004	In mouse ileum, stereoselectivity of propranolol and tertatolol was observed under beta(1)-/beta(2)-adrenoceptor blockade.	Propranolol	37-48	adrenergic receptor, beta 2	Mus musculus	92-112
15049075-1	2004	We present the data on functional status of the mineralocorticoid receptor system in rat kidney in the course of renal reflex degeneration induced by sciatic nerve transection at the background of both renal denervation and injections of beta blocker propranolol.	Propranolol	251-262	nuclear receptor subfamily 3, group C, member 2	Rattus norvegicus	48-74
14726153-9	2004	Beta adrenoceptors also seem to be involved directly or indirectly in the stress-mediated modulation of Cyp1A1, as propranolol (beta-antagonist) blocked the down-regulating effect of stress on B(alpha)P-induced Cyp1A1 gene expression.	Propranolol	115-126	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	104-110
14726153-9	2004	Beta adrenoceptors also seem to be involved directly or indirectly in the stress-mediated modulation of Cyp1A1, as propranolol (beta-antagonist) blocked the down-regulating effect of stress on B(alpha)P-induced Cyp1A1 gene expression.	Propranolol	115-126	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	211-217
14607281-6	2004	Propranolol, an inhibitor of phosphatidic acid (PA) phosphohydrolase, decreased diacylglycerol (DAG) formation and attenuated PTH 1-34- and PTH 3-34-stimulated PKCalpha translocation and IL-6 promoter activity, suggesting a phospholipase D (PLD)-dependent mechanism.	Propranolol	0-11	parathyroid hormone	Rattus norvegicus	126-131
14607281-6	2004	Propranolol, an inhibitor of phosphatidic acid (PA) phosphohydrolase, decreased diacylglycerol (DAG) formation and attenuated PTH 1-34- and PTH 3-34-stimulated PKCalpha translocation and IL-6 promoter activity, suggesting a phospholipase D (PLD)-dependent mechanism.	Propranolol	0-11	parathyroid hormone	Rattus norvegicus	126-129
14607281-6	2004	Propranolol, an inhibitor of phosphatidic acid (PA) phosphohydrolase, decreased diacylglycerol (DAG) formation and attenuated PTH 1-34- and PTH 3-34-stimulated PKCalpha translocation and IL-6 promoter activity, suggesting a phospholipase D (PLD)-dependent mechanism.	Propranolol	0-11	protein kinase C, alpha	Rattus norvegicus	160-168
14607281-6	2004	Propranolol, an inhibitor of phosphatidic acid (PA) phosphohydrolase, decreased diacylglycerol (DAG) formation and attenuated PTH 1-34- and PTH 3-34-stimulated PKCalpha translocation and IL-6 promoter activity, suggesting a phospholipase D (PLD)-dependent mechanism.	Propranolol	0-11	interleukin 6	Rattus norvegicus	187-191
14613922-7	2003	We found that the slowing of transit by fat, PYY, or norepinephrine was reversed by propranolol.	Propranolol	84-95	FAT atypical cadherin 1	Canis lupus familiaris	40-43
15898827-8	2004	In a canine model of propranolol intoxication, high-dose insulin provided a sustained increase in systemic blood pressure, cardiac performance and survival rate compared with glucagon or epinephrine.	Propranolol	21-32	insulin	Canis lupus familiaris	57-64
15898827-10	2004	In another study, high-dose insulin reversed the negative inotropic effect of propranolol to 80% of control function and normalised heart rate.	Propranolol	78-89	insulin	Homo sapiens	28-35
15249727-7	2004	Treatment with propranolol augmented the epinephrine-induced increase of splenocyte apoptosis, did not affect the decrease of splenocyte proliferation and IL-2 release, augmented the release of IL-6 and antagonized the mobilization of natural killer cells observed in epinephrine-treated animals.	Propranolol	15-26	interleukin 6	Mus musculus	194-198
15249727-9	2004	Coadministration of propranolol and epinephrine augmented the propranolol-induced changes of splenocyte apoptosis and IL-6 release and was associated with the highest mortality of septic mice.	Propranolol	20-31	interleukin 6	Mus musculus	118-122
15249727-9	2004	Coadministration of propranolol and epinephrine augmented the propranolol-induced changes of splenocyte apoptosis and IL-6 release and was associated with the highest mortality of septic mice.	Propranolol	62-73	interleukin 6	Mus musculus	118-122
14613922-7	2003	We found that the slowing of transit by fat, PYY, or norepinephrine was reversed by propranolol.	Propranolol	84-95	peptide YY	Canis lupus familiaris	45-48
14608456-0	2003	Intrinsic sympathomimetic activity of (-)-pindolol mediated through a (-)-propranolol-resistant site of the beta1-adrenoceptor in human atrium and recombinant receptors.	Propranolol	70-85	adrenoceptor beta 1	Homo sapiens	108-126
15143490-2	2004	Propranolol increased the stimulative effect of TRH, isoproterenol exerted an opposite effect.	Propranolol	0-11	thyrotropin releasing hormone	Rattus norvegicus	48-51
14735227-2	2003	Ring hydroxylation of nonselective beta-adrenergic blocking agent propranolol is mediated mainly by cytochrome P450 (CYP) 2D6 and N-desisopropylation by CYP1A2 in human and rat liver microsomes.	Propranolol	66-77	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	153-159
14608456-2	2003	Recent work indicates the existence of a (-)-propranolol-resistant site of the cardiac beta(1)-adrenoceptor and we propose that it mediates the cardiostimulation evoked by (-)-pindolol.	Propranolol	41-56	adrenoceptor beta 1	Homo sapiens	87-107
14608456-8	2003	(-)-CGP12177, known to act through the (-)-propranolol-resistant site of the beta(1)-adrenoceptor, also increased with similar potency atrial contractile force (-logEC(50)M=7.6) and cAMP at recombinant beta(1)-adrenoceptors (-logEC(50)M=7.7).	Propranolol	39-54	adrenoceptor beta 1	Homo sapiens	77-97
14645666-9	2003	Propranolol, however, produced paradoxical effects; it reduced basal cAMP accumulation (via beta2-mediated inverse agonism) but stimulated beta2-mediated CRE gene transcription.	Propranolol	0-11	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	92-97
14608456-12	2003	We conclude that the cardiostimulant effects of (-)-pindolol in human atrial myocardium are mediated through a (-)-propranolol-resistant site of the beta(1)-adrenoceptor with low affinity for (-)-pindolol.	Propranolol	111-126	adrenoceptor beta 1	Homo sapiens	149-169
14645666-9	2003	Propranolol, however, produced paradoxical effects; it reduced basal cAMP accumulation (via beta2-mediated inverse agonism) but stimulated beta2-mediated CRE gene transcription.	Propranolol	0-11	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	139-144
14568334-6	2003	In the presence of C6 astroglial co-culture b.End3 monolayers achieved a maximal transendothelial electrical resistance of 130 Omega cm2, but lacked real discrimination with respect to the permeation of transcellular and paracellular probes, e.g. permeability coefficients (x 10(-6) cm s(-1)) for propranolol of approximately 23 vs. 16 for sucrose.	Propranolol	297-308	Eph receptor A3	Mus musculus	46-50
14645666-12	2003	Propranolol CRE gene transcription responses were attenuated by p42/44-MAP kinase inhibitors and propranolol was also found to directly stimulate the p42/44-MAP kinase pathway.	Propranolol	0-11	cyclin dependent kinase 20	Homo sapiens	64-67
14645666-12	2003	Propranolol CRE gene transcription responses were attenuated by p42/44-MAP kinase inhibitors and propranolol was also found to directly stimulate the p42/44-MAP kinase pathway.	Propranolol	0-11	cyclin dependent kinase 20	Homo sapiens	150-153
14645666-12	2003	Propranolol CRE gene transcription responses were attenuated by p42/44-MAP kinase inhibitors and propranolol was also found to directly stimulate the p42/44-MAP kinase pathway.	Propranolol	97-108	cyclin dependent kinase 20	Homo sapiens	150-153
14645666-14	2003	These data suggest that propranolol can simultaneously act as an inverse agonist through a Gs-coupled mechanism while stimulating the p42/44-MAP kinase pathway through an alternative G-protein-independent mechanism.	Propranolol	24-35	cyclin dependent kinase 20	Homo sapiens	134-137
18758717-3	2003	To address this question, we investigated the effects of the beta-adrenergic agonist L-isoproterenol or antagonist DL-propranolol on in vivo LTP of area CA1 and the spatial learning in Morris water maze.	Propranolol	115-129	carbonic anhydrase 1	Rattus norvegicus	153-156
18758717-4	2003	In the presence of L-isoproterenol (through local infusion into area CA1), the theta-pulse stimulation with the parameter of 10 Hz, 150 pulses/train, 1 train, a frequency weakly modifying synaptic strength, induced a robust LTP, and this effect was blocked when DL-propranolol was co-administered.	Propranolol	262-276	carbonic anhydrase 1	Rattus norvegicus	69-72
18758717-5	2003	By contrast, the theta-pulse stimulation with the parameter of 5 Hz, 150 pulses/train, 3 trains, a frequency strongly modifying synaptic strength, induced a significantly smaller LTP when DL-propranolol was administered into area CA1.	Propranolol	188-202	carbonic anhydrase 1	Rattus norvegicus	230-233
18758717-6	2003	Accordingly, DL-propranolol impaired the spatial learning in the water maze when infused into area CA1 20 min pretraining.	Propranolol	13-27	carbonic anhydrase 1	Rattus norvegicus	99-102
14570767-8	2003	Mechanism-based inhibition of CYP1A2 may explain why zileuton decreases the oral clearance of antipyrine, propranolol, (R)-warfarin, and theophylline, at doses that have a minimal effect on the pharmacokinetics of (S)-warfarin, phenytoin, and terfenadine.	Propranolol	106-117	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	30-36
12932837-6	2003	The hippocampal motilin-induced stimulation of gastric motility (30.6+/-5.5%) was completely abolished by subdiaphragmal vagotomy (-2.8+/-4.4%) but unaffected by the intravenously applied receptor blockers atropine, phentolamine and propranolol.	Propranolol	233-244	motilin	Rattus norvegicus	16-23
14676386-7	2003	CD69 expression was significantly higher than the control when only propranolol was added.	Propranolol	68-79	CD69 molecule	Homo sapiens	0-4
12768272-7	2003	Intra-CeA injections of beta-adrenoceptor antagonists propranolol (30 nmol per side) and timolol (10 nmol per side) significantly attenuated the morphine withdrawal-induced CPA.	Propranolol	54-65	carcinoembryonic antigen gene family 4	Rattus norvegicus	6-9
13679574-3	2003	Here we show that beta2AR ligands like ICI118551 and propranolol, which are inverse agonists for Gs-stimulated adenylyl cyclase, induce partial agonist responses for the mitogen-activated protein kinases extracellular signal-regulated kinase (ERK) 1/2 thus behaving as dual efficacy ligands.	Propranolol	53-64	adrenergic receptor, beta 2	Mus musculus	18-25
13679574-3	2003	Here we show that beta2AR ligands like ICI118551 and propranolol, which are inverse agonists for Gs-stimulated adenylyl cyclase, induce partial agonist responses for the mitogen-activated protein kinases extracellular signal-regulated kinase (ERK) 1/2 thus behaving as dual efficacy ligands.	Propranolol	53-64	mitogen-activated protein kinase 3	Mus musculus	204-251
12812919-13	2003	We conclude that burned children receiving propranolol showed a significant upregulation in genes involved in muscle metabolism and downregulation of an important enzyme involved in gluconeogenesis and insulin resistance compared with burned children receiving placebo.	Propranolol	43-54	insulin	Homo sapiens	202-209
12967946-8	2003	(6) In GAL-1R-KO mice, stimulation of the sympathetic nerve in the presence of propranolol evoked an attenuation of DeltaPI not significantly different from the response in control mice in the presence of BIIE0246.	Propranolol	79-90	galanin and GMAP prepropeptide	Mus musculus	7-10
12900383-8	2003	Furthermore, pretreatment with a beta-blocker, propranolol (15 or 25 mg/kg ip), inhibited both stress- and LPS-induced increases in the level of IL-6 mRNA, but pretreatment with an alpha-blocker, phentolamine (5 mg/kg sc), did not inhibit them in mouse calvaria.	Propranolol	47-58	interleukin 6	Mus musculus	145-149
14575314-5	2003	Also, TGF-beta2 increased after 12 h, peaked after 24 h and declined thereafter, while TGF-beta, was only elevated after 72 h. Treatment with propranolol had a negative chronotropic effect throughout the observation period of 72 h. It attenuated the initial elevation in LVEDP and increased cardiac output ultimately.	Propranolol	142-153	transforming growth factor, beta receptor 2	Rattus norvegicus	6-15
14575314-5	2003	Also, TGF-beta2 increased after 12 h, peaked after 24 h and declined thereafter, while TGF-beta, was only elevated after 72 h. Treatment with propranolol had a negative chronotropic effect throughout the observation period of 72 h. It attenuated the initial elevation in LVEDP and increased cardiac output ultimately.	Propranolol	142-153	transforming growth factor, beta 1	Rattus norvegicus	6-14
14575314-6	2003	Furthermore, propranolol attenuated IL-1beta mRNA expression, but had not effect on the other cytokines.	Propranolol	13-24	interleukin 1 beta	Rattus norvegicus	36-44
14575314-7	2003	Moreover, MMP-9 gelatinolytic activity was markedly attenuated by propranolol indicating a delayed resorption of the necrotic tissue and, possibly, collagen turnover.	Propranolol	66-77	matrix metallopeptidase 9	Rattus norvegicus	10-15
12865312-4	2003	Norepinephrine caused a parallel increase in phosphorylated p42/44 MAPK (p42/44(MAPK)) and p90RSK that was reduced by prazosin or propranolol, indicating involvement of both alpha(1)- and beta-adrenergic receptors.	Propranolol	130-141	mitogen activated protein kinase 1	Rattus norvegicus	60-71
12869636-1	2003	CYP2C19 is an important human drug-metabolizing enzyme that metabolizes a number of clinically used drugs including the antiulcer drug omeprazole, the anxiolytic drug diazepam, the beta-blocker propranolol, the antimalarial drug proguanil, certain antidepressants and barbiturates, and the prototype substrate S-mephenytoin.	Propranolol	194-205	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	0-7
12890576-5	2003	The effect of adrenaline to NHE 1 was counteracted by prazocin and by propranolol as well indicating the involvement of both alpha and beta 2 adrenergic receptors.	Propranolol	70-81	solute carrier family 9 member A1	Homo sapiens	28-33
12872987-7	2003	Propranolol inhibition of phosphatidic acid phosphohydrolase (PPH) increased PA accumulation and enhanced LPS-dependent COX-2 protein synthesis.	Propranolol	0-11	prostaglandin-endoperoxide synthase 2	Homo sapiens	120-125
12665506-2	2003	We found that treatment of adult male mice by ISO (15 mg/kg body weight, intraperitoneal) caused a delayed STAT3 activation (at 60-120 min), which was fully abolished by beta-AR antagonist, propranolol.	Propranolol	190-201	signal transducer and activator of transcription 3	Mus musculus	107-112
12665506-2	2003	We found that treatment of adult male mice by ISO (15 mg/kg body weight, intraperitoneal) caused a delayed STAT3 activation (at 60-120 min), which was fully abolished by beta-AR antagonist, propranolol.	Propranolol	190-201	adrenergic receptor, beta 1	Mus musculus	170-177
12846980-10	2003	While amphiphilic cations, such as dibucaine and propranolol, inhibit Bax-mediated cytochrome c release, transient receptor potential channel inhibitors inhibit mitochondrial swelling and cytochrome c release induced by the inner membrane permeability transition.	Propranolol	49-60	BCL2 associated X, apoptosis regulator	Homo sapiens	70-73
12736183-4	2003	The increase in GyK activity induced by cold exposure was not affected by phenoxybenzamine, but was markedly inhibited by previous administration of propranolol or actinomycin D.	Propranolol	149-160	glycerol kinase	Rattus norvegicus	16-19
12846980-10	2003	While amphiphilic cations, such as dibucaine and propranolol, inhibit Bax-mediated cytochrome c release, transient receptor potential channel inhibitors inhibit mitochondrial swelling and cytochrome c release induced by the inner membrane permeability transition.	Propranolol	49-60	cytochrome c, somatic	Homo sapiens	83-95
12732361-5	2003	The non-selective beta(1)-/-beta(2)-AR antagonists; propranolol and CGP 12177, at 10(-7)M, inhibited luciferase activity induced by these agonists by 80-96%.	Propranolol	52-63	adrenoceptor beta 2	Homo sapiens	28-38
12773135-12	2003	Propranolol infusion significantly increased the GHRH-induced GH secretion, but it did not block glucose-induced suppression of GH secretion.	Propranolol	0-11	growth hormone releasing hormone	Homo sapiens	49-53
12773135-12	2003	Propranolol infusion significantly increased the GHRH-induced GH secretion, but it did not block glucose-induced suppression of GH secretion.	Propranolol	0-11	growth hormone 1	Homo sapiens	49-51
12773135-12	2003	Propranolol infusion significantly increased the GHRH-induced GH secretion, but it did not block glucose-induced suppression of GH secretion.	Propranolol	0-11	growth hormone 1	Homo sapiens	62-64
12752794-1	2003	The present study investigated the effects of intra-CA1 infusion of d,l-propranolol, the beta-adrenergic antagonist, on memory for contextual fear conditioning.	Propranolol	68-83	carbonic anhydrase 1	Homo sapiens	52-55
12778365-6	2003	Furthermore, inhibition of AQPap gene expression could be almost completely reversed by pretreating 3T3-L1 adipocytes with the beta-adrenoceptor antagonist propranolol.	Propranolol	156-167	aquaporin 7	Homo sapiens	27-32
12734935-0	2003	[Stereoselective determination of propranolol enantiomer in transgenic cell lines expressing human cytochrome P450].	Propranolol	34-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-114
12482765-9	2003	Propranolol completely abolished the increase in vWF elicited by isoproterenol [F(1,12) = 10.25; P = 0.008] but had no significant effect on tissue factor and D-dimer.	Propranolol	0-11	von Willebrand factor	Homo sapiens	49-52
12684459-8	2003	Contrary to the hypothesis that dibucaine and propranolol act by inhibiting the insertion of Bax into the mitochondrial outer membrane, membrane insertion of Bax was not inhibited in mitochondria or liposomes, indicating a mechanism of drug action downstream from this event.	Propranolol	46-57	BCL2 associated X, apoptosis regulator	Rattus norvegicus	93-96
12684459-9	2003	These results suggest that dibucaine and propranolol inhibit Bax-induced permeability changes through a direct interaction with the lipid membrane and present a novel target for the development of neuroprotective, antiapoptotic therapeutics.	Propranolol	41-52	BCL2 associated X, apoptosis regulator	Rattus norvegicus	61-64
12734935-1	2003	OBJECTIVE: To establish a chiro chromatography for studying the stereoselective metabolism of propranolol (PL) in S(9) incubates prepared from transgenic cell lines expressing human cytochrome P450.	Propranolol	94-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	182-197
12734935-1	2003	OBJECTIVE: To establish a chiro chromatography for studying the stereoselective metabolism of propranolol (PL) in S(9) incubates prepared from transgenic cell lines expressing human cytochrome P450.	Propranolol	107-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	182-197
12734935-9	2003	The time-dependent studies showed that PL had the stereoselectivity of S-(-)-isomer in metabolism via CYP2C18 and the stereoselectivity of R-(+)-isomer in metabolism via CYP2C9.	Propranolol	39-41	cytochrome P450 family 2 subfamily C member 18	Homo sapiens	102-109
12734935-9	2003	The time-dependent studies showed that PL had the stereoselectivity of S-(-)-isomer in metabolism via CYP2C18 and the stereoselectivity of R-(+)-isomer in metabolism via CYP2C9.	Propranolol	39-41	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	170-176
12749257-4	2003	RESULTS: In three patients, plasma renin activity and aldosterone concentrations were markedly increased before propranolol administration, but fell to normal levels thereafter.	Propranolol	112-123	renin	Homo sapiens	35-40
12642394-6	2003	Addition of the beta-AR antagonist, propranolol, blocked the ADR-induced alpha(2A)-AR desensitization.	Propranolol	36-47	adrenoceptor beta 2	Homo sapiens	16-23
12642394-12	2003	(5) Chronic ADR treatment produced a significant increase in GRK3 levels and this was blocked by propranolol or GRK2/3 antisense DNA treatment.	Propranolol	97-108	G protein-coupled receptor kinase 3	Homo sapiens	61-65
12620376-9	2003	The enhancing effect of iNOS synthesis by epinephrine and norepinephrine on LPS-induced macrophages was down regulated by beta-adrenoceptor antagonist, propranolol, and dexamethasone.	Propranolol	152-163	nitric oxide synthase 2, inducible	Mus musculus	24-28
12535832-8	2003	Propranolol also attenuated myocardial lesions, but to a lesser extent, and increased IL-12 and IFN-gamma levels.	Propranolol	0-11	interferon gamma	Homo sapiens	96-105
12534357-5	2003	RESULTS: Propranolol treatment decreased heart rate (by 20%), diastolic blood pressure (by 20%), and plasma ACTH, and increased serum cortisol, serum DHEAS, and the molar ratio of cortisol/17OHP, cortisol/DHEA, and DHEAS/DHEA similarly in female and male subjects.	Propranolol	9-20	proopiomelanocortin	Homo sapiens	108-112
14516163-12	2003	In OVX+P4 animals, PHEN alone or in combination with PHENT and also ISOP alone or with PROP enhanced PRL output from the cells.	Propranolol	87-91	prolactin	Homo sapiens	101-104
14516163-15	2003	In turn, in the OVX+EB I group, effect of PHENT and PROP on PRL secretion by pituitary cells was inhibitory.	Propranolol	52-56	prolactin	Homo sapiens	60-63
12684459-0	2003	Inhibition of Bax-induced cytochrome c release from neural cell and brain mitochondria by dibucaine and propranolol.	Propranolol	104-115	BCL2 associated X, apoptosis regulator	Rattus norvegicus	14-17
12684459-4	2003	This study tested the hypothesis that the amphiphilic membrane-active cationic drugs dibucaine and propranolol block BH3 peptide-initiated cyt c efflux by preventing the integration of Bax into the mitochondrial outer membrane.	Propranolol	99-110	BCL2 associated X, apoptosis regulator	Rattus norvegicus	185-188
12728976-0	2003	Dose-response relationships of propranolol in Chinese subjects with different CYP2D6 genotypes.	Propranolol	31-42	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	78-84
12728976-2	2003	Propranolol is metabolized by polymorphic CYP2D6.	Propranolol	0-11	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	42-48
12728976-3	2003	We postulate that the lower propranolol dosage in Chinese is due to a slower CYP2D6 metabolism.	Propranolol	28-39	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	77-83
12728976-5	2003	Chinese subjects of different CYP2D6*1/CYP2D6*10 genotypes have been shown to have different propranolol pharmacokinetic characteristics.	Propranolol	93-104	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	30-36
12728976-5	2003	Chinese subjects of different CYP2D6*1/CYP2D6*10 genotypes have been shown to have different propranolol pharmacokinetic characteristics.	Propranolol	93-104	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	39-45
12728976-6	2003	In this study, we compared the beta-blockade effects of propranolol in Chinese subjects of the two different CYP2D6 genotypes.	Propranolol	56-67	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	109-115
12728976-12	2003	RESULTS: Despite therebeing higher S-propranolol plasma concentration in CYP2D6*10 subjects than in CYP2D6*1 subjects at 10- and 20-mg dosage, the dose-response relationship was not significantly different in these subjects.	Propranolol	35-48	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	73-79
12648529-5	2003	In neonatal rat cardiomyocytes, norepinephrine-induced ERKs activation was inhibited by an alpha(1)-adrenoceptor blocker (prazosin), but not by an beta-adrenoceptor blocker (propranolol).	Propranolol	174-185	mitogen activated protein kinase 3	Rattus norvegicus	55-59
12616336-0	2003	(-)-CGP 12177 increases contractile force and hastens relaxation of human myocardial preparations through a propranolol-resistant state of the beta 1-adrenoceptor.	Propranolol	108-119	adrenoceptor beta 1	Homo sapiens	143-162
12619890-10	2003	It further increased up to 48 h. The effect of NE on IL-6 mRNA was abolished by the beta-adrenoceptor blockers propranolol, metoprolol (beta1) and ICI 118.551 (beta2), but not by the alpha-adrenoceptor blockers prazosin (alpha1) and yohimbine (alpha2).	Propranolol	111-122	interleukin 6	Rattus norvegicus	53-57
12616336-1	2003	Two forms of the activated beta1-adrenoceptor exist, one that is stabilized by (-)-noradrenaline and is sensitive to blockade by (-)-propranolol and another which is stabilized by partial agonists such as (-)-pindolol and (-)-CGP 12177 but is relatively insensitive to (-)-propranolol.	Propranolol	129-144	adrenoceptor beta 1	Homo sapiens	27-45
12616336-1	2003	Two forms of the activated beta1-adrenoceptor exist, one that is stabilized by (-)-noradrenaline and is sensitive to blockade by (-)-propranolol and another which is stabilized by partial agonists such as (-)-pindolol and (-)-CGP 12177 but is relatively insensitive to (-)-propranolol.	Propranolol	269-284	adrenoceptor beta 1	Homo sapiens	27-45
12616336-2	2003	We investigated the effects of stimulation of the propranolol-resistant beta1-adrenoceptor in the human heart.	Propranolol	50-61	adrenoceptor beta 1	Homo sapiens	72-90
12606818-8	2002	Both Anti-TGF-beta antibody and propranolol inhibited ANG II-induced ROS generation and apoptosis.	Propranolol	32-43	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	54-60
12616336-9	2003	Our results show that (-)-CGP 12177 increases contractility and hastens relaxation through a cyclic AMP pathway in human myocardium, consistent with mediation through a (-)-propranolol-resistant state of the beta1-adrenoceptor.	Propranolol	169-184	adrenoceptor beta 1	Homo sapiens	208-226
12585693-7	2002	The role of the autonomic nervous system in CNP response was assessed by atropine or combined phentolamine and propranolol administration.	Propranolol	111-122	natriuretic peptide C	Rattus norvegicus	44-47
12442276-12	2002	Inderal or propanolol (a beta blocker) appears to be effective in preventing arrhythmias and syncope for an LQTS patient with the KCNQ1 L191P mutation.	Propranolol	0-7	potassium voltage-gated channel subfamily Q member 1	Homo sapiens	130-135
12442276-12	2002	Inderal or propanolol (a beta blocker) appears to be effective in preventing arrhythmias and syncope for an LQTS patient with the KCNQ1 L191P mutation.	Propranolol	11-21	potassium voltage-gated channel subfamily Q member 1	Homo sapiens	130-135
12606818-13	2002	Propranolol increased HO activity; whereas pre-treatment with propranolol prevented ANG II-induced apoptosis.	Propranolol	62-73	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	84-90
12464799-1	2002	CYP2C19 is a clinically important enzyme responsible for the metabolism of a number of therapeutic drugs, such as mephenytoin, omeprazole, diazepam, proguanil, propranolol and certain antidepressants.	Propranolol	160-171	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	0-7
12398570-8	2002	RESULTS: Compared with the ordinary dose of carvedilol 10 mg once a day, the improper regimen (10 mg after breakfast followed by 5 mg after lunch and dinner) increases the beta(2)-adrenoceptor binding occupancy at night (2300) to as high as the mean beta(2)-adrenoceptor binding occupancy after an ordinary dose of propranolol.	Propranolol	315-326	adrenoceptor beta 2	Homo sapiens	172-192
12167561-13	2002	Propranolol 4-hydroxylation was catalyzed by CYP2D2, CYP2D4, and CYP2D6.	Propranolol	0-11	cytochrome P450, family 2, subfamily d, polypeptide 2	Rattus norvegicus	45-51
12167561-13	2002	Propranolol 4-hydroxylation was catalyzed by CYP2D2, CYP2D4, and CYP2D6.	Propranolol	0-11	cytochrome P450, family 2, subfamily d, polypeptide 4	Rattus norvegicus	53-59
12167561-13	2002	Propranolol 4-hydroxylation was catalyzed by CYP2D2, CYP2D4, and CYP2D6.	Propranolol	0-11	cytochrome P450, family 2, subfamily d, polypeptide 4	Rattus norvegicus	65-71
12167561-14	2002	The 7-hydroxylation of propranolol was catalyzed only by CYP2D2.	Propranolol	23-34	cytochrome P450, family 2, subfamily d, polypeptide 2	Rattus norvegicus	57-63
12499785-0	2002	[Relationship of propranolol pharmacokinetic parameters with portosystemic shunt in CCl4-induced cirrhotic rats].	Propranolol	17-28	C-C motif chemokine ligand 4	Rattus norvegicus	84-88
12499785-1	2002	BACKGROUND/AIMS: This study was designed to determine the relationship of propranolol pharmacokinetic parameters with portosystemic shunt in CCl4-induced cirrhotic rats.	Propranolol	74-85	C-C motif chemokine ligand 4	Rattus norvegicus	141-145
12499785-9	2002	The serum concentrations of propranolol were significantly (p &lt; 0.01) elevated in CCl4-induced cirrhotic rats.	Propranolol	28-39	C-C motif chemokine ligand 4	Rattus norvegicus	85-89
15166499-4	2003	When cardiac myocytes were stimulated with 1 micro M norepinephrine for 24 h in the presence or absence of the specific alpha - and beta -adrenoceptor antagonists prazosin and propranolol, respectively, VEGF mRNA levels and splice variant pattern did not change, whereas atrial natriuretic peptide mRNA levels increased 3 to 4-fold.	Propranolol	176-187	vascular endothelial growth factor A	Rattus norvegicus	203-207
12438532-7	2002	Propranolol permeability, which is not influenced by PGP, showed similar regional variation in both wild-type and mdr1a(-/-) tissues, suggesting that differences are at the level of transcellular permeability.	Propranolol	0-11	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	114-119
12427424-0	2002	Influence of propranolol, enalaprilat, verapamil, and caffeine on adenosine A(2A)-receptor-mediated coronary vasodilation.	Propranolol	13-24	adenosine A2a receptor	Canis lupus familiaris	66-90
12421339-12	2002	For comparison, the beta-adrenergic antagonist propranolol inhibits Aa-nat gene expression in 2-day-old rat.	Propranolol	47-58	aralkylamine N-acetyltransferase	Rattus norvegicus	68-74
12566976-3	2002	In 6 pigs, infusion of 0.004 IU kg(-1) min(-1) of insulin decreased coronary flow despite increasing left ventricular dP dT(max)(-1); when the latter was abolished by propranolol, the coronary flow response was augmented.	Propranolol	167-178	insulin	Sus scrofa	50-57
12566976-7	2002	In 18 pigs given propranolol, three incremental doses of insulin caused graded coronary flow decreases whether L-NAME was given (6 pigs) or not (6 pigs) beforehand, and caused graded coronary flow increases after phentolamine (6 pigs).	Propranolol	17-28	insulin	Sus scrofa	57-64
12135702-8	2002	The internal Ca(2+) release induced by ET-1 was inhibited by U73122 (phospholipase C inhibitor), propranolol (phospholipase D inhibitor) and aristolochic acid (phospholipase A2 inhibitor).	Propranolol	97-108	endothelin 1	Rattus norvegicus	39-43
12358736-10	2002	Similarly, pre-treatment with the beta antagonist, propranolol (3 mg/kg intraperitoneally), significantly prevented withdrawal-induced Fos expression.	Propranolol	51-62	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	135-138
12239942-11	2002	The addition of propranolol decreased significantly plasma renin activity in both groups and cardiac output in those receiving 5-isosorbide mononitrate but did not change other variables.	Propranolol	16-27	renin	Homo sapiens	59-64
12015346-7	2002	Areas under the insulin and C-peptide curves were 42 and 39% greater (P &lt; 0.05), respectively, in CAF than in PL, PR, and CAF + PR.	Propranolol	131-133	insulin	Homo sapiens	16-23
12080442-9	2002	The effects of dexamethasone and catecholamines on IL-6 and leptin were abrogated by RU486 and propranolol, respectively.	Propranolol	95-106	interleukin 6	Homo sapiens	51-55
12084597-6	2002	RESULTS: Propranolol in the absence of epinephrine significantly prolonged the mean cQT(p) value but not the mean cQT(e) value, thus decreasing the mean cT(p-e) value in both LQT1 and LQT2 patients; the differences with propranolol were significantly larger in LQT1 than in LQT2 (p &lt; 0.05).	Propranolol	9-20	potassium voltage-gated channel subfamily Q member 1	Homo sapiens	175-179
12084597-6	2002	RESULTS: Propranolol in the absence of epinephrine significantly prolonged the mean cQT(p) value but not the mean cQT(e) value, thus decreasing the mean cT(p-e) value in both LQT1 and LQT2 patients; the differences with propranolol were significantly larger in LQT1 than in LQT2 (p &lt; 0.05).	Propranolol	9-20	potassium voltage-gated channel subfamily H member 2	Homo sapiens	184-188
12015346-7	2002	Areas under the insulin and C-peptide curves were 42 and 39% greater (P &lt; 0.05), respectively, in CAF than in PL, PR, and CAF + PR.	Propranolol	117-119	insulin	Homo sapiens	16-23
12212743-1	2002	A direct and simple non-protected room temperature phosphorimetry (NP-RTP) for determine propranolol, which using I- as a heavy atom perturber and sodium sulfite as a deoxygenator, has been developed.	Propranolol	89-100	MORN repeat containing 4	Homo sapiens	70-73
12212743-4	2002	The influence of I- concentration on RTP lifetime of propranolol was studied and the luminescence kinetic parameters were calculated.	Propranolol	53-64	MORN repeat containing 4	Homo sapiens	37-40
12074941-6	2002	injections of mecamylamine (ganglion blocker) and propranolol (beta-adrenoceptor antagonist) markedly augmented the depressor response to human urotensin II, but almost completely attenuated the tachycardia.	Propranolol	50-61	urotensin 2	Homo sapiens	144-156
12482211-9	2002	The efficacy of donepezil was compared with that of the beta-blocker propranolol (40 mg bid per os), showing higher activity.	Propranolol	69-80	BH3 interacting domain death agonist	Homo sapiens	88-91
11988078-4	2002	CREB phosphorylation was partly inhibitable, both by the beta-adrenergic antagonist propranolol and by the alpha(1)-adrenergic antagonist prazosin.	Propranolol	84-95	cAMP responsive element binding protein 1	Mus musculus	0-4
12055293-11	2002	Furthermore, the addition of propranolol attenuated the stimulation of PI4P5K activity during morphogenesis.	Propranolol	29-40	phosphatidylinositol-5-phosphate 4-kinase type 2 gamma	Homo sapiens	71-77
12032367-7	2002	Burn trauma activated p38 MAPK, JNK, and NF-kappaB, and this stress response was blocked by either prazosin or propranolol.	Propranolol	111-122	mitogen activated protein kinase 14	Rattus norvegicus	22-25
21179802-5	2002	(3) Pretreatment with propranolol abolished the effect of 50 u/ml IL-2 on the isolated heart.	Propranolol	22-33	interleukin 2	Rattus norvegicus	66-70
12092004-8	2002	Thus, in this study, propranolol has been found to be not only a selective inhibitor of CYP2D6 isoenzyme-dependent reactions, but also a nonspecific inhibitor of other cytochrome P450 isoenzymes.	Propranolol	21-32	cytochrome P450, family 2, subfamily d, polypeptide 4	Rattus norvegicus	88-94
11888550-12	2002	Finally, in line with species differences, the affinities of several ligands including CP93,129, RU24,969, (-)-pindolol and (-)-propanolol in rat 5-HT(1B) sites were markedly different to guinea pig 5-HT(1B) sites labelled with [3H]GR125,743.	Propranolol	124-138	5-hydroxytryptamine receptor 1B	Rattus norvegicus	146-153
11964604-14	2002	Inclusion of propranolol in the perfusion buffer blocked the isoproterenol-induced inhibition of HX-XO-stimulated TNF-alpha release and release of cyclic AMP into the coronary effluent.	Propranolol	13-24	tumor necrosis factor	Rattus norvegicus	114-123
11927837-1	2002	CYP2C19 is a polymorphically expressed cytochrome P450 responsible for the metabolism of several clinically used drugs, including some barbiturates, diazepam, proguanil, propranolol and several proton pump inhibitors.	Propranolol	170-181	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	0-7
12269395-0	2002	Side-chain metabolism of propranolol: involvement of monoamine oxidase and mitochondrial aldehyde dehydrogenase in the metabolism of N-desisopropylpropranolol to naphthoxylactic acid in rat liver.	Propranolol	25-36	monoamine oxidase A	Rattus norvegicus	53-70
12269395-0	2002	Side-chain metabolism of propranolol: involvement of monoamine oxidase and mitochondrial aldehyde dehydrogenase in the metabolism of N-desisopropylpropranolol to naphthoxylactic acid in rat liver.	Propranolol	25-36	aldehyde dehydrogenase 2 family member	Rattus norvegicus	75-111
11888550-12	2002	Finally, in line with species differences, the affinities of several ligands including CP93,129, RU24,969, (-)-pindolol and (-)-propanolol in rat 5-HT(1B) sites were markedly different to guinea pig 5-HT(1B) sites labelled with [3H]GR125,743.	Propranolol	124-138	5-hydroxytryptamine receptor 1B	Rattus norvegicus	199-206
11756451-7	2002	However, SPP1 has some significantly different enzymological properties than the LPPs: the aliphatic cation propanolol, which is an effective inhibitor of type 1 phosphatidate phosphohydrolase activities and is only modestly effective as an inhibitor of LPPs, is a potent inhibitor of SPP1; the activity was partially sensitive to N-ethylmaleimide but not to the thioreactive compound iodoacetamide; and importantly, low concentrations of Triton X-100 and other non-ionic detergents were strongly inhibitory.	Propranolol	108-118	secreted phosphoprotein 1	Homo sapiens	9-13
11756451-7	2002	However, SPP1 has some significantly different enzymological properties than the LPPs: the aliphatic cation propanolol, which is an effective inhibitor of type 1 phosphatidate phosphohydrolase activities and is only modestly effective as an inhibitor of LPPs, is a potent inhibitor of SPP1; the activity was partially sensitive to N-ethylmaleimide but not to the thioreactive compound iodoacetamide; and importantly, low concentrations of Triton X-100 and other non-ionic detergents were strongly inhibitory.	Propranolol	108-118	secreted phosphoprotein 1	Homo sapiens	285-289
11861783-5	2002	Recently, this putative beta4-adrenoceptor has been identified to be a propranolol-insensitive state of the beta1-adrenoceptor.	Propranolol	71-82	adrenoceptor beta 1	Homo sapiens	108-126
11724949-8	2001	Propranolol (beta-receptor antagonist) produced a significant increase in plasma leptin but had no effect on the response to LPS.	Propranolol	0-11	leptin	Rattus norvegicus	81-87
11777541-5	2002	Since the beta-adrenoceptor antagonist propranolol completely prevented the inhibitory effect of dopamine on IL-12 p40 production, the suppressive effect of dopamine on IL-12 p40 production by J774.1 cells is mediated by beta-adrenoceptors.	Propranolol	39-50	interleukin 12b	Mus musculus	109-118
12053770-2	2002	Administrated beta 2-agonists were observed to result in reducing iNOs activity in the rats with BA, while propranolol intensified iNOs expression.	Propranolol	107-118	nitric oxide synthase 2	Rattus norvegicus	131-135
11724949-12	2001	The findings that phentolamine and propranolol increased plasma leptin concentrations suggest that leptin release is inhibited by the sympathetic nervous system mediated principally by alpha-adrenergic receptors because phentolamine, but not propranolol, augmented the response to LPS.	Propranolol	35-46	leptin	Rattus norvegicus	99-105
11705764-8	2001	Intravenous administration of the alpha(1)-adrenergic receptor antagonist prazosin (0.5 mg/kg) or the beta-adrenergic receptor antagonist propranolol (0.5 mg/kg) markedly diminished, respectively, the orexin A-induced increase of MAP and HR.	Propranolol	138-149	hypocretin neuropeptide precursor	Rattus norvegicus	201-209
11822472-3	2001	One week of ingesting propranolol modestly elevated the numbers of CD62L+ (P&lt;0.019) but not CD62L- T-lymphocytes.	Propranolol	22-33	selectin L	Homo sapiens	67-72
11822472-3	2001	One week of ingesting propranolol modestly elevated the numbers of CD62L+ (P&lt;0.019) but not CD62L- T-lymphocytes.	Propranolol	22-33	selectin L	Homo sapiens	95-100
11822472-4	2001	Moreover, propranolol preferentially blunted-psychological stress-induced increases in naive T-helper (CD4+CD62L+; P&lt;0.049) and naive T-cytotoxic lymphocytes (CD8+CD62L+; P&lt;0.003), as well as activated T-cytotoxic lymphocytes (CD8+CD29+; P&lt;0.005).	Propranolol	10-21	CD4 molecule	Homo sapiens	103-106
11822472-4	2001	Moreover, propranolol preferentially blunted-psychological stress-induced increases in naive T-helper (CD4+CD62L+; P&lt;0.049) and naive T-cytotoxic lymphocytes (CD8+CD62L+; P&lt;0.003), as well as activated T-cytotoxic lymphocytes (CD8+CD29+; P&lt;0.005).	Propranolol	10-21	selectin L	Homo sapiens	107-112
11822472-4	2001	Moreover, propranolol preferentially blunted-psychological stress-induced increases in naive T-helper (CD4+CD62L+; P&lt;0.049) and naive T-cytotoxic lymphocytes (CD8+CD62L+; P&lt;0.003), as well as activated T-cytotoxic lymphocytes (CD8+CD29+; P&lt;0.005).	Propranolol	10-21	CD8a molecule	Homo sapiens	162-165
11822472-4	2001	Moreover, propranolol preferentially blunted-psychological stress-induced increases in naive T-helper (CD4+CD62L+; P&lt;0.049) and naive T-cytotoxic lymphocytes (CD8+CD62L+; P&lt;0.003), as well as activated T-cytotoxic lymphocytes (CD8+CD29+; P&lt;0.005).	Propranolol	10-21	selectin L	Homo sapiens	166-171
11822472-4	2001	Moreover, propranolol preferentially blunted-psychological stress-induced increases in naive T-helper (CD4+CD62L+; P&lt;0.049) and naive T-cytotoxic lymphocytes (CD8+CD62L+; P&lt;0.003), as well as activated T-cytotoxic lymphocytes (CD8+CD29+; P&lt;0.005).	Propranolol	10-21	CD8a molecule	Homo sapiens	233-236
11822472-4	2001	Moreover, propranolol preferentially blunted-psychological stress-induced increases in naive T-helper (CD4+CD62L+; P&lt;0.049) and naive T-cytotoxic lymphocytes (CD8+CD62L+; P&lt;0.003), as well as activated T-cytotoxic lymphocytes (CD8+CD29+; P&lt;0.005).	Propranolol	10-21	integrin subunit beta 1	Homo sapiens	237-241
11822472-6	2001	In contrast to the effect on the numbers of adhesion-molecule-bearing cells, there was only a modest effect of propranolol on stress-induced alterations of the density of CD62L, CD54 and CD11a.	Propranolol	111-122	selectin L	Homo sapiens	171-176
11822472-6	2001	In contrast to the effect on the numbers of adhesion-molecule-bearing cells, there was only a modest effect of propranolol on stress-induced alterations of the density of CD62L, CD54 and CD11a.	Propranolol	111-122	intercellular adhesion molecule 1	Homo sapiens	178-182
11822472-6	2001	In contrast to the effect on the numbers of adhesion-molecule-bearing cells, there was only a modest effect of propranolol on stress-induced alterations of the density of CD62L, CD54 and CD11a.	Propranolol	111-122	integrin subunit alpha L	Homo sapiens	187-192
11701618-7	2001	AFC in beta(2)AR overexpressing lungs from adrenalectomized or propranolol-treated rats revealed clearance rates that were the same or less than normal, untreated, sham-infected controls.	Propranolol	63-74	adrenoceptor beta 2	Rattus norvegicus	7-16
11874552-7	2002	The noradrenergic blockers phentholamine and propranolol significantly diminished RMCP II concentration in basal conditions and completely blocked the response to OVH.	Propranolol	45-56	mast cell protease 2	Rattus norvegicus	82-89
11818034-2	2002	We hypothesized that with ID 1) intravenous norepinephrine would alter heart rate (HR) and contractility, 2) abdominal aorta would be larger and more distensible, and 3) the beta-blocker propanolol would reduce hypertrophy.	Propranolol	187-197	inhibitor of DNA binding 1, HLH protein	Rattus norvegicus	26-30
15618653-0	2002	Induction of cytochrome P450 1A1 in mice by repeated oral administration of propranolol.	Propranolol	76-87	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	13-32
15618653-1	2002	Pretreatment of adult male C57BL/6 mice with propranolol (PL, 100 mg/kg, p.o., once a day for five days) significantly increased PL N-deisopropylase activity and decreased PL 7-hydroxylase activity in liver microsomes, whereas PL 4- and 5-hydroxylase activities remained unchanged.	Propranolol	45-56	lethal, Chr 9, Russell 4	Mus musculus	227-231
15618653-1	2002	Pretreatment of adult male C57BL/6 mice with propranolol (PL, 100 mg/kg, p.o., once a day for five days) significantly increased PL N-deisopropylase activity and decreased PL 7-hydroxylase activity in liver microsomes, whereas PL 4- and 5-hydroxylase activities remained unchanged.	Propranolol	58-60	lethal, Chr 9, Russell 4	Mus musculus	227-231
15618653-7	2002	These results show that repeated oral administration of PL in mice induces mainly CYP1A1 and also CYP1A2 to some extent, which contrasts from our previous results in rats in which CYP1A2 only was induced with PL pretreatment [Narimatsu et al., Chemico-Biol.	Propranolol	56-58	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	82-88
15618653-7	2002	These results show that repeated oral administration of PL in mice induces mainly CYP1A1 and also CYP1A2 to some extent, which contrasts from our previous results in rats in which CYP1A2 only was induced with PL pretreatment [Narimatsu et al., Chemico-Biol.	Propranolol	56-58	cytochrome P450, family 1, subfamily a, polypeptide 2	Mus musculus	98-104
15618653-7	2002	These results show that repeated oral administration of PL in mice induces mainly CYP1A1 and also CYP1A2 to some extent, which contrasts from our previous results in rats in which CYP1A2 only was induced with PL pretreatment [Narimatsu et al., Chemico-Biol.	Propranolol	56-58	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	180-186
15618653-7	2002	These results show that repeated oral administration of PL in mice induces mainly CYP1A1 and also CYP1A2 to some extent, which contrasts from our previous results in rats in which CYP1A2 only was induced with PL pretreatment [Narimatsu et al., Chemico-Biol.	Propranolol	209-211	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	180-186
11871761-1	2002	BACKGROUND: Propranolol causes splanchnic arterial vasoconstriction owing to the unopposed alpha vasoconstriction resulting from the blockade of beta-2 adrenoceptors.	Propranolol	12-23	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	145-151
12579892-9	2002	Moreover, G6PDH activity of rat hepatocyte was significantly decreased by 43.36% (P &lt; 0.05) with clenbuterol treatment (1 x 10(-6) mol.L-1), and the declined effect of clenbuterol was antagonized by propranolol.	Propranolol	202-213	glucose-6-phosphate dehydrogenase	Rattus norvegicus	10-15
11854913-6	2001	The enzyme activity of CHL-UGT1A9 towards propranolol in S9 protein of the cell was determined by HPLC.	Propranolol	42-53	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	27-33
11854913-9	2001	The cell lines established expressed the protein of UGT1A9, and the enzyme activity towards propranolol in S9 protein was found to be 101+/- 24 pmol x min(-1) x mg(-1) protein (n=3), but was not detectable in parental CHL cells.	Propranolol	92-103	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	52-58
11682141-5	2001	The accumulation of phosphatidic acid (PA) by preincubating PC12 cells with propranolol (an inhibitor of PA phosphohydrolase) also decreased the ERK phosphorylation.	Propranolol	76-87	Eph receptor B1	Rattus norvegicus	145-148
11724949-12	2001	The findings that phentolamine and propranolol increased plasma leptin concentrations suggest that leptin release is inhibited by the sympathetic nervous system mediated principally by alpha-adrenergic receptors because phentolamine, but not propranolol, augmented the response to LPS.	Propranolol	35-46	leptin	Rattus norvegicus	64-70
11576779-7	2001	The most hydrophobic beta-ligand, propranolol, a known Pgp substrate, gave the largest increase in Rh123 accumulation in this therapeutic class.	Propranolol	34-45	ATP binding cassette subfamily B member 1	Homo sapiens	55-58
11765139-2	2001	The inhibition of recombinant CYP1A1 and CYP1A2 activity by quinidine and quinine was evluated using ethoxyresorutin O-deethylation, phenacetin O-deethylation and propranolol desisopropylation as probe catalytic pathways.	Propranolol	163-174	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	30-36
11765139-2	2001	The inhibition of recombinant CYP1A1 and CYP1A2 activity by quinidine and quinine was evluated using ethoxyresorutin O-deethylation, phenacetin O-deethylation and propranolol desisopropylation as probe catalytic pathways.	Propranolol	163-174	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	41-47
11588108-13	2001	Treatment of A549 cells with LTA caused NF-kappaB activation by detecting the formation of NF-kappaB-specific DNA-protein complex in the nucleus; this effect was inhibited by dexamethasone, D-609, propranolol, Go 6976, Ro 31-8220, or PDTC.	Propranolol	197-208	nuclear factor kappa B subunit 1	Homo sapiens	40-49
11588108-13	2001	Treatment of A549 cells with LTA caused NF-kappaB activation by detecting the formation of NF-kappaB-specific DNA-protein complex in the nucleus; this effect was inhibited by dexamethasone, D-609, propranolol, Go 6976, Ro 31-8220, or PDTC.	Propranolol	197-208	nuclear factor kappa B subunit 1	Homo sapiens	91-100
11749856-0	2001	Propranolol increases phosphatidic acid level via activation of phospholipase D.	Propranolol	0-11	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	64-79
11589377-9	2001	Pretreatment with either a nitric oxide synthase inhibitor or phentolamine and propranolol reversed the inhibitory effect of glucagon, GLP-1 and GLP-2 on contractions in the pouch, but did not alter the inhibitory effect of glucagon and GLP-1 on motility in the neurally intact stomach and duodenum.	Propranolol	79-90	glucagon	Canis lupus familiaris	135-140
11589377-9	2001	Pretreatment with either a nitric oxide synthase inhibitor or phentolamine and propranolol reversed the inhibitory effect of glucagon, GLP-1 and GLP-2 on contractions in the pouch, but did not alter the inhibitory effect of glucagon and GLP-1 on motility in the neurally intact stomach and duodenum.	Propranolol	79-90	glucagon	Canis lupus familiaris	237-242
11642551-8	2001	When the PC12 cells were pretreated with propranolol, a specific inhibitor for phosphatidic acid phosphohydrolase resulting in the accumulation of PA, ATP-induced Fak activation and paxillin phosphorylation were also reduced.	Propranolol	41-52	protein tyrosine kinase 2	Rattus norvegicus	163-166
11749856-1	2001	AIM: To investigate the propranolol-induced phospholipase D (PLD) activity, its contribution to the increase in the level of phosphatidic acid, and the role of protein kinase C (PKC) in this event.	Propranolol	24-35	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	44-59
11749856-1	2001	AIM: To investigate the propranolol-induced phospholipase D (PLD) activity, its contribution to the increase in the level of phosphatidic acid, and the role of protein kinase C (PKC) in this event.	Propranolol	24-35	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	61-64
11749856-3	2001	PKC inhibitors and prolonged phorbol-12-myristate-13-acetate (PMA) treatment were used to study the involvement of PKC in propranolol-induced PLD activation.	Propranolol	122-133	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	142-145
11749856-5	2001	RESULTS: Treatment of A-549 cells with propranolol in the presence of butanol, resulted in the rapid activation of PLD.	Propranolol	39-50	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	115-118
11749856-6	2001	Propranolol induced the formation of phosphatidylbutanol (PBut), a unique product of PLD, at the expense of phosphatidic acid (PA) formation.	Propranolol	0-11	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	85-88
11749856-7	2001	Pretreatment of cells with PKC inhibitors Ro-31-8220, staurosporine, and rottlerin increased the propranolol-induced PLD.	Propranolol	97-108	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	117-120
11749856-8	2001	Down-regulation of PKC by prolonged treatment of cells with PMA also potentiated the propranolol-induced PLD activity.	Propranolol	85-96	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	105-108
11749856-9	2001	CONCLUSION: Propranolol induces rapid activation of PLD activity, which results in the increase in intracellular level of PA.	Propranolol	12-23	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	52-55
11749856-10	2001	The data also indicate that propranolol-induced PLD activity could be negatively regulated by PKC.	Propranolol	28-39	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	48-51
11558582-0	2001	Inactivation of rat cytochrome P450 2D enzyme by a further metabolite of 4-hydroxypropranolol, the major and active metabolite of propranolol.	Propranolol	82-93	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	20-35
11489433-0	2001	Side-chain metabolism of propranolol: involvement of monoamine oxidase and aldehyde reductase in the metabolism of N-desisopropylpropranolol to propranolol glycol in rat liver.	Propranolol	25-36	monoamine oxidase A	Rattus norvegicus	53-70
11489433-0	2001	Side-chain metabolism of propranolol: involvement of monoamine oxidase and aldehyde reductase in the metabolism of N-desisopropylpropranolol to propranolol glycol in rat liver.	Propranolol	25-36	aldo-keto reductase family 1, member B7	Rattus norvegicus	75-93
11453892-14	2001	CONCLUSIONS: These results suggest that propranolol increases plasma concentrations of rizatriptan by inhibiting monoamine oxidase-A.	Propranolol	40-51	monoamine oxidase A	Homo sapiens	113-132
11478592-5	2001	A relatively low sensitivity to the beta-adrenergic antagonist propranolol (pK(B) approximately 6) indicated that arotinolol interacted with the beta3-adrenergic receptor.	Propranolol	63-74	adrenergic receptor, beta 3	Mus musculus	145-170
11500953-7	2001	Propranolol, which inhibits phosphatidic acid phosphohydrolase, also suppressed ET-1-induced Pi transport.	Propranolol	0-11	endothelin 1	Mus musculus	80-84
11602512-2	2001	A series of 1"-mono-, di-, and trifluorinated analogs of propranolol and related steric congeners was prepared, and their metabolism was examined in recombinant-expressed CYP2D6.	Propranolol	57-68	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	171-177
11564965-4	2001	Propranolol treatment before discontinuation of octreotide infusin prevented the recurrence of bleeding from PHC.	Propranolol	0-11	solute carrier family 25 member 3	Homo sapiens	109-112
11602221-7	2001	The panic symptom response and the cardiovascular response to bolus injection of 50 microg of CCK-4 was assessed in subjects pretreated with either propranolol or placebo infusions prior to the CCK-4 challenge.	Propranolol	148-159	protein tyrosine kinase 7 (inactive)	Homo sapiens	94-99
11516621-8	2001	The effect of propranolol was reproduced by labetolol, a beta-adrenergic antagonist with membrane-stabilizing properties, but not by atenolol, which blocks beta-adrenergic receptors but has no effect on the stability of the membrane.	Propranolol	14-25	amyloid beta precursor protein	Rattus norvegicus	55-61
11558582-1	2001	Repetitive administration of propranolol (PL) in rats decreases the activities of cytochrome P450 (CYP) 2D enzyme(s) in hepatic microsomes.	Propranolol	29-40	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	82-97
11558582-1	2001	Repetitive administration of propranolol (PL) in rats decreases the activities of cytochrome P450 (CYP) 2D enzyme(s) in hepatic microsomes.	Propranolol	29-40	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	99-102
11558582-1	2001	Repetitive administration of propranolol (PL) in rats decreases the activities of cytochrome P450 (CYP) 2D enzyme(s) in hepatic microsomes.	Propranolol	42-44	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	82-97
11558582-1	2001	Repetitive administration of propranolol (PL) in rats decreases the activities of cytochrome P450 (CYP) 2D enzyme(s) in hepatic microsomes.	Propranolol	42-44	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	99-102
11322936-6	2001	These effects of epinephrine on the clearance of Ca(2+) from the cytosol of FMLP-activated neutrophils were attenuated by propranolol, and are compatible with enhancement of the activity of the cAMP-dependent Ca(2+) sequestering/resequestering endo-membrane Ca(2+)-ATPase.	Propranolol	122-133	formyl peptide receptor 1	Homo sapiens	76-80
11441921-2	2001	In the presence of 10 microM propranolol, the treatment of cells with 10 microM NE for 4-72 h down-regulated alpha1A- and alpha1D-AR.	Propranolol	29-40	calcium voltage-gated channel subunit alpha1 A	Homo sapiens	109-116
21171413-4	2001	But glibenclamide (10(-6) mol/L) and propranolol (10(-6) mol/L) could decrease the vasodilation of CNP obviously, in addition, CNP couldn"t inhibit the vasoconstriction of NE.	Propranolol	37-48	2',3'-cyclic-nucleotide 3'-phosphodiesterase	Oryctolagus cuniculus	99-102
11368160-6	2001	U-73122, an inhibitor of phospholipase C, and propranolol, a phosphatidic acid phosphohydrolase inhibitor, suppressed the bFGF-stimulated HSP27 accumulation.	Propranolol	46-57	fibroblast growth factor 2	Mus musculus	122-126
11368160-6	2001	U-73122, an inhibitor of phospholipase C, and propranolol, a phosphatidic acid phosphohydrolase inhibitor, suppressed the bFGF-stimulated HSP27 accumulation.	Propranolol	46-57	heat shock protein 1	Mus musculus	138-143
11245615-5	2001	Addition of 1 microM Ca2+ to permeable cells caused myosin light chain (MLC) phosphorylation, which was inhibited by the PKC inhibitor chelerythrine, by D609 [phosphatidylcholine-specific phospholipase C inhibitor], and by propranolol (phosphatidic acid phosphohydrolase inhibitor).	Propranolol	223-234	modulator of VRAC current 1	Homo sapiens	52-70
11245615-5	2001	Addition of 1 microM Ca2+ to permeable cells caused myosin light chain (MLC) phosphorylation, which was inhibited by the PKC inhibitor chelerythrine, by D609 [phosphatidylcholine-specific phospholipase C inhibitor], and by propranolol (phosphatidic acid phosphohydrolase inhibitor).	Propranolol	223-234	modulator of VRAC current 1	Homo sapiens	72-75
11306460-4	2001	The beta1/2-blocker propranolol but not the beta1-blocker atenolol inhibited this increase.	Propranolol	20-31	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	4-11
11270482-0	2001	Effect of propranolol plus exercise on melatonin and growth hormone levels in children with growth delay.	Propranolol	10-21	growth hormone 1	Homo sapiens	53-67
11373471-7	2001	MEASUREMENTS AND MAIN RESULTS: Epinephrine and norepinephrine increased the production of IL-6 but not of IL-1alpha in normal abdominal skin, and these increases were reversed by a beta-blocker (propranolol hydrochloride) but not an alpha-blocker (phentolamine mesylate).	Propranolol	195-220	interleukin 6	Mus musculus	90-94
11259557-6	2001	This hypothesis was confirmed by determining that beta(3)-adrenergic receptor agonist-evoked tachycardia was attenuated in the presence of propranolol and in ganglion-blocked animals, under which conditions there was no reduction in the evoked vasodilatation, lipolysis, or increase in metabolic rate.	Propranolol	139-150	adrenoceptor beta 3	Macaca mulatta	50-77
11259081-5	2001	Pretreatment with propranolol (20 mg/kg IP) reversed CRH-induced suppression of IgG responses but had no effect on IgM levels.	Propranolol	18-29	corticotropin releasing hormone	Rattus norvegicus	53-56
11270482-10	2001	These data suggest an inverse relationship between melatonin and GH after the propranolol + exercise test, and the reduction in melatonin may be related to its depletion by exercise-induced oxidative stress.	Propranolol	78-89	growth hormone 1	Homo sapiens	65-67
11141226-13	2001	Whenever beta-blockers are chosen for treatment of hyperthyroidism, propranolol (beta 1 + beta 2) has an advantage because it reduces the metabolic rate, whereas selective beta 1-blockade seemed to provide only symptomatic relief, related to the normalization of heart rate.	Propranolol	68-79	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	81-96
11368349-3	2001	Although cyclosporin A and bongkrekic acid were without effect, dibucaine, propanolol, dextran, and the uncoupler FCCP were each able to inhibit signal peptide-induced swelling and cytochrome c release.	Propranolol	75-85	cytochrome c, somatic	Homo sapiens	181-193
11159726-7	2001	The maximum extent of attenuation was RANTES &gt; or = eotaxin &gt; GM-CSF &gt;&gt; IL-8, and was prevented by either propranolol (1 microM), a non-selective beta-adrenoceptor antagonist, or ICI 118511 (IC(50) 15 nM), a selective beta(2)-adrenoceptor antagonist.	Propranolol	118-129	C-C motif chemokine ligand 5	Homo sapiens	38-44
11159726-7	2001	The maximum extent of attenuation was RANTES &gt; or = eotaxin &gt; GM-CSF &gt;&gt; IL-8, and was prevented by either propranolol (1 microM), a non-selective beta-adrenoceptor antagonist, or ICI 118511 (IC(50) 15 nM), a selective beta(2)-adrenoceptor antagonist.	Propranolol	118-129	colony stimulating factor 2	Homo sapiens	68-74
11159726-7	2001	The maximum extent of attenuation was RANTES &gt; or = eotaxin &gt; GM-CSF &gt;&gt; IL-8, and was prevented by either propranolol (1 microM), a non-selective beta-adrenoceptor antagonist, or ICI 118511 (IC(50) 15 nM), a selective beta(2)-adrenoceptor antagonist.	Propranolol	118-129	C-X-C motif chemokine ligand 8	Homo sapiens	84-88
11159726-7	2001	The maximum extent of attenuation was RANTES &gt; or = eotaxin &gt; GM-CSF &gt;&gt; IL-8, and was prevented by either propranolol (1 microM), a non-selective beta-adrenoceptor antagonist, or ICI 118511 (IC(50) 15 nM), a selective beta(2)-adrenoceptor antagonist.	Propranolol	118-129	adrenoceptor beta 2	Homo sapiens	230-250
11273730-2	2001	Norepinephrine (NE; 1 microM) in the presence of the beta -AR antagonist propranolol (Pro; 2 microM) caused activation of Ras (&gt;six-fold), MAPK/ERK kinase 1 and 2 (MEK1/2, &gt;10-fold) and extracellular signal-regulated kinases 1 and 2 (ERK1/2, approximately 30-fold) within 5 min, as determined by kinase activity assays and Western blots using phospho-specific antibodies.	Propranolol	73-84	mitogen activated protein kinase kinase 1	Rattus norvegicus	167-173
11273730-2	2001	Norepinephrine (NE; 1 microM) in the presence of the beta -AR antagonist propranolol (Pro; 2 microM) caused activation of Ras (&gt;six-fold), MAPK/ERK kinase 1 and 2 (MEK1/2, &gt;10-fold) and extracellular signal-regulated kinases 1 and 2 (ERK1/2, approximately 30-fold) within 5 min, as determined by kinase activity assays and Western blots using phospho-specific antibodies.	Propranolol	73-84	mitogen activated protein kinase 3	Rattus norvegicus	192-238
11273730-2	2001	Norepinephrine (NE; 1 microM) in the presence of the beta -AR antagonist propranolol (Pro; 2 microM) caused activation of Ras (&gt;six-fold), MAPK/ERK kinase 1 and 2 (MEK1/2, &gt;10-fold) and extracellular signal-regulated kinases 1 and 2 (ERK1/2, approximately 30-fold) within 5 min, as determined by kinase activity assays and Western blots using phospho-specific antibodies.	Propranolol	73-84	mitogen activated protein kinase 3	Rattus norvegicus	240-246
11141226-13	2001	Whenever beta-blockers are chosen for treatment of hyperthyroidism, propranolol (beta 1 + beta 2) has an advantage because it reduces the metabolic rate, whereas selective beta 1-blockade seemed to provide only symptomatic relief, related to the normalization of heart rate.	Propranolol	68-79	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	81-87
11752888-8	2001	RESULTS: Among all the drugs tested, only propranolol increased plasma TNF-alpha.	Propranolol	42-53	tumor necrosis factor	Rattus norvegicus	71-80
11243572-4	2001	In the presence of (+/-)-propranolol (1 microM), the non-selective beta1-, beta2- and beta3-adrenoceptor antagonist (+/-)-bupranolol (30 microM) induced a rightward shift of the concentration-response curves for (+/-)-pindolol (apparent pA2 = 5.41 +/- 0.06).	Propranolol	19-36	beta-2 adrenergic receptor	Cavia porcellus	67-104
11752888-11	2001	On the contrary, propranolol, a beta-receptor blocker, induced a highly significant 3-fold increase in plasma TNF-alpha concentrations at 30 min and augmented the response to LPS 2-fold after endotoxin injection.	Propranolol	17-28	tumor necrosis factor	Rattus norvegicus	110-119
11752888-15	2001	The fact that isoproterenol decreased the LPS-induced TNF-alpha release, whereas propranolol augmented basal and LPS-induced release suggests that the sympathetic nervous system inhibits basal and LPS-stimulated TNF-alpha release via beta-adrenergic receptors.	Propranolol	81-92	tumor necrosis factor	Rattus norvegicus	212-221
11516836-9	2001	In addition, the day-time pineal arylalkylamine N-acetyltransferase mRNA expression in ganglionectomized rats persisted after adrenal gland removal but was reduced by 50% after propranolol injection.	Propranolol	177-188	aralkylamine N-acetyltransferase	Rattus norvegicus	33-67
11146120-4	2000	Effects of clenbuterol on NGF mRNA were antagonized by propranolol.	Propranolol	55-66	nerve growth factor	Mus musculus	26-29
11108260-3	2000	Treatment with prazosin or propranolol significantly reduced the effect of NE on MAPK phosphorylation, suggesting the involvement of both alpha- and beta-adrenergic receptors.	Propranolol	27-38	mitogen activated protein kinase 3	Rattus norvegicus	81-85
11093795-11	2000	Finally, isoproterenol and forskolin activated ERK, an effect that was blunted by propranolol.	Propranolol	82-93	Eph receptor B1	Rattus norvegicus	47-50
12567907-3	2000	RESULTS: The beta-AR antagonist propranolol 15 mg.kg-1 i.p.	Propranolol	32-43	adrenergic receptor, beta 1	Mus musculus	13-20
11128215-2	2000	Large retention differences were observed on the propranolol MIP for both the template molecule and the structural analogue metoprolol compared to that observed on the corresponding blank polymer.	Propranolol	49-60	major intrinsic protein of lens fiber	Homo sapiens	61-64
11128215-6	2000	After a number of days under supercritical fluid conditions, the performance of the photochemically initiated L-PA MIP was found to significantly deteriorate whereas the thermally initiated propranolol MIP revealed only small changes in its separation performance after a long term of operation.	Propranolol	190-201	major intrinsic protein of lens fiber	Homo sapiens	202-205
11104878-9	2000	CONCLUSION: Although high dose Captopril was not evaluated in this study, when compared to patients on low Captopril dosages, infants who received Propranolol treatment showed improvement in heart failure scores, shorter lengths of hospital stay, lower plasma renin activities and better diastolic ventricular functions.	Propranolol	147-158	renin	Homo sapiens	260-265
11085356-7	2000	Propranolol downregulated the levels of TRalpha1 by 44% (p &lt; 0.0005) and beta1 mRNA by 39% (p &lt; 0.0005) in mouse heart, in comparison to the control, while no difference in the TRalpha2 or beta2 mRNA levels occurred.	Propranolol	0-11	thyroid hormone receptor alpha	Mus musculus	40-48
11085356-7	2000	Propranolol downregulated the levels of TRalpha1 by 44% (p &lt; 0.0005) and beta1 mRNA by 39% (p &lt; 0.0005) in mouse heart, in comparison to the control, while no difference in the TRalpha2 or beta2 mRNA levels occurred.	Propranolol	0-11	hemoglobin, beta adult major chain	Mus musculus	76-81
11085356-7	2000	Propranolol downregulated the levels of TRalpha1 by 44% (p &lt; 0.0005) and beta1 mRNA by 39% (p &lt; 0.0005) in mouse heart, in comparison to the control, while no difference in the TRalpha2 or beta2 mRNA levels occurred.	Propranolol	0-11	thyroid hormone receptor alpha	Mus musculus	183-191
11085356-7	2000	Propranolol downregulated the levels of TRalpha1 by 44% (p &lt; 0.0005) and beta1 mRNA by 39% (p &lt; 0.0005) in mouse heart, in comparison to the control, while no difference in the TRalpha2 or beta2 mRNA levels occurred.	Propranolol	0-11	hemoglobin, beta adult minor chain	Mus musculus	195-200
11038161-8	2000	Metoprolol and dextromethorphan were primarily CYP2D6 substrates and propranolol was metabolized by CYP2D6 (59%), CYP1A2 (26%), and CYP2C19 (15%).	Propranolol	69-80	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	100-106
11038161-8	2000	Metoprolol and dextromethorphan were primarily CYP2D6 substrates and propranolol was metabolized by CYP2D6 (59%), CYP1A2 (26%), and CYP2C19 (15%).	Propranolol	69-80	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	114-120
11038161-8	2000	Metoprolol and dextromethorphan were primarily CYP2D6 substrates and propranolol was metabolized by CYP2D6 (59%), CYP1A2 (26%), and CYP2C19 (15%).	Propranolol	69-80	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	132-139
18968085-9	2000	The interaction with propranolol, clonidine, phenylephrine, carbachol and tripeptide fMLP, which hinder adenylate cyclase (AdC) and activate Ca-polyphosphoinisitide (Ca-PPI) signaling system of a cell, initiates structural rearrangements similar to acidic transitions of albumin.	Propranolol	21-32	formyl peptide receptor 1	Homo sapiens	85-89
18968085-9	2000	The interaction with propranolol, clonidine, phenylephrine, carbachol and tripeptide fMLP, which hinder adenylate cyclase (AdC) and activate Ca-polyphosphoinisitide (Ca-PPI) signaling system of a cell, initiates structural rearrangements similar to acidic transitions of albumin.	Propranolol	21-32	albumin	Homo sapiens	271-278
10992416-9	2000	2) Propranolol (a non-selective beta-AR antagonist) and ICI-118,551 concentration-dependently displaced [3H]-dihydroalprenolol binding to the membrane with Ki values of 1.5 x 10-9 M and 6.3 x 10-9 M, respectively, while metoprolol (a beta1-AR antagonist) was less effective in this assay.	Propranolol	3-14	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	234-239
11005159-12	2000	Previous injection of HOE140 or propranolol into the gingiva diminished the stimulatory effect of topical warming on albumin clearance.	Propranolol	32-43	albumin	Bos taurus	117-124
10960071-8	2000	To confirm beta-adrenoceptor antagonists as substrates for OCT2, we demonstrate, in cells transiently transfected with an epitope tagged version of hOCT2 (hOCT2-V5):(1) Decynium-22 sensitive [(14)C]-propranolol uptake, (2) cis-inhibition of OCT2 by a range of beta-adrenoceptor antagonists and (3) metoprolol induced intracellular acidification.	Propranolol	199-210	POU class 2 homeobox 2	Homo sapiens	148-153
10942707-8	2000	Exercise goes along with an increase of catecholamines, and mobilization of the CD14(+)CD16(+) monocytes can be substantially reduced by treatment of donors with the beta-adrenergic receptor blocker propranolol.	Propranolol	199-210	CD14 molecule	Homo sapiens	80-84
10942707-8	2000	Exercise goes along with an increase of catecholamines, and mobilization of the CD14(+)CD16(+) monocytes can be substantially reduced by treatment of donors with the beta-adrenergic receptor blocker propranolol.	Propranolol	199-210	Fc gamma receptor IIIa	Homo sapiens	87-91
10993216-4	2000	The administration of 20 mg/kg propranolol inhibited the expression of Fos-ir cells in all three layers.	Propranolol	31-42	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	71-74
10960078-6	2000	ICI 118551 (log K(D)-9.73+/-0.07) and propranolol (log K(D)-9.25+/-0.12) both behaved as conventional competitive antagonists of isoprenaline-stimulated cyclic AMP accumulation in high expressing CHO-beta(2)4 cells.	Propranolol	38-49	hemoglobin, beta adult minor chain	Mus musculus	200-206
10969154-3	2000	In the presence of propranolol (1 microM), however, the non-selective beta(1)-, beta(2)- and beta(3)-adrenoceptor antagonist, bupranolol (30 microM), caused a rightward shift of the concentration-response curves for carteolol (apparent pA(2)=5.31).	Propranolol	19-30	beta-3 adrenergic receptor	Cavia porcellus	93-113
10945865-5	2000	Significant correlations were noted between propranolol 4-hydroxylation and ethoxyresorufin-O-deethylation (marker of CYP1A2 activity), with marked improvement in the correlations when CYP2D6-mediated propranolol 4-hydroxylation was inhibited with quinidine.	Propranolol	44-55	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	118-124
10940268-7	2000	Propranolol, a beta(1), beta(2) non-selective antagonist, at high concentrations (10(-5) mol/l) prevented taenia relaxation by CGP 12177 and SR 58611A; its quantitative antagonism of isoprenaline (in common with that of CGP 12177 used as an antagonist) was competitive in circular strips but not on taenia.	Propranolol	0-11	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	15-22
10940268-7	2000	Propranolol, a beta(1), beta(2) non-selective antagonist, at high concentrations (10(-5) mol/l) prevented taenia relaxation by CGP 12177 and SR 58611A; its quantitative antagonism of isoprenaline (in common with that of CGP 12177 used as an antagonist) was competitive in circular strips but not on taenia.	Propranolol	0-11	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	24-31
10945865-5	2000	Significant correlations were noted between propranolol 4-hydroxylation and ethoxyresorufin-O-deethylation (marker of CYP1A2 activity), with marked improvement in the correlations when CYP2D6-mediated propranolol 4-hydroxylation was inhibited with quinidine.	Propranolol	44-55	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	185-191
10945865-5	2000	Significant correlations were noted between propranolol 4-hydroxylation and ethoxyresorufin-O-deethylation (marker of CYP1A2 activity), with marked improvement in the correlations when CYP2D6-mediated propranolol 4-hydroxylation was inhibited with quinidine.	Propranolol	201-212	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	185-191
10945865-6	2000	Inhibition studies showed that quinidine inhibited approximately 55% of propranolol 4-hydroxylation and furaphylline (CYP1A2-selective inhibitor) inhibited about 45% of propranolol 4-hydroxylation.	Propranolol	169-180	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	118-124
10945865-8	2000	CYP1A2- and CYP2D6-mediated propranolol 4-hydroxylation was about 70 and 100% higher (P &lt;.05 for both), respectively, in African-Americans compared with Caucasians.	Propranolol	28-39	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	0-6
10945865-8	2000	CYP1A2- and CYP2D6-mediated propranolol 4-hydroxylation was about 70 and 100% higher (P &lt;.05 for both), respectively, in African-Americans compared with Caucasians.	Propranolol	28-39	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	12-18
11043449-3	2000	The ISO-induced increase in [Ca2+]i was completely inhibited by the beta-adrenoceptor antagonist propranolol but not by the alpha-adrenoceptor antagonist phentolamine.	Propranolol	97-108	carbonic anhydrase 2	Rattus norvegicus	29-32
11260363-9	2000	In the presence of (+/-)-propranolol (1 microM), the additional presence of (+/-)-bupranolol (3-30 microM), a non-selective beta1-, beta2- and beta3-adrenoceptor antagonist, caused a concentration-dependent rightward shift of the CRCs to catecholamines and beta3-adrenoceptor agonists.	Propranolol	19-36	beta-2 adrenergic receptor	Cavia porcellus	124-161
10960604-6	2000	The following receptor blockers attenuated the action of PACAP on this consolidation: haloperidol, phenoxybenzamine, propranolol and methysergide.	Propranolol	117-128	adenylate cyclase activating polypeptide 1	Homo sapiens	57-62
10882842-4	2000	In the present study, we demonstrate that clozapine- and olanzapine-induced Fos expression in the mPFC are inhibited by propranolol.	Propranolol	120-131	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	76-79
10952459-4	2000	Lipoprotein lipase activity in adipose and muscle tissues was assessed in the freely fed and fasted states and at various times during refeeding, with or without beta-adrenergic blockade (propranolol).	Propranolol	188-199	lipoprotein lipase	Rattus norvegicus	0-18
10952459-9	2000	Giving propranolol to lean rats before refeeding abolished the atypical response of muscle lipoprotein lipase to food intake and restored the early (1 h after refeeding) increase in adipose lipoprotein lipase but had no effect in obese rats.	Propranolol	7-18	lipoprotein lipase	Rattus norvegicus	91-109
10952459-9	2000	Giving propranolol to lean rats before refeeding abolished the atypical response of muscle lipoprotein lipase to food intake and restored the early (1 h after refeeding) increase in adipose lipoprotein lipase but had no effect in obese rats.	Propranolol	7-18	lipoprotein lipase	Rattus norvegicus	190-208
10889169-8	2000	Aortic NOS3 expressions were more marked in portal vein-stenosed aortas than in controls, but NOS3 expressions were reduced after propranolol administration.	Propranolol	130-141	nitric oxide synthase 3	Rattus norvegicus	94-98
10965930-0	2000	Propranolol stimulates histone phosphorylation by a putative PK-C in partially purified homogenate of rat testicular interstitial cells.	Propranolol	0-11	protein kinase C, gamma	Rattus norvegicus	61-65
10903420-5	2000	Inhibition studies using antibodies and characterization of CYP2D6 enzymes expressed in insect cells or human lymphoblastoid cells indicated that the enantioselectivity of PL oxidation, especially the ring 4- and 5-hydroxylations reflected the properties of CYP2D6 in human liver microsomes.	Propranolol	172-174	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	60-66
10903420-5	2000	Inhibition studies using antibodies and characterization of CYP2D6 enzymes expressed in insect cells or human lymphoblastoid cells indicated that the enantioselectivity of PL oxidation, especially the ring 4- and 5-hydroxylations reflected the properties of CYP2D6 in human liver microsomes.	Propranolol	172-174	transporter 1, ATP binding cassette subfamily B member	Homo sapiens	201-207
10903420-5	2000	Inhibition studies using antibodies and characterization of CYP2D6 enzymes expressed in insect cells or human lymphoblastoid cells indicated that the enantioselectivity of PL oxidation, especially the ring 4- and 5-hydroxylations reflected the properties of CYP2D6 in human liver microsomes.	Propranolol	172-174	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	258-264
10888304-0	2000	Role of P-glycoprotein in restricting propranolol transport in cultured rabbit conjunctival epithelial cell layers.	Propranolol	38-49	ATP-dependent translocase ABCB1	Oryctolagus cuniculus	8-22
11368887-5	2000	Of the agents tested, we found that ferulidilol, eugenodilol, eugenolol, isoeugenolol, and ferulinolol, as well as propranolol and metoprolol, possessed beta(3)-adrenoceptor blocking activities, others were nearly without effectiveness.	Propranolol	115-126	adrenoceptor beta 3	Rattus norvegicus	153-173
11368887-7	2000	Eugenodilol, eugenolol, metoprolol, isoeugenolol, and ferulinolol were less potent than both propranolol and ferulidilol in competing for the beta(3)-adrenoceptor binding sites.	Propranolol	93-104	adrenoceptor beta 3	Rattus norvegicus	142-162
11368887-8	2000	From the results of in vitro functional and binding studies, we suggested that propranolol, ferulidilol, eugenodilol, eugenolol, metoprolol, isoeugenolol, and ferulinolol all possessed beta(3)-adrenoceptor blocking activities.	Propranolol	79-90	adrenoceptor beta 3	Rattus norvegicus	185-205
10886465-8	2000	CYP2C19 enzyme participates in the metabolism of omeprazole, propranolol and psychotropic drugs such as hexobarbital, diazepam, citalopram, imipramine, clomipramine and amitriptyline.	Propranolol	61-72	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	0-7
10888304-1	2000	PURPOSE: To determine the role of P-glycoprotein (P-gp) in propranolol transport in cultured rabbit conjunctival epithelial cell layers (RCEC).	Propranolol	59-70	ATP-dependent translocase ABCB1	Oryctolagus cuniculus	34-48
10888304-1	2000	PURPOSE: To determine the role of P-glycoprotein (P-gp) in propranolol transport in cultured rabbit conjunctival epithelial cell layers (RCEC).	Propranolol	59-70	ATP-dependent translocase ABCB1	Oryctolagus cuniculus	50-54
10888304-3	2000	The role of P-gp in transepithelial transport and uptake of propranolol in conjunctival epithelial cells cultured on Transwell filters was evaluated in the presence and absence of P-gp competing substrates, an anti-P-gp monoclonal antibody (4E3 mAb), or a metabolic inhibitor, 2,4-dinitrophenol (2,4-DNP).	Propranolol	60-71	ATP-dependent translocase ABCB1	Oryctolagus cuniculus	12-16
10752952-6	2000	Norepinephrine pretreatment also decreased ET-1-induced [Ca2+]i (10 microM NE + ET-1; 619 +/- 64 nM) compared with ET-1 alone, and NE"s effect could be reversed by propranolol (beta-adrenergic antagonist) treatment.	Propranolol	164-175	endothelin 1	Homo sapiens	43-47
10758054-8	2000	Propranolol administration reduced baseline +dP/dt(max) to nontransgenic levels in all beta(2)AR transgenics except the 350-fold overexpressors, indicating that spontaneous activation of beta(2)AR was present at this level of expression.	Propranolol	0-11	adrenergic receptor, beta 2	Mus musculus	87-96
10758054-8	2000	Propranolol administration reduced baseline +dP/dt(max) to nontransgenic levels in all beta(2)AR transgenics except the 350-fold overexpressors, indicating that spontaneous activation of beta(2)AR was present at this level of expression.	Propranolol	0-11	adrenergic receptor, beta 2	Mus musculus	187-196
10830457-0	2000	Simultaneous stimulation of growth hormone, adrenocorticotropin and cortisol with L-dopa/L-carbidopa and propranolol in children of short stature.	Propranolol	105-116	growth hormone 1	Homo sapiens	28-42
10830457-9	2000	We conclude that the administration of L-dopa/L-carbidopa and propranolol is useful for the simultaneous evaluation of growth hormone, cortisol and ACTH secretion in children of short stature.	Propranolol	62-73	growth hormone 1	Homo sapiens	119-133
10830457-9	2000	We conclude that the administration of L-dopa/L-carbidopa and propranolol is useful for the simultaneous evaluation of growth hormone, cortisol and ACTH secretion in children of short stature.	Propranolol	62-73	proopiomelanocortin	Homo sapiens	148-152
10718926-4	2000	The in-vitro prolactin release-inhibiting effect of noradrenaline (10-7 mol/l) was not blocked by the dopamine antagonists pimozide (D2) or SCH23390 (D1) but was blocked by each of the adrenoceptor antagonists (alpha1-adrenoceptor antagonists prazosin and WB4101, the alpha2-adrenoceptor antagonist yohimbine and the beta-adrenoceptor antagonist propranolol).	Propranolol	346-357	prolactin	Ovis aries	13-22
11249525-6	2000	An important but complex MAO-A interaction between a metabolite of propranolol and rizatriptan mandates dosage reduction (to 5 mg) for rizatriptan in the presence of propranolol treatment.	Propranolol	67-78	monoamine oxidase A	Homo sapiens	25-30
10712234-9	2000	Propranolol, a substance that inhibits the phospholipase D (PLD) pathway, strongly reduced the response to muscarinic stimulation and its potentiation by TNF-alpha.	Propranolol	0-11	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	43-58
10712234-9	2000	Propranolol, a substance that inhibits the phospholipase D (PLD) pathway, strongly reduced the response to muscarinic stimulation and its potentiation by TNF-alpha.	Propranolol	0-11	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	60-63
10712234-9	2000	Propranolol, a substance that inhibits the phospholipase D (PLD) pathway, strongly reduced the response to muscarinic stimulation and its potentiation by TNF-alpha.	Propranolol	0-11	tumor necrosis factor	Homo sapiens	154-163
11249525-6	2000	An important but complex MAO-A interaction between a metabolite of propranolol and rizatriptan mandates dosage reduction (to 5 mg) for rizatriptan in the presence of propranolol treatment.	Propranolol	166-177	monoamine oxidase A	Homo sapiens	25-30
10702597-3	2000	Apo A-IV mRNA levels in the ileum were significantly lower in hexamethonium- or atropine-infused rats than in saline- (control) or propranolol-infused rats.	Propranolol	131-142	apolipoprotein A4	Rattus norvegicus	0-8
10724452-12	2000	Pretreatment with 40 microM aristolochic acid to inhibit phospholipase A2 inhibited 50 microM fendiline-induced internal Ca2+ release by 48%, but inhibition of phospholipase C with 2 microM U73122 or inhibition of phospholipase D with 0.1 mM propranolol had no effect.	Propranolol	242-253	phospholipase A2 group IB	Canis lupus familiaris	57-73
10666319-9	2000	Propranolol (100 nM-10 microM), which inhibits PA phosphohydrolase, blocked the growth stimulated by Ang II, PLD, or PA by as much as 95%, an effect not shared by other beta-adrenergic antagonists.	Propranolol	0-11	angiotensinogen	Rattus norvegicus	101-107
10666319-10	2000	Propranolol also increased the production of PA in the presence of Ang II by 320% and reduced DAG and arachidonic acid (AA) accumulation.	Propranolol	0-11	angiotensinogen	Rattus norvegicus	67-73
10764948-4	2000	This effect was antagonized by two beta-adrenergic antagonists: propranolol (500 ng/rat) and metoprolol (400 ng/rat) applied 15 min before the alpha-MSH or NA.	Propranolol	64-75	proopiomelanocortin	Rattus norvegicus	143-152
11263248-7	2000	Treatment with norepinephrine (NE) in the presence of propranolol for 24 h increased DNA synthesis in HEK293/alpha 1A- or HEK293/alpha 1B-AR cells concentration-dependently, with EC50 values of 48.8 nmol.L-1 (95% confidence limits 9.7-246 nmol.L-1) and 8.4 nmol.L-1 (95% confidence limits 2.1-32.9 nmol.L-1), respectively.	Propranolol	54-65	calcium voltage-gated channel subunit alpha1 A	Homo sapiens	109-117
11263248-7	2000	Treatment with norepinephrine (NE) in the presence of propranolol for 24 h increased DNA synthesis in HEK293/alpha 1A- or HEK293/alpha 1B-AR cells concentration-dependently, with EC50 values of 48.8 nmol.L-1 (95% confidence limits 9.7-246 nmol.L-1) and 8.4 nmol.L-1 (95% confidence limits 2.1-32.9 nmol.L-1), respectively.	Propranolol	54-65	adrenoceptor alpha 1B	Homo sapiens	129-140
10768855-10	2000	Application of alpha1-blocker, prazosin, as well beta-blocker, propranolol, has partially prevented the increase in vasopressin release which was found immediately after superior cervical ganglionectomy.	Propranolol	63-74	arginine vasopressin	Rattus norvegicus	116-127
11819527-1	2000	AIM:To study the influence of inducers BNF and PB on the stereoselective metabolism of propranolol in rat hepatic microsomes.METHODS:Phase I metabolism of propranolol was studied by using the microsomes induced by BNF and PB and the non induced microsome as the control.The enzymatic kinetic parameters of propranolol enantiomers were calculated by regression analysis of Lineweaver-Burk plots.	Propranolol	87-98	natriuretic peptide B	Rattus norvegicus	39-42
11819527-1	2000	AIM:To study the influence of inducers BNF and PB on the stereoselective metabolism of propranolol in rat hepatic microsomes.METHODS:Phase I metabolism of propranolol was studied by using the microsomes induced by BNF and PB and the non induced microsome as the control.The enzymatic kinetic parameters of propranolol enantiomers were calculated by regression analysis of Lineweaver-Burk plots.	Propranolol	155-166	natriuretic peptide B	Rattus norvegicus	39-42
11819527-1	2000	AIM:To study the influence of inducers BNF and PB on the stereoselective metabolism of propranolol in rat hepatic microsomes.METHODS:Phase I metabolism of propranolol was studied by using the microsomes induced by BNF and PB and the non induced microsome as the control.The enzymatic kinetic parameters of propranolol enantiomers were calculated by regression analysis of Lineweaver-Burk plots.	Propranolol	155-166	natriuretic peptide B	Rattus norvegicus	39-42
11819527-16	2000	The enzyme parameters compared with unpaired t tests showed that no stereoselectivity was observed in enzymatic affinity of three microsomes to enantiomers and their catalytic abilities were quite different and had stereoselectivities.Compared with the control, microsome induced by BNF enhanced enzyme activity to propranolol R(+)enantiomer, and microsome induced by PB showed less enzyme activity to propranolol S(-)enantiomer which remains the same stereoselectivities as that of the control.CONCLUSION:Enzyme activity centers of the microsome were changed in composition and regioselectivity after the induction of BNF and PB, and the stereoselectivities of propranolol cytochrome P450 metabolism in rat hepatic microsomes were likely due to the stereoselectivities of the catalyzing function in enzyme.CYP1A subfamily induced by BNF exhibited pronounced contribution to propranolol metabolism with stereoselectivity to R(+)enantiomer.CYP2B subfamily induced by PB exhibited moderate contribution to propranolol metabolism, but still had the stereoselectivity of S(-)enantiomer.	Propranolol	315-326	natriuretic peptide B	Rattus norvegicus	283-286
11819527-16	2000	The enzyme parameters compared with unpaired t tests showed that no stereoselectivity was observed in enzymatic affinity of three microsomes to enantiomers and their catalytic abilities were quite different and had stereoselectivities.Compared with the control, microsome induced by BNF enhanced enzyme activity to propranolol R(+)enantiomer, and microsome induced by PB showed less enzyme activity to propranolol S(-)enantiomer which remains the same stereoselectivities as that of the control.CONCLUSION:Enzyme activity centers of the microsome were changed in composition and regioselectivity after the induction of BNF and PB, and the stereoselectivities of propranolol cytochrome P450 metabolism in rat hepatic microsomes were likely due to the stereoselectivities of the catalyzing function in enzyme.CYP1A subfamily induced by BNF exhibited pronounced contribution to propranolol metabolism with stereoselectivity to R(+)enantiomer.CYP2B subfamily induced by PB exhibited moderate contribution to propranolol metabolism, but still had the stereoselectivity of S(-)enantiomer.	Propranolol	402-413	natriuretic peptide B	Rattus norvegicus	283-286
11819527-16	2000	The enzyme parameters compared with unpaired t tests showed that no stereoselectivity was observed in enzymatic affinity of three microsomes to enantiomers and their catalytic abilities were quite different and had stereoselectivities.Compared with the control, microsome induced by BNF enhanced enzyme activity to propranolol R(+)enantiomer, and microsome induced by PB showed less enzyme activity to propranolol S(-)enantiomer which remains the same stereoselectivities as that of the control.CONCLUSION:Enzyme activity centers of the microsome were changed in composition and regioselectivity after the induction of BNF and PB, and the stereoselectivities of propranolol cytochrome P450 metabolism in rat hepatic microsomes were likely due to the stereoselectivities of the catalyzing function in enzyme.CYP1A subfamily induced by BNF exhibited pronounced contribution to propranolol metabolism with stereoselectivity to R(+)enantiomer.CYP2B subfamily induced by PB exhibited moderate contribution to propranolol metabolism, but still had the stereoselectivity of S(-)enantiomer.	Propranolol	402-413	natriuretic peptide B	Rattus norvegicus	283-286
11819527-16	2000	The enzyme parameters compared with unpaired t tests showed that no stereoselectivity was observed in enzymatic affinity of three microsomes to enantiomers and their catalytic abilities were quite different and had stereoselectivities.Compared with the control, microsome induced by BNF enhanced enzyme activity to propranolol R(+)enantiomer, and microsome induced by PB showed less enzyme activity to propranolol S(-)enantiomer which remains the same stereoselectivities as that of the control.CONCLUSION:Enzyme activity centers of the microsome were changed in composition and regioselectivity after the induction of BNF and PB, and the stereoselectivities of propranolol cytochrome P450 metabolism in rat hepatic microsomes were likely due to the stereoselectivities of the catalyzing function in enzyme.CYP1A subfamily induced by BNF exhibited pronounced contribution to propranolol metabolism with stereoselectivity to R(+)enantiomer.CYP2B subfamily induced by PB exhibited moderate contribution to propranolol metabolism, but still had the stereoselectivity of S(-)enantiomer.	Propranolol	402-413	natriuretic peptide B	Rattus norvegicus	283-286
11819527-16	2000	The enzyme parameters compared with unpaired t tests showed that no stereoselectivity was observed in enzymatic affinity of three microsomes to enantiomers and their catalytic abilities were quite different and had stereoselectivities.Compared with the control, microsome induced by BNF enhanced enzyme activity to propranolol R(+)enantiomer, and microsome induced by PB showed less enzyme activity to propranolol S(-)enantiomer which remains the same stereoselectivities as that of the control.CONCLUSION:Enzyme activity centers of the microsome were changed in composition and regioselectivity after the induction of BNF and PB, and the stereoselectivities of propranolol cytochrome P450 metabolism in rat hepatic microsomes were likely due to the stereoselectivities of the catalyzing function in enzyme.CYP1A subfamily induced by BNF exhibited pronounced contribution to propranolol metabolism with stereoselectivity to R(+)enantiomer.CYP2B subfamily induced by PB exhibited moderate contribution to propranolol metabolism, but still had the stereoselectivity of S(-)enantiomer.	Propranolol	402-413	natriuretic peptide B	Rattus norvegicus	283-286
10634941-7	2000	Both hormone-sensitive lipase translocation and lipolysis are reversed by the incubation of cells with the beta-adrenergic receptor antagonist, propranolol.	Propranolol	144-155	lipase, hormone sensitive	Mus musculus	5-29
10685507-9	2000	The augmentation of NAT activity by parathion also caused significant reduction in pineal serotonin (5-HT); again, this response was blocked by propranolol treatment.	Propranolol	144-155	N-acetyltransferase 1	Rattus norvegicus	20-23
11032053-5	2000	administration of (+/-) propranolol (100-200-300 microg/animal/day, during 7 days) or (+/-) verapamil (40-80-160 microg/animal/day, during 7 days) afforded a significant protection (with the exception of the lowest dose) on the investigated parameters: arrhythmias, ischemic zone (in coronary ligated rats), lactate dehydrogenase and aspartate aminotransferase activity of the serum, focal necrosis (in isoproterenol treated rats).	Propranolol	18-35	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	334-360
11193870-5	2000	Administration of the beta-adrenoreceptor agonist isoproterenol mimicked the stimulatory effect of PACAP on both steroid secretion whereas preincubation of fetal cells with the beta-adrenoreceptor antagonist propranolol suppressed the steroidogenic effect of PACAP.	Propranolol	208-219	adenylate cyclase activating polypeptide 1	Homo sapiens	259-264
10894553-0	2000	Effect of thromboxane synthase inhibitor, CS-518, on propranolol-induced bronchoconstriction in guinea pigs.	Propranolol	53-64	thromboxane-A synthase	Cavia porcellus	10-30
10665782-7	2000	In conclusion, the study revealed that propranolol treatment in both immature and adult rats alters the relative proportion of CD4+ 8+ and CD4+ 8- thymocytes, but in opposite fashion, and the data suggest that this treatment affects distinct fractions within the population of CD4+ 8+ thymocytes with respect to expression of TCR alphabeta.	Propranolol	39-50	Cd4 molecule	Rattus norvegicus	127-130
10665782-7	2000	In conclusion, the study revealed that propranolol treatment in both immature and adult rats alters the relative proportion of CD4+ 8+ and CD4+ 8- thymocytes, but in opposite fashion, and the data suggest that this treatment affects distinct fractions within the population of CD4+ 8+ thymocytes with respect to expression of TCR alphabeta.	Propranolol	39-50	Cd4 molecule	Rattus norvegicus	139-142
10665782-7	2000	In conclusion, the study revealed that propranolol treatment in both immature and adult rats alters the relative proportion of CD4+ 8+ and CD4+ 8- thymocytes, but in opposite fashion, and the data suggest that this treatment affects distinct fractions within the population of CD4+ 8+ thymocytes with respect to expression of TCR alphabeta.	Propranolol	39-50	Cd4 molecule	Rattus norvegicus	139-142
10630733-14	2000	The order of potency of beta1- and beta2-adrenoceptor antagonist activity against [3H]CGP-12177 binding was (-)propranolol (pKi, 8.59 for beta1 and 8.09 for beta2) &gt; vanidipinedilol (pKi, 7.09 for beta1 and 6.64 for beta2) &gt; atenolol (pKi, 6.58 for beta1 and 5.12 for beta2).	Propranolol	111-122	adrenoceptor beta 1	Rattus norvegicus	24-53
10617676-3	2000	The tyrosine kinase inhibitors (genistein and tyrphostin AG126) and phosphatidylcholine-phospholipase C inhibitor (D-609) prevented IL-1beta-induced prostaglandin E(2) (PGE(2)) release and COX-2 expression, whereas U-73122 (a phosphatidylinositol-phospholipase C inhibitor) and propranolol (a phosphatidate phosphohydrolase inhibitor) had no effect.	Propranolol	278-289	interleukin 1 beta	Homo sapiens	132-140
10629867-3	1999	In the presence of propranolol (1 microM) or atenolol (100 microM) plus butoxamine (100 microM), bupranolol caused a concentration-dependent rightward shift of the concentration-response curves for catecholamines and beta 3-adrenoceptor agonists.	Propranolol	19-30	beta-3 adrenergic receptor	Cavia porcellus	217-236
10854348-4	2000	Although a positive family history, alcohol sensitivity, and propranolol responsiveness are characteristic of ET, these factors should not be considered necessary for the diagnosis of ET.	Propranolol	61-72	major facilitator superfamily domain containing 11	Homo sapiens	110-112
10572244-8	1999	HSP27 induction by PGF(2alpha) was reduced by U-73122, a phospholipase C inhibitor, or propranolol, a phosphatidic acid phosphohydrolase inhibitor.	Propranolol	87-98	heat shock protein 1	Mus musculus	0-5
10592302-3	1999	Intraperitoneal administration of the ganglion blocker hexamethonium (20 mg/kg) or the beta-adrenergic antagonist propranolol (5 mg/kg) suppressed the CGRP-induced increases in VO(2), HR, T(co), and T(IBAT).	Propranolol	114-125	calcitonin-related polypeptide alpha	Rattus norvegicus	151-155
10592302-3	1999	Intraperitoneal administration of the ganglion blocker hexamethonium (20 mg/kg) or the beta-adrenergic antagonist propranolol (5 mg/kg) suppressed the CGRP-induced increases in VO(2), HR, T(co), and T(IBAT).	Propranolol	114-125	solute carrier family 10 member 2	Rattus norvegicus	201-205
10505977-8	1999	injection of the nonspecific beta-adrenergic receptor blocker propranolol, and of a specific beta2-adrenergic receptor antagonist, likewise prevented these effects of central alpha-MSH; blockade of cholinergic, alpha-adrenergic, or beta1-adrenergic receptors did not.	Propranolol	62-73	pro-opiomelanocortin-alpha	Mus musculus	175-184
10516241-7	1999	The decrease in HR induced by nociceptin was blocked by propranolol but not by atropine, which indicates that nociceptin is acting by inhibiting cardiac sympathetic outflow.	Propranolol	56-67	prepronociceptin	Rattus norvegicus	30-40
10516241-7	1999	The decrease in HR induced by nociceptin was blocked by propranolol but not by atropine, which indicates that nociceptin is acting by inhibiting cardiac sympathetic outflow.	Propranolol	56-67	prepronociceptin	Rattus norvegicus	110-120
10541912-9	1999	A beta-adrenergic blocking agent (propranolol) led to a marked increase in the amplitude of EGG and its power spectrum.	Propranolol	34-45	amyloid beta precursor protein	Homo sapiens	0-6
10800773-8	2000	Furthermore, propranolol (3 x 10(-7) M) produced a dextral shift in the concentration response to isoproterenol in atria from both the beta3 receptor knockout and wild type mice with negative log K(B) values of 8.03 and 8.09, respectively.	Propranolol	13-24	calcium channel, voltage-dependent, beta 3 subunit	Mus musculus	135-140
10600794-12	1999	U-73122 and propranolol, a phosphatidic acid phosphohydrolase inhibitor, reduced the ET-1-stimulated HSP 27 accumulation.	Propranolol	12-23	endothelin 1	Mus musculus	85-89
10600794-12	1999	U-73122 and propranolol, a phosphatidic acid phosphohydrolase inhibitor, reduced the ET-1-stimulated HSP 27 accumulation.	Propranolol	12-23	heat shock protein 1	Mus musculus	101-107
10567230-6	1999	The treatment of intact cells with phorbol ester or with adrenaline (epinephrine) plus propranolol increased calreticulin phosphorylation, which was blocked by the pretreatment of cells with the PKC-specific inhibitor Ro 31-8220.	Propranolol	87-98	calreticulin	Rattus norvegicus	109-121
10567230-6	1999	The treatment of intact cells with phorbol ester or with adrenaline (epinephrine) plus propranolol increased calreticulin phosphorylation, which was blocked by the pretreatment of cells with the PKC-specific inhibitor Ro 31-8220.	Propranolol	87-98	protein kinase C, alpha	Rattus norvegicus	195-198
10488110-7	1999	Inhibition of PAP-1 activity by three different strategies (i.e. use of bromoenol lactone, propranolol, and ethanol) resulted in inhibition of COX-2 expression and hence of PGE(2) production.	Propranolol	91-102	lipin 1	Homo sapiens	14-19
10488110-7	1999	Inhibition of PAP-1 activity by three different strategies (i.e. use of bromoenol lactone, propranolol, and ethanol) resulted in inhibition of COX-2 expression and hence of PGE(2) production.	Propranolol	91-102	prostaglandin-endoperoxide synthase 2	Homo sapiens	143-148
10487769-3	1999	TG mice and age-matched wild-type littermates were treated with the beta-AR blocker propranolol for 6-7 months, starting at a time when the cardiomyopathy was developing but was not yet severe enough to induce significant cardiac depression (9.5 months of age), and ending at a time when cardiac depression and cardiomyopathy would have been clearly manifest (16 months of age).	Propranolol	84-95	adrenergic receptor, beta 1	Mus musculus	68-75
10452985-6	1999	When the beta-adrenergic antagonist propranolol was added to the stimulation cultures of l -PAM TuB spleen cells at a concentration that prevented NE-induced cAMP elevation, the NE-mediated decrease in TNF-alpha mRNA and NE-mediated inhibition of CTL generation were reversed.	Propranolol	36-47	tumor necrosis factor	Mus musculus	202-211
10478972-5	1999	Among a series of clinical, laboratory, and instrument-based parameters, the only one related to first bleeding, selected by the Cox regression model, was the percentage decrease in maximal portal flow velocity observed after initial administration of propranolol (P &lt; 0.01).	Propranolol	252-263	cytochrome c oxidase subunit 8A	Homo sapiens	129-132
10582659-6	1999	In addition, U-73122, an inhibitor of phospholipase C, and propranolol, a phosphatidic acid phosphohydrolase inhibitor, enhanced the PGD2-induced IL-6 synthesis.	Propranolol	59-70	interleukin 6	Mus musculus	146-150
10475307-7	1999	In both the low and high propranolol groups, average cortical rCBF was 35% lower than that in the control group.	Propranolol	25-36	CCAAT/enhancer binding protein zeta	Rattus norvegicus	62-66
10533957-11	1999	Propranolol completely blocked the increase in necrosis produced by PLA2 when given with ISO.	Propranolol	0-11	phospholipase A2 group IB	Rattus norvegicus	68-72
10480313-4	1999	Propranolol, quin 2-AM, ruthenium red, and neomycin all inhibited LPL release more potently than the increase in activity.	Propranolol	0-11	lipoprotein lipase	Rattus norvegicus	66-69
10629868-5	1999	Propranolol and bopindolol have high affinity to beta 1 and beta 2 subtypes, but low affinity to beta 3 subtype.	Propranolol	0-11	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	49-66
10425466-4	1999	General stimulation of adrenergic receptors with epinephrine (10(-7) M) induced significant GLP-1 and PYY secretions (94+/-38 and 257+/-59 fmol/8 min respectively) which were abolished upon propranolol (10(-7) M) pretreatment and strongly decreased upon infusion with 10(-8) M prazosin.	Propranolol	190-201	glucagon	Rattus norvegicus	92-97
10425466-4	1999	General stimulation of adrenergic receptors with epinephrine (10(-7) M) induced significant GLP-1 and PYY secretions (94+/-38 and 257+/-59 fmol/8 min respectively) which were abolished upon propranolol (10(-7) M) pretreatment and strongly decreased upon infusion with 10(-8) M prazosin.	Propranolol	190-201	peptide YY	Rattus norvegicus	102-105
10411572-1	1999	Cytochrome P-450 (CYP) 2C19 is responsible for the metabolism of a number of therapeutic agents such as S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.	Propranolol	174-185	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	0-27
10344463-6	1999	Treatment with the nonselective beta antagonist propranolol significantly attenuated the preferential increase of circulating CD8(+)CD62L(-) lymphocytes (p = 0.01) but had no effect on CD8(+)CD62L(+) T cells.	Propranolol	48-59	CD8a molecule	Homo sapiens	126-129
10525174-6	1999	Clenbuterol-induced NGF expression was reduced to the control levels by coadministration of beta-adrenoceptor antagonist propranolol.	Propranolol	121-132	nerve growth factor	Rattus norvegicus	20-23
10445382-4	1999	Moreover, propranolol abolished cytochrome p-450 protecting effect of verapamil when administered together.	Propranolol	10-21	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	32-48
10445382-5	1999	A direct, LPO-independent decreasing effect on cytochrome p-450 was observed upon in vitro incubation of microsomes with propranolol.	Propranolol	121-132	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	47-63
10415666-6	1999	Pretreatment with the beta antagonist, propranolol, markedly reduces OW symptoms and the number of Fos+ cells in the BNST.	Propranolol	39-50	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	99-102
10215671-5	1999	Propranolol completely reversed the rise in heart rate and cardiac output, the fall in peripheral resistance, the shortening of electromechanical systole, and the rise in insulin; it blunted the increase in free fatty acids and gastrin.	Propranolol	0-11	insulin	Homo sapiens	171-178
10215671-5	1999	Propranolol completely reversed the rise in heart rate and cardiac output, the fall in peripheral resistance, the shortening of electromechanical systole, and the rise in insulin; it blunted the increase in free fatty acids and gastrin.	Propranolol	0-11	gastrin	Homo sapiens	228-235
10353694-1	1999	This stimulation was dependent on the dose of GM-CSF, with an EC50 of 140 pM, and was further enhanced (up to 350%) with the PA phosphatase inhibitor propranolol in a dose-dependent manner.	Propranolol	150-161	colony stimulating factor 2	Homo sapiens	46-52
10067853-6	1999	Propranolol treatment, bilateral superior cervical ganglionectomy, or constant light exposure significantly suppressed the nocturnal rise in type II iodothyronine deiodinase mRNA as well as the deiodinase activity.	Propranolol	0-11	iodothyronine deiodinase 2	Rattus norvegicus	141-173
10407186-10	1999	Isoproterenol"s effects on PKA, PKC and ERK-dependent activities were blocked by propranolol, a betaAR antagonist.	Propranolol	81-92	Eph receptor B1	Rattus norvegicus	40-43
10440090-4	1999	In the presence of propranolol (1 microM), however, a non-selective beta1-, beta2- and beta3-adrenoceptor antagonist bupranolol caused a concentration-dependent rightward shift of the concentration-response curves for catecholamines and beta3-adrenoceptor agonists.	Propranolol	19-30	beta-2 adrenergic receptor	Cavia porcellus	68-105
10440090-4	1999	In the presence of propranolol (1 microM), however, a non-selective beta1-, beta2- and beta3-adrenoceptor antagonist bupranolol caused a concentration-dependent rightward shift of the concentration-response curves for catecholamines and beta3-adrenoceptor agonists.	Propranolol	19-30	beta-3 adrenergic receptor	Cavia porcellus	87-105
10455254-7	1999	ICI-118,551 and propranolol treatment restored the elevated myocardial G-inhibitory protein (Gialpha) levels to that of wild type.	Propranolol	16-27	guanine nucleotide binding protein (G protein), alpha inhibiting 2	Mus musculus	93-100
10395986-2	1999	Inhibition of the activity of the key heme biosynthesis enzyme delta-ALAS was most pronounced and prolonged during the first hours after CoCl2 and CoCl2 plus propranolol injections; this was associated with accumulation of Co2+--protoporphyrin-containing products of hemolysis.	Propranolol	158-169	5'-aminolevulinate synthase 1	Rattus norvegicus	69-73
10395986-3	1999	Inhibition of delta-ALAS after propranolol injection is not mediated by hemolysis.	Propranolol	31-42	5'-aminolevulinate synthase 1	Rattus norvegicus	20-24
10408809-12	1999	Furthermore, application of the beta2-adrenoreceptor antagonist propranolol prevented the decrease of lymphocytes and diminished the neutrophilia.	Propranolol	64-75	adrenoceptor beta 2	Homo sapiens	32-52
10229647-2	1999	A HPLC technique using alpha-1 acid glycoprotein (chiral AGP) column was developed to study the racemization of propranolol enantiomers during synthesis and hydrolysis studies.	Propranolol	112-123	orosomucoid 1	Rattus norvegicus	57-60
10086986-7	1999	The maximum increase in heart rate elicited by xamoterol and bucindolol was inhibited by treatment with propranolol, carvedilol, and betaxolol (beta1-adrenoceptor antagonist) but not by ICI 118551 (beta2-adrenoceptor antagonist) in neonatal rat.	Propranolol	104-115	adrenoceptor beta 1	Rattus norvegicus	144-162
10086986-7	1999	The maximum increase in heart rate elicited by xamoterol and bucindolol was inhibited by treatment with propranolol, carvedilol, and betaxolol (beta1-adrenoceptor antagonist) but not by ICI 118551 (beta2-adrenoceptor antagonist) in neonatal rat.	Propranolol	104-115	adrenoceptor beta 2	Rattus norvegicus	198-216
10077737-6	1999	In addition, 18-502, 20-785, and propranolol also interacted with sites at the same positions as those of beta2-ARs.	Propranolol	33-44	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	106-111
10372513-6	1999	Previous treatment with prazosin and propranolol reduced the water intake induced by ANG II.	Propranolol	37-48	angiotensinogen	Homo sapiens	85-91
10070041-5	1999	The beta-AR antagonist propranolol sensitized the F28 livers to Jo2.	Propranolol	23-34	adrenergic receptor, beta 1	Mus musculus	4-11
10050748-3	1999	The cold-induced reduction in leptin mRNA can be prevented by a combination of propranolol and SR 59230A but not by either antagonist alone, indicating that beta3-adrenergic receptors and classical beta1/beta2-adrenergic receptors both mediate responses to sympathetic stimulation.	Propranolol	79-90	leptin	Mus musculus	30-36
9927320-11	1999	The synergistic increases in IL-6 release caused by IL-1beta and isoproterenol as well as IL-1beta and norepinephrine were blocked by the pretreatment of C6 cells with the beta-receptor antagonist propranolol.	Propranolol	197-208	interleukin 6	Rattus norvegicus	29-33
9927320-11	1999	The synergistic increases in IL-6 release caused by IL-1beta and isoproterenol as well as IL-1beta and norepinephrine were blocked by the pretreatment of C6 cells with the beta-receptor antagonist propranolol.	Propranolol	197-208	interleukin 1 beta	Rattus norvegicus	52-60
9927320-11	1999	The synergistic increases in IL-6 release caused by IL-1beta and isoproterenol as well as IL-1beta and norepinephrine were blocked by the pretreatment of C6 cells with the beta-receptor antagonist propranolol.	Propranolol	197-208	interleukin 1 beta	Rattus norvegicus	90-98
9922315-5	1999	This was dose-dependently enhanced by vasoactive intestinal polypeptide (VIP), calcitonin gene-related peptide (CGRP), and norepinephrine and inhibited by [LYS1,PRO2,5,ARG3,4,TYR6]VIP and propranolol, respectively.	Propranolol	188-199	vasoactive intestinal peptide	Rattus norvegicus	38-71
9922315-5	1999	This was dose-dependently enhanced by vasoactive intestinal polypeptide (VIP), calcitonin gene-related peptide (CGRP), and norepinephrine and inhibited by [LYS1,PRO2,5,ARG3,4,TYR6]VIP and propranolol, respectively.	Propranolol	188-199	calcitonin-related polypeptide alpha	Rattus norvegicus	112-116
9927616-6	1999	In addition, BRL 37344 and propranolol, ligands that act as agonists in the stimulation of cyclase, act as antagonists for ERK activation.	Propranolol	27-38	mitogen-activated protein kinase 1	Homo sapiens	123-126
9878881-14	1999	Blocking the sympathetic nervous system (SNS) transmission by application of the beta2-adrenoreceptor antagonist propranolol not only inhibited the increase but further downregulated the endotoxin induced IL-10 concentration in the media of whole blood cell cultures, whereas the TNF-alpha decrease was only partially prevented.	Propranolol	113-124	adrenoceptor beta 2	Homo sapiens	81-101
9878881-14	1999	Blocking the sympathetic nervous system (SNS) transmission by application of the beta2-adrenoreceptor antagonist propranolol not only inhibited the increase but further downregulated the endotoxin induced IL-10 concentration in the media of whole blood cell cultures, whereas the TNF-alpha decrease was only partially prevented.	Propranolol	113-124	interleukin 10	Homo sapiens	205-210
9878881-14	1999	Blocking the sympathetic nervous system (SNS) transmission by application of the beta2-adrenoreceptor antagonist propranolol not only inhibited the increase but further downregulated the endotoxin induced IL-10 concentration in the media of whole blood cell cultures, whereas the TNF-alpha decrease was only partially prevented.	Propranolol	113-124	tumor necrosis factor	Homo sapiens	280-289
9988104-9	1999	The PACAP-27-induced tachycardia was unaffected by chlorisondamine, but was virtually abolished by propranolol.	Propranolol	99-110	adenylate cyclase activating polypeptide 1	Rattus norvegicus	4-9
9873044-9	1999	The effects of the beta2-AR agonists, salbutamol and salmeterol, were dependent upon binding to the beta2-AR, because blocking of beta2-AR with propranolol abrogated GR activation.	Propranolol	144-155	adrenoceptor beta 2	Homo sapiens	19-27
9873044-9	1999	The effects of the beta2-AR agonists, salbutamol and salmeterol, were dependent upon binding to the beta2-AR, because blocking of beta2-AR with propranolol abrogated GR activation.	Propranolol	144-155	adrenoceptor beta 2	Homo sapiens	100-108
9873044-9	1999	The effects of the beta2-AR agonists, salbutamol and salmeterol, were dependent upon binding to the beta2-AR, because blocking of beta2-AR with propranolol abrogated GR activation.	Propranolol	144-155	adrenoceptor beta 2	Homo sapiens	100-108
10029201-9	1999	The intracerebroventricular injection of the alpha- and beta-adrenergic receptor antagonists phentolamine and propranolol significantly reversed the inhibitory influence of alcohol when it was administered 15 min, but not 60 min, before hCG.	Propranolol	110-121	chorionic gonadotropin subunit beta 5	Homo sapiens	237-240
9887016-4	1999	Addition of the alpha-adrenergic blocker prazosin or the beta-adrenergic blocker propranolol partially reduced the NE-mediated increase in iNOS mRNA expression and NO-2 production.	Propranolol	81-92	nitric oxide synthase 2	Rattus norvegicus	139-143
9887016-5	1999	Addition of prazosin and propranolol together completely abolished the NE-induced increase in iNOS mRNA expression and NO-2 production.	Propranolol	25-36	nitric oxide synthase 2	Rattus norvegicus	94-98
10092983-5	1999	This ET-1-reducing effect was even more pronounced in thrombin-stimulated cells (10(-5) mol L-1 of propranolol, metoprolol and celiprolol: 19% +/- 5.8%, 25% +/- 4% and 37% +/- 5.2% respectively).	Propranolol	99-110	endothelin 1	Homo sapiens	5-9
10092983-5	1999	This ET-1-reducing effect was even more pronounced in thrombin-stimulated cells (10(-5) mol L-1 of propranolol, metoprolol and celiprolol: 19% +/- 5.8%, 25% +/- 4% and 37% +/- 5.2% respectively).	Propranolol	99-110	coagulation factor II, thrombin	Homo sapiens	54-62
10092983-7	1999	Furthermore, the ET-1-reducing effect of propranolol, metoprolol and celiprolol was not due to a compensatory increase in prostacyclin and was not reversible by N-nitro-L-arginine.	Propranolol	41-52	endothelin 1	Homo sapiens	17-21
9920093-12	1999	In cultured GC, DA and SKF-38393 induced increased threonine-phosphorylation of DARPP-32, even in the presence of propranolol but not in the presence of D1-R antagonist SCH-23390.	Propranolol	114-125	protein phosphatase 1 regulatory inhibitor subunit 1B	Homo sapiens	80-88
10688323-8	1999	Propranolol (1 micromol/L), a beta blocker, completely prevented the effect of isoproterenol to persistently or transiently increase TDR and to induce TdP in the LQT1 and LQT2 models, but facilitated TdP in the LQT3 model.	Propranolol	0-11	potassium voltage-gated channel subfamily Q member 1	Homo sapiens	162-166
10688323-8	1999	Propranolol (1 micromol/L), a beta blocker, completely prevented the effect of isoproterenol to persistently or transiently increase TDR and to induce TdP in the LQT1 and LQT2 models, but facilitated TdP in the LQT3 model.	Propranolol	0-11	potassium voltage-gated channel subfamily H member 2	Homo sapiens	171-175
10688323-8	1999	Propranolol (1 micromol/L), a beta blocker, completely prevented the effect of isoproterenol to persistently or transiently increase TDR and to induce TdP in the LQT1 and LQT2 models, but facilitated TdP in the LQT3 model.	Propranolol	0-11	sodium voltage-gated channel alpha subunit 5	Homo sapiens	211-215
10072193-2	1999	The effects on blood pressure induced by endothelin-1 were significantly (p&lt;0.05) reduced by pre-administration into the superior colliculus of the alpha1-adrenoceptor agonist phenylephrine (1 nmol) (46 +/- 5%, n=5), beta1-adrenoceptor antagonist acebutolol (5 nmol) (51 +/- 6%, n=5) or beta1/beta2-adrenoceptor antagonist propranolol (3.4 nmol) (51 +/- 11%, n=5).	Propranolol	326-337	endothelin 1	Rattus norvegicus	41-53
10075105-7	1999	CGRP induced increase in rearing activity was blocked by naloxone, phenoxybenzamine and propranolol.	Propranolol	88-99	calcitonin-related polypeptide alpha	Rattus norvegicus	0-4
10075105-8	1999	The CGRP-induced increase in grooming behavior was prevented by atropine, haloperidol, naloxone, methysergide and propranolol.	Propranolol	114-125	calcitonin-related polypeptide alpha	Rattus norvegicus	4-8
10328520-4	1999	Serum concentrations of IGF-1 were lower in GB rats treated with enalapril, alpha-methyldopa and propanolol (p&lt;0.01), but not in those treated with losartan.	Propranolol	97-107	insulin-like growth factor 1	Rattus norvegicus	24-29
10353628-6	1999	Co-administration of difluoromethylornithine, an irreversible inhibitor of ODC, or propranolol, a nonspecific beta-antagonist, with clenbuterol completely prevented the induction of ODC activity as well as the increase in polyamine levels in heart.	Propranolol	83-94	ornithine decarboxylase, structural 1	Mus musculus	182-185
10408599-1	1999	We compared the effects of the D1/D5 receptor antagonist SCH-23390 with the beta-adrenergic receptor antagonist propranolol on the persistence of long-term potentiation in the CA1 and dentate gyrus subregions of the hippocampus.	Propranolol	112-123	carbonic anhydrase 1	Homo sapiens	176-179
10344463-6	1999	Treatment with the nonselective beta antagonist propranolol significantly attenuated the preferential increase of circulating CD8(+)CD62L(-) lymphocytes (p = 0.01) but had no effect on CD8(+)CD62L(+) T cells.	Propranolol	48-59	selectin L	Homo sapiens	132-137
9794415-5	1998	Norepinephrine-mediated decreases in Thy-1 mRNA levels were prevented by the beta-adrenergic receptor antagonist propranolol (10 microM).	Propranolol	113-124	thymus cell antigen 1, theta	Mus musculus	37-42
9877326-6	1998	The facilitatory effects of isoprenaline and salbutamol were inhibited by the non-specific beta-antagonist propranolol (1.0 micromol/l), while that of salbutamol was inhibited in the presence of ICI-188,551 (1.0 micromol/l), a selective beta2-antagonist, as well.	Propranolol	107-118	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	237-242
9845423-6	1998	Suppression in the DL-propranolol-treated DS and C3H/He mice was not very marked on sensitization with undiluted or slightly diluted IgG1 ascites but quite striking on sensitization with properly diluted ascites.	Propranolol	19-33	LOC105243590	Mus musculus	133-137
9846642-14	1998	Treatment of hamsters with propranolol resulted in increased density of beta1-adrenoceptors in both strains, but had no effect on their functional efficacy.	Propranolol	27-38	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	72-77
9846642-15	1998	Moreover, beta2-adrenergic stimulation of adenylyl cyclase was even reduced in propranolol-treated animals, which could not be explained by changes in cardiac G-protein content.	Propranolol	79-90	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	10-15
9846642-18	1998	The paradoxical reduction in beta2-adrenergic efficiency in propranolol-treated myopathic and control hamsters deserves further investigation.	Propranolol	60-71	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	29-34
9662372-4	1998	We found that in a rat model of acute brain injury, the beta-receptor antagonist propranolol prevented the increase of interleukin-10 plasma levels.	Propranolol	81-92	interleukin 10	Rattus norvegicus	119-133
9777252-8	1998	Administration of propranolol prior to the exposure to the stress inhibited the stress-induced decrease in IGF-II mRNA in the cerebellum.	Propranolol	18-29	insulin-like growth factor 2	Rattus norvegicus	107-113
9688646-6	1998	The contraction induced by CCK was inhibited by the phospholipase C (PLC) inhibitor U-73122, anti-PLC-beta3 antibody, and the IP3 receptor antagonist heparin but was not inhibited by the the phospholipase D inhibitor propranolol or antibodies against PLC-beta1 or PLC-beta2.	Propranolol	217-228	cholecystokinin	Homo sapiens	27-30
9683538-11	1998	Conversely, the treatment of F3II cells with H7, a specific PKC inhibitor, or propranolol, which blocks PA conversion to DAG, significantly decreased CD44 expression levels.	Propranolol	78-89	CD44 antigen	Mus musculus	150-154
9726658-7	1998	The curves obtained in the presence of antagonists suggested an action mediated by beta3-adrenoceptor stimulation, since propranolol did not antagonize the action of SR 59119A and SR 59104A, whereas the combination of propranolol and SR 59230A significantly displaced the concentration-response curve of these agonists to the right.	Propranolol	121-132	adrenoceptor beta 3	Homo sapiens	83-101
9726658-7	1998	The curves obtained in the presence of antagonists suggested an action mediated by beta3-adrenoceptor stimulation, since propranolol did not antagonize the action of SR 59119A and SR 59104A, whereas the combination of propranolol and SR 59230A significantly displaced the concentration-response curve of these agonists to the right.	Propranolol	218-229	adrenoceptor beta 3	Homo sapiens	83-101
9763638-11	1998	The beta-adrenoceptor antagonist propranolol blocked the ability of noradrenaline to increase both steady-state pHi and rates of pHi recovery from acid loads.	Propranolol	33-44	glucose-6-phosphate isomerase	Rattus norvegicus	112-115
9763638-11	1998	The beta-adrenoceptor antagonist propranolol blocked the ability of noradrenaline to increase both steady-state pHi and rates of pHi recovery from acid loads.	Propranolol	33-44	glucose-6-phosphate isomerase	Rattus norvegicus	129-132
9765516-10	1998	In brief, significantly lower concentrations of gentamycin than propranolol or lidocaine were required for half-maximal dissociation of cyt c from liposomes, although the final extent of protein detachment by gentamycin was less complete.	Propranolol	64-75	cytochrome c, somatic	Homo sapiens	136-141
9765516-11	1998	ATP augmented the dissociation of cyt c from membranes by lidocaine and propranolol.	Propranolol	72-83	cytochrome c, somatic	Homo sapiens	34-39
9733352-0	1998	Ca2+ channel-blocking activity of propranolol and betaxolol in isolated bovine retinal microartery.	Propranolol	34-45	carbonic anhydrase 2	Bos taurus	0-3
9733352-11	1998	Thus propranolol and betaxolol are equipotent vasorelaxant drugs in retinal microartery, both probably acting via Ca2+ channel blockade.	Propranolol	5-16	carbonic anhydrase 2	Bos taurus	114-117
9807240-7	1998	The interaction with propranolol, clonidine, phenylephrine, carbachol and tripeptide fMLP which hinder adenylate cyclase (AdC) and activate Ca-polyphosphoinositide (Ca-PPI) signaling system of a cell initiates structural rearrangements similar to acidic transitions.	Propranolol	21-32	formyl peptide receptor 1	Homo sapiens	85-89
9748542-0	1998	Propranolol attenuates haloperidol-induced Fos expression in discrete regions of rat brain: possible brain regions responsible for akathisia.	Propranolol	0-11	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	43-46
9748542-5	1998	To identify the neural substrates of akathisia, we investigated the effects of propranolol on haloperidol-induced Fos expression in rat brain.	Propranolol	79-90	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	114-117
9748542-7	1998	Pretreatment with propranolol (5 mg/kg) reduced the number of Fos-positive nuclei in the cingulate cortex area 3, the piriform cortex and area 1 of the parietal cortex.	Propranolol	18-29	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	62-65
9745899-1	1998	The report describes the results of a study the effect of pH and binding of six physiologically active compounds (isoproterenol, yohimbine, theophylline, propranolol, clonidine and carbachol) on the molecular structure of human serum albumin (HSA) using dynamic light scattering.	Propranolol	154-165	albumin	Homo sapiens	228-241
9670518-1	1998	Propranolol, a beta-adrenergic blocking agent commonly used in the treatment of hypertension, decreases mesenteric blood flow during exercise, at rest, and in cirrhosis.	Propranolol	0-11	amyloid beta precursor protein	Homo sapiens	13-19
9861628-11	1998	CCK-8 enhances bradycardia evoked by propranolol.	Propranolol	37-48	cholecystokinin	Rattus norvegicus	0-3
9861628-6	1998	CCK-33 diminishes the influence of propranolol on the function of isolated heart.	Propranolol	35-46	cholecystokinin	Rattus norvegicus	0-3
9712176-5	1998	(4) Treatment with propranolol (beta-adrenoceptor blocker, 1 mg/kg body weight) did not reduce the vagus effects alone, but decreased the modulatory AII effects.	Propranolol	19-30	angiotensinogen	Rattus norvegicus	149-152
9754635-17	1998	)-induced increases in c-fos and c-jun mRNA expressions were inhibited by the pre-treatment with prazosin or with propranolol, but not with yohimbine.	Propranolol	114-125	FBJ osteosarcoma oncogene	Mus musculus	23-28
9754635-17	1998	)-induced increases in c-fos and c-jun mRNA expressions were inhibited by the pre-treatment with prazosin or with propranolol, but not with yohimbine.	Propranolol	114-125	jun proto-oncogene	Mus musculus	33-38
9861628-10	1998	CCK-8 enhances the influence of propranolol and does not change the influence of phentolamine on the function of isolated heart.	Propranolol	32-43	cholecystokinin	Rattus norvegicus	0-3
9861628-12	1998	3) CCK-4 does not change the influence of noradrenaline and isoprenaline on arterial blood pressure and diminishes the hypotensive effect of phentolamine and propranolol.	Propranolol	158-169	cholecystokinin	Rattus norvegicus	3-6
9538270-0	1998	Regio- and stereoselectivity in propranolol metabolism by dog liver microsomes and the expressed dog CYP2D15.	Propranolol	32-43	cytochrome P450 2D15	Canis lupus familiaris	101-108
9657354-7	1998	However, a combination of the adrenergic blockers phentolamine and propranolol (1 mg/kg each) (n = 8) completely blocked motor actions of GLP-1 in all the organs studied.	Propranolol	67-78	glucagon	Rattus norvegicus	138-143
9538270-5	1998	At the substrate concentrations used, 4-hydroxylation was the preferred pathway for the metabolism of both enantiomers, and S(-)-propranolol was the preferred substrate over R(+)-propranolol for all three monooxygenations catalyzed by CYP2D15.	Propranolol	124-140	cytochrome P450 2D15	Canis lupus familiaris	235-242
9538270-5	1998	At the substrate concentrations used, 4-hydroxylation was the preferred pathway for the metabolism of both enantiomers, and S(-)-propranolol was the preferred substrate over R(+)-propranolol for all three monooxygenations catalyzed by CYP2D15.	Propranolol	174-190	cytochrome P450 2D15	Canis lupus familiaris	235-242
9538270-7	1998	These findings suggest that CYP2D15 is highly responsible for the stereoselective 4- and 5-hydroxylations of propranolol in dog liver microsomes.	Propranolol	109-120	cytochrome P450 2D15	Canis lupus familiaris	28-35
9568379-0	1998	Effects of hexamethonium, phenothiazines, propranolol and ephedrine on acetylcholinesterase carbamylation by physostigmine, aldicarb and carbaryl: interaction between the active site and the functionally distinct peripheral sites in acetylcholinesterase.	Propranolol	42-53	acetylcholinesterase (Cartwright blood group)	Homo sapiens	71-91
9543699-6	1998	Blocking of phospholipase D (PLD)-derived diacylglycerol (DAG) formation by propranolol abrogated IFN-gamma increased HLA class II expression and IL-1 beta secretion, but had little effect on IFN-gamma induced TNF-alpha production.	Propranolol	76-87	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	12-27
9543699-6	1998	Blocking of phospholipase D (PLD)-derived diacylglycerol (DAG) formation by propranolol abrogated IFN-gamma increased HLA class II expression and IL-1 beta secretion, but had little effect on IFN-gamma induced TNF-alpha production.	Propranolol	76-87	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	29-32
9543699-6	1998	Blocking of phospholipase D (PLD)-derived diacylglycerol (DAG) formation by propranolol abrogated IFN-gamma increased HLA class II expression and IL-1 beta secretion, but had little effect on IFN-gamma induced TNF-alpha production.	Propranolol	76-87	interferon gamma	Homo sapiens	98-107
9543699-6	1998	Blocking of phospholipase D (PLD)-derived diacylglycerol (DAG) formation by propranolol abrogated IFN-gamma increased HLA class II expression and IL-1 beta secretion, but had little effect on IFN-gamma induced TNF-alpha production.	Propranolol	76-87	interleukin 1 beta	Homo sapiens	146-155
9543699-6	1998	Blocking of phospholipase D (PLD)-derived diacylglycerol (DAG) formation by propranolol abrogated IFN-gamma increased HLA class II expression and IL-1 beta secretion, but had little effect on IFN-gamma induced TNF-alpha production.	Propranolol	76-87	tumor necrosis factor	Homo sapiens	210-219
9578144-3	1998	This effect was blunted by propranolol, inhibitors of phospholipase A2 (PLA2), cyclooxygenase and verapamil, pointing to a participation of arachidonic acid (AA) metabolites and calcium in the phenomenon.	Propranolol	27-38	phospholipase A2 group IB	Homo sapiens	54-70
9568379-8	1998	Ephedrine, propranolol and phenothiazines including trifluoparazine (TPZ) caused non-competitive inhibition, while hexamethonium caused an uncompetitive inhibition of AChE activity.	Propranolol	11-22	acetylcholinesterase (Cartwright blood group)	Homo sapiens	167-171
9568379-10	1998	The fluorescence intensity of TPZ-AChE complex was effectively decreased by ephedrine, but not by propranolol or hexamethonium.	Propranolol	98-109	acetylcholinesterase (Cartwright blood group)	Homo sapiens	34-38
9627098-3	1998	Propranolol (10.5 mg/kg) pretreatment partly abolished the increase in renin activity induced by glucose injection.	Propranolol	0-11	renin	Rattus norvegicus	71-76
9627098-7	1998	The 27.5 mM glucose-stimulated increase in renin activity was not changed by the addition of 1 microM phentolamine, while it was completely abolished by the addition of 1 microM propranolol.	Propranolol	178-189	renin	Rattus norvegicus	43-48
9635150-1	1998	The vasoconstrictors norepinephrine (NE) and angiotensin II (AII) mediate increases in oxygen uptake (VO2) by the constant flow perfused rat hind limb that are inhibited by quinidine-like membrane-stabilizing effects (involving the interruption of action potential) of (+/-)-propranolol with little effect on vasoconstriction.	Propranolol	269-286	angiotensinogen	Rattus norvegicus	45-59
9635150-1	1998	The vasoconstrictors norepinephrine (NE) and angiotensin II (AII) mediate increases in oxygen uptake (VO2) by the constant flow perfused rat hind limb that are inhibited by quinidine-like membrane-stabilizing effects (involving the interruption of action potential) of (+/-)-propranolol with little effect on vasoconstriction.	Propranolol	269-286	angiotensinogen	Rattus norvegicus	61-64
9543699-0	1998	Effect of propranolol and IFN-beta on the induction of MHC class II expression and cytokine production by IFN-gamma IN THP-1 human monocytic cells.	Propranolol	10-21	interferon gamma	Homo sapiens	106-115
9543699-0	1998	Effect of propranolol and IFN-beta on the induction of MHC class II expression and cytokine production by IFN-gamma IN THP-1 human monocytic cells.	Propranolol	10-21	GLI family zinc finger 2	Homo sapiens	119-124
9543699-1	1998	This study was undertaken to investigate the effects of propranolol, IFN-beta, and the protein kinase modulators on IFN-gamma induction of MHC class II antigen expression and cytokine production in THP-1 human monocytic cells.	Propranolol	56-67	interferon gamma	Homo sapiens	116-125
9543699-1	1998	This study was undertaken to investigate the effects of propranolol, IFN-beta, and the protein kinase modulators on IFN-gamma induction of MHC class II antigen expression and cytokine production in THP-1 human monocytic cells.	Propranolol	56-67	major histocompatibility complex, class II, DR beta 6 (pseudogene)	Homo sapiens	139-159
9458777-6	1998	Phentolamine significantly enhanced, whereas propranolol inhibited, motilin-induced insulin release.	Propranolol	45-56	insulin	Canis lupus familiaris	84-91
9435911-1	1997	Although the beta-adrenergic antagonist propranolol (1) binds at rodent 5-HT1B serotonin receptors, it displays low affinity (Ki &gt; 10,000 nM) for its species homologue 5-HT1D beta (i.e., h5-HT1B) receptors.	Propranolol	40-51	5-hydroxytryptamine receptor 1B	Homo sapiens	171-182
9517445-5	1997	The effect of MKC-242 on cortical ACh release was attenuated by pretreatment with the 5-HT1A receptor antagonists (10 mg/kg, s.c.) propranolol and N-tert-butyl-3-(4-(2-methoxyphenyl)piperazin-1-yl)-2-phenylpropana mide.	Propranolol	129-142	5-hydroxytryptamine receptor 1A	Rattus norvegicus	86-92
9375671-4	1997	Diminished noradrenergic activity, produced by intracerebroventricular infusion of 6-hydroxydopamine (6-OHDA) or chronic subcutaneous infusion of propranolol, decreased the intensities of the protein bands for the 109- and 102-kDa PDE4A variants in rat cerebral cortex but not of the 98- or 91-kDa PDE4 forms.	Propranolol	146-157	phosphodiesterase 4A	Rattus norvegicus	231-236
9401758-12	1997	However, the AII-evoked femoral vasodilatation was not due to an autonomic or neuroendocrine reflex because it was not depressed by hexamethonium (75 mumol kg-1), prazosin (0.25 mumol kg-1) or propranolol (3 mumol kg-1).	Propranolol	193-204	angiotensinogen	Rattus norvegicus	13-16
9376229-11	1997	Propranolol, a phosphatidic acid phosphohydrolase inhibitor, also enhanced the IL-6 synthesis by bFGF.	Propranolol	0-11	interleukin 6	Mus musculus	79-83
9399616-0	1997	Impact of CYP2D6 poor metabolizer phenotype on propranolol pharmacokinetics and response.	Propranolol	47-58	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	10-16
9399616-1	1997	We conducted an open-label study to determine the impact of cytochrome P-4502D6 (CYP2D6) on propranolol pharmacokinetics and response in 12 healthy men with CYP2D6 extensive metabolizer (EM) phenotype and 3 healthy men with CYP2D6 poor metabolizer (PM) phenotype.	Propranolol	92-103	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	60-79
9399616-1	1997	We conducted an open-label study to determine the impact of cytochrome P-4502D6 (CYP2D6) on propranolol pharmacokinetics and response in 12 healthy men with CYP2D6 extensive metabolizer (EM) phenotype and 3 healthy men with CYP2D6 poor metabolizer (PM) phenotype.	Propranolol	92-103	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	81-87
9369345-9	1997	The order of potency for these agonists in the presence of phentolamine, propranolol, guanethidine and L-NNA was: 6-bromo-APB &gt; SKF38393 &gt; dopamine &gt; LY171555.	Propranolol	73-84	arginyl aminopeptidase	Homo sapiens	122-125
9281306-6	1997	Propranolol, a phosphatidic acid phosphohydrolase inhibitor, enhanced the IL-6 synthesis by thrombin.	Propranolol	0-11	interleukin 6	Mus musculus	74-78
9281306-6	1997	Propranolol, a phosphatidic acid phosphohydrolase inhibitor, enhanced the IL-6 synthesis by thrombin.	Propranolol	0-11	coagulation factor II	Mus musculus	92-100
9365827-6	1997	The ANP-evoked reduction in MAP was not affected in haloperidol- or phentolamine-treated rats (-8.8 +/- 2.3 and -10.5 +/- 2.4%, respectively; both p &lt; 0.005 vs. vehicle) but was abolished in propranolol-treated rats (+3.2 +/- 1.3%; p = ns vs. vehicle).	Propranolol	194-205	natriuretic peptide A	Rattus norvegicus	4-7
9365827-7	1997	The ANP-induced increase in hematocrit was slightly attenuated in haloperidol-, phentolamine-, and propranolol-treated rats (7.5 +/- 0.7, 7.3 +/- 0.8, and 6.0 +/- 1%, respectively).	Propranolol	99-110	natriuretic peptide A	Rattus norvegicus	4-7
9316857-8	1997	P450 ML2d had the oxidation activities for the rat CYP2D-substrates, such as propranolol 4-hydroxylation and imipramine 2-hydroxylation, in higher rates than those of the microsomes, but did not exhibit debrisoquine 4-hydroxylase activity.	Propranolol	77-88	cytochrome P450, 2d region	Mus musculus	51-56
9261814-2	1997	Administration of a selective 5-HT1A agonist, 8-OH-DPAT (0.1 mg kg-1) significantly depressed the monosynaptic mass reflex (MMR) amplitude, which was prevented effectively by S(-)-propranolol, a 5-HT1A antagonist.	Propranolol	175-191	5-hydroxytryptamine receptor 1A	Rattus norvegicus	30-36
9651107-5	1998	However, the inhibition of the IL-6 and TNF mRNAs in SHR was prevented by propranolol treatment.	Propranolol	74-85	interleukin 6	Rattus norvegicus	31-35
9651107-5	1998	However, the inhibition of the IL-6 and TNF mRNAs in SHR was prevented by propranolol treatment.	Propranolol	74-85	tumor necrosis factor-like	Rattus norvegicus	40-43
9300319-5	1997	The relaxation caused by CGRP was also slightly inhibited at 2 x 10(-8) M by removal of endothelium and in the presence of methylene blue, NG-nitro-L-arginine methylester (L-NAME), or glibenclamide but was not affected by atropine, propranolol, indomethacin, or tetrodotoxin.	Propranolol	232-243	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	25-29
9279965-8	1997	A weak inhibition of phospholipase-A2 activity was demonstrated by betamethasone, bupivacaine, digoxin, hydrocortisone, lidocaine, metoprolol, propranolol, and vancomycin.	Propranolol	143-154	phospholipase A2 group IB	Homo sapiens	21-37
9376229-11	1997	Propranolol, a phosphatidic acid phosphohydrolase inhibitor, also enhanced the IL-6 synthesis by bFGF.	Propranolol	0-11	fibroblast growth factor 2	Mus musculus	97-101
9263740-11	1997	Long-term propranolol treatment enhanced the contractile reactivity of mesenteric artery to KCl and vasopressin in PVL rats, and the contractile profiles were corrected towards those in sham-treated animals.	Propranolol	10-21	arginine vasopressin	Rattus norvegicus	100-111
9315342-5	1997	Similarly, 100 microM (+/-)-propranolol (a dose likely to cause plasma membrane stabilizing effects involving interruption and (or) prevention of action potentials) blocked increases in VO2, lactate, and glycerol efflux by 5 nM angiotensin II (a nonadrenergic vasoconstrictor) with only marginal effects on pressure development.	Propranolol	22-39	angiotensinogen	Rattus norvegicus	228-242
9256169-6	1997	The binding of [3H]GBR-12935 to CYP2D6 was decreased partially by substrates or inhibitors of CYP2D isoforms (quinine, quinidine, propranolol, bufuralol, imipramine, and desipramine).	Propranolol	130-141	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	32-38
9256169-6	1997	The binding of [3H]GBR-12935 to CYP2D6 was decreased partially by substrates or inhibitors of CYP2D isoforms (quinine, quinidine, propranolol, bufuralol, imipramine, and desipramine).	Propranolol	130-141	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	32-37
9227545-3	1997	The ESPVR was shifted upward in an enhanced contractility by dobutamine and downward in a depressed contractility by propranolol; ESP at a midrange V of 0.1 ml/g LV on each ESPVR increased from 131 +/- 11 to 192 +/- 17 mmHg and decreased from 136 +/- 10 to 110 +/- 7 mmHg, respectively.	Propranolol	117-128	protein tyrosine phosphatase, receptor type, V	Rattus norvegicus	4-7
9189894-4	1997	The increase in working memory errors induced by intrahippocampal administration of 0.32 microgram/side scopolamine to rats treated with 10 mg/kg propranolol was decreased by concurrent injection of the cholinesterase inhibitor physostigmine (3.2 micrograms/side).	Propranolol	146-157	butyrylcholinesterase	Rattus norvegicus	203-217
9192090-0	1997	dl-propranolol negatively regulates the transcription of proliferating cell nuclear antigen (PCNA)-gene and thereby suppresses DNA synthesis in regenerating rat liver.	Propranolol	0-14	proliferating cell nuclear antigen	Rattus norvegicus	57-91
9192090-0	1997	dl-propranolol negatively regulates the transcription of proliferating cell nuclear antigen (PCNA)-gene and thereby suppresses DNA synthesis in regenerating rat liver.	Propranolol	0-14	proliferating cell nuclear antigen	Rattus norvegicus	93-97
9192090-1	1997	Previous reports have suggested that dl-propranolol (PRL) suppresses DNA synthesis by blocking cAMP-mediated signaling in rat liver after partial hepatectomy (PH).	Propranolol	37-51	cathelicidin antimicrobial peptide	Rattus norvegicus	95-99
9144502-4	1997	Several lines of evidence suggest that pleckstrin is phosphorylated in part by a nonconventional PKC following stimulation by FMLP: 1) chelation of intracellular Ca2+ had only a partial inhibitory effect; 2) diacylglycerol kinase inhibitors shortened the duration of phosphorylation, while the phosphatidic acid phosphohydrolase antagonist propranolol extended it; and 3) wortmannin and erbstatin blocked the phosphorylation of pleckstrin.	Propranolol	340-351	pleckstrin	Homo sapiens	39-49
9144502-4	1997	Several lines of evidence suggest that pleckstrin is phosphorylated in part by a nonconventional PKC following stimulation by FMLP: 1) chelation of intracellular Ca2+ had only a partial inhibitory effect; 2) diacylglycerol kinase inhibitors shortened the duration of phosphorylation, while the phosphatidic acid phosphohydrolase antagonist propranolol extended it; and 3) wortmannin and erbstatin blocked the phosphorylation of pleckstrin.	Propranolol	340-351	formyl peptide receptor 1	Homo sapiens	126-130
10072936-1	1997	AIM: To determine if any correlation between the side-chain oxidative capacity for propranolol and S-mephenytoin 4"-hydroxylase (cytochrome P-450 2C19, CYP2C19) activity in healthy Chinese of Han nationality.	Propranolol	83-94	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	99-127
9145928-2	1997	R- and S-enantiomers of propranolol, penbutolol, and alprenolol were investigated for their ability to bind to human 5-HT1A wild-type and Asn386Val mutant receptors.	Propranolol	24-35	5-hydroxytryptamine receptor 1A	Homo sapiens	117-123
9145928-6	1997	In addition, a series of analogues of propranolol with structural variation in the oxypropanolamine moiety was synthesized, and affinities for wild-type and Asn386Val mutant 5-HT1A receptors were determined.	Propranolol	38-49	5-hydroxytryptamine receptor 1A	Homo sapiens	174-180
10072936-1	1997	AIM: To determine if any correlation between the side-chain oxidative capacity for propranolol and S-mephenytoin 4"-hydroxylase (cytochrome P-450 2C19, CYP2C19) activity in healthy Chinese of Han nationality.	Propranolol	83-94	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	152-159
9150275-10	1997	Furthermore, phosphatidic acid significantly stimulated uPA production meanwhile propranolol, which blocks phosphatidic acid availability, reduced it, suggesting a main regulatory role for this intermediary metabolite.	Propranolol	81-92	plasminogen activator, urokinase	Mus musculus	56-59
9113375-5	1997	(-)-isoprenaline caused relaxation of longitudinal smooth muscle preparations with pEC50-7.39 +/- 0.12, and this response was inhibited by both propranolol (0.1 microM, pKB 8.55 +/- 0.12) and the selective beta 1-antagonist, CGP 20712A (0.1 microM, pKB 8.80 +/- 0.20), while the selective beta 2-antagonist, ICI 118551 (0.1 microM) failed to inhibit isoprenaline relaxation consistently.	Propranolol	144-155	protein tyrosine kinase 2 beta	Homo sapiens	169-172
9113375-5	1997	(-)-isoprenaline caused relaxation of longitudinal smooth muscle preparations with pEC50-7.39 +/- 0.12, and this response was inhibited by both propranolol (0.1 microM, pKB 8.55 +/- 0.12) and the selective beta 1-antagonist, CGP 20712A (0.1 microM, pKB 8.80 +/- 0.20), while the selective beta 2-antagonist, ICI 118551 (0.1 microM) failed to inhibit isoprenaline relaxation consistently.	Propranolol	144-155	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	206-212
9113375-5	1997	(-)-isoprenaline caused relaxation of longitudinal smooth muscle preparations with pEC50-7.39 +/- 0.12, and this response was inhibited by both propranolol (0.1 microM, pKB 8.55 +/- 0.12) and the selective beta 1-antagonist, CGP 20712A (0.1 microM, pKB 8.80 +/- 0.20), while the selective beta 2-antagonist, ICI 118551 (0.1 microM) failed to inhibit isoprenaline relaxation consistently.	Propranolol	144-155	protein tyrosine kinase 2 beta	Homo sapiens	249-252
9113375-5	1997	(-)-isoprenaline caused relaxation of longitudinal smooth muscle preparations with pEC50-7.39 +/- 0.12, and this response was inhibited by both propranolol (0.1 microM, pKB 8.55 +/- 0.12) and the selective beta 1-antagonist, CGP 20712A (0.1 microM, pKB 8.80 +/- 0.20), while the selective beta 2-antagonist, ICI 118551 (0.1 microM) failed to inhibit isoprenaline relaxation consistently.	Propranolol	144-155	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	289-295
9140695-8	1997	In the hippocampus, propranolol had a similar effect, indicating that beta-adrenergic receptors are also involved in the stress-induced increase in c-fos mRNA.	Propranolol	20-31	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	148-153
9140695-10	1997	On the other hand, the increase in c-fos mRNA produced by the stress of the injection was inhibited in the cerebral cortex by diazepam or propranolol and in the hippocampus only by diazepam.	Propranolol	138-149	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	35-40
8969945-7	1996	The addition of propranolol, a beta-adrenergic antagonist, to the incubation medium attenuated VIP-induced corticosteroid secretion.	Propranolol	16-27	vasoactive intestinal peptide	Homo sapiens	95-98
9057095-5	1997	Propranolol, an inhibitor of phosphatidic acid phosphohydrolase, significantly inhibited the ET-1-induced arachidonic acid release in a dose-dependent manner as well as the ET-1-induced diacylglycerol formation.	Propranolol	0-11	endothelin 1	Mus musculus	93-97
9057095-5	1997	Propranolol, an inhibitor of phosphatidic acid phosphohydrolase, significantly inhibited the ET-1-induced arachidonic acid release in a dose-dependent manner as well as the ET-1-induced diacylglycerol formation.	Propranolol	0-11	endothelin 1	Mus musculus	173-177
9057095-7	1997	The pretreatment with propranolol and RHC-80267 also inhibited the ET-1-induced PGE2 synthesis.	Propranolol	22-33	endothelin 1	Mus musculus	67-71
9127437-8	1997	dl-Propranolol, a beta-adrenoceptor antagonist, abrogated the inhibition of TNF-alpha and IL-1 beta production by procaterol.	Propranolol	0-14	tumor necrosis factor	Homo sapiens	76-85
9127437-8	1997	dl-Propranolol, a beta-adrenoceptor antagonist, abrogated the inhibition of TNF-alpha and IL-1 beta production by procaterol.	Propranolol	0-14	interleukin 1 beta	Homo sapiens	90-99
9037095-8	1997	Inhibition of the PLD pathway by ethanol and propranolol reduced diacylglycerol production and caused a concomitant fall in GnRH release.	Propranolol	45-56	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	18-21
9037095-8	1997	Inhibition of the PLD pathway by ethanol and propranolol reduced diacylglycerol production and caused a concomitant fall in GnRH release.	Propranolol	45-56	gonadotropin releasing hormone 1	Homo sapiens	124-128
9547558-0	1997	Dual effect of propranolol on the human platelet activation by thrombin: potentiation of free intracellular Ca2+ mobilization and inhibition of phospholipase D activity.	Propranolol	15-26	coagulation factor II, thrombin	Homo sapiens	63-71
9013808-5	1997	These actions of R(+)- and S(-)-NDP were 1700-times and 100-times less potent, respectively, than those of propranolol.	Propranolol	107-118	norrin cystine knot growth factor NDP	Rattus norvegicus	32-35
9653807-18	1997	Propranolol produced a major activation of the renin-angiotensin system and of the cortical blood flow in ischemic cephalic hypoxia, the renin-angiotensin system being located in the cerebral structure.	Propranolol	0-11	renin	Canis lupus familiaris	47-52
9653807-18	1997	Propranolol produced a major activation of the renin-angiotensin system and of the cortical blood flow in ischemic cephalic hypoxia, the renin-angiotensin system being located in the cerebral structure.	Propranolol	0-11	renin	Canis lupus familiaris	137-142
8982727-3	1996	Propranolol given either intraperitoneally or orally reduced ethanol-induced mucosal damage and myeloperoxidase activity.	Propranolol	0-11	myeloperoxidase	Homo sapiens	96-111
8982098-5	1996	Treatment of the macrophages with propranolol, a beta-antagonist, potentiated the effect of epinephrine.	Propranolol	34-45	amyloid beta (A4) precursor protein	Mus musculus	47-53
8982101-3	1996	We demonstrated that under septic-like conditions in the presence of bacteria and lipopolysaccharide (LPS), electrically induced inhibition of interleukin 6 (IL-6) secretion was attenuated by the beta-adrenergic antagonist propranolol.	Propranolol	223-234	toll-like receptor 4	Mus musculus	102-105
8982101-3	1996	We demonstrated that under septic-like conditions in the presence of bacteria and lipopolysaccharide (LPS), electrically induced inhibition of interleukin 6 (IL-6) secretion was attenuated by the beta-adrenergic antagonist propranolol.	Propranolol	223-234	interleukin 6	Mus musculus	143-156
8982101-3	1996	We demonstrated that under septic-like conditions in the presence of bacteria and lipopolysaccharide (LPS), electrically induced inhibition of interleukin 6 (IL-6) secretion was attenuated by the beta-adrenergic antagonist propranolol.	Propranolol	223-234	interleukin 6	Mus musculus	158-162
9119995-5	1997	In contrast, treatment before hemorrhage with the beta-adrenergic receptor antagonist propranolol was associated with increases in mRNA levels for IL-1beta, TNF-alpha, and TGF-beta1, which were greater than those present in untreated hemorrhaged mice, and did not prevent hemorrhage-associated increases in lung IL-1beta protein.	Propranolol	86-97	interleukin 1 beta	Mus musculus	147-155
9119995-5	1997	In contrast, treatment before hemorrhage with the beta-adrenergic receptor antagonist propranolol was associated with increases in mRNA levels for IL-1beta, TNF-alpha, and TGF-beta1, which were greater than those present in untreated hemorrhaged mice, and did not prevent hemorrhage-associated increases in lung IL-1beta protein.	Propranolol	86-97	tumor necrosis factor	Mus musculus	157-166
9119995-5	1997	In contrast, treatment before hemorrhage with the beta-adrenergic receptor antagonist propranolol was associated with increases in mRNA levels for IL-1beta, TNF-alpha, and TGF-beta1, which were greater than those present in untreated hemorrhaged mice, and did not prevent hemorrhage-associated increases in lung IL-1beta protein.	Propranolol	86-97	transforming growth factor, beta 1	Mus musculus	172-181
9119995-5	1997	In contrast, treatment before hemorrhage with the beta-adrenergic receptor antagonist propranolol was associated with increases in mRNA levels for IL-1beta, TNF-alpha, and TGF-beta1, which were greater than those present in untreated hemorrhaged mice, and did not prevent hemorrhage-associated increases in lung IL-1beta protein.	Propranolol	86-97	interleukin 1 beta	Mus musculus	312-320
9116917-3	1997	D.L.-Propranolol hydrochloride (propranolol), an inhibitor of phosphatidic acid phosphohydrolase, significantly inhibited the Ang II-induced release of AA metabolites.	Propranolol	32-43	angiotensinogen	Rattus norvegicus	126-132
9116917-7	1997	Both propranolol and RHC-80267 inhibited the Ang II-induced synthesis of 6-keto-prostaglandin F1 alpha, a stable metabolite of prostacyclin.	Propranolol	5-16	angiotensinogen	Rattus norvegicus	45-51
9050006-12	1997	The beta-AR ligands isoprenaline and propranolol showed affinities expected for functional beta 2-ARs.	Propranolol	37-48	adrenoceptor beta 2	Homo sapiens	4-11
9050006-12	1997	The beta-AR ligands isoprenaline and propranolol showed affinities expected for functional beta 2-ARs.	Propranolol	37-48	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	91-97
9530436-6	1997	The addition of propranolol (10(-6) M) caused a 250% increase in LHRH release from the stalk-median eminence explants of neonatal males (p = 0.08) and females (p &lt; 0.05).	Propranolol	16-27	gonadotropin releasing hormone 1	Sus scrofa	65-69
9530436-9	1997	Propranolol evoked a significant increase in LHRH secretion from the stalk-median eminence in the control group, but not in the groups given oestradiol benzoate.	Propranolol	0-11	gonadotropin releasing hormone 1	Sus scrofa	45-49
8975881-13	1996	Propranolol (150 microM), an inhibitor of phosphatidate phosphohydrolase, blocked both H202 and lactoferrin release, suggesting that the conversion of phosphatidic acid to diradylglycerol is an important step in PMN activation by TGF-beta1.	Propranolol	0-11	transforming growth factor beta 1	Homo sapiens	230-239
9004162-9	1996	However, cAMP synthesis could only be partially blocked by propranolol, suggesting that IL-2 stimulated cAMP synthesis both by a direct, beta-adrenergic independent mechanism and by a beta-adrenergic dependent pathway.	Propranolol	59-70	interleukin 2	Rattus norvegicus	88-92
8982673-4	1996	Propranolol, however, was found to bind to and to change the conformation of S100C protein in the presence of Mg2+ or Zn2+ with ED50 of approximately 1.0 microM.	Propranolol	0-11	mucin 7, secreted	Homo sapiens	110-113
8903410-10	1996	Butanol and propranolol at concentrations which effectively inhibited the formation of DG, suppressed HGF-induced expression of c-jun and c-fos mRNAs.	Propranolol	12-23	hepatocyte growth factor	Rattus norvegicus	102-105
9064274-5	1996	On the other hand, beta-adrenoceptor blockers (e.g. [-]-pindolol, [-]-propranolol) have been shown to have antagonistic properties on the 5-HT1A receptor side.	Propranolol	66-81	5-hydroxytryptamine receptor 1A	Homo sapiens	138-153
8903410-10	1996	Butanol and propranolol at concentrations which effectively inhibited the formation of DG, suppressed HGF-induced expression of c-jun and c-fos mRNAs.	Propranolol	12-23	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	138-143
8897928-6	1996	When antisense oligodeoxyribonucleotides to Mn-SOD were added to myocyte cultures, the increase in Mn-SOD activity (U/mg total protein) and the attenuation of CK release after the addition of NE in the presence of propranolol and yohimbine were not observed.	Propranolol	214-225	superoxide dismutase 2	Homo sapiens	44-50
8945677-6	1996	The positive inotropic and chronotropic effects of BK and des-Arg9-BK were found to be mediated by the sympathetic nervous system, because they were abolished by propranolol.	Propranolol	162-173	kininogen 1	Canis lupus familiaris	51-53
8930204-8	1996	Elevated plasma renin activity and aldosterone levels seen in untreated controls were significantly decreased by propranolol (P &lt; .05), and to a considerably greater extent by the same dose of carvedilol (P &lt; .01).	Propranolol	113-124	renin	Rattus norvegicus	16-21
8930356-9	1996	Moreover, a single injection of the beta-adrenergic antagonist, propranolol, prevented the nocturnal increase of pineal HIOMT mRNA.	Propranolol	64-75	acetylserotonin O-methyltransferase	Rattus norvegicus	120-125
8870689-11	1996	These results suggest that P450-1A2 is a major PL N-desisopropylase in the PL-treated rats, and P450-3A related enzyme(s) and P450-2E1 as a moderate or minor enzyme are also involved in PL N-dealkylation in native and PL-treated rats.	Propranolol	75-77	phospholamban	Rattus norvegicus	47-51
8946477-3	1996	The promethazine hydroxylase in human liver microsomes was inhibited by SKF-525A, propranolol, sparteine, quinidine and anti-CYP2D6 serum suggesting involvement of a P450 related to CYP2D6.	Propranolol	82-93	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	182-188
8870689-0	1996	Cytochrome P450 enzymes involved in the enhancement of propranolol N-desisopropylation after repeated administration of propranolol in rats.	Propranolol	55-66	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	0-15
8870689-11	1996	These results suggest that P450-1A2 is a major PL N-desisopropylase in the PL-treated rats, and P450-3A related enzyme(s) and P450-2E1 as a moderate or minor enzyme are also involved in PL N-dealkylation in native and PL-treated rats.	Propranolol	75-77	phospholamban	Rattus norvegicus	186-190
8870689-0	1996	Cytochrome P450 enzymes involved in the enhancement of propranolol N-desisopropylation after repeated administration of propranolol in rats.	Propranolol	120-131	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	0-15
8877032-0	1996	Variable contribution of CYP2D6 to the N-dealkylation of S-(-)-propranolol by human liver microsomes.	Propranolol	57-74	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	25-31
8870689-1	1996	Repeated oral administration of propranolol (PL, 100 mg/kg daily, for 5, 10 and 15 days) to male Wistar rats increased PL N-desisopropylase and decreased PL 4-,5- and 7-hydroxylase activities in liver microsomes.	Propranolol	32-43	phospholamban	Rattus norvegicus	119-123
8870689-1	1996	Repeated oral administration of propranolol (PL, 100 mg/kg daily, for 5, 10 and 15 days) to male Wistar rats increased PL N-desisopropylase and decreased PL 4-,5- and 7-hydroxylase activities in liver microsomes.	Propranolol	45-47	phospholamban	Rattus norvegicus	119-123
8877032-1	1996	Recombinant cDNA expression systems for CYP2D6 have been shown to have significant catalytic activity with respect to the N-dealkylation of propranolol.	Propranolol	140-151	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	40-46
8877032-3	1996	We have re-evaluated the role of CYP2D6 in the dealkylation of S-(-)-propranolol using a bank of 10 human livers characterized for their specific CYP2D6 and CYP1A2 activities, the latter enzyme being known to be involved substantially in the formation of N-desisopropylpropranolol.	Propranolol	63-80	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	33-39
8877882-5	1996	Also, the stereospecificity of P-gp for its substrates was investigated by comparing the inhibitory effects of the enantiomers and the racemic mixtures of verapamil and propranolol.	Propranolol	169-180	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	31-35
8909986-0	1996	Modification of systemic and regional circulatory effects of intracerebroventricular administration of endothelin-1 by propranolol in anesthetized rats.	Propranolol	119-130	endothelin 1	Rattus norvegicus	103-115
8909986-6	1996	Propranolol significantly attenuated the decrease in blood pressure, cardiac output and stroke volume induced by centrally administered ET-1.	Propranolol	0-11	endothelin 1	Rattus norvegicus	136-140
8909986-7	1996	The reduction in blood flow to the brain, heart, kidneys, gastrointestinal tract, portal system, musculoskeletal system and skin induced by centrally administered ET-1 was blocked by propranolol.	Propranolol	183-194	endothelin 1	Rattus norvegicus	163-167
8902882-6	1996	The effects of either catecholamine on IL-12 or IL-10 secretion were blocked completely by propranolol, a beta-adrenoreceptor antagonist, indicating that they were mediated by the beta-adrenergic receptor.	Propranolol	91-102	interleukin 10	Homo sapiens	48-53
8870048-2	1996	In support of previous findings by others, it was found that blockade of beta-1 and beta-2 receptors by propranolol delayed arousal from halothane anesthesia and that this effect was attributable to blockade of beta-1 receptors because it was duplicated by betaxolol but not by ICI 118,551.	Propranolol	104-115	hemoglobin, beta adult major chain	Mus musculus	73-79
8870048-2	1996	In support of previous findings by others, it was found that blockade of beta-1 and beta-2 receptors by propranolol delayed arousal from halothane anesthesia and that this effect was attributable to blockade of beta-1 receptors because it was duplicated by betaxolol but not by ICI 118,551.	Propranolol	104-115	hemoglobin, beta adult minor chain	Mus musculus	84-90
8870048-2	1996	In support of previous findings by others, it was found that blockade of beta-1 and beta-2 receptors by propranolol delayed arousal from halothane anesthesia and that this effect was attributable to blockade of beta-1 receptors because it was duplicated by betaxolol but not by ICI 118,551.	Propranolol	104-115	hemoglobin, beta adult major chain	Mus musculus	211-217
8864547-17	1996	In the presence of 200 nM (-)-propranolol the beta 3-adrenoceptor-selective agonists BRL 37344 (6 microM), SR 58611A (6 microM), ZD 2079 (60 microM) and CL 316243 (60 microM) did not cause stimulant effects or modify the potency and efficacy of the effects of (-)-CGP 12177 in right and left atria.	Propranolol	26-41	adrenoceptor beta 3	Rattus norvegicus	46-65
8694859-3	1996	However, inhibition of superoxide generation by neutrophils activated with phorbol myristate acetate (PMA), opsonized zymosan (OZ), and arachidonate (AA) only occurred with higher concentrations of propranolol, and coincided with decreased intracellular calcium fluxes, phospholipase A2 (PLA2) activity and synthesis of platelet-activating factor (PAF).	Propranolol	198-209	phospholipase A2 group IB	Homo sapiens	270-286
8756004-10	1996	Moreover, inhibitors of phosphatidate phosphohydrolase (propranolol) and diacylglycerol lipase (RHC-80267), attenuated ET-1-induced 6-keto-PGF1 alpha formation.	Propranolol	56-67	endothelin 1	Rattus norvegicus	119-123
8694859-3	1996	However, inhibition of superoxide generation by neutrophils activated with phorbol myristate acetate (PMA), opsonized zymosan (OZ), and arachidonate (AA) only occurred with higher concentrations of propranolol, and coincided with decreased intracellular calcium fluxes, phospholipase A2 (PLA2) activity and synthesis of platelet-activating factor (PAF).	Propranolol	198-209	phospholipase A2 group IB	Homo sapiens	288-292
8694859-3	1996	However, inhibition of superoxide generation by neutrophils activated with phorbol myristate acetate (PMA), opsonized zymosan (OZ), and arachidonate (AA) only occurred with higher concentrations of propranolol, and coincided with decreased intracellular calcium fluxes, phospholipase A2 (PLA2) activity and synthesis of platelet-activating factor (PAF).	Propranolol	198-209	PCNA clamp associated factor	Homo sapiens	320-346
8694859-3	1996	However, inhibition of superoxide generation by neutrophils activated with phorbol myristate acetate (PMA), opsonized zymosan (OZ), and arachidonate (AA) only occurred with higher concentrations of propranolol, and coincided with decreased intracellular calcium fluxes, phospholipase A2 (PLA2) activity and synthesis of platelet-activating factor (PAF).	Propranolol	198-209	PCNA clamp associated factor	Homo sapiens	348-351
8694859-5	1996	A mechanistic relationship between the anti-oxidative and membrane-stabilizing properties of propranolol was suggested by the observation that pretreatment of neutrophils with LPC or PAF eliminated the inhibitory effects of the drug on superoxide generation by PMA-activated neutrophils.	Propranolol	93-104	PCNA clamp associated factor	Homo sapiens	183-186
8781788-0	1996	Propranolol 4- and 5-hydroxylation and N-desisopropylation by cloned human cytochrome P4501A1 and P4501A2.	Propranolol	0-11	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	75-93
8647917-13	1996	Propranolol, an inhibitor of phosphatidic acid phosphohydrolase, inhibited both the thrombin-induced diacylglycerol formation and DNA synthesis.	Propranolol	0-11	coagulation factor II	Mus musculus	84-92
8799658-8	1996	Plasma GLP-1 levels were similar on the two GLP-1 infusion days and resulted in: (1) a significant decrease in plasma glucose from 5.2 +/- 0.2 to 4.1 +/- 0.1 mmol l-1 with GLP-1/propranolol infusion, and from 5.2 +/- 0.1 to 4.0 +/- 0.1 mmol l-1 with GLP-1/saline infusion (NS); (2) a corresponding significant increase in plasma insulin from 58.0 +/- 6.3 to 144.5 +/- 22.3 pmol l-1 and from 61.7 +/- 6.4 to 148.2 +/- 34.0 pmol l-1, respectively (NS); (3) a significant decrease in plasma glucagon from 11.7 +/- 1.6 to 6.5 +/- 1.5 pmol l-1 and from 10.4 +/- 1.6 to 4.6 +/- 1.0 pmol l-1, respectively; (4) a significant decrease in the rate of glucose appearance which was not significantly different on the two GLP-1 infusion days; and (5) an increase in catecholamine levels in the GLP-1/saline experiment and also in the beta-blockade experiments.	Propranolol	178-189	glucagon	Homo sapiens	7-12
8816991-11	1996	Therefore, we propose that the PC-PLC pathway may be temporarily inactivated for a short period of time by exposure to pulsed stimuli, and the PC-PLD pathway is up-regulated based on: (1) cellular release of [3H]choline; (2) rapid intracellular formation of [3H]PA followed by [3H]DAG; (3)active transphosphatidylation; and (4) blockade of DAG formation by propranolol.	Propranolol	357-368	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	146-149
8652650-14	1996	Propranolol, an inhibitor of PA phosphohydrolase, totally abolished the bradykinin-induced increase in 12-HETE DAG while increasing the magnitude and duration of 12-HETE PA release.	Propranolol	0-11	kininogen 1	Bos taurus	72-82
8652650-15	1996	The inhibiting effect of propranolol on bradykinin-induced increase of 12-HETE DAG demonstrates that 12-HETE PA is the principal precursor for 12-HETE DAG.	Propranolol	25-36	kininogen 1	Bos taurus	40-50
8835645-2	1996	Electrical stimulation of the vagus nerve in atropine-treated and propranolol-treated guinea pigs caused a 38.1% decrease in dynamic compliance (Cdyn), which was suppressed by the combination of the tachykinin NK1-receptor antagonist (+/-)-CP-96345 and NK2-receptor antagonist SR 48968.	Propranolol	66-77	substance-K receptor	Cavia porcellus	253-265
8793085-8	1996	The beta-adrenergic antagonist propanolol induced a suppression of the odour-related patterns of Fos accumulation similar to the one caused by the surgical deafferentation of the olfactory bulb.	Propranolol	31-41	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	97-100
8615803-2	1996	Propranolol, a beta-blocker, inhibited or stimulated ryanodine binding to both the membrane-bound and purified ryanodine receptor (RyR) depending on the assay conditions.	Propranolol	0-11	ryanodine receptor 1	Homo sapiens	131-134
8627519-12	1996	Acute administration of propranolol, which blocks beta-adrenergic receptors, reduced the number of cells staining for Fos-LI in limbic cortical regions, resembling the effects produced by chronic imipramine, desipramine and nisoxetine.	Propranolol	24-35	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	118-121
8738251-3	1996	Administration of propranolol, a beta-adrenergic receptor antagonist increased the Na+, K+, and urine excretion induced by ANG II.	Propranolol	18-29	angiotensinogen	Homo sapiens	123-129
8615803-7	1996	Modulators of the RyR that are known to alter its conformational states, such as adenine nucleotides, Ca2+ concentration and pH, modified the effect of propranolol on ryanodine binding.	Propranolol	152-163	ryanodine receptor 1	Homo sapiens	18-21
8615803-10	1996	Propranolol immediately and completely blocked the channel opening of RyR reconstituted into a planar lipid bilayer.	Propranolol	0-11	ryanodine receptor 1	Homo sapiens	70-73
8615803-15	1996	These results suggest that propranolol interacts directly with the RyR and modifies its ryanodine binding and single-channel activities.	Propranolol	27-38	ryanodine receptor 1	Homo sapiens	67-70
8615803-16	1996	Propranolol effects are altered by the RyR conformational state, suggesting its possible use as a conformational probe for RyR.	Propranolol	0-11	ryanodine receptor 1	Homo sapiens	39-42
8615803-16	1996	Propranolol effects are altered by the RyR conformational state, suggesting its possible use as a conformational probe for RyR.	Propranolol	0-11	ryanodine receptor 1	Homo sapiens	123-126
8641030-16	1996	Furthermore, the insulin-induced attenuation of sympathetic vasoconstriction was partially corrected by propranolol.	Propranolol	104-115	insulin	Homo sapiens	17-24
8738584-28	1996	D-propranolol injection had an effect on plasma IL-6 activity in open field-exposed rats.	Propranolol	0-13	interleukin 6	Rattus norvegicus	48-52
9112665-1	1996	The interaction of C-terminal cholecystokinin octapeptide (CCK-8) with beta-adrenoceptors agonist (isoprenaline-ISO) and antagonist (propranolol) and their influence on arterial blood pressure and function of isolated heart in rats with streptozotocin-induced diabetes mellitus (DM) was studied.	Propranolol	133-144	cholecystokinin	Rattus norvegicus	30-45
8730750-5	1996	Systemic production of TNF alpha in response to LPS was increased in adrenalectomized animals and in normal animals treated with the beta-adrenoceptor antagonist, propranolol.	Propranolol	163-174	tumor necrosis factor	Mus musculus	23-32
8842867-8	1996	In both strains, propranolol (1 microM) potentiated the responses to EFS, and this increase was observed at lower frequencies in TGR arteries.	Propranolol	17-28	thioredoxin reductase 3	Mus musculus	129-132
8724032-1	1996	We report the case of a patient who developed jaundice, encephalopathy, a marked increase in serum aminotransferase activity and a decrease in prothrombin and proaccelerin levels, after 6 weeks" treatment with carbimazole and propranolol for hyperthyroidism.	Propranolol	226-237	coagulation factor II, thrombin	Homo sapiens	143-154
8735816-1	1996	The effects of bromadryl, dithiaden, chloroquine and propranolol on thrombin-stimulated rat platelet aggregation (measured turbidimetrically) and thromboxane B2 generation (detected by an RIA method) were compared with four selected physico-chemical parameters of these drugs.	Propranolol	53-64	coagulation factor II	Rattus norvegicus	68-76
8786576-5	1996	The inhibitory effects elicited by 8-OH-DPAT could be selectively blocked by perfusion of the spinal cord with S-(--)-propranolol, a selective 5-HT(1A) antagonist.	Propranolol	111-129	5-hydroxytryptamine receptor 1A	Rattus norvegicus	143-150
9157684-8	1996	Regulation of secondary granule (lactoferrin) release was complex, as it was significantly depressed by propranolol, enhanced by PT and unaffected by staurosporine.	Propranolol	104-115	lactotransferrin	Bos taurus	33-44
8734469-6	1996	The responses to prenalterol and salbutamol were inhibited by propranolol at relatively low concentrations, suggesting their effects were mediated by beta 1AR and beta 2AR, respectively.	Propranolol	62-73	adrenergic receptor, beta 1	Mus musculus	150-158
8734469-6	1996	The responses to prenalterol and salbutamol were inhibited by propranolol at relatively low concentrations, suggesting their effects were mediated by beta 1AR and beta 2AR, respectively.	Propranolol	62-73	adrenergic receptor, beta 2	Mus musculus	163-171
8734469-7	1996	However, propranolol was a particularly weak antagonist of BRL 37344 and, unexpectedly, of the clenbuterol UCP responses, which suggests that both induce UCP synthesis via the beta 3AR.	Propranolol	9-20	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	154-157
8734469-7	1996	However, propranolol was a particularly weak antagonist of BRL 37344 and, unexpectedly, of the clenbuterol UCP responses, which suggests that both induce UCP synthesis via the beta 3AR.	Propranolol	9-20	adrenergic receptor, beta 3	Mus musculus	176-184
8660292-6	1996	The cold-induced increases in both UCP and LPL gene expression were abolished by the beta-adrenergic antagonist propranolol.	Propranolol	112-123	uncoupling protein 1	Rattus norvegicus	35-38
8660292-6	1996	The cold-induced increases in both UCP and LPL gene expression were abolished by the beta-adrenergic antagonist propranolol.	Propranolol	112-123	lipoprotein lipase	Rattus norvegicus	43-46
8730513-3	1996	The rapid and large [Ca+]i response, which was inhibited by 90% by the alpha 1-antagonist prazosin and only by 20% by the non-specific beta antagonist (-)-propranolol, was considered to be mediated by the alpha 1-adrenoceptor.	Propranolol	151-166	adrenoceptor alpha 1D	Homo sapiens	205-212
8867872-3	1996	Pretreatment with propranolol (beta-adrenergic receptor antagonist that also has binding affinity for 5-HT1A, 5-HT1B and 5-HT2B sites), yohimbine (alpha 2-noradrenergic antagonist that also has binding affinity for 5-HT2B sites), MDL-72222 or ondansetron (5-HT3 antagonists) did not attenuate m-CPP-induced hyperthermia.	Propranolol	18-29	5-hydroxytryptamine receptor 1A	Rattus norvegicus	102-108
9026523-8	1996	In contrast, incubation with propranolol blocked the effects of isoproterenol on LDL receptor expression.	Propranolol	29-40	low density lipoprotein receptor	Rattus norvegicus	81-93
8838601-9	1996	We suggest that the inhibitory effects of propranolol and pindolol may involve interactions with 5-HT1A receptors in the CNS.	Propranolol	42-53	5-hydroxytryptamine receptor 1A	Rattus norvegicus	97-103
8838601-10	1996	Alternatively, it may be that the adverse effects of pindolol and propranolol are due to the simultaneous blockade of both beta 1- and beta 2-adrenoceptors.	Propranolol	66-77	adrenoceptor beta 1	Rattus norvegicus	123-155
8950281-5	1996	Replacing prazosin with benextramine (which blocks NPY in addition to alpha-adrenergic receptors) attenuated the pressor response unmasked by propranolol.	Propranolol	142-153	neuropeptide Y	Rattus norvegicus	51-54
8658370-7	1996	Propranolol blunted the heart rate delta response to exercise, consistent with beta 1 blockade, whilst salmeterol and formoterol had no effect.	Propranolol	0-11	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	79-85
8569707-3	1996	However, the specific involvement of the propranolol oxygen atoms in binding to the wild-type and T355N mutant 5-HT1D beta receptors has never been addressed experimentally.	Propranolol	41-52	5-hydroxytryptamine receptor 1B	Homo sapiens	111-122
8569707-5	1996	Propranolol was docked with the wild-type and T355N mutant 5-HT1D beta receptor models in an attempt to understand the difference in affinity of the ligand for the receptors.	Propranolol	0-11	5-hydroxytryptamine receptor 1B	Homo sapiens	59-70
8878215-1	1996	Serotonin 5-HT1A-type and beta-adrenergic receptors have similar molecular characteristics, which explains why certain substances like propranolol have affinities for both receptor types.	Propranolol	135-146	5-hydroxytryptamine receptor 1A	Oryctolagus cuniculus	10-16
8591729-2	1995	Hepatic microsomes from dogs lacked the ability to catalyze PL 7-hydroxylation, which is mediated by the CYP2D subfamily in rats.	Propranolol	60-62	cytochrome P450 2D15	Canis lupus familiaris	105-110
8562484-5	1995	The ability of NE to stimulate the expression of FGF-2 mRNA was blocked by actinomycin D or was inhibited partly by propranolol.	Propranolol	116-127	fibroblast growth factor 2	Rattus norvegicus	49-54
7583579-6	1995	By means of butanol, the PA-phosphohydrolase (PPH) inhibitor propranolol, and the PC-PLC inhibitor D609, we demonstrated that the initial PC-derived DG formation occurred primarily by a coupled PLD/PPH pathway and that a major part of the sustained DG formation was derived directly from PC by PC-PLC.	Propranolol	61-72	enolase 1	Homo sapiens	46-49
7583579-6	1995	By means of butanol, the PA-phosphohydrolase (PPH) inhibitor propranolol, and the PC-PLC inhibitor D609, we demonstrated that the initial PC-derived DG formation occurred primarily by a coupled PLD/PPH pathway and that a major part of the sustained DG formation was derived directly from PC by PC-PLC.	Propranolol	61-72	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	194-197
8703649-6	1995	infused propranolol (0.1 mu kg-1 min-1) was determined during normoxaemia and hypoxaemia (peripheral oxygen saturation; SpO2 80%), and compared with the contra-lateral (control) arm.	Propranolol	8-19	CD59 molecule (CD59 blood group)	Homo sapiens	33-38
7472585-8	1995	After propranolol treatment, Kmono decreased (0.082 +/- 0.014 min-1) but remained significantly higher in eight patients than normal subject levels (p &lt; 0.05), while the rate pressure product decreased significantly (7500 +/- 1700) toward the normal range (7900 +/- 1500).	Propranolol	6-17	CD59 molecule (CD59 blood group)	Homo sapiens	62-67
7554699-0	1995	Propranolol disposition in Chinese subjects of different CYP2D6 genotypes.	Propranolol	0-11	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	57-63
8593456-1	1995	1-Acetamino-3-(1-naphthyloxy)-2-propanol (AcNDP) detected in human urine was formed as a metabolite of propranolol (PL) via 1-amino-3-(L-naphthyloxy)-2-propanol (N-desisopropylpropranolol, NDP).	Propranolol	103-114	norrin cystine knot growth factor NDP	Homo sapiens	44-47
8593456-1	1995	1-Acetamino-3-(1-naphthyloxy)-2-propanol (AcNDP) detected in human urine was formed as a metabolite of propranolol (PL) via 1-amino-3-(L-naphthyloxy)-2-propanol (N-desisopropylpropranolol, NDP).	Propranolol	116-118	norrin cystine knot growth factor NDP	Homo sapiens	44-47
7476903-5	1995	Thus, the beta 2-adrenoceptor agonists albuterol and procaterol partially (approximately 40%) suppressed TNF-alpha generation in a propranolol-sensitive manner.	Propranolol	131-142	adrenoceptor beta 2	Homo sapiens	10-29
7476903-5	1995	Thus, the beta 2-adrenoceptor agonists albuterol and procaterol partially (approximately 40%) suppressed TNF-alpha generation in a propranolol-sensitive manner.	Propranolol	131-142	tumor necrosis factor	Homo sapiens	105-114
8564220-18	1995	However, propranolol itself markedly potentiated the bradykinin response which confounded the interpretation of its effects on formoterol.6 The study has shown, in a preparation of rat trachea in situ, that supramaximal doses of the beta2-adrenoceptor agonist, formoterol (a) produced a sustained, but incomplete, inhibition of plasma exudation (induced by topical bradykinin), and (b) did not prevent bradykinin-induced leaky microvessels.	Propranolol	9-20	adrenoceptor beta 2	Rattus norvegicus	233-251
7557093-9	1995	The association of propranolol (n = 8) but not furosemide (n = 7) to prazosin increased the reduction in HVPG and attenuated the increase in plasma renin activity.	Propranolol	19-30	renin	Homo sapiens	148-153
7554699-1	1995	Propranolol pharmacokinetics among different genotypes of CYP2D6 was compared in this study.	Propranolol	0-11	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	58-64
7554699-10	1995	This study shows a different propranolol disposition in Chinese subjects of different CYP2D6 genotypes.	Propranolol	29-40	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	86-92
8565792-2	1995	Other CYP2D-dependent reactions (such as bunitrolol 4-hydroxylation, lidocaine 3-hydroxylation, and propranolol 4-, 5- and 7-hydroxylations) were also impaired by the treatment, but not those catalyzed by other CYP isozymes.	Propranolol	100-111	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	6-9
7653628-10	1995	Prop partially inhibited the Iso-evoked increases in ANF and FN mRNA, completely prevented the Iso-induced changes in TGF-beta 1 and SERCA mRNA, but had no effect on the Iso-stimulated changes in SK and PNK gene expression.	Propranolol	0-4	natriuretic peptide A	Rattus norvegicus	53-56
7591743-8	1995	Propranolol 80 mg bid ($7.80/month) is inexpensive and frequently a good choice among beta-blockers.	Propranolol	0-11	BH3 interacting domain death agonist	Homo sapiens	18-21
7657823-3	1995	Concomitant with the increases in plasma renin activity, renin mRNA levels in the kidney were significantly increased in intraperitoneal hypertonic saline-injected rats, and these increases were prevented by beta-adrenergic receptor blockade with propranolol.	Propranolol	247-258	renin	Rattus norvegicus	41-46
7657823-3	1995	Concomitant with the increases in plasma renin activity, renin mRNA levels in the kidney were significantly increased in intraperitoneal hypertonic saline-injected rats, and these increases were prevented by beta-adrenergic receptor blockade with propranolol.	Propranolol	247-258	renin	Rattus norvegicus	57-62
7593548-5	1995	The role of beta-adrenoceptors and endogenous catecholamines is further substantiated by the finding that pretreatment of animals with propranolol alone resulted in a dose-dependent increase of the TNF-alpha response induced by LPS, and that isoproterenol, a non-selective beta-adrenoceptor agonist, decreased it.	Propranolol	135-146	tumor necrosis factor	Mus musculus	198-207
7593548-5	1995	The role of beta-adrenoceptors and endogenous catecholamines is further substantiated by the finding that pretreatment of animals with propranolol alone resulted in a dose-dependent increase of the TNF-alpha response induced by LPS, and that isoproterenol, a non-selective beta-adrenoceptor agonist, decreased it.	Propranolol	135-146	toll-like receptor 4	Mus musculus	228-231
8587948-5	1995	CGRP induced a delay in the extinction of an active avoidance response, which could be prevented by haloperidol, propranolol, methysergide and naloxone.	Propranolol	113-124	calcitonin-related polypeptide alpha	Rattus norvegicus	0-4
7669062-5	1995	The increase in HSL activity could be prevented by pretreating the mice with propranolol, 10 mg/kg, i.p., 30 min prior to the agonist.	Propranolol	77-88	lipase, hormone sensitive	Mus musculus	16-19
7669062-6	1995	The activation of HSL activity by the beta 3-adrenoceptor agonists was associated with an increase in tissue cAMP production which was also prevented by pretreatment with propranolol.	Propranolol	171-182	lipase, hormone sensitive	Mus musculus	18-21
7669062-6	1995	The activation of HSL activity by the beta 3-adrenoceptor agonists was associated with an increase in tissue cAMP production which was also prevented by pretreatment with propranolol.	Propranolol	171-182	adrenergic receptor, beta 3	Mus musculus	38-57
7653572-7	1995	Moreover, the action of CAP on secretin release was significantly inhibited in the recipient rats pretreated with TTX, BSV, and topical applications of capsaicin but was not suppressed in the recipient rats pretreated with atropine, hexamethonium, or propranolol.	Propranolol	251-262	secretin	Rattus norvegicus	31-39
7653628-10	1995	Prop partially inhibited the Iso-evoked increases in ANF and FN mRNA, completely prevented the Iso-induced changes in TGF-beta 1 and SERCA mRNA, but had no effect on the Iso-stimulated changes in SK and PNK gene expression.	Propranolol	0-4	fibronectin 1	Rattus norvegicus	61-63
7653628-10	1995	Prop partially inhibited the Iso-evoked increases in ANF and FN mRNA, completely prevented the Iso-induced changes in TGF-beta 1 and SERCA mRNA, but had no effect on the Iso-stimulated changes in SK and PNK gene expression.	Propranolol	0-4	transforming growth factor, beta 1	Rattus norvegicus	118-128
7579706-6	1995	Inhibition of PA-phosphohydrolase activity by propranolol also decreased GnRH-induced DG production and, in contrast to ethanol, increased PA and cytidine diphosphate diacylglycerol levels.	Propranolol	46-57	gonadotropin releasing hormone 1	Homo sapiens	73-77
7579706-7	1995	The fall in DG production caused by ethanol and propranolol was accompanied by inhibition of GnRH-induced c-fos expression, whereas agonist-induced luteinizing hormone release was not affected.	Propranolol	48-59	gonadotropin releasing hormone 1	Homo sapiens	93-97
7579706-7	1995	The fall in DG production caused by ethanol and propranolol was accompanied by inhibition of GnRH-induced c-fos expression, whereas agonist-induced luteinizing hormone release was not affected.	Propranolol	48-59	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	106-111
7858743-5	1995	Pretreatment with the beta-adrenergic antagonist propranolol inhibited secretion of the POMC peptides in response to HA, 2-TEA or 4-MeHA.	Propranolol	49-60	proopiomelanocortin	Rattus norvegicus	88-92
7589193-4	1995	The anti-immobility effect was antagonized by 5-HT1A receptor antagonists such as propranolol and N-tert-butyl-3-(4-(2-methoxyphenyl)piperazin-1-yl)-2-phenylpropana mide.	Propranolol	82-93	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	46-61
7549561-2	1995	Propranolol, a beta-adrenergic blocker, can act on the vasomotor centers within the hypothalamus and brain stem to reduce the activity of the sympathetic nerves and the cerebral metabolic need for oxygen and glucose.	Propranolol	0-11	amyloid beta (A4) precursor protein	Mus musculus	13-19
7758118-6	1995	Serotonin- or 8-OH-DPAT-induced increase in proliferation could be blocked by the 5-HT1A receptor antagonists (+)WAY 100135 and propranolol.	Propranolol	128-139	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	82-97
8529044-4	1995	In the first experiment, the changes in renin release induced by DA and the effects of a non-selective DA antagonist, haloperidol and a beta antagonist, propranolol on DA-induced renin release were examined.	Propranolol	153-164	renin	Rattus norvegicus	179-184
7560861-11	1995	CONCLUSION: The results of the present study suggest that the cardiovascular actions of propranolol are predominantly mediated through blockade of peripheral beta 2-adrenoceptor.	Propranolol	88-99	adrenoceptor beta 2	Rattus norvegicus	158-177
7783654-8	1995	A significant decrease in LPL activity was observed during the addition of propranolol to vasodilators as compared with vasodilators alone.	Propranolol	75-86	lipoprotein lipase	Homo sapiens	26-29
7738189-8	1995	When adipose tissue was pretreated with the beta 1/beta 2-selective adrenoceptor blocker propranolol the glycerol increasing effect of dobutamine or terbutaline was inhibited by 80-85% but the glycerol response to CGP 12177 was not influenced.	Propranolol	89-100	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	44-57
7621902-7	1995	Subcutaneous infusion of propranolol for seven days with miniosmotic pumps was accompanied by an increase in beta 1- and beta 2-adrenoceptor densities in young rats only (beta 1-, 38%, P &lt; 0.05; beta 2- 52%, P &lt; 0.025).	Propranolol	25-36	adrenoceptor beta 1	Rattus norvegicus	109-140
7600375-6	1995	The potentiating effect of salbutamol on IgE production was blocked by two antagonists of beta 2-adrenoceptor, namely butoxamine and D,L-propranolol, suggesting a beta-adrenoceptor-mediated event.	Propranolol	133-148	adrenoceptor beta 2	Homo sapiens	90-109
7741768-6	1995	The reconstituted system containing P450(b-1) catalyzed the metabolism of aminopyrine, benzo[a]pyrene, 7-ethoxycoumarin, imipramine and propranolol, of which P450(b-1) most strongly catalyzed aminopyrine N-demethylation and imipramine N-demethylation.	Propranolol	136-147	UDP glucuronosyltransferase family 1 member A1	Rattus norvegicus	36-44
7741768-6	1995	The reconstituted system containing P450(b-1) catalyzed the metabolism of aminopyrine, benzo[a]pyrene, 7-ethoxycoumarin, imipramine and propranolol, of which P450(b-1) most strongly catalyzed aminopyrine N-demethylation and imipramine N-demethylation.	Propranolol	136-147	UDP glucuronosyltransferase family 1 member A1	Rattus norvegicus	158-166
8584140-5	1995	In SK-N-MCIXC cells isoproterenol increased CCK mRNA levels at all time points examined, the beta-adrenergic antagonist propranolol blocked this effect.	Propranolol	120-131	cholecystokinin	Homo sapiens	44-47
7619088-5	1995	These data suggest that propranolol inhibits signal transduction in thrombin-stimulated platelets by interacting at the level of phospholipase C and exclude interaction of the drug with the downstream effector enzyme protein kinase C.	Propranolol	24-35	coagulation factor II, thrombin	Homo sapiens	68-76
7616849-8	1995	Basal insulin level was only slightly reduced during propranolol treatment, whereas the insulin response to alanine was significantly blunted.	Propranolol	53-64	insulin	Homo sapiens	6-13
7567595-9	1995	After administration of beta 1-, beta 2-blocker, propranolol (30 mg/day), cAMP at 3 minutes of tilt decreased significantly compared to the baseline tilt (16.9 +/- 1.4 pmol/mL vs 25.3 +/- 2.0 pmol/mL; P &lt; 0.05) and propranolol prevented the syncope in all six patients.	Propranolol	218-229	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	24-31
7785793-2	1995	Administration of propranolol for twelve weeks to untreated subjects resulted in a significant (P &lt; 0.001) rise in plasma ANP levels (from 37.9 +/- 21.2 to 66.7 +/- 46.2 pg/mL, mean +/- SD).	Propranolol	18-29	natriuretic peptide A	Homo sapiens	125-128
7785793-7	1995	These results suggest that the increased plasma ANP levels may contribute to the antihypertensive effect with propranolol.	Propranolol	110-121	natriuretic peptide A	Homo sapiens	48-51
7640150-0	1995	Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers--N-desisopropylation is mediated mainly by CYP1A2.	Propranolol	67-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-27
7640150-0	1995	Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers--N-desisopropylation is mediated mainly by CYP1A2.	Propranolol	67-78	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	134-140
7640150-2	1995	Studies using human liver microsomes and six recombinant human CYP isoforms (i.e. CYP1A2, 2A6, 2B6, 2D6, 2E1 and 3A4) were performed to identify the cytochrome P450 (CYP) isoform(s) involved in the ring 4-hydroxylation and side-chain N-desisopropylation of propranolol enantiomers in humans.	Propranolol	257-268	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	149-164
7640150-4	1995	alpha-Naphthoflavone and 7-ethoxyresorufin (selective inhibitors of CYP1A1/2) inhibited the N-desisopropylation of R- and S-propranolol by human liver microsomes by 20 and 40%, respectively, while quinidine (a selective inhibitor of CYP2D6) abolished the 4-hydroxylation of both propranolol enantiomers almost completely.	Propranolol	124-135	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	68-74
7640150-4	1995	alpha-Naphthoflavone and 7-ethoxyresorufin (selective inhibitors of CYP1A1/2) inhibited the N-desisopropylation of R- and S-propranolol by human liver microsomes by 20 and 40%, respectively, while quinidine (a selective inhibitor of CYP2D6) abolished the 4-hydroxylation of both propranolol enantiomers almost completely.	Propranolol	124-135	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	233-239
7640150-4	1995	alpha-Naphthoflavone and 7-ethoxyresorufin (selective inhibitors of CYP1A1/2) inhibited the N-desisopropylation of R- and S-propranolol by human liver microsomes by 20 and 40%, respectively, while quinidine (a selective inhibitor of CYP2D6) abolished the 4-hydroxylation of both propranolol enantiomers almost completely.	Propranolol	279-290	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	68-74
7640150-15	1995	Recombinant human CYP1A2 and CYP2D6 exhibited comparable catalytic activity with respect to the N-desisopropylation of both propranolol enantiomers; only expressed CYP2D6 exhibited a marked catalytic activity with respect to the 4-hydroxylation of both propranolol enantiomers.	Propranolol	124-135	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	18-24
7640150-15	1995	Recombinant human CYP1A2 and CYP2D6 exhibited comparable catalytic activity with respect to the N-desisopropylation of both propranolol enantiomers; only expressed CYP2D6 exhibited a marked catalytic activity with respect to the 4-hydroxylation of both propranolol enantiomers.	Propranolol	124-135	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	29-35
7640150-15	1995	Recombinant human CYP1A2 and CYP2D6 exhibited comparable catalytic activity with respect to the N-desisopropylation of both propranolol enantiomers; only expressed CYP2D6 exhibited a marked catalytic activity with respect to the 4-hydroxylation of both propranolol enantiomers.	Propranolol	124-135	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	164-170
7640150-15	1995	Recombinant human CYP1A2 and CYP2D6 exhibited comparable catalytic activity with respect to the N-desisopropylation of both propranolol enantiomers; only expressed CYP2D6 exhibited a marked catalytic activity with respect to the 4-hydroxylation of both propranolol enantiomers.	Propranolol	253-264	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	18-24
7640150-15	1995	Recombinant human CYP1A2 and CYP2D6 exhibited comparable catalytic activity with respect to the N-desisopropylation of both propranolol enantiomers; only expressed CYP2D6 exhibited a marked catalytic activity with respect to the 4-hydroxylation of both propranolol enantiomers.	Propranolol	253-264	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	29-35
7640150-15	1995	Recombinant human CYP1A2 and CYP2D6 exhibited comparable catalytic activity with respect to the N-desisopropylation of both propranolol enantiomers; only expressed CYP2D6 exhibited a marked catalytic activity with respect to the 4-hydroxylation of both propranolol enantiomers.	Propranolol	253-264	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	164-170
7716784-4	1995	The augmentation of NAT activity by parathion also caused significant reductions in pineal serotonin (5-HT); again, this response was blocked by propranolol treatment.	Propranolol	145-156	N-acetyltransferase 1	Rattus norvegicus	20-23
7605599-0	1995	Night-time rise in rat pineal N-acetyltransferase due to carbaryl administration is reduced by propranolol treatment.	Propranolol	95-106	N-acetyltransferase 1	Rattus norvegicus	30-49
7599912-6	1995	Thus, in these doses bisoprolol antagonized only beta 1-adrenoceptor mediated effects, propranolol both beta 1- and beta 2-adrenoceptor mediated effects, but both antagonists had no alpha-adrenoceptor antagonistic effects.	Propranolol	87-98	adrenoceptor beta 1	Homo sapiens	104-135
7542715-8	1995	In addition, the tachycardia resulting from intrathecal injections of PBE was inhibited by pretreatment with propranolol (0.3 mg/kg, i.v.).	Propranolol	109-120	enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase	Rattus norvegicus	70-73
7759768-2	1995	Ketanserin (5-HT2 receptor ligand) and propranolol (5-HT1A and beta-adrenergic ligand) did not block the suppressive effect of serotonin if used along with it in equimolar concentrations (10(-9) M).	Propranolol	39-50	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	52-58
7843777-5	1995	delta SBP was markedly suppressed by the administration of both propranolol and prazosin.	Propranolol	64-75	selenium binding protein 1	Homo sapiens	6-9
7753335-8	1995	Blockade of beta-adrenergic receptors with propranolol inhibited the beta-END- and alpha-MSH responses to restraint stress whereas the ACTH response was unaffected.	Propranolol	43-54	proopiomelanocortin	Rattus norvegicus	83-92
7701450-8	1995	Whilst propranolol blunted exercise heart rate in keeping with beta 1 blockade, salbutamol had no effect.	Propranolol	7-18	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	63-69
7487140-5	1995	The addition of propranolol resulted in prolongation of ICAM-1 expression on keratinocytes induced by IFN gamma.	Propranolol	16-27	intercellular adhesion molecule 1	Homo sapiens	56-62
7487140-5	1995	The addition of propranolol resulted in prolongation of ICAM-1 expression on keratinocytes induced by IFN gamma.	Propranolol	16-27	interferon gamma	Homo sapiens	102-111
7707880-4	1995	Isoproterenol produced concentration-dependent responses in oocytes injected with mRNA encoding beta 2-adrenergic receptors and CFTR, and co-administration of propranolol antagonized these responses.	Propranolol	159-170	cystic fibrosis transmembrane conductance regulator L homeolog	Xenopus laevis	128-132
7777207-2	1995	The peak release of ATP 5 min after 1 microM isoprenaline was inhibited by 1 microM propranolol and 1 microM butoxamine, but not by 1 microM atenolol, showing that the ATP release is due to stimulation of the presynaptic beta 2-adrenoceptor by isoprenaline.	Propranolol	84-95	beta-2 adrenergic receptor	Cavia porcellus	221-240
8846619-2	1995	Cytochrome P450 1A2 (CYP1A2) accounts for about 10 to 15% of the total CYP content of human liver and is the major enzyme involved in the metabolism of imipramine, propranolol, clozapine, theophylline, and caffeine.	Propranolol	164-175	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	0-19
8846619-2	1995	Cytochrome P450 1A2 (CYP1A2) accounts for about 10 to 15% of the total CYP content of human liver and is the major enzyme involved in the metabolism of imipramine, propranolol, clozapine, theophylline, and caffeine.	Propranolol	164-175	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	21-27
8846619-2	1995	Cytochrome P450 1A2 (CYP1A2) accounts for about 10 to 15% of the total CYP content of human liver and is the major enzyme involved in the metabolism of imipramine, propranolol, clozapine, theophylline, and caffeine.	Propranolol	164-175	peptidylprolyl isomerase G	Homo sapiens	21-24
7843740-6	1995	The enhancing effect of isoproterenol was inhibited by the presence of propranolol (beta 1- and beta 2-adrenergic receptor antagonist) and ICI 118,551 (beta 2-adrenergic receptor antagonist) but not by the presence of atenolol (beta 1-adrenergic receptor antagonist).	Propranolol	71-82	adrenergic receptor, beta 1	Mus musculus	84-122
7723353-5	1995	The effect of AII was not influenced by propranolol 10(-6) M or phentolamine 10(-7) M but was blocked by 250 microM DuP 753.	Propranolol	40-51	angiotensinogen	Rattus norvegicus	14-17
8586949-4	1995	Studies of the biochemistry of the aortic wall have shown that Propranolol has an independent effect on blood pressure, stimulation lysyl-oxidase and production of intermolecular elastin bridges which strengthen the arterial wall.	Propranolol	63-74	elastin	Homo sapiens	179-186
8748665-11	1995	A high dose of the mixed beta 1 and beta 2 adrenoceptor antagonist propranolol (8.0 mg/kg, i.p.)	Propranolol	67-78	adrenoceptor beta 1	Rattus norvegicus	25-55
7899461-3	1995	EGF, IGF-I, and bFGF caused significant and dose-dependent increases in [3H]phosphatidic acid (PA) accumulation in the presence of propranolol, a phosphatidic acid phosphohydrolase inhibitor.	Propranolol	131-142	epidermal growth factor	Rattus norvegicus	0-3
7899461-3	1995	EGF, IGF-I, and bFGF caused significant and dose-dependent increases in [3H]phosphatidic acid (PA) accumulation in the presence of propranolol, a phosphatidic acid phosphohydrolase inhibitor.	Propranolol	131-142	insulin-like growth factor 1	Rattus norvegicus	5-10
7899461-3	1995	EGF, IGF-I, and bFGF caused significant and dose-dependent increases in [3H]phosphatidic acid (PA) accumulation in the presence of propranolol, a phosphatidic acid phosphohydrolase inhibitor.	Propranolol	131-142	fibroblast growth factor 2	Rattus norvegicus	16-20
7753967-3	1995	Pretreatment with propranolol (beta-adrenoceptor antagonist that also has binding affinity for 5-HT1A, 5-HT1B and 5-HT2C sites), MDL-72222 or ondansetron (5-HT3 antagonists) did not attenuate DOI-induced hyperthermia.	Propranolol	18-29	5-hydroxytryptamine receptor 1A	Rattus norvegicus	95-101
7985599-3	1994	The hyperinsulinemic euglycemic clamp method showed that the significant decrease in insulin sensitivity (p &lt; 0.01) induced by treatment with pindolol, propanolol, metoprolol, atenolol, or hydrochlorothiazide after 4 to 6 months persisted after 2 to 3 years of treatment.	Propranolol	155-165	insulin	Homo sapiens	9-16
7867028-11	1994	That the effect was not beta adrenergic was demonstrated in eight experiments using atropine plus propranolol, 1 x 10(-7) M. A vagally induced increment in rate still occurred (p &lt; 0.05) and was abolished by [D-p-CL-Phe6, Leu17]VIP.	Propranolol	98-109	vasoactive intestinal peptide	Rattus norvegicus	231-234
8925676-6	1995	However, the anorectic effect of 5-HTP was also antagonized by propranolol (PROP 1mg/kg, i.p.)	Propranolol	63-74	PROP paired-like homeobox 1	Rattus norvegicus	76-82
7867028-12	1994	The ability to ascribe a rate change to VIP release was maximal in the presence of propranolol and atropine, intermediate in the presence of atropine alone, and minimal in the absence of muscarinic or beta blockade.	Propranolol	83-94	vasoactive intestinal peptide	Rattus norvegicus	40-43
7898082-6	1994	Prazosin and propranolol, adrenergic blocking agents, and reserpine, a depletor of catecholamine stores, reduced either ET-1 or L-NAME pressor effects.	Propranolol	13-24	endothelin 1	Rattus norvegicus	120-124
7881705-8	1994	The apolipoprotein B/A ratio was elevated in the propranolol group.	Propranolol	49-60	apolipoprotein B	Homo sapiens	4-20
7731062-5	1994	The significant diacylglycerol increase at 10(-10) M ANF, in the presence of propranolol, a potent inhibitor of phosphatidate phosphatase which can hydrolyse phosphatidate to give diacylglycerol, suggested a direct involvement of PC-PLC.	Propranolol	77-88	natriuretic peptide A	Rattus norvegicus	53-56
7708122-8	1994	In the absence of Triton X-100, propranolol and metoprolol enhanced the PAP activity.	Propranolol	32-43	acid phosphatase 3	Rattus norvegicus	72-75
7696378-9	1994	Respective values for (S)-propranolol after single isomer administration (20 mg) were 86 (36) and 57 (25) ml min-1 kg-1 in single dose and steady state situations.	Propranolol	22-37	CD59 molecule (CD59 blood group)	Homo sapiens	109-119
7986200-6	1994	In a reconstituted system containing P450BTL, NADPH-cytochrome P450 reductase (fp2) and dilauroylphosphatidylcholine, propranolol 4-, 5- and 7-hydroxylase activities decreased time dependently following preincubation with propranolol in the presence of NADPH, indicating time-dependent inactivation of P450BTL.	Propranolol	118-129	cytochrome p450 oxidoreductase	Rattus norvegicus	46-77
7986200-6	1994	In a reconstituted system containing P450BTL, NADPH-cytochrome P450 reductase (fp2) and dilauroylphosphatidylcholine, propranolol 4-, 5- and 7-hydroxylase activities decreased time dependently following preincubation with propranolol in the presence of NADPH, indicating time-dependent inactivation of P450BTL.	Propranolol	222-233	cytochrome p450 oxidoreductase	Rattus norvegicus	46-77
7895609-0	1994	Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes.	Propranolol	37-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
7895609-3	1994	We characterized cytochrome P450 isozymes responsible for propranolol metabolism, especially N-desisopropylation and 5-hydroxylation, in human liver microsomes.	Propranolol	58-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-32
7895609-7	1994	Propranolol N-desisopropylase activity in the samples highly correlated with CYP1A2 content and phenacetin O-deethylase activity, but not with the other P450 isozyme contents or metabolic activities.	Propranolol	0-11	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	77-83
7895609-8	1994	Quinidine, a specific inhibitor of CYP2D6, inhibited propranolol 4- and 5-hydroxylase activities selectively and in a concentration-dependent manner.	Propranolol	53-64	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	35-41
7929822-7	1994	This induction of TGF-beta 1 mRNA occurred at norepinephrine concentrations as low as 1 nM and was blocked by prazosin, but not propranolol.	Propranolol	128-139	transforming growth factor, beta 1	Rattus norvegicus	18-28
8077660-9	1994	The increases in AP-1 enhancer activity induced by PA or anti-CD3 mAb were efficiently abrogated by the presence of propranolol, an inhibitor of PA phosphohydrolase and protein kinase C (PKC).	Propranolol	116-127	JunD proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	17-21
7965815-6	1994	Yohimbine, an alpha-2 antagonist, and propranolol, a beta antagonist, did not inhibit the effect of phenylephrine on L-type current.	Propranolol	38-49	amyloid beta precursor protein	Rattus norvegicus	51-57
7965820-8	1994	The immunostimulatory effects of IL-2 were also blocked in mice administered the beta adrenergic antagonist propranolol (5 mg/kg) immediately and 1 day after IL-2 administration.	Propranolol	108-119	interleukin 2	Mus musculus	33-37
7965820-8	1994	The immunostimulatory effects of IL-2 were also blocked in mice administered the beta adrenergic antagonist propranolol (5 mg/kg) immediately and 1 day after IL-2 administration.	Propranolol	108-119	interleukin 2	Mus musculus	158-162
7927201-8	1994	We also report that the administration of the beta-adrenergic blocker, D,L-propranolol inhibited the accumulation of calmodulin protein without significantly affecting the increase of the messenger RNAs.	Propranolol	71-86	calmodulin 1	Rattus norvegicus	117-127
7931078-13	1994	Propranolol, an inhibitor of phosphatidate phosphohydrolase, and calyculin A, a phosphatase 1 and 2A inhibitor, blocked DAG production in response to FMLP but not to IL-4.	Propranolol	0-11	formyl peptide receptor 1	Homo sapiens	150-154
7965707-3	1994	Pretreatment with propranolol (beta adrenoceptor antagonist that also has high binding affinity for 5-HT1A, 5-HT1B and 5-HT2C sites), MDL-72222 and ondansetron (5-HT3 antagonists) attenuated DOM"s effect on plasma prolactin, but did not attenuate DOM-induced increases in either ACTH or corticosterone.	Propranolol	18-29	5-hydroxytryptamine receptor 1A	Rattus norvegicus	100-106
7965707-3	1994	Pretreatment with propranolol (beta adrenoceptor antagonist that also has high binding affinity for 5-HT1A, 5-HT1B and 5-HT2C sites), MDL-72222 and ondansetron (5-HT3 antagonists) attenuated DOM"s effect on plasma prolactin, but did not attenuate DOM-induced increases in either ACTH or corticosterone.	Propranolol	18-29	5-hydroxytryptamine receptor 2C	Rattus norvegicus	119-125
7869608-5	1994	In addition, the Ang II (1 nmol)-induced antidiuretic effects were partially inhibited by phenoxybenzamine (80 nmol) in the SON and by phenoxybenzamine, timolol (100 nmol) and propranolol (100 nmol) in the PVN.	Propranolol	176-187	angiotensinogen	Rattus norvegicus	17-23
7945339-5	1994	Metoprolol or propranolol partially reversed the receptor population shift back to AT1, indicating that the AT2 receptor subtype may play a role in the heart enlargement induced by volume overload and suggesting a functional interrelationship between the beta adrenergic receptors and AII receptors.	Propranolol	14-25	angiotensin II receptor, type 1a	Rattus norvegicus	83-86
7945339-5	1994	Metoprolol or propranolol partially reversed the receptor population shift back to AT1, indicating that the AT2 receptor subtype may play a role in the heart enlargement induced by volume overload and suggesting a functional interrelationship between the beta adrenergic receptors and AII receptors.	Propranolol	14-25	angiotensin II receptor, type 2	Rattus norvegicus	108-111
7531010-5	1994	The results indicated the interaction of atenolol and propranolol with mast cell membranes, particularly with the phospholipid bilayer, resulting in a possible inhibition of phospholipase A2 activation.	Propranolol	54-65	phospholipase A2 group IB	Rattus norvegicus	174-190
7946545-5	1994	The low-responder rate to L-dopa-propranolol provocative test among short children who are not GH deficient was 12.5%.	Propranolol	33-44	growth hormone 1	Homo sapiens	95-97
7921620-8	1994	Although the pharmacological profiles of the human and murine beta 3-receptor were very similar, some quantitative or even qualitative differences were observed for particular compounds such as propranolol, which exhibited weak and partial agonistic effects at the human beta 3-receptors and antagonistic effects at the murine beta 3-receptors.	Propranolol	194-205	eukaryotic translation elongation factor 1 beta 2 pseudogene 2	Homo sapiens	62-68
7921620-8	1994	Although the pharmacological profiles of the human and murine beta 3-receptor were very similar, some quantitative or even qualitative differences were observed for particular compounds such as propranolol, which exhibited weak and partial agonistic effects at the human beta 3-receptors and antagonistic effects at the murine beta 3-receptors.	Propranolol	194-205	eukaryotic translation elongation factor 1 beta 2 pseudogene 2	Homo sapiens	271-277
7921620-8	1994	Although the pharmacological profiles of the human and murine beta 3-receptor were very similar, some quantitative or even qualitative differences were observed for particular compounds such as propranolol, which exhibited weak and partial agonistic effects at the human beta 3-receptors and antagonistic effects at the murine beta 3-receptors.	Propranolol	194-205	eukaryotic translation elongation factor 1 beta 2 pseudogene 2	Homo sapiens	271-277
7946944-0	1994	Inhibition of CYP2D6 activity by treatment with propranolol and the role of 4-hydroxy propranolol.	Propranolol	48-59	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	14-20
7946944-2	1994	The 4-hydroxylation of propranolol by rat and human liver microsomes is associated with formation of a chemically reactive species which binds irreversibly to cytochrome P4502D6 (CYP2D6) destroying its catalytic function.	Propranolol	23-34	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	159-177
7946944-2	1994	The 4-hydroxylation of propranolol by rat and human liver microsomes is associated with formation of a chemically reactive species which binds irreversibly to cytochrome P4502D6 (CYP2D6) destroying its catalytic function.	Propranolol	23-34	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	179-185
7946944-12	1994	We conclude that, although treatment with propranolol 80 mg twice daily significantly decreases the catalytic function of CYP2D6, the inhibition is insufficient to result in phenocopying.	Propranolol	42-53	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	122-128
7895609-9	1994	alpha-Naphthoflavone, a potent inhibitor of CYP1A2, inhibited all of the propranolol oxidation activities, and the IC50 value for N-desisopropylase activity was much smaller than the values for ring-hydroxylase activities.	Propranolol	73-84	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	44-50
7895609-12	1994	These results indicate that propranolol 5-hydroxylation, as well as 4-hydroxylation, is mainly catalyzed by CYP2D6 in human liver microsomes.	Propranolol	28-39	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	108-114
8035308-3	1994	Pretreatment with propranolol [a beta adrenoceptor antagonist that also has high binding affinity for serotonin (5-HT) 5-HT1A, 5-HT1B and 5-HT2C sites], bemesetron or ondansetron (5-HT3 antagonists) did not attenuate either DOM-induced hypophagia or hyperthermia.	Propranolol	18-29	5-hydroxytryptamine receptor 1A	Rattus norvegicus	119-125
8035308-3	1994	Pretreatment with propranolol [a beta adrenoceptor antagonist that also has high binding affinity for serotonin (5-HT) 5-HT1A, 5-HT1B and 5-HT2C sites], bemesetron or ondansetron (5-HT3 antagonists) did not attenuate either DOM-induced hypophagia or hyperthermia.	Propranolol	18-29	5-hydroxytryptamine receptor 1B	Rattus norvegicus	127-133
7969811-4	1994	The 5-HT1A antagonists, (-)pindolol, (-)propranolol and spiperone, inhibited the effect of 8-OH-DPAT on wr-RSA.	Propranolol	40-51	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
8207217-4	1994	In the presence of propranolol (phosphatidic acid (PA) phosphohydrolase inhibitor), or ethanol, the activation of PLD results in the modulation of PA and/or diglyceride (DG) generation, producing an irregularity in O2- production.	Propranolol	19-30	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	114-117
8014870-4	1994	The effects of systemic 8-OH-DPAT on 5-HT release were blocked completely by systemic administration of the 5-HT/beta adrenergic receptor antagonist, (-)-propranolol, but not by the beta-1 adrenergic receptor antagonist betaxolol or the beta-2 adrenergic receptor antagonist ICI-118,551.	Propranolol	150-165	adrenoceptor beta 2	Rattus norvegicus	237-263
7936115-8	1994	In the presence of the vasopressin antagonist, d(CH2)5(Tyr(Et))DAVP, alone or in combination with phentolamine and propranolol, the pressor response to carbachol was substantially reduced, while the renal and superior mesenteric vasoconstrictor effects were completely abolished; the bradycardia was not significantly affected by this treatment.	Propranolol	115-126	arginine vasopressin	Rattus norvegicus	23-34
8023334-3	1994	To evaluate the possibility of evoking the flushing reaction with drugs less toxic than disulfiram, we studied the effects of propranolol and dipyridamole on ALDH and PGI2.	Propranolol	126-137	aldehyde dehydrogenase 3 family, member A1	Rattus norvegicus	158-162
8185671-3	1994	The present study demonstrates that in [14C]palmitic acid-labeled NIH 3T3 fibroblasts, propranolol (50-100 microM) and sphingosine had similar stimulatory effects on PLD-mediated synthesis of phosphatidylethanol in the presence of ethanol.	Propranolol	87-98	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	166-169
8062098-6	1994	Inhibition of either alpha 1 adrenergic receptor with prazosin or beta adrenergic receptor with propranolol did not cause any change in the basal GnRH mRNA levels but reduced NMDA-induced GnRH mRNA levels.	Propranolol	96-107	gonadotropin releasing hormone 1	Rattus norvegicus	188-192
7520314-4	1994	However, six weeks of CE-2 diet containing propranolol hydrochloride (525 mg/kg CE-2) a non-selective beta-blocker, markedly reduced the specific and total binding of GDP in BAT mitochondria, leading to weight gain in both MSG- and saline-treated mice.	Propranolol	43-68	catalase activity, kidney	Mus musculus	22-26
7520314-4	1994	However, six weeks of CE-2 diet containing propranolol hydrochloride (525 mg/kg CE-2) a non-selective beta-blocker, markedly reduced the specific and total binding of GDP in BAT mitochondria, leading to weight gain in both MSG- and saline-treated mice.	Propranolol	43-68	catalase activity, kidney	Mus musculus	80-84
8185671-0	1994	Sphingosine-like stimulatory effects of propranolol on phospholipase D activity in NIH 3T3 fibroblasts.	Propranolol	40-51	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	55-70
8185671-9	1994	The present study identified the PLD system as another common target for the pharmacological actions of sphingosine and propranolol.	Propranolol	120-131	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	33-36
8045100-3	1994	Concomitant treatment of animals with the beta-adrenergic antagonist propranolol completely blocked the noradrenaline-induced suppression of GH.	Propranolol	69-80	somatotropin	Ovis aries	141-143
8032617-6	1994	This response was inhibited by propranolol, the beta 1- and beta 2-adrenoceptor antagonist, with a pA2 of 9.20 suggesting that the prejunctional beta-adrenoceptors are not of the beta 3-subtype.	Propranolol	31-42	adrenoceptor beta 1	Rattus norvegicus	48-79
8021907-5	1994	Beta-thromboglobulin (beta-TG) concentration, reflecting the status of platelet activation in vivo, was significantly decreased after propranolol (129.6 +/- 13.5 vs. 77.9 +/- 8.6 ng/ml) and verapamil (129.6 +/- 13.5 vs. 90.7 +/- 10.1 ng/ml) treatments while platelet aggregation induced by ADP, collagen, arachidonic acid or adrenaline and the production of thromboxane B2 (TXB2), 6-ketoprostaglandin F1 alpha (6-keto-PGF1 alpha) and platelet cyclic 3"-5" adenosine monophosphate (C-AMP) concentration were not affected.	Propranolol	134-145	pro-platelet basic protein	Homo sapiens	0-20
8021907-5	1994	Beta-thromboglobulin (beta-TG) concentration, reflecting the status of platelet activation in vivo, was significantly decreased after propranolol (129.6 +/- 13.5 vs. 77.9 +/- 8.6 ng/ml) and verapamil (129.6 +/- 13.5 vs. 90.7 +/- 10.1 ng/ml) treatments while platelet aggregation induced by ADP, collagen, arachidonic acid or adrenaline and the production of thromboxane B2 (TXB2), 6-ketoprostaglandin F1 alpha (6-keto-PGF1 alpha) and platelet cyclic 3"-5" adenosine monophosphate (C-AMP) concentration were not affected.	Propranolol	134-145	pro-platelet basic protein	Homo sapiens	22-29
8054864-5	1994	This appeared to be due to a direct effect of propranolol on endogenous insulin secretion, while whole body insulin sensitivity remained unchanged as assessed using the hyperinsulinemic-euglycemic clamp technique.	Propranolol	46-57	insulin	Homo sapiens	72-79
8028022-3	1994	Activation of alpha 1-adrenergic receptors by norepinephrine (in the presence of propranolol) increased the rate of ANP secretion approximately two-fold (EC50 = 0.32 microM).	Propranolol	81-92	natriuretic peptide A	Rattus norvegicus	116-119
8111570-5	1994	The IL-1 beta-induced inhibition of the contractile responses was not affected by pretreatment of tissues with indomethacin or propranolol, but it was greatly attenuated by mechanical removal of epithelium.	Propranolol	127-138	interleukin 1 beta	Homo sapiens	4-13
7908853-3	1994	Propranolol (a nonselective beta-adrenoceptor blocker) antagonized the water ingestion and enhanced the Na+, and urine excretion induced by ANGII.	Propranolol	0-11	angiotensinogen	Rattus norvegicus	140-145
8165061-2	1994	Group I consisted of eight neonates in whom VIP was administered after bilateral vagotomy and beta-blockade with propranolol.	Propranolol	113-124	vasoactive intestinal peptide	Canis lupus familiaris	44-47
7984276-5	1994	Using [3H]5-HT, we found that the affinities of all the mutant receptors for propranolol and pindolol were significantly increased by 100-1000 fold, 5-HT1D alpha and 5-HT1F receptors showing the highest and the 5-HT1E receptor displaying the lowest affinity.	Propranolol	77-88	5-hydroxytryptamine receptor 1D	Homo sapiens	149-161
7984276-5	1994	Using [3H]5-HT, we found that the affinities of all the mutant receptors for propranolol and pindolol were significantly increased by 100-1000 fold, 5-HT1D alpha and 5-HT1F receptors showing the highest and the 5-HT1E receptor displaying the lowest affinity.	Propranolol	77-88	5-hydroxytryptamine receptor 1F	Homo sapiens	166-172
7984276-5	1994	Using [3H]5-HT, we found that the affinities of all the mutant receptors for propranolol and pindolol were significantly increased by 100-1000 fold, 5-HT1D alpha and 5-HT1F receptors showing the highest and the 5-HT1E receptor displaying the lowest affinity.	Propranolol	77-88	5-hydroxytryptamine receptor 1E	Homo sapiens	211-217
7988622-7	1994	After exercise, dilevalol and propranolol produced similar falls in the induced increases in arterial pressure, heart rate and cardiac output, and had the same effects on regional haemodynamics, plasma renin activity and atrial natriuretic factor.	Propranolol	30-41	renin	Homo sapiens	202-207
7906887-5	1994	Pretreatment with atropine, naloxone, phenoxybenzamine, or propranolol blocked the antiamnesic action of CGRP.	Propranolol	59-70	calcitonin-related polypeptide alpha	Rattus norvegicus	105-109
8185745-6	1994	In the presence of 0.1 microM propranolol, compound 2f (5 to 30 microM) antagonised in competitive manner the negative inotropic effect induced by N6-(R-phenylisopropyl) adenosine (R-PIA) (0.01-1.0 microM), a stable adenosine receptor agonist.	Propranolol	30-41	ribose-5-phosphate isomerase	Cavia porcellus	147-186
7908422-6	1994	Two injections of the alpha 1-adrenoceptor blocker prazosin 45 and 90 min before sacrifice, alone or together with the beta-blocker propranolol, prevented the changes in MBH hypophysiotropic hormone content, as well as in serum GH and PRL levels, found in SCGx rats 20 h after surgery.	Propranolol	132-143	prolactin	Rattus norvegicus	235-238
8171910-2	1994	Phentolamine (alpha-AR blocker, 1 mg/kg) or obsidan (beta-AR blocker, 1 mg/kg) injections resulted in a loss of the dominant rank of CBA/Lac mice and did not affect the PT mice behaviour.	Propranolol	44-51	adrenergic receptor, beta 1	Mus musculus	53-60
7712117-2	1994	Site-directed mutagenesis studies have demonstrated that substitution of the conserved residues Asp(113) to an Asn or Glu greatly reduces the binding affinity of propranolol in the beta-adrenergic receptor and the substitution of an Asp(114) has similar effects in the dopamine D2 receptor.	Propranolol	162-173	dopamine receptor D2	Homo sapiens	269-289
7912102-0	1993	Extent of beta 1- and beta 2-receptor occupancy in plasma assesses the antagonist activity of metoprolol, pindolol, and propranolol in the elderly.	Propranolol	120-131	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	10-16
8123802-4	1993	At the same time, beta-adrenoblocker (propranolol, 5 mg/kg) inhibited IL-3 production.	Propranolol	38-49	interleukin 3	Mus musculus	70-74
7912102-0	1993	Extent of beta 1- and beta 2-receptor occupancy in plasma assesses the antagonist activity of metoprolol, pindolol, and propranolol in the elderly.	Propranolol	120-131	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	22-28
7912102-1	1993	We estimated antagonist activity of metoprolol, pindolol, and propranolol in elderly cardiovascular patients by determining the extent to which the drugs occupied rabbit lung beta 1- and rat reticulocyte beta 2-adrenoceptors in plasma samples during drug treatment.	Propranolol	62-73	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	175-181
7912102-1	1993	We estimated antagonist activity of metoprolol, pindolol, and propranolol in elderly cardiovascular patients by determining the extent to which the drugs occupied rabbit lung beta 1- and rat reticulocyte beta 2-adrenoceptors in plasma samples during drug treatment.	Propranolol	62-73	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	204-210
7912102-5	1993	The results and conclusions were the following: (a) The extent to which metoprolol, pindolol, and propranolol occupied rabbit lung beta 1- and rat reticulocyte beta 2-adrenoceptors in plasma samples estimated accurately the intensity of beta-receptor antagonism in the patients who did not tolerate physiological and pharmacological tests measuring the degree of beta 1- and beta 2-adrenoceptor blockade.	Propranolol	98-109	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	131-137
7912102-5	1993	The results and conclusions were the following: (a) The extent to which metoprolol, pindolol, and propranolol occupied rabbit lung beta 1- and rat reticulocyte beta 2-adrenoceptors in plasma samples estimated accurately the intensity of beta-receptor antagonism in the patients who did not tolerate physiological and pharmacological tests measuring the degree of beta 1- and beta 2-adrenoceptor blockade.	Propranolol	98-109	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	160-166
7912102-5	1993	The results and conclusions were the following: (a) The extent to which metoprolol, pindolol, and propranolol occupied rabbit lung beta 1- and rat reticulocyte beta 2-adrenoceptors in plasma samples estimated accurately the intensity of beta-receptor antagonism in the patients who did not tolerate physiological and pharmacological tests measuring the degree of beta 1- and beta 2-adrenoceptor blockade.	Propranolol	98-109	adrenoceptor beta 1	Homo sapiens	363-394
7912102-6	1993	(b) The mean beta 1- and beta 2-receptor occupancy of pindolol and propranolol varied between 76% and 99% during the treatments.	Propranolol	67-78	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	13-19
7912102-6	1993	(b) The mean beta 1- and beta 2-receptor occupancy of pindolol and propranolol varied between 76% and 99% during the treatments.	Propranolol	67-78	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	25-31
8011559-2	1993	In this study, the effects of the combination of a beta-blocker (propranolol) and a Ca2+ antagonist (nifedipine) on the spontaneous recovery, as well as the adrenergic response of the isolated, perfused, working rat heart after a period of cardioplegic arrest were evaluated.	Propranolol	65-76	amyloid beta precursor protein	Rattus norvegicus	49-55
8150026-0	1993	DL-propranolol inhibits lens hexokinase activity and affects lens optics.	Propranolol	0-14	hexokinase 1	Homo sapiens	29-39
8150026-1	1993	A clinico-biochemical study indicated that the beta-blocker DL-propranolol may affect human lens epithelial hexokinase (HK) activity.	Propranolol	60-74	hexokinase 1	Homo sapiens	108-118
8150026-1	1993	A clinico-biochemical study indicated that the beta-blocker DL-propranolol may affect human lens epithelial hexokinase (HK) activity.	Propranolol	60-74	hexokinase 1	Homo sapiens	120-122
8263781-6	1993	Conversely, propranolol and p-chloromercuribenzoic acid (pCMB), which inhibit a phosphatidylcholine-specific phospholipase D (PLD)-dependent pathway, reduced contraction of esophageal but not of LES muscle cells.	Propranolol	12-23	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	109-124
8263781-6	1993	Conversely, propranolol and p-chloromercuribenzoic acid (pCMB), which inhibit a phosphatidylcholine-specific phospholipase D (PLD)-dependent pathway, reduced contraction of esophageal but not of LES muscle cells.	Propranolol	12-23	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	126-129
8216298-3	1993	Additionally, a bolus infusion of adrenomedullin (300 and 500 pmol) produced a long-lasting vasodilator response, which was not affected in the presence of atropine (10(-7) M) and propranolol (10(-7) M).	Propranolol	180-191	adrenomedullin	Rattus norvegicus	34-48
7907025-5	1993	Spiperone, spiperone plus propranolol, LY 53857, ketanserin and propranolol antagonised the pressor effects of DOI suggesting the stimulation of both 5-HT2 and 5-HT1C receptors.	Propranolol	26-37	5-hydroxytryptamine receptor 2C	Rattus norvegicus	160-166
7907025-5	1993	Spiperone, spiperone plus propranolol, LY 53857, ketanserin and propranolol antagonised the pressor effects of DOI suggesting the stimulation of both 5-HT2 and 5-HT1C receptors.	Propranolol	64-75	5-hydroxytryptamine receptor 2C	Rattus norvegicus	160-166
7907025-6	1993	Propranolol and spiperone plus propranolol suppressed the weak increase in heart rate induced by DOI, indicating the stimulation of 5-HT1C receptors.	Propranolol	0-11	5-hydroxytryptamine receptor 2C	Rattus norvegicus	132-138
7907025-6	1993	Propranolol and spiperone plus propranolol suppressed the weak increase in heart rate induced by DOI, indicating the stimulation of 5-HT1C receptors.	Propranolol	31-42	5-hydroxytryptamine receptor 2C	Rattus norvegicus	132-138
7905378-0	1993	Regioselective contribution of the cytochrome P-450 2D subfamily to propranolol metabolism in rat liver microsomes.	Propranolol	68-79	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	35-51
7905378-9	1993	These results indicate that a polymorphic cytochrome P-450 isozyme(s) belonging to the CYP2D subfamily is involved predominantly in propranolol 4-, 5-, and 7-hydroxylations at low substrate concentrations in the rat.	Propranolol	132-143	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	42-58
8279990-2	1993	Propranolol (a beta-adrenergic antagonist) is a commonly used antihypertensive agent that is prescribed for long-term use.	Propranolol	0-11	amyloid beta precursor protein	Rattus norvegicus	13-19
8408075-8	1993	The Cer-1-P phosphatase activity is enriched in a rat liver plasma membrane fraction and appears to be distinct from the phosphatase that hydrolyzes phosphatidic acid (PA), PA phosphohydrolase, as shown by the difference in sensitivity of Cer-1-P and PA hydrolysis to propranolol, detergent, and heat treatment.	Propranolol	268-279	cerberus 1, DAN family BMP antagonist	Rattus norvegicus	4-9
8411742-7	1993	The multivariate Cox model indicated that drug compliance in the propranolol group and high portal pressure in the sclerotherapy group were factors predictive of the first hemorrhage.	Propranolol	65-76	cytochrome c oxidase subunit 8A	Homo sapiens	17-20
7903565-2	1993	beta-Adrenoceptor blocking drugs inhibited thrombin-stimulated malondialdehyde formation according to their liposolubility in the rank order of potency: atenolol &lt; practolol &lt; oxprenolol &lt; metipranolol approximately alprenolol approximately propranolol.	Propranolol	250-261	coagulation factor II	Rattus norvegicus	43-51
8265999-7	1993	Only minor effects on ANF extraction were observed after reduction of the blood flow with propranolol.	Propranolol	90-101	natriuretic peptide A	Homo sapiens	22-25
8277227-7	1993	The initial stimulation of insulin secretion provoked by 10 nmol adrenaline/l was abolished when islets were incubated in the presence of the beta-antagonist, propranolol (1 mumol/l), consistent with activation of beta-adrenoceptors.	Propranolol	159-170	insulin	Homo sapiens	27-34
8101796-7	1993	After blocking beta 2-receptors with propranolol, we observed a prevention of the beta 2-agonist effects on both O2- release and bacterial killing.	Propranolol	37-48	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	15-21
8213198-5	1993	Propranolol, causing a 20% reduction in heart rate, had no effect on either flow during the actual test, but induced a rise in GBF after the ischaemic period.	Propranolol	0-11	Kruppel like factor 6	Homo sapiens	127-130
8101796-7	1993	After blocking beta 2-receptors with propranolol, we observed a prevention of the beta 2-agonist effects on both O2- release and bacterial killing.	Propranolol	37-48	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	82-88
8413845-3	1993	The effect of the alpha 2-adrenoceptor agonist clonidine, the antagonists prazosin (alpha 1 selective) and yohimbine (alpha 2 selective) and the beta-adrenoceptor antagonist propranolol were all shown to modulate the evoked release of NPY.	Propranolol	174-185	neuropeptide Y	Rattus norvegicus	235-238
8335198-6	1993	Atropine, hexamethonium, ICS205-930, BRL43694, phentolamine, yohimbine, and propranolol significantly inhibited motilin-induced contractions.	Propranolol	76-87	motilin	Canis lupus familiaris	112-119
8413845-6	1993	Propranolol had the most profound effect on release of NPY, causing a significant decrease in basal release and a large decrease in the potassium-evoked release of NPY from slices of hypothalamus.	Propranolol	0-11	neuropeptide Y	Rattus norvegicus	55-58
8413845-6	1993	Propranolol had the most profound effect on release of NPY, causing a significant decrease in basal release and a large decrease in the potassium-evoked release of NPY from slices of hypothalamus.	Propranolol	0-11	neuropeptide Y	Rattus norvegicus	164-167
8391422-1	1993	The beta-adrenergic antagonist propranolol binds to serotonin (5HT) receptors (5HT1B &gt; 5HT1A &gt; 5HT2) in brain membranes.	Propranolol	31-42	5-hydroxytryptamine receptor 1B	Rattus norvegicus	79-84
8335105-3	1993	An enhancement of ET-1-stimulated Ins(1,4,5)P3 accumulation was also seen when the product of PLD activity was either diverted into phosphatidyl butanol in the presence of butanol, or phosphatidate phosphohydrolase (PPH) activity was inhibited by DL-propranolol.	Propranolol	247-261	endothelin 1	Homo sapiens	18-22
8335105-3	1993	An enhancement of ET-1-stimulated Ins(1,4,5)P3 accumulation was also seen when the product of PLD activity was either diverted into phosphatidyl butanol in the presence of butanol, or phosphatidate phosphohydrolase (PPH) activity was inhibited by DL-propranolol.	Propranolol	247-261	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	94-97
8346419-8	1993	The phosphatidic acid phosphatase (PAPase) inhibitor propranolol, inhibiting the generation of diacylglycerol (DAG) and further AA from phosphatidic acid (PA), could totally down-regulate the IFN-gamma-induced release of AA.	Propranolol	53-64	interferon gamma	Rattus norvegicus	192-201
8391422-1	1993	The beta-adrenergic antagonist propranolol binds to serotonin (5HT) receptors (5HT1B &gt; 5HT1A &gt; 5HT2) in brain membranes.	Propranolol	31-42	5-hydroxytryptamine receptor 1A	Rattus norvegicus	90-95
8396157-8	1993	In Fallot patients treated with the beta-antagonist propranolol, a significant increased beta-AR number compared with untreated Fallot patients was found.	Propranolol	52-63	adrenoceptor beta 1	Homo sapiens	89-96
8243716-6	1993	Propranolol in the same dose also blocked the stimulatory action of i. v. injected alpha-thrombin (50 NIH/kg) on heparin secretion from mast cells of subcutaneous connective tissue.	Propranolol	0-11	coagulation factor II	Rattus norvegicus	89-97
8361577-3	1993	These responses were antagonised by the 5-HT1A antagonists (-)-propranolol and (-)-pindolol.	Propranolol	59-74	5-hydroxytryptamine receptor 1A	Rattus norvegicus	40-46
8102503-6	1993	After propranolol administration ureteral occlusion increased renin release from 5 +/- 2 micrograms AI min-1 to 38 +/- 12 micrograms AI min-1 in six dogs.	Propranolol	6-17	renin	Canis lupus familiaris	62-67
8102926-18	1993	The affinities of the tested compounds at the propranolol-resistant (- )-[125I]-CYP binding site show similarities to their affinities at "atypical" beta-adrenoceptors in adipocytes and gastrointestinal tissues and at the cloned beta 3-adrenoceptor.	Propranolol	46-57	adrenoceptor beta 3	Rattus norvegicus	229-248
8392360-2	1993	A double-blind placebo-controlled study was conducted on the effects of oral terbutaline (beta 2-adrenoceptor agonist) and propranolol (beta 1 beta 2-adrenoceptor antagonist) on basal heat production of skeletal muscle, measured ex vivo by direct microcalorimetry.	Propranolol	123-134	adrenoceptor beta 2	Homo sapiens	143-162
8104518-2	1993	beta 1-Adrenolytic (atria) structure-activity correlations indicated that replacement of the 1-naphthyl moiety of propranolol by a 4-quinolyl- (10), 2-quinolyl- (24), or 2-pyrimidyl- (26) heterocyclic moiety resulted in a 10-16 fold reduction in activity.	Propranolol	114-125	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	0-6
8103195-4	1993	After treatment with propranolol, the positive chronotropic effect of angiotensin II was abolished.	Propranolol	21-32	angiotensinogen	Rattus norvegicus	70-84
8103195-6	1993	When aortic blood pressure was controlled and the beta-receptors were blocked by propranolol, angiotensin II caused a dose-dependent increase in dP/dtmax without affecting the left ventricular enddiastolic pressure.	Propranolol	81-92	angiotensinogen	Rattus norvegicus	94-108
8101966-1	1993	We previously reported that Asn312 of the beta 2-adrenergic receptor and Asn385 in the homologous position in the 5-hydroxytryptamine1A receptor are important for binding to a class of beta-adrenergic receptor antagonists including propranolol and alprenolol.	Propranolol	232-243	adrenoceptor beta 2	Homo sapiens	42-68
8098917-7	1993	In propranolol-infused rats, but not in those receiving atenolol or phentolamine, the TNF-induced decrease in whole body glucose uptake was partially prevented.	Propranolol	3-14	tumor necrosis factor-like	Rattus norvegicus	86-89
8098917-9	1993	Propranolol was also able to ameliorate the hepatic insulin resistance produced by TNF.	Propranolol	0-11	tumor necrosis factor-like	Rattus norvegicus	83-86
8482183-7	1993	Pretreatment with propranolol antagonized, whereas phentolamine did not affect, the suppressive effect of central neuropeptide Y.	Propranolol	18-29	neuropeptide Y	Rattus norvegicus	114-128
8099803-0	1993	Receptor occupancy in lumbar CSF as a measure of the antagonist activity of atenolol, metoprolol and propranolol in the CNS.	Propranolol	101-112	colony stimulating factor 2	Rattus norvegicus	29-32
8099803-2	1993	The antagonist activity of atenolol, metoprolol and propranolol in the CNS was estimated by determining the extent to which the drugs occupy animal beta 1- and beta 2-receptors in CSF ex vivo at the time of lumbar puncture.	Propranolol	52-63	colony stimulating factor 2	Rattus norvegicus	180-183
8099803-14	1993	Although propranolol concentrations in CSF were only 1/20-1/40 of those in plasma, the receptor occupancy of propranolol in CSF was similar to that in plasma.	Propranolol	9-20	colony stimulating factor 2	Rattus norvegicus	39-42
8099803-14	1993	Although propranolol concentrations in CSF were only 1/20-1/40 of those in plasma, the receptor occupancy of propranolol in CSF was similar to that in plasma.	Propranolol	109-120	colony stimulating factor 2	Rattus norvegicus	124-127
8494173-3	1993	Drug displacement of Nile Red from alpha 1-acid glycoprotein was achieved with both D,L-propranolol and flufenamic acid, showing that the binding site is less electrostatic and more hydrophobic in nature.	Propranolol	84-99	alpha-1-acid glycoprotein	Bos taurus	35-60
7686438-5	1993	The effect on CD23 expression of salbutamol and fenoterol, but not of IL-4, was blocked in the presence of D,L-propranolol (1 microM) or butoxamine (1 microM).	Propranolol	107-122	Fc epsilon receptor II	Homo sapiens	14-18
8443869-1	1993	We determined whether a 3-minute period of intense cardiac sympathetic stimulation, which is known to release neuropeptide Y (NPY), elicits a sustained poststimulatory coronary vasoconstriction in anesthetized dogs that had received propranolol.	Propranolol	233-244	neuropeptide Y	Canis lupus familiaris	110-124
8443869-1	1993	We determined whether a 3-minute period of intense cardiac sympathetic stimulation, which is known to release neuropeptide Y (NPY), elicits a sustained poststimulatory coronary vasoconstriction in anesthetized dogs that had received propranolol.	Propranolol	233-244	neuropeptide Y	Canis lupus familiaris	126-129
7682614-6	1993	Spiperone, propranolol and pindolol (mixed 5-HT1A and 5-HT1B antagonists) effectively reversed both the tail-flick facilitation and the antagonistic effect on morphine sulfate-induced antinociception produced by 8-OH-DPAT and 5-CT.	Propranolol	11-22	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	43-49
7682614-6	1993	Spiperone, propranolol and pindolol (mixed 5-HT1A and 5-HT1B antagonists) effectively reversed both the tail-flick facilitation and the antagonistic effect on morphine sulfate-induced antinociception produced by 8-OH-DPAT and 5-CT.	Propranolol	11-22	5-hydroxytryptamine (serotonin) receptor 1B	Mus musculus	54-60
8474022-6	1993	Other putative human CYP1A xenobiotic substrates and inhibitors, including caffeine, 5- and 8-methoxypsoralen, nifedipine, paraxanthine, propranolol and theophylline similarly inhibited CYP1A1- and 1A2-catalyzed phenacetin O-deethylation and the high-affinity human liver phenacetin O-deethylase.	Propranolol	137-148	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	186-192
7681493-1	1993	The possibility that D-myo-inositol-1,2,6-triphosphate (PP56), which has shown some specificity for antagonism of neuropeptide Y (NPY) in vitro, may antagonize responses to sympathetic nerve stimulation was investigated in canine blood-perfused gracilis muscle in situ after pretreatment with irreversible alpha-adrenoceptor blockade by phenoxybenzamine and beta-adrenoceptor blockade by propranolol.	Propranolol	388-399	neuropeptide Y	Canis lupus familiaris	130-133
8472759-4	1993	The effect of intrahippocampal 8-OH-DPAT (10 micrograms/side) on working memory was blocked by the 5-HT1A receptor antagonist, (-)-propranolol, at 5 mg/kg i.p.	Propranolol	127-142	5-hydroxytryptamine receptor 1A	Rattus norvegicus	99-105
8452524-1	1993	In an inositol-depleted 1321 N1 astrocytoma cell line, propranolol at 0.5 mM concentration and carbachol in the presence of Li+ induce a large increase (30-60-fold) in the amount of CMP-phosphatidate, the lipid substrate of PtdIns synthase.	Propranolol	55-66	CDP-diacylglycerol--inositol 3-phosphatidyltransferase	Homo sapiens	224-239
8386213-6	1993	The suppressive effects of 8-OH-DPAT and DOI on CRH-stimulated ACTH release were antagonized by (-)propranolol, a beta-adrenergic receptor antagonist which binds the 5-HT1A receptor with elevated affinity, and ketanserin, a 5-HT2 receptor antagonist respectively.	Propranolol	96-110	corticotropin releasing hormone	Rattus norvegicus	48-51
8095694-3	1993	Furthermore, beta-adrenergic antagonists such as propranolol and pindolol, which have been reported to be partial agonists or antagonists at the 5-HT1B receptors in other systems, were found to be full agonists.	Propranolol	49-60	5-hydroxytryptamine receptor 1B	Rattus norvegicus	145-151
8316397-0	1993	Comparison of the potentiating effect of pyridostigmine, arginine and propranolol on the GHRH-induced GH release in short children.	Propranolol	70-81	growth hormone releasing hormone	Homo sapiens	89-93
8095722-4	1993	Even though TRH-induced tremors were decreased significantly only by propranolol and high doses of arotinolol, all drugs had a tendency to reduce the tremor.	Propranolol	69-80	thyrotropin releasing hormone	Mus musculus	12-15
8440692-4	1993	Both fMLP-induced PAF production and the activation of lyso-PAF:acetyl-CoA acetyltransferase were diminished by propranolol.	Propranolol	112-123	formyl peptide receptor 1	Homo sapiens	5-9
8381412-3	1993	PKC activation by either 12-O-tetradecanoylphorbol-13-acetate (TPA) or by alpha-adrenoreceptor (phenylephrine plus propranolol) stimulation results in phosphorylation of the same two proteins to similar extents.	Propranolol	115-126	protein kinase C, gamma	Rattus norvegicus	0-3
8383904-7	1993	Propranolol induced a fall of alpha-MSH-LI between 30 and 60 min (p &lt; 0.001), followed by a return to preinfusion concentrations beginning at 75 min, and completely prevented the stimulatory effect of isoproterenol.	Propranolol	0-11	proopiomelanocortin	Homo sapiens	30-39
8498970-11	1993	The vascular renin-angiotensin system is subject to the action of a number of drugs and chemicals, most notably specific inhibitors of the angiotensin-converging enzyme and drugs affecting kidney function (furosemide) and/or vessel tone (propranolol).	Propranolol	238-249	renin	Homo sapiens	13-18
8093875-4	1993	Intracolonic infusion of a mixture of tryptophan and phenylalanine (Trp+Phe; 100 mM; 200 ml/h) resulted in a significant release of PYY [integrated PYY release, 74.5 +/- 14.0 ng (0-120 min)/ml], which was not affected by iv atropine, hexamethonium, or propranolol treatment.	Propranolol	252-263	peptide YY	Canis lupus familiaris	132-135
7679155-9	1993	Propranolol (10 microM) was the only beta-adrenoceptor antagonist tested that inhibited [3H]thymidine incorporation, with effects of approximately 50 and 75% on basal and endothelin-1-mediated stimulation, respectively.	Propranolol	0-11	endothelin 1	Rattus norvegicus	171-183
8094392-8	1993	Conversely, either beta-adrenergic blockade (PRO), or alpha 2-adrenergic agonism (CLO), or the enhancement of muscarinic cholinergic tone (PD) significantly increased the GH response to GHRH (peaks: 43 +/- 4.6, 55.6 +/- 5.6 and 51.2 +/- 7, micrograms/L; PRO, CLO, and PD, respectively; P &lt; 0.01 vs. P study).	Propranolol	45-48	growth hormone releasing hormone	Homo sapiens	186-190
8094392-9	1993	After nocturnal DEX administration, both PRO and CLO, but not PD, were able to reverse the inhibitory effect of DEX on GHRH-elicited GH release (peaks: 39 +/- 5.5, 25.9 +/- 3.9 and 12.9 +/- 3.1, micrograms/L; DEX + PRO, DEX + CLO, and DEX + PD, respectively).	Propranolol	41-44	growth hormone releasing hormone	Homo sapiens	119-123
8381798-6	1993	The NE/hCG-evoked calcium signal was not abolished in the presence of the beta-adrenergic receptor antagonist propranolol and was not affected by removal of extracellular Ca2+.	Propranolol	110-121	chorionic gonadotropin subunit beta 5	Homo sapiens	7-10
8094756-4	1993	The maximal inhibitory effect of the chroman derivatives was not additive with that of 8-hydroxy-2-(di-n- propylamino)tetralin and could be competitively reduced by 5-HT1A antagonists such as (-)-propranolol and (+/-)-tertatolol.	Propranolol	192-207	5-hydroxytryptamine receptor 1A	Rattus norvegicus	165-171
8094228-4	1993	This effect was specific since a beta-adrenoceptor antagonist, D,L-propranolol, inhibited the IL-4-induced IgE production by these cells.	Propranolol	63-78	interleukin 4	Homo sapiens	94-98
8381505-8	1993	Propranolol (5 mg/kg, intraperitoneally), a lipophilic BAR antagonist, blocked the induction of NGF and bFGF mRNA mediated by either isoproterenol or clenbuterol, whereas nadolol (5 mg/kg, intraperitoneally), a BAR antagonist that does not cross the blood-brain barrier, blocked only the effect of isoproterenol.	Propranolol	0-11	nerve growth factor	Rattus norvegicus	96-99
8381505-8	1993	Propranolol (5 mg/kg, intraperitoneally), a lipophilic BAR antagonist, blocked the induction of NGF and bFGF mRNA mediated by either isoproterenol or clenbuterol, whereas nadolol (5 mg/kg, intraperitoneally), a BAR antagonist that does not cross the blood-brain barrier, blocked only the effect of isoproterenol.	Propranolol	0-11	fibroblast growth factor 2	Rattus norvegicus	104-108
8386288-4	1993	The GIP-induced (2 or 20 micrograms) insulin release was partly inhibited by propranolol pretreatment (0.5 mg/kg subcutaneously [SC]), and GLP-1-induced (2 or 20 micrograms) insulin release was partly inhibited by propranolol or metoprolol (35 mg/kg SC).	Propranolol	77-88	gastric inhibitory polypeptide	Rattus norvegicus	4-7
8386288-4	1993	The GIP-induced (2 or 20 micrograms) insulin release was partly inhibited by propranolol pretreatment (0.5 mg/kg subcutaneously [SC]), and GLP-1-induced (2 or 20 micrograms) insulin release was partly inhibited by propranolol or metoprolol (35 mg/kg SC).	Propranolol	214-225	gastric inhibitory polypeptide	Rattus norvegicus	4-7
8386288-4	1993	The GIP-induced (2 or 20 micrograms) insulin release was partly inhibited by propranolol pretreatment (0.5 mg/kg subcutaneously [SC]), and GLP-1-induced (2 or 20 micrograms) insulin release was partly inhibited by propranolol or metoprolol (35 mg/kg SC).	Propranolol	214-225	glucagon	Rattus norvegicus	139-144
8418897-6	1993	Enzyme activity was markedly inhibited by NaF, not influenced by excess glycerophosphate and slightly attenuated by propranolol, an inhibitor of PA phosphohydrolase in other systems.	Propranolol	116-127	C-X-C motif chemokine ligand 8	Homo sapiens	42-45
8361879-1	1993	An effect of nonselective beta-adrenergic blockade with propranolol on the blood plasma level of glucagon during insulin-induced hypoglycemia was studies in 20 control dogs and 20 alloxan diabetic dogs.	Propranolol	56-67	insulin	Canis lupus familiaris	113-120
8361879-3	1993	However, glucagon response to insulin-induced hypoglycemia following propranolol administration was increased.	Propranolol	69-80	insulin	Canis lupus familiaris	30-37
8424804-0	1993	Influence of human recombinant interleukin-1 beta on the enantioselective disposition of propranolol in rats.	Propranolol	89-100	interleukin 1 beta	Homo sapiens	31-49
8424804-2	1993	administration of 10 micrograms/kg recombinant human interleukin-1 beta (rhIL-1 beta), a putative mediator of inflammation, on the pharmacokinetics and metabolism of the propranolol enantiomers was studied in rats aged 3, 12 and 24 months.	Propranolol	170-181	interleukin 1 beta	Homo sapiens	53-71
8424804-7	1993	The enantioselective influence of IL-1 beta treatment on the pharmacokinetics of propranolol was also present in 12- and 24-month-old rats, although somewhat less pronounced in the latter group.	Propranolol	81-92	interleukin 1 beta	Rattus norvegicus	34-43
8424804-8	1993	Our results show an enantioselective influence of IL-1 beta treatment on the pharmacokinetics of propranolol in the rat, favouring the (R)-enantiomer.	Propranolol	97-108	interleukin 1 beta	Rattus norvegicus	50-59
8316397-5	1993	Our results confirm that pyridostigmine and arginine have a striking potentiating effect on the GHRH-induced GH rise in children and show that the tests with GHRH + PD and GH + H + ARG are ore reliable than that with GHRH + PROP to explore the secretory capacity of somatotroph cells.	Propranolol	224-228	growth hormone releasing hormone	Homo sapiens	96-100
8094272-7	1993	In addition to this study, the alpha 1-, alpha 2-, beta 1-, beta 2-, and beta 3-agonists norepinephrine and epinephrine were infused with simultaneous infusion of the beta 1- and beta 2-blocker propranolol.	Propranolol	194-205	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	167-185
7914713-8	1993	It is concluded that obsidan-induced changes in lymphocytic beta 2-adrenoreceptors correlate with alterations in the activity of renin-angiotensin-aldosterone system and myocardial hypertrophy dynamics.	Propranolol	21-28	renin	Homo sapiens	129-134
8287830-4	1993	On the other hand, after administration of 160 mg/day of propranolol, a specific blocker of beta-adrenergic receptors, to five hyperthyroid patients for twenty-eight days, plasma VWF:Ag levels returned to normal range, while T3, T4 levels remained high without significant alteration.	Propranolol	57-68	von Willebrand factor	Homo sapiens	179-182
8157045-1	1993	A double blind placebo-controlled study was conducted of the effects of oral propranolol (beta 1 beta 2-adrenoceptor antagonist) and terbutaline (beta 2-adrenoceptor agonist) on erythrocyte heat production, measured by direct microcalorimetry under static conditions at 37 degrees C and pH 7.4.	Propranolol	77-88	adrenoceptor beta 2	Homo sapiens	97-116
8423527-1	1993	Regio- and stereoselectivity of cytochrome P-450-mediated propranolol metabolism (4-, 5- and 7-hydroxylations and N-desisopropylation) was studied using 15 purified cytochrome P-450 species.	Propranolol	58-69	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	32-48
8423527-6	1993	Propranolol, with its multiple metabolic pathways and optical isomers, is an extremely interesting substrate for characterization of cytochrome P-450 species.	Propranolol	0-11	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	133-149
1438344-7	1992	Additionally, propranolol, a nonspecific beta-blocker, partially reversed the suppression of platelet production by L-thyroxine, lending credence to the assertion that the direct, beta 2-adrenergic receptor-mediated stimulation of the erythroid cell line by thyroxine reported to exist in vitro may also be important in vivo.	Propranolol	14-25	adrenergic receptor, beta 2	Mus musculus	180-206
19912901-7	1992	(+/-)-Cyanopindolol and (-)-propranolol are more than 100-fold selective for the rat 5-HT(1B) receptor over the rat 5-HT(1D) receptor, while mianserin is more than 100-fold selective for the rat 5-HT(1D) receptor.	Propranolol	24-39	5-hydroxytryptamine receptor 1B	Rattus norvegicus	85-92
19912901-7	1992	(+/-)-Cyanopindolol and (-)-propranolol are more than 100-fold selective for the rat 5-HT(1B) receptor over the rat 5-HT(1D) receptor, while mianserin is more than 100-fold selective for the rat 5-HT(1D) receptor.	Propranolol	24-39	5-hydroxytryptamine receptor 1D	Rattus norvegicus	116-123
19912901-7	1992	(+/-)-Cyanopindolol and (-)-propranolol are more than 100-fold selective for the rat 5-HT(1B) receptor over the rat 5-HT(1D) receptor, while mianserin is more than 100-fold selective for the rat 5-HT(1D) receptor.	Propranolol	24-39	5-hydroxytryptamine receptor 1D	Rattus norvegicus	195-202
1432690-3	1992	In contrast, pretreatment with various doses of metergoline (5-HT1/5-HT2 antagonist), propranolol (beta adrenoceptor antagonist that also has binding affinity for 5-HT1A, 5-HT1B and 5-HT1C sites), mesulergine and mianserin (5-HT1C/5-HT2 antagonists) attenuated m-CPP-induced increases in plasma prolactin.	Propranolol	86-97	5-hydroxytryptamine receptor 1A	Rattus norvegicus	163-169
1363256-2	1992	Beta-adrenoceptor blocking (BAB) drugs inhibited thrombin-stimulated TXB2 formation in the following rank order of potency: metipranolol approximately alprenolol approximately propranolol &gt; oxprenolol &gt; practolol.	Propranolol	176-187	coagulation factor II	Rattus norvegicus	49-57
1432685-5	1992	Reduction of prepulse inhibition by 8-OHDPAT was antagonized by (-)propranolol, a 5-HT1a receptor antagonist, and partially by haloperidol, a dopamine D2 receptor antagonist, but not by ketanserin or methysergide, 5-HT2 receptor antagonists.	Propranolol	64-78	5-hydroxytryptamine receptor 1A	Rattus norvegicus	82-88
1535370-11	1992	However, phosphatidic acid-induced TNF-alpha production was strongly inhibited by the presence of propranolol, an inhibitor of phosphatidic acid phosphohydrolase.	Propranolol	98-109	tumor necrosis factor	Homo sapiens	35-44
1535370-12	1992	Moreover, in cells responding to phorbol myristate acetate, a compound that triggers activation of phospholipase D, TNF-alpha synthesis was also inhibited by propranolol.	Propranolol	158-169	tumor necrosis factor	Homo sapiens	116-125
8385523-6	1993	The nonselective beta-blocker propranolol and the beta 1 selective blocker atenolol attenuated losartan-induced renin release approximately 70 and 80% respectively without altering blood pressure.	Propranolol	30-41	renin	Rattus norvegicus	112-117
1360316-6	1992	The c-fos-li response to yohimbine was blocked by prior administration of the beta receptor antagonist, dl-propranolol, and to a lesser degree by the alpha-1 antagonist, prazosin.	Propranolol	104-118	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	4-9
1472140-4	1992	CCl4-induced loss of glycogen was equally moderated by metoprolol and propranolol.	Propranolol	70-81	C-C motif chemokine ligand 4	Rattus norvegicus	0-4
1472140-7	1992	Cytochrome P-450 decline in microsomal fraction was greater in metoprolol, than in propranolol treated healthy animals.	Propranolol	83-94	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	0-16
1472140-11	1992	The serious inhibition caused by CCl4 was moderated by metoprolol and with a better result by propranolol.	Propranolol	94-105	C-C motif chemokine ligand 4	Rattus norvegicus	33-37
1326583-6	1992	Propranolol, an inhibitor of diacylglycerol formation from phosphatidic acid, caused a prolonged transmembrane influx of Ca2+ and partially reversed the inhibitory effect of ethanol on FMLP-induced O2- production.	Propranolol	0-11	formyl peptide receptor 1	Homo sapiens	185-189
1331768-8	1992	The beta-adrenergic blocking agent propranolol inhibited the stimulatory effect of isoproterenol on PLMT activity in control and diabetic adipocytes.	Propranolol	35-46	phosphatidylethanolamine N-methyltransferase	Rattus norvegicus	100-104
1285669-4	1992	However, the histamine H1 receptor antagonist pyrilamine (1 x 10(-6) M) reduced the potentiation effect of propranolol.	Propranolol	107-118	histamine H1 receptor	Cavia porcellus	13-34
1331660-3	1992	Propranolol prevented NGF induction by isoproterenol, but not by 4-methylcatechol or serum.	Propranolol	0-11	nerve growth factor	Mus musculus	22-25
1446373-5	1992	The plasma protein binding of propranolol was also determined in relation to the plasma concentrations of AGP and albumin in all the experimental models.	Propranolol	30-41	orosomucoid 1	Rattus norvegicus	106-109
1446373-6	1992	Propranolol binding, expressed as bound to free ratio, showed a good correlation with the AGP concentration (r = 0.940; p &lt; 0.001), but not with the albumin concentration.	Propranolol	0-11	orosomucoid 1	Rattus norvegicus	90-93
1293974-0	1992	In vivo administration of propranolol decreases exaggerated amounts of serum TNF-alpha in patients with migraine without aura.	Propranolol	26-37	tumor necrosis factor	Homo sapiens	77-86
1293974-3	1992	In this study in 18 patients with MWA the in vivo effect of propranolol, a beta blocker agent, was evaluated with regard to the TNF serum levels before and after treatment.	Propranolol	60-71	tumor necrosis factor	Homo sapiens	128-131
1324618-7	1992	Propranolol had no effect in the SHR and WKY animals, but significantly reduced the renin response at 50 mmHg in the Sprague-Dawley rats.	Propranolol	0-11	renin	Rattus norvegicus	84-89
1366265-7	1992	The insulin sensitivity index was decreased by 34% during propranolol treatment and by 17% during pindolol treatment.	Propranolol	58-69	insulin	Homo sapiens	4-11
1366265-10	1992	A significant reduction of lipoprotein lipase activity in skeletal muscle during propranolol treatment probably explains the pronounced increase in serum triglyceride concentration during propranolol treatment despite lower free fatty acids and higher lipoprotein lipase activity in adipose tissue.	Propranolol	81-92	lipoprotein lipase	Homo sapiens	27-45
1366265-10	1992	A significant reduction of lipoprotein lipase activity in skeletal muscle during propranolol treatment probably explains the pronounced increase in serum triglyceride concentration during propranolol treatment despite lower free fatty acids and higher lipoprotein lipase activity in adipose tissue.	Propranolol	81-92	lipoprotein lipase	Homo sapiens	252-270
1366265-10	1992	A significant reduction of lipoprotein lipase activity in skeletal muscle during propranolol treatment probably explains the pronounced increase in serum triglyceride concentration during propranolol treatment despite lower free fatty acids and higher lipoprotein lipase activity in adipose tissue.	Propranolol	188-199	lipoprotein lipase	Homo sapiens	27-45
1320939-8	1992	The amphiphilic amines, sphingosine, chlorpromazine and propranolol, also decrease membrane-bound PAP-1 activity in the absence of fatty acids, but they do not alter, significantly, the activity of the cytosolic PAP-1.	Propranolol	56-67	regenerating family member 3 beta	Rattus norvegicus	98-103
1320939-8	1992	The amphiphilic amines, sphingosine, chlorpromazine and propranolol, also decrease membrane-bound PAP-1 activity in the absence of fatty acids, but they do not alter, significantly, the activity of the cytosolic PAP-1.	Propranolol	56-67	regenerating family member 3 beta	Rattus norvegicus	212-217
1320939-9	1992	In the presence of 1 mM oleate, sphingosine, chlorpromazine and propranolol decrease the translocation of PAP-1 from the cytosol to the membranes.	Propranolol	64-75	regenerating family member 3 beta	Rattus norvegicus	106-111
1359908-2	1992	Replacement of the naphthyloxy moiety of propranolol by a 1-[1-(4-n-butyl)-3-(4,4-dimethyloxazolin-2-yl)-1,4-dihydropyrid yl] group resulted in a significant decrease in cardiac beta 1-adrenergic antagonist activity which indicates that this group is not a suitable isostere for an aryloxy moiety.	Propranolol	41-52	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	178-184
1432690-3	1992	In contrast, pretreatment with various doses of metergoline (5-HT1/5-HT2 antagonist), propranolol (beta adrenoceptor antagonist that also has binding affinity for 5-HT1A, 5-HT1B and 5-HT1C sites), mesulergine and mianserin (5-HT1C/5-HT2 antagonists) attenuated m-CPP-induced increases in plasma prolactin.	Propranolol	86-97	5-hydroxytryptamine receptor 2C	Rattus norvegicus	182-188
1432690-3	1992	In contrast, pretreatment with various doses of metergoline (5-HT1/5-HT2 antagonist), propranolol (beta adrenoceptor antagonist that also has binding affinity for 5-HT1A, 5-HT1B and 5-HT1C sites), mesulergine and mianserin (5-HT1C/5-HT2 antagonists) attenuated m-CPP-induced increases in plasma prolactin.	Propranolol	86-97	5-hydroxytryptamine receptor 2C	Rattus norvegicus	224-230
1632813-7	1992	Propranolol and quinidine, specific inhibitors of debrisoquine 4-hydroxylase, markedly inhibited lidocaine 3-hydroxylase activity of Wistar male rats, but not N-deethylase activity.	Propranolol	0-11	cytochrome P450, family 2, subfamily d, polypeptide 4	Rattus norvegicus	50-76
1333579-3	1992	A somewhat weaker effect was observed in experiments with propranolol: embryos incubated in the propranolol-containing medium after the addition of dioctanoyl-cAMP were capable of one to two cleavage divisions.	Propranolol	96-107	cathelicidin antimicrobial peptide	Mus musculus	159-163
1363893-8	1992	Besides alpha-adrenergic and cholinergic receptor blockers the beta-adrenergic blocker propranolol was also effective in preventing the antiamnesic action of the BNP.	Propranolol	87-98	natriuretic peptide B	Rattus norvegicus	162-165
1533667-5	1992	Contractions induced by 8-hydroxy-2-(di-n-propylamino)-tetralin or alpha-methylserotonin maleate were attenuated by pretreatment with S(-)propranolol (2.6 microM), a relatively selective 5-HT1A and 5-HT1B receptor antagonist, and ketanserin (0.3 microM), a selective 5-HT2 receptor antagonist, respectively.	Propranolol	138-149	5-hydroxytryptamine receptor 1A	Bos taurus	187-199
1534312-9	1992	The 95% confidence intervals showed that none of the drugs in this trial produced an effect equivalent to that previously reported between captopril and methyldopa in the Psychological General Well Being Index or between captopril and methyldopa or propranolol in Trail Making test B.	Propranolol	249-260	TNF superfamily member 10	Homo sapiens	264-269
1349041-3	1992	The ability of propranolol to modulate parathyroid hormone (PTH) and isoproterenol effects on adenylate cyclase activity and on alkaline phosphatase expression was studied in the osteoblast-like rat osteosarcoma cell line ROS 17/2.8.	Propranolol	15-26	parathyroid hormone	Rattus norvegicus	39-58
1533667-6	1992	Pretreatment with S(-)propranolol or ketanserin also attenuated serotonin-induced contraction, demonstrating that serotonin mediates contraction through both 5-HT1A and 5-HT2 receptors in bovine large coronary arteries.	Propranolol	18-33	5-hydroxytryptamine receptor 1A	Bos taurus	158-170
1315978-5	1992	The relaxing capacity of ET-1 was absent when the tissue was precontracted by potassium yet was resistant to pretreatments with tetrodotoxin, capsaicin, propranolol, indomethacin, NG-methyl-L-arginine or glibenclamide.	Propranolol	153-164	endothelin 1	Rattus norvegicus	25-29
1614460-3	1992	In three female patients with deletions of chromosome 18 and retarded bone age serum growth hormone was investigated after insulin induced hypoglycemia, after glucagon-propranolol and after stimulation with growth hormone releasing hormone.	Propranolol	168-179	growth hormone 1	Homo sapiens	85-99
1470566-9	1992	However, after additional pretreatment with propranolol the pancreatic vascular and metabolic responses to PYY were abolished.	Propranolol	44-55	peptide YY	Canis lupus familiaris	107-110
1598835-3	1992	THP, SPD, and THB, as well as propranolol, played a remarkable role in diminishing the MIS within 24 h and decreasing the rise of creatine kinase (CK) and aspartate aminotransferase (AST) in the serum within 4 h after the ligation of the coronary artery.	Propranolol	30-41	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	155-181
1566928-4	1992	Combined alpha- and beta-adrenergic blockade (phentolamine and propranolol infusion) prevented the TNF-alpha-induced increase in glucose Ra without influencing plasma glucagon or corticosterone levels.	Propranolol	63-74	tumor necrosis factor	Rattus norvegicus	99-108
1601068-0	1992	Propranolol reduces rat dopamine-beta-hydroxylase activity and catecholamine levels.	Propranolol	0-11	dopamine beta-hydroxylase	Rattus norvegicus	24-49
1628159-7	1992	Both effects were not additive, and could be prevented by 5-HT1B receptor antagonists such as propranolol and penbutolol.	Propranolol	94-105	5-hydroxytryptamine (serotonin) receptor 1B	Mus musculus	58-73
1350578-1	1992	We describe a case of carpal tunnel syndrome (CTS) in a hypertensive man on long term treatment with a beta-blocker, propranolol.	Propranolol	117-128	transthyretin	Homo sapiens	46-49
1640364-3	1992	In isolated hepatocytes, the intrinsic clearance of free drug increased three- to fourfold as albumin and alpha 1-acid glycoprotein (AAG) concentrations increased, suggesting that albumin and AAG facilitate the elimination of propranolol by hepatocytes.	Propranolol	226-237	orosomucoid 1	Rattus norvegicus	106-131
1640364-3	1992	In isolated hepatocytes, the intrinsic clearance of free drug increased three- to fourfold as albumin and alpha 1-acid glycoprotein (AAG) concentrations increased, suggesting that albumin and AAG facilitate the elimination of propranolol by hepatocytes.	Propranolol	226-237	orosomucoid 1	Rattus norvegicus	192-195
1640364-5	1992	With 40 g/L of albumin and 2 g/L of AAG in the perfusate, the free fraction of propranolol decreased to 0.031, but extraction remained high (E = 0.960).	Propranolol	79-90	orosomucoid 1	Rattus norvegicus	36-39
1640364-8	1992	These data indicate that propranolol extraction is sensitive to changes in binding at very low free fraction values and suggest a facilitation of propranolol clearance by albumin and AAG.	Propranolol	25-36	orosomucoid 1	Rattus norvegicus	183-186
1598835-3	1992	THP, SPD, and THB, as well as propranolol, played a remarkable role in diminishing the MIS within 24 h and decreasing the rise of creatine kinase (CK) and aspartate aminotransferase (AST) in the serum within 4 h after the ligation of the coronary artery.	Propranolol	30-41	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	183-186
1540217-4	1992	Further studies using purified debrisoquine 4-hydroxylase are required to identify a P450 isozyme(s) responsible for the metabolic activation of propranolol.	Propranolol	145-156	cytochrome P450, family 2, subfamily d, polypeptide 2	Rattus norvegicus	31-57
1531103-10	1992	Propranolol abolished the release of ANP by Iso but not that induced by stretching.	Propranolol	0-11	natriuretic peptide A	Rattus norvegicus	37-40
1575041-5	1992	The action of ANG II on the ESP was blocked by propranolol (beta-adrenergic antagonist).	Propranolol	47-58	angiotensinogen	Homo sapiens	14-20
1575041-5	1992	The action of ANG II on the ESP was blocked by propranolol (beta-adrenergic antagonist).	Propranolol	47-58	protein tyrosine phosphatase receptor type V, pseudogene	Homo sapiens	28-31
1444872-8	1992	Individual groups analysis showed significative reductions of SAP, DAP and HR in propranolol group.	Propranolol	81-92	SH2 domain containing 1A	Homo sapiens	62-65
1444872-8	1992	Individual groups analysis showed significative reductions of SAP, DAP and HR in propranolol group.	Propranolol	81-92	death associated protein	Homo sapiens	67-70
1542139-2	1992	Treatment with propranolol, a beta blocker, is not recommended since it may produce be an alpha agonist with the potential for further elevated blood pressure.	Propranolol	15-26	amyloid beta precursor protein	Homo sapiens	28-34
1364034-13	1992	The inhibitory action of PYY on 2-DG-stimulated secretion of gastric acid persisted after treatment with phentolamine (69 +/- 14%; p &lt; 0.05), but it was blocked by treatment with propranolol.	Propranolol	182-193	peptide YY	Homo sapiens	25-28
1596682-11	1992	In the presence of phentolamine and propranolol, the pressor and bradycardic responses to neurotensin were unaffected, whereas the tachycardia was abolished.	Propranolol	36-47	neurotensin	Rattus norvegicus	90-101
1541316-3	1992	Equivalent doses of the pure antagonists atenolol (beta 1) and propranolol (beta 1, beta 2) produced similar reductions in heart rate, systolic blood pressure, and cardiac index, and increases in stroke volume and total peripheral resistance, particularly during exercise.	Propranolol	63-74	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	76-90
1568034-2	1992	Pressor responses to angiotensin II and to phenylephrine were markedly decreased prior to treatment and were improved by administration of indomethacin, dextran, KCl, captopril, propranolol or pindolol.	Propranolol	178-189	angiotensinogen	Homo sapiens	21-35
1336615-4	1992	The lactoferrin-induced increase in Isc was not altered by amiloride, indomethacin, or propranolol but was abolished by diphenylamine-2-carboxylate or substitution of Cl with iodide in the medium.	Propranolol	87-98	lactotransferrin	Canis lupus familiaris	4-15
1354322-13	1992	Propranolol potentiated cocaine"s pressor effect through beta-2 independent mechanisms.	Propranolol	0-11	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	57-63
1365860-2	1992	Pretreatment with spiperone (5-HT1A/5-HT2/D2 antagonist), propranolol or CGP361A (beta-adrenoceptor antagonists that also have binding affinities for 5-HT1A and 5-HT1B sites) and MDL-72222 (5-HT3 antagonist) did not attenuate DOI-induced suppression of food intake.	Propranolol	58-69	5-hydroxytryptamine receptor 1A	Rattus norvegicus	150-156
1553429-0	1992	Effect of propranolol on growth hormone response to GH releasing hormone (GHRH 1-44) in the dog.	Propranolol	10-21	somatotropin	Canis lupus familiaris	25-39
1553429-0	1992	Effect of propranolol on growth hormone response to GH releasing hormone (GHRH 1-44) in the dog.	Propranolol	10-21	growth hormone releasing hormone	Canis lupus familiaris	52-72
1553429-0	1992	Effect of propranolol on growth hormone response to GH releasing hormone (GHRH 1-44) in the dog.	Propranolol	10-21	growth hormone releasing hormone	Canis lupus familiaris	74-78
1553429-5	1992	When GHRH was injected after propranolol the mean peak (59.1 +/- 14.7 ng ml-1) and secretory area (AUC: 2631.0 +/- 474.4 ng min ml-1) were greater than those observed after GHRH alone.	Propranolol	29-40	growth hormone releasing hormone	Canis lupus familiaris	5-9
1683743-3	1991	Salicylic acid, acetaminophen, propranolol, ethacrynic acid, and three H2-receptor antagonists all inhibited rat gastric ADH in vitro, indicating that several commonly used medications have the potential to enhance alcohol absorption.	Propranolol	31-42	alcohol dehydrogenase 1C (class I), gamma polypeptide	Rattus norvegicus	121-124
1836757-5	1991	Transient expression of this clone demonstrated high-affinity binding of [3H]5-HT with a pharmacological profile corresponding to that of the 5-HT1B subtype: 5-CT, 5-HT greater than propranolol greater than methysergide greater than rauwolscine greater than 8-OH-DPAT.	Propranolol	182-193	5-hydroxytryptamine receptor 1B	Rattus norvegicus	142-148
1724971-7	1991	Cd2+ added to a Ca(2+)-free Ringer type medium containing propranolol enhanced K+ permeability similar to that obtained with Ca2+.	Propranolol	58-69	CD2 molecule	Homo sapiens	0-3
1664503-8	1991	Pretreatment with the dopamine receptor agonist bromocriptine or the beta-adrenergic receptor antagonist propranolol inhibited the alpha-MSH response to HA or stress.	Propranolol	105-116	proopiomelanocortin	Rattus norvegicus	131-140
1784347-8	1991	The intravenous administration of the mixed 5-HT1A receptor/beta-adrenoceptor blocker (-)-propranolol (5 mg/kg) to fasted rats did not modify plasma glucose and catecholamine peak responses to insulin; however, at later times, insulin triggered hypoglycemic convulsions in (-)-propranolol- but not in saline-pretreated rats.	Propranolol	86-101	5-hydroxytryptamine receptor 1A	Rattus norvegicus	44-50
1951115-0	1991	Effect of propranolol (long-acting) on the circadian fluctuation of tissue-plasminogen activator and plasminogen activator inhibitor-1.	Propranolol	10-21	chromosome 20 open reading frame 181	Homo sapiens	68-96
1951115-0	1991	Effect of propranolol (long-acting) on the circadian fluctuation of tissue-plasminogen activator and plasminogen activator inhibitor-1.	Propranolol	10-21	serpin family E member 1	Homo sapiens	101-134
1659906-3	1991	Propranolol (150 microM) enhanced the production of O2- in response to the receptor agonists n-formyl-methionyl-leucyl-phenylalanine (FMLP, 292 +/- 94% of controls), platelet-activating factor (PAF, 932 +/- 215%) and leukotriene B4 (LTB4, 1305 +/- 475%).	Propranolol	0-11	formyl peptide receptor 1	Homo sapiens	134-138
1660516-4	1991	The effect of adrenaline on the expression of P450scc was abolished by the beta-blocker propranolol, while propranolol had no effect on ACTH-induced P450scc mRNA accumulation.	Propranolol	88-99	cholesterol side-chain cleavage enzyme, mitochondrial	Bos taurus	46-53
1686311-3	1991	The induction of IL-1 beta mRNA was blocked by intraperitoneal pretreatment with beta-blockers propranolol (0.1-1 mg/kg, but not 0.01 mg/kg) and pindolol (0.3 and 1 mg/kg).	Propranolol	95-106	interleukin 1 beta	Rattus norvegicus	17-26
1686311-6	1991	), propranolol, but neither prazosin nor yohimbine, significantly suppressed the methamphetamine-induced expression of IL-1 beta mRNA at a dose of 1 nmol/rat.	Propranolol	3-14	interleukin 1 beta	Rattus norvegicus	119-128
1806288-1	1991	Plasma protein binding of weakly basic drugs such as propranolol and quinidine was determined in rats with carbon tetrachloride (CCl4)-induced hepatic disease.	Propranolol	53-64	C-C motif chemokine ligand 4	Rattus norvegicus	129-133
1806288-2	1991	Free fractions of propranolol and quinidine in the plasma of rats at 24 h after CCl4-intoxication were decreased by 41 and 30%, respectively, compared to those of control rats.	Propranolol	18-29	C-C motif chemokine ligand 4	Rattus norvegicus	80-84
1806288-4	1991	Plasma concentration of AGP in CCl4-intoxicated rats was elevated 2.7-fold of that in control rats at 24 h after the CCl4 intoxication and reached a peak of 4.8-fold elevation at 48 h. A regression analysis revealed a high degree of positive correlation between ratios of bound to free fraction of propranolol and plasma concentrations of AGP.	Propranolol	298-309	orosomucoid 1	Rattus norvegicus	24-27
1806288-4	1991	Plasma concentration of AGP in CCl4-intoxicated rats was elevated 2.7-fold of that in control rats at 24 h after the CCl4 intoxication and reached a peak of 4.8-fold elevation at 48 h. A regression analysis revealed a high degree of positive correlation between ratios of bound to free fraction of propranolol and plasma concentrations of AGP.	Propranolol	298-309	C-C motif chemokine ligand 4	Rattus norvegicus	31-35
1761284-0	1991	Acute effect of propranolol on the growth hormone (GH) response to GH-releasing hormone in patients with hyperthyroidism.	Propranolol	16-27	growth hormone 1	Homo sapiens	35-49
1761284-0	1991	Acute effect of propranolol on the growth hormone (GH) response to GH-releasing hormone in patients with hyperthyroidism.	Propranolol	16-27	growth hormone 1	Homo sapiens	51-53
1761284-0	1991	Acute effect of propranolol on the growth hormone (GH) response to GH-releasing hormone in patients with hyperthyroidism.	Propranolol	16-27	growth hormone 1	Homo sapiens	67-69
1758576-9	1991	Two injections of the alpha 1-adrenoceptor blocker prazosin 45 and 90 min before sacrifice, alone or together with the beta-blocker propranolol, prevented the increase in plasma AVP found in SCGx rats 6 h after surgery, and the decrease in plasma AVP and the increase of NIL-AVP found 16 h after SCGx.	Propranolol	132-143	arginine vasopressin	Rattus norvegicus	178-181
1659260-3	1991	Aerosol administration of the beta antagonists, propranolol (beta 1 and beta 2), atenolol (beta 1), and butoxamine (beta 2) decreased dynamic compliance (Cdyn) and increased pulmonary resistance (RL) in the principal ponies during airway obstruction, but were without effect when the ponies were in clinical remission.	Propranolol	48-59	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	61-78
1659260-3	1991	Aerosol administration of the beta antagonists, propranolol (beta 1 and beta 2), atenolol (beta 1), and butoxamine (beta 2) decreased dynamic compliance (Cdyn) and increased pulmonary resistance (RL) in the principal ponies during airway obstruction, but were without effect when the ponies were in clinical remission.	Propranolol	48-59	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	61-67
1659260-3	1991	Aerosol administration of the beta antagonists, propranolol (beta 1 and beta 2), atenolol (beta 1), and butoxamine (beta 2) decreased dynamic compliance (Cdyn) and increased pulmonary resistance (RL) in the principal ponies during airway obstruction, but were without effect when the ponies were in clinical remission.	Propranolol	48-59	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	72-78
1686209-17	1991	When compared to the field-stimulated vas, the values of pKB for propranolol and IMA against isoprenaline were respectively 1.3 and 0.6 log units larger.	Propranolol	65-76	arginine vasopressin	Rattus norvegicus	38-41
1756444-8	1991	beta-Adrenoceptor stimulation caused a dose-dependent outflow of both active and inactive renin, an effect antagonized by propranolol.	Propranolol	122-133	renin	Homo sapiens	90-95
1744378-11	1991	Pretreatment with yohimbine caused a three to four-fold increase in plasma delta NPY-LI, which was slightly reduced both in the presence of isoprenaline (-39%) and propranolol (-27%).	Propranolol	164-175	pro-neuropeptide Y	Cavia porcellus	81-84
1653766-3	1991	Isoproterenol caused vasodilation and a dose-dependent active and inactive renin, angiotensin II, and norepinephrine outflow, an effect blunted by propranolol (10 micrograms/100 ml/min).	Propranolol	147-158	renin	Homo sapiens	75-80
1653766-3	1991	Isoproterenol caused vasodilation and a dose-dependent active and inactive renin, angiotensin II, and norepinephrine outflow, an effect blunted by propranolol (10 micrograms/100 ml/min).	Propranolol	147-158	angiotensinogen	Homo sapiens	82-96
1757729-7	1991	Insulin response to GIP was resistant to atropine (24210 +/- 9470 microU/10 min) and propranolol (26450 +/- 4930 mu/10 min).	Propranolol	85-96	gastric inhibitory polypeptide	Rattus norvegicus	20-23
1654511-7	1991	In the presence of the beta-adrenergic receptor antagonist propranolol, norepinephrine activated a background current with properties similar to those of the PKC-sensitive current.	Propranolol	59-70	protein kinase C, gamma	Rattus norvegicus	158-161
1834508-3	1991	The numbers of head weaves elicited in the streptozotocin-diabetic and control animals by the two drugs were suppressed by pre-treatment with propranolol (5-hydroxytryptamine 1A receptor antagonist) and methysergide (5-hydroxytryptamine 1 and 2 receptor antagonist), but not by ketanserin (5-hydroxytryptamine 2 receptor antagonist), confirming the involvement of the 5-HT1A receptor.	Propranolol	142-153	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	290-320
1839146-4	1991	Pretreatment with (-)-propranolol (1 microM), a mixed 5-HT1A/B receptor antagonist, blocked by 50% the inhibition of unit activity elicited by MDL 73005EF.	Propranolol	18-33	5-hydroxytryptamine receptor 1A	Rattus norvegicus	54-60
1723323-9	1991	Lap was significantly reduced by 15% by propranolol (P less than 0.005) at the lowest exercise intensity (55.6% VO2max), remained unchanged at 79.4% VO2max and was significantly enhanced by 16% during the recovery period following the run at 92% VO2max.	Propranolol	40-51	LAP	Homo sapiens	0-3
1650298-2	1991	Adult rat left ventricular myocytes bathed in 1 mM [Ca2+] (Ca0) and electrically stimulated at 0.2 Hz responded to alpha-adrenergic stimulation with 50 microM phenylephrine and 1 microM propranolol with an increase in twitch amplitude to 177.1 +/- 25.6% of control (mean +/- SEM).	Propranolol	186-197	carbonic anhydrase 2	Rattus norvegicus	52-55
1868676-0	1991	Increased suppression of exercise-induced increase in renin by propranolol in Chinese subjects.	Propranolol	63-74	renin	Homo sapiens	54-59
1868676-8	1991	The reduction in exercise heart rate and mean blood pressure produced by propranolol were well correlated to the reduction in exercise plasma renin activity in both populations.	Propranolol	73-84	renin	Homo sapiens	142-147
1834508-3	1991	The numbers of head weaves elicited in the streptozotocin-diabetic and control animals by the two drugs were suppressed by pre-treatment with propranolol (5-hydroxytryptamine 1A receptor antagonist) and methysergide (5-hydroxytryptamine 1 and 2 receptor antagonist), but not by ketanserin (5-hydroxytryptamine 2 receptor antagonist), confirming the involvement of the 5-HT1A receptor.	Propranolol	142-153	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	368-383
1717272-2	1991	This effect is stereoselectively inhibited by (-)-propranolol and is inhibited also by the beta 1-selective adrenergic antagonists, bisoprolol and metoprolol.	Propranolol	46-61	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	91-97
1856262-9	1991	Propranolol was given at a dose of 14 micrograms/kg, iv, 10 min before the injection of saline, GHRH (10 micrograms/kg), or GHRP (1 mg/kg).	Propranolol	0-11	somatoliberin	Macaca fascicularis	96-100
1864964-4	1991	Pretreatment of cells with various concentrations of propranolol enhanced (less than or equal to 200 microM) or inhibited (greater than 300 microM) PLD-induced production of PA (mass and radiolabel) in a manner that correlated with enhancement or inhibition of O2 consumption in PMN stimulated with 1 microM FMLP in the absence of cytochalasin B.	Propranolol	53-64	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	148-151
1864964-4	1991	Pretreatment of cells with various concentrations of propranolol enhanced (less than or equal to 200 microM) or inhibited (greater than 300 microM) PLD-induced production of PA (mass and radiolabel) in a manner that correlated with enhancement or inhibition of O2 consumption in PMN stimulated with 1 microM FMLP in the absence of cytochalasin B.	Propranolol	53-64	formyl peptide receptor 1	Homo sapiens	308-312
1856262-11	1991	However, propranolol pretreatment doubled the GH responses to both GHRH and GHRP compared with those to GHRH or GHRP alone 28 +/- 5 micrograms/L vs. 14 +/- 5 (P less than 0.05) and 54 +/- 2 vs. 25 +/- 6 micrograms/L (P less than 0.001), respectively].	Propranolol	9-20	somatoliberin	Macaca fascicularis	67-71
1864964-5	1991	The concentration-dependent effects of propranolol on FMLP-induced NADPH oxidase activation was confirmed by direct assay of the enzyme in subcellular fractions.	Propranolol	39-50	formyl peptide receptor 1	Homo sapiens	54-58
1864964-6	1991	In PA extracted from cells pretreated with 200 microM propranolol before stimulation with 1 microM FMLP, phospholipase A1 (PLA1)-digestion for 90 min, followed by quantitation of residual PA, showed that a minimum of 44% of PA in control (undigested) sample was diacyl-PA; alkylacyl-PA remained undigested by PLA1.	Propranolol	54-65	formyl peptide receptor 1	Homo sapiens	99-103
1856262-11	1991	However, propranolol pretreatment doubled the GH responses to both GHRH and GHRP compared with those to GHRH or GHRP alone 28 +/- 5 micrograms/L vs. 14 +/- 5 (P less than 0.05) and 54 +/- 2 vs. 25 +/- 6 micrograms/L (P less than 0.001), respectively].	Propranolol	9-20	growth hormone secretagogue receptor	Homo sapiens	76-80
1864964-6	1991	In PA extracted from cells pretreated with 200 microM propranolol before stimulation with 1 microM FMLP, phospholipase A1 (PLA1)-digestion for 90 min, followed by quantitation of residual PA, showed that a minimum of 44% of PA in control (undigested) sample was diacyl-PA; alkylacyl-PA remained undigested by PLA1.	Propranolol	54-65	lipase H	Homo sapiens	105-121
1864964-7	1991	Propranolol was also observed to have a concentration-dependent enhancement of mass of 1,2-DG formed in PMN stimulated with FMLP.	Propranolol	0-11	formyl peptide receptor 1	Homo sapiens	124-128
1864964-6	1991	In PA extracted from cells pretreated with 200 microM propranolol before stimulation with 1 microM FMLP, phospholipase A1 (PLA1)-digestion for 90 min, followed by quantitation of residual PA, showed that a minimum of 44% of PA in control (undigested) sample was diacyl-PA; alkylacyl-PA remained undigested by PLA1.	Propranolol	54-65	lipase H	Homo sapiens	123-127
1864964-6	1991	In PA extracted from cells pretreated with 200 microM propranolol before stimulation with 1 microM FMLP, phospholipase A1 (PLA1)-digestion for 90 min, followed by quantitation of residual PA, showed that a minimum of 44% of PA in control (undigested) sample was diacyl-PA; alkylacyl-PA remained undigested by PLA1.	Propranolol	54-65	lipase H	Homo sapiens	309-313
1680600-7	1991	Administration of propranolol during exercise produced a clear-cut additional increase in plasma NPY-Li as well as in noradrenaline and adrenaline.	Propranolol	18-29	neuropeptide Y	Homo sapiens	97-100
1718548-5	1991	The augmentation of NAT activity by lindane also caused significant reductions in pineal serotonin (5-HT) and 5-hydroxyindole acetic acid (5-HIAA); again, both these responses were blocked by propranolol treatment.	Propranolol	192-203	N-acetyltransferase 1	Rattus norvegicus	20-23
1680600-9	1991	The additional elevation in plasma NPY-Li and catecholamines after propranolol during exercise is probably due to increased nerve activity and/or decreased disposal.	Propranolol	67-78	neuropeptide Y	Homo sapiens	35-38
2059222-3	1991	Evidence is also presented that phagocytosis of C3b/bi and IgG-opsonized yeast particles and associated respiratory burst can take place independently of diglyceride formation and of the activity of this second messenger on protein kinase C. In fact: a) propranolol while completely inhibited the formation of diglyceride mass did not modify either the phagocytosis or respiratory burst; b) these two processes were insensitive to staurosporine.	Propranolol	254-265	endogenous retrovirus group K member 3	Homo sapiens	48-51
1680761-5	1991	The radio-immunological determination of plasma growth hormone showed increased concentrations of growth hormone in propranolol-treated rats (P less than 0.05), whereas hypothalamic somatostatin content was not significantly changed.	Propranolol	116-127	gonadotropin releasing hormone receptor	Rattus norvegicus	48-62
1680761-5	1991	The radio-immunological determination of plasma growth hormone showed increased concentrations of growth hormone in propranolol-treated rats (P less than 0.05), whereas hypothalamic somatostatin content was not significantly changed.	Propranolol	116-127	gonadotropin releasing hormone receptor	Rattus norvegicus	98-112
1779513-3	1991	A single dose of anapriline resulted in a significant reduction in SBP and MBP at rest and during dynamic exercise (p less than 0.05-0.001), in DBP at rest (p less than 0.05) and in an insignificant decrease in SBP, DBP, and MBP during isometric exercise and DBP during dynamic exercise.	Propranolol	17-27	selenium binding protein 1	Homo sapiens	67-70
1779513-3	1991	A single dose of anapriline resulted in a significant reduction in SBP and MBP at rest and during dynamic exercise (p less than 0.05-0.001), in DBP at rest (p less than 0.05) and in an insignificant decrease in SBP, DBP, and MBP during isometric exercise and DBP during dynamic exercise.	Propranolol	17-27	D-box binding PAR bZIP transcription factor	Homo sapiens	144-147
1779513-3	1991	A single dose of anapriline resulted in a significant reduction in SBP and MBP at rest and during dynamic exercise (p less than 0.05-0.001), in DBP at rest (p less than 0.05) and in an insignificant decrease in SBP, DBP, and MBP during isometric exercise and DBP during dynamic exercise.	Propranolol	17-27	selenium binding protein 1	Homo sapiens	211-214
1779513-3	1991	A single dose of anapriline resulted in a significant reduction in SBP and MBP at rest and during dynamic exercise (p less than 0.05-0.001), in DBP at rest (p less than 0.05) and in an insignificant decrease in SBP, DBP, and MBP during isometric exercise and DBP during dynamic exercise.	Propranolol	17-27	D-box binding PAR bZIP transcription factor	Homo sapiens	216-219
1779513-3	1991	A single dose of anapriline resulted in a significant reduction in SBP and MBP at rest and during dynamic exercise (p less than 0.05-0.001), in DBP at rest (p less than 0.05) and in an insignificant decrease in SBP, DBP, and MBP during isometric exercise and DBP during dynamic exercise.	Propranolol	17-27	D-box binding PAR bZIP transcription factor	Homo sapiens	216-219
1657319-2	1991	The current study examines the effects of lesions caused by 6-hydroxydopamine administration to neonatal rats, or of gestational exposure to propranolol, on the subsequent development of the ODC response to beta-adrenergic stimulation elicited by an acute intracisternal challenge with isoproterenol.	Propranolol	141-152	ornithine decarboxylase 1	Rattus norvegicus	191-194
1907839-0	1991	Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin.	Propranolol	36-47	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	56-73
1657319-5	1991	On the other hand, blockade of fetal beta-receptors by maternal propranolol infusions resulted in immediate postnatal attenuation of the ODC response in cerebral cortex, but not cerebellum.	Propranolol	64-75	ornithine decarboxylase 1	Rattus norvegicus	137-140
2033506-6	1991	Phenylephrine caused a small but significant secretion of mucin which was blocked partially by phentolamine and completely by propranolol.	Propranolol	126-137	solute carrier family 13 member 2	Rattus norvegicus	58-63
2066692-6	1991	These adrenergic antagonists did not modify serum prolactin or progesterone levels in intact or RU 486-treated rats, but serum prolactin levels in the prostaglandin F2 alpha-treated group were significantly reduced by treatment with propranolol, metoprolol or prazosin.	Propranolol	233-244	prolactin	Rattus norvegicus	127-136
19912807-4	1991	The induction of IL-1beta mRNA in these areas was suppressed by the beta-blocker propranolol (0.1 mg/kg, ip).	Propranolol	81-92	interleukin 1 beta	Rattus norvegicus	17-25
2033510-9	1991	We conclude that cocaine-induced coronary vasoconstriction elicited in the presence of DL-propranolol can be mediated through local adrenergic mechanisms involving beta receptor antagonism and activation of both alpha-1 and alpha-2 adrenoceptors.	Propranolol	87-101	adrenoceptor alpha 1D	Homo sapiens	212-219
1850243-1	1991	Relatively high levels of propranolol (170 microM) markedly attenuated the generation of 1,2 diacylglycerol in neutrophils stimulated with either FMLP plus cytochalasin B or with 20.0 mM NaF.	Propranolol	26-37	formyl peptide receptor 1	Homo sapiens	146-150
1672696-4	1991	The results demonstrated that epinephrine and terbutaline (a beta 2 agonist) significantly stimulated gastrin release above basal which could be blocked by the addition of propranolol (beta-adrenergic antagonist).	Propranolol	172-183	gastrin	Homo sapiens	102-109
1676680-5	1991	Assuming that all the beta-adrenoceptor antagonists tested had access to the developing fetal brain, the effect of dl-propranolol and sotalol on behavior could stem from central beta 2-adrenoceptor blockade.	Propranolol	115-129	adrenoceptor beta 2	Rattus norvegicus	178-197
1707670-1	1991	Previously it has been shown that the mitochondrial inner membrane anion channel is reversibly inhibited by matrix Mg2+, matrix H+ and cationic amphiphiles such as propranolol.	Propranolol	164-175	mucin 7, secreted	Homo sapiens	115-118
1707670-10	1991	It is suggested that modification of this latter site exerts an effect on the binding of Mg2+, H+ and propranolol by inducing a conformational change.	Propranolol	102-113	mucin 7, secreted	Homo sapiens	89-92
1850243-1	1991	Relatively high levels of propranolol (170 microM) markedly attenuated the generation of 1,2 diacylglycerol in neutrophils stimulated with either FMLP plus cytochalasin B or with 20.0 mM NaF.	Propranolol	26-37	C-X-C motif chemokine ligand 8	Homo sapiens	187-190
1850243-5	1991	However, propranolol induced a similar dose-dependent inhibition of O2- generation in neutrophils stimulated with either FMLP + cytochalasin B or with 20.0 mM NaF.	Propranolol	9-20	formyl peptide receptor 1	Homo sapiens	121-125
1850243-5	1991	However, propranolol induced a similar dose-dependent inhibition of O2- generation in neutrophils stimulated with either FMLP + cytochalasin B or with 20.0 mM NaF.	Propranolol	9-20	C-X-C motif chemokine ligand 8	Homo sapiens	159-162
1850243-3	1991	Although propranolol enhanced phosphatidic acid levels in neutrophils treated with FMLP alone, the drug had only a slight inhibitory influence on diglyceride generation in these cells.	Propranolol	9-20	formyl peptide receptor 1	Homo sapiens	83-87
1850243-4	1991	The effect of propranolol on enhancement of PA levels in neutrophils treated with FMLP alone strongly correlated with enhancement of FMLP-induced O2- generation.	Propranolol	14-25	formyl peptide receptor 1	Homo sapiens	82-86
2009081-0	1991	Impairment of debrisoquine 4-hydroxylase and related monooxygenase activities in the rat following treatment with propranolol.	Propranolol	114-125	cytochrome P450, family 2, subfamily d, polypeptide 2	Rattus norvegicus	14-40
2009081-5	1991	These results suggest the selective impairment of debrisoquine 4-hydroxylase by propranolol pretreatment.	Propranolol	80-91	cytochrome P450, family 2, subfamily d, polypeptide 2	Rattus norvegicus	50-76
1850243-4	1991	The effect of propranolol on enhancement of PA levels in neutrophils treated with FMLP alone strongly correlated with enhancement of FMLP-induced O2- generation.	Propranolol	14-25	formyl peptide receptor 1	Homo sapiens	133-137
1671724-3	1991	For example, propranolol is a nonselective beta-blocker with antagonist effects on both beta 1 and beta 2 receptors, atenolol is a selective beta 1-antagonist, and celiprolol is a selective beta 1-antagonist, partial beta 2-agonist.	Propranolol	13-24	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	88-94
1671724-3	1991	For example, propranolol is a nonselective beta-blocker with antagonist effects on both beta 1 and beta 2 receptors, atenolol is a selective beta 1-antagonist, and celiprolol is a selective beta 1-antagonist, partial beta 2-agonist.	Propranolol	13-24	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	99-105
1671724-3	1991	For example, propranolol is a nonselective beta-blocker with antagonist effects on both beta 1 and beta 2 receptors, atenolol is a selective beta 1-antagonist, and celiprolol is a selective beta 1-antagonist, partial beta 2-agonist.	Propranolol	13-24	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	217-223
1848410-4	1991	Administration of prazosin (500 micrograms/kg) and propranolol (400 micrograms/kg) to rats abolished phenylephrine (50 micrograms/kg)-induced increases in mean arterial pressure, hepatic portal pressure, and blood glucose concentration but did not prevent PAF (1 microgram/kg)-induced alterations in these parameters.	Propranolol	51-62	PCNA clamp associated factor	Rattus norvegicus	256-259
1671783-7	1991	After propranolol treatment, plasma CgA remained unaltered.	Propranolol	6-17	chromogranin A	Homo sapiens	36-39
2023113-5	1991	Beta-Adrenergic receptor activation was blocked by the infusion of dl-propranolol (17 micrograms kg-1 min-1).	Propranolol	67-81	CD59 molecule (CD59 blood group)	Homo sapiens	102-107
1845926-6	1991	Preinduction K+ changes were determined in patients given a single preoperative dose of propranolol (beta 1/beta 2-antagonist), atenolol (beta 1-antagonist), or no beta-blocker (control).	Propranolol	88-99	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	101-107
1845926-9	1991	The ability of propranolol but not atenolol to block this change suggests that the acute decrease in K+ levels was due to beta 2-adrenergic receptor stimulation.	Propranolol	15-26	adrenoceptor beta 2	Homo sapiens	122-148
1671406-7	1991	The beta-antagonist, propranolol, inhibited the [Ca++]i increase induced by epinephrine and salbutamol (a beta-2-agonist).	Propranolol	21-32	carbonic anhydrase 1	Homo sapiens	49-55
1671406-7	1991	The beta-antagonist, propranolol, inhibited the [Ca++]i increase induced by epinephrine and salbutamol (a beta-2-agonist).	Propranolol	21-32	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	106-112
1716879-7	1991	Propranolol and atropine, antagonists of isoproterenol and carbachol, respectively, completely inhibited not only amylase secretion and ornithine decarboxylase induction but also protein phosphorylation stimulated by the corresponding agonists.	Propranolol	0-11	ornithine decarboxylase 1	Rattus norvegicus	136-159
1670741-4	1991	Following propranolol and pindolol, resting acceleration fell by 4.5 and 2 m/sec2, respectively p less than 0.05.	Propranolol	10-21	fucosyltransferase 2	Homo sapiens	77-81
1676960-10	1991	Its effect on bPTH (1-34) may be related to beta-stimulation by PTH or to some other non-specific inhibitory effect of propranolol.	Propranolol	119-130	parathyroid hormone	Bos taurus	15-18
1712266-1	1991	We evaluated the degree of inhibition of angiotensin converting enzyme (ACE), principally by cilazapril, by assessing the blood pressure response to a continuous infusion of increasing doses of angiotensin I, and assessed the possible pharmacokinetic and pharmacodynamic interactions between cilazapril and propranolol in healthy volunteers and patients with mild to severe essential hypertension.	Propranolol	307-318	angiotensin I converting enzyme	Homo sapiens	41-70
1712266-1	1991	We evaluated the degree of inhibition of angiotensin converting enzyme (ACE), principally by cilazapril, by assessing the blood pressure response to a continuous infusion of increasing doses of angiotensin I, and assessed the possible pharmacokinetic and pharmacodynamic interactions between cilazapril and propranolol in healthy volunteers and patients with mild to severe essential hypertension.	Propranolol	307-318	angiotensin I converting enzyme	Homo sapiens	72-75
1855781-3	1991	The use of the inhibitors DL-propranolol and RO2-0683 with alpha-naphthylacetate as substrate (at 37 degrees C) was efficient for discriminating between the CHE1 U and CHE1 UF phenotypes.	Propranolol	26-40	apoptosis antagonizing transcription factor	Homo sapiens	157-161
1855781-3	1991	The use of the inhibitors DL-propranolol and RO2-0683 with alpha-naphthylacetate as substrate (at 37 degrees C) was efficient for discriminating between the CHE1 U and CHE1 UF phenotypes.	Propranolol	26-40	apoptosis antagonizing transcription factor	Homo sapiens	168-172
1725542-9	1991	When compared to placebo or beta 1-selective blockers, propranolol, a non-selective beta-adrenergic blocker without partial agonist activity, reduced ADP and adrenaline threshold values for ex vivo platelet aggregation in hypertensive subjects and impaired fibrinolytic activity in the normal volunteers as well as in the hypertensive groups by increasing ECLT and reducing t-PA.	Propranolol	55-66	plasminogen activator, tissue type	Homo sapiens	374-378
1820453-0	1991	Influence of ketamine and propranolol on plasma renin activity (PRA) in female rabbits and guinea pigs.	Propranolol	26-37	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	48-53
1820453-2	1991	Plasma renin activity was measured in non pregnant rabbits and guinea pigs under Ketamine-induced general anesthesia after pretreatment either with Propranolol or with a Placebo.	Propranolol	148-159	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	7-12
1820453-8	1991	In the same way, renin activity was significantly higher (P less than 0.001) in guinea pigs without Propranolol than in those who had received this drug.	Propranolol	100-111	renin	Cavia porcellus	17-22
1685253-6	1991	The present as well as previously reported results suggest that the anxiolytic effect of propranolol injected into the DPAG is due to increased release of 5-HT acting on post-synaptic 5-HT2 receptors, resultant from blockade of 5-HT1B autoreceptors that inhibit amine release from serotonergic nerve endings.	Propranolol	89-100	5-hydroxytryptamine receptor 1B	Rattus norvegicus	228-234
1669018-6	1991	Propranolol reduced both the density of lesions, from 0.32 to 0.06 lesions/mm2 (p &lt; 0.01), and the area fraction of lesions, from 9.8 x 10(-4) to 2.5 x 10(-4) lesion area/mm2 (p &lt; 0.01).	Propranolol	0-11	PNMA family member 2	Homo sapiens	75-78
1669018-6	1991	Propranolol reduced both the density of lesions, from 0.32 to 0.06 lesions/mm2 (p &lt; 0.01), and the area fraction of lesions, from 9.8 x 10(-4) to 2.5 x 10(-4) lesion area/mm2 (p &lt; 0.01).	Propranolol	0-11	PNMA family member 2	Homo sapiens	174-177
2176212-9	1990	It appears that most of the DG is formed through the action of PLD, since propranolol (which inhibits the conversion of PA to DG) and down-regulation of protein kinase C (which prevents activation of PLD by carbachol) both markedly inhibit DG production.	Propranolol	74-85	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	63-66
2260972-9	1990	The stimulatory effect by 10(-9) M HgCl2 in 10(-11) M ANG II-induced [Ca++]i increase was completely inhibited by propranolol.	Propranolol	114-125	angiotensinogen	Rattus norvegicus	54-60
2260972-10	1990	Moreover, 10(-4) M propranolol completely blocked the stimulatory effect of HgCl2 on ANG II-mediated IP3 production.	Propranolol	19-30	angiotensinogen	Rattus norvegicus	85-91
1980994-7	1990	When treated with the nonspecific beta-adrenoceptor blocker propranolol, the elevated plasma renin activity and atrial-specific granule number in rats on a low sodium intake were significantly less.	Propranolol	60-71	renin	Rattus norvegicus	93-98
1980994-9	1990	Conversely, propranolol treatment resulted in lower plasma ANP levels in rats with high sodium intake.	Propranolol	12-23	natriuretic peptide A	Rattus norvegicus	59-62
1980994-11	1990	The results suggest that dietary sodium intake is an important determinant of the response of atrial-specific granule number and plasma ANP levels following beta-adrenoceptor blockade with propranolol.	Propranolol	189-200	natriuretic peptide A	Rattus norvegicus	136-139
2148091-4	1990	Prior administration of a long-acting propranolol, 160 mg daily for 3 consecutive days, markedly elevated plasma ANP levels before, during and after exercise.	Propranolol	38-49	natriuretic peptide A	Homo sapiens	113-116
2148091-6	1990	When increments in plasma ANP concentrations during exercise in individual subjects were compared with those in Hct, there was a significant positive correlation between the two variables before and after propranolol administration.	Propranolol	205-216	natriuretic peptide A	Homo sapiens	26-29
1698583-8	1990	Adrenalin evokes high levels of IL-6, and this effect can be blocked by propranolol.	Propranolol	72-83	interleukin 6	Rattus norvegicus	32-36
2171909-13	1990	In contrast, a significant (P less than 0.01) dose-dependent reduction in the ACTH response to intra-ME IL-1 beta (30 ng) was observed in rats pretreated with either a nonselective alpha or beta adrenoreceptor antagonist (phentolamine, 2-40 micrograms or propranolol, 2-20 micrograms, respectively, into the ME).	Propranolol	255-266	interleukin 1 beta	Rattus norvegicus	104-113
2282930-6	1990	Analysis of individual patient responses revealed that propranolol prolonged peak pacing time and hence peak pacing heart rate (from 126 +/- 24 to 140 +/- 23 beats min-1, P less than 0.05) in five patients.	Propranolol	55-66	CD59 molecule (CD59 blood group)	Homo sapiens	164-169
1977390-7	1990	Propranolol reduces similarly the initial 4 hr-rise of ODC activity.	Propranolol	0-11	ornithine decarboxylase 1	Rattus norvegicus	55-58
2289290-1	1990	Some thermodynamic and structural aspects of propranolol-DPPC liposomes interaction were investigated by DSC and X-ray diffraction: the lamellar arrangement of the lipid matrix remains intact even at high concentrations of the drug (until 1:1 drug/lipid molar ratio).	Propranolol	45-56	desmocollin 3	Homo sapiens	105-108
1963201-3	1990	Exposing the same patients treated with obsidan to PES revealed more pronounced values and responsiveness of diastolic pressure in a subgroup of patients showing simultaneously a dramatic decrease in Mb levels, which is indicative of alpha-adrenoreceptor activation after beta 2-receptor blockade.	Propranolol	40-47	myoglobin	Homo sapiens	200-202
1762283-13	1991	In the group of patients treated with propranolol the values of EDF, LDF and ratio EDF/LDF were similar to those before treatment.	Propranolol	38-49	interleukin 5	Homo sapiens	64-67
1762283-13	1991	In the group of patients treated with propranolol the values of EDF, LDF and ratio EDF/LDF were similar to those before treatment.	Propranolol	38-49	interleukin 5	Homo sapiens	83-90
1976400-12	1990	Isoprenaline (0.2 mg kg-1) elicited hyperglycaemic and insulinotropic responses which were attenuated by propranolol (1.0 mg kg-1) and the selective beta 2-adrenoceptor antagonist ICI 118551 (1.0 mg kg-1), but not by the beta 1-selective antagonists atenolol (1.0 mg kg-1) and betaxolol (1.0 mg kg-1).	Propranolol	105-116	adrenoceptor beta 2	Rattus norvegicus	149-168
2103314-3	1990	Adrenaline infusions in man produce increases in both factor VIII and fibrinolysis and the rise in factor VIII is blocked by pretreatment with propranolol.	Propranolol	143-154	cytochrome c oxidase subunit 8A	Homo sapiens	61-65
2103314-3	1990	Adrenaline infusions in man produce increases in both factor VIII and fibrinolysis and the rise in factor VIII is blocked by pretreatment with propranolol.	Propranolol	143-154	cytochrome c oxidase subunit 8A	Homo sapiens	106-110
2103314-4	1990	Receptor blockade with propranolol also prevents the rise in factor VIII associated with hypoglycaemia to support the view that adrenaline is an important mediator under these circumstances.	Propranolol	23-34	cytochrome c oxidase subunit 8A	Homo sapiens	68-72
2169833-3	1990	We also studied the affinity of human lymphocyte beta 2-adrenoceptor for (+)-sotalol, (-)-sotalol, and (+/-)-propranolol.	Propranolol	103-120	adrenoceptor beta 2	Homo sapiens	49-68
2169833-14	1990	The affinity of the human lymphocyte beta 2-adrenoceptor was approximately 60-fold greater for (-)-sotalol (Ki, 108 +/- 12 nM) than for (+)-sotalol (Ki, 6,410 +/- 1,020 nM), and approximately 20,000-fold greater for (+/-)-propranolol (Ki, 0.33 +/- 0.08 nM) than for (+)-sotalol.	Propranolol	216-233	adrenoceptor beta 2	Homo sapiens	37-56
2104263-0	1990	Effect of propranolol on phosphate reabsorption by superficial nephron segments in response to parathyroid hormone in phosphate-deprived rats.	Propranolol	10-21	parathyroid hormone	Rattus norvegicus	95-114
2104263-2	1990	The decreased phosphaturic response to parathyroid hormone in rats fed a low phosphate diet for 1 day can be restored by propranolol infusion.	Propranolol	121-132	parathyroid hormone	Rattus norvegicus	39-58
2104263-3	1990	Free-flow micropuncture studies were performed to localize the nephron site of restoration of the phosphaturic effect of parathyroid hormone by propranolol in rats deprived of phosphate for one day.	Propranolol	144-155	parathyroid hormone	Rattus norvegicus	121-140
2104263-6	1990	We conclude that the restoration of the phosphaturic effect of parathyroid hormone by propranolol infusion in rats deprived of phosphate for 1 day is primarily due to decreased reabsorption of phosphate by superficial loop segments, most likely the pars recta segment of the proximal tubule.	Propranolol	86-97	parathyroid hormone	Rattus norvegicus	63-82
1977175-9	1990	It was suggested that the strongly inhibitory effects of propranolol and pindolol on male rat sex behavior may well be due to their 5-HT1A antagonistic binding properties rather than their beta-antagonistic properties.	Propranolol	57-68	5-hydroxytryptamine receptor 1A	Rattus norvegicus	132-138
1973420-13	1990	beta-Blockade by propranolol resulted in enhanced GH responses to GHRH, but did not prevent the attenuation of GH responses to the second GHRH injection (first, 1937 +/- 366 micrograms/L.min; second, 614 +/- 99).	Propranolol	17-28	growth hormone 1	Homo sapiens	50-52
1981665-12	1990	(-)Propranolol (5 mg/kg), a beta-blocker with a 5-HT1A antagonistic action, affected the 8-OH-DPAT-induced blood pressure elevation (37% reduction).	Propranolol	3-14	5-hydroxytryptamine receptor 1A	Rattus norvegicus	48-54
2228599-13	1990	Propranolol 60 mg bid was started.	Propranolol	0-11	BH3 interacting domain death agonist	Homo sapiens	18-21
1973196-5	1990	Beta-1 adrenoceptor blocking activity of YM-16151-1 was 2 times weaker than that of propranolol.	Propranolol	84-95	adrenoceptor beta 1	Rattus norvegicus	0-19
2168526-3	1990	Pretreatment with the beta-adrenergic antagonist propranolol reduced the stress-induced increase in the circulating levels of alpha-MSH, but had no effect on the basal plasma concentrations of this hormone or the stress-induced decrease in DOPAC/DA in the intermediate lobe.	Propranolol	49-60	proopiomelanocortin	Rattus norvegicus	126-135
2159347-6	1990	Other calcium antagonists such as diltiazem, nifedipine, nitrendipine or amphiphilic drugs such as phenothiazines and propranolol also enhanced HDL3 uptake by Hep G2 cells.	Propranolol	118-129	HDL3	Homo sapiens	144-148
2112814-5	1990	Propranolol was found significantly to inhibit beta 2 microglobulin production.	Propranolol	0-11	beta-2-microglobulin	Homo sapiens	47-67
2286747-4	1990	Biochemical markers indicated a delay in cellular development caused by propranolol: basal ornithine decarboxylase activity was elevated in the fetus and DNA was subnormal for the first week after birth.	Propranolol	72-83	ornithine decarboxylase 1	Rattus norvegicus	91-114
2390085-5	1990	Furthermore, the PPH inhibitor, propranolol, inhibited the formation of both [3H]alkyl-DG and [32P]PO4, while increasing alkyl-PA levels (containing both 3H and 32P).	Propranolol	32-43	enolase 1	Homo sapiens	17-20
2115711-14	1990	In conclusion, oral administration of propranolol is able to increase GH responsiveness to GHRH without changing the great individual variability.	Propranolol	38-49	growth hormone releasing hormone	Homo sapiens	91-95
2115711-15	1990	The response to a repeated GHRH stimulation is only partially restored by propranolol.	Propranolol	74-85	growth hormone releasing hormone	Homo sapiens	27-31
2167779-13	1990	Using the same dose schedules, propranolol completely blocked the isoprenaline-induced increases in plasma active renin secretion even though it had no effect on the basal active renin levels.	Propranolol	31-42	renin	Ovis aries	114-119
2167779-18	1990	Therefore, both a beta-adrenoceptor agonist (isoprenaline) and two beta-adrenoceptor antagonists (propranolol and atenolol) decreased plasma inactive renin concentration in conscious sheep.	Propranolol	98-109	renin	Ovis aries	150-155
2357863-1	1990	Because both quinidine and propranolol bind to the cytochrome P-450 responsible for the oxidation of debrisoquin, six healthy male subjects were studied to determine whether an interaction occurred between the two drugs and the pharmacodynamic consequences of that interaction.	Propranolol	27-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-67
1974548-8	1990	Propranolol blocked the inhibitory effect of epinephrine on insulin binding.	Propranolol	0-11	insulin	Sus scrofa	60-67
2172554-6	1990	Propranolol effectively blocked the cooperative effect of insulin on catecholamine stimulation of ODC activity, and markedly inhibited the stimulation of ODC by 10% serum.	Propranolol	0-11	ornithine decarboxylase 1	Rattus norvegicus	98-101
2172554-6	1990	Propranolol effectively blocked the cooperative effect of insulin on catecholamine stimulation of ODC activity, and markedly inhibited the stimulation of ODC by 10% serum.	Propranolol	0-11	ornithine decarboxylase 1	Rattus norvegicus	154-157
2328008-4	1990	In fact: 1) in neutrophils treated with propranolol, an inhibitor of phosphatidate phosphohydrolase, FMLP plus cytochalasin B induces a respiratory burst associated with a stimulation of phospholipase D, formation of phosphatidic acid and complete inhibition of that of diacylglycerol.	Propranolol	40-51	formyl peptide receptor 1	Homo sapiens	101-105
2328008-5	1990	2) The respiratory burst by FMLP plus cytochalasin B lasts a few minutes and may be restimulated by propranolol which induces an accumulation of phosphatidic acid.	Propranolol	100-111	formyl peptide receptor 1	Homo sapiens	28-32
2328305-3	1990	Oral propranolol doses of 40 mg BID were initiated on Day 3, titrated gradually to 80 mg TID by Day 10, and continued at 80 mg TID through Day 17.	Propranolol	5-16	BH3 interacting domain death agonist	Homo sapiens	32-35
2345041-4	1990	Propranolol concentrations greater than 80 microM had a negative effect on all movement variables, except VCL and ALHMEAN, which showed a slight, non-significant, initial increase.	Propranolol	0-11	vinculin	Homo sapiens	106-109
2345041-6	1990	The presence of 800 microM propranolol immobilized all sperm within 4 h. Caffeine at 1.7 and 5 mM, increased VCL and ALHMEAN.	Propranolol	27-38	vinculin	Homo sapiens	109-112
2322324-3	1990	This effect of propranolol is mainly due to an increase in LDL receptor number.	Propranolol	15-26	low density lipoprotein receptor	Homo sapiens	59-71
2190232-7	1990	Phentolamine had no effect on the cardiorenal actions of ET-1 whereas propranolol enhanced ET-1-induced changes in mean arterial blood pressure; mean arterial blood pressure increased 38 +/- 2% at 30 min during ET-1 + propranolol infusion (P less than 0.01 versus value with ET-1 alone).	Propranolol	70-81	endothelin 1	Rattus norvegicus	91-95
2190232-7	1990	Phentolamine had no effect on the cardiorenal actions of ET-1 whereas propranolol enhanced ET-1-induced changes in mean arterial blood pressure; mean arterial blood pressure increased 38 +/- 2% at 30 min during ET-1 + propranolol infusion (P less than 0.01 versus value with ET-1 alone).	Propranolol	70-81	endothelin 1	Rattus norvegicus	91-95
2190232-7	1990	Phentolamine had no effect on the cardiorenal actions of ET-1 whereas propranolol enhanced ET-1-induced changes in mean arterial blood pressure; mean arterial blood pressure increased 38 +/- 2% at 30 min during ET-1 + propranolol infusion (P less than 0.01 versus value with ET-1 alone).	Propranolol	70-81	endothelin 1	Rattus norvegicus	91-95
2322324-7	1990	Pretreatment of cultured fibroblasts with propranolol induced an increase in hydroxymethyl-glutaryl-coenzyme A reductase activity and a decrease in acyl-coenzyme A: cholesterol-O-acyltransferase (ACAT) activity.	Propranolol	42-53	sterol O-acyltransferase 1	Homo sapiens	196-200
2322324-8	1990	Propranolol inhibited the induction of ACAT activity by exogenous cholesterol.	Propranolol	0-11	sterol O-acyltransferase 1	Homo sapiens	39-43
2322324-9	1990	Preincubation of a cell-free extract with propranolol also induced inhibition of ACAT activity.	Propranolol	42-53	sterol O-acyltransferase 1	Homo sapiens	81-85
1969403-9	1990	The percentage of cells in which PCNA could be detected was higher in the norepinephrine and norepinephrine plus propranolol groups.	Propranolol	113-124	proliferating cell nuclear antigen	Rattus norvegicus	33-37
2307846-13	1990	Propranolol does not inhibit phosphoinositide-specific PLC and yet it causes almost complete inhibition of the total DG mass accumulation in C5a-stimulated neutrophils.	Propranolol	0-11	complement C5a receptor 1	Homo sapiens	141-144
2374086-0	1990	Propranolol blocks cocaine-induced potentiation of the contraction in the smooth muscle of the rat vas deferens.	Propranolol	0-11	arginine vasopressin	Rattus norvegicus	99-102
2307846-10	1990	Propranolol, a PA phosphohydrolase (PPH) inhibitor, decreases the formation of both [3H]alkyl-DG and [32P]PO4, although increasing alkyl-PA accumulation.	Propranolol	0-11	enolase 1	Homo sapiens	15-34
2307846-10	1990	Propranolol, a PA phosphohydrolase (PPH) inhibitor, decreases the formation of both [3H]alkyl-DG and [32P]PO4, although increasing alkyl-PA accumulation.	Propranolol	0-11	enolase 1	Homo sapiens	36-39
2374086-4	1990	The cocaine-induced enhancement of the methacholine contraction and its blockade by propranolol was observed in the dibenamine-treated vas deferens.	Propranolol	84-95	arginine vasopressin	Rattus norvegicus	135-138
2374086-6	1990	Together with the previous study demonstrating the calcium-antagonist action for propranolol, these results suggest that propranolol blocks the cocaine-induced enhancement by inhibiting the calcium influx through the potential-dependent calcium channel in the rat vas deferens.	Propranolol	121-132	arginine vasopressin	Rattus norvegicus	264-267
2216936-1	1990	The purpose of the study was to evaluate the effect of 6 weeks treatment with hydrochlorothiazide or propranolol on gastric acid and gastrin secretion in essential hypertension.	Propranolol	101-112	gastrin	Homo sapiens	133-140
2308263-8	1990	Thus, the higher rise in potassium concentration during exercise with propranolol could only be explained by adrenergic blockade at the beta-2 receptor site.	Propranolol	70-81	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	136-142
1968323-4	1990	The ratio of the preejection period (PEPc) to the left ventricular ejection time (LVETc), an indirect measure of left ventricular performance, tended to increase with atenolol and propranolol and remained unchanged with pindolol.	Propranolol	180-191	peptidase C	Homo sapiens	37-41
2137698-8	1990	The putative 5-HT1A autoreceptor antagonist spiperone reversed the cocaine-induced depression of firing rate in 64% of 5-HT neurons tested whereas receptor antagonists for dopamine D2 (haloperidol), 5-HT2 (ketanserin), gamma-aminobutyric acid (picrotoxin) and 5-HT1/beta-adrenergic (propranolol) were ineffective.	Propranolol	283-294	5-hydroxytryptamine receptor 1A	Rattus norvegicus	13-19
2339543-1	1990	The authors studied the effect of anaprilin monotherapy (dose: 160-200 mg/daily for 10 months) on the level of atherogenic apolipoproteins (apo A, apo B) and fractions of plasma cholesterol in 34 patients with ischemic heart disease, stable exertion angina pectoris (class 2-3).	Propranolol	34-43	apolipoprotein A1	Homo sapiens	140-152
2252306-4	1990	Antagonists at the 5-HT1B site include the drugs metitepin, metergoline, cyanopindolol, isamoltane, and propranolol but none of these drugs are selective for this receptor.	Propranolol	104-115	5-hydroxytryptamine receptor 1B	Rattus norvegicus	19-25
1689116-5	1990	Perfusion with 10(-6) M propranolol further decreased insulin and somatostatin output during SNS, when expressed as the total decrement beneath basal during stimulation.	Propranolol	24-35	somatostatin	Rattus norvegicus	66-78
2252308-7	1990	Rat 5-HT1B receptors recognize with high affinity a number of beta-adrenoceptor antagonists, such as SDZ 21-009, cyanopindolol, pindolol, propranolol and isamoltane.	Propranolol	138-149	5-hydroxytryptamine receptor 1B	Rattus norvegicus	4-10
2314485-2	1990	PAF caused a dose-dependent vasodilation of norepinephrine-contracted mesenteric vascular bed, which was sensitive to CV-3988, a PAF antagonist, but insensitive to tetrodotoxin, atropine, propranolol and indomethacin.	Propranolol	188-199	PCNA clamp associated factor	Rattus norvegicus	0-3
2275726-2	1990	It has been observed that subcutaneous administration of noradrenaline, dihydroergotoxine, isoprenaline, propranolol and adrenaline influence the amplitudes of ERG and VEP waves.	Propranolol	105-116	transcriptional regulator ERG	Oryctolagus cuniculus	160-163
2295247-4	1990	A 59-year-old man developed pneumonitis which showed all the characteristics of a drug-associated pneumonitis due to propranolol: BAL demonstrated a lymphocytosis, the variations of which closely correlated with a provocation test.	Propranolol	117-128	poly(ADP-ribose) polymerase family member 9	Homo sapiens	130-133
2295247-5	1990	The LIF appeared to be released by the patient"s peripheral blood lymphocytes when cultured with optimal doses of propranolol.	Propranolol	114-125	LIF interleukin 6 family cytokine	Homo sapiens	4-7
2295247-6	1990	Production of LIF by the patients" lymphocytes suggests the existence of a drug-specific cellular immune response in propranolol-associated pneumonitis.	Propranolol	117-128	LIF interleukin 6 family cytokine	Homo sapiens	14-17
2188847-0	1990	Insulin-induced increase in heart rate and its prevention by propranolol.	Propranolol	61-72	insulin	Homo sapiens	0-7
2188847-8	1990	After insulin administration, a rapid and statistically significant increase in heart rate was observed when the patients were pretreated with placebo; pretreatment with propranolol completely prevented this effect.	Propranolol	170-181	insulin	Homo sapiens	6-13
1980473-8	1990	As competitive beta 1-adrenoceptor antagonists, (-)-propranolol was over a 100 times more potent than (+)-propranolol.	Propranolol	48-63	adrenoceptor beta 1	Rattus norvegicus	15-34
1980473-8	1990	As competitive beta 1-adrenoceptor antagonists, (-)-propranolol was over a 100 times more potent than (+)-propranolol.	Propranolol	102-117	adrenoceptor beta 1	Rattus norvegicus	15-34
2153810-6	1990	After weaning, animals exposed to prenatal propranolol showed interference with basal activity of ornithine decarboxylase (an enzyme involved in transduction of neuronal and hormonal trophic stimuli) and its response to acute beta adrenergic challenge.	Propranolol	43-54	ornithine decarboxylase 1	Rattus norvegicus	98-121
2175824-1	1990	To determine the degree to which increased sympathetic activity contributes to the increase in renin secretion produced by a low sodium diet, the beta-adrenergic blocking drug propranolol or saline vehicle was injected through indwelling jugular cannulas in rats fed a normal diet and rats fed a low sodium diet for 9 days.	Propranolol	176-187	renin	Rattus norvegicus	95-100
33944911-3	2021	In anesthetized mice, while neuronal regulations are suppressed, PDE4 inhibition potentiates a beta-adrenoceptor-induced salivation, that is ablated by the beta-blocker Propranolol and is absent in homozygous DeltaF508-CFTR mice lacking functional CFTR.	Propranolol	169-180	cystic fibrosis transmembrane conductance regulator	Mus musculus	219-223
2287488-3	1990	This antiaversive effect of propranolol, which is similar to that of benzodiazepine anxiolytics, was prevented by microinjection into the same brain site of the 5-HT-2 receptor blocker ritanserin.	Propranolol	28-39	5-hydroxytryptamine receptor 2A	Homo sapiens	161-176
33944911-3	2021	In anesthetized mice, while neuronal regulations are suppressed, PDE4 inhibition potentiates a beta-adrenoceptor-induced salivation, that is ablated by the beta-blocker Propranolol and is absent in homozygous DeltaF508-CFTR mice lacking functional CFTR.	Propranolol	169-180	cystic fibrosis transmembrane conductance regulator	Mus musculus	248-252
33776033-6	2021	Propranolol inhibited migration, network formation, vascular endothelial growth factor A production, and vascular endothelial growth factor receptor 2 activation and down-regulated PI3K/AKT and mitogen-activated protein kinase signaling in hemangioma endothelial cells, but it increased ERK1/2 activity in hemangioma stem cells.	Propranolol	0-11	vascular endothelial growth factor A	Homo sapiens	52-88
33776033-6	2021	Propranolol inhibited migration, network formation, vascular endothelial growth factor A production, and vascular endothelial growth factor receptor 2 activation and down-regulated PI3K/AKT and mitogen-activated protein kinase signaling in hemangioma endothelial cells, but it increased ERK1/2 activity in hemangioma stem cells.	Propranolol	0-11	kinase insert domain receptor	Homo sapiens	105-150
33776033-6	2021	Propranolol inhibited migration, network formation, vascular endothelial growth factor A production, and vascular endothelial growth factor receptor 2 activation and down-regulated PI3K/AKT and mitogen-activated protein kinase signaling in hemangioma endothelial cells, but it increased ERK1/2 activity in hemangioma stem cells.	Propranolol	0-11	AKT serine/threonine kinase 1	Homo sapiens	186-189
33776033-6	2021	Propranolol inhibited migration, network formation, vascular endothelial growth factor A production, and vascular endothelial growth factor receptor 2 activation and down-regulated PI3K/AKT and mitogen-activated protein kinase signaling in hemangioma endothelial cells, but it increased ERK1/2 activity in hemangioma stem cells.	Propranolol	0-11	mitogen-activated protein kinase 3	Homo sapiens	287-293
33814413-6	2021	Propranolol significantly reduced the production of IL-2, IL-10 and IFN-gamma in PHA-stimulated Jurkat cells (p<0.05).	Propranolol	0-11	interleukin 2	Homo sapiens	52-56
33814413-6	2021	Propranolol significantly reduced the production of IL-2, IL-10 and IFN-gamma in PHA-stimulated Jurkat cells (p<0.05).	Propranolol	0-11	interleukin 10	Homo sapiens	58-63
33814413-6	2021	Propranolol significantly reduced the production of IL-2, IL-10 and IFN-gamma in PHA-stimulated Jurkat cells (p<0.05).	Propranolol	0-11	interferon gamma	Homo sapiens	68-77
31857968-1	2019	Purpose: Propranolol as a novel adjuvant, was used to evaluate the immunogenic effect of three doses of recombinant SAG-1 (rSAG-1) antigen of Toxoplasma gondii in BALB/c mice for finding the optimal dose, and was compared with efficacy of tachyzoite lysate antigen (TLA).	Propranolol	9-20	histocompatibility 2, T region locus 18	Mus musculus	266-269
31857968-6	2019	Results: The mice group that received propranolol adjuvant and 20 microg of r SAG-1 antigen per dose of injection showed significantly more IFN-gamma production, more proliferation of splenic lymphocytes and higher anti-TLA-specific IgG2a production (three main indexes for cell mediated immunity) in comparison with other groups.	Propranolol	38-49	interferon gamma	Mus musculus	140-149
31857968-6	2019	Results: The mice group that received propranolol adjuvant and 20 microg of r SAG-1 antigen per dose of injection showed significantly more IFN-gamma production, more proliferation of splenic lymphocytes and higher anti-TLA-specific IgG2a production (three main indexes for cell mediated immunity) in comparison with other groups.	Propranolol	38-49	histocompatibility 2, T region locus 18	Mus musculus	220-223
31857968-6	2019	Results: The mice group that received propranolol adjuvant and 20 microg of r SAG-1 antigen per dose of injection showed significantly more IFN-gamma production, more proliferation of splenic lymphocytes and higher anti-TLA-specific IgG2a production (three main indexes for cell mediated immunity) in comparison with other groups.	Propranolol	38-49	immunoglobulin heavy variable V1-9	Mus musculus	233-238
24763891-0	2014	Topical application of a new monoclonal antibody against fibroblast growth factor 10 (FGF 10) mitigates propranolol-induced psoriasis-like lesions in guinea pigs.	Propranolol	104-115	fibroblast growth factor 10	Cavia porcellus	57-84
24763891-0	2014	Topical application of a new monoclonal antibody against fibroblast growth factor 10 (FGF 10) mitigates propranolol-induced psoriasis-like lesions in guinea pigs.	Propranolol	104-115	fibroblast growth factor 10	Cavia porcellus	86-92
24763891-3	2014	The aim of this study is to investigate whether FGF10 blockage, a new monoclonal antibody against FGF10 we generated, could mitigate topical propranolol-induced psoriasis-like lesions in guinea pigs.	Propranolol	141-152	fibroblast growth factor 10	Cavia porcellus	48-53
24763891-3	2014	The aim of this study is to investigate whether FGF10 blockage, a new monoclonal antibody against FGF10 we generated, could mitigate topical propranolol-induced psoriasis-like lesions in guinea pigs.	Propranolol	141-152	fibroblast growth factor 10	Cavia porcellus	98-103
24763891-11	2014	CONCLUSIONS: The newly generated anti-FGF10 monoclonal antibody inhibited the proliferation of human keratinocytes in vitro and mitigated inflammation and pathogenic changes in propranolol-induced psoriasis-like lesions in animals.	Propranolol	177-188	fibroblast growth factor 10	Homo sapiens	38-43
34383343-1	2021	Retraction: "Propranolol suppresses HUVEC viability, migration, VEGF expression, and promotes apoptosis by downregulation of miR-4295", by Feng Zhao, Xiaoliang Yang, Guangqi Xu, Jianhai Bi, Renrong Lv, and Ran Huo, J Cell Biochem.	Propranolol	13-24	vascular endothelial growth factor A	Homo sapiens	64-68
34534638-0	2021	Micro-injection of propranolol within basolateral amygdala impaired fear and spatial memory and dysregulated evoked responses of CA1 neurons following foot shock stress in rats.	Propranolol	19-30	carbonic anhydrase 1	Rattus norvegicus	129-132
34534638-10	2021	Propranolol significantly amplified the slope and amplitude of fEPSP in the CA1 area of the hippocampus only in stressed rats.	Propranolol	0-11	carbonic anhydrase 1	Rattus norvegicus	76-79
34662551-0	2021	Propranolol and low-dose isoproterenol ameliorate insulin resistance, enhance beta-arrestin2 signaling, and reduce cardiac remodeling in high-fructose, high-fat diet-fed mice: Comparative study with metformin.	Propranolol	0-11	arrestin, beta 2	Mus musculus	78-92
34662551-3	2021	The current study examined the effects of the beta-blocker propranolol and a low dose of the agonist isoproterenol (L-D-ISOPROT) on beta-arrestin2 signaling, insulin resistance, and cardiac remodeling in high-fructose, high-fat diet (HFrHFD)-fed mice.	Propranolol	59-70	arrestin, beta 2	Mus musculus	132-146
34581987-7	2021	Propranolol (a CYP2D mechanism-based inhibitor), versus vehicle pre-treatments, increased brain oxycodone, and decreased brain oxymorphone/oxycodone drug level ratios (an in vivo CYP2D activity phenotype in the brain) in males and females in estrus, but not in females in diestrus.	Propranolol	0-11	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	15-20
34581987-7	2021	Propranolol (a CYP2D mechanism-based inhibitor), versus vehicle pre-treatments, increased brain oxycodone, and decreased brain oxymorphone/oxycodone drug level ratios (an in vivo CYP2D activity phenotype in the brain) in males and females in estrus, but not in females in diestrus.	Propranolol	0-11	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	179-184
34546404-7	2021	A beta-AR blocker, propranolol (10 mM), was topically administered onto the V1 surface, and the drug effect on behavioral and neuronal activities was quantified by comparing pre-and post-drug administration.	Propranolol	19-30	amyloid beta precursor protein	Rattus norvegicus	0-6
34546404-7	2021	A beta-AR blocker, propranolol (10 mM), was topically administered onto the V1 surface, and the drug effect on behavioral and neuronal activities was quantified by comparing pre-and post-drug administration.	Propranolol	19-30	ferredoxin reductase	Rattus norvegicus	7-9
34858728-10	2021	Further study revealed that the expressions of IL-6 and JAK/STAT3 signaling pathways were upregulated by chronic stress in mice, and this upregulation could be inhibited by propranolol.	Propranolol	173-184	interleukin 6	Mus musculus	47-51
34858728-10	2021	Further study revealed that the expressions of IL-6 and JAK/STAT3 signaling pathways were upregulated by chronic stress in mice, and this upregulation could be inhibited by propranolol.	Propranolol	173-184	signal transducer and activator of transcription 3	Mus musculus	60-65
34858728-12	2021	Besides, propranolol inhibited the expression of IL-6 in supernatant of 4T1 cells induced by isoproterenol and reduced the proportion of inducible MDSCs in vitro.	Propranolol	9-20	interleukin 6	Mus musculus	49-53
34811362-8	2021	The NE-mediated NED was effectively inhibited by the Adrbeta2 blocker propranolol.	Propranolol	70-81	adrenoceptor alpha 2A	Homo sapiens	53-61
34970031-7	2022	Propranolol administration reduced insulin resistance, lipolysis, proteolysis, cardiac work, and bone loss resulting from burn-associated hypermetabolism.	Propranolol	0-11	insulin	Homo sapiens	35-42
34784367-8	2021	Levels of IL-1beta were higher in both male and female rats, and treatment with propranolol restored IL-1beta to basal levels.	Propranolol	80-91	interleukin 1 alpha	Rattus norvegicus	101-109
34784367-9	2021	We observed that Nef expression decreased staining of the tight junction protein claudin-5 in brain tissue while animals co-treated with propranolol restored claudin-5 expression.	Propranolol	137-148	claudin 5	Rattus norvegicus	158-167
34784367-10	2021	Lungs and SI of rats in the Nef group showed histological signs of damage including larger Peyer"s Patches, increased tissue thickness, and infiltration of immune cells; these findings were abrogated by propranolol co-treatment.	Propranolol	203-214	S100 calcium binding protein B	Homo sapiens	28-31
34766341-8	2022	Adrenaline had no effect in tumor-bearing beta1beta2-AR knockout mice, in which beta1- and beta2-ARs are lacking, but it reduced tumor growth when co-administered with propranolol suggesting that tumor beta2-ARs negatively regulate adrenaline antitumor activity.	Propranolol	168-179	ST3 beta-galactoside alpha-2,3-sialyltransferase 5	Mus musculus	202-207
34988191-0	2021	Propranolol inhibits stemness of hemangioma through Jagged1.	Propranolol	0-11	jagged canonical Notch ligand 1	Homo sapiens	52-59
34988191-3	2021	Propranolol is a non-selective beta2-AR blocker that was shown to inhibit demethylation adrenaline-induced Jagged1 expression.	Propranolol	0-11	adenosine A2a receptor	Homo sapiens	31-39
34988191-3	2021	Propranolol is a non-selective beta2-AR blocker that was shown to inhibit demethylation adrenaline-induced Jagged1 expression.	Propranolol	0-11	jagged canonical Notch ligand 1	Homo sapiens	107-114
34662551-10	2021	SIGNIFICANCE: Propranolol and L-D-ISOPROT like metformin can reduce insulin-resistance and cardiac remodeling in HFrHFD-fed mice, possibly by upregulating beta-arrestin2 signaling activity.	Propranolol	14-25	arrestin, beta 2	Mus musculus	155-169
34783996-5	2021	Higenamine induced phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2), which can be blocked by propranolol, an inhibitor of beta2-AR.	Propranolol	114-125	mitogen-activated protein kinase 1	Homo sapiens	38-79
34783996-5	2021	Higenamine induced phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2), which can be blocked by propranolol, an inhibitor of beta2-AR.	Propranolol	114-125	mitogen-activated protein kinase 3	Homo sapiens	81-87
34783996-5	2021	Higenamine induced phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2), which can be blocked by propranolol, an inhibitor of beta2-AR.	Propranolol	114-125	adenosine A2a receptor	Homo sapiens	143-151
34988191-12	2021	Conclusions: Jagged1/Notch signaling regulated the stemness of IH, and propranolol inhibited it through suppression of Notch signaling.	Propranolol	71-82	jagged canonical Notch ligand 1	Homo sapiens	13-20
34145181-7	2021	To evaluate the mechanisms mediating the effect of propranolol on the development of MNU-induced cancer, we investigated several parameters of the tumor microenvironment and found that propranolol increased gene expression of Casp3.	Propranolol	51-62	caspase 3	Rattus norvegicus	226-231
34145181-7	2021	To evaluate the mechanisms mediating the effect of propranolol on the development of MNU-induced cancer, we investigated several parameters of the tumor microenvironment and found that propranolol increased gene expression of Casp3.	Propranolol	185-196	caspase 3	Rattus norvegicus	226-231
34383343-1	2021	Retraction: "Propranolol suppresses HUVEC viability, migration, VEGF expression, and promotes apoptosis by downregulation of miR-4295", by Feng Zhao, Xiaoliang Yang, Guangqi Xu, Jianhai Bi, Renrong Lv, and Ran Huo, J Cell Biochem.	Propranolol	13-24	microRNA 4295	Homo sapiens	125-133
34383343-1	2021	Retraction: "Propranolol suppresses HUVEC viability, migration, VEGF expression, and promotes apoptosis by downregulation of miR-4295", by Feng Zhao, Xiaoliang Yang, Guangqi Xu, Jianhai Bi, Renrong Lv, and Ran Huo, J Cell Biochem.	Propranolol	13-24	RAN, member RAS oncogene family	Homo sapiens	206-209
34650198-8	2021	RESULTS: In propranolol-treated HMC-1s, the expressions of ADRB1 (beta1-AR) and ADRB2 (beta2-AR) were reduced by 70% and 60%, respectively, and that of cytokines and mediators were reduced.	Propranolol	12-23	adrenoceptor beta 1	Homo sapiens	59-64
34721024-7	2021	Western blotting showed that cotreatment significantly enhanced the expression of cleaved caspase-3 in HCT116 and MC38 cells compared with the propranolol or T1012G alone.	Propranolol	143-154	caspase 3	Homo sapiens	90-99
34721024-8	2021	In addition, propranolol or T1012G treatment induced a 35.06% +- 0.53% or 35.49% +- 2.68% reduction in VEGF secretion in HUVECs (p < 0.01/p < 0.01).	Propranolol	13-24	vascular endothelial growth factor A	Homo sapiens	103-107
34721024-9	2021	Cotreatment further inhibited VEGF secretion compared with the monotherapies (compared with propranolol treatment: 75.06% +- 1.50% decrease, compared with T1012G treatment: 74.91% +- 0.68%; p<0.001, p < 0.001).	Propranolol	92-103	vascular endothelial growth factor A	Homo sapiens	30-34
34309718-10	2021	Hisense CAS has advantages in evaluating the tumour volume before and after propranolol treatment.	Propranolol	76-87	BCAR1 scaffold protein, Cas family member	Homo sapiens	8-11
34697590-0	2021	Propranolol Suppresses Proliferation and Migration of HUVECs through Regulation of the miR-206/VEGFA Axis.	Propranolol	0-11	microRNA 206	Homo sapiens	87-94
34697590-0	2021	Propranolol Suppresses Proliferation and Migration of HUVECs through Regulation of the miR-206/VEGFA Axis.	Propranolol	0-11	vascular endothelial growth factor A	Homo sapiens	95-100
34697590-2	2021	In the present study, microRNA (miRNA/miR) sequencing analysis was performed to identify differentially expressed miRNAs in human umbilical vascular endothelial cells (HUVECs) treated with propranolol.	Propranolol	189-200	membrane associated ring-CH-type finger 8	Homo sapiens	38-41
34697590-8	2021	It was observed that propranolol induced the upregulation of miR-206 in HUVECs, which was caused by demethylation of the miR-206 promoter.	Propranolol	21-32	microRNA 206	Homo sapiens	61-68
34697590-8	2021	It was observed that propranolol induced the upregulation of miR-206 in HUVECs, which was caused by demethylation of the miR-206 promoter.	Propranolol	21-32	microRNA 206	Homo sapiens	121-128
34697590-9	2021	Moreover, propranolol significantly inhibited the proliferation of HUVECs by inducing apoptosis, while these phenomena were reversed by miR-206 antagomir.	Propranolol	10-21	microRNA 206	Homo sapiens	136-143
34697590-11	2021	In addition, propranolol notably inhibited the migration and induced G1 arrest of the HUVECs, whereas these results were eliminated by miR-206 antagomir.	Propranolol	13-24	microRNA 206	Homo sapiens	135-142
34697590-12	2021	Collectively, the findings of the present study demonstrated that propranolol may inhibit the proliferation and migration in HUVECs via modulating the miR-206/VEGFA axis.	Propranolol	66-77	microRNA 206	Homo sapiens	151-158
34697590-12	2021	Collectively, the findings of the present study demonstrated that propranolol may inhibit the proliferation and migration in HUVECs via modulating the miR-206/VEGFA axis.	Propranolol	66-77	vascular endothelial growth factor A	Homo sapiens	159-164
34650198-8	2021	RESULTS: In propranolol-treated HMC-1s, the expressions of ADRB1 (beta1-AR) and ADRB2 (beta2-AR) were reduced by 70% and 60%, respectively, and that of cytokines and mediators were reduced.	Propranolol	12-23	adrenoceptor beta 1	Homo sapiens	66-74
34650198-8	2021	RESULTS: In propranolol-treated HMC-1s, the expressions of ADRB1 (beta1-AR) and ADRB2 (beta2-AR) were reduced by 70% and 60%, respectively, and that of cytokines and mediators were reduced.	Propranolol	12-23	adrenoceptor beta 2	Homo sapiens	80-85
34650198-8	2021	RESULTS: In propranolol-treated HMC-1s, the expressions of ADRB1 (beta1-AR) and ADRB2 (beta2-AR) were reduced by 70% and 60%, respectively, and that of cytokines and mediators were reduced.	Propranolol	12-23	adenosine A2a receptor	Homo sapiens	87-95
34650198-10	2021	However, propranolol can work well in shRNA-ADRB1 or shRNA-ADRB2 transfected HMC-1s.	Propranolol	9-20	adrenoceptor beta 1	Homo sapiens	44-49
34650198-10	2021	However, propranolol can work well in shRNA-ADRB1 or shRNA-ADRB2 transfected HMC-1s.	Propranolol	9-20	adrenoceptor beta 2	Homo sapiens	59-64
34650198-11	2021	CONCLUSIONS: Propranolol inhibit the proliferation of HemECs and promote their apoptosis and autophagy through acting on both beta1 and beta2 adrenoceptor in mast cell.	Propranolol	13-24	BCL2 related protein A1	Homo sapiens	126-131
34650198-11	2021	CONCLUSIONS: Propranolol inhibit the proliferation of HemECs and promote their apoptosis and autophagy through acting on both beta1 and beta2 adrenoceptor in mast cell.	Propranolol	13-24	adrenoceptor beta 2	Homo sapiens	136-154
34650198-14	2021	Propranolol can work well in shRNA-ADRB1 or shRNA-ADRB2 transfected HMC-1s.	Propranolol	0-11	adrenoceptor beta 1	Homo sapiens	35-40
34650198-14	2021	Propranolol can work well in shRNA-ADRB1 or shRNA-ADRB2 transfected HMC-1s.	Propranolol	0-11	adrenoceptor beta 2	Homo sapiens	50-55
34650198-15	2021	Mast cells may have a role in the action of propranolol in infantile hemangioma through both beta1 and beta2 adrenoceptors to inhibit the angiogenic capacity of hemangioma endothelial cells.	Propranolol	44-55	BCL2 related protein A1	Homo sapiens	93-98
34650198-15	2021	Mast cells may have a role in the action of propranolol in infantile hemangioma through both beta1 and beta2 adrenoceptors to inhibit the angiogenic capacity of hemangioma endothelial cells.	Propranolol	44-55	ATPase H+ transporting V0 subunit a2	Homo sapiens	103-108
34683887-0	2021	Proving Nanoscale Chiral Interactions of Cyclodextrins and Propranolol Enantiomers by Means of SERS Measurements Performed on a Solid Plasmonic Substrate.	Propranolol	59-70	seryl-tRNA synthetase 2, mitochondrial	Homo sapiens	95-99
34417358-7	2021	We found that intra-dDG infusions of ISO given prior to retrieval caused deficits in working and reference memory which was blocked by pretreatment with the BAR-antagonist, propranolol (PRO).	Propranolol	173-184	adrenoceptor beta 2	Homo sapiens	157-160
34417358-7	2021	We found that intra-dDG infusions of ISO given prior to retrieval caused deficits in working and reference memory which was blocked by pretreatment with the BAR-antagonist, propranolol (PRO).	Propranolol	186-189	adrenoceptor beta 2	Homo sapiens	157-160
34414453-10	2021	Propranolol also elevated mRNA and protein expression levels of BMP2, RunX2, COL-1 and OCN in tissue and cells, and decreased the expression of beta2-AR.	Propranolol	0-11	bone morphogenetic protein 2	Mus musculus	64-68
34414453-10	2021	Propranolol also elevated mRNA and protein expression levels of BMP2, RunX2, COL-1 and OCN in tissue and cells, and decreased the expression of beta2-AR.	Propranolol	0-11	runt related transcription factor 2	Mus musculus	70-75
34414453-10	2021	Propranolol also elevated mRNA and protein expression levels of BMP2, RunX2, COL-1 and OCN in tissue and cells, and decreased the expression of beta2-AR.	Propranolol	0-11	osteocalcin	Oryctolagus cuniculus	87-90
34596055-0	2021	Propranolol inhibits cavernous vascular malformations by beta1 adrenergic receptor antagonism in animal models.	Propranolol	0-11	adrenoceptor beta 1	Homo sapiens	57-82
34683887-5	2021	Here we present Raman/SERS experimental data that provide useful information concerning the nanoscale interactions between propranolol enantiomers and alpha, beta, and gamma cyclodextrins.	Propranolol	123-134	seryl-tRNA synthetase 2, mitochondrial	Homo sapiens	22-26
34431177-5	2021	Propranolol used to inhibit PA hydrolysis triggers this pathway, which then activates p38 and ERK1/2 downstream PKA inhibition.	Propranolol	0-11	mitogen-activated protein kinase 1	Homo sapiens	86-89
34431177-5	2021	Propranolol used to inhibit PA hydrolysis triggers this pathway, which then activates p38 and ERK1/2 downstream PKA inhibition.	Propranolol	0-11	mitogen-activated protein kinase 3	Homo sapiens	94-100
34646131-6	2021	In addition to reduce tumor growth, both propranolol and SR59230A, beta1-/beta2-and beta3-AR antagonists, respectively, attenuated mechanical allodynia, the number of macrophages and an oxidative stress by-product accumulated in the ipsilateral tibial nerve.	Propranolol	41-52	brain protein 1	Mus musculus	67-72
34638341-0	2021	Beta 2 Adrenergic Receptor Antagonist Propranolol and Opioidergic Receptor Antagonist Naltrexone Produce Synergistic Effects on Breast Cancer Growth Prevention by Acting on Cancer Cells and Immune Environment in a Preclinical Model of Breast Cancer.	Propranolol	38-49	adrenoceptor beta 2	Homo sapiens	0-26
34638341-2	2021	The effects of beta2-adrenergic blocker propranolol (PRO) and mu-opioid receptor antagonist naltrexone (NTX) were tested using a preclinical model of human breast cancer.	Propranolol	40-51	G protein-coupled receptor 162	Homo sapiens	15-20
34646131-6	2021	In addition to reduce tumor growth, both propranolol and SR59230A, beta1-/beta2-and beta3-AR antagonists, respectively, attenuated mechanical allodynia, the number of macrophages and an oxidative stress by-product accumulated in the ipsilateral tibial nerve.	Propranolol	41-52	ST3 beta-galactoside alpha-2,3-sialyltransferase 5	Mus musculus	74-89
34646131-6	2021	In addition to reduce tumor growth, both propranolol and SR59230A, beta1-/beta2-and beta3-AR antagonists, respectively, attenuated mechanical allodynia, the number of macrophages and an oxidative stress by-product accumulated in the ipsilateral tibial nerve.	Propranolol	41-52	ferredoxin reductase	Mus musculus	90-92
34544479-8	2021	The impact of propranolol on IFN-alpha/beta-mediated inhibition of viral propagation and the expression of antiviral gene PKR was detected by viral replication assays and western blot.	Propranolol	14-25	interferon alpha 2	Homo sapiens	29-43
34684044-4	2021	Studies have reported a link between chronic use of the beta2AR antagonist propranolol and an increased risk of PD, and chronic use of beta2AR agonists has been associated with a decreased risk of PD.	Propranolol	75-86	adenosine A2a receptor	Homo sapiens	56-63
34684044-10	2021	Propranolol, a type of beta2AR antagonist, was related to an increased risk of PD (RR = 2.820, 95% CI, 2.618 to 3.036. p < 0.005).	Propranolol	0-11	adenosine A2a receptor	Homo sapiens	23-30
34544479-8	2021	The impact of propranolol on IFN-alpha/beta-mediated inhibition of viral propagation and the expression of antiviral gene PKR was detected by viral replication assays and western blot.	Propranolol	14-25	eukaryotic translation initiation factor 2-alpha kinase 2	Mus musculus	122-125
34544479-11	2021	Propranolol pretreatment significantly enhanced the p-STAT3 (2.9-fold, P < 0.05) and suppressed p-PKR (65.94% +- 10.11%, P < 0.05) compared with T1012G only group.	Propranolol	0-11	signal transducer and activator of transcription 3	Mus musculus	54-59
34544479-11	2021	Propranolol pretreatment significantly enhanced the p-STAT3 (2.9-fold, P < 0.05) and suppressed p-PKR (65.94% +- 10.11%, P < 0.05) compared with T1012G only group.	Propranolol	0-11	eukaryotic translation initiation factor 2-alpha kinase 2	Mus musculus	98-101
34544479-12	2021	In addition, propranolol could counteract IFN-alpha/beta-mediated inhibition of viral propagation (compared with IFNalpha: 5.1-fold, P < 0.001; IFNbeta: 4.6-fold, P < 0.01) or enhancement of PKR activation (IFNalpha: 92.57% +- 1.77%, P < 0.001, IFNbeta: 99.34% +- 0.13% decrease, P < 0.001).	Propranolol	13-24	interferon alpha 2	Homo sapiens	42-56
34544479-12	2021	In addition, propranolol could counteract IFN-alpha/beta-mediated inhibition of viral propagation (compared with IFNalpha: 5.1-fold, P < 0.001; IFNbeta: 4.6-fold, P < 0.01) or enhancement of PKR activation (IFNalpha: 92.57% +- 1.77%, P < 0.001, IFNbeta: 99.34% +- 0.13% decrease, P < 0.001).	Propranolol	13-24	eukaryotic translation initiation factor 2-alpha kinase 2	Mus musculus	191-194
34544479-12	2021	In addition, propranolol could counteract IFN-alpha/beta-mediated inhibition of viral propagation (compared with IFNalpha: 5.1-fold, P < 0.001; IFNbeta: 4.6-fold, P < 0.01) or enhancement of PKR activation (IFNalpha: 92.57% +- 1.77%, P < 0.001, IFNbeta: 99.34% +- 0.13% decrease, P < 0.001).	Propranolol	13-24	interferon alpha 1	Homo sapiens	207-215
34477031-0	2022	Vascular endothelial growth factor response with propranolol therapy in patients with infantile hemangioma.	Propranolol	49-60	vascular endothelial growth factor A	Homo sapiens	0-34
34521309-6	2022	Post-HDI the maximum measured plasma insulin concentration was 6345 microU/mL and elimination half-life 5.5 h. A man ingesting propranolol received HDI for approximately 12 h (maximum dose 1.5 U/kg/h) and supplemental intravenous dextrose for 4 h post-HDI.	Propranolol	127-138	insulin	Homo sapiens	37-44
34477031-8	2022	Propranolol therapy induced a significant decline in VEGF levels at the 3-month evaluation in patients in the proliferative phase; however, this did not reach the levels of IH in the involuting phase.	Propranolol	0-11	vascular endothelial growth factor A	Homo sapiens	53-57
34287102-9	2022	This metabolic profile in a patient with normal CYP2D6-metabolizer status based on genotyping supports CYP2D6 inhibition by paroxetine and propranolol, two strong mechanism-based inhibitors.	Propranolol	139-150	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	48-54
34376038-0	2021	Propranolol Inhibits the Proliferation of Human Glioblastoma Cell Lines through Notch1 and Hes1 Signaling System.	Propranolol	0-11	notch receptor 1	Homo sapiens	80-86
34376038-0	2021	Propranolol Inhibits the Proliferation of Human Glioblastoma Cell Lines through Notch1 and Hes1 Signaling System.	Propranolol	0-11	hes family bHLH transcription factor 1	Homo sapiens	91-95
34376038-7	2021	The impact of propranolol on gene expression (Notch and Hes) was evaluated using real-time polymerase chain reaction (RT-PCR, whereas protein levels of Notch1 and Hes1 were measured using Western blotting (WB), simultaneously.	Propranolol	14-25	notch receptor 1	Homo sapiens	46-51
34376038-7	2021	The impact of propranolol on gene expression (Notch and Hes) was evaluated using real-time polymerase chain reaction (RT-PCR, whereas protein levels of Notch1 and Hes1 were measured using Western blotting (WB), simultaneously.	Propranolol	14-25	ribosome binding protein 1	Homo sapiens	56-59
34376038-10	2021	RT-PCR showed an increase in Notch1 and Hes1 expression by propranolol, whereas WB demonstrated increase in Notch1 protein, but a decrease in Hes1 by propranolol.	Propranolol	59-70	notch receptor 1	Homo sapiens	29-35
34376038-10	2021	RT-PCR showed an increase in Notch1 and Hes1 expression by propranolol, whereas WB demonstrated increase in Notch1 protein, but a decrease in Hes1 by propranolol.	Propranolol	59-70	hes family bHLH transcription factor 1	Homo sapiens	40-44
34376038-10	2021	RT-PCR showed an increase in Notch1 and Hes1 expression by propranolol, whereas WB demonstrated increase in Notch1 protein, but a decrease in Hes1 by propranolol.	Propranolol	150-161	hes family bHLH transcription factor 1	Homo sapiens	142-146
34376038-12	2021	Conclusion: These results demonstrated that propranolol suppressed the proliferation of glioblastoma cell lines and neuroblastoma cell line, and Hes1 was more closely involved than Notch1 was in glioblastoma proliferation.	Propranolol	44-55	hes family bHLH transcription factor 1	Homo sapiens	145-149
34376038-12	2021	Conclusion: These results demonstrated that propranolol suppressed the proliferation of glioblastoma cell lines and neuroblastoma cell line, and Hes1 was more closely involved than Notch1 was in glioblastoma proliferation.	Propranolol	44-55	notch receptor 1	Homo sapiens	181-187
34414453-10	2021	Propranolol also elevated mRNA and protein expression levels of BMP2, RunX2, COL-1 and OCN in tissue and cells, and decreased the expression of beta2-AR.	Propranolol	0-11	adenosine A2a receptor	Mus musculus	144-152
34425806-5	2021	The activity of beta-ARs was modulated by an agonist, norepinephrine (NE), and antagonists, including propranolol, atenolol, nebivolol, and nadolol.	Propranolol	102-113	alanyl-tRNA synthetase 1	Homo sapiens	16-24
34425806-7	2021	Treatment of chondrocytes with IL-1beta and beta-blockers, including propranolol, atenolol, nebivolol, and nadolol, for 6 h significantly upregulated IL-1beta-induced expression of MMP-1, -3, and - 13, compared to chondrocytes treated with IL-1beta alone, indicating that antagonism of beta-AR confers catabolic signals.	Propranolol	69-80	interleukin 1 alpha	Homo sapiens	31-39
34425806-7	2021	Treatment of chondrocytes with IL-1beta and beta-blockers, including propranolol, atenolol, nebivolol, and nadolol, for 6 h significantly upregulated IL-1beta-induced expression of MMP-1, -3, and - 13, compared to chondrocytes treated with IL-1beta alone, indicating that antagonism of beta-AR confers catabolic signals.	Propranolol	69-80	interleukin 1 alpha	Homo sapiens	150-158
34425806-7	2021	Treatment of chondrocytes with IL-1beta and beta-blockers, including propranolol, atenolol, nebivolol, and nadolol, for 6 h significantly upregulated IL-1beta-induced expression of MMP-1, -3, and - 13, compared to chondrocytes treated with IL-1beta alone, indicating that antagonism of beta-AR confers catabolic signals.	Propranolol	69-80	matrix metallopeptidase 1	Homo sapiens	181-200
34287102-9	2022	This metabolic profile in a patient with normal CYP2D6-metabolizer status based on genotyping supports CYP2D6 inhibition by paroxetine and propranolol, two strong mechanism-based inhibitors.	Propranolol	139-150	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	103-109
34287102-11	2022	CONCLUSION: Marked and prolonged serotonin toxicity was attributed to increased M2 production due to paroxetine- and propranolol-related CYP2D6 inhibition of tramadol metabolism.	Propranolol	117-128	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	137-143
34298835-3	2021	D-Propranolol (D-Prop), the non-beta blocker enantiomer of propranolol, was previously shown to induce EGFR internalization through a PKA inhibitory pathway that blocks the recycling of the receptor.	Propranolol	59-70	epidermal growth factor receptor	Homo sapiens	103-107
35569122-10	2022	CMap analysis showed that the small molecules scriptaid, torasemide, dexpropranolol, ipratropium bromide, and harmine were potential negative regulators of TGIF1.	Propranolol	69-83	TGFB induced factor homeobox 1	Homo sapiens	156-161
34115934-0	2021	Propranolol Activates the Orphan Nuclear Receptor TLX to Counteract Proliferation and Migration of Glioblastoma Cells.	Propranolol	0-11	CD46 molecule	Homo sapiens	50-53
34115934-4	2021	Propranolol evolved as the strongest TLX agonist and promoted TLX-regulated gene expression in human glioblastoma cells.	Propranolol	0-11	CD46 molecule	Homo sapiens	37-40
34115934-4	2021	Propranolol evolved as the strongest TLX agonist and promoted TLX-regulated gene expression in human glioblastoma cells.	Propranolol	0-11	CD46 molecule	Homo sapiens	62-65
34115934-5	2021	Structure-activity relationship elucidation of propranolol as a TLX ligand yielded a structurally related negative control compound.	Propranolol	47-58	CD46 molecule	Homo sapiens	64-67
34309518-10	2021	Small skin arteries and arterioles, pre-treated with prazosin and stimulated with NE, exhibited ADRB2-mediated vasodilation, which was inhibited by the beta blockers, propranolol or timolol.	Propranolol	167-178	adrenoceptor beta 2	Homo sapiens	96-101
34113256-7	2021	Our results showed that propranolol, when administered immediately after CS exposure but not 6 h later, can significantly attenuate cue-induced and drug-primed reinstatement of heroin seeking, suggesting that propranolol has the ability to disrupt heroin memory and reduce relapse.	Propranolol	24-35	citrate synthase	Rattus norvegicus	73-75
34113256-7	2021	Our results showed that propranolol, when administered immediately after CS exposure but not 6 h later, can significantly attenuate cue-induced and drug-primed reinstatement of heroin seeking, suggesting that propranolol has the ability to disrupt heroin memory and reduce relapse.	Propranolol	209-220	citrate synthase	Rattus norvegicus	73-75
34430434-0	2021	Propranolol inhibits infantile hemangioma by regulating the miR-424/vascular endothelial growth factor-A (VEGFA) axis.	Propranolol	0-11	vascular endothelial growth factor A	Homo sapiens	106-111
34430434-2	2021	We aimed to explore the effect of propranolol on the expression of microRNA (miR)-424 in IHA tissues and XPTS-1 cells, as well as its molecular mechanism of inhibiting XPTS-1 cell activity.	Propranolol	34-45	microRNA 424	Homo sapiens	67-85
34430434-10	2021	As the concentration of propranolol increased, XPTS-1 cell viability gradually decreased (P<0.05), and the expression level of VEGFA decreased (P<0.05).	Propranolol	24-35	vascular endothelial growth factor A	Homo sapiens	127-132
34430434-11	2021	The expression of miR-424 increased with the time of propranolol treatment (P<0.05).	Propranolol	53-64	microRNA 424	Homo sapiens	18-25
34430434-15	2021	Compared with the propranolol group, the XPTS-1 cell viability and invasion ability in the propranolol + VEGFA-si group were significantly decreased (P<0.05), while the level of apoptosis increased (P<0.05).	Propranolol	18-29	vascular endothelial growth factor A	Homo sapiens	105-110
34430434-15	2021	Compared with the propranolol group, the XPTS-1 cell viability and invasion ability in the propranolol + VEGFA-si group were significantly decreased (P<0.05), while the level of apoptosis increased (P<0.05).	Propranolol	91-102	vascular endothelial growth factor A	Homo sapiens	105-110
34430434-17	2021	Conclusions: Propranolol affects the malignant biological behavior of IHA cells by regulating the miR-424/VEGFA axis.	Propranolol	13-24	microRNA 424	Homo sapiens	98-105
34430434-17	2021	Conclusions: Propranolol affects the malignant biological behavior of IHA cells by regulating the miR-424/VEGFA axis.	Propranolol	13-24	vascular endothelial growth factor A	Homo sapiens	106-111
34115202-0	2021	Effect of the acyl-group length on the chemoselectivity of the lipase-catalyzed acylation of propranolol-a computational study.	Propranolol	93-104	PAN0_003d1715	Moesziomyces antarcticus	63-69
34115202-9	2021	The nucleophilic attack of propranolol to the acylated lipase was found to be more favorable through the classical mechanism when compared with the proton shuttle mechanism.	Propranolol	27-38	PAN0_003d1715	Moesziomyces antarcticus	55-61
35622651-9	2022	Cardiac immunohistochemistry revealed an LV upregulation of FGF-23 in the catecholamine groups, and this improved in low-dose propranolol groups.	Propranolol	126-137	fibroblast growth factor 23	Rattus norvegicus	60-66
35533760-6	2022	This correlated with lower GC B cell count and the shift in Tfr/Tfh cell and Tfr/GC B cell ratio towards Tfr in propranolol-treated mice compared with controls.	Propranolol	112-123	natriuretic peptide receptor 2	Mus musculus	27-31
35533760-6	2022	This correlated with lower GC B cell count and the shift in Tfr/Tfh cell and Tfr/GC B cell ratio towards Tfr in propranolol-treated mice compared with controls.	Propranolol	112-123	transferrin receptor	Mus musculus	60-63
35533760-6	2022	This correlated with lower GC B cell count and the shift in Tfr/Tfh cell and Tfr/GC B cell ratio towards Tfr in propranolol-treated mice compared with controls.	Propranolol	112-123	transferrin receptor	Mus musculus	77-80
35533760-6	2022	This correlated with lower GC B cell count and the shift in Tfr/Tfh cell and Tfr/GC B cell ratio towards Tfr in propranolol-treated mice compared with controls.	Propranolol	112-123	natriuretic peptide receptor 2	Mus musculus	81-85
35622651-11	2022	Low-dose propranolol exerted cardio-preventative effects through FGF-23 downregulation and hemodynamic-parameter improvement in our model of hyper-acute catecholamine-induced heart failure.	Propranolol	9-20	fibroblast growth factor 23	Rattus norvegicus	65-71
35586822-1	2022	Background and Purpose: This study was conducted to explore the plasma drug concentration of propranolol in Chinese Han patients with infantile haemangioma (IH) and the influencing factors, as well as the relationship among plasma drug concentrations of propranolol, beta1-AR mutation and CYP2D6 188C>T, efficacy, and safety.	Propranolol	93-104	immunoglobulin kappa variable 2D-30	Homo sapiens	267-272
35586822-1	2022	Background and Purpose: This study was conducted to explore the plasma drug concentration of propranolol in Chinese Han patients with infantile haemangioma (IH) and the influencing factors, as well as the relationship among plasma drug concentrations of propranolol, beta1-AR mutation and CYP2D6 188C>T, efficacy, and safety.	Propranolol	93-104	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	289-295
35563024-7	2022	In turn, the suppressive effects of isoproterenol were abolished by the treatment with either ICI 118,551, a beta2-AR antagonist, or propranolol, suggesting that isoproterenol effects are mainly mediated by the beta2-AR stimulation.	Propranolol	133-144	adenosine A2a receptor	Mus musculus	211-219
35533760-6	2022	This correlated with lower GC B cell count and the shift in Tfr/Tfh cell and Tfr/GC B cell ratio towards Tfr in propranolol-treated mice compared with controls.	Propranolol	112-123	transferrin receptor	Mus musculus	105-108
35533760-9	2022	Additionally, in propranolol-treated mice, in accordance with the changes in INF-gamma/IL-4 ratio in dLN cell/splenocyte cultures, serum IgG2a/IgG1 ratio was shifted towards IgG1 reflecting decreased IgG2a response.	Propranolol	17-28	immunoglobulin heavy variable V1-9	Mus musculus	137-142
35533760-9	2022	Additionally, in propranolol-treated mice, in accordance with the changes in INF-gamma/IL-4 ratio in dLN cell/splenocyte cultures, serum IgG2a/IgG1 ratio was shifted towards IgG1 reflecting decreased IgG2a response.	Propranolol	17-28	immunoglobulin heavy constant gamma 1 (G1m marker)	Mus musculus	143-147
35533760-9	2022	Additionally, in propranolol-treated mice, in accordance with the changes in INF-gamma/IL-4 ratio in dLN cell/splenocyte cultures, serum IgG2a/IgG1 ratio was shifted towards IgG1 reflecting decreased IgG2a response.	Propranolol	17-28	immunoglobulin heavy constant gamma 1 (G1m marker)	Mus musculus	174-178
35533760-9	2022	Additionally, in propranolol-treated mice, in accordance with the changes in INF-gamma/IL-4 ratio in dLN cell/splenocyte cultures, serum IgG2a/IgG1 ratio was shifted towards IgG1 reflecting decreased IgG2a response.	Propranolol	17-28	immunoglobulin heavy variable V1-9	Mus musculus	200-205
35122666-1	2022	Although the non-selective beta-blocker, propranolol, improves bone density with PTH treatment in mice, the mechanism of this effect is unclear.	Propranolol	41-52	parathyroid hormone	Mus musculus	81-84
35122666-5	2022	In vitro, propranolol amplified the acute, PTH-induced, intracellular calcium signal in osteoblast-like cells.	Propranolol	10-21	parathyroid hormone	Mus musculus	43-46
35122666-7	2022	Despite this, PTH-induced receptor activator of nuclear factor kappa-B ligand (RANKL) mRNA and protein levels were unaltered by propranolol, which led us to hypothesize that propranolol could act directly on osteoclasts.	Propranolol	174-185	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	26-77
35122666-7	2022	Despite this, PTH-induced receptor activator of nuclear factor kappa-B ligand (RANKL) mRNA and protein levels were unaltered by propranolol, which led us to hypothesize that propranolol could act directly on osteoclasts.	Propranolol	174-185	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	79-84
35481228-8	2022	Propranolol reversed CREB and Nrf2 activity (ps < .03).	Propranolol	0-11	cAMP responsive element binding protein 1	Mus musculus	21-25
35481228-8	2022	Propranolol reversed CREB and Nrf2 activity (ps < .03).	Propranolol	0-11	nuclear factor, erythroid derived 2, like 2	Mus musculus	30-34
35395139-9	2022	Conversely, the most potent inhibitors against PON1 were propafenone (Ki : 0.35 microM), Lacidipine (Ki : 0.78 microM), Lidocaine HCl (Ki : 1.78 microM), and Propranolol (Ki : 1.86 microM).	Propranolol	158-169	paraoxonase 1	Homo sapiens	47-51
35397163-3	2022	In the capillary electrochromatography (CEC) system, the novel capillary column with carboxymethyl-beta-cyclodextrin (CM-beta-CD) as a chiral selector has completed the enantioseparation of four basic drugs (propranolol, metoprolol, amlodipine and chlorpheniramine).	Propranolol	208-219	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	121-128
35240444-0	2022	Propranolol inhibits cell viability and expression of the pro-tumorigenic proteins Akt, NF-kB, and VEGF in oral squamous cell carcinoma.	Propranolol	0-11	AKT serine/threonine kinase 1	Homo sapiens	83-86
35266887-12	2022	Propranolol treatment elevated the activity of caspase-3 and expression of bax, Wee1, GADD153 and apoptosis-inducing factor, but decreased bcl-2 which is an antiapoptotic protein.	Propranolol	0-11	caspase 3	Homo sapiens	47-56
35266887-12	2022	Propranolol treatment elevated the activity of caspase-3 and expression of bax, Wee1, GADD153 and apoptosis-inducing factor, but decreased bcl-2 which is an antiapoptotic protein.	Propranolol	0-11	BCL2 associated X, apoptosis regulator	Homo sapiens	75-78
35266887-12	2022	Propranolol treatment elevated the activity of caspase-3 and expression of bax, Wee1, GADD153 and apoptosis-inducing factor, but decreased bcl-2 which is an antiapoptotic protein.	Propranolol	0-11	WEE1 G2 checkpoint kinase	Homo sapiens	80-84
35266887-12	2022	Propranolol treatment elevated the activity of caspase-3 and expression of bax, Wee1, GADD153 and apoptosis-inducing factor, but decreased bcl-2 which is an antiapoptotic protein.	Propranolol	0-11	DNA damage inducible transcript 3	Homo sapiens	86-93
35266887-12	2022	Propranolol treatment elevated the activity of caspase-3 and expression of bax, Wee1, GADD153 and apoptosis-inducing factor, but decreased bcl-2 which is an antiapoptotic protein.	Propranolol	0-11	BCL2 apoptosis regulator	Homo sapiens	139-144
35266887-13	2022	Propranolol treatment also inhibited ERK and JNK activity.	Propranolol	0-11	mitogen-activated protein kinase 1	Homo sapiens	37-40
35266887-13	2022	Propranolol treatment also inhibited ERK and JNK activity.	Propranolol	0-11	mitogen-activated protein kinase 8	Homo sapiens	45-48
35240444-0	2022	Propranolol inhibits cell viability and expression of the pro-tumorigenic proteins Akt, NF-kB, and VEGF in oral squamous cell carcinoma.	Propranolol	0-11	vascular endothelial growth factor A	Homo sapiens	99-103
34874911-5	2022	As our previous work implicated the transcription factor SRY(Sex Determining Region Y)-Box Transcription Factor-18 (SOX18) in propranolol-mediated inhibition of HemSC to endothelial differentiation, we tested in parallel a known SOX18 small molecule inhibitor (Sm4) and show that this compound inhibited HemSC vessel formation in vivo with a similar efficacy as the R(+) enantiomers.	Propranolol	126-137	sex determining region of Chr Y	Mus musculus	57-114
35370486-4	2022	We conducted a correlative study of a randomized controlled trial evaluating the effects of the nonselective beta-antagonist propranolol on expression and prenylation of Rap1A and Rap1B during neutrophil and platelet engraftment in 25 individuals receiving an autologous HCT for multiple myeloma.	Propranolol	125-136	RAP1B, member of RAS oncogene family	Homo sapiens	180-185
34984921-7	2022	Ileal SGLT1-mediated glucose transport and BBM expression were Inhibited by the beta-adrenergic receptor (betaAR) blocker propranolol in EW and LW pigs.	Propranolol	122-133	solute carrier family 5 member 1	Sus scrofa	6-11
34984921-8	2022	In contrast, propranolol enhanced ileal GLUT2-mediated glucose transport (P=0.015) and BBMV abundance (P=0.035) LW pigs, but not EW pigs.	Propranolol	13-24	solute carrier family 2 member 2	Sus scrofa	40-45
35104803-6	2022	The efficacy of propranolol was independent of its beta-AR blocker activity and was attributable to the direct targeting of the transcription factor SOX18, which, in turn, reduced hemangioma blood vessel formation.	Propranolol	16-27	SRY-box transcription factor 18	Homo sapiens	149-154
35088452-9	2022	We found that exposure to propranolol either by combination with carbachol facilitates additive effects on inhibition of caspase 3 and 8 expression in chronic myeloid leukemia K562 cells.	Propranolol	26-37	caspase 3	Homo sapiens	121-136
35088452-10	2022	But caspase 9 expression level was increased by propranolol alone or with propranolol and Carbachol combination.	Propranolol	48-59	caspase 9	Homo sapiens	4-13
35088452-10	2022	But caspase 9 expression level was increased by propranolol alone or with propranolol and Carbachol combination.	Propranolol	74-85	caspase 9	Homo sapiens	4-13
35370486-4	2022	We conducted a correlative study of a randomized controlled trial evaluating the effects of the nonselective beta-antagonist propranolol on expression and prenylation of Rap1A and Rap1B during neutrophil and platelet engraftment in 25 individuals receiving an autologous HCT for multiple myeloma.	Propranolol	125-136	RAP1A, member of RAS oncogene family	Homo sapiens	170-175
34874911-6	2022	We next examined how R(+) propranolol alters SOX18 transcriptional activity.	Propranolol	26-37	SRY (sex determining region Y)-box 18	Mus musculus	45-50
34874911-7	2022	Using a suite of biochemical, biophysical and quantitative molecular imaging assays we show that R(+) propranolol directly interferes with SOX18 target gene trans-activation, disrupts SOX18-chromatin binding dynamics and reduced SOX18 dimer formation.	Propranolol	102-113	SRY (sex determining region Y)-box 18	Mus musculus	139-144
34874911-7	2022	Using a suite of biochemical, biophysical and quantitative molecular imaging assays we show that R(+) propranolol directly interferes with SOX18 target gene trans-activation, disrupts SOX18-chromatin binding dynamics and reduced SOX18 dimer formation.	Propranolol	102-113	SRY (sex determining region Y)-box 18	Mus musculus	184-189
34874911-7	2022	Using a suite of biochemical, biophysical and quantitative molecular imaging assays we show that R(+) propranolol directly interferes with SOX18 target gene trans-activation, disrupts SOX18-chromatin binding dynamics and reduced SOX18 dimer formation.	Propranolol	102-113	SRY (sex determining region Y)-box 18	Mus musculus	229-234
35163250-3	2022	In the present study, we wanted to look deep into the effects of the ADRB2 blockers propranolol and ICI-118,551 on two main aspects of cancer progression: (i) the changes on the inflammatory response of ccRCC cells; and (ii) the modulation on the Warburg effect (glycolytic metabolism), concretely, on the expression of genes involved in the cell reactive oxygen species (ROS) balance and levels.	Propranolol	84-95	adrenoceptor beta 2	Homo sapiens	69-74
35017664-9	2022	Flow cytometry-based analysis and RNA sequencing of FACS-sorted cells show that propranolol treatment leads to an upregulation of PD-L1 on tumor associated macrophages (TAMs) and changes in their chemokine expression profile.	Propranolol	80-91	CD274 molecule	Homo sapiens	130-135
35017664-10	2022	Lastly, we observe that the co-administration of propranolol significantly enhances the efficacy of anti-CTLA4 therapy.	Propranolol	49-60	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	105-110
35089188-8	2022	Finally, the ROS level, cell proliferation, and apoptosis were measured again in both active HUVECs and HUVECs, in which the p38 proteins were inhibited.The combination of CyA and PROP reversed the effect of CyA on cell viability, reduced the ROS level and the cell apoptosis induced by PROP.	Propranolol	180-184	mitogen-activated protein kinase 14	Homo sapiens	125-128
35089188-9	2022	Moreover, inhibition of p38 protein catalase activity immediately stopped the effect of CyA-propranolol in HUVECs.The effect of the CyA-propranolol combination on HUVECs is associated with the p38 pathway changes, which is proven to be a potential chemotherapeutic agent that minimizes the side effects of PROP in hemangioma therapy.	Propranolol	306-310	mitogen-activated protein kinase 14	Homo sapiens	193-196
2575615-14	1989	The electrically induced increase in blood pressure subsequent to administration of high doses of prazosin, rauwolscine plus propranolol was diminished by suramin and by the low and high dose of mATP.	Propranolol	125-136	solute carrier family 45, member 2	Mus musculus	195-199
2576226-1	1989	The mixed beta-adrenoceptor and 5-HT1A receptor antagonists, (-)-pindolol and propranolol, enhance rather than inhibit the hyperlocomotion induced in rats by the 5-HT1A receptor agonist, 8-OH-DPAT.	Propranolol	78-89	5-hydroxytryptamine receptor 1A	Rattus norvegicus	32-38
2576226-1	1989	The mixed beta-adrenoceptor and 5-HT1A receptor antagonists, (-)-pindolol and propranolol, enhance rather than inhibit the hyperlocomotion induced in rats by the 5-HT1A receptor agonist, 8-OH-DPAT.	Propranolol	78-89	5-hydroxytryptamine receptor 1A	Rattus norvegicus	162-168
2556048-7	1989	Coincubation of 20 microM propranolol, a beta-adrenergic antagonist, with 2 microM isoproterenol and thrombin blocked the permeability-decreasing effect of isoproterenol.	Propranolol	26-37	coagulation factor II, thrombin	Bos taurus	101-109
2557010-7	1989	Administration of the beta-antagonist propranolol 8 h after the injection of isoprenaline suppressed the increase in DNA synthesis, the preceding changes in the concentration of cyclic AMP and in the activity of cyclic AMP-dependent protein kinase, as well as the increased phosphorylation of p110 and p130.	Propranolol	38-49	RB transcriptional corepressor like 2	Rattus norvegicus	302-306
2573510-8	1989	Blockade of adrenergic receptors by the concomitant administration of prazosin and propanolol prevented the simultaneous actions of phenylephrine and isoproterenol on the corticotrophs, but did not significantly alter the effect of peripherally administered Il-1 alpha on ACTH release.	Propranolol	83-93	interleukin 1 alpha	Rattus norvegicus	258-268
2573614-4	1989	Propranolol infusion (80 micrograms/min) started 2 h before the onset of sleep or the stimulus enhanced GH responses to GHRH and insulin alone and in the presence of GH.	Propranolol	0-11	growth hormone 1	Homo sapiens	104-106
2573614-4	1989	Propranolol infusion (80 micrograms/min) started 2 h before the onset of sleep or the stimulus enhanced GH responses to GHRH and insulin alone and in the presence of GH.	Propranolol	0-11	growth hormone releasing hormone	Homo sapiens	120-124
2573614-4	1989	Propranolol infusion (80 micrograms/min) started 2 h before the onset of sleep or the stimulus enhanced GH responses to GHRH and insulin alone and in the presence of GH.	Propranolol	0-11	insulin	Homo sapiens	129-136
2573614-4	1989	Propranolol infusion (80 micrograms/min) started 2 h before the onset of sleep or the stimulus enhanced GH responses to GHRH and insulin alone and in the presence of GH.	Propranolol	0-11	growth hormone 1	Homo sapiens	120-122
2517685-3	1989	Bradykinin-induced relaxation was not inhibited by acetylsalicylic acid (10(-4) M), indomethacin (10(-6) M), and combined treatment with phentolamine (10(-6) M) and propranolol (10(-6) M).	Propranolol	165-176	kininogen 1	Homo sapiens	0-10
2576201-14	1989	At the end of 1 week repeated application of the patches mean supine resting plasma renin activity (PRA) was significantly reduced by propranolol but not by mepindolol, and the mean PRA responses to 5 min i.v.	Propranolol	134-145	renin	Homo sapiens	84-89
2679151-5	1989	Veratridine-stimulated (300 microM) active renin secretion was antagonized by tetrodotoxin (0.5 and 5.0 microM) and DL-propranolol (1 microM) in fetal renal cortical slices.	Propranolol	116-130	renin	Ovis aries	43-48
2571235-4	1989	Following the administration of the alpha- and beta-adrenoceptor antagonists phenoxybenzamine and propranolol, the vasoconstrictor response to exogenous NA was reduced by 98%, whereas that of NPY was unaltered.	Propranolol	98-109	neuropeptide Y	Sus scrofa	192-195
2550032-6	1989	Oral administration of three different antihypertensive agents (propranolol, captopril, or hydralazine) for 12 weeks normalized blood pressure and POMC biosynthesis in the SHR but had no effect on either variable in the WKY.	Propranolol	64-75	proopiomelanocortin	Rattus norvegicus	147-151
2790382-5	1989	In the presence of propranolol, steady-state values after carbachol, R-PIA or NECA amounted to about 50% of control values.	Propranolol	19-30	ribose 5-phosphate isomerase A	Homo sapiens	69-74
2527473-0	1989	Effects of propranolol and pindolol on plasma ANP levels in humans at rest and during exercise.	Propranolol	11-22	natriuretic peptide A	Homo sapiens	46-49
2526588-12	1989	Phentolamine (1.3 microM) and propranolol (0.1 microM) each reduced peak hypoxia-induced (0% O2) ANF release to 333 and 310%, respectively, whereas atropine sulfate (15 microM) had no inhibitory effect.	Propranolol	30-41	natriuretic peptide A	Rattus norvegicus	97-100
2546456-3	1989	Propranolol was used to block neural stimulation of renin release.	Propranolol	0-11	renin	Canis lupus familiaris	52-57
2598215-4	1989	Propranolol inhibited the isoprenaline stimulated ornithine decarboxylase activity in all the regions.	Propranolol	0-11	ornithine decarboxylase 1	Rattus norvegicus	50-73
2546456-6	1989	The combined infusion of ANF and propranolol produced an additive and complete inhibition of the renin response to TIVCC; therefore the effect of ANF is independent of neural stimulation of renin release.	Propranolol	33-44	renin	Canis lupus familiaris	97-102
2590727-1	1989	A new method based on displacement electrophoresis has been developed for the determination of the total and free concentration of propranolol, a beta-adrenergic blocker drug, in plasma.	Propranolol	131-142	amyloid beta precursor protein	Homo sapiens	144-150
2600859-10	1989	Propranolol reduced resting heart rate with tubocurarine to 56 beats min-1 with no effect on blood pressure in seven subjects.	Propranolol	0-11	CD59 molecule (CD59 blood group)	Homo sapiens	69-74
2573188-3	1989	It was two decades later that propranolol, a beta blocker was shown to decrease portal pressure.	Propranolol	30-41	amyloid beta precursor protein	Homo sapiens	43-49
2732950-11	1989	5-HT1A-1B (propranolol and cyanopindolol), 5-HT1C (mesulergine) and 5-HT3 (MDL 7222 and GR 38032F) selective drugs were almost completely devoid of significant antagonistic activity.	Propranolol	11-22	5-hydroxytryptamine receptor 1A	Homo sapiens	0-6
2571198-1	1989	The dose-dependent inhibition of thrombin stimulated platelet aggregation due to beta-adrenoceptor blocking drugs followed the rank order of potency: propranolol greater than alprenolol greater than metipranolol and correlated with arachidonic acid (3H-AA) liberation.	Propranolol	150-161	coagulation factor II, thrombin	Homo sapiens	33-41
2500035-6	1989	Propranolol (1 microM) inhibited ISO (10(-6) M)-stimulated active renin secretion at all ages.	Propranolol	0-11	renin	Ovis aries	66-71
2570368-4	1989	All studies were conducted in dogs receiving an intravenous infusion of propranolol to prevent changes in renin secretion mediated indirectly via the sympathetic nervous system.	Propranolol	72-83	renin	Canis lupus familiaris	106-111
2733424-7	1989	This protection is mediated by a beta-adrenergic receptor mechanism as it can be blocked by prior treatment with propranolol, but does not involve stabilization of mucosal or submucosal mast cell membranes.	Propranolol	113-124	amyloid beta precursor protein	Rattus norvegicus	31-37
2542698-11	1989	beta-Adrenergic antagonists, such as propranolol, inhibit both LTP and NE-induced LLP in dentate (Stanton and Sarvey, J.	Propranolol	37-48	LLP homolog, long-term synaptic facilitation factor	Homo sapiens	82-85
2566282-7	1989	Vasopressin concentration was lower at rest and during exercise under propranolol (3.5 +/- 1.3 vs. 4.9 +/- 0.9 and 6.1 +/- 2.2 vs. 9.9 +/- 1.5 pg/ml, respectively), which might reflect a dissociation between activity of the renin-angiotensin system and vasopressin release.	Propranolol	70-81	renin	Canis lupus familiaris	224-229
2542716-3	1989	In an additional investigation, proenkephalin A mRNA levels were determined after 9 h of treatment with dbcAMP, NE, isoproterenol, NE + propranolol and dbcAMP + DEX.	Propranolol	136-147	proenkephalin	Homo sapiens	32-47
2530590-3	1989	The corticosterone response to 8-OH-DPAT was also antagonized by spiperone, (+/-)- and (-)-pindolol and (+/-)-propranolol, all of which have been shown to have a high affinity for 5-HT1A receptors, though in most cases no complete blockade was found.	Propranolol	104-121	5-hydroxytryptamine receptor 1A	Rattus norvegicus	180-186
2570449-2	1989	Administration of propranolol, inhibited the renin release mediated by isoproterenol.	Propranolol	18-29	renin	Rattus norvegicus	45-50
2570449-3	1989	Likewise, metoprolol and practolol, showed a similar potency to propranolol in inhibiting isoproterenol-induced renin secretion.	Propranolol	64-75	renin	Rattus norvegicus	112-117
2757879-7	1989	As expected the heart rate on exercise was 25% less (-35 beats min-1) on propranolol (P less than 0.05).	Propranolol	73-84	CD59 molecule (CD59 blood group)	Homo sapiens	63-68
2566321-7	1989	The maximal expiratory flow at 50% vital capacity (MEF.50), was significantly lower after propranolol compared with placebo and celiprolol.	Propranolol	90-101	E74 like ETS transcription factor 4	Homo sapiens	51-54
2795980-8	1989	In group II, beta-adrenergic blockade with propranolol administration showed that sympathetic positive chronotropy was a critical compensatory factor around the upper limit of the CL of IHRp.	Propranolol	43-54	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	186-190
2744085-6	1989	The subsequent addition of propranolol to the alpha-adrenoceptor antagonists was followed by reappearance at a considerable portion of the perfusion pressure response while the output of [3H]NA or NA and NPY-LI was slightly reduced.	Propranolol	27-38	neuropeptide Y	Sus scrofa	204-207
2467944-4	1989	Blocking of the induction was achieved with the beta-antagonist, propranolol, but not with the alpha-antagonist phentolamine, indicating that this is a beta-adrenergic receptor-mediated phenomenon.	Propranolol	65-76	amyloid beta precursor protein	Homo sapiens	150-156
2545461-7	1989	Furthermore NPY (10(-7) M) seemed to be more potent to inhibit both contractile components than noradrenaline (10(-6) M) in the presence of propranolol (3 X 10(-6) M).	Propranolol	140-151	pro-neuropeptide Y	Cavia porcellus	12-15
2539818-0	1989	Effects of alpha-1-acid glycoprotein administration on propranolol binding and beta blockade in rats.	Propranolol	55-66	orosomucoid 1	Rattus norvegicus	11-36
2704229-7	1989	There was a 147% increase in insoluble elastin with propranolol and a lesser increase of 54% in insoluble collagen.	Propranolol	52-63	elastin	Mus musculus	39-46
2539818-1	1989	Alpha-1-acid glycoprotein (AAG), 750 mg/kg, was administered to rats to determine its effect on propranolol binding and beta blockade.	Propranolol	96-107	orosomucoid 1	Rattus norvegicus	0-25
2539480-3	1989	The beta-adrenergic antagonist propranolol binds stereoselectively both at 5-HT1A and 5-HT1B sites (with a several-fold selectivity for the latter) and, whereas it is a 5-HT1A antagonist, it appears to be a 5-HT1B agonist.	Propranolol	31-42	5-hydroxytryptamine receptor 1A	Homo sapiens	75-81
2539480-3	1989	The beta-adrenergic antagonist propranolol binds stereoselectively both at 5-HT1A and 5-HT1B sites (with a several-fold selectivity for the latter) and, whereas it is a 5-HT1A antagonist, it appears to be a 5-HT1B agonist.	Propranolol	31-42	5-hydroxytryptamine receptor 1A	Homo sapiens	169-175
2539480-3	1989	The beta-adrenergic antagonist propranolol binds stereoselectively both at 5-HT1A and 5-HT1B sites (with a several-fold selectivity for the latter) and, whereas it is a 5-HT1A antagonist, it appears to be a 5-HT1B agonist.	Propranolol	31-42	5-hydroxytryptamine receptor 1B	Homo sapiens	86-92
2539480-5	1989	The purpose of the present study was to modify the structure of propranolol in such a manner so as to reduce its affinity for 5-HT1B and beta-adrenergic sites while, at the same time, retaining its affinity for 5-HT1A sites.	Propranolol	64-75	5-hydroxytryptamine receptor 1B	Homo sapiens	126-132
2539480-5	1989	The purpose of the present study was to modify the structure of propranolol in such a manner so as to reduce its affinity for 5-HT1B and beta-adrenergic sites while, at the same time, retaining its affinity for 5-HT1A sites.	Propranolol	64-75	5-hydroxytryptamine receptor 1A	Homo sapiens	211-217
2539480-6	1989	Removal of the side-chain hydroxyl group of propranolol, and conversion of its secondary amine to a tertiary amine, reduced affinity for 5-HT1B and beta-adrenergic sites.	Propranolol	44-55	5-hydroxytryptamine receptor 1B	Homo sapiens	137-143
2525784-3	1989	The results indicate that propranolol at concentrations near the therapeutic range, significantly inhibit collagen and thrombin-induced platelet aggregation and TxB2 synthesis from PRP.	Propranolol	26-37	coagulation factor II, thrombin	Homo sapiens	119-127
2744218-5	1989	The inhibiting effect of amiodarone and propranolol on follicular production of cAMP, Tg and FT3 appears to result from several factors: (1) inhibition of thyroid 5"-deiodinase; (2) amiodarone high iodine content; (3) a quinidine-like effect of propranolol involving a membrane-stabilizing mechanism.	Propranolol	40-51	cathelicidin antimicrobial peptide	Homo sapiens	80-84
2535052-8	1989	Plasma renin activity rose on fosenopril and fell on propranolol.	Propranolol	53-64	renin	Homo sapiens	7-12
2522986-5	1989	The inhibitory effects of these two compounds were not additive and were prevented by 5-HT1A antagonists such as spiperone and dl-propranolol.	Propranolol	127-141	5-hydroxytryptamine receptor 1A	Rattus norvegicus	86-92
2744218-3	1989	Amiodarone and propranolol induced a dose-dependent reduction or blocking of the follicular production of cyclic AMP (cAMP), thyroglobulin (Tg) and free triiodothyronine (FT3) under 200 microU/ml medium.	Propranolol	15-26	cathelicidin antimicrobial peptide	Homo sapiens	118-122
2744218-5	1989	The inhibiting effect of amiodarone and propranolol on follicular production of cAMP, Tg and FT3 appears to result from several factors: (1) inhibition of thyroid 5"-deiodinase; (2) amiodarone high iodine content; (3) a quinidine-like effect of propranolol involving a membrane-stabilizing mechanism.	Propranolol	40-51	thyroglobulin	Homo sapiens	86-88
2744218-3	1989	Amiodarone and propranolol induced a dose-dependent reduction or blocking of the follicular production of cyclic AMP (cAMP), thyroglobulin (Tg) and free triiodothyronine (FT3) under 200 microU/ml medium.	Propranolol	15-26	thyroglobulin	Homo sapiens	125-138
2744218-3	1989	Amiodarone and propranolol induced a dose-dependent reduction or blocking of the follicular production of cyclic AMP (cAMP), thyroglobulin (Tg) and free triiodothyronine (FT3) under 200 microU/ml medium.	Propranolol	15-26	thyroglobulin	Homo sapiens	140-142
2744218-5	1989	The inhibiting effect of amiodarone and propranolol on follicular production of cAMP, Tg and FT3 appears to result from several factors: (1) inhibition of thyroid 5"-deiodinase; (2) amiodarone high iodine content; (3) a quinidine-like effect of propranolol involving a membrane-stabilizing mechanism.	Propranolol	245-256	cathelicidin antimicrobial peptide	Homo sapiens	80-84
2644850-4	1989	Sympathetic neural control of renin release was reversibly blocked with propranolol.	Propranolol	72-83	renin	Canis lupus familiaris	30-35
2568003-6	1989	Both propranolol and atenolol produced significant beta-1-adrenoceptor blockade, as evidenced by the production of significant bradycardic effects in conscious rats at the doses employed.	Propranolol	5-16	adrenoceptor beta 1	Rattus norvegicus	51-70
2563317-8	1989	Thirty-two per cent of patients receiving pancuronium received propranolol for heart rates greater than 90 beats.min-1 versus 7% of those who received vecuronium (P approximately 0.01).	Propranolol	63-74	CD59 molecule (CD59 blood group)	Homo sapiens	113-118
2550130-7	1989	For the propranolol treated animals, the basal c-AMP concentrations remained unchanged.	Propranolol	8-19	cathelicidin antimicrobial peptide	Rattus norvegicus	47-52
2550130-10	1989	Although intraplatelet metabolic changes (blockade of stimulated c-AMP formation) after chronic application of propranolol should have resulted in enhancement of platelet aggregability, an inhibition of aggregation was observed.	Propranolol	111-122	cathelicidin antimicrobial peptide	Rattus norvegicus	65-70
2563311-8	1989	Apolipoprotein B decreased by 17 percent with prazosin and increased by 15 percent with propranolol (p less than 0.005).	Propranolol	88-99	apolipoprotein B	Homo sapiens	0-16
2657057-4	1989	Verapamil increased fasting serum immunoreactive insulin: diltiazem and propranolol tended to reduce it.	Propranolol	72-83	insulin	Homo sapiens	49-56
2927024-4	1989	Propranolol, a beta-adrenoceptor blocking agent, and guanethidine, an adrenergic neurone blocking agent, were able to reduce the inhibitory effect of NT on the response to RNS while potentiating the contractile effect of NT on the rectal muscle.	Propranolol	0-11	neurotensin	Gallus gallus	150-152
2927024-4	1989	Propranolol, a beta-adrenoceptor blocking agent, and guanethidine, an adrenergic neurone blocking agent, were able to reduce the inhibitory effect of NT on the response to RNS while potentiating the contractile effect of NT on the rectal muscle.	Propranolol	0-11	neurotensin	Gallus gallus	221-223
2508196-5	1989	The results demonstrate that calmodulin, capable of blocking calcium outside the cell, can exert its effect only when propranolol is also present in the erythrocytes of normotensive but not in the hypertensive patients.	Propranolol	118-129	calmodulin 1	Homo sapiens	29-39
2722116-3	1989	We studied the pharmacokinetics of 3 drugs in control rats and in rats with turpentine-induced inflammation: propranolol, which is bound extensively to alpha 1-acid glycoprotein (alpha 1-AGP); metoprolol, another high extraction drug, but which is negligibly bound to alpha 1-AGP; and antipyrine, a low extraction drug, not bound to serum proteins.	Propranolol	109-120	orosomucoid 1	Rattus norvegicus	152-177
2557726-11	1989	Based on experiments in the pithed guinea-pig, it is suggested that prejunctional facilitatory beta-adrenoceptors may also be involved in the regulation of the NPY release, since infusion of isoprenaline elicited a facilitation of the PNS-induced increase of plasma NPY-LI levels which could be antagonised by propranolol.	Propranolol	310-321	pro-neuropeptide Y	Cavia porcellus	160-163
2562912-11	1989	Heart rate and active renin were, however, lowered to a much greater extent with propranolol as compared with pindolol.	Propranolol	81-92	renin	Homo sapiens	22-27
2527545-0	1989	Pharmacokinetic and pharmacodynamic interactions between the ACE inhibitor cilazapril and beta-adrenoceptor antagonist propranolol in healthy subjects and in hypertensive patients.	Propranolol	119-130	angiotensin I converting enzyme	Homo sapiens	61-64
2910639-1	1989	The relative contributions of the debrisoquin and mephenytoin isozymes of hepatic cytochrome P-450 to the stereoselective metabolism of propranolol have been studied in a panel of volunteers of known oxidative phenotypes.	Propranolol	136-147	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-98
2910639-8	1989	The partial metabolic clearance to NLA was 55% less in the PMM group than in the EM and PMD groups, indicating that S-mephenytoin 4-hydroxylase contributes to the metabolic conversion of propranolol to NLA.	Propranolol	187-198	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	116-143
2570700-3	1989	Two hours following single oral doses of 200 mg diprafenone (3.61 micrograms; 1.53-44.15) or 40 mg propranolol (16.06 micrograms; 9.15-27.04) significantly higher CD25-values were found.	Propranolol	99-110	interleukin 2 receptor subunit alpha	Homo sapiens	163-167
2722116-3	1989	We studied the pharmacokinetics of 3 drugs in control rats and in rats with turpentine-induced inflammation: propranolol, which is bound extensively to alpha 1-acid glycoprotein (alpha 1-AGP); metoprolol, another high extraction drug, but which is negligibly bound to alpha 1-AGP; and antipyrine, a low extraction drug, not bound to serum proteins.	Propranolol	109-120	orosomucoid 1	Rattus norvegicus	179-190
2545988-4	1989	Propranolol (10(-7) M) completely inhibited the ability of epinephrine to augment the stimulatory actions of AII.	Propranolol	0-11	angiotensinogen	Rattus norvegicus	109-112
2551787-3	1989	The lower limits for CBF beyond which blood flow was decreased steeply were 72% of resting values in the control, 44 in the PBZ and 80 in the PPL group.	Propranolol	142-145	CCAAT/enhancer binding protein zeta	Rattus norvegicus	21-24
2535853-3	1989	The propranolol infusion enhanced the stimulatory effect of hypoglycemia on ACTH, cortisol, and AVP secretion and also enhanced the stimulatory effect of CRH on ACTH and cortisol secretion.	Propranolol	4-15	corticotropin releasing hormone	Homo sapiens	154-157
2535853-6	1989	The propranolol-induced enhancement of the ACTH response to hypoglycemia was almost the same as the ACTH response to CRH alone.	Propranolol	4-15	corticotropin releasing hormone	Homo sapiens	117-120
2535853-7	1989	From these results we conclude that propranolol may act at the pituitary level to enhance CRH action, rather than AVP action, and that the ACTH response to hypoglycemia may be mediated by hypothalamic alpha-adrenergic activation.	Propranolol	36-47	corticotropin releasing hormone	Homo sapiens	90-93
2657144-6	1989	Plasma renin activity at rest and during exercise were more strongly suppressed by propranolol than acebutolol.	Propranolol	83-94	renin	Homo sapiens	7-12
2694115-0	1989	[Effect of propranolol therapy on the secretion of insulin, glucagon, gastrin and pancreatic polypeptide in patients with essential hypertension].	Propranolol	11-22	insulin	Homo sapiens	51-58
2694115-0	1989	[Effect of propranolol therapy on the secretion of insulin, glucagon, gastrin and pancreatic polypeptide in patients with essential hypertension].	Propranolol	11-22	gastrin	Homo sapiens	70-77
2694115-0	1989	[Effect of propranolol therapy on the secretion of insulin, glucagon, gastrin and pancreatic polypeptide in patients with essential hypertension].	Propranolol	11-22	pancreatic polypeptide	Homo sapiens	82-104
2694115-4	1989	After propranolol therapy, the authors found a significant change of glucagonemia profile and pancreatic polypeptide concentration induced by a test meal.	Propranolol	6-17	pancreatic polypeptide	Homo sapiens	94-116
2501811-6	1989	Additionally, d,l-propranolol was used as a 5HT-1 antagonist and was found to block the behavioral effects of the 5HT-1A agonists ipsapirone and buspirone without having significant effects by itself.	Propranolol	14-29	5-hydroxytryptamine receptor 1A	Rattus norvegicus	114-120
2596109-0	1989	[The diagnostic value of the propranolol-glucagon test for somatotropin secretion].	Propranolol	29-40	growth hormone 1	Homo sapiens	59-71
2975944-2	1988	Preincubation of sarcoplasmic reticulum (SR) with propranolol or tetracaine inhibits Ca2+ accumulation and stimulates ATPase activity by more than 2-fold.	Propranolol	50-61	dynein axonemal heavy chain 8	Homo sapiens	118-124
2851006-2	1988	VIP (10(-10) to 10(-6) M) produced a dose-dependent increase in [3H]glycoconjugate release of up to 300% of controls, which was inhibited by VIP antiserum and not inhibited by atropine, propranolol, or phentolamine.	Propranolol	186-197	vasoactive intestinal peptide	Homo sapiens	0-3
3224360-0	1988	Differential responses of rat pineal thyroxine type II 5"-deiodinase and N-acetyltransferase activities to either light exposure, isoproterenol, phenylephrine, or propranolol.	Propranolol	163-174	iodothyronine deiodinase 2	Rattus norvegicus	47-68
2907348-3	1988	A more detailed analysis revealed that all beta-adrenoceptor antagonists increased right atrial beta 1-adrenoceptor density, but right atrial beta 2-adrenoceptor density was increased only in the sotalol/propranolol group, remaining unchanged in the metoprolol and atenolol groups, and was decreased in the pindolol group.	Propranolol	204-215	adrenoceptor beta 2	Homo sapiens	142-161
3072488-5	1988	The increases in plasma renin activity were blocked by propranolol.	Propranolol	55-66	renin	Rattus norvegicus	24-29
2849675-0	1988	Propranolol antagonizes the enhanced conditioned fear produced by corticotropin releasing factor.	Propranolol	0-11	corticotropin releasing hormone	Homo sapiens	66-96
2849675-1	1988	A series of experiments examined the effects of systemic administration of the beta adrenergic antagonist propranolol on the enhanced conditioned fear and the locomotor hyperactivity induced by central administration of corticotropin releasing factor (CRF).	Propranolol	106-117	corticotropin releasing hormone	Homo sapiens	220-250
2901818-7	1988	INTERVENTION: The beta-1-nonselective blocker was propranolol, 80 mg twice daily.	Propranolol	50-61	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	18-24
3142274-6	1988	Propranolol did not affect the concentration-response curve to serotonin under control conditions; it prevented the facilitated contraction to the monoamine but not the augmented secondary relaxation caused by the inhibitors of cyclooxygenase.	Propranolol	0-11	prostaglandin-endoperoxide synthase 1	Canis lupus familiaris	228-242
3075044-4	1988	The systemic administration of either prazosin, an alpha-adrenergic antagonist (0.2 or 1 mg/kg), or propranolol, a beta-adrenergic antagonist (20 mg/kg), totally suppressed LHRH-induced lordosis in sexually inexperienced Ss (mean LQs = 8 +/- 11; 5 +/- 10; 18 +/- 31, respectively).	Propranolol	100-111	gonadotropin releasing hormone 1	Rattus norvegicus	173-177
2902805-5	1988	These results are consistent with propranolol antagonizing beta 1-adrenoceptor-mediated effects on the heart and the renin-angiotensin system that act to offset a beta 2-adrenoceptor-mediated vasodilatation, which contributes to the effects elicited by alpha-adrenoceptor antagonism.	Propranolol	34-45	adrenoceptor beta 1	Rattus norvegicus	59-78
2902805-5	1988	These results are consistent with propranolol antagonizing beta 1-adrenoceptor-mediated effects on the heart and the renin-angiotensin system that act to offset a beta 2-adrenoceptor-mediated vasodilatation, which contributes to the effects elicited by alpha-adrenoceptor antagonism.	Propranolol	34-45	adrenoceptor beta 2	Rattus norvegicus	163-182
2901994-6	1988	The forskolin-potentiated responses of these compounds were abolished by the beta AR-antagonist propranolol.	Propranolol	96-107	adrenergic receptor, beta 1	Mus musculus	77-84
3048776-15	1988	Plasma renin was maximally suppressed 2 hours after treatment, thus before any change in mean arterial pressure had occurred with acebutolol, atenolol, and propranolol.	Propranolol	156-167	renin	Homo sapiens	7-12
2971708-0	1988	Effect of vasoactive intestinal peptide (VIP) on propranolol-induced bronchoconstriction.	Propranolol	49-60	vasoactive intestinal peptide	Homo sapiens	10-39
2971708-0	1988	Effect of vasoactive intestinal peptide (VIP) on propranolol-induced bronchoconstriction.	Propranolol	49-60	vasoactive intestinal peptide	Homo sapiens	41-44
2971358-0	1988	Antagonism of 5-hydroxytryptamine1A (5-HT1A) receptor-mediated modulation of adenylate cyclase activity by pindolol and propranolol isomers.	Propranolol	120-131	5-hydroxytryptamine receptor 1A	Rattus norvegicus	14-35
2465449-5	1988	The depressor effect of intrathecal NPY was attenuated by prior treatment with yohimbine and propranolol but not prazosin.	Propranolol	93-104	neuropeptide Y	Rattus norvegicus	36-39
2459368-5	1988	The potency of propranolol (KB = 6 X 10(-10) M) was the same for competitively antagonizing isoproterenol mediated inhibition of histamine, LTC4 or PGD2 release.	Propranolol	15-26	prostaglandin D2 synthase	Homo sapiens	148-152
2971358-0	1988	Antagonism of 5-hydroxytryptamine1A (5-HT1A) receptor-mediated modulation of adenylate cyclase activity by pindolol and propranolol isomers.	Propranolol	120-131	5-hydroxytryptamine receptor 1A	Rattus norvegicus	37-43
2971358-1	1988	The interactions of the stereoisomers of pindolol and propranolol with 5-hydroxytryptamine1A (5-HT1A) binding sites and adenylate cyclase activity were examined in rat hippocampus.	Propranolol	54-65	5-hydroxytryptamine receptor 1A	Rattus norvegicus	71-92
2971358-1	1988	The interactions of the stereoisomers of pindolol and propranolol with 5-hydroxytryptamine1A (5-HT1A) binding sites and adenylate cyclase activity were examined in rat hippocampus.	Propranolol	54-65	5-hydroxytryptamine receptor 1A	Rattus norvegicus	94-100
2971358-2	1988	(-)Pindolol and (-)propranolol displayed high affinity for 5-HT1A binding sites, and their affinities were not affected significantly by the addition of 10(-4) M GTP to the radioligand assay.	Propranolol	19-30	5-hydroxytryptamine receptor 1A	Rattus norvegicus	59-65
3409482-7	1988	The delayed humorally mediated vasodilator response was blocked by propranolol or ICI 118551, indicating that it was mediated by a circulating factor with beta 2-stimulating properties.	Propranolol	67-78	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	155-161
3143655-4	1988	Propranolol premedication caused a significant rise of both basal and peak GHRH-induced relative increases in all subjects tested, whereas GHRH-induced relative increases of GH remained unchanged.	Propranolol	0-11	growth hormone releasing hormone	Homo sapiens	75-79
2539818-4	1989	AAG treatment significantly increased the heart rate response to isoproterenol, compared to albumin (95.4 +/- 19.6 vs 28.3 +/- 16.7% of baseline value, measured 45 min after propranolol, P less than 0.001).	Propranolol	174-185	orosomucoid 1	Rattus norvegicus	0-3
2539818-5	1989	AAG-treated rats had greater [3H]propranolol binding in serum (93.0 +/- 3.2 vs 76.7 +/- 3.0%, P less than 0.01) and a lower calculated unbound [3H]propranolol concentration in serum (2.7 +/- 1.3 vs 7.4 +/- 3.1 X 10(6) dpm/ml, P less than 0.001) than albumin-treated rats.	Propranolol	33-44	orosomucoid 1	Rattus norvegicus	0-3
2539818-5	1989	AAG-treated rats had greater [3H]propranolol binding in serum (93.0 +/- 3.2 vs 76.7 +/- 3.0%, P less than 0.01) and a lower calculated unbound [3H]propranolol concentration in serum (2.7 +/- 1.3 vs 7.4 +/- 3.1 X 10(6) dpm/ml, P less than 0.001) than albumin-treated rats.	Propranolol	147-158	orosomucoid 1	Rattus norvegicus	0-3
2539818-6	1989	These data demonstrate that AAG can alter propranolol pharmacokinetics and pharmacodynamics even when administered after the propranolol effect is evident.	Propranolol	42-53	orosomucoid 1	Rattus norvegicus	28-31
2539818-6	1989	These data demonstrate that AAG can alter propranolol pharmacokinetics and pharmacodynamics even when administered after the propranolol effect is evident.	Propranolol	125-136	orosomucoid 1	Rattus norvegicus	28-31
2539818-7	1989	Because the reported affinity of propranolol for cardiac beta receptors is 10,000 times greater than its affinity for AAG, these data suggest that AAG acted by altering propranolol disposition rather than by directly competing with beta receptors for drug.	Propranolol	33-44	orosomucoid 1	Rattus norvegicus	147-150
2539818-7	1989	Because the reported affinity of propranolol for cardiac beta receptors is 10,000 times greater than its affinity for AAG, these data suggest that AAG acted by altering propranolol disposition rather than by directly competing with beta receptors for drug.	Propranolol	169-180	orosomucoid 1	Rattus norvegicus	147-150
2901969-5	1988	Propranolol completely inhibited the effects on glucose, lactate, non-esterified fatty acids and insulin.	Propranolol	0-11	insulin	Bos taurus	97-104
2902891-9	1988	Similarly, in corresponding lymphocytes, only sotalol or propranolol increased beta 2-adrenoceptor density, while metoprolol and atenolol did not affect it and pindolol decreased it.	Propranolol	57-68	adrenoceptor beta 2	Homo sapiens	79-98
3389407-6	1988	Serum T3, free T3, T3 plasma pool, T3 mass transfer rate to REP and SEP, and the T3 pool masses were all significantly decreased during propranolol to a similar extent as the T3 plasma production rate (PR).	Propranolol	136-147	plexin B1	Homo sapiens	68-71
2902891-7	1988	All beta-adrenoceptor antagonists increased right atrial beta 1-adrenoceptor density; on the other hand, only sotalol and propranolol also increased right atrial beta 2-adrenoceptor density, whereas metoprolol and atenolol did not affect it and pindolol decreased it.	Propranolol	122-133	adrenoceptor beta 2	Homo sapiens	162-181
2840395-4	1988	We also examined the effects of isoproterenol and propranolol on the immunoreactive Ang I and II release.	Propranolol	50-61	angiotensinogen	Rattus norvegicus	84-96
2840395-7	1988	Isoproterenol (10(-6) M) failed to cause a change in the release of both peptides, but propranolol (10(-6) M) slightly decreased the release of immunoreactive Ang I and II by 28 +/- 4% (p less than 0.001) and 32 +/- 4% (p less than 0.001), respectively.	Propranolol	87-98	angiotensinogen	Rattus norvegicus	159-171
2840395-8	1988	There was a highly significant positive correlation between the released amount of immunoreactive Ang I and that of immunoreactive Ang II altered by indomethacin (r = 0.91), meclofenamate (r = 0.94), or propranolol administration (r = 0.90).	Propranolol	203-214	angiotensinogen	Rattus norvegicus	131-137
2839668-5	1988	After propranolol administration, in vitro beta-1 and beta-2 adrenoceptor occupancy declined from initially 97% to less than 10% within 48 hr.	Propranolol	6-17	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	43-49
2971358-6	1988	These data suggest that (-)pindolol and (-)propranolol are potent antagonists at 5-HT1A receptors in rat hippocampus.	Propranolol	43-54	5-hydroxytryptamine receptor 1A	Rattus norvegicus	81-87
2839668-5	1988	After propranolol administration, in vitro beta-1 and beta-2 adrenoceptor occupancy declined from initially 97% to less than 10% within 48 hr.	Propranolol	6-17	adrenoceptor beta 2	Homo sapiens	54-73
2904983-1	1988	Propranolol binding to isolated human alpha-1-acid glycoprotein (AGP) and human albumin (HSA) was studied by equilibrium dialysis at 37 degrees C. With AGP (0.067%) and HSA (4%), total propranolol concentration was varied from 0.7 to 93,000 ng mL-1.	Propranolol	0-11	L1 cell adhesion molecule	Mus musculus	244-248
3147455-0	1988	Propranolol and methylatropine antagonize the cardiovascular effects produced by microinjection of the TRH analog MK-771 into the preoptic suprachiasmatic nucleus.	Propranolol	0-11	thyrotropin releasing hormone	Rattus norvegicus	103-106
2837913-10	1988	Pretreatment with both captopril and propranolol dramatically potentiated the magnitude of the increase in protein clearance, the filtration rate, and edema formation produced by BK but failed to affect the duration of the transient increase in vascular permeability.	Propranolol	37-48	kininogen 1	Homo sapiens	179-181
3384954-4	1988	10(-11)-10(-7) M CCK-8 and 4 X 10(-11)-5 X 10(-7) M VIP generated dose-related sphincter of Oddi relaxation, which was unaffected by atropine, propranolol, and phentolamine.	Propranolol	143-154	vasoactive intestinal peptide	Canis lupus familiaris	52-55
2835408-5	1988	In Group 3, a beta-adrenergic blocking dose of propranolol was added to the infusion of 50 ng/kg per min of epinephrine.	Propranolol	47-58	amyloid beta precursor protein	Homo sapiens	12-18
3384954-7	1988	10(-11)-10(-7) M CCK-8 stimulated dose-dependent release of VIP (0.5-2.2 fm/ml.mg tissue), which was not inhibited by atropine, propranolol, and phentolamine, but was antagonized by 10(-3) M Bt2 cGMP and tetrodotoxin.	Propranolol	128-139	vasoactive intestinal peptide	Canis lupus familiaris	60-63
3384954-8	1988	In addition CCK-8 and VIP generated dose-related (10(-10)-10(-7) M) increases in sphincter of Oddi cAMP levels that were not affected by atropine, propranolol, and phentolamine.	Propranolol	147-158	vasoactive intestinal peptide	Canis lupus familiaris	22-25
2836443-4	1988	Propanolol also inhibited the early prereplicative surge of cyclic AMP and the increase of calmodulin in liver cells proliferatively activated by partial hepatectomy.	Propranolol	0-10	calmodulin 1	Rattus norvegicus	91-101
2901480-3	1988	Pharmacokinetic analysis for the perfusate propranolol concentration-time curves when loaded at 1 to 10 micrograms mL-1 yielded almost comparable values for the pulmonary perfusion clearance (0.387 +/- 0.092 to 0.486 +/- 0.095 mL min-1 g-1).	Propranolol	43-54	L1 cell adhesion molecule	Mus musculus	115-119
3389051-5	1988	Pre-administration of phenoxybenzamine (an alpha antagonist, 0.15 mumol) which was confirmed to abolish the effect of phenylephrine, or propranolol (a beta antagonist, 0.15 mumol) did not block the effect of ANG II.	Propranolol	136-147	amyloid beta precursor protein	Rattus norvegicus	149-155
2901369-3	1988	The blockade of beta-adrenoreceptors with propranolol reduced contractile responses to exogenous (i. a. administration) and endogenous (electrical stimulation of the n. vagus" efferent fibers) acetylcholine, histamine and bradykinin.	Propranolol	42-53	kininogen 1	Homo sapiens	222-232
3044806-5	1988	The insulin leakage under the conditions of pharmacologic blockade of insulin secretion by means of epinephrine and propranolol provides a measure of complement-mediated cytotoxicity of human serum against rats islets in vitro.	Propranolol	116-127	insulin	Homo sapiens	4-11
3373482-1	1988	A conformational study of four 5-HT1A (serotonin) receptor ligands ((R-(-)-methiothepin, spiperone, (S)-(-)-propranolol, and buspirone) led to the definition of a pharmacophore and a three-dimensional map of the 5-HT1A antagonist recognition site.	Propranolol	100-119	5-hydroxytryptamine receptor 1A	Rattus norvegicus	31-37
2458109-6	1988	The same extent of inhibition in the renin secretion response to RNS was also obtained during the infusion of dl-propranolol (100 micrograms/min).	Propranolol	110-124	renin	Canis lupus familiaris	37-42
2895586-8	1988	The inhibitory action of PYY on 2-DG-stimulated insulin release persisted in the presence of atropine or phentolamine treatment; however, hexamethonium alone or phentolamine plus propranolol treatment blocked the inhibitory action of PYY.	Propranolol	179-190	peptide YY	Canis lupus familiaris	25-28
3420006-4	1988	Adrenergic (norepinephrine, isoproterenol) stimulation of antral gastrin release was prevented by propranolol, and cholinergic- (carbachol) mediated peptide release was blocked by both atropine and pirenzepine.	Propranolol	98-109	gastrin	Rattus norvegicus	65-72
2831035-5	1988	Moreover, combined treatment with both norepinephrine (10(-6) M) and hCG (1 ng/ml) unmasked a synergistic interaction subject to stereospecific blockade by beta (propranolol)- but not alpha (phentolamine)-selective adrenergic antagonists.	Propranolol	162-173	hypertrichosis 2 (generalised, congenital)	Homo sapiens	69-72
2837398-6	1988	Nicotine evoked a calcium-dependent release of VIP, which was blocked by tetrodotoxin (1 microM), d-propranolol (0.5 microM) or, as previously shown, by apamin (0.2 microM).	Propranolol	98-111	VIP peptides	Cavia porcellus	47-50
2836304-0	1988	Propranolol enhances in vitro interleukin 2 receptor expression on human lymphocytes.	Propranolol	0-11	interleukin 2 receptor subunit alpha	Homo sapiens	30-52
2836245-4	1988	The stimulation of adenylate cyclase by erythropoietin was observed also in the presence of the beta-antagonist propranolol, when both were added either to whole cells or to isolated membranes.	Propranolol	112-123	erythropoietin	Oryctolagus cuniculus	40-54
2840752-7	1988	Pretreatment with the beta-blocker propranolol completely blocked the increase in t-PA.	Propranolol	35-46	tissue-type plasminogen activator	Canis lupus familiaris	82-86
3371417-3	1988	In euhydrated rats the single dose of propranolol diminished significantly the vasopressin and oxytocin content in the neurohypophysis.	Propranolol	38-49	arginine vasopressin	Rattus norvegicus	79-90
2834262-4	1988	In the presence of propranolol, hypercapnia elicited a pronounced activation of pyruvate kinase (PyK) (measured at both low and high phosphoenolpyruvate (PEP) concentrations) and inactivation of both total glycogen phosphorylase (GPase) and glycogen phosphorylase a (GPase a).	Propranolol	19-30	pyruvate kinase PKM	Oncorhynchus mykiss	80-95
2834262-4	1988	In the presence of propranolol, hypercapnia elicited a pronounced activation of pyruvate kinase (PyK) (measured at both low and high phosphoenolpyruvate (PEP) concentrations) and inactivation of both total glycogen phosphorylase (GPase) and glycogen phosphorylase a (GPase a).	Propranolol	19-30	pyruvate kinase PKM	Oncorhynchus mykiss	97-100
3252038-9	1988	AAG administration resulted in a 22% decrease in mean unbound fraction of plasma and a 52% increase in mean total plasma propranolol concentration (35% decrease in mean systemic clearance).	Propranolol	121-132	alpha-1-acid glycoprotein	Bos taurus	0-3
2834262-5	1988	In the absence of propranolol, the changes in enzyme activities were significantly reduced (low PEP PyK activity) or totally absent (GPase inactivation).	Propranolol	18-29	pyruvate kinase PKM	Oncorhynchus mykiss	100-103
2896373-2	1988	Intracarotid injections of VIP produced secretion of saliva from the ovine gland which continued after administration of atropine, phentolamine and propranolol.	Propranolol	148-159	vasoactive intestinal peptide	Sus scrofa	27-30
3348371-9	1988	In a separate group of experiments a complete adrenergic blockade, produced by the constant infusion of propranolol and phentolamine, completely prevented PAF-induced increases in glucose kinetics and the hyperglucagonemia.	Propranolol	104-115	PCNA clamp associated factor	Rattus norvegicus	155-158